<SEC-DOCUMENT>0001494650-19-000020.txt : 20190306
<SEC-HEADER>0001494650-19-000020.hdr.sgml : 20190306
<ACCEPTANCE-DATETIME>20190306071459
ACCESSION NUMBER:		0001494650-19-000020
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		94
CONFORMED PERIOD OF REPORT:	20181231
FILED AS OF DATE:		20190306
DATE AS OF CHANGE:		20190306

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OptiNose, Inc.
		CENTRAL INDEX KEY:			0001494650
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				421771610
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38241
		FILM NUMBER:		19661223

	BUSINESS ADDRESS:	
		STREET 1:		1020 STONY HILL ROAD
		STREET 2:		SUITE 300
		CITY:			YARDLEY
		STATE:			PA
		ZIP:			19067
		BUSINESS PHONE:		267-364-3500

	MAIL ADDRESS:	
		STREET 1:		1020 STONY HILL ROAD
		STREET 2:		SUITE 300
		CITY:			YARDLEY
		STATE:			PA
		ZIP:			19067
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>optn12-31x201810xk.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s43509D1377EC555F9F9FE384B05FD284"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Washington, D.C.&#160;&#160;20549</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">FORM 10-K</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:25px;"></td><td style="width:37px;"></td><td style="width:620px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">For the fiscal year ended </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OR</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:25px;"></td><td style="width:37px;"></td><td style="width:620px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font><font style="font-family:Arial;font-size:10pt;">For the transition period from ___________ to ______________.</font></div><div style="line-height:120%;text-align:center;text-indent:58px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Commission file number: 001-38241</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:10px;"><img src="optinoselogorgba25.jpg" alt="optinoselogorgba25.jpg" style="height:64px;width:254px;"></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">OPTINOSE, INC. </font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:73.828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:39%;"></td><td style="width:19%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">42-1771610</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(State of other jurisdiction of incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(I.R.S. Employer Identification Number)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1020 Stony Hill Road, Suite 300<br>Yardley, Pennsylvania 19067<br></font><font style="font-family:Arial;font-size:10pt;">(Address of principal executive offices, including zip code)</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(267) 364-3500 </font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Registrant&#8217;s telephone number, including area code)</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:Arial;font-size:10pt;">Securities registered pursuant to Section 12(b) of the Act:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.8671875%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:47%;"></td><td style="width:53%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Title of Each Class</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Name of each exchange on which registered </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Common Stock, $0.001 par value</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Nasdaq Global Select Market </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Securities registered pursuant to Section 12(g) of the Act: None</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.     Yes</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o </font><font style="font-family:Arial;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#160; </font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.     Yes</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o </font><font style="font-family:Arial;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#160; </font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.       Yes</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253; </font><font style="font-family:Arial;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#160; </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div><br></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).       Yes</font><font style="font-family:inherit;font-size:10pt;">&#160; </font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font><font style="font-family:inherit;font-size:10pt;">&#160; </font><font style="font-family:Arial;font-size:10pt;">No&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:Arial;font-size:10pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (&#167; 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:Arial;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:70%;"></td><td style="width:30%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Large&#160;accelerated&#160;filer</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accelerated&#160;filer</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Non-accelerated&#160;filer</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Arial;font-size:10pt;">&#160;(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Smaller&#160;reporting&#160;company</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Emerging growth&#160;company</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).Yes</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;">&#160;No</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of June 29, 2018 (the last business day of the registrant's most recently completed second fiscal quarter), the aggregate market value of the registrant's common stock held by non-affiliates was approximately $682.4 million based on the last reported sale price of the registrant's common stock on June 30, 2018. </font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The number of shares of common stock outstanding at March 1, 2019 was </font><font style="font-family:Arial;font-size:10pt;">41,264,422</font><font style="font-family:Arial;font-size:10pt;">&#32;shares.</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Portions of the registrant&#8217;s definitive proxy statement for its 2019 annual meeting of stockholders are incorporated by reference into Part III of this Form 10-K where indicated. Such definitive proxy statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><hr style="page-break-after:always"><div><a name="sA071692F10A856EE9C9C70B526949937"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:10%;"></td><td style="width:83%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sE8291DA3F0105720A80B1B459831AC20"><font style="font-family:Arial;font-size:10pt;">NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;text-decoration:none;" href="#sE8291DA3F0105720A80B1B459831AC20">1</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sedc4874d90af49b0bb7d9053c60683d2"><font style="font-family:Arial;font-size:10pt;">MARKET, INDUSTRY AND OTHER DATA</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;text-decoration:none;" href="#sedc4874d90af49b0bb7d9053c60683d2">2</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s6A26FA8113B9529E9FD7A5A14E72F3BB"><font style="font-family:Arial;font-size:10pt;">PART I </font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s63835C3000085A1496B0CC03C6167DA9"><font style="font-family:Arial;font-size:10pt;">ITEM 1.</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s63835C3000085A1496B0CC03C6167DA9"><font style="font-family:Arial;font-size:10pt;">BUSINESS</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;text-decoration:none;" href="#s63835C3000085A1496B0CC03C6167DA9">3</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s7BE26810FD4D592EA61C57006AE3B252"><font style="font-family:Arial;font-size:10pt;">ITEM 1A.</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s7BE26810FD4D592EA61C57006AE3B252"><font style="font-family:Arial;font-size:10pt;">RISK FACTORS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;text-decoration:none;" href="#s7BE26810FD4D592EA61C57006AE3B252">40</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s1187D9BBC6E758EC94580370401DA952"><font style="font-family:Arial;font-size:10pt;">ITEM 1B.</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s1187D9BBC6E758EC94580370401DA952"><font style="font-family:Arial;font-size:10pt;">UNRESOLVED STAFF COMMENTS</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;text-decoration:none;" href="#s1187D9BBC6E758EC94580370401DA952">84</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sD24F3C30573E5238AEFFACF92C813D3A"><font style="font-family:Arial;font-size:10pt;">ITEM 2.</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sD24F3C30573E5238AEFFACF92C813D3A"><font style="font-family:Arial;font-size:10pt;">PROPERTIES</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;text-decoration:none;" href="#sD24F3C30573E5238AEFFACF92C813D3A">84</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s3FA6225D8D9E54228A58FBB4EA8AC4D8"><font style="font-family:Arial;font-size:10pt;">ITEM 3.</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s3FA6225D8D9E54228A58FBB4EA8AC4D8"><font style="font-family:Arial;font-size:10pt;">LEGAL PROCEEDINGS</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;text-decoration:none;" href="#s3FA6225D8D9E54228A58FBB4EA8AC4D8">84</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s08B247C026A9516DBA66EBF747A13221"><font style="font-family:Arial;font-size:10pt;">ITEM 4.</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s08B247C026A9516DBA66EBF747A13221"><font style="font-family:Arial;font-size:10pt;">MINE SAFETY DISCLOSURE</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;text-decoration:none;" href="#s08B247C026A9516DBA66EBF747A13221">84</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sB722D72872015260A52AC7EA23A44345"><font style="font-family:Arial;font-size:10pt;">PART II</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s8E102D097BB5550C8DF856A8F2B41191"><font style="font-family:Arial;font-size:10pt;">ITEM 5.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s8E102D097BB5550C8DF856A8F2B41191"><font style="font-family:Arial;font-size:10pt;">MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;text-decoration:none;" href="#s8E102D097BB5550C8DF856A8F2B41191">84</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sE19CE4699E7A51ECA5EAAC3886527125"><font style="font-family:Arial;font-size:10pt;">ITEM 6.</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sE19CE4699E7A51ECA5EAAC3886527125"><font style="font-family:Arial;font-size:10pt;">SELECTED CONSOLIDATED FINANCIAL DATA</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;text-decoration:none;" href="#sE19CE4699E7A51ECA5EAAC3886527125">85</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s6D1D6533390B5CAC8EB36BDB2BE4BFFE"><font style="font-family:Arial;font-size:10pt;">ITEM 7.</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s6D1D6533390B5CAC8EB36BDB2BE4BFFE"><font style="font-family:Arial;font-size:10pt;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;text-decoration:none;" href="#s6D1D6533390B5CAC8EB36BDB2BE4BFFE">85</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sF38D7AECF2A751CF8D0C9016DFA1272A"><font style="font-family:Arial;font-size:10pt;">ITEM 7A.</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sF38D7AECF2A751CF8D0C9016DFA1272A"><font style="font-family:Arial;font-size:10pt;">QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;text-decoration:none;" href="#sF38D7AECF2A751CF8D0C9016DFA1272A">97</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sD2EC1E6E15A053DAAAC52584A157C92A"><font style="font-family:Arial;font-size:10pt;">ITEM 8.</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sD2EC1E6E15A053DAAAC52584A157C92A"><font style="font-family:Arial;font-size:10pt;">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;text-decoration:none;" href="#sD2EC1E6E15A053DAAAC52584A157C92A">97</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s38E97CB35D285B2D9AE0A9E35C26D8D2"><font style="font-family:Arial;font-size:10pt;">ITEM 9.</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s38E97CB35D285B2D9AE0A9E35C26D8D2"><font style="font-family:Arial;font-size:10pt;">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;text-decoration:none;" href="#s38E97CB35D285B2D9AE0A9E35C26D8D2">97</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s73D75ADD19095ED5880BEB9839E93006"><font style="font-family:Arial;font-size:10pt;">ITEM 9A.</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s73D75ADD19095ED5880BEB9839E93006"><font style="font-family:Arial;font-size:10pt;">CONTROLS AND PROCEDURES</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;text-decoration:none;" href="#s73D75ADD19095ED5880BEB9839E93006">97</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s63DB44EE979353DEBC569EB62FB27E8B"><font style="font-family:Arial;font-size:10pt;">ITEM 9B.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s63DB44EE979353DEBC569EB62FB27E8B"><font style="font-family:Arial;font-size:10pt;">OTHER INFORMATION</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;text-decoration:none;" href="#s63DB44EE979353DEBC569EB62FB27E8B">99</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s7B0D5AFED3A05884B20B099CFAA9FB78"><font style="font-family:Arial;font-size:10pt;">PART III</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s3CD940376DD251739BD6CC2654CA967F"><font style="font-family:Arial;font-size:10pt;">ITEM 10.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s3CD940376DD251739BD6CC2654CA967F"><font style="font-family:Arial;font-size:10pt;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;text-decoration:none;" href="#s3CD940376DD251739BD6CC2654CA967F">99</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sF531A5A9BF855DC58B2AF72099DD6F60"><font style="font-family:Arial;font-size:10pt;">ITEM 11.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sF531A5A9BF855DC58B2AF72099DD6F60"><font style="font-family:Arial;font-size:10pt;">EXECUTIVE COMPENSATION</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;text-decoration:none;" href="#sF531A5A9BF855DC58B2AF72099DD6F60">99</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s481E20F9765B53229B2A7EBB09DBDFB8"><font style="font-family:Arial;font-size:10pt;">ITEM 12.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s481E20F9765B53229B2A7EBB09DBDFB8"><font style="font-family:Arial;font-size:10pt;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;text-decoration:none;" href="#s481E20F9765B53229B2A7EBB09DBDFB8">99</a></div><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sD2F00FC2BCA354E5A2A3E469CD521D92"><font style="font-family:Arial;font-size:10pt;">ITEM 13.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sD2F00FC2BCA354E5A2A3E469CD521D92"><font style="font-family:Arial;font-size:10pt;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;text-decoration:none;" href="#sD2F00FC2BCA354E5A2A3E469CD521D92">99</a></div><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sDA87DC37D53B5975BFBE4C764F8B2BD4"><font style="font-family:Arial;font-size:10pt;">ITEM 14.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sDA87DC37D53B5975BFBE4C764F8B2BD4"><font style="font-family:Arial;font-size:10pt;">PRINCIPAL ACCOUNTANT FEES AND SERVICES</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;text-decoration:none;" href="#sDA87DC37D53B5975BFBE4C764F8B2BD4">99</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA0F92E279724560FAB661EA8B02682E2"><font style="font-family:Arial;font-size:10pt;">PART IV</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sFC512B1C65885524A24D66D58ABF0C29"><font style="font-family:Arial;font-size:10pt;">ITEM 15.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sFC512B1C65885524A24D66D58ABF0C29"><font style="font-family:Arial;font-size:10pt;">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;text-decoration:none;" href="#sFC512B1C65885524A24D66D58ABF0C29">99</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s255B684B0C785025863CCCF06A095A1C"><font style="font-family:Arial;font-size:10pt;">SIGNATURE PAGE</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sFC512B1C65885524A24D66D58ABF0C29"><font style="font-family:Arial;font-size:10pt;">EXHIBIT INDEX</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">_________________________</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unless the context otherwise requires, all references in this Form 10-K to "Optinose," "Company," "we," "us," and "our" refer to OptiNose, Inc. and its subsidiaries. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">_________________________</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Trademark Notice</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">OPTINOSE&#174; and XHANCE&#174; are registered trademarks of Optinose in the United States. This Form 10-K contains references to our trademarks and to trademarks belonging to other entities. All other trademarks, trade names and service marks appearing in this Form 10-K are the property of their respective owners. We do not intend our use or display of other companies' trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. </font></div><div><br></div><hr style="page-break-after:always"><div><a name="sE8291DA3F0105720A80B1B459831AC20"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This Form 10-K contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, among others, statements relating to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the potential advantages of XHANCE</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">, our product candidates and Exhalation Delivery System (EDS) devices and technologies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our plan to internalize our contract sales team and deploy an additional 20 territory managers in &#8220;XHANCE naive&#8221; geographies to expand our reach among the ear, nose and throat and allergy specialist universe, and our expectation that doing so will grow the target audience for our sales team by approximately 25% to approximately 9,500 healthcare providers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our expectation to continue to secure broader market access over time, and our intention to eventually increase the size of our sales force to approximately 120 territory managers based upon an expanded target audience of approximately 14,000 specialists or &#8220;specialty-like&#8221; primary care physicians;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our expectation to target additional physicians through digital and non-personal promotion in areas where we do and do not have territory managers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our analyses suggesting that XHANCE will have a comparatively low pharmacy budget impact;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our clinical trial data suggesting that XHANCE may produce an offsetting benefit by helping reduce other healthcare resource utilization;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our belief that the cost of XHANCE to insurance plans will likely be significantly less than the projected costs of monoclonal antibodies that are currently in development for the treatment of nasal polyps;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our believe that the current practice of postoperative intranasal steroid use could support XHANCE&#8217;s adoption as a maintenance therapy to improve outcomes following sinus surgery; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">planned product development activities, studies and clinical trials, including our plans to initiate a second phase 3b clinical trial of XHANCE in 2019 in pursuit of a follow-on indication for chronic sinusitis;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our intention to execute a branded, multi-channel direct to consumer pilot in three cities targeting diagnosed and undiagnosed nasal polyp patients in 2019, and our anticipation to broaden the direct to consumer pilot to a national campaign in 2020 if the 2019 campaign is successful;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our expectation that our GAAP operating expenses in 2019 will be between $135 - $142 million and that our non-cash stock-based compensation expense will be between $10 - $12 million;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our expectation that our existing cash and cash equivalents will be sufficient to meet our debt service obligations under our Senior Secured Notes, and to carry out our planned development and commercial activities into the fourth quarter of 2020; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our expectation that the average net revenue per prescription for XHANCE in the first quarter of 2019 will be between $155 - $175 and our expectation that the average net revenue per prescription will improve though 2019 and that the full-year 2019 average net revenue per prescription will be between $185 - $205;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the size and growth potential of the markets for XHANCE and our product candidates, and our ability to service those markets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the rate and degree of market acceptance of XHANCE and our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our ability to maintain regulatory approval of XHANCE and our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our ability to attract collaborators with development, regulatory and commercialization expertise;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">regulatory developments in the United States (U.S.) and foreign countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our ability to operate our business without infringing the intellectual property rights of others;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the scope and duration of patent protection and other barriers to entry that we expect to benefit XHANCE and our product candidates;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the performance of our third-party suppliers, manufacturers and contract sales organizations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the success of competing products that are or become available;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our expectations regarding our ability to obtain and adequately maintain sufficient intellectual property protection for XHANCE and our other product candidates and to avoid claims of infringement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the accuracy of our estimates regarding expenses, future revenue, capital requirements and need for additional financing; </font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">as well as other statements relating to our future operations, financial performance and financial condition, prospects, strategies, objectives or other future events. Forward-looking statements appear primarily in the sections of this Form 10-K entitled "Item 1 - Business," "Item 1A - Risk Factors," "Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations," and "Item 7 - Quantitative and Qualitative Disclosures About Market Risk."  In some cases, you can identify forward-looking statements by words such as "may,&#8221; "will,&#8221; "could," "would," "should," "expect," "intend," "plan," "anticipate," "target," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing," "scheduled" and similar expressions, although not all forward-looking statements contain these identifying words.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Forward-looking statements are based upon our current expectations and assumptions and are subject to a number of known and unknown risks, uncertainties and other factors that could cause actual results to differ materially and adversely from those expressed or implied by such statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under section "Item 1A - Risk Factors" of this Form 10-K. As a result, you should not place undue reliance on forward-looking statements.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Additionally, the forward-looking statements contained in this Form 10-K represent our views only as of the date of this Form 10-K (or any earlier date indicated in such statement). While we may update certain forward-looking statements from time to time, we specifically disclaim any obligation to do so, even if new information becomes available in the future. However, you are advised to consult any further disclosures we make on related subjects in the reports that we file with the SEC.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The foregoing cautionary statements are intended to qualify all forward-looking statements wherever they may appear in this Form 10-K. For all forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="sedc4874d90af49b0bb7d9053c60683d2"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">MARKET, INDUSTRY AND OTHER DATA</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This Form 10-K contains estimates, projections, market research and other information concerning our industry, our business, markets for XHANCE and our product candidates and the size of those markets, the prevalence of certain medical conditions, XHANCE market access and brand awareness, the perceptions and preferences of patients and physicians regarding certain therapies and other prescription, physician, patient and payor data. Unless otherwise expressly stated, we obtain this information from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources as well as from our own internal estimates and research and from publications, research, surveys and studies conducted by third parties on our behalf. Information that is based on estimates, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are reflected in this information. As a result, you are cautioned not to give undue weight to such information.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="s6A26FA8113B9529E9FD7A5A14E72F3BB"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PART I</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="s63835C3000085A1496B0CC03C6167DA9"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ITEM 1. BUSINESS</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Our Company</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">W</font><font style="font-family:Arial;font-size:10pt;">e are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;(fluticasone propionate) nasal spray, 93 mcg, is a therapeutic utilizing our proprietary Optinose Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). Chronic rhinosinusitis is a serious nasal inflammatory disease that is currently treated using therapies, such as intranasal steroids (INS), which have significant limitations. We believe XHANCE has a differentiated clinical profile with the potential to become part of the standard of care for this disease because it is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by current INS.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On September 18, 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18&#160;years of age or older.&#160;XHANCE was made widely available through retail channels in April 2018.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Since the FDA approval of XHANCE, we have focused on executing our integrated launch plan and have made progress in each of these key strategic areas: </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Customer Model</font><font style="font-family:Arial;font-size:10pt;">.&#160;We have defined a sales force footprint of approximately 120 territories targeting approximately 14,000 ENTs, allergists and &#8220;specialty-like&#8221; primary care physicians and have deployed a hybrid sales model that combines an internal sales leadership team with a fully-dedicated contract sales force to call on our target health care provider (HCP) customer universe. We prioritized approximately 80 territories within our sales force footprint to deploy in 2018 based upon pre-launch expectations regarding where we could achieve an estimated 65% commercial market access within each territory. The initial 80 territory managers were deployed in March 2018, actively engaging approximately 7,600 ENTs, allergists and "specialty like" primary care physician targets to promote XHANCE for the treatment of nasal polyps. During the first half of 2019, we plan to internalize our contract sales team and deploy an additional 20 territory managers in &#8220;XHANCE naive&#8221; geographies to expand our reach among our target physician audience. This is expected to grow the target audience for our sales team by approximately 25% to approximately 9,500 HCPs. We intend to eventually increase the size of our sales force to approximately 120 territory managers to expand our called on target audience to approximately 14,000 ENT, allergists and specialty-like primary care physicians. Additionally, we expect to target additional physicians through digital and non-personal promotion in areas where we do and do not have territory managers.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">XHANCE Patient Affordability Programs.</font><font style="font-family:Arial;font-size:10pt;">&#32;In late August 2018, we implemented our current co-pay savings program. We believe this program, with an indefinite duration, provides an affordability solution for patients that physicians will support. The current program provides patient co-pay assistance including a first prescription at no out-of-pocket cost to patients ($0 co-pay) to commercially insured patients and low subsequent co-pays for refills. Our data suggests these programs are playing a role in building demand for XHANCE, particularly as they become more widely understood in the prescribing community.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Market Access.</font><font style="font-family:Arial;font-size:10pt;">&#160; In meeting with pharmacy benefit managers (PBMs) and health insurers/potential payors, we share what we believe is a compelling economic value proposition. Our analyses suggest that XHANCE will have a comparatively low pharmacy budget impact and our clinical trial data suggest that XHANCE may produce an offsetting benefit by helping reduce other healthcare resource utilization, most notably</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the rate of endoscopic surgery and, therefore, surgery-related costs. For an insurance plan, this could represent potential for overall cost reduction in the population of patients with nasal polyps, as the overall cost of XHANCE could be less than the offsetting costs related to the reduction in surgeries.&#160;During clinical trials, XHANCE was also associated with an improvement in&#160;reported work productivity in treated patients, which should be valued by employers and patients.&#160;Further, we believe the cost of XHANCE to insurance plans will likely be significantly less than the projected costs of monoclonal antibodies that are currently in development for the treatment of nasal polyps, including dupilumab, for which the submission of an Supplemental Biologics License Application (sBLA)&#160;was recently publicly announced.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Based on currently available third-party data and our internal analyses, we believe that greater than 75% of commercially insured lives are currently in a plan in which XHANCE is covered in a Tier 3 formulary position, and approximately 60% of commercially insured lives are in a plan that covers XHANCE in a &#8220;low hassle factor&#8221; position. However, payors may change coverage levels for XHANCE or controls such as step edits and prior authorization (PAs), positively or negatively, at any time. We use the term &#8220;hassle factor&#8221; to characterize the level of difficulty that physicians and patients must overcome to prescribe and fill XHANCE. We define a low &#8220;hassle factor&#8221; as Tier 3 unrestricted, Tier 3 single step edit, or Tier 3 with a simple PA requiring, for example, only the prior use of an over-the-counter or generic INS - although we acknowledge that any step edit or PA involves a level of burden for physicians and patients that could negatively impact XHANCE utilization. Our initial goal was for 75% of commercially insured lives to have access to XHANCE in a Tier 3 formulary position with a &#8220;low hassle factor" by the end of 2018. While at approximately 60% "low hassle factor" at December 31, 2018 we did not meet this goal, it remains an important concept for us as we seek to expand overall coverage for XHANCE. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have also contracted with the Centers for Medicare and Medicaid Services for coverage of certain government insured lives and continue to expand XHANCE market access for other government-insured populations.&#160;As noted above, we have in place a co-pay assistance program for patients covered by commercial insurers and plan to continue to analyze affordability issues and assess patient affordability programs to appropriately support patient access to XHANCE for government insured patients.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Infrastructure.</font><font style="font-family:Arial;font-size:10pt;">&#160;We continue to develop our internal capabilities in a manner commensurate with having become a fully integrated and publicly traded commercial-stage specialty pharmaceutical company.&#160;We have implemented an enterprise resource planning system to expand our operational and commercial finance capabilities.&#160;We have also implemented a robust healthcare compliance program to guide our staff&#8217;s and our partners' compliance with rules and regulations regarding pharmaceutical sales. In managing our growth, we have remained focused on fostering our One Mission culture.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">XHANCE Prescriptions.</font><font style="font-family:Arial;font-size:10pt;">&#32;&#32;Based on third-party prescription data as well as data from preferred pharmacy network partners, the total estimated number of XHANCE prescriptions in the second quarter, third quarter and fourth quarter 2018 were 8,611, 9,427, and 14,106, respectively, which represents 50% growth for prescriptions when comparing fourth quarter to third quarter. Estimated XHANCE prescriptions in December 2018 and January 2019 were 4,570 and 6,292, respectively, which represents 38% month-over-month growth. In addition, XHANCE prescriptions for the 4-week periods ended January 25 and February 22, 2019 were 5,156 and 7,186, respectively, which represents period-over-period growth of 39%.  </font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">XHANCE Development Update</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition to XHANCE&#8217;s existing indication for the treatment of nasal polyps, in order to broaden our U.S. market opportunity we initiated a clinical research program in pursuit of a follow-on indication for the treatment of chronic sinusitis in the U.S. The program will comprise two phase 3b clinical trials, the first of which was initiated in the fourth quarter of 2018. We expect to initiate the second trial in 2019.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">The Unmet Need</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Chronic rhinosinusitis is a serious nasal inflammatory disease characterized by chronic inflammation affecting tissues high and deep in the nasal passages, including the area where the openings from the sinuses normally ventilate and drain. This disease significantly impacts the quality of life and daily functioning of an estimated 30&#160;million adults in the U.S. The U.S. healthcare system spends approximately $60&#160;billion annually in direct costs treating patients with chronic rhinosinusitis and its associated symptoms, including an estimated $5&#160;billion on sinus surgeries. In the U.S., physicians perform over 500,000 sinus surgeries each year, and we estimate that over seven&#160;million adults have undergone sinus surgery to treat chronic rhinosinusitis with and without nasal polyps.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In medical literature and medical practice, chronic rhinosinusitis is commonly divided into two subgroups: chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps. Chronic rhinosinusitis patients with and without nasal polyps suffer from chronic inflammation of the lining of the deep nasal passages and sinuses. Patients with chronic rhinosinusitis with nasal polyps also develop non-cancerous polyps on these chronically inflamed surfaces, typically originating in the deep crevices or sinus cavities on both sides of the nose. We estimate that up to 10&#160;million adults in the U.S. have chronic rhinosinusitis with nasal polyps.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Both subgroups of chronic rhinosinusitis share the same four defining diagnostic symptoms: nasal congestion/obstruction; facial pain and pressure; purulent runny nose and postnasal drip; and loss of sense of smell and taste. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Additional symptoms may include headaches, chronic sleep problems, fatigue, frequent episodes of acute rhinosinusitis and mood disorders. There is evidence suggesting that the harm to a sufferer's quality of life from chronic rhinosinusitis, as measured in multiple domains, such as bodily pain, social functioning and mental health, is comparable to or worse than other serious diseases, including chronic obstructive pulmonary disease, congestive heart failure and angina. As a result, many patients eventually seek surgery for symptom relief.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Although the term chronic rhinosinusitis is often used in medical literature and medical practice, the FDA does not recognize chronic rhinosinusitis as a single indication for drug development purposes. Instead, the FDA recognizes chronic sinusitis, defined as inflammation of the sinuses with a duration longer than eight weeks, and nasal polyps, defined as non-cancerous polyps on the inflamed tissue of the nasal passages and sinuses, as separate indications for drug development purposes. For purposes of this 10-K, we use the terms chronic sinusitis and nasal polyps when referring to FDA treatment indications and our clinical trials and use the term chronic rhinosinusitis with and without nasal polyps when referring to disease and economic data reported in the medical literature, medical practice and our estimates of XHANCE's market opportunity.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Current Treatment Limitations</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Multiple current clinical practice guidelines specify the use of INS early in the treatment algorithm for chronic rhinosinusitis with and without nasal polyps. Steroids are generally pharmacologically effective at treating inflammation. However, conventional INS, including nasal sprays and nasal aerosols, are topically-acting and unable to effectively and consistently place the steroids onto the primary site of inflammation and nasal polyp origin, high and deep in the nasal passages. These products deposit a majority of the drug in the front of the nose or on the floor of the nasal passages, reducing their effectiveness and leaving many patients without sufficient symptomatic relief. These recognized limitations cause some physicians to seek out alternative treatment regimens such as high-volume steroid nasal rinses. This approach, however, has not been well studied, is difficult to administer, can be costly and may risk systemic side effects. Physicians may also prescribe oral steroids on an episodic basis to patients who have not received sufficient symptomatic relief from INS. Oral steroids, which are often effective in reducing inflammation and nasal polyps, offer only temporary benefit and are limited by the risk of significant systemic side effects associated with both short- and long-term use.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In cases where patients remain symptomatic despite medical management, physicians often recommend various forms of sinus surgery to help restore normal sinus ventilation or drainage. The effectiveness of sinus surgery can vary significantly, many patients experience persistent or recurrent symptoms, and surgery may not address the underlying cause of inflammation. In patients with nasal polyps, regrowth of the nasal polyps has been reported in as high as 60% of cases within four years. In addition, it has been reported that up to 80% of patients continue to have symptoms within two years of surgery. Because sinus surgery is often not curative and may not address the underlying cause of the inflammation, many patients continue to receive short- and long-term courses of INS after surgery.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Our Solution</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">XHANCE combines an Optinose EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. In multiple studies utilizing advanced imaging, an Optinose EDS produced a differentiated pattern of drug delivery in healthy subjects with significant drug deposited in the high and deep regions of the nasal passages, areas not well accessed by conventional INS delivery mechanisms. We believe XHANCE has the potential to become part of the standard of care for the treatment of patients with chronic rhinosinusitis before they progress to more costly treatment alternatives. We also believe that the current treatment practice of postoperative INS use could support XHANCE's adoption as a maintenance therapy to improve outcomes following sinus surgery.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We conducted five clinical trials evaluating over 1,500 adult patients, including two randomized, double-blinded, placebo-controlled Phase&#160;3 pivotal clinical trials in adults with nasal polyps and two supportive open-label Phase&#160;3 clinical trials in adults with symptoms of chronic sinusitis with or without nasal polyps. In both Phase&#160;3 pivotal clinical trials, patients treated with XHANCE experienced statistically significant reductions of both nasal congestion/obstruction symptoms and total polyp grade, which were the co-primary endpoints. Treatment benefits were also observed in all four defining symptoms of chronic rhinosinusitis, as well as in polyp elimination (polyp grade 0), quality of life measures, need for sinus surgery and patient global impression of change. In addition, the magnitude of improvement for patients treated by XHANCE in our Phase 3 pivotal clinical trials, as measured by the Sinonasal Outcome Test-22, a validated clinical outcome assessment, was comparable to the reported benefits in third-party studies of endoscopic sinus surgery (ESS) and balloon sinus dilation. In our supportive open-label Phase&#160;3 clinical </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">trials, which evaluated approximately 900 patients with symptoms of chronic sinusitis with and without nasal polyps for a period of up to one year, XHANCE was generally well tolerated and produced results on efficacy endpoints similar to those observed in our Phase&#160;3 pivotal clinical trials. In these supportive trials, we observed comparable symptom improvements in patients with and without nasal polyps and continuing incremental polyp reduction and symptom improvement through 12&#160;months. XHANCE had an adverse event profile generally comparable to the profile reported in similarly designed trials with conventional INS.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We believe XHANCE offers a cost-effective treatment solution to payors who are increasingly being asked to pay for multiple high-cost therapies for a variety of diseases priced at tens of thousands of dollars per year. We priced XHANCE comparable to the only other branded INS that is currently approved to treat nasal polyps, but at a price higher than generic INS products. We expect XHANCE to be adopted by physicians at a natural point in the care pathway for use in patients with chronic rhinosinusitis with or without nasal polyps before they progress to costly surgical interventions or biologic monoclonal antibodies in development for nasal polyps. Sinus surgery costs on average $13,500 per procedure, and we expect that biologic monoclonal antibodies for the treatment of nasal polyps will cost approximately $37,000 per year based on the doses being studied in nasal polyps and the current costs per dose in other indications. We believe XHANCE will offer a cost-effective clinical benefit to payors that will reduce the perceived need for multiple step-edits and prior authorizations.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">U.S. Market Opportunity</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our initial target market for XHANCE consists of ENT physicians, allergists and primary care physicians in the U.S. that most frequently prescribe INS. This group of approximately 5,000 primary care physicians, which we refer to as "specialty-like" primary care physicians, account for approximately 25% of all INS prescriptions written by primary care physicians. We refer to these ENT physicians, allergists and high-decile INS-prescribing primary care physicians collectively as the specialty segment of our target market. We believe the approximately 15,000 physicians in this specialty segment together treat an estimated 3.5&#160;million U.S. patients with chronic rhinosinusitis, an estimated 1.2&#160;million of whom have chronic rhinosinusitis with nasal polyps. We believe the total annual U.S. market opportunity for XHANCE in this specialty segment is over $3.4&#160;billion, of which approximately one-third consists of patients with chronic rhinosinusitis with nasal polyps. If we are able to obtain approval for the follow-on indication of chronic sinusitis, we intend to broaden our commercialization efforts to target additional primary care physicians that we believe treat an additional estimated 6.25&#160;million U.S. patients with chronic rhinosinusitis, an estimated one-third of whom have chronic rhinosinusitis with nasal polyps. We refer to these additional primary care physicians as the primary care segment of our target market. We believe the total additional annual U.S. market opportunity for XHANCE in this primary care segment is over $6.0&#160;billion, of which approximately one-third consists of patients with chronic rhinosinusitis with nasal polyps. Therefore, we estimate the total annual U.S. market opportunity for the combined specialty and primary care segments is over $9.5&#160;billion, of which approximately one-third consists of patients with chronic rhinosinusitis with nasal polyps.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Intellectual Property and Barriers to Entry</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">XHANCE benefits from substantial intellectual property and other technical barriers to entry, including regulatory and drug delivery complexities. Our XHANCE U.S. patent portfolio consists of 13 issued device and method of use patents expiring through 2034, three issued design patents expiring through 2030 and 10 patent applications that, if granted, would expire through 2034. The 13 issued device and method of use patents are published in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.  </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We believe the unique features of an Optinose EDS, as well as its delivery of a topically-acting drug, will present generic and 505(b)(2) NDA competitors of XHANCE with human factors engineering challenges specific to drug-device combination products and chemistry, manufacturing and controls challenges unique to suspension and respiratory products. We also believe that any future substitutable generic competitors would be required to conduct, among other things, non-inferiority clinical trials demonstrating equivalent efficacy and safety outcomes to establish clinical bioequivalence to XHANCE. We believe these clinical trials would require a significant amount of time and capital investment and present clinical development uncertainties.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Our Management Team</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are led by a management team with an average of over 20 years of experience developing and commercializing products at large, multinational pharmaceutical and medical device companies, such as Johnson&#160;&amp; Johnson, Sanofi-Aventis, Bristol Myers-Squibb, Takeda and Novartis. Our management team's experience is complemented by its expertise at growing emerging healthcare companies, such as Cephalon, NuPathe and Take Care Health System. Our team previously developed our first product using an Optinose Exhalation Delivery System, Onzetra</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Xsail</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">. We believe the experience of our management team and our broad network of relationships with leaders within the industry and the medical community provide us with insight into product development and identification of product opportunities that benefit patients and physicians in the ENT and allergy specialty segments.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Our Growth Strategy</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our goal is to become a leading specialty pharmaceutical company dedicated to developing proprietary products that become a part of the standard of care for diseases in the ENT and allergy segments. We also plan to expand the use of Optinose EDS devices into additional indications with significant unmet needs, including potential nose-to-brain drug delivery for central nervous system disorders. The key elements of our strategy are to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Commercialize XHANCE in the ENT and allergy specialty segments in the U.S.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;When we launched XHANCE in 2018, we initially deployed a specialty sales force of approximately 80 territory managers to call on a defined prescriber base of approximately 6,000 ENT and allergy specialists, as well as approximately 1,500 "specialty-like" primary care physicians, and filled territories were based on regions where we predicted comparatively favorable early market access. Based on results showing growth in prescription volume in the called-on audience and considering increases in market access during 2018 and planned efforts to further increase market access for XHANCE in 2019, we intend to incrementally increase the size of our sales force. In the first half of 2019 we expect to field territory managers in approximately 20 additional territories, increasing coverage to 100 of the approximately 120 territory nationwide structure that was initially established. The 120-territory structure was based on a target audience of approximately 14,000 specialists or "specialty-like" primary care physicians. Additionally, we expect to continue to target physicians through digital and non-personal promotion in areas where we do and do not have territory managers. We believe that approximately 15,000 targeted physicians treat an estimated 3.5&#160;million chronic rhinosinusitis patients, an estimated 1.2&#160;million of whom have chronic rhinosinusitis with nasal polyps. With data suggesting that prescribing continues to be suitably responsive to promotion and as market access improves, we may continue to increase the size of our deployed sales team.  In addition, in 2019 we intend to execute a branded direct-to-consumer pilot in three cities targeting diagnosed and undiagnosed nasal polyp patients. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Pursue pipeline development of XHANCE for chronic sinusitis to broaden our market opportunity.</font><font style="font-family:Arial;font-size:10pt;">&#32;We plan to seek a follow-on indication for XHANCE for the treatment of chronic sinusitis.  We met with FDA and, in the fourth quarter of 2018, we initiated a Phase 3b clinical trial program in pursuit of that indication. We believe XHANCE would be the first drug therapy product approved for the treatment of chronic sinusitis. In the future, as appropriate, we plan to broaden our marketing to additional primary care physicians that we believe treat an additional estimated 6.25&#160;million patients in the U.S. with chronic rhinosinusitis, an estimated one-third of whom have chronic rhinosinusitis with nasal polyps. In addition, at some point in the future, we intend to consider directing promotional resources to an additional estimated 20&#160;million adult chronic rhinosinusitis sufferers who are not regularly under the care of physicians for this disease using programs such as direct-to-consumer and direct-to-patient promotion.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Develop a pipeline of additional products focused on the ENT and allergy specialty segments.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;We are evaluating the use of the Optinose EDS to deliver other proprietary drugs or drug combinations to treat diseases primarily managed by ENT and allergy specialists. We also intend to explore complementary drug, diagnostic or device technologies or products to make effective use of our commercial infrastructure. We plan to evaluate strategic licensing, acquisition, development and commercial partnerships that could increase our commercial efficiencies.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Explore business development activities for Optinose EDS outside of the ENT and allergy segments.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;We are exploring the possibility of the use of an Optinose EDS to support development of central nervous system treatments, particularly those enabled by nose-to-brain drug delivery. We have engaged in early stage clinical development activities for OPN-300, which combines an Optinose EDS with oxytocin with potential applications including treatment of Prader-Willi syndrome and autism spectrum disorder.  We have completed planned internal development activities for OPN-300 and may pursue external partnerships in the future for further development. In addition, in January 2019, we completed a licensing arrangement with Inexia Limited whereby we granted Inexia an exclusive license to our EDS devices and other intellectual property for the research, development and commercialization of products containing orexin receptor agonist and/or orexin receptor positive modulator molecules. Inexia has announced that specific target indications will be determined as the program advances, and is expected to include narcolepsy, a rare sleep disorder.  The Inexia License Agreement has the potential to create value </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-top:10px;"><font style="font-family:Arial;font-size:10pt;">in the form of milestones payments and royalties.  We may evaluate other business development activities to capture additional value through the development of Optinose EDS devices outside of ENT and allergy.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Expand XHANCE into international markets.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;We have engaged in initial assessment of potential development and commercialization of XHANCE in markets outside the U.S. and currently intend to remain opportunistic in pursuit of select international options. Upon receipt of additional data in the chronic sinusitis indication, we intend to more aggressively explore strategic collaboration opportunities in Europe and the rest of the world in order to maximize the commercial potential and the availability of XHANCE to patients.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Chronic Rhinosinusitis and Market Opportunity</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Chronic Rhinosinusitis</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Chronic rhinosinusitis is a serious nasal inflammatory disease significantly impacting patients' quality of life and daily functioning. Chronic rhinosinusitis, unlike allergic rhinitis, is characterized by chronic inflammation affecting tissues high and deep in the nasal passages, including the area where the openings from the sinuses normally ventilate and drain, causing symptoms that persist for a period of 8 to 12&#160;weeks or longer. Chronic rhinosinusitis patients typically suffer from these symptoms four to six months a year, with symptoms often persisting for many years.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In medical literature and medical practice, chronic rhinosinusitis is commonly divided into two subgroups: chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps. Chronic rhinosinusitis patients with and without nasal polyps suffer from chronic inflammation of the lining of the deep nasal passages and sinuses. Patients with chronic rhinosinusitis with nasal polyps also develop non-cancerous polyps on these chronically inflamed surfaces, typically originating in the deep crevices or sinus cavities on both sides of the nose. We estimate that up to 10&#160;million adults in the U.S. have chronic rhinosinusitis with nasal polyps. Both subgroups of chronic rhinosinusitis share the same four defining diagnostic symptoms: nasal congestion/obstruction; facial pain and pressure; purulent runny nose, and postnasal drip; and loss of sense of smell and taste. Additional symptoms may include headaches, chronic sleep problems, fatigue, frequent episodes of acute rhinosinusitis and mood disorders. There is evidence suggesting that the harm to a sufferer's quality of life from chronic rhinosinusitis, as measured in multiple domains, such as bodily pain, social functioning and mental health, is comparable to or worse than other serious diseases, including chronic obstructive pulmonary disease, congestive heart failure and angina. As a result, many patients eventually seek surgery for symptom relief.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Although the term chronic rhinosinusitis is often used in medical literature and medical practice, the FDA does not recognize chronic rhinosinusitis as a single indication for drug development purposes. Instead, the FDA recognizes chronic sinusitis, defined as inflammation of the sinuses with a duration longer than eight weeks, and nasal polyps defined as non-cancerous polyps on the inflamed tissue of the nasal passages and sinuses, as separate indications for drug development purposes.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The American Academy of Otolaryngology-Head and Neck Surgery estimates that approximately 30&#160;million adults in the U.S. have chronic rhinosinusitis, and it is estimated that up to 10&#160;million adults have chronic rhinosinusitis with nasal polyps. Chronic rhinosinusitis imposes a significant healthcare burden on insurers and employers. It has been reported that the U.S. healthcare system spends approximately $60&#160;billion annually in direct costs treating patients with chronic rhinosinusitis and its associated symptoms, including an estimated $5&#160;billion on sinus surgeries. In the U.S., physicians perform over 500,000 sinus surgeries each year, and we estimate that over seven&#160;million adults have undergone sinus surgery to treat chronic rhinosinusitis with and without nasal polyps. Chronic rhinosinusitis has been reported to account for an aggregate of 73&#160;million restricted activity days per year. Additionally, people with chronic rhinosinusitis have been reported to be absent from work because of this disease 6.5% of the time and to suffer a 38% loss of productivity.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">U.S. Market Opportunity</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We estimate that approximately 9.75&#160;million chronic rhinosinusitis patients are currently being treated in physician offices in the U.S. We derived this estimate from a large patient claims database that reflects actual treatment patterns of chronic rhinosinusitis over a two-year period from 2010 to 2012. We also estimate that approximately 10,000 ENT and allergy specialists, as well as approximately 5,000 "specialty-like" primary care physicians, treat approximately 36% of all chronic rhinosinusitis patients in the U.S., or approximately 3.5&#160;million patients, an estimated 1.2&#160;million of whom have chronic rhinosinusitis with nasal polyps. In accordance with multiple published clinical practice guidelines, physicians typically medically manage chronic rhinosinusitis patients by prescribing INS despite the fact that there are no FDA-approved products for the treatment of chronic sinusitis without nasal polyps. We have defined a sales force footprint of approximately 120 territories targeting approximately 14,000 ENTs, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">allergists and &#8220;specialty-like&#8221; primary care physicians. If we obtain FDA approval for the follow-on indication for chronic sinusitis, we intend to broaden our marketing outreach to additional primary care physicians that treat an additional estimated 6.25&#160;million U.S. patients with chronic rhinosinusitis, an estimated one-third of whom have chronic rhinosinusitis with nasal polyps. We may also direct promotional resources to an additional estimated 20&#160;million chronic rhinosinusitis sufferers who are not regularly under the care of physicians for this disease using programs such as direct-to-consumer and direct-to-patient promotion.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Based on internal estimates, we believe the total annual U.S. market opportunity for XHANCE in the specialty segment is over $3.4&#160;billion, of which approximately one-third consists of patients with chronic rhinosinusitis with nasal polyps. Based on these same estimates, we believe the total additional annual U.S. market opportunity for XHANCE in the primary care segment is over $6.0&#160;billion, of which approximately one-third consists of patients with chronic rhinosinusitis with nasal polyps. Therefore, we estimate the total annual U.S. market opportunity for the combined specialty and primary care segments is over $9.5&#160;billion, of which approximately one-third consists of patients with chronic rhinosinusitis with nasal polyps.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Treatment Landscape</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The treatment of chronic rhinosinusitis with and without nasal polyps typically begins with medical management. In cases where patients remain symptomatic despite medical management, physicians often recommend various forms of sinus surgery to help restore normal sinus ventilation and drainage. The following is a brief description of the current and potential future treatment landscape for chronic rhinosinusitis with and without nasal polyps:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:26px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Current Therapies</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Intranasal Steroids.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;Multiple published clinical practice guidelines generally recommend topically-acting INS as the first line of prescription therapy for the treatment of chronic rhinosinusitis with and without polyps. As a result, physicians typically prescribe INS nasal sprays or nasal aerosols despite the fact that there are no FDA-approved products for the treatment of chronic sinusitis without nasal polyps. Therefore, the majority of chronic rhinosinusitis sufferers being treated have tried INS. We estimate that physicians in the U.S. prescribe approximately 17&#160;million INS prescriptions each year for the treatment of chronic rhinosinusitis, which includes, among other INS products, a generic fluticasone propionate nasal spray. Nasonex, or mometasone furoate nasal spray, is currently the only other branded INS approved by the FDA for the treatment of nasal polyps. A generic version of Nasonex, mometasone furoate monohydrate, was approved by the FDA for, among other indications, the treatment of nasal polyps and launched in 2016. Physicians not only prescribe INS as a standalone therapy, but also typically prescribe INS following sinus surgery as some third-party clinical trials suggest that INS treatment can improve symptoms and delay symptom recurrence.  In lieu of prescription INS nasal sprays, physicians may recommend use of over-the-counter INS nasal sprays. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Oral steroids.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;Physicians may prescribe oral steroids on an episodic basis to patients who have not received sufficient symptomatic relief from INS. Oral steroids are often effective at treating the underlying inflammation associated with the disease and reducing postoperative scarring, but the benefit is temporary. As inflammation returns, many patients resume INS therapy.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Other medical management.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;Physicians commonly employ a variety of other non-surgical treatments in the medical management of chronic rhinosinusitis, including nasal saline rinses, multi-week courses of antibiotics, leukotriene antagonists, decongestants, aspirin desensitization and antifungals. The recognized limitations of drug deposition with current INS cause some physicians to seek out alternative treatment regimens, such as high doses of locally compounded liquid budesonide in high-volume nasal rinses. Chronic rhinosinusitis is one of the most common reasons for adult outpatient antibiotic use in the U.S., comprised of approximately 37&#160;million prescriptions per year.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Sinus surgery and other procedures.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;Physicians generally recommend surgical treatment of chronic rhinosinusitis with and without nasal polyps only after patients fail medical management. The primary surgical alternative is ESS, which attempts to open the sinus drainage pathways while preserving as much bone and sinus tissue lining as possible. The physician typically uses rigid steel instruments and powered cutting tools to remove inflamed tissue, including any nasal polyps, and underlying bone and cartilage to create a larger passage through the nasal anatomy to the sinuses. At the conclusion of the procedure, patients often have their nasal passages packed with a material that acts as a spacer to prevent surgical adhesions and control bleeding. Patients typically require one or more follow-up debridement treatments in </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-top:10px;"><font style="font-family:Arial;font-size:10pt;">which the physician may remove more tissue, crusting, scabs or scar tissue at the area of surgery in order to keep the sinus drainage pathway open and promote proper healing.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Several companies have developed less invasive technologies for the treatment of chronic rhinosinusitis since the introduction of ESS, such as balloon sinus dilation devices and steroid-releasing sinus implants. Balloon sinus dilation employs a high pressure inflated balloon to open blocked sinus pathways to increase ventilation and mucus drainage. Steroid-releasing sinus implants are used to hold open the surgically enlarged sinus, while releasing a steroid over a period of time in order to reduce postoperative sinus inflammation and scarring.</font></div><div style="line-height:120%;padding-top:10px;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition, SINUVA</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">TM</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;is a commercially available corticosteroid-eluting implant indicated for the treatment of nasal polyps in adult patients who have had ethmoid sinus surgery that can be placed in the ethmoid sinus under endoscopic visualization for up to 90 days. In the SINUVA clinical studies, patients were advised to use nasal steroid sprays and sinus rinses for the duration of the study.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:26px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Potential Future Therapies</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;padding-left:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Several biologic monoclonal antibodies, some of which are already approved for other indications, are being developed for the treatment of nasal polyps, and are believed to inhibit specific pathways of inflammation present in nasal polyps. These biologic monoclonal antibodies include omalizumab, reslizumab, mepolizumab and dupilumab.</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition, there are new small molecules, including fevipiprant, being developed for the treatment of nasal polyps, that are also believed to inhibit specific pathways of inflammation present in nasal polyps.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Limitations of Therapies</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The current and potential future therapies to treat patients suffering from chronic rhinosinusitis with and without nasal polyps have a number of limitations, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Limited efficacy of INS treatments using traditional nasal sprays and nasal aerosols.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;Although steroids are generally pharmacologically effective, conventional INS, including nasal sprays and nasal aerosols, are unable to effectively and consistently place the steroids onto the primary site of inflammation and nasal polyp origin, high and deep in the nasal passages. These products deposit a majority of the drug in the front of the nose or on the floor of the nasal passages, reducing their effectiveness and leaving many patients without sufficient symptomatic relief.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Short-term benefits of oral steroids outweighed by significant side effects.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;Oral steroids offer only temporary benefit and are limited by the risk of significant systemic side effects associated with both short- and long-term use. These side effects include, among others, weight gain; increased risk of infections; loss of bone mineral density; death of bone tissue; cataract formation; glaucoma; adrenal suppression; and psychiatric complications, including mania, depression, and psychosis.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Varying degrees of efficacy with other medical management.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;Other non-surgical treatments have varying degrees of supporting data and efficacy. In addition, high-volume steroid nasal rinses are difficult to administer, can be costly, may risk systemic side effects due to the absorption of the steroid into the body, can be associated with fluid draining from the nose after the procedure and are difficult for patients to comply with over prolonged courses of outpatient therapy.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Sinus surgery and other procedures are costly and may not be a complete solution.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;The effectiveness of sinus surgery varies significantly and many patients experience persistent or recurrent</font><font style="font-family:Arial;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">symptoms. Reports indicate that nasal polyp regrowth following surgery occurs in as high as 60% of cases within four years. In addition, it has been reported that up to 80% of patients continued to have symptoms within two years of surgery. Because sinus surgery is often not curative and may not address the underlying cause of the inflammation, many patients receive short- and long-term courses of INS after surgery and approximately 20% of patients elect surgical revisions. Postoperative scarring and persistent inflammation are common and can compromise symptom outcomes and also negatively impact the ability of the sinuses to heal. Sinus surgery is also a costly procedure, with estimated costs on average $13,500 per procedure. While balloon sinus dilation has the ability to open sinuses in a less invasive manner, it also may not address the underlying cause of the inflammation associated with chronic rhinosinusitis and is costly. Similarly, steroid-releasing sinus implants have limited duration of anti-inflammatory effect, are costly and face reimbursement challenges.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Potential future biologic monoclonal antibodies treatment may be costly, difficult to administer or have negative side effects.</font><font style="font-family:Arial;font-size:10pt;">&#32;The risks and benefits associated with the use of biologic monoclonal antibodies for the treatment of nasal polyps are not yet fully established. We expect the use of biologic monoclonal antibodies for the treatment of nasal polyps to be costly, with estimated costs of approximately $37,000 per year based on the doses being studied in nasal polyps and the current costs per dose in other indications. These drugs also require subcutaneous injections or intravenous administration that require frequent physician office visits. We believe the systemic nature of these treatments, which target components of the immune response, may result in more adverse side effects than treatments with topically-acting steroids.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Our Solution</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">XHANCE</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">XHANCE combines an Optinose EDS with a liquid formulation of fluticasone propionate, a potent, well-characterized, second-generation anti-inflammatory corticosteroid for the treatment of serious nasal diseases characterized by chronic inflammation, such as chronic rhinosinusitis. XHANCE is designed to deliver fluticasone propionate into the high and deep regions of the nasal passages where nasal polyps or inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. On September 18, 2017, the FDA approved our NDA for XHANCE for the treatment of nasal polyps in patients 18&#160;years of age or older. We initiated a phase 3b clinical trial of XHANCE in the fourth quarter of 2018 for a follow-on indication for the treatment of chronic sinusitis and expect to initiate a second phase 3b trial in 2019. Similar to our NDA for XHANCE for the treatment of nasal polyps, we believe we will be able to use the FDA's Section 505(b)(2) regulatory pathway for potential U.S. approval for XHANCE for the treatment of chronic sinusitis.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We believe XHANCE could become a part of the standard of care for the treatment of patients with chronic rhinosinusitis with and without nasal polyps before they progress to more costly treatment alternatives and could also be adopted as a maintenance therapy to improve outcomes following sinus surgery. We believe the following factors could contribute to the potential success of XHANCE:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">High patient dissatisfaction with current INS treatments.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;In a market research study that we commissioned, we surveyed 438 patients with chronic sinusitis with and without nasal polyps. In this study, approximately 80% of the patients reported being frustrated with the symptom relief offered from their current INS medication and approximately 90% of the patients reported they would be interested in using a new product if it would improve symptom relief.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Strong physician interest in XHANCE product profile.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;We surveyed approximately 700 physicians, consisting of 400&#160;ENT and allergy specialists and 300 primary care physicians that currently treat patients with chronic sinusitis with and without nasal polyps. Approximately 75% of these physicians, including both specialists and primary care physicians, agreed, in part, that INS medications do not work well in patients with chronic sinusitis due to their belief that conventional INS do not sufficiently reach the high and deep regions of the nasal passages where inflammation occurs. In addition, 70% to 80% of these physicians reported that they would "definitely" or "probably" prescribe their patients a product with a clinical profile similar to XHANCE. As of February 8, 2019, 4,920 healthcare professionals have prescribed XHANCE as a result of our direct selling efforts targeting approximately 7,500 physicians and indirect promotional efforts.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Fluticasone propionate is the most widely-prescribed INS in the U.S.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;XHANCE contains fluticasone propionate, a potent, well-characterized, second-generation, anti-inflammatory corticosteroid with a low bioavailability, meaning that only a small percentage of the drug is absorbed into the body. Corticosteroids provide multiple anti-inflammatory mechanisms of action and are used in forms such as pills, creams, inhalers and nasal sprays, to treat many sites of inflammation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">XHANCE was designed to overcome the limitations of current INS therapies by delivering medication high and deep in the nasal passages</font><font style="font-family:Arial;font-size:10pt;">. In multiple studies utilizing advanced imaging, an Optinose EDS produced a differentiated pattern of drug delivery with significant drug deposited at the primary site of inflammation high and deep in the nasal passages where nasal polyps or inflamed and swollen membranes produce nasal symptoms and can obstruct normal sinus ventilation and drainage.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Strong clinical data demonstrating safety and efficacy.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;In two randomized, double-blinded, placebo-controlled Phase&#160;3 pivotal clinical trials evaluating adult patients with nasal polyps, we met our co-primary endpoints of statistically significant reductions of nasal congestion/obstruction symptoms and total polyp grade. XHANCE also produced treatment benefits in all four defining symptoms of chronic rhinosinusitis, as </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-top:10px;"><font style="font-family:Arial;font-size:10pt;">well as in polyp elimination (polyp grade 0), quality of life measures, need for sinus surgery and patient global impression of change. In two supportive open-label Phase&#160;3 clinical trials evaluating approximately 900&#160;patients with symptoms of chronic sinusitis with and without nasal polyps for a period of up to one year, XHANCE was generally well tolerated. In these supportive trials, we observed comparable symptom improvements in patients with and without nasal polyps and continuing incremental polyp reduction and symptom improvement through 12&#160;months.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">XHANCE is easy to use.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;In a market study that we commissioned, 98% of patients reported that XHANCE was easy to use after four weeks of use and 93% stated the ease of use was comparable to other INS.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Potential for broad payor access.</font><font style="font-family:Arial;font-size:10pt;">&#160;Prior to the XHANCE launch in 2018, we commissioned a market research study that surveyed 26 health insurance plans representing over 150&#160;million covered lives. Most payors reacted positively to a profile of XHANCE with respect to its product design, mechanism of action and efficacy results based upon our clinical data. This research further suggested that market access for XHANCE would be dependent on XHANCE's pricing. A majority of payors surveyed in our study indicated that they do not intend to actively manage INS products priced below a certain dollar threshold and many surveyed payors indicated that they would provide access without prior authorization to INS products priced within a certain dollar range. The surveyed payors reported the following potential coverage based on the XHANCE profile: (i)&#160;no step edits on plans covering approximately 27% of commercial lives, meaning that payors would not require patients to use generic INS before seeking reimbursement for XHANCE, (ii)&#160;a single step edit on plans covering approximately 48% of commercial lives, (iii)&#160;a prior authorization requirement on plans covering approximately 10% of commercial lives and (iv)&#160;no coverage by plans covering approximately 15% of commercial lives.</font></div></td></tr></table><div style="line-height:120%;padding-top:10px;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Informed by the above study and formal pricing research, at launch XHANCE was priced comparable to the only other branded intranasal steroid indicated for the treatment of nasal polyps, at their nasal polyp dose. We are actively engaging payors to secure broad market access for XHANCE in the commercial segment by targeting Tier&#160;3 payor coverage, single step edit with no prior authorization. This level of coverage indicates that payors would require patients to use a generic INS as a first step in treating their disease prior to the payor covering XHANCE. However, such coverage would not require the prior authorization of the payor. Tier&#160;3 payor coverage requires a patient co-pay that is higher than that required for generics or drugs within a payor's formulary. Greater than 75% of commercial plans cover XHANCE as of December 31, 2018. We believe we are on track to achieve similar levels of commercial market access as indicated from our pre-launch payor market research. We intend to contract with Commercial, Medicare Part D plans and Medicaid to accelerate physician adoption of XHANCE.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Cost-Effective Solution.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;We launched XHANCE with a price comparably to the only other branded INS that is approved to treat nasal polyps, but at a price higher than generic INS products. We believe XHANCE offers a cost-effective, clinical benefit to payors when compared to surgery and expensive monoclonal antibodies and that this benefit will reduce the perceived need for multiple step-edits and prior authorizations, which we believe will increase the likelihood of successful commercial adoption of XHANCE.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Optinose EDS</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our Optinose EDS devices enable the development of drug-device combination products intended for self-administration. We have developed both a liquid delivery system and a powder delivery system utilizing natural functional behaviors of the upper nasal airways to offer better drug deposition. These systems are designed to overcome many limitations inherent in conventional nasal spray and nasal aerosol delivery systems, most notably, enabling higher and deeper intranasal drug delivery.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:26px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Liquid EDS</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The liquid EDS depicted below, which is the EDS used in XHANCE, consists of the primary drug container for the liquid drug formulation, an amber glass vial sealed by a crimp-fitted metering spray pump, enclosed within a proprietary liquid delivery subassembly. The nasal spray applicator, which is a component of the subassembly, is attached to the pump and extends to the top of the nosepiece of the liquid delivery subassembly. The EDS includes a flexible mouthpiece and an asymmetrically-shaped nosepiece as part of a mechanism that uses the patient's exhaled breath to naturally seal closed the soft palate and to facilitate delivery of drug to the nasal passages through the sealing nosepiece. The nosepiece is designed to create a seal with the nostril and also to expand and stent the upper part of the nasal valve, which is an important anatomical structure that is the narrowest part of the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">entire respiratory tract and a barrier that causes most medication delivered by conventional INS to deposit in the front part of the nose.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;"><img src="capture.jpg" alt="capture.jpg" style="height:356px;width:193px;"></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:26px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Powder EDS</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The powder EDS depicted below, which is the EDS used in Onzetra Xsail, consists of a reusable device body incorporating a flexible mouthpiece to adjust to individual anatomic variations, and a white button piercing assembly to pierce the medication capsule. Disposable nosepieces are provided in a foil pouch to be inserted into the drug delivery device body. Each pre-filled nosepiece section contains a medication capsule containing a dry powder formulation and a clear release tab. The capsule is pierced by pressing and releasing the white button piercing assembly. The flexible mouthpiece and an asymmetrically-shaped nosepiece are part of the mechanism that uses the patient's exhaled breath to naturally seal closed the soft palate and to facilitate delivery of drug to the nasal passages through the sealing nosepiece. The medication capsule is intended for single dose administration and is not refillable or removable from the nosepiece.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Following drug administration, the disposable nosepiece, including the dose-expended medication capsule, is then removed and discarded.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;"><img src="powderedsa02.jpg" alt="powderedsa02.jpg" style="height:337px;width:240px;"></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:26px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:26px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">How an Optinose EDS works</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">When exhaling into an EDS, the soft palate automatically elevates and creates an air-tight seal separating the nasal cavity from the throat and lungs. This natural action is the same as that which prevents air from escaping from the nose when trying to blow up a balloon or blow a trumpet. The exhaled air is then routed through the EDS which introduces medication into the air flow and then directs the air and medication through the sealing nosepiece. The positive air pressure, which is the opposite of the negative pressure produced by sniffing with ordinary nasal sprays, acts to dynamically expand the nasal valve and the narrowed nasal passages, helping to deliver the drug around obstructing anatomic barriers and fill one side of the nasal cavity. This enables high and deep deposition of medication in the nasal passages. The positive air pressure, proportional to the pressure on the other side of the soft palate, helps to open a passage between the two sides of the nasal cavity, behind the back edge of the nasal septum. The picture below illustrates this action, which allows the exhaled air pressure to escape from the opposite nostril.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;"><img src="edsworksa01.jpg" alt="edsworksa01.jpg" style="height:259px;width:684px;"></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The drug delivery mechanism of an Optinose EDS is designed to overcome the drug deposition shortcomings of conventional nasal sprays and nasal aerosols. In conventional nasal sprays and nasal aerosols, the medication is inhaled or sniffed into the nose creating negative pressure within the nasal passages, which does not facilitate the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">expansion of the nasal valve or the nasal passages and may obstruct the drug from reaching deep into the nose where most nasal polyps and inflamed and swollen sinus membranes exist.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The pattern of drug deposition produced by conventional nasal sprays and an Optinose EDS has been evaluated in multiple studies using a combination of advanced imaging modalities to depict the regions of the nasal passages where drug is deposited after administration in healthy human volunteers. In an open label, crossover study conducted by a third party in nine patients with allergic rhinitis, investigators examined the nasal deposition of radio-labeled materials that allow for traceability following use of Qnasl (HFA-beclomethasone, nasal aerosol), Flonase (fluticasone propionate, nasal spray) and Nasonex (mometasone furoate monohydrate, nasal spray). In this study, gamma cameras were used to capture emitted radiation from these tracers to create two-dimensional images in a similar process to the capture of x-ray images. These gamma images were merged with magnetic resonance images (MRI) to quantify regional deposition within the nasal passages. The images below illustrate how the pattern of drug deposition in the nasal passages produced by Qnasl, Flonase and Nasonex was concentrated in the front and lower regions of the nasal passages, as opposed to the high and deep regions of the nasal passages targeted in the treatment of chronic rhinosinusitis.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;"><img src="gammamria01.jpg" alt="gammamria01.jpg" style="height:147px;width:684px;"></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:26px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Reprinted with permission from JOURNAL OF AEROSOL MEDICINE &amp; PULMONARY DRUG DELIVERY 28/8, 2015, by Leach et al, published by Mary Ann Liebert, Inc., New Rochelle, NY.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We conducted six deposition studies evaluating 53 healthy subjects that produced approximately 250 images. As depicted in the representative figures below, an Optinose EDS produced a differentiated pattern of drug delivery with significantly more drug deposited in the high and deep regions of the nasal passages.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;"><img src="gammamri2a01.jpg" alt="gammamri2a01.jpg" style="height:284px;width:588px;"></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:26px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">The pictures above use gamma camera image information, which was then superimposed on the corresponding MRI section. These images represent deposition in healthy subjects two minutes after delivery using a traditional liquid nasal spray and a version of our liquid EDS device. Deposition with traditional liquid nasal spray was greatest in the front parts of the nose, whereas deposition with an Optinose EDS was greatest in the high and deep regions of the nose.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The pictures below illustrate how an Optinose EDS (with exhalation) places medication higher and deeper in the nasal passages than a conventional nasal spray (without sniffing) in nasal cast models.  As depicted below, although conventional nasal spray systems can reach, and therefore treat, large nasal polyps, they are not </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">generally suitable for reaching nasal polyps or inflammation in the higher and deeper regions where obstruction of the sinus openings occurs.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;"><img src="nasalpassagea01.jpg" alt="nasalpassagea01.jpg" style="height:207px;width:684px;"></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">An Optinose EDS is also designed to address user dissatisfaction with standard nasal delivery by reducing drug drip-out from the front and back of the nose and the bad taste that often accompanies drug entering the throat. By reducing the loss of drug to non-targeted sites, such as the gastrointestinal tract by swallowing, or lungs, an Optinose EDS has the potential to improve the efficiency of drug activity and to improve tolerability by reducing off-target effects.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Our Pipeline</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;"><img src="pipeline2019a04.jpg" alt="pipeline2019a04.jpg" style="height:406px;width:621px;"></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">XHANCE for Chronic Sinusitis</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We initiated a Phase 3b clinical trial program for XHANCE in the fourth quarter of 2018 to pursue a follow-on indication for the treatment of chronic sinusitis. We believe XHANCE would be the first drug therapy product approved for the treatment of chronic sinusitis. In the future, as appropriate, we intend to broaden our commercialization efforts to additional primary care physicians that we believe treat an additional estimated 6.25&#160;million U.S. patients with chronic rhinosinusitis, an estimated one-third of whom have chronic rhinosinusitis with nasal polyps. In addition, at some point in the future, we intend to consider directing promotional resources to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">an additional estimated 20&#160;million adults who are not regularly under the care of physicians for this disease using programs such as direct-to-consumer and direct-to-patient promotion.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Other Product Candidates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Although our initial focus is to prioritize the successful commercialization and continued development of XHANCE for the ENT and allergy specialty segments, we have applied an Optinose EDS to other product candidates in our pipeline across a broad range of disease areas. By placing drug high and deep in the nose, in regions where cranial nerves connect directly with the brain, we believe it may be possible to deliver medications directly into the brain and avoid the difficulties of getting drug past the blood-brain barrier. This may enable treatment of brain diseases using small or large molecules that otherwise do not readily enter the nervous system.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:26px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">OPN-300</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have engaged in early clinical development activities for OPN-300, which combines an Optinose EDS with oxytocin. Oxytocin is a small, naturally occurring peptide currently used to stimulate lactation in breastfeeding women. Oxytocin acts as a neurotransmitter in the brain and has recently been considered a potential novel treatment alternative in several brain disorders due to a growing body of evidence of its critical role in social cognition and behavior. Because oxytocin is a peptide with poor oral bioavailability, nasal administration with an Optinose EDS may allow for improved delivery. With standard liquid nasal spray delivery, only a small amount of the drug reaches systemic circulation. It is estimated that less than 0.01% of oxytocin in the blood enters the brain across the blood-brain barrier.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">OPN-300 has been developed to target two orphan indications: Prader-Willi syndrome, a rare genetic disorder that is the leading genetic cause of obesity; and autism spectrum disorder. We conducted a Phase&#160;1 clinical trial in late 2013 using OPN-300 in healthy volunteers. In that trial, a low dose of oxytocin delivered using an Optinose EDS produced a statistically significantly greater social-cognitive effect as measured with functional magnetic resonance imaging, performance on cognitive tests, and physiological markers, than intravenous administration of the same active ingredient that produced blood levels that were not statistically different. We believe this clinical trial supports the possibility of direct nose-to-brain activity of medication delivered using an Optinose EDS. In a second pilot clinical trial of OPN-300 in adult male patients with autism spectrum disorder, adult men with autism spectrum disorder receiving nasal oxytocin showed statistically significant differences in interpretation of facial expressions. We have completed planned internal development activities and in the future may pursue external partnerships for further development.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:26px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Other</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are evaluating the use of the Optinose EDS to deliver other drugs or drug combinations to treat diseases primarily managed by ENT and allergy specialists, and we opportunistically evaluate opportunities to develop product candidates using our EDS intellectual property for indications and markets outside of our ENT and allergy focus through business development and partnering activities.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Our Commercial Strategy</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are implementing our commercial strategy for XHANCE to focus on the following four phases of penetrating the chronic rhinosinusitis markets and becoming part of the standard of care treatment:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Efficient entry in the ENT and Allergy specialty segments:</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;In 2018 we deployed an efficient, go-to-market commercialization model, including the build-out of our commercial team and organization. Our fully-dedicated specialty sales force of approximately 80 territory managers initiated promotion of XHANCE in March 2018 to a defined prescriber base of approximately 6,000 ENT and allergy specialists, as well as approximately 1,500 "specialty-like" primary care physicians. During the first half of 2019, we plan to internalize our contract sales team and deploy an additional 20 territory managers in &#8220;XHANCE naive&#8221; geographies to expand our reach among the ENT and allergy specialty universe. This is expected to grow the target audience for our sales team by approximately 25% to approximately 9,500 healthcare providers. Because we expect to continue to secure broader market access over time, we intend to eventually increase the size of our sales force to approximately 120 territory managers based upon an expanded target audience of approximately 14,000 specialists or "specialty-like" primary care physicians. Additionally, we expect to target additional physicians through digital and non-personal promotion in areas where we do and do not have territory managers. We believe that approximately 15,000 physicians treat an estimated 3.5 million chronic rhinosinusitis patients, an estimated 1.2 million of whom have chronic rhinosinusitis with nasal polyps. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Targeted patient demand generation:</font><font style="font-family:Arial;font-size:10pt;">&#32;In 2019, we intend to execute a branded, multi-channel direct to consumer (DTC) pilot in three cities targeting diagnosed and undiagnosed nasal polyp patients. Based upon extensive patient research, we believe a high level of frustration exists among nasal polyp patients and these patients are motivated to seek new treatments to relieve their suffering. If successful, we anticipate broadening the DTC pilot to a national campaign in 2020.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Facilitate broader adoption:</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;We are pursing a follow-on indication for XHANCE for the treatment of chronic sinusitis. If approved for the follow-on indication, we intend to broaden our commercialization efforts to target primary care physicians that we believe treat an additional estimated 6.25&#160;million U.S. patients with chronic rhinosinusitis, an estimated one-third of whom have chronic rhinosinusitis with nasal polyps. We may target these physicians through a commercial partnership.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Activate broad patient demand:</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;At some point in the future, we intend to consider directing promotional resources to an additional estimated 20&#160;million chronic rhinosinusitis sufferers who are not regularly under the care of physicians for this disease using programs such as direct-to-consumer and direct-to-patient promotion.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are efficiently commercializing XHANCE into the ENT and allergy specialty segments by utilizing the following strategies:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Define a clear patient type for XHANCE.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;We are focusing on moderate-to-severely symptomatic nasal polyp patients who have not achieved satisfactory results with currently available INS.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Establish a compelling brand position in the medical continuum of care.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;In an effort to establish our brand position within the continuum of care, we are, among other things, educating physicians, payors and patients on XHANCE's unique mechanism of action and differentiated efficacy profile.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Develop a meaningful payor and patient-friendly value proposition.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;We are establishing a meaningful value proposition for physicians, payors and patients by highlighting the potential for XHANCE to reduce or delay the need for surgical intervention, reduce antibiotic prescribing and increase patient satisfaction with treatment outcomes. We believe the health economic data related to XHANCE are compelling.&#160;Our analyses show that XHANCE will have a comparatively low pharmacy budget impact and our clinical trial data suggest that XHANCE may produce an offsetting benefit by helping reduce the rate of surgery and its related costs. For an insurance plan, this could represent a potential overall cost reduction for the population of patients with chronic rhinosinusitis with nasal polyps, as the overall cost of XHANCE would be less than the offsetting costs related to the reduction in surgeries.&#160;During clinical studies, XHANCE was also associated with an improvement in&#160;reported work productivity in treated patients, which should be valued by employers and patients.&#160;In addition, we believe the cost of XHANCE to insurance plans will likely be significantly less than the projected costs of monoclonal antibodies that are currently in development for the treatment of nasal polyps.&#160;Furthermore, we developed and implemented a patient affordability program that reduces the real and perceived economic barriers for patients to experience the potential benefits of XHANCE.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition to our affordability program we offer patients the option of filling prescriptions through a network of preferred pharmacies that may be able to better serve the needs of patients through services including delivery of XHANCE by mail.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Drive awareness, adoption and access.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;We are engaging with physicians and payors to educate both constituencies about XHANCE and its benefits, with the goal of securing broad market access for XHANCE through specialty and retail pharmacies.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Physicians:</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;In early March 2018, we trained and deployed a dedicated sales force of 80 territory managers to promote XHANCE to our target audience of ENTs, allergists and "specialty-like" primary care physicians. The focus of the sales team is to (i) highlight the unmet medical need and limitations of current treatments,&#160;(ii) define the target nasal polyp patient type for XHANCE, (iii) differentiate EDS and highlight the strong data supporting the efficacy of XHANCE and, (iv)&#160;ensure HCP awareness and appreciation of the XHANCE patient affordability program. In April 2019, we plan to increase our sales force by 20 territory managers and expand our reach within our target physician audience by approximately 25%.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Payors:</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;We continue to engage with payors with the objective of securing broad market access in the commercial segment by targeting Tier&#160;3 payor coverage, single step edit with no prior authorization. Specifically, we are targeting pharmaceutical benefit managers, national plans and regional plans representing, in the aggregate, up to approximately 160&#160;million of the estimated 180&#160;million U.S. covered commercial lives. We also intend to contract for Medicare Part D and Medicaid lives.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Patients:</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;We have completed the build-out of a patient and physician support ecosystem in an effort to accelerate physician adoption and reduce the risk of patient abandonment during the fulfillment process. This ecosystem includes (i)&#160;patient samples, (ii)&#160;a co-pay assistance program for patients who have commercial coverage, (iii)&#160;savings cards for cash payors, (iv)&#160;reimbursement support programs for the retail channel, (v)&#160;a supplemental distribution channel through preferred pharmacy network partners to assist patients with the complexities of the payor landscape, and (vi)&#160;a patient assistance program to provide access to XHANCE to people who have no or inadequate insurance.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Since FDA approval on September 18, 2017, the commercial team has been executing a launch plan to drive awareness and appreciation of the clinical differentiation of XHANCE, designing and implementing our customer model to drive physician trial and adoption, and building market access for XHANCE to facilitate adoption and fulfillment through specialty and retail pharmacies. Our progress across each of these key strategic areas is described below:</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Drive product awareness and appreciation of the clinical differentiation of XHANCE</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Executed broad multi-channel awareness campaign leveraging digital, non-personal promotion, journal advertising, and an 85 person nurse educator team calling on a universe of about 7,000 ENT and allergists and achieved 87% aided branded awareness of XHANCE among the ENT and allergy specialist universe prior to launch.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Finalized XHANCE core marketing strategies and launch tactic including a compliant, value optimizing and cost-effective promotion mix to appropriately engage our target audience</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the early launch phase of XHANCE, we introduced the XHANCE Xperience program to offer physicians and their patients an opportunity to gain initial experience with XHANCE. As part of this program, patients received up to two XHANCE prescriptions at no out-of-pocket cost to them ($0 co-pay). In order to receive the second prescription, patients were required to complete a brief survey regarding their use of XHANCE. The survey results were encouraging and also provided physicians an opportunity to receive individual feedback on early patient responses to treatment. As planned, we closed the Xperience program to new enrollments at the end of June 2018.  From March 2018 through June 2018, over 11,000 patients were prescribed XHANCE through the XHANCE Xperience program by over 3,000 physicians.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Based upon a quantitative Awareness, Trial and Usage (ATU) market research study that we commissioned in January 2019, a majority of ENT and allergy specialists in our target audience, believed that XHANCE performed better on several efficacy measures than traditional intranasal steroids (e.g. Flonase) including improvement of four core symptoms of CRS with nasal polyps (congestion, rhinorrhea, facial pain and pressure and loss of sense of taste/smell), reduction in nasal polyp grade, polyp elimination, and improvement in quality of life.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Design and deploy our customer facing model to drive physician trial and adoption</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Designed hybrid sales model that leverages a fully dedicated contract sales organization reporting into an Optinose Sales Leadership Team</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Defined footprint of approximately 120 territories that will ultimately target approximately about 14,000 ENTs, allergists and &#8220;specialty like&#8221; primary care physicians </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Recruited, hired and trained 11 Optinose Regional Business Directors with an average of approximately 11 years of sales leadership experience </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In partnership with our contract sales organization, approximately 80 territory managers were recruited, hired and trained. The territory managers have an average of 13 years of pharmaceutical sales experience and over 70% have experience in the respiratory therapeutic category. The </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:8px;text-align:left;"><font style="font-family:Arial;font-size:10pt;">territory managers were deployed in early March 2018 in geographies where we expected to have greater than 65% coverage of commercial lives during launch. </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In April 2019, we plan to expand our sales force by 20 territory managers to call on an incremental 1,800 "XHANCE naive" physicians. We also intend to internalize the contract sales force in April 2019.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Engage commercial payors with the objective of securing tier 3 commercial coverage</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Developed</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:10pt;">compelling economic value proposition </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Created value pack, budget impact model, supporting health economics and outcomes research (HEOR) payor messages and payor partnership models</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Completed pricing study to inform pricing decision and contracting strategy and launched with a Wholesaler Acquisition Cost (WAC) of $425 per unit of XHANCE. As of January 1, 2019, the WAC price for XHANCE was $468.12 per unit.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Created HEOR-related communication tools for use with payors </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Completed development of our clinical and economic evidence of pharmaceuticals in support of formulary consideration using the Academy of Managed Care Pharmacy (AMCP) Dossier format</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Engaged with approximately 40 plans representing approximately 85% of commercial lives</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Introduced co-pay assistance program and other patient affordability programs to appropriately support patient access to XHANCE</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Based on currently available third-party data and our internal analyses as of December 31, 2018, we believe greater than 75% of commercially insured lives in the U.S. are plans that cover XHANCE in a tier 3 position</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">XHANCE Clinical Development</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We evaluated XHANCE in the following five clinical trials comprised of over 1,500 patients:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">two randomized, double-blinded, placebo-controlled Phase&#160;3 pivotal clinical trials designed to compare the safety and efficacy of XHANCE to a placebo EDS in adults with bilateral nasal polyps, which we refer to as NAVIGATE I and NAVIGATE II or collectively, our pivotal clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">two open-label Phase&#160;3 clinical trials to evaluate the safety of XHANCE in adults with symptoms of chronic sinusitis with or without nasal polyps, which we refer to as EXHANCE-3 and EXHANCE-12 or collectively, our supportive clinical trials; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">one Phase&#160;1, open-label, randomized, single-dose, bioavailability study to compare the bioavailability of fluticasone propionate from XHANCE to Flonase and Flovent HFA in healthy patients and patients with mild-to-moderate asthma.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Clinical Trial Highlights</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our Phase&#160;3 clinical development program included a population of patients generally reflective of our intended patient population, with approximately 90% having previously tried INS therapy and almost one-third having previously undergone sinus surgery. Key results from our Phase 3 clinical trial program include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In our pivotal clinical trials, XHANCE produced statistically significant benefits on both of the co-primary endpoints: a reduction of nasal congestion/obstruction symptoms at week&#160;4 and a reduction in total polyp grade at week&#160;16.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Patients with nasal polyps generally experienced greater improvements in symptoms and reductions in polyp grade with longer duration of use.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In our pivotal clinical trials, approximately 16% of patients treated with XHANCE had nasal polyps eliminated (polyp grade 0) in at least one nostril after 16&#160;weeks of treatment, and approximately 27% had nasal polyps eliminated in at least one nostril after an additional eight weeks of treatment. In our supportive </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-top:10px;"><font style="font-family:Arial;font-size:10pt;">clinical trials, we observed complete response rates in at least one nostril of 48% of patients in EXHANCE-3 and 47.1% of patients in EXHANCE-12.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In our pivotal clinical trials, XHANCE produced improvement across all four defining symptoms of chronic rhinosinusitis.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Over 85% of patients receiving XHANCE across our pivotal clinical trials reported improvement, and approximately two-thirds reported being "much" or "very much" improved, compared to approximately one-third of patients in the placebo EDS group. In our supportive clinical trials, approximately 70% of patients with symptoms of chronic sinusitis, both with and without nasal polyps, reported that they were "much" or "very much" improved after treatment with XHANCE.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On a Sinonasal Outcome Test-22, the improvement with the 186- and 372-microgram (mcg) doses of XHANCE was superior to the placebo EDS in both NAVIGATE I and NAVIGATE II. The magnitude of improvement associated with treatment with XHANCE was approximately 20&#160;points. Although cross-trial comparisons have significant limitations and must be interpreted with caution, in a previous third-party study evaluating a large cohort (n=1468) of patients who were underwent sinus surgery, the degree of change on this outcome measure was approximately 18&#160;points.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">After 12&#160;months of treatment with XHANCE in our supportive clinical trials, at least 50% of patients had a Sinonasal Outcome Test-22 score that was at or below 9.3, which is the average score that has been reported for healthy individuals.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">XHANCE was well tolerated and had an adverse event profile generally similar to that observed in several comparably designed third party studies, including those of mometasone furoate in nasal polyps patients and of fluticasone propionate formulations in nasal polyp and allergic rhinitis patients.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Phase&#160;3 Pivotal Clinical Trials (NAVIGATE I and NAVIGATE II)</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have conducted two independent but comparable randomized double-blinded, placebo controlled Phase&#160;3 clinical trials to examine the safety and efficacy of XHANCE versus a placebo EDS in adults with bilateral nasal polyps and moderate nasal congestion/obstruction. These clinical trials, which we refer to as NAVIGATE I and NAVIGATE II, also provided dose-ranging information to support the selection of clinically appropriate dose(s) for commercialization of XHANCE and served as pivotal clinical trials in our NDA for the treatment of adults with nasal polyps. These pivotal clinical trials were conducted in the U.S., Canada, South Africa and several European countries.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:26px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Study Design</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Each pivotal clinical trial included a single-blind EDS-placebo lead-in and a placebo EDS control group, a multi-center, multi-national study population to increase generalizability, an assessment of the efficacy of multiple doses (93, 186 or 372 mcg twice daily) over a 16-week period and experts in nasal endoscopy to assess objective efficacy outcomes and adverse events (AEs) in all patients. Patients who completed the double-blinded phase of the pivotal clinical trials were allowed to continue in an open-label extension phase in which all patients received 372 mcg of XHANCE twice daily for up to eight additional weeks. All patients and investigators remained blinded to the original treatment during the open-label phase, allowing for a comparison of as-randomized initial treatments through the end of the open-label extension phase at week 24. We treated a total of 646 adults across both pivotal clinical trials with 568 adults completing the open-label extension phase.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Each of NAVIGATE I and NAVIGATE II had co-primary endpoints of (i)&#160;change in subjective nasal congestion/obstruction symptoms from baseline to week 4 and (ii)&#160;change in objectively-measured total (bilateral) nasal polyp grade from baseline to week 16. The severity of nasal symptoms was recorded by patients in an electronic diary immediately before dosing in the morning (AM) and evening (PM), and was measured using 7-day average instantaneous AM diary scores. Total (bilateral) nasal polyp grading was assessed with nasoendoscopy and is based on polyp protrusion past certain anatomical landmarks. These grading assessments were performed at screening (baseline) and at weeks 4, 8, 12, 16 (which was the end of the double-blinded phase) and 24 (which was the end of the open-label phase) using a 0 to 3 point scale for each nostril, with 0 representing no polyps and 3 representing severe polyposis. The scores for each nostril were summed to yield a range of 0 to 6 for both nostrils.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">These trials also evaluated several secondary endpoints, including the impact of XHANCE treatment on surgical eligibility and changes in the Sinonasal Outcome Test-22 score, which considers the core defining signs and symptoms of nasal polyps and the impact on functioning, quality of life and sleep. We also conducted a complete </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">response analysis to evaluate the percentage of patients with a recorded nasal polyp grade of zero on at least one side of the nasal cavity.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:26px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Efficacy Results</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The 186- and 372-mcg treatment groups achieved statistically significant reductions in the primary assessments of congestion severity at week 4 and reductions in polyp grade at week 16 relative to a placebo EDS. In NAVIGATE I, the differences from the placebo EDS generally increased with each increasing dose of XHANCE for both co-primary endpoints, meaning that administering higher doses to a patient led to a greater decrease in nasal congestion/obstruction symptoms and bilateral nasal polyp grade. In NAVIGATE II, the 186-mcg group achieved the largest numerical reduction in the primary assessment of congestion symptom severity, and the 372-mcg group achieved the largest numerical reduction in the primary assessment of polyp grade. On average, patients in both pivotal clinical trials had moderate nasal polyps (with an average bilateral score of approximately 3.9) at baseline. Patients treated with 372 mcg had the largest mean change in polyp grade in each pivotal clinical trial, with decreases in grade after 16&#160;weeks of 1.1 and 1.4 in NAVIGATE I and NAVIGATE II, respectively. There was also a consistent decrease in average polyp grade over time through 24&#160;weeks.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes the mean change in congestion scores in each of the pivotal clinical trials:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Mean Changes from Baseline in AM Congestion Score After 4 Weeks of Treatment in</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Adult Patients with Nasal Polyps</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Difference from Placebo EDS</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">N</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Baseline Score</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Standard</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Deviation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Mean (Standard</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Error) Change</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">from Baseline</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Mean</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">95%</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">confidence</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">interval</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">p-value</font><font style="font-family:inherit;font-size:6pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">NAVIGATE I</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">XHANCE&#160;372 mcg</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">79</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.29 (0.44)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8211;0.62 (0.08)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8211;0.38</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8211;0.57, &#8211;0.19</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&lt;0.001</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">XHANCE&#160;186 mcg</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.24 (0.42)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8211;0.54 (0.08)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8211;0.30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8211;0.48, &#8211;0.11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.002</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Placebo EDS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.31 (0.41)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8211;0.24 (0.07)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">NAVIGATE II</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">XHANCE&#160;372 mcg</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.25 (0.42)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8211;0.62 (0.07)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8211;0.38</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8211;0.58, &#8211;0.18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&lt;0.001</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">XHANCE&#160;186 mcg</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.20 (0.37)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8211;0.68 (0.07)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8211;0.45</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8211;0.65, &#8211;0.25</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&lt;0.001</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Placebo EDS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">79</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.29 (0.43)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8211;0.24 (0.07)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">________________________________________________________________________________________________________________________</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup>&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">The p-value (probability value) is a measure of statistical significance reflecting the likelihood that an observed result occurred by chance.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following charts summarize the mean change in bilateral nasal polyps score in each of the pivotal clinical trials:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><img src="navigateia01.jpg" alt="navigateia01.jpg" style="height:221px;width:281px;"><font style="font-family:Arial;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><img src="navigateiia01.jpg" alt="navigateiia01.jpg" style="height:218px;width:281px;"></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition to the co-primary efficacy endpoints described above, we also assessed a number of secondary endpoints in the pivotal clinical trials, including the following:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Sinonasal Outcome Test-22.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;In a Sinonasal Outcome Test-22, which broadly assesses the impact of nasal polyps on certain outcomes, including the symptoms of nasal polyps, functioning and quality of life, the change observed with the 186- and 372-mcg doses of XHANCE was superior to the placebo EDS in both of the pivotal clinical trials. The magnitude of improvement associated with treatment with XHANCE was approximately 20 points.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Quality of Sleep.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;A positive impact of XHANCE on sleep was shown for the 372-mcg dose in both pivotal clinical trials through the "Sleep" sub-scale of the Sinonasal Outcome Test-22 and, in NAVIGATE II, a positive effect was further shown across a number of the sub-scales of the MOS-Sleep-R, a validated set of measures commonly used in clinical studies to assess changes in sleep quality.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Defining Symptoms.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;The 186- and 372-mcg treatment groups, in pooled data for NAVIGATE I and NAVIGATE II, achieved statistically significant improvement in all four of the core defining symptoms of nasal polyps at the end of the double-blinded phase.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Patient Global Impression of Change.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;Patient global impression of change is a summary measure of treatment benefit from the perspective of the patient measuring their perception of improvement or worsening of their condition. At the end of the double-blinded phase, the percentage of patients who were improved was substantially higher with XHANCE compared with the placebo EDS. Of the patients receiving 186 or 372 mcg of XHANCE, 86% reported improvement combined across both pivotal clinical trials, and 65.9% reported being "much" or "very much" improved. A post-hoc analysis of a subgroup of patients in the NAVIGATE I and II trials who were using a marketed INS at the time of study entry showed similar results, with 65% of patients treated with 186 or 372 mcg of XHANCE reporting being "much" or "very much improved" after 16&#160;weeks of treatment compared with 28% of patients treated with the placebo EDS.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Need for Surgery.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;Surgical eligibility was assessed using study-defined criteria. Surgery was not necessarily planned or pending for these patients. The proportion of patients meeting the study-defined surgical eligibility criteria among the 186-mcg and 372-mcg dose groups combined across both pivotal trials was reduced by 54% after 16&#160;weeks of treatment with XHANCE versus 36% with the EDS-placebo group and was reduced by approximately 64% after the additional eight weeks of active treatment with the 372-mcg dose.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Complete Response Analysis.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;The polyp grading scale is neither linear nor a direct measure of polyp mass, making it difficult to interpret mean change scores. Therefore, we also performed a complete response analysis to evaluate the percentage of patients who had nasal polyps eliminated (polyp grade 0) on at least one side of the nasal passages. The percentage of patients who had nasal polyps eliminated on at least one side of the nasal passages at the end of the double-blinded phase was 14.1% in the 186- and 372-mcg dose groups combined across both pivotal clinical trials, compared to 7.8% of placebo EDS recipients. By the end of 24&#160;weeks, after all patients received up to an additional eight weeks of active treatment with the 372-mcg dose, the complete response rate was 17.3% in patients previously treated with the placebo EDS compared to 26.2% in patients who previously received XHANCE across the 186- and 372-mcg dose groups in both pivotal clinical trials.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:26px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Safety Results</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">XHANCE was generally well tolerated across the 186- and 372-mcg dose groups in NAVIGATE I and NAVIGATE II. The most commonly reported AEs in the active treatment groups in the pivotal clinical trials, which are shown in the table below, were associated with local effects at the site of administration in the nasal passages or associated with the underlying disease. Most local AEs were not spontaneously reported but were identified as a result of active monitoring of all patients at scheduled intervals by endoscopic nasal examination at each visit. The majority of these AEs were reported to be mild and were observed to resolve with continued use of XHANCE. A total of six patients in the pivotal clinical trials experienced a total of seven serious adverse events (SAEs) only one of which, in a patient in the placebo group, was determined to be treatment-related. 5.0% of subjects treated with XHANCE 186 mcg twice daily and 1.2% of subjects treated with 372&#160;mcg twice daily discontinued from the clinical trials prior to the open-label extension phase based of adverse reactions compared to 4.3% of subjects treated with placebo.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Summary of Adverse Events with XHANCE Reported in &#8805; 3% of Patients with Nasal Polyps and More Common Than Placebo EDS in Phase&#160;3 Pivotal Clinical Trials</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:57%;"></td><td style="width:15%;"></td><td style="width:14%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">XHANCE</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Adverse Event</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Placebo EDS</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(N&#160;= 161)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">n (%)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">186 mcg bid</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(N&#160;= 160)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">n (%)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">372 mcg bid</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(N&#160;= 161)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">n (%)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Epistaxis</font><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">1</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4 (2.5)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">19 (11.9)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16 (9.9)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Nasopharyngitis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8 (5.0)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3 (1.9)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12 (7.5)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Nasal septal ulceration</font><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">2</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3 (1.9)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11 (6.9)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12 (7.5)</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Nasal congestion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6 (3.7)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7 (4.4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9 (5.6)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Acute sinusitis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6 (3.7)</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7 (4.4)</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8 (5.0)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Headache</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5 (3.1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8 (5.0)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6 (3.7)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pharyngitis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2 (1.2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2 (1.3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5 (3.1)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Nasal mucosal ulceration</font><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">2</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2 (1.2)</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6 (3.8)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4 (2.5)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Nasal mucosal erythema</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6 (3.7)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9 (5.6)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8 (5.0)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Nasal septal erythema</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3 (1.9)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6 (3.8)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7 (4.3)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">________________________________________________________________________________________________________________________</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">bid&#160;= twice daily.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">N&#160;= number of patients; n&#160;= number of patients in subset.</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:6pt;">1&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:8pt;">Includes spontaneous adverse reaction reports.</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:6pt;">2&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:8pt;">Includes ulcerations and erosions</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Phase&#160;3 Open-Label Clinical Trials (EXHANCE-3 and EXHANCE-12)</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We also conducted two supportive, open-label Phase&#160;3 clinical trials in adults with symptoms of chronic sinusitis with or without nasal polyps. The supportive clinical trials, which we refer to as EXHANCE-3 and EXHANCE-12, were conducted in the U.S. with a primary objective to assess the safety of twice-daily intranasal administration of the 372 mcg dose of XHANCE in an expanded number of patients and over an extended period of time. We also assessed a variety of objective and subjective efficacy parameters, including an assessment of each patient's symptoms and functioning and qualification for surgical intervention based on study-defined surgical eligibility criteria.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:26px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Study Design</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Eligibility for enrollment, endpoint and study design were similar in EXHANCE-3 and EXHANCE-12 with the exception of duration (3&#160;months in the case of EXHANCE-3 and 12&#160;months in the case of EXHANCE-12). Across both supportive clinical trials, a total of 898 adults were treated, including 762 adults with chronic sinusitis without nasal polyps and 136 adults with symptoms of chronic sinusitis with nasal polyps.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:26px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Safety Results</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">XHANCE was generally well tolerated. As shown in the table below, 59.2% of patients in the supportive clinical trials experienced at least one treatment-emergent AE, with the most common being similar to those in the XHANCE treatment groups of the pivotal clinical trials. The most common AEs were local (in the nose) and not systemic. Most AEs were mild and resolved with continued use of XHANCE. A total of 12 patients experienced a total of 14 SAEs in the supportive clinical trials, none of which were deemed treatment-related. Approximately 80% of patients completed the supportive clinical trials, with approximately 5% discontinuing due to an AE and 1% discontinuing for lack of efficacy.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Summary of Adverse Events Reported in &#8805;3% of Patients in EXHANCE 3 AND EXHANCE 12</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">________________________________________________________________________________________________________________________</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:86%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Adverse Event</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">XHANCE</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">372 mcg</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(N&#160;= 898)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">n (%)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Patients with at least 1 Adverse Event</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">532 (59.2)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Epistaxis</font><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">1</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">73 (8.1)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Nasal mucosal disorder (erythema or&#160;ulceration not at the nasal septum)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">109 (12.1)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Nasal septum disorder (erythema)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">71 (7.9)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Nasal septum&#160;ulceration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">53 (5.9)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Acute sinusitis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">48 (5.3)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upper respiratory tract infection</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">46 (5.1)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Headache</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">44 (4.9)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Nasal congestion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">34 (3.8)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cough</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">27 (3.0)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">________________________________________________________________________________________________________________________</font></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><font style="font-family:Arial;font-size:6pt;">1&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:8pt;">Includes spontaneous adverse reaction reports.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:26px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Efficacy Results</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Efficacy was also measured in EXHANCE-3 and EXHANCE-12. Key efficacy results from EXHANCE-3 and EXHANCE-12 included:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On the Lund-Mackay scale, which is an endoscopic objective assessment of disease in the nasal passages, scores for edema, nasal discharge and nasal polyps decreased through up to 12&#160;months of treatment, with similar benefits observed in patients who did or did not have nasal polyps at baseline. Among those patients entering the clinical trials with endoscopic evidence of edema within the nasal cavity, approximately 35% with polyps and 53% without polyps in EXHANCE-3 and 50% with polyps and 56% without polyps in EXHANCE-12 no longer had observable edema by the end of the study.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Patients with nasal polyps experienced improvement in nasal polyp grades. As observed in the pivotal clinical trials, mean nasal polyp grading scale scores improved more with longer durations of treatment. In addition, the percentage of nasal polyp patients with a polyp grade of 0 on at least one side of the nose was 47.1% in EXHANCE-12 and 48.0% in EXHANCE-3 by the end of their participation in the study.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mean total Sinonasal Outcome Test-22 scores improved throughout both supportive clinical trials. After 12&#160;months of treatment with XHANCE in our supportive clinical trials, at least 50% of patients had a score that was at or below 9.3, which is the average score that has been reported for healthy individuals.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Phase&#160;1 Bioavailability Clinical Trial</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We performed a Phase&#160;1, open-label, randomized, single-dose, bioavailability clinical trial of XHANCE and Flonase in healthy patients and XHANCE and Flovent HFA in patients with mild-to-moderate asthma. We conducted the Phase&#160;1 clinical trial to establish a bridge between XHANCE, which consists of our fluticasone propionate formulation combined with an Optinose EDS, and Flonase and Flovent HFA, the reference listed drugs for our NDA. We chose fluticasone propionate in part because it has limited absorption into the body. In our NDA, we relied in part on the FDA's previous findings of safety for Flonase and Flovent HFA, including non-clinical toxicology findings and findings of systemic safety risks related to hypothalamic-pituitary-adrenal (HPA) axis suppression, which is a known side effect of corticosteroids. To do so, we were required to establish that the systemic exposure, or the amount of drug absorbed into the body, to fluticasone propionate following use of XHANCE did not exceed the exposure produced by Flovent HFA.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:26px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Study Design</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Part one of the clinical trial was a three-way, three-treatment, three-sequence crossover study in healthy patients in which patients were randomized to a sequence containing the following treatments: 186 mcg (1&#160;&#215;&#160;93 mcg to each nostril) of XHANCE; 372 mcg (2&#160;&#215;&#160;93 mcg to each nostril) of XHANCE; and 400&#160;mcg (4&#160;&#215;&#160;50 mcg to each nostril) of Flonase. The primary objective of part one was to assess and compare the systemic exposure of a single dose of 186 mcg and 372 mcg of XHANCE with 400&#160;mcg of Flonase in healthy patients. If one or both of the test doses resulted in a systemic exposure that was at least 125% of that of Flonase, then part two was to be conducted. Part two of the clinical trial was a two-way, two-treatment, two-sequence crossover study in mild-to-moderate asthmatic patients in which patients were randomized to a sequence containing the following: 372 mcg (4&#160;&#215;&#160;93 mcg) of XHANCE and 440 mcg (2&#160;&#215;&#160;220 mcg) of Flovent HFA. The primary objective of part two was to assess and compare the systemic exposure produced by a single dose of 372 mcg of XHANCE with 440 mcg of Flovent HFA in mild-to-moderate asthmatic patients. A total of 112 adults were examined across both parts of the clinical trial.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:26px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Results</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In part one of the clinical trial, peak and total exposure to fluticasone propionate was higher following 372 mcg of XHANCE compared to 400 mcg of Flonase. Peak exposure to fluticasone propionate was also higher for 186 mcg of XHANCE than 400 mcg of Flonase, but total exposure was higher for 400 mcg of Flonase than 186 mcg of XHANCE. In part two of the clinical trial, doses of 372&#160;mcg of XHANCE produced systemic exposure substantially lower than that of 440 mcg of Flovent HFA. In particular, peak plasma of the drug (C</font><font style="font-family:Arial;font-size:8pt;">max)</font><font style="font-family:Arial;font-size:10pt;">&#32;and the total amount of absorption, known as the area under the curve from time 0 to infinity (AUC0-&#8734;) were approximately 37% and 50% lower following administration of 372&#160;mcg of XHANCE relative to 440 mcg of Flovent HFA, respectively. We believe these results supported our use of Flonase and Flovent HFA as referenced listed drugs in our NDA for XHANCE.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Regulatory Exclusivity and Barriers to Entry</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">XHANCE benefits from substantial intellectual property and regulatory barriers to entry, including the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Strong patent protection.</font><font style="font-family:Arial;font-size:10pt;">&#160; Our XHANCE U.S. patent portfolio consists of 13 issued device and method of use patents expiring through 2034, three issued design patents expiring through 2030 and U.S. patent applications that, if granted, would expire through 2034. We rely primarily on the protections afforded by device and method of use patents. Our issued U.S. patents and patent applications for XHANCE are based on an Optinose EDS, including the combination of this technology with fluticasone propionate.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Complex drug-delivery system.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;We believe the unique features of an Optinose EDS, as well as its delivery of a topical-acting corticosteroid, affords us significant protection against generic competition, as well as against a potential 505(b)(2) NDA, that seeks to reference XHANCE in order to obtain approval for a therapeutically equivalent, substitutable competitor product. XHANCE, utilizing our proprietary EDS, presents human factors engineering complexities for drug-device combination products and chemistry,</font><font style="font-family:Arial;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">manufacturing and controls challenges unique to suspension and respiratory products. Any future substitutable generic entrant will need to have considerable combination product know-how to develop and validate a substitutable drug delivery device or technology to compete with an Optinose EDS.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Clinical and regulatory complexity.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;We have conducted a clinical development program comprised of over 1,500 patients to support our NDA for XHANCE to treat nasal polyps, including human factors studies and Phase&#160;3 clinical trial assessments evaluating and validating the use of an Optinose EDS. As with other drugs that primarily have local activity, we believe the regulatory pathway for products seeking approval as substitutable generic equivalents to XHANCE will be more complex and costly than the pharmacokinetic studies generally required for systemically-acting medications. We believe current FDA guidance for substitutable INS generally requires the demonstration of "clinical bioequivalence," which has caused developers to conduct non-inferiority clinical trials. Clinical trials in nasal polyps are different from those that have been performed to support approval of generic INS for allergic rhinitis. We believe potential generic competitors to XHANCE must not only demonstrate efficacy versus placebo, but must also show equivalent efficacy and safety outcomes to establish clinical bioequivalence to XHANCE, requiring a significant amount of time and capital investment and presenting clinical development uncertainties.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Three-year regulatory exclusivity.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;The FDA has granted XHANCE a three-year period of regulatory exclusivity that will end in September 2020. This exclusivity means that we are afforded at least three years in which to market our product free of generic or 505(b)(2) competition post-NDA approval.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Intellectual Property</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We strive to protect our proprietary technology that we believe is important to our business, including seeking and maintaining patents intended to cover our product candidates and technologies that are important to the development of our business. We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection, as well as know-how, trademarks, continuing technological innovation and in-licensing opportunities to develop and maintain our proprietary position. We internally developed our intellectual property related to the Optinose EDS, AVP-825, XHANCE and our product candidates. We have sought and intend to continue to seek appropriate patent protection for our product candidates, as well as other proprietary technologies and their uses by filing patent applications in the U.S. and selected other countries.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Patents</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of February 28, 2019, we owned a total of 47 U.S. patents and 27 pending U.S. patent applications. These U.S. patents will expire between 2020 and 2034. These U.S. patent applications, subject to issuance, would be projected to expire between 2020 and 2039, with potential patent term adjustments that would extend the patent term. In addition to our U.S. intellectual property, we also own 207 foreign issued patents, which will expire between 2020 and 2033 and 77 foreign patent applications, which will expire between 2020 and 2035, subject to issuance.  </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our XHANCE U.S. patent portfolio consists of 13 issued device and method of use patents, three issued design patents and 10 pending patent applications. The 13 device and method of use patents expire between 2020 and 2034, the three design patents expire between 2029 and 2030 and the 10 pending patent applications would be projected to expire, subject to issuance, between 2022 and 2034, with potential patent term adjustments that would extend the patent term.  The 13 device and method of use patents are published in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an abbreviated NDA (ANDA), or a 505(b)(2) NDA. If any of these potential generic competitors claim that their product will not infringe XHANCE's listed patents, or that such patents are invalid, then they must send notice to us once the ANDA or 505(b)(2) NDA has been accepted for filing by the FDA. We may then initiate a patent infringement lawsuit in response to the notice of the Paragraph&#160;IV certification, which would automatically prevent the FDA from approving the ANDA or 505(b)(2) NDA until the earlier of 30&#160;months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA or 505(b)(2) NDA applicant.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The rest of our patent portfolio largely relates to patents and applications owned by us and directed to AVP-825 and other product candidates, including OPN-300, and our EDS devices and related technologies.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Trade Secrets and Other Proprietary Information</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We seek to protect our proprietary information, including our trade secrets and proprietary know-how, by requiring our employees, consultants and other advisors to execute confidentiality agreements upon the commencement of their employment or engagement. These agreements generally provide that all confidential information developed or made known during the course of the relationship with us be kept confidential and not be disclosed to third parties except in specific circumstances. In the case of our employees, the agreements also typically provide that all inventions resulting from work performed for us, utilizing our property or relating to our business and conceived or completed during employment shall be our exclusive property to the extent permitted by law. Where appropriate, agreements we obtain with our consultants also typically contain similar assignment of invention provisions. Further, we generally require confidentiality agreements from business partners and other third parties that receive our confidential information.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Trademarks</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We also rely on trademarks and trade designs to develop and maintain our competitive position. OPTINOSE</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174; </sup></font><font style="font-family:Arial;font-size:10pt;">&#32;and XHANCE</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;are registered trademarks of ours in the U.S.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">License Agreements</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">AVP-825 License Agreement</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In July 2013, we, through our wholly-owned subsidiary, OptiNose AS, entered into a license agreement (the AVP-825 License Agreement) with Avanir pursuant to which we granted an exclusive license to Avanir to further develop and commercialize AVP-825, a combination of an Optinose EDS with a lose-dose sumatriptan powder, for the acute treatment of migraines in adults, in the U.S., Canada and Mexico. AVP-825 was approved by the FDA in </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">January 2016 for the acute treatment of migraines in adults and became commercially available in May 2016 under the brand name Onzetra Xsail.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have received $70.0&#160;million in aggregate licensing revenues to date, consisting of an up-front payment of $20.0&#160;million received in 2013, a $2.5&#160;million payment received in June 2014 upon the achievement of a development milestone and a $47.5&#160;million payment received in February 2016 upon FDA approval of AVP-825. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On December 10, 2018, we received written notice from Avanir of its election to terminate the AVP-825 License Agreement.&#160;As a result, the AVP-825 License Agreement is expected to terminate on March 10, 2019.&#160;Upon termination, we may elect to continue to commercialize Onzetra Xsail ourselves or through a new licensee, from which we may be required to pay Avanir a low double digit royalty until net sales reach a specified amount.&#160;We do not expect to receive any additional proceeds from the AVP-825 License Agreement.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Inexia</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On January 31, 2019, we entered into a License Agreement (Inexia License Agreement), with Inexia Limited (Inexia).  Under the terms of the Inexia License Agreement, we granted Inexia an exclusive, royalty-bearing, worldwide, non-transferable, sublicensable license to our EDS and other intellectual property for the use, sale, import and manufacture of products containing orexin receptor agonist and/or orexin receptor positive modulator molecule(s) as the sole active pharmaceutical ingredient(s) for the treatment, diagnosis or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. The license excludes the treatment of any disease or condition affecting the ear, nose or throat, or the treatment of any disease or condition associated primarily with another receptor, other than the Orexin 1 and Orexin 2 receptors. Inexia is solely responsible for all costs and activities related to its identification, development and commercialization of products under the Inexia License Agreement.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Under the terms of the Inexia License Agreement, we received a $0.5 million upfront payment. For each product developed under the Inexia License Agreement, we are eligible to receive up to $8.0 million of development milestone payments and up to $37.0 million of sales milestone payments. In addition, we are eligible to receive tiered, low-to-mid single digit royalties based on net sales of any products successfully developed and commercialized under the Inexia License Agreement.  Other than the upfront payment, we do not anticipate the receipt of any milestone or royalty payments from Inexia in the near term. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As a result of the Inexia License Agreement, we have discontinued our preclinical OPN-021 program, which combined our EDS with orexin agonist molecules for the treatment of narcolepsy and symptoms of other diseases potentially amenable to the same pharmacologic activity, such as Parkinson's disease.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Manufacturing and Distribution</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Manufacturing</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We currently contract with third parties for the manufacture, testing and storage of our product candidates. In our experience, contract manufacturers (CMOs) are generally cost-efficient and reliable and therefore we currently have no plans to build our own clinical or commercial manufacturing capabilities. Because we rely on CMOs, we employ personnel with extensive technical, manufacturing, analytical and quality experience to oversee contract manufacturing and testing activities, and to compile manufacturing and quality information for our regulatory submissions. Manufacturing is subject to extensive regulations that impose various procedural and documentation requirements, and which govern record-keeping, manufacturing processes and controls, personnel, quality control and quality assurance, among other activities. Our systems and our contractors are required to comply with these regulations, and we assess this compliance regularly through monitoring of performance and a formal audit program. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have entered into the following key supply agreements for the commercial manufacture and supply of XHANCE:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A supply agreement with Hovione Inter Ltd (Hovione) for the supply of fluticasone propionate, the active pharmaceutical ingredient included in the liquid suspension formulation. This agreement has a term of five years from commercial launch of XHANCE, subject to earlier termination or extension in accordance with the terms of the agreement. Either we or Hovione may terminate the agreement prior to that date for uncured material breach or insolvency of the other party. We may also terminate the agreement in the event Hovione, among other things, (i)&#160;loses any required FDA approval rendering it unable to fulfill its contractual obligations, (ii)&#160;is engaged in felonious or fraudulent activities or (iii)&#160;does not submit a Corrective and </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-top:10px;"><font style="font-family:Arial;font-size:10pt;">Preventive Action plan to the FDA within a specified period of time of being notified of deficiencies in Hovione's facility.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A manufacture and supply agreement with Contract Pharmaceuticals Limited Canada (CPL) for the formulation and assembly of the finished drug product during the fill/pack operation. This agreement terminates in September 2022, subject to earlier termination or extension in accordance with the terms of the agreement. Either we or CPL may terminate the agreement prior to that date by mutual consent or for uncured material breach by or insolvency of the other party. We may also terminate the agreement if, among other things, any intellectual property of any third party is reasonably alleged by a third party to be infringed, misappropriated or otherwise violated by the manufacture, import, use, sale or distribution of XHANCE or if any regulatory authority requires us to cease production of the sale of XHANCE.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A manufacturing services agreement with Advance Mold &amp; Manufacturing, Inc. (Flex) for the manufacture of the liquid delivery sub-assembly, which consists of injection molded parts and other purchased components. The initial term of the agreement expires on October 24, 2021 but will automatically renew for successive one-year terms unless either party provides at least ninety days prior written notice to the other that it does not intend to renew the agreement.&#160;We have certain rights to terminate the agreement, including upon advance notice to Flex, if Flex fails an inspection or suffers a disciplinary action by a governmental authority and fails to cure such issue within a specified period of time, or if Flex fails to gain recommendation for approval by the FDA to manufacture the liquid delivery subassembly component to be manufactured pursuant to the agreement.&#160;Either party may terminate the Agreement for uncured material breaches or insolvency of the other party.&#160;  </font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We believe our third-party manufacturers have adequate capacity to manufacture sufficient quantities of XHANCE to meet anticipated commercial demands.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Distribution</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We sell XHANCE to wholesale pharmaceutical distributors, who, in turn, sell XHANCE to pharmacies, hospitals and other customers. We have also established relationship with preferred pharmacy network partners into which we sell XHANCE. We established this channel to offer patients the option of filling prescriptions through a network of preferred pharmacies that may be able to better serve the needs of patients through services including delivery of XHANCE by mail. We have contracted with a&#160;third-party logistics provider for key services related to logistics, warehousing and inventory management, and distribution. Further, our third-party logistics provider provides customer order fulfillment services and accounts receivable management. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Customers</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Approximately 42% of our XHANCE net revenues during the&#160;fiscal year ended&#160;</font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;were to the three largest pharmaceutical wholesalers, Cardinal Health, McKesson Corporation, and AmerisourceBergen Drug Corporation.  Additionally, approximately 57% of our XHANCE net revenues during the&#160;fiscal year ended&#160;</font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;were to preferred pharmacy network partners, the majority of which were to Foundation Care LLC.  The remaining 1% of our XHANCE net sales were to regional pharmaceutical distributors. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Competition</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our industry is highly competitive and subject to rapid and significant technological change as research provides a deeper understanding of the pathology of diseases and new technologies and treatments are developed. We believe our scientific knowledge, technology, and development capabilities provide us with substantial competitive advantages, but we face potential competition from multiple sources, including large pharmaceutical, biotechnology, specialty pharmaceutical and, to a lesser degree, medical device companies.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">XHANCE competes primarily with INS, oral steroids and other medical management products, including locally compounded liquid budesonide in high-volume nasal rinses. XHANCE also competes with surgical procedures, balloon sinus dilation products and steroid-releasing sinus implants. Key competitive factors affecting the commercial success of XHANCE and any other product candidates we may develop are likely to be efficacy, safety and tolerability profile, reliability, convenience of administration, price and reimbursement.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The only other branded INS on the market indicated for the treatment of nasal polyps is Nasonex, which is marketed by Merck&#160;&amp;&#160;Co.,&#160;Inc. A generic version of Nasonex, mometasone furoate monohydrate, was approved by the FDA for, among other indications, the treatment of nasal polyps and launched in 2016.  In addition, Beconase AQ, which is an INS marketed by GlaxoSmithKline, is indicated for the prophylaxis of nasal polyps after surgical </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">resection. In addition, SINUVA</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">TM</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;is a commercially available corticosteroid-eluting implant indicated for the treatment of nasal polyps in adult patients who have had ethmoid sinus surgery that can be placed in the ethmoid sinus under endoscopic visualization for up to 90 days. In the SINUVA clinical studies, patients were advised to use nasal steroid sprays and sinus rinses for the duration of the study. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">There are no products approved for the treatment of chronic sinusitis without nasal polyps. There are two categories of INS: first-generation INS products, which include Rhinocort, Nasacort AQ and Qnasl; and second-generation INS products, which include Flonase, Veramyst, Omnaris and Zetonna. The primary difference between first- and second-generation INS products is that first-generation INS are absorbed into the blood to a greater extent than second-generation INS, with systemic bioavailability ranging from 10% to 50% compared to a systemic bioavailability with fluticasone propionate, a second-generation INS, of less than 2%. Many of the most widely-prescribed INS products are available in generic form and some, such as Flonase (which contains the same active pharmaceutical ingredient as XHANCE), are available over-the-counter.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Several companies are also currently developing biologic monoclonal antibodies for the treatment of nasal polyps. These biologic monoclonal antibodies, which inhibit specific pathways of inflammation present in nasal polyps, include omalizumab, reslizumab, mepolizumab and dupilumab. Omalizumab has been studied in investigator-initiated Phase&#160;2 clinical trials. GlaxoSmithKline has studied mepolizumab in a sponsor-initiated Phase&#160;2 clinical trial and has initiated patient enrollment in a Phase&#160;3 clinical trial with study completion anticipated in 2019. If these biologic monoclonal antibodies are successfully developed and approved for marketing, they could represent significant competition for XHANCE. In addition, there are new small molecules, including fevipiprant, being developed for the treatment of nasal polyps, that are also believed to inhibit specific pathways of inflammation present in nasal polyps.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Government Regulation</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are subject to extensive regulation by the FDA and other federal, state, and local regulatory agencies. The Federal Food, Drug and Cosmetic Act (the FD&amp;C Act) and FDA's implementing regulations set forth, among other things, requirements for the testing, development, manufacture, quality control, safety, effectiveness, approval, labeling, storage, record-keeping, reporting, distribution, import, export, advertising and promotion of our products and product candidates. Although the discussion below focuses on regulation in the U.S., because that is currently our primary focus, we anticipate seeking approval for, and marketing, our products in other countries in the future. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the U.S., although there can be important differences.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Development and Approval</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Under the FD&amp;C Act, FDA approval of an NDA is required before any new drug can be marketed in the U.S. NDAs require extensive studies and submission of a large amount of data by the applicant.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Preclinical Testing.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;Before testing any compound in human patients in the U.S., a company must generate extensive preclinical data. Preclinical testing generally includes laboratory evaluation of product chemistry and formulation, as well as toxicological and pharmacological studies in several animal species to assess the quality and safety of the product. Certain animal studies must be performed in compliance with the FDA's Good Laboratory Practice (GLP) regulations and the U.S. Department of Agriculture's Animal Welfare Act.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">IND Application.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;Human clinical trials in the U.S. cannot commence until an investigational new drug (IND) application is submitted and becomes effective. A company must submit preclinical testing results to the FDA as part of the IND, and the FDA must evaluate whether there is an adequate basis for testing the drug in initial clinical studies in human volunteers. Unless the FDA raises concerns, the IND becomes effective 30&#160;days following its receipt by the FDA. Once human clinical trials have commenced, the FDA may stop a clinical trial by placing it on "clinical hold" because of concerns about the safety of the product being tested, or for other reasons.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Clinical Trials.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;Clinical trials involve the administration of a drug to healthy human volunteers or to patients, under the supervision of a qualified investigator. The conduct of clinical trials is subject to extensive regulation, including compliance with the FDA's bioresearch monitoring regulations and Good Clinical Practice (GCP) requirements, which establish standards for conducting, recording data from, and reporting the results of, clinical trials, and are</font><font style="font-family:Arial;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">intended to assure that the data and reported results are credible and accurate, and that the rights, safety, and well-being of study participants are protected. Clinical trials must be conducted under protocols that detail the study objectives, parameters for monitoring safety, and the efficacy criteria, if any, to be evaluated. Each protocol is reviewed by the FDA as part of the IND. In addition, each clinical trial must be reviewed and approved by, and conducted under the auspices of, an Institutional Review Board (IRB). Companies sponsoring the clinical trials, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">investigators, and IRBs also must comply with, as applicable, regulations and guidelines for obtaining informed consent from the study patients, following the protocol and investigational plan, adequately monitoring the clinical trial, and timely reporting of AEs. Foreign studies conducted under an IND must meet the same requirements that apply to studies being conducted in the U.S. Data from a foreign study not conducted under an IND may be submitted in support of an NDA if the study was conducted in accordance with GCP and the FDA is able to validate the data.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A study sponsor is required to publicly post specified details about certain clinical trials and clinical trial results on government or independent websites (e.g.,&#160;http://clinicaltrials.gov). Human clinical trials typically are conducted in three sequential phases, although the phases may overlap with one another:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Phase&#160;1 clinical trials involve the initial administration of the investigational drug to humans, typically to a small group of healthy human patients, but occasionally to a group of patients with the targeted disease or disorder. Phase&#160;1 clinical trials generally are intended to determine the metabolism and pharmacologic actions of the drug, the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Phase&#160;2 clinical trials generally are controlled studies that involve a relatively small sample of the intended patient population, and are designed to develop initial data regarding the product's effectiveness, to determine dose response and the optimal dose range, and to gather additional information relating to safety and potential AEs.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Phase&#160;3 clinical trials are conducted after preliminary evidence of effectiveness has been obtained, and are intended to gather the additional information about safety and effectiveness necessary to evaluate the drug's overall risk-benefit profile, and to provide a basis for physician labeling. Generally, Phase&#160;3 clinical development programs consist of expanded, large-scale studies of patients with the target disease or disorder to obtain statistical evidence of the efficacy and safety of the drug at the proposed dosing regimen.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The sponsoring company, the FDA, or the IRB may suspend or terminate a clinical trial at any time on various grounds, including a finding that the patients are being exposed to an unacceptable health risk. Further, success in early-stage clinical trials does not assure success in later-stage clinical trials. Data obtained from clinical activities are not always conclusive and may be subject to alternative interpretations that could delay, limit or prevent regulatory approval.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">NDA Submission and Review.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;The FD&amp;C Act provides two pathways for the approval of new drugs through an NDA. An NDA under Section&#160;505(b)(1) of the FD&amp;C Act is a comprehensive application to support approval of a product candidate that includes, among other things, data and information to demonstrate that the proposed drug is safe and effective for its proposed uses, that production methods are adequate to ensure its identity, strength, quality, and purity of the drug, and that proposed labeling is appropriate and contains all necessary information. A 505(b)(1) NDA contains results of the full set of preclinical studies and clinical trials conducted by or on behalf of the applicant to characterize and evaluate the product candidate.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Section&#160;505(b)(2) of the FD&amp;C Act provides an alternate regulatory pathway to obtain FDA approval for new formulations or new uses of previously approved drug products. Specifically, Section&#160;505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. The applicant may rely to some extent upon the FDA's findings of safety and effectiveness for an approved product that acts as the reference listed drug (RLD) and submit its own product-specific data&#160;&#8212; which may include data from preclinical studies or clinical trials conducted by or on behalf of the applicant&#160;&#8212; to address differences between the product candidate and the RLD. We obtained FDA approval of XHANCE through the Section&#160;505(b)(2) regulatory approval pathway, with Flonase and Flovent HFA as the RLDs. Flonase and Flovent HFA contain fluticasone propionate, which is also used in XHANCE.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The submission of an NDA under either Section&#160;505(b)(1) or Section&#160;505(b)(2) generally requires payment of a substantial user fee to the FDA. The FDA reviews applications to determine, among other things, whether a product is safe and effective for its intended use and whether the manufacturing controls are adequate to assure and</font><font style="font-family:Arial;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">preserve the product's identity, strength, quality, and purity. For some NDAs, the FDA may convene an advisory committee to seek insights and recommendations on issues relevant to approval of the application. Although the FDA is not bound by the recommendation of an advisory committee, the agency usually has followed such recommendations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our product and product candidates include products that combine drug and device components in a manner that the FDA considers to meet the definition of a "combination product" under FDA regulations. The FDA exercises significant discretion over the regulation of combination products, including the discretion to require separate marketing applications for the drug and device components in a combination product. For XHANCE, FDA's Center for Drug Evaluation and Research (CDER) had primary jurisdiction for review of the NDA, and both the drug and device were reviewed under one marketing application. However, for a drug-device combination product CDER typically consults with the Center for Devices and Radiological Health in the NDA review process.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The FDA may determine that a Risk Evaluation and Mitigation Strategy (REMS) is necessary to ensure that the benefits of a new product outweigh its risks, and the product can therefore be approved. A REMS may include various elements, ranging from a medication guide or patient package insert to limitations on who may prescribe or dispense the drug, depending on what the FDA considers necessary for the safe use of the drug. Under the Pediatric Research Equity Act, certain applications for approval must also include an assessment, generally based on clinical study data, of the safety and effectiveness of the subject drug in relevant pediatric populations. Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with current Good Manufacturing Practice (cGMP) requirements and adequate to assure consistent production of the product within required specifications.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Once the FDA accepts an NDA submission&#160;&#8212; which occurs, if at all, within 60&#160;days after submission of the NDA&#160;&#8212; the FDA's goal for a non-priority review of an NDA is ten months. The review process can be and often is significantly extended, however, by FDA requests for additional information, studies, or clarification. After review of an NDA, the FDA may decide to not approve the application or may issue a complete response letter outlining the deficiencies in the submission. The complete response letter also may request additional information, including additional preclinical or clinical data. Even if such additional information and data are submitted, the FDA may decide that the NDA still does not meet the standards for approval. Data from clinical trials are not always conclusive and the FDA may interpret data differently than the sponsor.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Obtaining regulatory approval often takes a number of years, involves the expenditure of substantial resources, and depends on a number of factors, including the severity of the disease in question, the availability of alternative treatments, and the risks and benefits demonstrated in clinical trials. Additionally, as a condition of approval, the FDA may impose restrictions that could affect the commercial success of a drug or require post-approval commitments, including the completion within a specified time period of additional clinical studies, which often are referred to as "Phase&#160;4" or "post-marketing" studies. For example, the FDA originally required us to conduct a randomized, double-blind, placebo controlled, parallel group clinical study in children and adolescents 6 to 17 years of age with bilateral nasal polyps associated with nasal congestion to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of XHANCE in improving nasal polyp grade and symptoms (nasal congestion/obstruction, sense of smell, rhinorrhea and facial pain or pressure). On October 30, 2017, the FDA notified us that in response to our request it had modified the required age range to 12 to 17 years of age.  We submitted our final protocol to the FDA with respect to the pediatric study by January 2018 as required, and we have since contracted with various clinical trial sites and begun patient enrollment.  We are required to complete the study by January 2022 and submit a final report with respect to the study by July 2022.  </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Post-approval modifications to the drug, such as changes in indications, labeling, or manufacturing processes or facilities, may require a sponsor to develop additional data or conduct additional preclinical studies or clinical trials, to be submitted in a new or supplemental NDA, which would require FDA approval.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Post-Approval Regulation</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Once approved, products are subject to continuing regulation by the FDA. If ongoing regulatory requirements are not met or if safety problems occur after the product reaches the market, the FDA may at any time withdraw product approval or take actions that would limit or suspend marketing. Additionally, the FDA may require post-marketing studies or clinical trials if there are new safety information developments.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Good Manufacturing Practices.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;Companies engaged in manufacturing drug products or their components must comply with applicable cGMP requirements and product-specific regulations enforced by the FDA and other regulatory agencies. Compliance with cGMP includes adhering to requirements relating to organization and training of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, quality control and quality assurance, packaging and labeling controls, holding and distribution, laboratory controls, and records and reports. The FDA regulates and inspects equipment, facilities, and processes used in manufacturing pharmaceutical products prior to approval. If, after receiving approval, a company </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">makes a material change in manufacturing equipment, location, or process (all of which are, to some degree, incorporated in the NDA), additional regulatory review and approval may be required. The FDA also conducts regular, periodic visits to re-inspect equipment, facilities, and processes following the initial approval of a product. Failure to comply with applicable cGMP requirements and conditions of product approval may lead the FDA to seek sanctions, including fines, civil penalties, injunctions, suspension of manufacturing operations, operating restrictions, withdrawal of FDA approval, seizure or recall of products, and criminal prosecution. Although we periodically monitor the FDA compliance of our third-party manufacturers, we cannot be certain that our present or future third-party manufacturers will consistently comply with cGMP and other applicable FDA regulatory requirements.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">It is also likely that we will need to comply with some of FDA's manufacturing regulations for devices. FDA has discretion in determining post-approval compliance requirements for products that combine a drug product with a delivery system device. In addition to cGMP, FDA may require that our drug-device combination product, if approved, comply with the Quality System Regulation (QSR), which sets forth the FDA's manufacturing quality standards for medical devices.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Advertising and Promotion.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;The FDA and other federal regulatory agencies closely regulate the marketing and promotion of drugs through, among other things, standards and regulations for direct-to-consumer advertising, advertising and promotion to healthcare professionals, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and promotional activities involving the Internet. A product cannot be commercially promoted before it is approved. After approval, product promotion can include only those claims relating to safety and effectiveness that are consistent with the labeling approved by the FDA. Healthcare providers are permitted to prescribe drugs for "off-label" uses&#160;&#8212; that is, uses not approved by the FDA and not described in the product's labeling&#160;&#8212; because the FDA does not regulate the practice of medicine. However, FDA regulations impose restrictions on manufacturers' communications regarding off-label uses. Broadly speaking, a manufacturer may not promote a drug for off-label use, but under certain conditions may engage in non-promotional, balanced, scientific communication regarding off-label use. Failure to comply with applicable FDA requirements and restrictions in this area may subject a company to adverse publicity and enforcement action by the FDA, the Department of Justice, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes a drug.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Other Requirements.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;NDA holders must comply with other regulatory requirements, including submitting annual reports, reporting information about adverse drug experiences, and maintaining certain records.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Hatch-Waxman Act</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act) establishes two abbreviated approval pathways for pharmaceutical products that are in some way follow-on versions of already approved products.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Generic Drugs.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;A generic version of an approved drug is approved by means of an ANDA, by which the sponsor demonstrates that the proposed product is the same as the approved, brand-name drug, which is referred to as the RLD. Generally, an ANDA must contain data and information showing that the proposed generic product and RLD (i)&#160;have the same active ingredient, in the same strength and dosage form, to be delivered via the same route of administration, (ii)&#160;are intended for the same uses, and (iii)&#160;are bioequivalent. This is instead of independently demonstrating the proposed product's safety and effectiveness, which are inferred from the fact that the product is the same as the RLD, which the FDA previously found to be safe and effective.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">505(b)(2) NDAs.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;As discussed above, if a product is similar, but not identical, to an already approved product, it may be submitted for approval via an NDA under section&#160;505(b)(2) of the FD&amp;C Act. Unlike an ANDA, this does not excuse the sponsor from demonstrating the proposed product's safety and effectiveness. Rather, the sponsor is permitted to rely to some degree on the FDA's finding that the RLD is safe and effective, and must submit its own product-specific data of safety and effectiveness to an extent necessary because of the differences between the products. An NDA approved under 505(b)(2) may in turn serve as an RLD for subsequent applications from other sponsors.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">RLD Patents.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;In an NDA, a sponsor must identify patents that claim the drug substance or drug product or a method of using the drug. When the drug is approved, those patents are among the information about the product that is listed in the FDA publication, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Approved Drug Products with Therapeutic Equivalence Evaluations</font><font style="font-family:Arial;font-size:10pt;">, which is </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">referred to as the </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Orange Book</font><font style="font-family:Arial;font-size:10pt;">. The sponsor of an ANDA or 505(b)(2) application seeking to rely on an approved product as the RLD must make one of several certifications regarding each listed patent. A "Paragraph&#160;III" certification is the sponsor's statement that it will wait for the patent to expire before obtaining approval for its product. A "Paragraph&#160;IV" certification is an assertion that the patent does not block approval of the later product, either because the patent is invalid or unenforceable or because the patent, even if valid, is not infringed by the new product.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Regulatory Exclusivities.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;The Hatch-Waxman Act provides periods of regulatory exclusivity for products that would serve as RLDs for an ANDA or 505(b)(2) application. If a product is a "new chemical entity," or NCE&#160;&#8212; generally meaning that the active moiety has never before been approved in any drug&#160;&#8212; there is a period of five years from the product's approval during which the FDA may not accept for filing any ANDA or 505(b)(2) application for a drug with the same active moiety. An ANDA or 505(b)(2) application may be submitted after four years, however, if the sponsor of the application makes a Paragraph&#160;IV certification.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A product that is not an NCE may qualify for a three-year period of exclusivity if the NDA contains new clinical data, derived from studies conducted by or for the sponsor, that were necessary for approval. In that instance, the exclusivity period does not preclude filing or review of an ANDA or 505(b)(2) application; rather, the FDA is precluded from granting final approval to the ANDA or 505(b)(2) application until three years after approval of the RLD. Additionally, the exclusivity applies only to the conditions of approval that required submission of the clinical data.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Once the FDA accepts for filing an ANDA or 505(b)(2) application containing a Paragraph&#160;IV certification, the applicant must within 20&#160;days provide notice to the RLD NDA holder and patent owner that the application has been submitted, and provide the factual and legal basis for the applicant's assertion that the patent is invalid or not infringed. If the NDA holder or patent owner files suit against the ANDA or 505(b)(2) applicant for patent infringement within 45&#160;days of receiving the Paragraph&#160;IV notice, the FDA is prohibited from approving the ANDA or 505(b)(2) application for a period of 30&#160;months or the resolution of the underlying suit, whichever is earlier. If the RLD has NCE exclusivity and the notice is given and suit filed during the fifth year of exclusivity, the 30-month stay does not begin until five years after the RLD approval. The FDA may approve the proposed product before the expiration of the 30-month stay if a court finds the patent invalid or not infringed or if the court shortens the period because the parties have failed to cooperate in expediting the litigation.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Patent Term Restoration.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;A portion of the patent term lost during product development and FDA review of an NDA is restored if approval of the application is the first permitted commercial marketing of a drug containing the active ingredient. The patent term restoration period is generally one-half the time between the effective date of the IND or the date of patent grant (whichever is later) and the date of submission of the NDA, plus the time between the date of submission of the NDA and the date of FDA approval of the product. The maximum period of restoration is five years, and the patent cannot be extended to more than 14&#160;years from the date of FDA approval of the product. Only one patent claiming each approved product is eligible for restoration and the patent holder must apply for restoration within 60&#160;days of approval. The U.S. Patent and Trademark Office (PTO) in consultation with the FDA, reviews and approves the application for patent term restoration. When any of our products is approved, we intend to seek patent term restoration for an applicable patent when it is appropriate.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Other Exclusivities</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Pediatric Exclusivity.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;Section&#160;505A of the FD&amp;C Act provides for six months of additional exclusivity or patent protection if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data does not need to show that the product is effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA's request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Orange Book</font><font style="font-family:Arial;font-size:10pt;">&#32;listed patent protection that cover the drug are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve an ANDA or 505(b)(2) application owing to regulatory exclusivity or listed patents. When any product is approved, we will evaluate seeking pediatric exclusivity as appropriate.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Orphan Drug Exclusivity.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;The Orphan Drug Act provides incentives for the development of drugs intended to treat rare diseases or conditions, which generally are diseases or conditions affecting less than 200,000 individuals in the U.S. If a sponsor demonstrates that a drug is intended to treat a rare disease or condition, the FDA grants orphan drug designation to the product for that use. The benefits of orphan drug designation include research and development tax credits and exemption from user fees. A drug that is approved for the orphan drug designated indication generally is granted seven years of orphan drug exclusivity. During that period, the FDA generally may not </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">approve any other application for the same product for the same indication, although there are exceptions, most notably when the later product is shown to be clinically superior to the product with exclusivity. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">U.S. Healthcare Reform  </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, which we refer to together as the Affordable Care Act, is a sweeping measure intended to expand healthcare coverage within the U.S., primarily through the imposition of health insurance mandates on employers and individuals and expansion of the Medicaid program. This law substantially changed the way healthcare is financed by both governmental and private insurers and significantly impacts the pharmaceutical industry. Changes that may affect our business include those governing enrollment in federal healthcare programs, reimbursement changes, benefits for patients within a coverage gap in the Medicare Part&#160;D prescription drug program (commonly known as the "donut hole"), rules regarding prescription drug benefits under the health insurance exchanges, changes to the Medicaid Drug Rebate program, expansion of the Public Health Service's 340B drug pricing discount program (340B program), fraud and abuse, and enforcement. These changes impact existing government healthcare programs and have resulted in the development of new programs, including Medicare payment for performance initiatives and improvements to the physician quality reporting system and feedback program. Details of the changes to the Medicaid Drug Rebate program and the 340B program are discussed under the risk factor "</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">If we are able to successfully commercialize XHANCE and if we participate in but fail to comply with our reporting and payment obligations under the Medicaid drug rebate program, or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines which could have a material adverse effect on our business, financial condition, results of operations and growth prospects</font><font style="font-family:Arial;font-size:10pt;">" in the "Risk Factors" section of this 10-K.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Some states have elected not to expand their Medicaid programs to individuals with an income of up to 133% of the federal poverty level, as is permitted under the Affordable Care Act. For each state that does not choose to expand its Medicaid program, there may be fewer insured patients overall, which could impact our sales of products and product candidates for which we receive regulatory approval, and our business and financial condition. Where new patients receive insurance coverage under any of the new Medicaid options made available through the Affordable Care Act, the possibility exists that manufacturers may be required to pay Medicaid rebates on drugs used under these circumstances, a decision that could impact manufacturer revenues. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Some of the provisions of the Affordable Care Act have yet to be fully implemented, and certain provisions have been subject to judicial and Congressional challenges. In addition, there have been efforts by the Trump Administration to repeal or replace certain aspects of the Affordable Care Act and to alter the implementation of the Affordable Care Act and related laws. For example, on December 22, 2017, the U.S. government signed into law comprehensive tax legislation, referred to as the Tax Cuts and Jobs Act (the Tax Act), which includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; Further, the Bipartisan Budget Act of 2018, among other things, amended the Medicare statute to reduce the coverage gap in most Medicare drugs plans, commonly known as the &#8220;donut hole,&#8221; by raising the required manufacturer point-of-sale discount from 50% to 70% off the negotiated price effective as of January 1, 2019. Additional legislative changes, regulatory changes, and judicial challenges related to the Affordable Care Act remain possible. It is unclear how the Affordable Care Act and its implementation, as well as efforts to repeal or replace, or invalidate, the Affordable Care Act, or portions thereof, will affect our business, financial condition and results of operations. It is possible that the Affordable Care Act, as currently enacted or as it may be amended or replaced in the future, and other healthcare reform measures that may be adopted in the future, could have a material adverse effect on our industry generally and on our ability to maintain or increase sales of our products or product candidates for which we receive regulatory approval or to successfully commercialize our products and product candidates.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">U.S. Tax Reform </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On December 22, 2017, the U.S. enacted major tax reform legislation, Public Law No. 115-97, commonly referred to as the Tax Cuts and Jobs Act (2017 Tax Act). The 2017 Tax Act imposes a repatriation tax on accumulated earnings of foreign subsidiaries, implements a territorial tax system together with a current tax on certain foreign earnings and lowers the general corporate income tax rate to 21%.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Coverage and Reimbursement</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Significant uncertainty exists as to the coverage and reimbursement status of our products and any product candidates for which we may obtain regulatory approval. Sales of any of our products and product candidates, if approved, will depend, in part, on the extent to which the costs of the products will be covered by third-party payors, including government healthcare programs such as Medicare and Medicaid, and private payors, such as commercial health insurers and managed care organizations. Third-party payors determine which drugs they will cover and the amount of reimbursement they will provide for a covered drug. In the U.S., there is no uniform system among payors for making coverage and reimbursement decisions. In addition, the process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In order to secure coverage and reimbursement for our products we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costly studies required to obtain FDA or other comparable regulatory approvals. Even if we conduct pharmacoeconomic studies, our products and product candidates may not be considered medically necessary or cost-effective by payors. Further, a payor's decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the past, payors have implemented reimbursement metrics and periodically revised those metrics as well as the methodologies used as the basis for reimbursement rates, such as average sales price (ASP), average manufacturer price (AMP), and actual acquisition cost. The existing data for reimbursement based on these metrics is relatively limited, although certain states have begun to survey acquisition cost data for the purpose of setting Medicaid reimbursement rates. The Centers for Medicare and Medicaid Services (CMS) surveys and publishes retail pharmacy acquisition cost information in the form of National Average Drug Acquisition Cost files to provide state Medicaid agencies with a basis of comparison for their own reimbursement and pricing methodologies and rates.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Participation in the Medicaid Drug Rebate program requires us to pay a rebate for each unit of drug reimbursed by Medicaid. The amount of the "basic" portion of the rebate for each product is set by law as the larger of: (i)&#160;23.1% of quarterly AMP, or (ii)&#160;the difference between quarterly AMP and the quarterly best price available from us to any commercial or non-governmental customer (Best Price). AMP must be reported on a monthly and quarterly basis and Best Price is reported on a quarterly basis only. In addition, the rebate also includes the "additional" portion, which adjusts the overall rebate amount upward as an "inflation penalty" when the drug's latest quarter's AMP exceeds the drug's AMP from the first full quarter of sales after launch, adjusted for increases in the Consumer Price Index-Urban. The upward adjustment in the rebate amount per unit is equal to the excess amount of the current AMP over the inflation-adjusted AMP from the first full quarter of sales. The rebate amount is recomputed each quarter based on our report to CMS of current quarterly AMP and Best Price for our drug. The terms of our participation in the program would impose a requirement for us to report revisions to AMP or Best Price within a period not to exceed 12 quarters from the quarter in which the data was originally due. Any such revisions could have the impact of increasing or decreasing our rebate liability for prior quarters, depending on the direction of the revision.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Federal law requires that any manufacturer that participates in the Medicaid Drug Rebate program also participate in the 340B program in order for federal funds to be available for the manufacturer's drugs under Medicaid and Medicare Part&#160;B. The 340B program, which is administered by the Health Resource and Services Administration (HRSA) requires participating manufacturers to agree to charge statutorily defined covered entities no more than the 340B "ceiling price" for the manufacturer's covered outpatient drugs. These 340B covered entities include a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients. The 340B ceiling price is calculated using a statutory formula, which is based on the AMP and rebate amount for the covered outpatient drug as calculated under the Medicaid Drug Rebate program. Any changes to the definition of AMP and the Medicaid rebate amount under the Affordable Care Act or other legislation could affect our 340B ceiling price calculations and negatively impact our results of operations. HRSA issued a final regulation regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities, which became effective on January 1, 2019.  It is currently unclear how HRSA will apply its enforcement authority under the new regulation. HRSA also is implementing a ceiling price reporting requirement related to the 340B program during the first quarter of 2019 under which we will be required to report </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">340B ceiling prices to HRSA on a quarterly basis. In addition, legislation may be introduced that, if passed, would further expand the 340B program to additional covered entities or would require participating manufacturers to agree to provide 340B discounted pricing on drugs used in an inpatient setting.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Federal law also requires that a company that participates in the Medicaid Drug Rebate Program report ASP information each quarter to CMS for certain categories of drugs that are paid under the Medicare Part B program. Manufacturers calculate the average sales price based on a statutorily defined formula as well as regulations and interpretations of the statute by CMS. CMS uses these submissions to determine payment rates for drugs under Medicare Part B. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the U.S. Medicare program, outpatient prescription drugs may be covered under Medicare Part&#160;D. Medicare Part&#160;D is a voluntary prescription drug benefit, through which Medicare beneficiaries may enroll in prescription drug plans offered by private entities for coverage of outpatient prescription drugs. Part&#160;D plans include both stand-alone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare Advantage plans provided for under Medicare Part&#160;C.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Coverage and reimbursement for covered outpatient drugs under Part&#160;D are not standardized. Part&#160;D prescription drug plan sponsors are not required to pay for all covered Part&#160;D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. Any formulary used by a Part&#160;D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Although Part&#160;D prescription drug formularies must include drugs within each therapeutic category and class of covered Part&#160;D drugs, they have some flexibility to establish those categories and classes and are not required to cover all of the drugs in each category or class. Medicare Part&#160;D prescription drug plans may use formularies to limit the number of drugs that will be covered in any therapeutic class and/or impose differential cost sharing or other utilization management techniques.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The availability of coverage under Medicare Part&#160;D may increase demand for our products and any product candidates for which we receive marketing approval. However, in order for the products that we market to be included on the formularies of Part&#160;D prescription drug plans, we likely will have to offer pricing that is lower than the prices we might otherwise obtain. Changes to Medicare Part&#160;D that give plans more freedom to limit coverage or manage utilization, and other cost reduction initiatives in the program could decrease the coverage and price that we receive for any approved products and could harm our business.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In order to be eligible to have our products or any future products paid for with federal funds under the Medicaid and Medicare Part&#160;B programs, as applicable, and purchased by certain federal agencies and grantees, we also participate in the U.S. Department of Veterans Affairs (VA) Federal Supply Schedule (FSS) pricing program. Under this program, we are obligated to make our "innovator" drugs available for procurement on an FSS contract and charge a price to four federal agencies&#160;&#8212; the VA, U.S. Department of Defense (DoD) Public Health Service and U.S. Coast Guard&#160;&#8212; that is no higher than the statutory Federal Ceiling Price (FCP). The FCP is based on the non-federal average manufacturer price (Non-FAMP), which we calculate and report to the VA on a quarterly and annual basis. We also participate in the Tricare Retail Pharmacy program, under which we pay quarterly rebates on utilization of innovator products that are dispensed through the Tricare Retail Pharmacy network to Tricare beneficiaries. The rebates are calculated as the difference between the annual Non-FAMP and FCP.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by manufacturers, governmental or regulatory agencies, and the courts. Significant civil monetary penalties can be applied if a manufacturer is found to have knowingly submitted any false price information to the government or fails to submit the required price data on a timely basis. Such conduct also could be grounds for CMS to terminate the manufacturer's Medicaid drug rebate agreement, in which case federal payments may not be available under Medicaid or Medicare Part&#160;B for the manufacturer's covered outpatient drugs. Civil monetary penalties could also be applied if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price. In addition, claims submitted to federally-funded healthcare programs, such as Medicare and Medicaid, for drugs priced based on incorrect pricing data provided by a manufacturer can implicate the False Claims Act.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures, and foreign governments have shown significant interest in implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement, and requirements for substitution of generic products for branded prescription drugs. For example, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs, and reform government program reimbursement methodologies for drug products.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Beginning April&#160;1, 2013, Medicare payments for all items and services, including drugs, were reduced by 2% under the sequestration (i.e.,&#160;automatic spending reductions) required by the Budget Control Act of 2011, as amended by the American Taxpayer Relief Act of 2012. Subsequent legislation extended the 2% reduction, on average, to 2027. If Congress does not take action in the future to modify these sequestrations, Medicare Part&#160;D plans could seek to reduce their negotiated prices for drugs. Other legislative or regulatory cost containment legislation could have a similar effect.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Further, the Affordable Care Act may reduce the profitability of drug products. It expanded manufacturers' rebate liability under the Medicaid program from fee-for-service Medicaid utilization to include the utilization of Medicaid managed care organizations as well, increased the minimum Medicaid rebate due for most innovator drugs, and capped the total rebate amount at 100% of AMP. The Affordable Care Act and subsequent legislation also changed the definition of AMP. On February&#160;1, 2016, CMS issued final regulations to implement the changes to the Medicaid drug rebate program under the Affordable Care Act. These regulations became effective on April&#160;1, 2016.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Affordable Care Act requires pharmaceutical manufacturers of branded prescription drugs to pay a branded prescription drug fee to the federal government. Each such manufacturer pays a prorated share of the branded prescription drug fee of $2.8&#160;billion in 2019, based on the dollar value of its branded prescription drug sales to certain federal programs identified in the law. The Affordable Care Act also expanded the Public Health Service's 340B program to include additional types of covered entities. Substantial new provisions affecting compliance have also been enacted, which may affect our business practices with healthcare practitioners. It appears likely that the Affordable Care Act will continue the pressure on pharmaceutical pricing, especially under the Medicare and Medicaid programs, and may also increase our regulatory burdens and operating costs.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Additional legislative changes, regulatory changes and judicial challenges related to the Affordable Care Act remain possible, as discussed above under the heading "U.S. Healthcare Reform." In addition, there likely will continue to be proposals by legislators at both the federal and state levels, regulators, and third-party payors to contain healthcare costs. Thus, even if we obtain favorable coverage and reimbursement status for our products and any product candidates for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Additional information regarding these programs is discussed under the risk factor "</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">If we are able to successfully commercialize XHANCE and if we participate in but fail to comply with our reporting and payment obligations under the Medicaid drug rebate program, or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines which could have a material adverse effect on our business, financial condition, results of operations and growth prospects</font><font style="font-family:Arial;font-size:10pt;">" in the "Risk Factors" section of this 10-K.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Healthcare Fraud and Abuse Laws</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition to FDA restrictions on marketing of pharmaceutical products, our business is subject to healthcare fraud and abuse regulation and enforcement by both the federal government and the states in which we conduct our business. These laws include, but are not limited to, the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The federal Anti-kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any healthcare item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. A violation of the Anti-Kickback Statute may be established without proving actual knowledge of the statute or specific intent to violate it. The government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly and practices that involve remuneration to those who prescribe, purchase, or recommend pharmaceuticals, including certain discounts, or engaging such individuals as consultants, speakers or advisors, may be subject to scrutiny if they do not fit squarely within the exception or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from anti-kickback liability. Moreover, there are no safe harbors for many common practices, such as educational and </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:10px;padding-top:10px;"><font style="font-family:Arial;font-size:10pt;">research grants, charitable donations, product support and patient assistance programs. Arrangements that implicate the Anti-Kickback Statute and do not fit within an exception or safe harbor are reviewed on a case-by-case basis to determine whether, based on the facts and circumstances, they violate the statute.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The federal civil False Claims Act prohibits any person from, among other things, knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds, or knowingly making, using, or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. Actions under the False Claims Act may be brought by private individuals known as qui tam relators in the name of the government. In recent years, several pharmaceutical and other healthcare companies have faced enforcement actions under the False Claims Act for, among other things, providing free product to customers with the expectation that the customers would bill federal programs for the product, and other interactions with prescribers and other customers including interactions that may have affected customers' billing or coding practices on claims submitted to the federal government. Other companies have faced enforcement actions for causing false claims to be submitted because of the company's marketing the product for unapproved, and thus non-reimbursable, uses. Federal enforcement agencies also have shown increased interest in pharmaceutical companies' product and patient assistance programs, including reimbursement and co-pay support services, and a number of investigations into these programs have resulted in significant civil and criminal settlements.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, which we refer to collectively as HIPAA, prohibits, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party payors. HIPAA also prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services. We may obtain health information from third parties that are subject to privacy and security requirements under HIPAA and we could potentially be subject to criminal penalties if we, our affiliates, or our agents knowingly obtain or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The majority of states also have statutes or regulations similar to the federal anti-kickback and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Several states now require pharmaceutical companies to report expenses relating to the marketing and promotion of pharmaceutical products in those states and to report gifts and payments to individual health care providers in those states. Some of these states also prohibit certain marketing-related activities including the provision of gifts, meals, or other items to certain health care providers. Other states have laws requiring pharmaceutical sales representatives to be registered or licensed, and still others impose limits on co-pay assistance that pharmaceutical companies can offer to patients. In addition, several states require pharmaceutical companies to implement compliance programs or marketing codes.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Physician Payments Sunshine Act, implemented as the Open Payments program, and its implementing regulations, requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children's Health Insurance Program (with certain exceptions) to report annually to CMS information related to direct or indirect payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held in the company by physicians and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report information regarding payments and transfers of value provided to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists and certified nurse-midwives.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Compliance with such laws and regulations will require substantial resources. Because of the breadth of these various fraud and abuse laws, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Such a challenge could have material adverse effects on our business, financial condition and results of operations. In the event governmental authorities conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations, they may impose sanctions under these laws, which are potentially significant and may include civil monetary penalties, damages, exclusion of an entity or individual from participation in government health care programs, criminal fines and imprisonment, additional reporting requirements if we become subject to a corporate </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">integrity agreement or other settlement to resolve allegations of violations of these laws, as well as the potential curtailment or restructuring of our operations. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Healthcare Privacy Laws</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We may be subject to laws and regulations covering data privacy and the protection of health-related and other personal information. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues which may affect our business. Numerous federal and state laws and regulations, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use, disclosure, and protection of personal information. Failure to comply with such laws and regulations could result in government enforcement actions and create liability for us (including the imposition of significant penalties), private litigation and/or adverse publicity that could negatively affect our business. In addition, healthcare providers who prescribe our products and research institutions we collaborate with are subject to privacy and security requirements under HIPAA.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Corrupt Practices Act</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition, the U.S. Foreign Corrupt Practices Act prohibits corporations and individuals from engaging in certain activities to obtain or retain business or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any official of another country, government staff member, political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in that capacity.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Employees</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of March 1, 2019, we had a total of 102 full-time employees and three part-time employees. The majority of our employees are located in the U.S., with the exception of three employees located in United Kingdom and two employees located in Norway. We have no collective bargaining agreements with our employees and none are represented by labor unions. We consider our current relations with our employees to be good.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Properties</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our principal office is located in Yardley, Pennsylvania, where we lease approximately 30,000 square feet of office space pursuant to a lease that expires in May 2021. We also lease facilities in Ewing, New Jersey, Oslo, Norway and Swindon, England. We believe our facilities are adequate to meet our current needs, although we may seek to negotiate new leases or evaluate additional or alternate space for our operations. We believe appropriate alternative space will be readily available on commercially reasonable terms.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are not currently a party to any legal proceedings.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Corporate Information </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We were incorporated under the laws of the State of Delaware in May 2010. Our predecessor entity OptiNose&#160;AS was formed under the laws of Norway in September&#160;2000. In 2010, OptiNose&#160;AS became our subsidiary as part of an internal reorganization. Our corporate office is located at 1020 Stony Hill Road, Suite 300, Yardley, PA 19067. Our telephone number is (267) 364-3500. We maintain an Internet website at www.optinose.com. The information contained on our website is not incorporated by reference into this Form 10-K. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We make available free of charge under the &#8220;Investors&#8212;SEC Filings&#8221; section of our website all of our filings with the SEC, including our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements and amendments to such documents, each of which is provided on our website as soon as reasonably practicable after we electronically file the information with the SEC. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="s7BE26810FD4D592EA61C57006AE3B252"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ITEM 1A. RISK FACTORS</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Investing in our common stock involves a high degree of risk. Before deciding to invest in our common stock, you should consider carefully the risks and uncertainties described below, together with general economic and business risks and all of the other information contained in this 10-K, including our consolidated financial statements and the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">related notes and the section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations." If any of the following risks actually occur, our business, financial condition, results of operations and prospects could be harmed. In that event, the price of our common stock could decline and you could lose all or part of your investment. This 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of specific factors, including the risks described below. See "Note Regarding Forward-Looking Statements."</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Risks Related to Our Financial Position and Capital Resources</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">We have incurred significant losses since our inception and anticipate that we will incur continued losses in the future.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are a specialty pharmaceutical company with a limited operating history. To date, we have focused primarily on developing XHANCE as well as other product candidates using our proprietary exhalation delivery system (EDS) technology. Since inception, we have incurred significant net losses and expect to continue to incur net losses for the foreseeable future. To date, we have generated revenue from sales of XHANCE since its launch in 2018 and from our license agreement (the AVP-825 License Agreement) with Avanir Pharmaceuticals, Inc. (Avanir), pursuant to which we granted them the exclusive right to further develop and commercialize AVP-825 for the acute treatment of migraines in adults. We incurred net losses of </font><font style="font-family:Arial;font-size:10pt;">$106.7 million</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$48.9 million</font><font style="font-family:Arial;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively.  As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, we had an accumulated deficit of </font><font style="font-family:Arial;font-size:10pt;">$317.9 million</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We expect to incur losses for the foreseeable future as we:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">continue to commercialize XHANCE and further scale up external manufacturing and distribution capabilities to commercialize XHANCE or any other product candidate for which we may obtain regulatory approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">continue to focus our regulatory compliance efforts on requirements applicable to marketed drugs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">continue clinical development activities for XHANCE, including the U.S. Food and Drug Administration (FDA) mandated pediatric studies, and a Phase 3b clinical trial in pursuit of a follow-on indication for the treatment of chronic sinusitis;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">seek to discover and develop, in-license or acquire additional products, product candidates and technology;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">maintain, expand and protect our intellectual property portfolio;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">hire additional commercial, clinical, manufacturing and scientific personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">add operational, financial and management information systems and personnel, including personnel to support commercialization efforts; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">incur additional legal, accounting and other expenses in operating as a publicly traded commercial-stage company.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Because of the numerous risks and uncertainties associated with drug development and commercialization, we are unable to accurately predict the timing or amount of expenses or when, or if, we will be able to achieve profitability. If we are required by regulatory authorities to perform studies in addition to those expected, or if there are any delays in the initiation and completion of our clinical trials or the development of any of our product candidates, our expenses could increase.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">We may never achieve or maintain profitability</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our ability to become and remain profitable will depend on our ability to generate revenue. Our ability to generate revenue depends upon our ability to successfully commercialize XHANCE and any of our other product candidates or any other product candidates, if approved, that we may in-license or acquire in the future, as well as from our ability to successfully out-license any of our products or technology. Our ability to generate revenue from our current or future products and product candidates will depend on a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our ability to successfully commercialize XHANCE for the treatment of nasal polyps;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our ability to successfully complete required clinical trials and submit a supplemental new drug application to the FDA and obtain regulatory approval for XHANCE for the treatment of chronic sinusitis;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our ability to complete and submit applications to, and obtain regulatory approval from, foreign regulatory authorities, if we choose to commercialize XHANCE outside the U.S.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the size of the markets in the territories for which we gain regulatory approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the performance of our contract sales organization, and once onboarded our internal sales team, in marketing and promoting XHANCE;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our ability to maintain and further develop a commercial organization capable of sales, marketing and distribution for XHANCE and any of our other product candidates for which we may obtain marketing approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our ability to maintain commercially reasonable agreements with wholesalers, distributors and other third parties in our supply chain;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our success in establishing a commercially viable price for our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our success in defending against potential generic competition and other developments in our market generally;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our ability to manufacture commercial quantities of our products at acceptable cost levels;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our ability to obtain coverage and adequate reimbursement from third parties, including government payors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our ability to commercialize and/or find a partner to commercialize AVP-825; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our ability to successfully complete development activities, including the necessary clinical trials, with respect to our other product candidates.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">XHANCE, as well as any of our other product candidates, if approved for commercial sale, may not gain market acceptance or achieve commercial success. If our addressable market is not as significant as we estimate or the treatment population is narrowed by competition, physician choice or clinical practice guidelines, we may not generate significant revenue from sales of XHANCE. In addition, we would anticipate incurring significant costs associated with commercializing any approved product. We may not achieve profitability soon after generating product sales, if ever. If we are unable to generate enough product revenues to cover our operating expenses and prior losses, we will not become profitable and may be unable to continue operations without continued funding.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our development efforts, obtain drug approvals, diversify our offerings or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">We will likely require additional capital to fund our operations and, if we fail to obtain necessary financing, we may be unable to continue the commercialization of XHANCE and the development of our other product candidates.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our operations have consumed substantial amounts of cash. To date, we have financed our operations primarily through the sale and issuance of common and preferred stock, debt, licensing revenues, 2018 XHANCE revenue and research grants. We expect to continue to spend substantial amounts to commercialize XHANCE and to advance the clinical development of XHANCE for the treatment of chronic sinusitis and our other product candidates. As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, we had cash and cash equivalents of </font><font style="font-family:Arial;font-size:10pt;">$201.0 million</font><font style="font-family:Arial;font-size:10pt;">. Although it is difficult to predict our future liquidity requirements, we believe that existing cash and cash equivalents at December 31, 2018 will be sufficient to meet our debt service obligations under our Notes, and to carry out our planned development and commercial activities into the fourth quarter of 2020. Our estimate of the period of time through which our financial resources will be adequate to support our operations is based on assumptions that may prove to be wrong, and we could deplete our available capital resources sooner than we currently expect.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the success of our commercialization of XHANCE for the treatment of nasal polyps including, among other things, patient and physician acceptance of XHANCE and our ability to obtain adequate insurance coverage and reimbursement for XHANCE; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the cost of commercialization activities for XHANCE, including product manufacturing, distribution, marketing and sales; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">net product revenues received from sales of XHANCE;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the costs and timing of internalizing and expanding our sales force;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the level of co-pay assistance and other patient affordability programs offered for XHANCE; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our clinical development plans for XHANCE, including FDA-mandated pediatric studies and clinical trials for the supplemental indication for the treatment of chronic sinusitis; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the outcome, timing and cost of the regulatory approval process of XHANCE for chronic sinusitis by the FDA, including the potential for the FDA to require that we perform more studies and clinical trials than those that we currently expect; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the costs involved in preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">fluctuations in the three-month LIBOR-based floating interest rate of our Notes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the initiation, progress, timing, costs and results of clinical trials and other research and development related to additional product candidates; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the extent to which we in-license, acquire or otherwise partner in development of other products, product candidates or technologies. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We cannot be certain that additional funding will be available when needed on acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts, when required or on acceptable terms, we also could be required to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">seek strategic collaborations to assist in the commercialization of XHANCE in the U.S. and other markets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">significantly delay, scale back or discontinue the development of XHANCE for the treatment of chronic sinusitis;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">relinquish or license on unfavorable terms our rights to our EDS devices and technologies or other product candidates that we otherwise would seek to develop or commercialize ourselves;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">delay, limit, reduce or terminate the drug development of our current or future product candidates, or seek collaborators for one or more of our current or future product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">significantly curtail our operations.</font></div></td></tr></table><div style="line-height:120%;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Although we may have the ability to obtain an additional $25.0 million through the issuance of additional senior secured notes pursuant to the Note Purchase Agreement, the availability of this $25.0 million is subject to certain conditions that we may not be able to meet. </font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Our failure to comply with the covenants or other terms of the Note Purchase Agreement, including as a result of events beyond our control, could result in a default under the Note Purchase Agreement that could materially and adversely affect the ongoing viability of our business.</font></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On December 29, 2017, we entered into a Note Purchase Agreement with Athyrium Opportunities III Acquisition LP, as collateral agent (the Collateral Agent) and the purchasers party thereto (the Purchasers) that provides for the issuance of up to $100.0 million of senior secured notes (the Notes). $75.0 million of the Notes were issued on December 29, 2017, of which $50.0 million were issued by OptiNose AS and $25.0 million were issued by OptiNose US, Inc. (the Issuers.) The remaining $25.0 million of Notes (the Delayed Draw Notes) may be issued by OptiNose US, Inc. and sold to the Purchasers between April 1, 2019 and August 14, 2019, subject to us and our consolidated subsidiaries achieving trailing four quarter net revenues (as calculated pursuant to the terms of the Note Purchase Agreement) of $15.0 million, a pro forma ratio of total debt to trailing four quarter net revenues not exceeding 6.50 to 1.00 and other specified conditions.  </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The unpaid principal amount under the Notes is due and payable on June 29, 2023 (the Maturity Date). The proceeds of the Notes were used to provide ongoing working capital to support the launch and commercialization of XHANCE, as well as for general corporate purposes. The Notes bear interest at a per annum rate of three-month LIBOR rate (subject to a 1.0% floor) plus 9.0%. The interest rate was </font><font style="font-family:Arial;font-size:10pt;">11.8125%</font><font style="font-family:Arial;font-size:10pt;">&#32;at </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">. The Issuers are required to make quarterly interest-only payments until the Maturity Date. In addition, the Issuers paid an upfront fee of 1% of the aggregate commitment amount of the Notes on December 29, 2017. We are also required to pay an exit fee of 2% of any principal payments (whether mandatory, voluntary or at maturity) made throughout the term of the Note Purchase Agreement. </font></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition, each Note holder may elect to accelerate the repayment of all unpaid principal and accrued interest under such holder&#8217;s Note upon consummation of a specified change of control transaction or occurrence of certain events of default (as specified in the Note Purchase Agreement), including, among other things:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our default in a payment obligation under the Notes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our breach of the restrictive covenants or other terms of the Notes; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our breach of reporting obligations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our failure to properly maintain the collateral; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">certain specified insolvency and bankruptcy-related events.</font></div></td></tr></table><div style="line-height:120%;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Subject to any applicable cure period set forth in the Notes, all amounts outstanding with respect to the Notes (principal and accrued interest) would become due and payable immediately upon an event of default. Our assets or cash flow may not be sufficient to fully repay our obligations under the Notes if the obligations thereunder are accelerated upon any events of default. Further, if we are unable to repay, refinance or restructure our obligations under the Notes, the holders of such Notes could proceed to protect and enforce their rights under the Notes by exercising such remedies as are available to the holders thereunder and in respect thereof under applicable law, either by suit in equity or by action at law, or both, whether for specific performance of any covenant or other agreement contained in the Notes or in aid of the exercise of any power granted in the Notes. The foregoing would materially and adversely affect the ongoing viability of our business.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Our Note Purchase Agreement contains restrictions that limit our flexibility in operating our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Note Purchase Agreement contains various covenants that limit our ability to engage in specified types of transactions without our lenders&#8217; prior consent. These covenants limit our ability to, among other things:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">sell, transfer, lease or dispose of our assets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">create, incur or assume additional indebtedness;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">encumber or permit liens on certain of our assets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">make restricted payments, including paying dividends on, repurchasing or making distributions with respect to our common stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">make specified investments (including loans and advances); </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">consolidate, merge, sell or otherwise dispose of all or substantially all of our assets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">enter into certain transactions with our affiliates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">grant certain license rights related to our products, technology and other intellectual property rights; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">permit our cash and cash equivalents held in certain deposit accounts to be less than $10,000,000 at any time.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The covenants in our Note Purchase Agreement and related security agreements may limit our ability to take certain actions that may be in our long-term best interests.&#160; In the event that we breach one or more covenants, our lenders may choose to declare an event of default and require that we immediately repay all amounts outstanding, plus penalties and interest, terminate their commitments to extend further credit and foreclose on the collateral granted to them to secure such indebtedness. Such repayment could have a material adverse effect on our business, operating results and financial condition.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Provisions of the Notes for certain potential payments to the holders of such Notes that could impede a sale of the Company.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Subject to certain exceptions, the Issuers are required to make mandatory prepayments of the Notes, with the proceeds of assets sales, extraordinary receipts and prohibited debt issuances, and upon the occurrence of a change of control. In addition, the Issuers may make voluntary prepayments of the Notes, in whole or in part. All mandatory and voluntary prepayments of the Notes are subject to the payment of prepayment premiums as follows: (i) if prepayment occurs prior to the second anniversary of the applicable date of issuance, an amount equal to the amount by which (a) the present value of 102% of the principal prepaid plus all interest that would have accrued on such principal through such second anniversary exceeds (b) the amount of principal prepaid, (ii) if prepayment occurs on or after the second anniversary of the applicable date of issuance but prior to the third anniversary of such issuance, an amount equal to 2% of the principal prepaid, and (iii) if prepayment occurs on or after the third anniversary of the applicable date of issuance but prior to the fourth anniversary of such issuance, an amount equal to 1% of the principal prepaid. No prepayment premium is due on any principal prepaid after the fourth anniversary of the applicable date of issuance of any Notes.  These provisions may make it more costly for a potential acquirer to engage in a business combination transaction with us. Provisions that have the effect of discouraging, delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect the price that some investors are willing to pay for our common stock.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We do not have any committed external source of funds other than the additional $25.0 million that may become available under the Note Purchase Agreement between April 1, 2019 and August 14, 2019, subject to us and our consolidated subsidiaries achieving trailing four quarter net revenues (as calculated pursuant to the terms of the Note Purchase Agreement) of $15.0 million, a pro forma ratio of total debt to trailing four quarter net revenues not exceeding 6.50 to 1.00 and other specified conditions. Until such time, if ever, as we can generate substantial revenue, we may seek additional capital through a combination of private and public equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Debt financings may be coupled with an equity component, such as warrants to purchase shares, which could also result in dilution of our existing stockholders' ownership. The incurrence of additional indebtedness would result in increased fixed payment obligations and could also result in certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business and may result in liens being placed on our assets and intellectual property. If we were to default on such indebtedness, we could lose such assets and intellectual property.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If we raise additional funds through collaborations, or strategic alliance, marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, product candidates or future revenue streams or grant licenses on terms that are not favorable to us.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Our ability to use our net operating loss carry forwards and other tax attributes may be limited.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, we had U.S. federal net operating loss (NOL) carry forwards of approximately </font><font style="font-family:Arial;font-size:10pt;">$86.6</font><font style="font-family:Arial;font-size:10pt;">&#32;million available to offset future U.S. taxable income and U.S. federal research and development (R&amp;D) tax credits of $2.4 million.&#160;While some of our federal NOL carry forwards will carry forward indefinitely, some of our U.S. NOL and credit carry forwards will expire if not utilized with the first expiration occurring in 2030.&#160;We also have state NOL carry forwards of </font><font style="font-family:Arial;font-size:10pt;">$57.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">. These state NOL carry forwards can only offset income in the same state in which they were generated and thus may not be utilized. The carry forward period varies among the states, with the first expiration in 2028, and some may expire unutilized. In addition, our Norwegian and UK subsidiaries have total foreign NOL carry forwards of </font><font style="font-family:Arial;font-size:10pt;">$50.5 million</font><font style="font-family:Arial;font-size:10pt;">&#32;as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">. These foreign NOL carry forwards do not expire but can only be used to offset profits generated in Norway or the United Kingdom, respectively, and may be limited in use based on the laws of those countries.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our U.S. NOL and tax credit carry forwards could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of the restrictions under U.S. tax law. Under Sections 382 and 383, if a corporation undergoes an &#8220;ownership change&#8221;, generally defined as a greater than 50% change, by value, in equity ownership during a three-year period, the corporation&#8217;s ability to offset pre-change tax attributes, such as </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">NOLs and R&amp;D tax credits, against post-change income or tax may be limited. We have not performed an analysis under Section 382 and cannot predict or otherwise determine whether utilization of our federal tax attribute carry forwards may be limited. As a result, if we have taxable income in the future, our ability to use existing U.S. NOL and R&amp;D tax credit carry forwards to reduce U.S. taxable income or tax liability may be subject to limitation resulting in increased future tax liabilities. Similar rules at the state level may also limit our ability to use state NOLs. Also, there may be periods when the use of NOLs is suspended or otherwise limited at the state level, which could accelerate or permanently increase state taxes owed.  </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We may have ownership changes in the future due to additional changes in our stock ownership which could be outside of our control. If an ownership change occurs and our ability to use our historical net operating loss and tax credit carry forwards is limited, it could adversely impact our future operating results by increasing our tax obligations.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">The termination of the AVP-825 License Agreement may generate additional expenses for us.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On December 10, 2018, we received written notice from Avanir of its election to terminate the AVP-825 License Agreement. As a result, the AVP-825 License Agreement is expected to terminate on March 10, 2019 (the Termination Date). We do not expect to receive any additional proceeds from the AVP-825 License Agreement.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upon termination of the AVP-825 License Agreement, we may elect to continue to commercialize Onzetra Xsail ourselves or through a new licensee. However, we may not be able to find a new licensee willing to enter into a license agreement on commercially reasonable terms, if at all. Further, we may incur additional expenses in connection with the process of identifying potential new licensees and in connection with the termination of the AVP-825 License Agreement.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Foreign exchange risks and controls may affect our financial position and results of operations.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Through the operation of our subsidiaries based in the United Kingdom and Norway, we are exposed to foreign currency fluctuations and exchange rate risks. In addition to the operations of our foreign subsidiaries, we also contract with vendors that are located outside the U.S., and in some cases make payment of invoices denominated in foreign currencies. We are subject to fluctuations in foreign currency rates in connection with these arrangements and we do not currently hedge our foreign currency exchange rate risk. In addition, because we maintain our consolidated financial statements in U.S. dollars, our financial results are vulnerable to fluctuations in the exchange rate between the U.S. dollar and foreign currencies, such as the British pound sterling, the euro, and the Norwegian krone. In preparing our consolidated financial statements, we must convert all non-U.S. dollar results to U.S. dollars, which impacts our results of operations, is reflected as a component of our stockholder's equity (deficit), and may be credited or charged to operations and reflected in other income (expense), net. The impact of changes in exchange rates has not been significant historically. However, changes in exchange rates could cause significant changes in our financial position and results of operations in the future.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Risks Related to Commercialization of XHANCE</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">We have a limited history of commercializing drugs, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Although our predecessor and subsidiary OptiNose AS commenced operations in 2000, our operations to date have been largely focused on raising capital and developing AVP-825 and XHANCE, including undertaking preclinical studies and conducting clinical trials, as well as commercializing XHANCE through the last nine months of 2018. While we conducted the pre-approval stages of clinical development for AVP-825, Avanir was responsible for completing the clinical development of, obtaining regulatory approval for, and initiating the commercial launch of that product under our license agreement with them. Further, while we have been commercializing XHANCE for the last nine months of 2018, we have limited history regarding sales, marketing, distribution and other activities necessary for successful product commercialization. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer history of successfully developing and commercializing drugs.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">If we are unable to successfully commercialize XHANCE, our business, financial condition and results of operations may be materially adversely affected and the price of our common stock may decline.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our ability to successfully commercialize XHANCE depends on many factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Wingdings;font-size:8pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our ability to manufacture commercial quantities of XHANCE at a reasonable cost and with sufficient speed to meet commercial demand;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our ability to manage our third-party sales organization, and once onboarded our internal sales team, to market, promote and sell XHANCE;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our success in educating physicians, patients and caregivers about the benefits, administration and use of XHANCE;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the availability, perceived advantages, relative cost, relative safety and relative efficacy of competing products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the availability of coverage and adequate reimbursement for XHANCE;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our ability to commercialize XHANCE at a profitable average net revenue per prescription;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our ability to contract with wholesalers distributors and/or preferred pharmacy network partners (PPNPs) on acceptable terms;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our ability to obtain regulatory approval for XHANCE for a follow-on indication for the treatment of chronic sinusitis;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the effectiveness of our marketing campaigns;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our ability to attract and retain qualified pharmaceutical industry personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our effective use of promotional resources;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a continued acceptable safety profile for XHANCE;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our ability to obtain and maintain appropriate state licenses in the states in which we sell or intend to sell XHANCE; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our ability to successfully defend any challenges to our intellectual property relating to XHANCE.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">It is difficult for us to predict future performance. As we gain additional commercial experience, a number of factors over which we have limited control may contribute to fluctuations in our financial results. Demand for our products may be impacted adversely by the annual resetting of patient healthcare insurance plan deductibles, both of which may cause patients to delay fulfilling an XHANCE prescription. Demand may also be impacted by the seasonal variation in patient visits with their doctor. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Many of these matters are beyond our control and are subject to other risks described elsewhere in this "Risk Factors" section. Accordingly, we cannot assure you that we will be able to successfully commercialize or generate enough revenue from XHANCE to achieve profitability. If we cannot do so, or are significantly delayed in doing so, our business, financial condition and results of operations may be materially adversely affected and the price of our common stock may decline.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">The commercial success of XHANCE will depend upon its acceptance by multiple stakeholders, including physicians, patients and healthcare payors.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Physicians may not prescribe XHANCE, in which case we would not generate the revenues we anticipate. The degree of market acceptance of XHANCE will depend on a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">demonstration of clinical safety and efficacy;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">relative convenience and ease of administration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">pricing and cost-effectiveness;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">availability of alternative treatments and perceived advantages over such alternative treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the clinical indications for which XHANCE is approved;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the prevalence and severity of any AEs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">limitations or warnings contained in the FDA-approved label for XHANCE;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the effectiveness of our or any future collaborators' sales and marketing strategies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">consolidation among healthcare providers, which increases the impact of the loss of any relationship;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the willingness of patients to pay out-of-pocket in the absence of third-party coverage.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If XHANCE does not achieve an adequate level of acceptance by physicians, patients and healthcare payors, we may not generate sufficient revenue in order to become or remain profitable.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">If third-party payors do not reimburse patients for XHANCE or if reimbursement levels are set too low for us to sell XHANCE at a profit, our ability to successfully commercialize XHANCE and our results of operations will be harmed.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our ability to commercialize XHANCE successfully depends in part on the extent to which coverage and adequate reimbursement for XHANCE will be available in a timely manner from third-party payors, including governmental healthcare programs such as Medicare and Medicaid, commercial health insurers and managed care organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, determine which medications they will cover and establish reimbursement levels. Reimbursement decisions by particular third-party payors depend upon a number of factors, including each third-party payor's determination that use of a product is:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a covered benefit under its health plan;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">appropriate and medically necessary for the specific condition or disease;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">cost effective; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">neither experimental nor investigational.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Obtaining coverage and reimbursement approval for XHANCE from government authorities or other third-party payors is a time consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data, including expensive pharmacoeconomic studies beyond the data required to obtain marketing approval, for the use of XHANCE to each government authority or other third-party payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement from government authorities or other third-party payors.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Third-party payors may deny reimbursement for covered products if they determine that a medical product was not used in accordance with cost-effective diagnosis methods, as determined by the third-party payor, or was used for an unapproved indication. Third-party payors also may refuse to reimburse for procedures and devices deemed to be experimental. Third-party payors may also limit coverage to specific products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement for medical products and services. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Levels of reimbursement may also decrease in the future, and future legislation, regulation or reimbursement policies of third-party payors may adversely affect the demand for and reimbursement available for XHANCE, which in turn, could negatively impact pricing.  Further, payors, including healthcare insurers, pharmacy benefit managers and group purchasing organizations, increasingly seek ways to reduce their costs. Many payors continue to adopt benefit plan changes that shift a greater portion of prescription costs to patients. Such measures include more limited benefit plan designs, higher patient co-pay or co-insurance obligations and limitations on patients&#8217; use of commercial manufacturer co-pay payment assistance programs (including through co-pay accumulator adjustment or maximization programs). Payors also increasingly seek price discounts or rebates in connection with the placement of our products on their formularies or those they manage. Payors may also control costs by imposing restrictions on access to or usage of our products, such as by requiring prior authorizations or "step-edits," and may choose to exclude certain indications for which our products are approved or even choose to exclude coverage entirely. For example, insurers may establish a step-edit system that requires a patient to first use a lower price alternative product prior to becoming eligible for reimbursement of a higher price product. Some providers may not complete the burdensome administrative process required to demonstrate or document that the patients for whom XHANCE has been prescribed meet the payors&#8217; utilization management criteria (i.e., prior authorizations or step-edits) and, as a result, patients will not gain access to XHANCE treatment. Further, other patients may obtain coverage for XHANCE but abandon their prescriptions rather than pay their co-pay payment which would result in a significant shortfall in achieving revenue expectations and negatively impact our business, prospects, results of operations and financial condition.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Significant consolidation in the health insurance industry has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage. Further consolidation among insurers, pharmacy benefit managers and other payors, including through integrated delivery systems, would increase the negotiating leverage such entities have over us and other drug manufacturers. Ultimately, further discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products.  </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">If we are unable to differentiate XHANCE from current and future products or existing methods of treatments, our ability to successfully commercialize XHANCE would be adversely affected.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are currently commercializing XHANCE for the treatment of nasal polyps and intend to seek FDA approval for a follow-on indication of XHANCE for the treatment of chronic sinusitis. Currently, Nasonex, marketed by Merck, is the only other branded drug therapy approved by the FDA for the treatment of nasal polyps. A generic version of Nasonex, mometasone furoate monohydrate, was approved by the FDA for, among other indications, the treatment of nasal polyps and launched in 2016. In addition, Beconase AQ, which is an INS marketed by GlaxoSmithKline, is indicated for the prophylaxis of nasal polyps after surgical resection, while SINUVA</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">TM</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;is a commercially available corticosteroid-eluting implant indicated for the treatment of nasal polyps in adult patients who have had ethmoid sinus surgery that can be placed in the ethmoid sinus under endoscopic visualization for up to 90 days. We are not aware of any product approved for the treatment of chronic sinusitis. In addition to competition from Nasonex and Beconase&#160;AQ, we will also need to differentiate XHANCE from other products and treatments identified in current clinical practice guidelines for the treatment of chronic rhinosinusitis with and without nasal polyps. Such products and treatments include the use of nasal rinses, decongestants, over-the-counter and INS products, oral steroids, antibiotics, and sinus surgery and other procedures, including functional endoscopic sinus surgery, balloon sinus dilation and steroid-releasing sinus implants. In addition, several biologic monoclonal antibodies are in clinical development for the treatment of nasal polyps, including omalizumab, reslizumab, mepolizumab and dupilumab. For dupilumab, the submission of an Supplemental Biologics License Application (sBLA)&#160;was recently publicly announced. In addition, there are new small molecules, including fevipiprant, being developed for the treatment of nasal polyps, that are also believed to inhibit specific pathways of inflammation present in nasal polyps. If we are unable to achieve significant differentiation for XHANCE against these other products and treatments, including on the basis of efficacy, safety and tolerability profile, reliability, convenience of administration, price and reimbursement, the opportunity for XHANCE to be commercialized successfully would be adversely affected.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">If the market opportunities for XHANCE are smaller than we believe, our revenue may be adversely affected, and our business may suffer.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our initial target market for XHANCE consists of ENT physicians, allergists and high-decile INS-prescribing primary care physicians that we believe treat an estimated 3.5&#160;million U.S. patients with chronic rhinosinusitis, an estimated 1.2&#160;million of whom have chronic rhinosinusitis with nasal polyps. If we are able to obtain a follow-on indication of XHANCE for the treatment of chronic sinusitis, we intend to broaden our reach and target primary care physicians that we believe treat an additional estimated 6.25&#160;million patients with chronic rhinosinusitis, an estimated one-third of whom have chronic rhinosinusitis with nasal polyps.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our projections of both the number of people who suffer from chronic rhinosinusitis with and without nasal polyps, as well as the subset of people with these diseases who have the potential to benefit from the use of XHANCE, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys we commissioned, prescription data or other market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of chronic rhinosinusitis or nasal polyps. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for XHANCE may be limited or may not be amenable to treatment with XHANCE, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Clinical practice guidelines and recommendations published by various organizations could have significant influence on the use of XHANCE.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Government agencies may promulgate clinical practice guidelines directly applicable to XHANCE. In addition, professional societies, practice management groups, private health and science foundations and organizations involved in various diseases from time to time may also publish guidelines or recommendations to the healthcare and patient communities. Recommendations of government agencies or these other groups or organizations may relate to such matters as usage, dosage, route of administration and use of concomitant therapies. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Recommendations or guidelines suggesting the reduced use of XHANCE or the use of competitive or alternative products as the standard of care to be followed by patients and healthcare providers could result in decreased use of XHANCE.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">If we are unable to maintain agreements with third parties to market and sell XHANCE, or we are unable to effectively onboard our third party sales force to employees, our business may be harmed.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We currently have limited sales, marketing or distribution capabilities. We have contracted to use an outsourced contract sales organization (CSO) to promote XHANCE to our defined specialty audience of ENT and allergy specialists and high-decile INS-prescribing primary care physicians. While we plan to transition to an internal sales force model in April 2019, our CSO may not dedicate sufficient resources to the commercialization of XHANCE prior to such transition or may otherwise fail in its commercialization due to factors beyond our control. Additionally, our CSO may fail to comply with applicable legal or regulatory requirements, or may enter into agreements with other parties that have products and services that could compete with XHANCE. Additionally, we may not effectively or efficiently manage such transition and our sales force may fail to comply with applicable legal or regulatory requirements. This could subject us to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional oversight and reporting requirements if we become subject to a corporate integrity agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We may also seek to enter into a strategic collaboration with a third party to commercialize XHANCE. We face significant competition in seeking appropriate strategic collaborators, and these strategic collaborations can be intricate and time-consuming to negotiate and document. We may not be able to negotiate strategic collaborations on acceptable terms, or at all. We are unable to predict when, if ever, we will enter into any strategic collaborations because of the numerous risks and uncertainties associated with establishing strategic partnerships.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">A significant portion of our sales are to a limited number of pharmaceutical wholesalers and PPNPs. Changes in terms required by these wholesalers, disruptions in these relationships or a default could harm our results of operations and financial condition.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Approximately 42% of our XHANCE net revenues during the&#160;fiscal year ended&#160;</font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;were to the three largest pharmaceutical wholesalers. Additionally, approximately 57% of our XHANCE net revenues during the&#160;fiscal year ended&#160;</font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;were to PPNPs, the majority of which relate to a particular PPNP, Foundation Care LLC.&#160;If any of these wholesalers or PPNPs ceases to purchase our product for any reason, then unless and until the remaining wholesalers or PPNPs increase their purchases of XHANCE or alternative distribution channels are established:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our commercial operations could be significantly disrupted;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the availability of XHANCE to patients could be disrupted; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">we may not achieve the sales of XHANCE that we expect, which could decrease our revenues.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We do not require collateral from our wholesalers or PPNPs but rather maintain credit limits and as a result we have an exposure to credit risk in our accounts receivable. A default by a large wholesaler or PPNP could harm our results of operations and financial condition.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">In addition to pharmaceutical wholesalers, we rely on PPNPs for distribution of XHANCE in the U.S., and the failure of those PPNPs to distribute XHANCE effectively would adversely affect sales of XHANCE. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our reliance on PPNPs for the distribution of XHANCE in the U.S. involves certain risks, including, but not limited to, risks that these PPNPs will: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">not provide us accurate or timely information regarding their inventories, the number of patients who are using our products or complaints about our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">reduce or discontinue their efforts to sell or support or otherwise not effectively sell or support our products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">not devote the resources necessary to sell our products in the volumes and within the time frames that we expect; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">engage in unlawful or inappropriate business practices that result in legal or regulatory enforcement activity which could result in liability to our Company or damage our goodwill with patients; or </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">be unable to satisfy financial obligations to us or others. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In the event that any of the PPNPs with whom we work do not fulfill their contractual obligations to us or refuse to or fail to adequately serve patients, or the agreements are terminated without adequate notice, shipments of XHANCE, and associated revenues, would be adversely affected. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">If we cannot successfully implement our patient affordability programs or improve formulary access for XHANCE in the face of increasing pressure to reduce the price of medications, the adoption of XHANCE by physicians and patients may decline. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">While we offer patient affordability programs through traditional retail pharmacies, part of our commercial strategy to increase adoption and access to XHANCE is to offer physicians the opportunity to have patients fill prescriptions through PPNPs that can apply appropriate patient affordability programs to help reduce eligible patients&#8217; out-of-pocket costs for prescriptions filled. Because of this assistance, eligible patients&#8217; out-of-pocket cost for XHANCE, when dispensed through PPNPs, may be lower than such costs when XHANCE is dispensed from traditional retail pharmacies. However, to the extent physicians do not direct prescriptions to the participating PPNPs, the adoption of XHANCE by physicians and patients may decline. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our ability to increase utilization of our patient affordability programs will depend on physician and patient awareness and comfort with the programs, and we have limited ability to influence whether physicians use our patient affordability programs to prescribe XHANCE or whether patients will agree to receive XHANCE through PPNPs. In addition, the patient affordability programs are not available to federal health care programs (such as Medicare and Medicaid) beneficiaries. We have also contracted with certain Pharmacy Benefit Managers (PBMs) and other payors to secure formulary status and reimbursement for XHANCE, which generally require us to pay administrative fees and rebates to the PBMs and other payors for qualifying prescriptions. While we have business relationships with three of the largest PBMs, as well as other PBMs, we believe these agreements will secure formulary status for XHANCE but we cannot guarantee that we will be able to agree to terms with other PBMs and other payors, or that such terms will be commercially reasonable to us. Despite our agreements with PBMs, the extent of formulary status and reimbursement will ultimately depend to a large extent upon individual healthcare plan formulary decisions. If healthcare plans that contract with PBMs with which we have agreements do not adopt formulary changes recommended by the PBMs with respect to XHANCE, we may not realize the expected access and reimbursement benefits from these agreements. Consequently, the success of our PBM contracting strategy will depend not only on our ability to expand formulary adoption among healthcare plans, but also upon the relative mix of healthcare plans that have PBM-chosen formularies versus custom formularies. If we are unable to realize the expected benefits of our contractual arrangements with the PBMs the adoption of XHANCE by physicians and patients may decline. If we are unable to increase adoption of PPNPs for filling prescriptions of XHANCE by physicians or to secure formulary status and reimbursement through arrangements with PBMs and other payors, particularly with healthcare plans that use custom formularies, our ability to achieve net sales growth for XHANCE would be impaired.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">The negative publicity regarding specialty pharmacies may result in physicians being less willing to participate in our patient affordability programs, which would limit our ability to increase patient access and adoption of XHANCE.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">There has been negative publicity and inquiries from Congress and enforcement authorities regarding the use of specialty pharmacies and drug pricing. PPNPs with whom we contract may be considered specialty pharmacies.  Our patient affordability programs are in place to assist in ensuring that when a physician determines XHANCE offers a potential clinical benefit to their patients and they prescribe it for an eligible patient, financial assistance may be available to reduce the patient&#8217;s out-of-pocket costs. We do not own or possess any option to purchase an ownership stake in any pharmacy that distributes XHANCE and our relationship with each pharmacy is non-exclusive and arm&#8217;s length. All of our sales are processed through pharmacies independent of us. Despite this, the negative publicity and interest from Congress and enforcement authorities regarding specialty pharmacies may result in physicians being less willing to participate in our patient affordability programs and thereby limit our ability to increase patient access and adoption of XHANCE.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">We may be unable to form and maintain relationships with pharmacies that participate in our patient affordability programs, which could adversely affect the commercialization of XHANCE and our operating results.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We may also encounter difficulty in forming and maintaining relationships with pharmacies that participate in our patient affordability programs. We currently depend on a limited number of PPNPs to fulfill patient prescriptions. If </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">these PPNPs are unable to process and fulfill the volume of patient prescriptions directed to them, our ability to maintain or increase prescriptions for XHANCE will be impaired. The commercialization of XHANCE and our operating results could be affected should any of the PPNPs choose not to continue to fulfill XHANCE prescriptions or by any adverse market events at any of the PPNPs. For example, pharmacies that dispense XHANCE could lose contracts that they currently maintain with managed care organizations (MCOs), including PBMs. Pharmacies often enter into agreements with MCOs. They may be required to abide by certain terms and conditions to maintain access to MCO networks, including terms and conditions that could limit their ability to participate in patient affordability programs like ours. Failure to comply with the terms of their agreements with MCOs could result in a variety of penalties, including termination of their agreement, which could negatively impact the ability of those pharmacies to dispense XHANCE and collect reimbursement from MCOs for such medicines.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Our patient affordability programs are subject to certain federal and state laws, the violation of which could have an adverse impact on our business and subject us to significant penalties.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our patient affordability programs may implicate certain federal and state laws related to, among other things, unlawful schemes to defraud, excessive fees for services, tortious interference with patient contracts and statutory or common law fraud. We have a comprehensive compliance program in place to address adherence with various laws and regulations relating to the selling, marketing and manufacturing of XHANCE. Despite our compliance efforts, to the extent the patient affordability programs are found to be inconsistent with applicable laws or the pharmacies that participate in our patient affordability programs do not comply with applicable laws, we may be required to restructure or discontinue such programs, terminate our relationship with certain pharmacies, or be subject to other significant penalties. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">If the cost of maintaining our patient affordability programs increases relative to our sales revenue, we could be force to reduce or eliminate our financial assistance programs, which could have an adverse effect on our financial results.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If the cost of maintaining our patient affordability programs increases relative to our sales revenues, we could be forced to reduce the amount of patient financial assistance that we offer or otherwise scale back or eliminate such programs, which could in turn have a negative impact on physicians&#8217; willingness to prescribe and patients&#8217; willingness to fill prescriptions of XHANCE. While we believe that our arrangements with PBMs will result in broader inclusion of certain of our therapies on healthcare plan formularies, and lower our cost of providing patient affordability programs, these arrangements generally require us to pay administrative and rebate payments to the PBMs and/or other payors and their effectiveness will ultimately depend to a large extent upon individual healthcare plan formulary decisions that are beyond the control of the PBMs. If our arrangements with PBMs and other payors do not result in increased prescriptions and reductions in our costs to provide our patient affordability programs that are sufficient to offset the administrative fees and rebate payments to the PBMs and/or other payors, our financial results may continue to be harmed.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">XHANCE may become associated with undesirable adverse reactions or have other properties that could result in significant negative consequences following regulatory approval.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If we or others identify adverse events (AEs) associated with XHANCE, a number of potentially significant negative consequences could result, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">we may be forced to suspend marketing of XHANCE;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the FDA may withdraw its approval of XHANCE or impose restrictions on its distribution;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the FDA may require additional warnings or contradictions in the label that could diminish the usage or otherwise limit the commercial success of XHANCE;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">we may be required to conduct additional post-marketing studies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">we could be sued and held liable for harm caused to patients; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our reputation may suffer.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Any of these events could prevent us from achieving or maintaining market acceptance of XHANCE.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">If the FDA or other applicable regulatory authorities approve generic or similar products that compete with XHANCE, or if the FDA or other applicable regulatory authorities change or create new pathways that may expedite approval of such products, it could decrease our expected sales of XHANCE.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Once an NDA, including a Section&#160;505(b)(2) application, is approved, the product covered thereby becomes a "listed drug" which can, in turn, be cited by potential competitors in support of approval of an abbreviated NDA (ANDA). The FD&amp;C Act, FDA regulations and other applicable regulations and policies provide incentives to manufacturers to create modified, non-infringing versions of a drug to facilitate the approval of an ANDA for generic substitutes. Manufacturers may be able to bring a generic product to market in a much more cost-efficient pathway than we currently anticipate. If the costs involved in bringing such a product to market are significantly less than our costs with respect to the development of XHANCE, companies that produce generic equivalents to XHANCE may be able to offer their products at lower prices. Further, if the timeline for bringing such a product to market is expedited, companies that produce generic equivalents to XHANCE may compete with XHANCE faster than we currently anticipate. For example, the FDA has communicated a priority to build on initiatives to accelerate generic entry of&#160;complex generics, which include locally acting nasal drug products. If the FDA provides for alternatives to comparative clinical endpoint bioequivalence studies for generic versions of locally-acting orally inhaled and nasal drug products, companies that produce generic equivalents to XHANCE may compete with XHANCE faster than we currently anticipate and a significant percentage of any future sales of XHANCE could be lost to such generic products. Moreover, in addition to generic competition, we could face competition from other companies seeking approval of products that are similar to ours using the Section&#160;505(b)(2) pathway. Such applicants may be able to rely on XHANCE or other approved drug products or published literature to develop drug products that are similar to ours. The introduction of a drug product similar to our products or product candidates could expose us to increased competition, leading to a decrease in sales of XHANCE. Competition that we may face from generic or similar versions of XHANCE could materially and adversely impact our future revenue, profitability, and cash flows.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Even though we have obtained regulatory approval for XHANCE, we will still face extensive FDA regulatory requirements and may face future regulatory difficulties.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Even though we have obtained regulatory approval in the U.S. for XHANCE, the FDA and state regulatory authorities may still impose significant restrictions on the indicated uses or marketing of XHANCE, or impose ongoing requirements for potentially costly post-approval studies or post-marketing surveillance. For example, as part of its approval of XHANCE for the treatment of nasal polyps in adults, the FDA required that we conduct a randomized, double-blind, placebo controlled clinical study in children and adolescents with nasal polyposis to assess the safety, efficacy, and pharmacokinetics of XHANCE in this population. The FDA originally indicated the study was to be conducted in children and adolescents 6 to 17 years of age. On October 30, 2017, the FDA notified us that in response to our request it had modified the required age range to 12 to 17 years of age.  We submitted our final protocol to the FDA with respect to the pediatric study by January 2018 as required, and we have since contracted with various clinical trial sites and begun patient enrollment. We are required to complete the study by January 2022 and to submit a final report with respect to the study by July 2022. Because the Optinose EDS for XHANCE was designed for use in adult patients, we may discover that the dimensions of this EDS make it unsuitable for use in pediatric patient populations. As such, this pediatric study may also require us to undergo a costly and time-consuming development process to design and manufacture as appropriate a modified EDS to conduct these studies.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are also subject to ongoing FDA requirements governing the labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, record-keeping and reporting of safety and other post-marketing information. The holder of an approved NDA is obligated to monitor and report AEs and any failure of a product to meet the specifications in the NDA. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA regulations and may be subject to other potentially applicable federal and state laws. The applicable regulations in countries outside the U.S. grant similar powers to the competent authorities and impose similar obligations on companies.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition, manufacturers of drug products and their facilities are subject to payment of substantial user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current Good Manufacturing Practice (cGMP) regulations and adherence to commitments made in the NDA. Since XHANCE is a combination product, we will also need to comply with some of the FDA's manufacturing regulations for devices. In addition to cGMP, the FDA requires that our drug-device combination product comply with the Quality System Regulation (QSR), which sets forth the FDA's manufacturing quality standards for medical devices, and other applicable government regulations and corresponding foreign standards. If we, or a regulatory authority, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">discover previously unknown problems with XHANCE, such as AEs, of unanticipated severity or frequency, or problems with a facility where the product is manufactured, a regulatory authority may impose restrictions relative to XHANCE or the manufacturing facility, including requiring recall or withdrawal of the product from the market, suspension of manufacturing, or other FDA action or other action by foreign regulatory authorities.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If we fail to comply with applicable regulatory requirements following approval of XHANCE, a regulatory authority may:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">issue a warning letter asserting that we are in violation of the law;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">seek an injunction or impose civil or criminal penalties or monetary fines;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">suspend, modify or withdraw regulatory approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">suspend any ongoing clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">refuse to approve a pending NDA or a pending application for marketing authorization or supplements to an NDA or to an application for marketing authorization submitted by us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">seize our product candidate; and/or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">refuse to allow us to enter into supply contracts, including government contracts.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Our relationships with physicians, patients and payors in the U.S. are subject to applicable anti-kickback, fraud and abuse laws and regulations. Our failure to comply with these laws could expose us to criminal, civil and administrative sanctions, reputational harm, and could harm our results of operations and financial conditions.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our current and future operations with respect to the commercialization and further development of XHANCE, as well as potential future development programs, are subject to various U.S. federal and state healthcare laws and regulations. These laws impact, among other things, our proposed sales, marketing, support and education programs and constrain our business and financial arrangements and relationships with third-party payors, healthcare professionals and others who may prescribe, recommend, purchase or provide XHANCE, and other parties through which we market, sell and distribute XHANCE. Finally, our current and future operations are subject to additional healthcare-related statutory and regulatory requirements and enforcement by foreign regulatory authorities in jurisdictions in which we conduct our business. The laws are described in greater detail in the previous section under "Business&#160;&#8212; Government Regulation&#160;&#8212; Healthcare Fraud and Abuse Laws," and include, but are not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the federal Anti-Kickback Statute, prohibits persons or entities from, among other things, knowingly and willfully soliciting, offering, receiving or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order, or arranging for or recommending the purchase, lease or order of, any good or service, for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the federal civil False Claims Act (which can be enforced through "qui tam," or whistleblower actions, by private citizens on behalf of the federal government) prohibits any person from, among other things, knowingly presenting, or causing to be presented false or fraudulent claims for payment of government funds or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the U.S. federal government.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the federal federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for healthcare benefits, items or services by a healthcare benefit program, which includes both government and privately funded benefits programs; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">numerous federal and state laws and regulations that address privacy and data security, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act (FTC Act)), govern the collection, use, disclosure and protection of health-related and other personal information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating relevant compliance efforts.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a majority of states whom have adopted laws and regulations analogous to federal laws, including state anti-kickback and false claims laws, that may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers. Other states have adopted laws that, among other things, require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities. In addition, some states have laws requiring pharmaceutical sales representatives to be registered or licensed, and still others impose limits on co-pay assistance that pharmaceutical companies can offer to patients.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the Physician Payments Sunshine Act, implemented as the Open Payments program, and its implementing regulations, requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children's Health Insurance Program (with certain exceptions) to report annually to CMS information related to direct or indirect payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held in the company by physicians and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report information regarding payments and transfers of value provided to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists and certified nurse-midwives.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The shifting commercial compliance environment and the need to build and maintain robust and expandable systems to comply with different compliance or reporting requirements in multiple jurisdictions increase the possibility that a healthcare or pharmaceutical company may fail to comply fully with one or more of these requirements. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with applicable fraud and abuse or other healthcare laws and regulations or guidance. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional oversight and reporting requirements if we become subject to a corporate integrity agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to the same criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our financial condition and divert resources and the attention of our management from operating our business.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The occurrence of any event or penalty described above may inhibit our ability to commercialize and further develop XHANCE and generate revenues which would have a material adverse effect on our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">If we are able to successfully commercialize XHANCE and if fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program, or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We participate in the Medicaid Drug Rebate Program, and other governmental pricing programs, and therefore we are obligated to pay certain specified rebates and report pricing information with respect to XHANCE. Pricing and rebate calculations are complex and are often subject to interpretation by us, governmental or regulatory agencies and the courts. We cannot assure you that our submissions will not be found by the Centers for Medicare&#160;&amp; Medicaid Services (CMS) to be incomplete or incorrect. Governmental agencies may also make changes in </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">program interpretations, requirements or conditions of participation, some of which may have implications for amounts previously estimated or paid. The Medicaid rebate amount is computed each quarter based on our submission to CMS of our current average manufacturer price (AMP) and best price for the quarter. If we become aware that our reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, we are obligated to resubmit the corrected data for a period not to exceed twelve quarters from the quarter in which the data originally were due, and CMS may request or require restatements for earlier periods as well. Such restatements and recalculations increase our costs for complying with the laws and regulations governing the Medicaid Drug Rebate Program. Any corrections to our rebate calculations could result in an overage or underage in our rebate liability for past quarters, depending on the nature of the correction. Price recalculations also may affect the ceiling price at which we are required to offer our products to certain covered entities, such as safety-net providers, under the Public Health Service's 340B drug pricing program (the 340B program) and under other similar government pricing programs. These programs are described in greater detail in the previous section under "Business&#160;&#8212; Government Regulation&#160;&#8212; Coverage and Reimbursement."</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We will also be liable for errors associated with our submission of pricing data. In addition to retroactive rebates and the potential for 340B program refunds, if we are found to have knowingly submitted false AMP, or best price information to the government, we may be liable for significant civil monetary penalties. Such failure also could be grounds for CMS to terminate our Medicaid drug rebate agreement, pursuant to which we participate in the Medicaid program. In the event that CMS terminates our rebate agreement, federal payments may not be available under Medicaid for XHANCE. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Health Resource and Services Administration (HRSA) issued a final regulation regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities, which became effective on January 1, 2019.  It is currently unclear how HRSA will apply its enforcement authority under the new regulation. HRSA also is implementing a ceiling price reporting requirement related to the 340B program during the first quarter of 2019 under which we will be required to report 340B ceiling prices to HRSA on a quarterly basis. In addition, legislation may be introduced that, if passed, would further expand the 340B program to additional covered entities or would require participating manufacturers to agree to provide 340B discounted pricing on drugs used in an inpatient setting.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Federal law also requires that a company that participates in the Medicaid Drug Rebate Program report ASP information each quarter to CMS for certain categories of drugs that are paid under the Medicare Part B program. Manufacturers calculate the average sales price based on a statutorily defined formula as well as regulations and interpretations of the statute by CMS. CMS uses these submissions to determine payment rates for drugs under Medicare Part B.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Federal law requires that a company must participate in the U.S. Department of Veterans Affairs (VA) Federal Supply Schedule (FSS) pricing program to be eligible to have its products paid for with federal funds. As part of this program, we are obligated to make XHANCE available for procurement on an FSS contract under which we must comply with standard government terms and conditions and charge a price that is no higher than the statutory Federal Ceiling Price (FCP) to four federal agencies (VA, U.S. Department of Defense (DOD) Public Health Service, and U.S. Coast Guard). The FCP is based on the Non-Federal Average Manufacturer Price (Non-FAMP), which we calculate and report to the VA on a quarterly and annual basis. If we overcharge the government in connection with our FSS contract or Section&#160;703 Agreement, whether due to a misstated FCP or otherwise, we are required to refund the difference to the government. Failure to make necessary disclosures and/or to identify contract overcharges can result in allegations against us under the U.S. civil False Claims Act and other laws and regulations. Unexpected refunds to the government, and responding to a government investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Regulatory approval for any approved product is limited by the FDA to those specific indications and conditions for which clinical safety and efficacy have been demonstrated.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our promotional materials, statements and training methods must comply with applicable laws and regulations, including FDA's prohibition of the promotion of unapproved, or off-label, use. Physicians may use our products off-label, as the FDA does not restrict or regulate a physician's independent choice of treatment within the practice of medicine. As healthcare professionals frequently prescribe corticosteroids for the treatment of chronic nasal inflammatory diseases, such as chronic rhinosinusitis, doctors often prescribe XHANCE for the treatment of chronic rhinosinusitis and other chronic nasal inflammatory diseases, even though the FDA has granted approval of XHANCE only for the treatment of nasal polyps and we promote the use of XHANCE only for the treatment of nasal polyps. If the FDA determines that our promotional materials, statements or activities constitute promotion of an off-</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">label use, we could be required to modify our promotional materials, statements or training methods or subject us to regulatory or enforcement actions, such as the issuance of an untitled letter, a warning letter, injunction, seizure, civil fine, disgorgement of money, operating restrictions or criminal penalties. We may also be subject to actions by other governmental entities or private parties, such as the U.S. civil False Claims Act, civil whistleblower or "qui tam" actions. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our promotional, materials or activities to constitute promotion of an off-label use, which could result in significant fines or penalties under other statutory authorities. In that event, our reputation could be damaged and market adoption of XHANCE could be impaired.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Even though we have obtained FDA approval for XHANCE in the U.S., we may never obtain approval for or successfully commercialize it outside of the U.S., which would limit our ability to realize its full market potential.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In order to market XHANCE outside of the U.S., we must obtain marketing authorizations and comply with numerous and varying regulatory requirements of other countries regarding quality, safety and efficacy. Clinical trials conducted in one country may not be accepted by foreign regulatory authorities, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and costs for us and require additional non-clinical studies or clinical trials, which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of XHANCE in those countries. While our management team has experience in obtaining foreign regulatory approvals at other companies, we do not have any product candidates approved for sale in any foreign jurisdiction, and we, as a company, do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approval in international markets is delayed, our target market for XHANCE will be reduced and we would not be able to realize the full market potential of XHANCE.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">The Affordable Care Act and any changes in healthcare law may increase the difficulty and cost for us to commercialize XHANCE and affect the prices we may obtain.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The U.S. and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could restrict or regulate post-approval activities and affect our ability to profitably sell XHANCE. The U.S. government, state legislatures and foreign governments also have shown significant interest in implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (collectively the Affordable Care Act) was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. These intended reforms are described in greater detail in the previous section under "Business&#160;&#8212; Government Regulation&#160;&#8212; U.S. Healthcare Reform."</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Among the provisions of the Affordable Care Act that have been implemented since enactment and are of importance to the commercialization of XHANCE are the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs or biologic agents;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">expansion of healthcare fraud and abuse laws, including the U.S. civil False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a new Medicare Part&#160;D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer's outpatient drugs to be covered under Medicare Part&#160;D;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">extension of manufacturers' Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">price reporting requirements for drugs that are inhaled, infused, instilled, implanted, or injected;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">expansion of eligibility criteria for Medicaid programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">expansion of the entity types eligible for discounts under the Public Health Service's 340B drug pricing program;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a requirement to annually report certain information regarding drug samples that manufacturers and distributors provide to physicians; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Some of the provisions of the Affordable Care Act have yet to be fully implemented, and certain provisions have been subject to judicial and Congressional challenges. In addition, there have been efforts by the Trump Administration to repeal or replace certain aspects of the Affordable Care Act and to alter the implementation of the Affordable Care Act and related laws. For example, on December 22, 2017, the U.S. government signed into law comprehensive tax legislation, referred to as the Tax Cuts and Jobs Act (the Tax Act), which includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; Further, the Bipartisan Budget Act of 2018, among other things, amended the Medicare statute to reduce the coverage gap in most Medicare drugs plans, commonly known as the &#8220;donut hole,&#8221; by raising the required manufacturer point-of-sale discount from 50% to 70% off the negotiated price effective as of January 1, 2019. Additional legislative changes, regulatory changes, and judicial challenges related to the Affordable Care Act remain possible. It is unclear how the Affordable Care Act and its implementation, as well as efforts to repeal or replace, or invalidate, the Affordable Care Act, or portions thereof, will affect our business, financial condition and results of operations.  We expect that the Affordable Care Act, as currently enacted or as it may be amended in the future, and other healthcare reform measures that may be adopted in the future, could have a material adverse effect on our industry generally and on our ability to maintain or increase sales of XHANCE or to successfully commercialize it.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We also expect that the Affordable Care Act, as well as other healthcare reform measures that have and may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for XHANCE and could seriously harm our future revenues. Any reduction in reimbursement from Medicare, Medicaid, or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenues, attain profitability or successfully commercialize XHANCE.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of XHANCE and any other product candidates that we may develop.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We currently face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials, and this risk will increase significantly as we commercialize XHANCE and other product candidates that we may develop. We may face product liability claims, regardless of FDA approval for commercial manufacturing and sale as product liability claims may be brought against us by patients who have used XHANCE in any of our clinical trials, future patients, healthcare providers or others using, administering or selling our products, if and when approved. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">decreased demand for XHANCE;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">injury to our reputation and significant negative media attention;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">termination of clinical trial sites or entire trial programs that we conduct in the future relating to XHANCE or our other product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">withdrawal of clinical trial participants from any future clinical trial relating to XHANCE or our other product candidates;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">significant costs to defend the related litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">substantial monetary awards to patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">loss of revenue;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">diversion of management and scientific resources from our business operations; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">an increase in product liability insurance premiums or an inability to maintain product liability insurance coverage.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We currently carry product liability insurance with coverage up to $10.0&#160;million in the aggregate, with a per incident limit of $10.0&#160;million, which may not be adequate to cover all liabilities that we may incur. Further, we may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Our inability to maintain sufficient product liability insurance at an acceptable cost could adversely affect our XHANCE product revenues, inhibit the development of XHANCE for additional indications or inhibit the development our other product candidates.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Additionally, any agreements we may enter into in the future with collaborators in connection with the development or commercialization of XHANCE, AVP-825, our exhalation device technology or any of our other product candidates may entitle us to indemnification against product liability losses, but such indemnification may not be available or adequate should any claim arise. In addition, several of our agreements require us to indemnify third parties and these indemnifications obligations may exceed the coverage under our product liability insurance policy. For example, under the terms of the license agreement we entered into with Inexia we expect to enter into a clinical supply agreement with Inexia whereby we will provide certain exhalation devices to Inexia, which may expose us to indemnification obligations that may exceed the coverage under our product liability insurance policy or otherwise expose us to third party product liability losses.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Risks Related to Clinical Development and Regulatory Approval of XHANCE for the Treatment of Chronic Sinusitis and Our Other Product Candidates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">The design and execution of clinical trials to support FDA-approval of XHANCE for the treatment of chronic sinusitis is subject to substantial risk and uncertainty.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have initiated a clinical program to support a follow-on indication of XHANCE for the treatment of chronic sinusitis. Similar to our NDA for XHANCE for the treatment of nasal polyps, we believe we may also be able to use the Section&#160;505(b)(2) pathway for potential U.S. approval for XHANCE for the treatment of chronic sinusitis. Because there is no FDA-approved product for the treatment of chronic sinusitis, we believe there is substantial risk and uncertainty in planning and conducting adequate clinical trials to meet FDA requirements to support approval for this indication. If the clinical program required by the FDA is more costly or time-consuming than anticipated, we may decide to cease to pursuit of this follow-on indication. Additionally, clinical trials for this indication may not demonstrate sufficient efficacy or safety to support FDA approval for a follow-on indication for XHANCE. If we do not obtain a follow-on indication for the treatment of chronic sinusitis, our promotion of XHANCE will be limited to nasal polyps, which would limit our potential sales of XHANCE.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">The regulatory approval processes of the FDA are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business may be substantially harmed.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The time required to obtain approval by the FDA is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory agency. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate's clinical development. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our product candidates could fail to receive regulatory approval for many reasons, including the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the FDA may not accept our NDA filing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the FDA may disagree with the design, scope or implementation of our clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">we may be unable to demonstrate to the satisfaction of the FDA that a product candidate is safe and effective for its proposed indication;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">we may be unable to demonstrate that a product candidate's clinical and other benefits outweigh its safety risks;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the FDA may disagree with our interpretation of data from preclinical studies or clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the FDA may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the approval policies or regulations of the FDA may change in a manner rendering our clinical data insufficient for approval.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The failure to obtain regulatory approval for a particular product candidate, could substantially harm our business. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Clinical development is a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. Clinical failure can occur at any stage of clinical development.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Clinical trials are expensive, can take many years to complete and have highly uncertain outcomes. Failure can occur at any time during the clinical trial process as a result of inadequate performance of a drug, inadequate adherence by patients or investigators to clinical trial protocols, investigators failure to comply with applicable laws, or other factors. Drug candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through earlier clinical trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials as a result of a lack of efficacy or adverse safety profiles, despite promising results in earlier trials. Our clinical trials for the follow-on indication of XHANCE for the treatment of chronic sinusitis or our other product candidates may not be successful or may be more expensive or time-consuming than we currently expect. If clinical trials for this or any other product candidate fail to demonstrate safety or efficacy to the satisfaction of the FDA, the FDA may not approve the product candidate and we would not be able to commercialize it, which could substantially harm our business.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Delays in clinical trials are common and have many causes, and any delay could result in increased costs to us and jeopardize or delay our ability to obtain regulatory approval and commence product sales.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We may experience delays in clinical trials of our product candidates or the time required to complete clinical trials for our product candidates may be longer than anticipated. Our ongoing and future clinical trials may not begin on time, have an effective design, enroll a sufficient number of patients, timely enroll patients, or be completed on schedule, if at all. Our clinical trials can be delayed for a variety of reasons, including, but not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">inability to raise funding necessary to initiate or continue a clinical trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">delays in obtaining regulatory approval to commence a clinical trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">delays in reaching agreement with the FDA or foreign regulatory authorities on final trial design or the scope of the development program;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">imposition of a clinical hold following an inspection of our clinical trial operations or trial sites by the FDA or foreign regulatory authorities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">delays in obtaining required institutional review board (IRB) approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">delays in recruiting suitable patients to participate in a clinical trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">delays as a result of interim analyses, if any, of clinical trials that indicate futility of the trial or necessitate an increase in the number of patients enrolled in trial; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">patients' delays or failure to complete participation in a clinical trial or return for post-treatment follow-up;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">clinical sites dropping out of a clinical trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">time required to add new clinical sites; or</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">delays by our contract manufacturing organizations (CMOs) to produce and deliver a sufficient supply of clinical trial materials.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If clinical trials for our product candidates are delayed for any of the above reasons or other reasons, our development costs may increase, our approval process could be delayed and our ability to commercialize our product candidates could be materially harmed.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">We will need to identify proprietary names for our product candidates that are acceptable to FDA, and any delay associated with doing so may adversely impact our business.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Any proprietary name we propose to use with our product candidates in the U.S. must be reviewed and accepted by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA reviews any proposed product name, including an evaluation of potential for confusion with other product names. The FDA may also object to a product name if it believes the name inappropriately implies medical claims or contributes to an overstatement of efficacy. If the FDA objects to any proposed proprietary product name, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable laws, not infringe the existing rights of third parties and be acceptable to the FDA.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Our product candidates, if approved, may require REMS, which may significantly increase our costs.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our product candidates, if approved, may require REMS. The REMS may include requirements for special labeling or medication guides for patients, special communication plans to healthcare professionals and restrictions on distribution and use. We cannot predict the specific scope or magnitude of REMS that may be required as part of the FDA's approval of our other product candidates. Depending on the extent of the REMS requirements, our costs to commercialize our product candidates may increase significantly and distribution restrictions could limit sales. Similar requirements may arise in countries outside of the U.S.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Changes in regulatory requirements and guidance may occur and we may need to amend clinical trial protocols submitted to applicable regulatory authorities to reflect these changes. Amendments may require us to resubmit clinical trial protocols to IRBs or ethics committees for re-examination, which may impact the costs, timing or successful completion of a clinical trial.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The FDA's and other regulatory authorities' policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our other product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If we are required to conduct additional clinical trials or other studies with respect to our product candidates beyond those that we currently contemplate, or if we are unable to successfully complete our clinical trials or other studies, we may be delayed in obtaining regulatory approval of any of our product candidates, we may not be able to obtain regulatory approval at all or we may obtain approval of indications that are not as broad as intended. Our product development costs will also increase if we experience delays in testing or approvals, and we may not have sufficient funding to complete the testing and approval process for our product candidates. Significant clinical trial delays could allow our competitors to bring products to market before we do and impair our ability to commercialize our products if and when approved. If any of this occurs, our business would be harmed.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Risks Related to Our Reliance on Third Parties</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">If we encounter difficulties in maintaining commercial manufacturing and supply agreements with our third-party manufacturers and suppliers of XHANCE, our ability to commercialize XHANCE would be impaired.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We do not own any manufacturing facilities. We currently have no plans to build our own clinical or commercial scale manufacturing facility. We lack the resources to manufacture and test, on a commercial scale, the technical performance of XHANCE and our other product candidates. We currently rely, and expect to continue to rely, on a limited number of experienced personnel and CMOs and suppliers who assist in the production, assembly, test, supply, storage and distribution of XHANCE and its components in our clinical trials and FDA registration, and we control only some of the aspects of their activities. We may not be able to maintain terms that are favorable to us.  We may not be able to enter into commercial manufacturing and supply agreements with any necessary third parties, should such additional agreements become necessary. If we are unable to enter into such agreements or </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">maintain existing agreements, each on commercially reasonable terms, our ability to commercialize XHANCE would be impaired, and our business, financial condition and results of operations would be materially adversely affected. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">If we encounter issues with our contract manufacturers or suppliers, we may need to qualify alternative manufacturers or suppliers, which could impair our ability to sufficiently and timely manufacture and supply XHANCE.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We currently depend on contract manufacturers and suppliers for XHANCE and its components. Although we could obtain each of these components from other third-party suppliers, we would need to qualify and obtain FDA approval for another contract manufacturer or supplier as an alternative source for each such component, which could be costly and cause significant delays. Each of our current commercial manufacturing and supply agreements include limitations on our ability to utilize alternative manufacturers or suppliers for these components above certain specified thresholds during the terms of the agreements, which impairs our ability to fully implement any future manufacturing strategies to prevent supply shortages or quality issues.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition, some of our suppliers, including our active pharmaceutical ingredient (API) supplier and our contract manufacturers, conduct their manufacturing operations for us at a single facility. Unless and until we qualify additional facilities, we may face limitations in our ability to respond to manufacturing and supply issues. For example, if regulatory, manufacturing or other problems require one of these manufacturers or suppliers to discontinue production at their respective facility, or if the equipment used for the production of XHANCE in these facilities is significantly damaged or destroyed by fire, flood, earthquake, power loss or similar events, the ability of such manufacturer or supplier to provide components or API needed for XHANCE, or to manufacture XHANCE may be significantly impaired. In the event that these parties suffer a temporary or protracted loss of its facility or equipment, we would still be required to obtain FDA approval to qualify a new manufacturer or supplier, as applicable, as an alternate manufacturer or source for the respective component before any components manufactured by such manufacturer or by such supplier could be sold or used.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Any production shortfall that impairs the supply of XHANCE or any of these components could have a material adverse effect on our business, financial condition and results of operations and adversely affect our ability to satisfy demand for XHANCE, which could adversely affect our product sales and operating results materially.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">If third-party manufacturers, wholesalers and distributors fail to devote sufficient time and resources to XHANCE or their performance is substandard, our product supply may be impacted.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our reliance on a limited number of manufacturers, wholesalers and distributors exposes us to the following risks, any of which could limit commercial supply of our products, result in higher costs, or deprive us of potential product revenues:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our CMOs, or other third parties we rely on, may encounter difficulties in achieving the volume of production needed to satisfy commercial demand, may experience technical issues that impact quality or compliance with applicable and strictly enforced regulations governing the manufacture of pharmaceutical products, and may experience shortages of qualified personnel to adequately staff production operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our wholesalers and distributors could become unable to sell and deliver XHANCE for regulatory, compliance and other reasons;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our CMOs, wholesalers and distributors could default on their agreements with us to meet our requirements for commercial supply of XHANCE;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our CMOs, wholesalers and distributors may not perform as agreed or may not remain in business for the time required to successfully produce, store, sell and distribute our products and we may incur additional cost; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">if our CMOs, wholesalers and distributors were to terminate our arrangements or fail to meet their contractual obligations, we may be forced to delay or cease sales and ongoing development of XHANCE, or find alternatives that may be more expensive than originally anticipated.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our reliance on third parties reduces our control over our product candidate development and commercialization activities but does not relieve us of our responsibility to ensure compliance with all required legal, regulatory and scientific standards. For example, the FDA and other regulatory authorities require that our product candidates and any products that we may eventually commercialize be manufactured according to cGMP and similar foreign standards. Any failure by our third-party manufacturers to comply with cGMP or failure to scale up manufacturing processes, including any failure to deliver sufficient quantities of product candidates in a timely manner, could lead </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to a delay in, or failure to obtain, regulatory approval of any of our product candidates or supply our commercial volume of XHANCE. In addition, such failure could be the basis for the FDA to issue a warning or untitled letter, withdraw approvals for product candidates previously granted to us, or take other regulatory or legal action, including recall or seizure, total or partial suspension of production, suspension of ongoing clinical trials, refusal to approve pending applications or supplemental applications, detention or product, refusal to permit the import or export of products, injunction, imposing civil penalties or pursuing criminal prosecution.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Manufacturing issues may arise that could increase product and regulatory approval costs or delay commercialization.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As we further scale up manufacturing of XHANCE and conduct required stability testing, issues may arise involving product-packaging and third-party equipment malfunctions. These issues may require refinement or resolution in order to continue with commercial marketing of XHANCE. In addition, quality issues may arise during scale-up and of commercial manufacturing processes. Any issues in our product or delivery devices could result in increased scrutiny by regulatory authorities, delays in our regulatory approval process, increases in our operating expenses, decreases in sales to customers, or failure to obtain or maintain approval for our products.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">We rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, or if they terminate their agreement with us, we may not be able to obtain regulatory approval for or commercialize our product candidates.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have relied upon and plan to continue to rely upon CROs to monitor and manage data for our prospective preclinical and clinical programs. We rely on these parties for execution of our clinical trials, and we control only some of the aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and clinical trials are conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with federal regulations and current Good Clinical Practices (GCP), which are international standards meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, advisors and monitors. GCPs are enforced by the FDA and foreign regulatory authorities in the form of International Conference on Harmonization (ICH) guidelines for all of our product candidates in clinical development. Regulatory authorities enforce these GCP through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCP and other regulations, including as a result of any recent changes in such regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements. In addition, our clinical trials must be conducted with product produced under cGMP requirements. While we have agreements governing activities of our CROs, we have limited influence over their actual performance. Failure to comply with applicable regulations in the conduct of the clinical trials for our product candidates may require us to repeat preclinical studies and clinical trials, which would increase our operating expenses and delay the regulatory approval process.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical and preclinical programs. If our CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons or if we receive additional FDA notices that do require corrective action, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, the commercial prospects for our product candidates would be harmed, our costs could increase substantially and our ability to generate revenue could be delayed.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Switching or adding additional CROs involves additional cost and requires management time and focus. Identifying, qualifying and managing performance of third-party service providers can be difficult, time-consuming and cause delays in our development programs. In addition, there is a natural transition period when a new CRO commences work and the new CRO may not provide the same type or level of services as the original provider. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. If any of our relationships with our CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Because we have relied on third parties, our internal capacity to perform these functions is limited. Outsourcing these functions involves risks that third parties may not perform to our standards, may not produce results in a timely manner or may fail to perform at all. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. We currently have a small number of employees, which limits the internal resources we have available to identify and monitor our third-party providers. To the extent we are unable to identify and successfully manage the performance of third-party service providers in the future, our ability to advance our product candidates through clinical trials will be compromised. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Risks Related to Our Business Operations and Industry</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Our future success depends on our ability to retain and have the full attention of our key executives and to attract, retain and motivate other qualified personnel.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are highly dependent on the management, development, clinical, financial and business development expertise of our executive team and, in particular, the services of Peter K. Miller, our Chief Executive Officer, and Ramy A. Mahmoud, our President and Chief Operating Officer. Each of Mr.&#160;Miller and Dr.&#160;Mahmoud is employed by us at will and is permitted to terminate his employment with us at any time. We entered into employment agreements with Mr.&#160;Miller and Dr.&#160;Mahmoud in October 2017, but Mr.&#160;Miller and Dr.&#160;Mahmoud continue to be employed at will. We do not maintain "key person" insurance for any of our executives or other employees. The loss of the services of Mr.&#160;Miller or Dr.&#160;Mahmoud could impede the achievement of our development and commercialization objectives.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Recruiting and retaining qualified employees for our business, including scientific, technical and sales and marketing personnel, will also be critical to our success. Competition for skilled personnel in our industry is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical companies for individuals with similar skill sets. In addition, failure to succeed in our commercialization efforts or in the performance of any future clinical studies may make it more challenging to recruit and retain qualified personnel. The inability to recruit or loss of the services of any executive or key employee could impede the progress of our research, development and commercialization objectives.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">We expect to grow the size of our organization, and we may experience difficulties in managing this growth.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Implementation of our development and commercialization strategies may require additional managerial, operational, sales, marketing, financial and other resources. Our current management, personnel and systems may not be adequate to effectively manage the expansion of our operations, including but not limited to in connection with the onboarding of our contract sales organization to become our internal sales team, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, employee turnover and reduced productivity. Future growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of our existing or future product candidates. Future growth would impose significant added responsibilities on members of management, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">managing the commercialization of XHANCE and any other products for which we obtain marketing approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">overseeing our preclinical studies and clinical trials effectively;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">identifying, recruiting, maintaining, motivating and integrating additional employees, including any sales and marketing personnel engaged in connection with the commercialization of any approved product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">managing our internal development efforts effectively while complying with our contractual obligations to licensors, licensees, contractors and other third parties; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">improving our managerial, development, operational and financial systems and procedures.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As our operations expand, we will need to manage additional relationships with various strategic collaborators, suppliers and other third parties. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and clinical trials effectively and hire, train and integrate additional management, administrative and sales and marketing personnel. Failure to accomplish any of these activities could prevent us from successfully growing our company.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">We are subject to intense competition and, if we are unable to compete effectively, our product candidates, if approved, may not reach their commercial potential.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The development and commercialization of new drugs is highly competitive and subject to rapid and significant technological change as research provides a deeper understanding of the pathology of diseases and new technologies and treatments are developed. We face competition with respect to XHANCE from prescription and over-the-counter INS, oral steroids and other medical management products, and will face competition with respect to any other product candidates that we may seek to develop or commercialize in the future, from many different sources, including large pharmaceutical, biotechnology, specialty pharmaceutical and, to a lesser degree, medical device companies.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The key competitive factors that we expect to impact the commercial success of XHANCE and any other product candidates we may develop are likely to be their efficacy, safety and tolerability profile, reliability, convenience of administration, price and reimbursement. Nasonex, marketed by Merck, is currently the only other branded drug therapy approved by the FDA for the treatment of nasal polyps, which is our initial indication for XHANCE. A generic version of Nasonex, mometasone furoate monohydrate, was approved by the FDA for, among other indications, the treatment of nasal polyps and launched in 2016. In addition, Beconase AQ, which is an INS marketed by GlaxoSmithKline, is indicated for the prophylaxis of nasal polyps after surgical resection, and SINUVA</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">TM</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;is a commercially available corticosteroid-eluting implant indicated for the treatment of nasal polyps in adult patients who have had ethmoid sinus surgery that can be placed in the ethmoid sinus under endoscopic visualization for up to 90 days. We are not aware of any drug therapy approved by the FDA or foreign regulatory agencies for the treatment of chronic sinusitis.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Even though they have not been approved for the treatment of such indications, published clinical practice guidelines do recommend the use of INS products for the treatment of chronic rhinosinusitis and nasal polyps in an effort to maximize medical therapy prior to surgical intervention. Currently approved branded INS products include Rhinocort, marketed by AstraZeneca, Nasacort AQ, marketed by sanofi-aventis, Beconase AQ, Flonase (which contains the same active pharmaceutical ingredient as XHANCE), and Veramyst, each marketed by GlaxoSmithKline, Qnasl, marketed by Teva Pharmaceuticals, and Omnaris and Zetonna, each marketed by Sunovion Pharmaceuticals. Due to the limitations of current treatments, several companies are investigating the treatment of nasal polyps with biologic monoclonal antibodies. To date, four biologic monoclonal antibodies have been studied in nasal polyps: omalizumab, reslizumab, mepolizumab and dupilumab. For dupilumab, the submission of an Supplemental Biologics License Application (sBLA)&#160;was recently publicly announced. In addition, there are new small molecules, including fevipiprant, being developed for the treatment of nasal polyps, that are also believed to inhibit specific pathways of inflammation present in nasal polyps. Most of these INS and biologics companies, as well as other potential competitors, have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of products and the commercialization of those products.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a small number of our competitors. Accordingly, our competitors may be more successful than we may be in obtaining FDA approval of drugs and achieving widespread market acceptance. Our competitors' drugs, or drugs they may develop in the future, may be more effective, or more effectively marketed and sold, than any drug we may commercialize and may render XHANCE or any of our other product candidates we may develop obsolete or non-competitive before we can recover the expenses of developing and commercializing XHANCE or any of our other product candidates. Our competitors may also obtain FDA or other regulatory approval of products more rapidly than expected or may obtain better or preferred market access by offering large rebates to payors or by other means. We may not have accurately or completely predicted the development of new and improved or low-cost surgical interventions, alternative medical therapies or other market-disrupting events. If we are unable to manufacture, distribute, stimulate demand reaching the predicted market share, overcome barriers to access or otherwise effectively commercialize the product, all of which factors may be influenced by current or future competition, then our opportunity to generate revenue from the sale of XHANCE or any of our other product candidates, if approved, will be compromised.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Our long-term growth depends on our ability to develop and commercialize additional ENT products.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">It is important to our business that we continue to build a more complete product offering within the ENT and allergy markets. We are evaluating the use of our proprietary EDS technology to develop new product candidates for the ENT and allergy markets. Developing additional product candidates is expensive and time-consuming and could divert management's attention away from the commercialization of XHANCE. Even if we are successful in </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">developing additional product candidates, the success of any new product candidates or enhancement to any existing product candidates will depend on several factors, including our ability to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">properly identify and anticipate ENT and allergy physician and patient needs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">develop, obtain necessary regulatory clearances or approvals, and introduce new product candidates or product enhancements in a timely manner;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">demonstrate, if required, the safety and efficacy of new product candidates with data from preclinical studies and clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">avoid infringing upon the intellectual property rights of third parties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">comply with all regulations relating to the marketing of new product candidates, including any new or modified EDS technologies; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">provide adequate training to potential users of our product candidates.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If we are unsuccessful in developing and commercializing additional product candidates in other areas of the ENT and allergy markets, our ability to gain and maintain profitability may be impaired.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">We may acquire other assets or businesses, or form collaborations or make investments in other companies or technologies, which could negatively impact our operating results, dilute our stockholders' ownership, increase our debt or cause us to incur significant expense.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As part of our business strategy, we may pursue acquisitions of assets, including preclinical, clinical or commercial-stage products or product candidates, businesses or strategic alliances and collaborations, to expand our existing technologies and operations. We may not identify or complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the anticipated benefits of any such transaction. We may not be able to find suitable acquisition candidates, and if we make any acquisitions, we may not be able to complete technology transfers and integrate these acquisitions successfully into our existing business and we may incur additional debt or assume unknown or contingent liabilities as part of the transaction. Integration of an acquired company or assets may also disrupt ongoing operations, require the hiring of additional personnel and the implementation of additional internal systems and infrastructure, especially the acquisition of commercial assets, and require management resources that would otherwise focus on developing our existing business. We may not be able to find suitable strategic collaborators or identify other investment opportunities, and we may experience losses related to any such investments.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">To finance any acquisitions or collaborations, we may choose to issue debt or shares of our common or preferred stock as consideration. Any such issuance of shares would dilute the ownership of our stockholders. If the price of our common stock is low or volatile, we may not be able to acquire other assets or companies or fund a transaction using our stock as consideration. Alternatively, it may be necessary for us to raise additional funds for acquisitions through public or private financings. Additional funds may not be available on terms that are favorable to us, or at all.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Our employees, collaborators, independent contractors, principal investigators, consultants, vendors and CROs may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are exposed to the risk that our employees, collaborators, independent contractors, principal investigators, consultants, vendors and CROs may engage in fraudulent or other illegal activity with respect to our business. Misconduct by these employees could include intentional, reckless and/or negligent conduct or unauthorized activity that violates:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">manufacturing standards;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">federal and state healthcare fraud and abuse laws and regulations; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">laws that require the true, complete and accurate reporting of financial information or data.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve individually identifiable information, including, without limitation, the improper use of information obtained in the course of clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions and serious harm to our reputation. Any incidents or any other conduct that leads to an employee receiving an FDA debarment could result in a loss of business from third parties and severe reputational harm.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have a Code of Business Conduct and Ethics to govern and deter such behaviors, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">If we fail to comply with data and privacy protection laws and regulations, we could be subject to government enforcement actions, which could include civil or criminal penalties, as well as private litigation and/or adverse publicity, any of which could negatively affect our operating results and business.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our business is subject to complex and evolving U.S., state and international data and privacy protection laws. In the U.S., numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g.,&#160;Section&#160;5 of the Federal Trade Commission Act) govern the collection, use, disclosure, and protection of health-related and other personal information. For instance, HIPAA imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information and imposes notification obligations in the event of a breach of the privacy or security of individually identifiable health information on entities subject to HIPAA and their business associates that perform certain activities that involve the use or disclosure of protected health information on their behalf. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Additionally, the General Data Protection Regulation (GDPR), applicable in the European Union (EU) as of May 25, 2018, applies to all of our activities conducted from an establishment in the EU or related to products and services that we may offer to EU users. The GDPR created a range of new compliance obligations, which could cause us to change our business practices, and has significantly increased financial penalties for noncompliance (including possible fines of up to 4% of global annual turnover for the preceding financial year or &#8364;20 million (whichever is higher) for the most serious infringements).</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Certain of these laws and regulations are described in greater detail in the previous section under "Business&#160;&#8212; Government Regulation&#160;&#8212; Healthcare Privacy Laws." Failure to comply with applicable data protection laws and regulations could result in government enforcement actions and create liability for us, which could include civil and/or criminal penalties, as well as private litigation and/or adverse publicity that could negatively affect our operating results and business.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Our business and operations would suffer in the event of computer system failures, cyberattacks or a deficiency in our cybersecurity or those of any business partners.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Despite the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures, cyberattacks or cyber-intrusions over the Internet, loss of funds or information from phishing or other fraudulent schemes, attachments to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. Such an event could cause interruption of our operations or loss of Company funds and have a negative financial consequence on our business. For example, the loss of data from completed or ongoing clinical trials for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">result in a loss of or damage to our data, or inappropriate disclosure of confidential, proprietary or personal information, we could incur material legal claims and liability and damage to our reputation and the development and commercialization of XHANCE and our product candidates could be delayed. Additionally, breach remediation costs may be significant&#160;</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">If we fail to successfully manage our global enterprise resource planning system, it could adversely affect our operations and operating results.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In 2018 we implemented a new global enterprise resource planning (ERP) system. This system replaces many of our existing operating and financial systems. Such an implementation was a major undertaking, both financially and from a management and personnel perspective. Any disruptions, delays or deficiencies in the maintenance of our ERP system could adversely affect our ability to process financial transactions, fulfill contractual obligations or otherwise operate our business. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">We are subject to risks inherent in foreign operations.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We currently operate portions of our business through our foreign subsidiaries, including through our Norwegian subsidiary, OptiNose AS, which currently owns a substantial portion of our intellectual property and conducts development activities, and our United Kingdom subsidiary OptiNose UK&#160;Ltd., which performs research and development and regulatory activities for the Optinose EDS technology as well as other services. We have committed, and intend to continue to commit, resources to our international operations. We are subject to a number of risks associated with our international business operations and activities that may increase liability, costs, and require significant management attention. These risks include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">compliance with the laws of the U.S., the United Kingdom, Norway, and other countries that apply to our international operations, including import and export legislation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">compliance with foreign data protection laws and regulations in the United Kingdom, Norway and other countries that apply to our international operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the complexities and expenses of administering a business abroad;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">complications in compliance with, and unexpected changes in, tariffs, trade barriers, price and exchange controls and other foreign regulatory requirements, including potential trade conflicts, changes to trade agreements/treaties, and the implementation of trade restrictions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">instability in economic or political conditions, including inflation, recession and actual or anticipated military conflicts, social upheaval or political uncertainty;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">uncertainties of laws and enforcement relating to the protection of intellectual property or secured technology;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">litigation in foreign court systems;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">language barriers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">changes in tax laws and regulations in the jurisdictions in which we operate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">compliance with tax, employment, immigration and labor laws, regulations and restrictions for employees living or traveling abroad;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">difficulties staffing and managing foreign operations; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">workforce uncertainty in countries where labor unrest is more common than in the U.S.;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">There can be no assurance that the policies and procedures we implement to address or mitigate these risks will be successful, that our personnel will comply with them or that we will not experience these factors in the future or that they will not have a material adverse effect on our business, results of operations and financial condition.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Our corporate structure and foreign operations may have adverse tax consequences and expose us to additional tax liabilities. In addition, tax returns we file are subject to examination by U.S. federal, state and foreign tax authorities.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have operations in Norway and the UK and a substantial portion of our intellectual property, including certain rights to XHANCE, are owned by OptiNose AS, our Norwegian subsidiary.  We file tax returns in various jurisdictions and those returns are subject to examination by the tax authorities.  During an examination, a tax authority could challenge positions taken on a return.  Such a challenge could result in the loss of tax attributes or in the payment of tax which could have an unfavorable impact on our financial condition.   </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We operate pursuant to written intercompany license, service and related agreements that establish prices for intellectual property and for services provided such as production, marketing, management, and technology development activities that are performed by one group company for another group company. The amounts paid under these intercompany agreements are commonly considered for tax purposes as transfer prices.  If the affiliated companies are located in different countries, the tax laws and regulations of each country generally require that transfer prices be at arm&#8217;s length as if between unrelated companies. Our transfer pricing arrangements consider requirements of the jurisdictions in which we operate but are not binding on the tax authorities.  If any tax authority is successful in challenging our transfer prices,  there could be an increase in taxable income in that jurisdiction which could increase our tax liabilities. Further, if the tax authority in the other country does not agree with the adjustment, both countries could tax the same income, resulting in double taxation.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Any income earned by our foreign subsidiaries, including a portion of the sales of XHANCE in the U.S., may be subject to additional tax liabilities. If our foreign operations generate cash that we want to repatriate to the U.S. or if cash generated by our U.S. operations is not sufficient to fund our U.S. operations, we may face additional tax liabilities in returning or otherwise providing such cash to support our U.S. operations or other strategic opportunities in the U.S. If we are forced to repatriate any foreign-held cash, we could incur a significant tax charge, and our business, operating results or financial condition could be adversely impacted.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If foreign subsidiary income is subject to the Subpart F, investment in US property or global intangible low-taxed income provisions, or similar provisions of the U.S. Internal Revenue Code, collectively referred to in this paragraph as Subpart F, the income may be subject to U.S. corporate income tax even if there is no cash distribution of those earnings to the U.S. For example, Subpart&#160;F income includes certain "passive" income, certain income from intercompany transactions, foreign subsidiary income over a legislative threshold or income of a foreign subsidiary which makes an "investment in U.S. property", such as holding the stock in, or making a loan to, a U.S. corporation. Any foreign subsidiary income subject to the Subpart&#160;F provisions would be included in determining U.S. taxable income and potentially subject to federal corporate income tax at rates up to 21%.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Comprehensive tax reform legislation could adversely affect our business and financial condition.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On December 22, 2017, the U.S. government signed into law comprehensive tax legislation, referred to as the Tax Cuts and Jobs Act (Tax Act). The Tax Act introduced significant changes to the U.S. corporate tax laws. The Tax Act changes include, but are not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a reduction in the corporate tax rate from a top rate of 35% to a flat rate of 21%;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">limits on the tax deductibility of interest expense;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">limits on the utilization of net operating losses generated after 2017 to 80% of current year taxable income; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">elimination of net operating loss carrybacks;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">accelerated deduction for certain investments instead of depreciation deductions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">allowing indefinite carry forward of net operating loss carry forwards generated after 2017;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">modifying or repealing certain business deductions and credits; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">limits on the deduction for certain compensation in excess of $1 million.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">While guidance has been provided on some of these new provisions, the overall impact of the Tax Act on our Company is uncertain and our business and financial condition could be adversely affected depending on how the new provisions are interpreted.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">69</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">We may be exposed to liabilities under the U.S. Foreign Corrupt Practices Act and other U.S. and foreign anti-corruption anti-money laundering, export control, sanctions, and other trade laws and regulations, and any determination that we violated these laws could have a material adverse effect on our business.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department's Office of Foreign Assets Control. We are also subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended (FCPA), the U.S. domestic bribery statute contained in 18&#160;U.S.C. &#167;&#160;201, the U.S. Travel Act, the USA PATRIOT Act, the United Kingdom Bribery Act 2010, the Proceeds of Crime Act 2002, and possibly other anti-bribery and anti-money laundering laws in countries outside of the U.S. in which we conduct our activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees and third-party intermediaries from authorizing, promising, offering, providing, soliciting, or accepting, directly or indirectly, improper payments or benefits to or from any person whether in the public or private sector. As we commercialize XHANCE and any other product candidates that we may develop, we may engage with third-party manufacturers and collaborators who operate abroad and are required to obtain certain necessary permits, licenses and other regulatory approvals with respect to our business. Our activities abroad create the risk of unauthorized payments or offers of payments by employees, consultants, sales agents or distributors, even though they may not always be subject to our control. We have implemented policies to discourage these practices by our employees, consultants, sales agents and distributors. However, our employees, consultants, sales agents, or distributors of our company may engage in conduct for which we might be held responsible, even if we do not explicitly authorize such activities.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Noncompliance with anti-corruption, anti-money laundering, export control, sanctions, and other trade laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension and/or debarment from contracting with certain persons, the loss of export privileges, reputational harm, adverse media coverage and other collateral consequences. If any subpoenas or investigations are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of operations and financial condition could be materially harmed. Responding to any action will likely result in a materially significant diversion of management's attention and resources and significant defense and compliance costs and other professional fees. In addition, the U.S. government may seek to hold us liable for successor liability FCPA violations committed by companies in which we invest or that we acquire. As a general matter, enforcement actions and sanctions could harm our business, results of operations, and financial condition.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Risks Related to Our Intellectual Property</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate to protect our technology, XHANCE or our other product candidates, our competitors could develop and commercialize technology similar to ours, and our competitive position could be harmed.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our commercial success will depend in large part on our ability to obtain and maintain patent and other intellectual property protection in the U.S. and other countries with respect to our proprietary technology and products. We rely on trade secret, patent, copyright and trademark laws, and confidentiality and other agreements with employees and third parties, all of which offer only limited protection. Our strategy is to seek patent protection for XHANCE, our other product candidates and their compositions, their methods of use and processes for their manufacture, and any other aspects of inventions that are commercially important to the development of our business.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The patent prosecution process is expensive and time-consuming, and we and any future licensors and licensees may not be able to apply for or prosecute patents on certain aspects of our product candidates or delivery technologies at a reasonable cost, in a timely fashion, or at all. We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents licensed to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. It is also possible that we or any future licensors or licensees, will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, our patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, such as with respect to proper priority claims, inventorship, claim scope or patent term adjustments. If any future licensors or licensees, are not fully cooperative or disagree with us as to the prosecution, maintenance, or enforcement of any patent rights, such patent rights could be compromised and we might not be able to prevent third parties from making, using, and selling competing products. If there are material defects in the form or preparation of our patents or patent applications, such patents or applications may be invalid or unenforceable. Moreover, our competitors may </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">70</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">independently develop equivalent knowledge, methods, and know-how. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business, financial condition, and operating results.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The patent positions of pharmaceutical companies generally are highly uncertain, involve complex legal and factual questions and have in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of any patents that issue, are highly uncertain. The steps we have taken to protect our proprietary rights may not be adequate to preclude misappropriation of our proprietary information or infringement of our intellectual property rights, both inside and outside the U.S. Further, the examination process may require us to narrow the claims of pending patent applications, which may limit the scope of patent protection that may be obtained if these applications issue. The rights that may be granted under future issued patents may not provide us with the proprietary protection or competitive advantages we are seeking. If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize technology and products similar or superior to ours, and our ability to successfully commercialize our technology and products may be impaired.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As February 28, 2019, we owned a total of 47 U.S. patents and 27 pending U.S. patent applications. These U.S. patents will expire between 2020 and 2034. With respect to these patent rights, we do not know whether any of our patent applications will result in issued patents or, if any of our patent applications do issue, whether such patents will protect our technology and drugs, in whole or in part, or whether such patents will effectively prevent others from commercializing competitive technologies and products. There is no guarantee that any of our issued or granted patents will not later be found invalid or unenforceable.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The laws of foreign countries may not protect our rights to the same extent as the laws of the U.S. or vice versa. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18&#160;months after filing or in some cases not at all, until they are issued as a patent. Therefore, we cannot be certain that we were the first to make the inventions claimed in our pending patent applications, that we were the first to file for patent protection of such inventions, or that we have found all of the potentially relevant prior art relating to our patents and patent applications that could invalidate one or more of our patents or prevent one or more of our patent applications from issuing. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may initiate oppositions, interferences, re-examinations, post-grant reviews, inter partes reviews, nullification or derivation actions in court or before patent offices or similar proceedings challenging the validity, enforceability, or scope of such patents, which may result in the patent claims being narrowed or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates, or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Furthermore, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the U.S. and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and drugs, or limit the duration of the patent protection of our technology and drugs. Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing drugs similar or identical to ours.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">We may become involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Competitors may infringe our patents or the patents of any party from whom we may license patents from in the future. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In a patent litigation in the U.S., defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the U.S. Patent and Trademark Office (USPTO) or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. A court may decide that a patent of ours or of any of our future licensors is not valid or is </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">71</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. In addition, to the extent that we have to file patent litigation in a federal court against a U.S. patent holder, we would be required to initiate the proceeding in the state of incorporation or residency of such entity. With respect to the validity question, for example, we cannot be certain that no invalidating prior art exists. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, found unenforceable, or interpreted narrowly, and it could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our products or certain aspects of the Optinose EDS technology. Such a loss of patent protection could compromise our ability to pursue our business strategy.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Interference proceedings brought by the USPTO may be necessary to determine the priority of inventions with respect to our patents and patent applications or those of our collaborators or licensors. An unfavorable outcome could require us to cease using the technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if a prevailing party does not offer us a license on terms that are acceptable to us. Litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distraction of our management and other employees. We may not be able to prevent, alone or with any of our future licensors, misappropriation of our proprietary rights, particularly in countries where the laws may not protect those rights as fully as in the U.S. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Moreover, we may be subject to a third-party pre-issuance submission of prior art to the USPTO or other foreign patent offices, or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or drugs and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop, or commercialize current or future product candidates.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Filing, prosecuting and defending patents on XHANCE, our other product candidates and the Optinose EDS technology throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. may be less extensive than those in the U.S. In addition, the laws and practices of some foreign countries do not protect intellectual property rights, especially those relating to life sciences, to the same extent as federal and state laws in the U.S. For example, novel formulations of existing drugs and manufacturing processes may not be patentable in certain jurisdictions, and the requirements for patentability may differ in certain countries, particularly developing countries. Also, some foreign countries, including European Union countries, India, Japan and China, have compulsory licensing laws under which a patent owner may be compelled under certain circumstances to grant licenses to third parties. Consequently, we may have limited remedies if patents are infringed or if we are compelled to grant a license to a third party, and we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions into or within the U.S. or other jurisdictions. This could limit our potential revenue opportunities. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products, and may export otherwise infringing products to territories where we have patent protection, but where enforcement is not as strong as that in the U.S. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing with us in these jurisdictions. Furthermore, the prevalence of counterfeit medicines, which is one that has been deliberately and fraudulently mislabeled as to its identity and source, is a significant and growing industry-wide issue that could impact our revenue and our reputation for which we may have limited or no recourse. Accordingly, our efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from our intellectual property. We may not prevail in any lawsuits that we initiate in these foreign countries and the damages or other remedies awarded, if any, may not be commercially meaningful.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">72</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and applications are required to be paid to the USPTO and various governmental patent agencies outside of the U.S. in several stages over the lifetime of the patents and applications. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and after a patent has issued. There are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which could be uncertain and could harm our business.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our commercial success depends upon our ability to develop, manufacture, market and sell XHANCE and our other product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. While our product candidates are in preclinical studies and clinical trials, we believe that the use of our product candidates in these preclinical studies and clinical trials falls within the scope of the exemptions provided by 35 U.S.C. Section&#160;271(e) in the U.S., which exempts from patent infringement liability activities reasonably related to the development and submission of information to the FDA. As XHANCE and our other product candidates progress toward commercialization, the possibility of a patent infringement claim against us increases. For instance, our use of the Section&#160;505(b)(2) regulatory pathway for the follow-on indication of chronic sinusitis or any of our other product candidates will require us to provide a Paragraph&#160;IV certification to the NDA and patent holders of the RLD pursuant to the Hatch-Waxman Act if the RLD is covered by Orange Book-listed patents. If the NDA or patent holder files&#160;a patent infringement lawsuit against us within 45&#160;days of its receipt of notice of our certification, the FDA is prevented from approving our Section&#160;505(b)(2) NDA until the earliest of 30&#160;months, expiration of the patents, settlement of the lawsuit or a court decision in the infringement case that is favorable to us. Accordingly, we may invest significant time and expense in the development of our product candidates only to be subject to significant delay and expensive and time-consuming patent litigation before our product candidates may be commercialized. There can be no assurance that our product candidates do not infringe other parties' patents or other proprietary rights and competitors or other parties may assert that we infringe their proprietary rights in any event.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our product candidates, including interference or derivation proceedings before the USPTO. Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are developing our drug candidates. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If we are found to infringe a third party's intellectual property rights, we could be required to obtain a license from such third party to continue commercializing our product candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if a license can be obtained on acceptable terms, the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to us. If we fail to obtain a required license, we may be unable to effectively market product candidates based on our technology, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. Alternatively, we may need to redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. Under certain circumstances, we could be forced, including by court order, to cease commercializing our product candidates. In addition, in any such proceeding or litigation, we could be found liable for substantial monetary damages, potentially including treble damages and attorneys' fees, if we are found to have willfully infringed. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could harm our business. Any claims by third parties that we have misappropriated their confidential information or trade secrets could have a similar negative impact on our business.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The cost to us in defending or initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our management's attention. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our commercialization efforts, delay our research and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">73</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">development efforts and limit our ability to continue our operations. There could also be public announcements of the results of the hearing, motions, or other interim proceedings or developments. If securities analysts or investors perceive those results to be negative, it could cause the price of shares of our common stock to decline.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our competitors may seek to market generic versions of any of our approved products by submitting ANDAs to the FDA or new products that use our approved products as the RLD, in each case where our competitors claim that our patents are invalid, unenforceable or not infringed. Alternatively, our competitors may seek approval to market their own products that are the same as, similar to or otherwise competitive with XHANCE and any future product candidates we may develop. In these circumstances, we may need to defend or assert our patents, by means including filing lawsuits alleging patent infringement requiring us to engage in complex, lengthy and costly litigation or other proceedings. In any of these types of proceedings, a court or government agency with jurisdiction may find our patents invalid, unenforceable or not infringed. We may also fail to identify patentable aspects of our research and development before it is too late to obtain patent protection. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Changes in either U.S. or foreign patent law or interpretation of such laws could diminish the value of patents in general, thereby impairing our ability to protect our products.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the pharmaceutical industry involve both technological and legal complexity, and it therefore is costly, time-consuming and inherently uncertain. In addition, on September&#160;16, 2011, the Leahy-Smith America Invents Act (the AIA) was signed into law. The AIA includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications will be prosecuted and may also affect patent litigation.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">An important change introduced by the AIA is that, as of March&#160;16, 2013, the U.S. transitioned to a "first-to-file" system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files&#160;a patent application in the USPTO after that date, but before us, could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file&#160;a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March&#160;16, 2013. Because of a lower evidentiary standard necessary to invalidate a patent claim in USPTO proceedings compared to the evidentiary standard in U.S. federal court, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Depending on decisions by the U.S. Congress, the federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">We may be subject to claims asserting that our employees, consultants, independent contractors and advisors have wrongfully used or disclosed confidential information and/or alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Although we try to ensure that our employees, consultants, independent contractors and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have inadvertently or otherwise used or disclosed confidential information and/or intellectual property, including trade secrets or other proprietary information, of the companies that any such individual currently or formerly worked for or provided services to. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">74</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our business.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition, while we require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Intellectual property rights do not prevent all potential threats to competitive advantages we may have.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and intellectual property rights may not adequately protect our business or permit us to maintain our competitive advantage.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following examples are illustrative:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Others may be able to make drug and device components that are the same as or similar to XHANCE and our other product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We or any of our licensors or collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We or any of our licensors or collaborators might not have been the first to file patent applications covering certain of our inventions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The prosecution of our pending patent applications may not result in granted patents;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Granted patents that we own or have licensed may not cover our products or may be held not infringed, invalid or unenforceable, as a result of legal challenges by our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">With respect to granted patents that we own or have licensed, especially patents that we either acquire or in-license, if certain information was withheld from or misrepresented to the patent examiner, such patents might be held to be unenforceable;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Patent protection on our product candidates may expire before we are able to develop and commercialize the product, or before we are able to recover our investment in the product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our competitors might conduct research and development activities in the U.S. and other countries that provide a safe harbor from patent infringement claims for such activities, as well as in countries in which we do not have patent rights, and may then use the information learned from such activities to develop competitive products for sale in markets where we intend to market our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We may not develop additional proprietary technologies that are patentable;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The patents of others may have an adverse effect on our business; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We may choose not to file&#160;a patent application for certain technologies, trade secrets or know-how, and a third party may subsequently file&#160;a patent covering such intellectual property.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">75</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition to seeking patent protection for certain aspects of our product candidates and delivery technologies, we also consider trade secrets, including confidential and unpatented know-how important to the maintenance of our competitive position. We protect trade secrets and confidential and unpatented know-how, in part, by customarily entering into non-disclosure and confidentiality agreements with parties who have access to such knowledge, such as our employees, outside scientific and commercial collaborators, CROs, CMOs, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants that obligate them to maintain confidentiality and assign their inventions to us. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. In addition, our trade secrets may otherwise become known, including through a potential cybersecurity breach, or may be independently developed by competitors.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts in the U.S. and certain foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">If our trademarks are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We expect to rely on trademarks as one means to distinguish any of our product candidates that are approved for marketing from the products of our competitors. OPTINOSE&#174; and XHANCE&#174; are registered trademarks of ours in the U.S. Our trademarks may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks, we may not be able to compete effectively.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Risks Related to Ownership of Our Common Stock and Our Status as a Public Company</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">An active market for our common stock may not develop. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We completed our initial public offering in October 2017, but prior to that offering there was no market for our shares of common stock. Although our common stock is listed on Nasdaq, an active market for our common stock may not develop.  The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also reduce the fair market value of your shares. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic collaborations or acquire companies or products by using our shares of common stock as consideration.      </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">The price of our common stock may be volatile and you may lose all or part of your investment.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The market price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. In addition to the factors discussed in this "Risk Factors" section and elsewhere in this 10-K, these factors include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our ability to successfully commercialize XHANCE;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">any delay in our regulatory approval or filings for XHANCE for a follow-on indication for the treatment of chronic sinusitis or any other product candidate we may develop, and any adverse development or perceived adverse development with respect to the applicable regulatory authority's review of such filings, including without limitation the FDA's issuance of a "refusal to file" letter, a request for additional information, or a CRL;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the success of competitive products or technologies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">adverse regulatory actions with respect to our product candidates, including the failure to receive regulatory approval, or our competitors' products or product candidates;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">76</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">actual or anticipated changes in our growth rate relative to our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">announcements by us or our competitors of significant acquisitions or divestitures, strategic collaborations, joint ventures, collaborations or capital commitments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the commencement, enrollment or results of planned clinical trials of our product candidates or any future clinical trials we may conduct, or any changes generally in the development status of our product candidates or those of our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">regulatory or legal developments in the U.S. and other countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the outcome of any investigations or regulatory scrutiny of our operations or litigation that may be brought against us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the recruitment or departure of key personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the level of expenses related to any of our product candidates or clinical development programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">actual or anticipated variations in our quarterly operating results;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the number and characteristics of our efforts to in-license or acquire additional product candidates or products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">introduction of new products or services by us or our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">failure to meet the estimates and projections of the investment community or financial guidance that we may otherwise provide to the public;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">actual or anticipated changes in estimates as to development timelines that we may provide to the public;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">variations in our financial results or those of companies that are perceived to be similar to us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">fluctuations in the valuation of companies perceived by investors to be comparable to us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">announcement or expectation of additional financing efforts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">sales of our common stock by us, our insiders or our other stockholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">significant lawsuits, including patent or stockholder litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">changes in the structure of healthcare payment systems;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">market conditions in the pharmaceutical and biotechnology sectors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">general political, economic, industry and market conditions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">investors' general perception of our company and our business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">publication of research reports about us, our competitors or our industry, or positive or negative recommendations or withdrawal of research coverage by securities or industry analysts; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">other events or factors, many of which are beyond our control.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition, the stock market in general, and pharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks stated above could have a material adverse effect on the market price of our common stock.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">77</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">A significant portion of our total outstanding shares are restricted from resale but may be sold into the market in the near future. Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall, even if our business is doing well.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that the holders of a large number of shares intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of March 1, </font><font style="font-family:Arial;font-size:10pt;">2019</font><font style="font-family:Arial;font-size:10pt;">, there were </font><font style="font-family:Arial;font-size:10pt;">41,264,422</font><font style="font-family:Arial;font-size:10pt;">&#32;outstanding shares of our common stock. Holders of an aggregate of 15,674,055 shares of our common stock have rights, subject to specified conditions, that require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. If we were to register the resale of these shares, they could be freely sold in the public market. Additionally, these shares are also eligible for sale without registration under Rule 144, subject to volume limitations applicable to affiliates. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Future issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We will likely require additional capital in the future to execute our business plan. To raise capital, we may sell substantial amounts of common stock or securities convertible into or exchangeable for common stock. These future issuances of common stock or common stock-related securities, together with the exercise of outstanding options, warrants and any additional shares issued in connection with acquisitions, if any, may result in material dilution to our investors. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to those of holders of our common stock.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Our principal stockholders and management own a majority of our stock and are able to exert significant control over matters subject to stockholder approval, which could prevent new investors from influencing significant corporate decisions.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our executive officers, directors, beneficial owners of 5% or more of our capital stock and their respective affiliates, in the aggregate, beneficially own approximately&#160;78.6% of our outstanding common stock as of March 1, </font><font style="font-family:Arial;font-size:10pt;">2019</font><font style="font-family:Arial;font-size:10pt;">.   Entities associated with Avista Capital Partners II,&#160;L.P. (Avista), our largest stockholder, collectively hold as a group approximately&#160;37.6% of our outstanding common stock as of March 1, </font><font style="font-family:Arial;font-size:10pt;">2019</font><font style="font-family:Arial;font-size:10pt;">. As a result, Avista can significantly influence the outcome of matters requiring stockholder approval, including the election of directors, amendments of our organizational documents, or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest. The interests of Avista may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock. For instance, under the terms of our fourth amended and restated certificate of incorporation, neither Avista nor any of its respective representatives on our board of directors are required to offer us any transaction opportunity of which they become aware, and they could take any such opportunity for themselves or offer it to other companies in which they have an investment, unless that opportunity is expressly offered to a person serving on our board of directors solely in his or her capacity as one of our directors. These actions might affect the prevailing market price for our common stock. In addition, because Avista and certain of our other principal stockholders have held their shares for several years, they may be more interested in selling our company to an acquiror than other investors, or they may want us to pursue strategies that deviate from the interests of other stockholders. Such concentration of ownership control may also:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">delay, defer or prevent a change in control;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">entrench our management and/or the board of directors; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">impede a merger, consolidation, takeover or other business combination involving us that other stockholders may desire.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We may also take actions that our other stockholders do not view as beneficial, which may adversely affect our results of operations and financial condition and cause the value of your investment to decline.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">78</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Provisions in our fourth amended and restated certificate of incorporation and our amended and restated bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders, or remove our current management. These include provisions that :</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">permit our board of directors to issue up to&#160;five&#160;million shares of preferred stock, with any rights, preferences and privileges as it may designate, which issuance could result in the loss of voting control by other stockholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">provide that our board of directors will be classified into three classes with staggered, three-year terms and that, subject to the rights of Avista to remove its respective director nominees with or without cause, directors may only be removed for cause by the affirmative vote of the holders of at least a majority of the voting power of outstanding shares of our capital stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">subject to any director nomination rights afforded Avista, provide that all vacancies on our board of directors, including as a result of newly created directorships, may, except as otherwise required by law, be filled only by the affirmative vote of a majority of directors then in office, even if less than a quorum;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">provide that, with the exception of director nominees submitted by Avista pursuant to our Stockholders Agreement, dated October 2, 2017 with Avista, stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder's notice;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">require that the amendment of certain provisions of our certificate of incorporation relating to anti-takeover measures may only be approved by a vote of 66</font><font style="font-family:Arial;font-size:8pt;">2</font><font style="font-family:Arial;font-size:10pt;">/</font><font style="font-family:Arial;font-size:8pt;">3</font><font style="font-family:Arial;font-size:10pt;">% of our outstanding common stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">require that the amendment of our bylaws be approved by the affirmative vote of a majority of directors then in office or 66</font><font style="font-family:Arial;font-size:8pt;">2</font><font style="font-family:Arial;font-size:10pt;">/</font><font style="font-family:Arial;font-size:8pt;">3</font><font style="font-family:Arial;font-size:10pt;">% of our outstanding common stock entitled to vote thereon;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">not provide for cumulative voting rights, thereby allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">provide that special meetings of our stockholders may be called only by the chairman or vice chairman of our board of directors, our chief executive officer, or a majority of our board of directors.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, who are responsible for appointing the members of our management. Under our fourth amended and restated certificate of incorporation, we have elected not to be governed by Section 203 of the Delaware General Corporation Law until such time that Avista ceases to own 15% or more of our capital stock. Our fourth amended and restated certificate of incorporation does, however, contain a provision that generally mirrors Section 203 of the Delaware General Corporation Law, except that it excludes Avista and its affiliates from the definition of "interested stockholder." At such time that Avista ceases to own 15% or more of our capital stock, we will be governed by the provisions of Section&#160;203 of the Delaware General Corporation Law. These provisions may discourage, delay or prevent someone from acquiring us or merging with us whether or not it is desired by or beneficial to our stockholders. Under Section&#160;203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other things, prior to the time the stockholder has become an interested stockholder, the board of directors has approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">These provisions of our fourth amended and restated certificate of incorporation, our amended and restated bylaws and Delaware law could have the effect of discouraging potential acquisition proposals and delaying or preventing a change in control. They could also have the effect of discouraging others from making tender offers for our common stock, including transactions that may be in your best interests or provide an opportunity for our stockholders to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">79</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">receive a premium for their shares of our common stock. These provisions could also affect the price that some investors are willing to pay for our common stock.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Our certificate of incorporation also provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our fourth amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or our bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. Our fourth amended and restated certificate of incorporation also provides that the U.S. District Court for the District of Delaware and any appellate courts thereof will be the exclusive forum for resolving any such complaint for which subject matter jurisdiction of such claim is vested exclusively in the federal courts of the U.S. of America. These choice of forum provisions may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find the choice of forum provisions contained in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">We may fail to qualify for continued listing on Nasdaq which could make it more difficult for investors to sell their shares.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We list our common stock on The Nasdaq Global Select Market. We will need to satisfy the continued listing requirements of The Nasdaq Stock Market,&#160;LLC (Nasdaq) for inclusion on The Nasdaq Global Select Market to maintain such listing, including, among other things, the maintenance of a minimum bid price of $1.00 per share and stockholders' equity of at least $10.0&#160;million. There can be no assurance that we will be able to maintain compliance with the continued listing requirements or that our common stock will not be delisted from Nasdaq in the future. If our common stock is delisted by Nasdaq, we could face significant material adverse consequences, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a limited availability of market quotations for our securities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">reduced liquidity with respect to our securities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a determination that our shares are a "penny stock," which will require brokers trading in our shares to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our shares;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a limited amount of news and analyst coverage for our company; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a decreased ability to issue additional securities or obtain additional financing in the future.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The trading market for our common stock will be influenced by the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">80</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain and you may never receive a return on your investment.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have never declared or paid cash dividends on our capital stock, and you should not rely on an investment in our common stock to provide dividend income. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, the terms of the Note Purchase Agreement precludes us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">We may be subject to securities litigation, which is expensive and could divert our management's attention.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As we operate in the pharmaceutical industry, we may be especially vulnerable to volatility in the market price of our common stock, especially to the extent that various factors affect the common stock of companies in our industry. In the past companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management's attention from other business concerns, which could seriously harm our business, and could also require us to make substantial payments to satisfy judgments or to settle litigation.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">We are an "emerging growth company" and intend to take advantage of reduced disclosure and governance requirements applicable to emerging growth companies, which could result in our common stock being less attractive to investors.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are an "emerging growth company," as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act) and we are eligible to and intend to take advantage of some of the exemptions from reporting requirements applicable to other public companies, but not to emerging growth companies, including, but not limited to, an exemption from the auditor attestation requirement of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure about executive compensation arrangements pursuant to the rules applicable to smaller reporting companies and no requirement to seek non-binding advisory votes on executive compensation or golden parachute arrangements. We will remain an emerging growth company until the earliest of (1)&#160;the beginning of the first fiscal year following the fifth anniversary of our initial public offering, or January&#160;1, 2023, (2)&#160;the beginning of the first fiscal year after our annual gross revenue is $1.07&#160;billion or more, (3)&#160;the date on which we have, during the previous three-year period, issued more than $1.0&#160;billion in non-convertible debt securities and (4)&#160;the end of any fiscal year in which the market value of our common stock held by non-affiliates exceeded $700.0&#160;million as of the end of the second quarter of that fiscal year.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition, Section&#160;107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. An emerging growth company can therefore delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. However, we have chosen to "opt out" of such extended transition period and, as a result, we will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. Section&#160;107 of the JOBS Act provides that our decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We cannot predict if investors will find our common stock less attractive as a result of our taking advantage of these exemptions. If some investors find our common stock less attractive as a result of our choices, there may be a less active trading market for our common stock and our stock price may be more volatile. We may also be unable to raise additional capital as and when we need it.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to timely and accurately report our financial condition, results of operations or cash flows, which may adversely affect investor confidence in us and, as a result, the value of our common stock.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are subject to the reporting requirements of the Securities Exchange Act of 1934 (the Exchange Act), as well as the Sarbanes-Oxley Act and the rules and regulations of the stock market on which our common stock is listed. The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal control over financial reporting. Commencing with our fiscal year ending December&#160;31, 2018, we are required, under Section&#160;404 of the Sarbanes-Oxley Act, to include in our Form&#160;10-K filing for that year a report by management on, among other things, the effectiveness of our internal control over financial reporting. This assessment will need to include disclosure of any </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">81</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">material weaknesses identified by our management in our internal control over financial reporting. A material weakness is a control deficiency, or combination of control deficiencies, in internal control over financial reporting that results in more than a reasonable possibility that a material misstatement of annual or interim consolidated financial statements will not be prevented or detected on a timely basis. Section&#160;404 of the Sarbanes-Oxley Act also generally requires an attestation from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. However, for as long as we remain an emerging growth company as defined in the JOBS Act, we intend to take advantage of an exemption from the independent registered public accounting firm attestation requirement.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our compliance with Section&#160;404's requirement to furnish a report by management requires that we incur substantial accounting expense and expend significant management efforts. Prior to our initial public offering in October 2017, we were never required to test our internal control within a specified period, and, as a result, we may experience difficulty in meeting these reporting requirements in a timely manner. We currently do not have an internal audit function. We may not be able to complete our evaluation, testing and any required remediation in a timely fashion, which could potentially subject us to sanctions or investigations by the Securities and Exchange Commission (the SEC) or other regulatory authorities.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We may identify weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our consolidated financial statements. During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Any failure to maintain internal control over financial reporting could severely inhibit our ability to timely and accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness in our internal control over financial reporting once that firm begins the testing procedures over internal controls, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are subject to the periodic reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">These inherent limitations reflect the reality that judgments can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. If that were to happen, the market price of our stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prior to the consummation of our initial public offering in October 2017, we were not subject to public company reporting obligations. We now incur significant additional legal, accounting, administrative and other costs and expenses as a public company. Compliance with the Sarbanes-Oxley Act, the Dodd-Frank Act of 2010, the Exchange Act, as well as rules of the SEC and Nasdaq, for example, resulted in, and will result in further, significant </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">82</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">initial costs to us as well as ongoing increases in our legal, audit and financial compliance costs, particularly after we are no longer an "emerging growth company." In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by Nasdaq and the SEC, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management's time and attention from revenue-generating activities to compliance activities. Any changes that we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and financial condition. Our board of directors, management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, failure to comply with these rules and regulations might make it more difficult and more expensive for us to obtain director and officer liability insurance, or we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to maintain the same or similar coverage.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">83</font></div></div><hr style="page-break-after:always"><div><a name="s1187D9BBC6E758EC94580370401DA952"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ITEM 1B. UNRESOLVED STAFF COMMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">None.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="sD24F3C30573E5238AEFFACF92C813D3A"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ITEM 2. PROPERTIES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our principal office is located in Yardley, Pennsylvania, where we lease approximately 30,000 square feet of office space pursuant to a lease that expires in May 2021. We also lease facilities in Ewing, New Jersey, Oslo, Norway and Swindon, England. We believe our facilities are adequate to meet our current needs, although we may seek to negotiate new leases or evaluate additional or alternate space for our operations. We believe appropriate alternative space will be readily available on commercially reasonable terms. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="s3FA6225D8D9E54228A58FBB4EA8AC4D8"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ITEM 3. LEGAL PROCEEDINGS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are not currently a party to any legal proceedings.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="s08B247C026A9516DBA66EBF747A13221"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ITEM&#160;4. MINE SAFETY DISCLOSURES</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Not applicable.</font></div><div><a name="sB722D72872015260A52AC7EA23A44345"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PART II</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="s8E102D097BB5550C8DF856A8F2B41191"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ITEM 5. MARKET FOR RESISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our common stock is traded on The Nasdaq Global Select Market under the symbol &#8220;OPTN&#8221;. As of March 1, </font><font style="font-family:Arial;font-size:10pt;">2019</font><font style="font-family:Arial;font-size:10pt;">, there were </font><font style="font-family:Arial;font-size:10pt;">41,264,422</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of our common stock outstanding. There were approximately 25 stockholders of record at March 1, </font><font style="font-family:Arial;font-size:10pt;">2019</font><font style="font-family:Arial;font-size:10pt;">. Because many of our shares are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these record holders. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Securities Authorized for Issuance under Equity Compensation Plans</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Information required by Item 5 of Form 10-K regarding our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Recent Sales of Unregistered Securities</font><font style="font-family:Arial;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In May 2018 and July 2018, we issued an aggregate of 14,647 shares of common stock to pursuant to the exercise of certain warrants issued prior to our initial public offering. The shares of common stock issued upon exercise of the warrants were offered and sold without registration under the Securities Act pursuant to the exemption provided by Section 4(a)(2) of the Securities Act and Rule 506 promulgated thereunder as transactions not involving a public offering. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The certificates representing the issued shares of common stock described in this Item 5 included appropriate legends setting forth that the applicable securities have not been registered and reciting the applicable restrictions on transfer. There were no underwriters employed in connection with any of the transactions set forth in this Item 5. Except as set forth above, we did not sell any shares of our common stock or our preferred stock, or grant any stock options or restricted stock awards, during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;that were not registered under the Securities Act of 1933, as amended (the Securities Act) and that have not otherwise been described in a Quarterly Report on Form 10-Q or a Periodic Report on Form 8-K.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We did not purchase any of our registered equity securities during the period covered by this Annual Report on Form 10-K. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Use of Proceeds from Registered Securities </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our initial public offering (IPO) was effected through a Registration Statement on Form S-1 (File No. 333-220515) that was declared effective by the SEC on October 12, 2017. On October 17, 2017, </font><font style="font-family:Arial;font-size:10pt;">8,625,000</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of our common stock were sold at a price to the public of $16.00 per share, for aggregate gross proceeds of </font><font style="font-family:Arial;font-size:10pt;">$138.0 million</font><font style="font-family:Arial;font-size:10pt;">. All of the securities registered pursuant to the offering were sold prior to termination of the offering. Jefferies </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">84</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">and Piper Jaffray acted as joint lead book-running managers in the IPO, and BMO Capital Markets and RBC Capital Markets acted as joint book-running managers in the IPO. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On October 17, 2017 we received proceeds from the IPO of </font><font style="font-family:Arial;font-size:10pt;">$128.3 million</font><font style="font-family:Arial;font-size:10pt;">, which was net of underwriting discounts and commissions of approximately </font><font style="font-family:Arial;font-size:10pt;">$9.7 million</font><font style="font-family:Arial;font-size:10pt;">. Of this amount, we paid offering expenses of approximately </font><font style="font-family:Arial;font-size:10pt;">$2.8 million</font><font style="font-family:Arial;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">There has been no material change in the use of proceeds from the IPO as described in the final prospectus for the IPO filed with the SEC on October 12, 2017 (the Final Prospectus). During the period from the closing of our IPO to </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, we used </font><font style="font-family:Arial;font-size:10pt;">$115.4 million</font><font style="font-family:Arial;font-size:10pt;">&#32;of the proceeds as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">approximately </font><font style="font-family:Arial;font-size:10pt;">$70.3 million</font><font style="font-family:Arial;font-size:10pt;">&#32;to support the launch of XHANCE, including investments in marketing and sales, inventory and our commercial infrastructure;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">approximately </font><font style="font-family:Arial;font-size:10pt;">$9.7 million</font><font style="font-family:Arial;font-size:10pt;">&#32;to fund further development efforts for XHANCE; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">approximately </font><font style="font-family:Arial;font-size:10pt;">$35.4 million</font><font style="font-family:Arial;font-size:10pt;">&#32;to fund other working capital and general corporate purposes, including costs of operating as a public company. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The balance of the funds totaling approximately </font><font style="font-family:Arial;font-size:10pt;">$10.1 million</font><font style="font-family:Arial;font-size:10pt;">&#32;are expected to be used in a manner consistent with the use of proceeds described in the Final Prospectus. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The foregoing expenses are a reasonable estimate of the expenses incurred by us in the offering and do not represent the exact amount of expenses incurred. All of the foregoing expenses were direct or indirect payments to persons other than (i) our directors, officers or any of their associates; (ii) persons owning 10% or more of our common stock; or (iii) our affiliates. </font></div><div><a name="sE19CE4699E7A51ECA5EAAC3886527125"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ITEM 6. SELECTED CONSOLIDATED FINANCIAL DATA</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item. </font></div><div><a name="s6D1D6533390B5CAC8EB36BDB2BE4BFFE"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our historical consolidated financial statements and the related notes thereto appearing in this Annual Report. In addition to historical information, some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, includes forward&#8209;looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Annual Report, our actual results could differ materially from the results described in or implied by the forward&#8209;looking statements contained in the following discussion and analysis.</font></div><div><a name="s00CABB47160A5D10A0733EE392D09F1D"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Company Overview</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">W</font><font style="font-family:Arial;font-size:10pt;">e are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;(fluticasone propionate) nasal spray, 93 mcg, is a therapeutic utilizing our proprietary Optinose Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). Chronic rhinosinusitis is a serious nasal inflammatory disease that is currently treated using therapies, such as intranasal steroids (INS), which have significant limitations. We believe XHANCE has a differentiated clinical profile with the potential to become part of the standard of care for this disease because it is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by current INS.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On September 18, 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18&#160;years of age or older.&#160;XHANCE was made widely available through retail channels in April 2018.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Since the FDA approval of XHANCE, we have focused on executing our integrated launch plan and have made progress in each of these key strategic areas: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Customer Model</font><font style="font-family:Arial;font-size:10pt;">.&#160;We have defined a sales force footprint of approximately 120 territories targeting approximately 14,000 ENTs, allergists and &#8220;specialty-like&#8221; primary care physicians and have deployed a hybrid sales model that combines an internal sales leadership team with a fully-dedicated contract sales </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">85</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:10px;padding-top:10px;text-align:left;"><font style="font-family:Arial;font-size:10pt;">force to call on our target health care provider (HCP) customer universe. We prioritized approximately 80 territories within our sales force footprint to deploy in 2018 based upon pre-launch expectations regarding where we could achieve an estimated 65% commercial market access within each territory. The initial 80 territory managers were deployed in March 2018, actively engaging approximately 7,600 ENTs, allergists and "specialty like" primary care physician targets to promote XHANCE for the treatment of nasal polyps. During the first half of 2019, we plan to internalize our contract sales team and deploy an additional 20 territory managers in &#8220;XHANCE naive&#8221; geographies to expand our reach among our target physician audience. This is expected to grow the target audience for our sales team by approximately 25% to approximately 9,500 HCPs. We intend to eventually increase the size of our sales force to approximately 120 territory managers to expand our called on target audience to approximately 14,000 ENT, allergists and specialty-like primary care physicians. Additionally, we expect to target additional physicians through digital and non-personal promotion in areas where we do and do not have territory managers.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">XHANCE Patient Affordability Programs.</font><font style="font-family:Arial;font-size:10pt;">&#32;In late August 2018, we implemented our current co-pay savings program. We believe this program, with an indefinite duration, provides an affordability solution for patients that physicians will support. The current program provides patient co-pay assistance including a first prescription at no out-of-pocket cost to patients ($0 co-pay) to commercially insured patients and low subsequent co-pays for refills. Our data suggests these programs are playing a role in building demand for XHANCE, particularly as they become more widely understood in the prescribing community.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Market Access.</font><font style="font-family:Arial;font-size:10pt;">&#160; In meeting with pharmacy benefit managers (PBMs) and health insurers/potential payors, we share what we believe is a compelling economic value proposition. Our analyses suggest that XHANCE will have a comparatively low pharmacy budget impact and our clinical trial data suggest that XHANCE may produce an offsetting benefit by helping reduce other healthcare resource utilization, most notably the rate of endoscopic surgery and, therefore, surgery-related costs. For an insurance plan, this could represent potential for overall cost reduction in the population of patients with nasal polyps, as the overall cost of XHANCE could be less than the offsetting costs related to the reduction in surgeries.&#160;During clinical trials, XHANCE was also associated with an improvement in&#160;reported work productivity in treated patients, which should be valued by employers and patients.&#160;Further, we believe the cost of XHANCE to insurance plans will likely be significantly less than the projected costs of monoclonal antibodies that are currently in development for the treatment of nasal polyps, including dupilumab, for which the submission of an Supplemental Biologics License Application (sBLA)&#160;was recently publicly announced.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Based on currently available third-party data and our internal analyses, we believe that greater than 75% of commercially insured lives are currently in a plan in which XHANCE is covered in a Tier 3 formulary position, and approximately 60% of commercially insured lives are in a plan that covers XHANCE in a &#8220;low hassle factor&#8221; position. However, payors may change coverage levels for XHANCE or controls such as step edits and prior authorization (PAs), positively or negatively, at any time. We use the term &#8220;hassle factor&#8221; to characterize the level of difficulty that physicians and patients must overcome to prescribe and fill XHANCE. We define a low &#8220;hassle factor&#8221; as Tier 3 unrestricted, Tier 3 single step edit, or Tier 3 with a simple PA requiring, for example, only the prior use of an over-the-counter or generic INS - although we acknowledge that any step edit or PA involves a level of burden for physicians and patients that could negatively impact XHANCE utilization. Our initial goal was for 75% of commercially insured lives to have access to XHANCE in a Tier 3 formulary position with a &#8220;low hassle factor" by the end of 2018. While at approximately 60% "low hassle factor" at December 31, 2018 we did not meet this goal, it remains an important concept for us as we seek to expand overall coverage for XHANCE. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have also contracted with the Centers for Medicare and Medicaid Services for coverage of certain government insured lives and continue to expand XHANCE market access for other government-insured populations.&#160;As noted above, we have in place a co-pay assistance program for patients covered by commercial insurers and plan to continue to analyze affordability issues and assess patient affordability programs to appropriately support patient access to XHANCE for government insured patients.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Infrastructure.</font><font style="font-family:Arial;font-size:10pt;">&#160;We continue to develop our internal capabilities in a manner commensurate with having become a fully integrated and publicly traded commercial-stage specialty pharmaceutical company.&#160;We have implemented an enterprise resource planning system to expand our operational and commercial finance capabilities.&#160;We have also implemented a robust healthcare compliance program to guide our staff&#8217;s and our partners' compliance with rules and regulations regarding pharmaceutical sales. In managing our growth, we have remained focused on fostering our One Mission culture.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">86</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">XHANCE Prescriptions.</font><font style="font-family:Arial;font-size:10pt;">&#32;&#32;Based on third-party prescription data as well as data from preferred pharmacy network partners, the total estimated number of XHANCE prescriptions in the second quarter, third quarter and fourth quarter 2018 were 8,611, 9,427, and 14,106, respectively, which represents 50% growth for prescriptions when comparing fourth quarter to third quarter. The INS market increased approximately 11% from third quarter to fourth quarter of 2018 based on third-party prescription data. Estimated XHANCE prescriptions in December 2018 and January 2019 were 4,570 and 6,292, respectively, which represents 38% month-over-month growth. The INS market increased approximately 5% from December 2018 to January 2019 based on third-party prescription data. In addition, XHANCE prescriptions for the 4-week periods ended January 25 and February 22, 2019 were 5,156 and 7,186, respectively, which represents period-over-period growth of 39%. The INS market decreased approximately 1% from the 4-week period ended January 25 to the 4-week period ended February 22 based on third-party prescription data. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">XHANCE prescribing may be subject to a seasonal effect historically observed in the INS market in which market volume generally peaks in the second quarter and declines in the third quarter of each calendar year. Although the underlying disease that we are treating is chronic and causes symptoms year-round, we believe the variation in patient flow through the offices of relevant specialists, and seasonality in disease flare-ups, may have an impact on the number of patients that present themselves and who are therefore available for prescribing a new medication like XHANCE. We also believe the annual resetting of patient healthcare insurance plan deductibles may have a negative impact on demand for XHANCE. Based on our limited commercial history, we are unable to estimate the extent to which INS market seasonality and deductible resets may affect XHANCE. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">XHANCE Development Update</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition to XHANCE&#8217;s existing indication for the treatment of nasal polyps, in order to broaden our U.S. market opportunity we initiated a clinical research program in pursuit of a follow-on indication for the treatment of chronic sinusitis in the U.S. The program will comprise two phase 3b clinical trials, the first of which was initiated in the fourth quarter of 2018. We expect to initiate the second trial in 2019.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="s3E78B0461BBB575489937120E7E5E268"></a></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Financial Operations Overview</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following discussion sets forth certain components of our consolidated statements of operations as well as factors that impact those items.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Net product revenues</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sales of XHANCE generated </font><font style="font-family:Arial;font-size:10pt;">$7.1</font><font style="font-family:Arial;font-size:10pt;">&#32;million in net product revenues for the </font><font style="font-family:Arial;font-size:10pt;">year ended December 31, 2018</font><font style="font-family:Arial;font-size:10pt;">. In accordance with GAAP, we determine net product revenues for XHANCE, with specific assumptions for variable consideration components including but not limited to trade discounts and allowances, co-pay assistance programs and payor rebates.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Based on available XHANCE prescription data purchased from third parties and data from our pharmacy network, our average net revenues per prescription for the </font><font style="font-family:Arial;font-size:10pt;">fourth</font><font style="font-family:Arial;font-size:10pt;">&#32;quarter of 2018 was approximately $214, which is favorable compared to our average net product revenues per prescription of approximately $202 and $148 in the third and second quarters of 2018, respectively. The 6% improvement in the average net revenue per prescription in the fourth quarter vs. the third quarter of 2018 is primarily attributable to lower rates of utilization of our patient affordability programs.  We calculate average net product revenues per prescription by dividing net product revenues for the quarter by the estimated number of XHANCE prescriptions dispensed during the quarter. As a result, average net product revenues per prescription is subject to variability. That variability is impacted by factors that do not necessarily reflect a change in the price that is paid for an individual unit of XHANCE, including but not limited to ordering patterns and inventory levels for our wholesale customers and preferred pharmacy network partners, patient utilization rates of affordability programs and the proportion of patients acquiring XHANCE through an insurance benefit. There is also the potential for variability that results from changes in estimation methodology by the third parties that we rely upon to provide prescription data which may lead to revisions of historical estimates of prescription volumes and our calculated average revenue per prescription.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Based on data available to date, we expect first quarter 2019 net revenue per prescription to be between $155 - $175. This decrease from the fourth quarter 2018 is a consequence of the reset of many patient insurance deductibles in January. As a result of this annual reset, we expect greater copay support to be provided by us under our assistance programs which are designed to support continued volume growth. For the remainder of 2019, we believe average net revenue per prescription will improve and we expect that the full-year 2019 average net </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">87</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">revenue per prescription will be between $185 - $205. Factors supporting this expected growth include patients meeting their out-of-pocket expense thresholds, expected improvements in insurance coverage and an increase in the proportion of prescription refills.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Costs of product sales</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Costs of product sales includes the cost of inventory sold, which includes direct and indirect manufacturing and supply chain costs.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Research and development expense</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prior to the FDA approval of XHANCE in September 2017, research and development expense consisted primarily of costs incurred in connection with the development and pursuit of regulatory approval for XHANCE for the treatment of nasal polyps. Post-FDA approval of XHANCE, research and development expense consists primarily of expenses incurred to prepare for, initiate and conduct our planned clinical trials, ongoing research efforts of new products and device improvements. We expense research and development costs as incurred. These expenses include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">personnel expenses, including salaries, benefits and stock-based compensation expense;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">costs of funding clinical development performed by third parties, including pursuant to agreements with contract research organizations (CROs), as well as investigative sites and consultants that conduct or support our nonclinical studies and clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">expenses associated with the continued development of our EDS devices;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">expenses related to the continued development of our product sample portfolio;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">expenses incurred under agreements with contract manufacturing organizations (CMOs), including manufacturing scale-up expenses prior to regulatory approval of products for commercial sale and the cost of acquiring and manufacturing preclinical study and clinical trial materials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">consultant fees and expenses associated with outsourced professional scientific development services;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">expenses for regulatory activities, including filing fees paid to regulatory agencies and costs incurred to compile and respond to filings with the FDA prior to regulatory approval of products for commercial sale;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">costs incurred to maintain, expand and protect our patent portfolio as it relates to product candidates in development; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">allocated expenses for facility costs, including rent, utilities, depreciation and maintenance.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Certain regulatory, patent and pre-commercialization expenses that were previously classified as research and development expenses (prior to the FDA approval of XHANCE in September 2017) have been classified as selling, general and administrative expenses if incurred post approval of XHANCE to the extent that these expenses support the commercialization of XHANCE.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We typically use our employee, consultant and infrastructure resources across our research and development programs. Although we track certain outsourced development costs by product candidate, we do not allocate personnel costs or other internal costs to specific product candidates.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We plan to incur research and development expenses for the foreseeable future as we expect to continue the development of XHANCE for the treatment of chronic sinusitis and our other product candidates. At this time, due to the inherently unpredictable nature of preclinical and clinical development, including rate of subject enrollment, number of subject required, and trial duration, and the early stage of our other product candidates, we are unable to estimate with any certainty the costs we will incur and the timelines we will require in our continued development efforts.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Selling, general and administrative expense</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">General and administrative expense consists primarily of personnel expenses, including salaries, benefits and stock-based compensation expense, for employees in executive, finance, accounting, business development, legal and human resource functions. General and administrative expense also includes corporate facility costs, including rent, utilities, depreciation and maintenance, not otherwise included in research and development expense, as well as regulatory fees and professional fees for legal, patent, accounting and other consulting services.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">88</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Early sales and marketing related expenses included expenses related to building brand awareness through advertising and the deployment of our nurse educator team, training and deploying our contract sales force and securing market access for XHANCE as well as salaries and related benefits for employees focused on such efforts. Current and expected commercial investments include our sales team and supporting promotional materials, digital promotion, peer to peer education, congresses / conventions, samples, and marketing activities such as direct to patient / direct to consumer initiatives.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Selling, general and administrative expenses increased in </font><font style="font-family:Arial;font-size:10pt;">2018</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">&#32;as a result of an expanded infrastructure and an increased headcount to support the commercial launch of XHANCE. We also incurred higher corporate infrastructure costs in 2018 as compared to 2017 including, but not limited to, accounting, legal, human resources, consulting and investor relations expenses, and increased director and officer insurance premiums associated with operating as a public company.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Interest (income) expense</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Interest (income) expense consists of interest earned on our cash and cash equivalents held with institutional banks and interest expense related to our long-term debt and amounts amortized and accrued under our convertible notes that were converted into preferred stock in March 2017.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Other (income) expense</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other (income) expense consists primarily of grant and other income as a result of government cost reimbursements for research and development activities over a contractually defined period, as well as foreign currency (income) losses due to exchange rate fluctuations on transactions denominated in a currency other than our functional currency.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Critical accounting policies</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (GAAP). The preparation of our consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reported period. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions and conditions.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements appearing elsewhere in this report, we believe that the following accounting policies are those most critical to the preparation of our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Revenue recognition</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We account for revenue in accordance with ASC Topic 606, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Arial;font-size:10pt;">, which was adopted on January 1, 2018. This standard applies to all contracts with customers with the exception of contracts that are within the scope of other standards, such as leases, insurance and financial instruments. Under ASC Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to be entitled in exchange for those goods or services.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We perform the following five steps to recognize revenue under ASC Topic 606: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only recognize revenue when it is probable that we will collect the consideration to which we are entitled in exchange for the goods or services that will be transferred to the customer. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Net Product Revenues</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We sell XHANCE to preferred pharmacy network partners and wholesalers in the U.S. (collectively, Customers). These Customers subsequently resell our products to healthcare providers, patients and other retail pharmacies. In addition to agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts for the purchase of our products.  </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">89</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We recognize revenue from product sales at the point the Customer obtains control of the product, which generally occurs upon delivery. The transaction price that is recognized as revenue for products includes an estimate of variable consideration, which is described below. Payment terms with Customers do not exceed one year and, therefore, we do not account for a financing component in our arrangements. Incremental costs of obtaining a contract with a Customer (for example, sales commissions) are expensed when incurred as the period of benefit is less than one year. Shipping and handling costs for product shipments to Customers are recorded as selling, general and administrative expenses.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Transaction Price, including Estimates of Variable Consideration</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue from products is recognized at the estimated net sales price (transaction price), which includes estimates of variable consideration. We include estimated amounts in the transaction price to the extent it is determined probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Components of Variable Consideration</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Components of variable consideration include provider chargebacks and discounts, trade discounts and allowances, product returns, government rebates, third-party payor rebates, sales order management fees and other incentives, such as voluntary patient assistance and other allowances that are offered within contracts between us and our Customers, payors and other indirect customers relating to our sale of products. Those components, as described below, are based on the amounts earned or to be claimed on the related sales and are presented as reductions of accounts receivable (if the amount is payable to the Customer) or as a current liability (if the amount is payable to a party other than the Customer). We consider all relevant factors, such as current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. </font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;text-decoration:underline;">Variable Consideration - Accounts Receivable Reductions</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Provider Chargebacks and Discounts.</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:10pt;">Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us.&#160;Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers.&#160;These components of variable consideration are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable.&#160;Reserves for chargebacks consist of credits we expect to issue for units that remain in the distribution channel inventories at each reporting period-end that we expect will be sold to qualified healthcare providers, as well as chargebacks that Customers have claimed but for which we have not yet issued a credit.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-24px;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Trade Discounts and Allowances.</font><font style="font-family:Arial;font-size:10pt;">&#32;&#32;We generally provide Customers with discounts that include incentive fees which are explicitly stated in our contracts. These discounts are recorded as a reduction of revenue and accounts receivable in the period in which the related product revenue is recognized. In addition, we reimburse our Customers (through discounts and allowances) for sales order management, data and distribution services.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:6px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-6px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;text-decoration:underline;">Variable Consideration - Current Liabilities</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Product Returns.</font><font style="font-family:Arial;font-size:10pt;">&#32;&#32;Consistent with industry practice, we have a product returns policy that provides Customers a right of return for product purchased within a specified period prior to and subsequent to the product&#8217;s expiration date. The right of return lapses upon shipment of the goods to a patient. We estimate the amount of our products that may be returned and present this amount as a reduction of revenue in the period the related product revenue is recognized in addition to establishing a liability. We consider several factors in the estimation process, including expiration dates of product shipped to preferred pharmacy network partners and wholesalers, inventory levels within the distribution channel, product shelf life, prescription trends and other relevant factors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Government Rebates</font><font style="font-family:Arial;font-size:10pt;">.  We are subject to discount obligations under state Medicaid programs and Medicare. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. For Medicaid, accruals are </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">90</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:60px;padding-bottom:10px;padding-top:10px;text-align:left;"><font style="font-family:Arial;font-size:10pt;">based on estimates of future Medicaid beneficiary utilization applied to the Medicaid unit rebate formula established by the Center for Medicaid and Medicare Services. The Medicare Part&#160;D prescription drug benefit mandates manufacturers to fund approximately 50% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. To estimate the cost to us of this Medicare coverage gap responsibility, we estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program. Our liability for these rebates consists of estimates of claims for the current quarter and estimated future claims that will be made for product that has been recognized as revenue but remains in the distribution channel inventories at the end of the reporting period.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Payor Rebates.</font><font style="font-family:Arial;font-size:10pt;">&#32;&#32;We contract with certain third-party payors, primarily health insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of our products. These rebates are based on contractual percentages applied to the amount of product prescribed to patients who are covered by the plan or the organization with which we contract. We estimate these rebates and record such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Other Incentives.</font><font style="font-family:Arial;font-size:10pt;">&#32;&#32;Other incentives that we offer include voluntary patient assistance programs, such as co-pay assistance programs, which are intended to provide financial assistance to qualified commercially insured patients with prescription drug co-payments required by payors, and coupon programs for cash payors.&#160;The calculation of the accruals for this assistance is based on an estimate of claims and the cost per claim that we expect to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Licensing Revenues</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Through December 31, 2017, our revenues were generated pursuant to the terms of a single license agreement (the AVP-825 License Agreement), with Avanir Pharmaceuticals,&#160;Inc. (Avanir) (Note&#160;7). The AVP-825 License Agreement included licensed rights to patented technology, non-refundable up-front payment, research services, and regulatory and sales milestones as well as royalty payments. Through </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, under the terms of the AVP-825 License Agreement, we received aggregate cash payments of $70.0 million in connection with the initial signing and the achievement of certain development milestones. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On December 10, 2018, we received written notice from Avanir of its election to terminate the AVP-825 License Agreement.&#160;As a result, the AVP-825 License Agreement is expected to terminate on March 10, 2019. Upon termination we may elect to continue to commercialize Onzetra Xsail ourselves or through a new licensee.  We do not expect to receive any additional proceeds from the AVP-825 License Agreement.  </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prior to the receipt of notice of termination of the License Agreement, we analyzed the performance obligations under the AVP-825 License Agreement, the consideration received to date and the consideration we could have received in the future as part of our analysis related to ASU 2014-09. The consideration received to date, which included an upfront payment, research and development funding and development milestone payments was recognized in prior years and our performance obligations pursuant to the arrangement have been completed. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Research and development expenses</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prior to the FDA approval of XHANCE in September 2017, research and development expense consisted primarily of costs incurred in connection with the development and pursuit of regulatory approval for XHANCE for the treatment of nasal polyps. Post-FDA approval of XHANCE, research and development expense consists primarily of expenses incurred to prepare for, initiate and conduct our clinical trials, ongoing research efforts of new products and device improvements. We expense research and development costs as incurred.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">At the end of each reporting period, we compare payments made to third-party service providers to the estimated progress toward completion of the applicable research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that we estimate has been made as a result of the service provided, we may record net prepaid or accrued expenses relating to these costs. To date, we have not made any material adjustments to our prior estimates of accrued research and development expenses.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">91</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based compensation</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We account for stock-based compensation awards in accordance with the FASB Accounting Standards Codification (ASC), Topic 718,&#160;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Compensation&#160;&#8212; Stock Compensation (</font><font style="font-family:Arial;font-size:10pt;">ASC 718). ASC 718 requires all stock-based compensation awards to employees to be recognized as expense based on their grant date fair values. We use the Black-Scholes option pricing model to value our stock option awards and shares issued under our employee stock purchase plan. We account for forfeitures of stock option awards as they occur. For awards issued to employees, we recognize compensation expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. Stock-based awards issued to nonemployees are revalued at each reporting period until the award vests in accordance with ASC Topic 505,&#160;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Equity</font><font style="font-family:Arial;font-size:10pt;">. The resulting increase or decrease in value, if any, is recognized as expense or income, respectively, during the period the related services are rendered. Expense for awards with performance conditions is estimated and adjusted on a quarterly basis based upon our assessment of the probability that the performance condition will be met. We have not issued awards where vesting is subject to market conditions; however, if we were to grant such awards in the future, recognition would be based on the derived service period.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Estimating the fair value of option shares issued under the employee stock purchase plan requires the input of subjective assumptions, including the estimated fair value of our common stock, the expected life of the option, stock price volatility, the risk-free interest rate and expected dividends. The assumptions used in our Black-Scholes option-pricing model represent management's best estimates and involve a number of variables, uncertainties and assumptions and the application of management's judgment, as they are inherently subjective. If any assumptions change, our stock-based compensation expense could be materially different in the future.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">These assumptions used in our Black-Scholes option-pricing model are estimated as follows:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Expected Term.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;Due to the lack of sufficient company-specific historical data, the expected term of employee options is determined using the "simplified" method, as prescribed in SEC's Staff Accounting Bulletin (SAB) No.&#160;107, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option. The expected term of nonemployee options is equal to the contractual term.&#160;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Expected Volatility.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;The expected volatility is based on historical volatilities of similar entities within our industry which were commensurate with the expected term assumption as described in SAB No.&#160;107.&#160;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Risk-Free Interest Rate.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.&#160;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Expected Dividends.</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;The expected dividend yield is 0% because we have not historically paid, and do not expect for the foreseeable future to pay, a dividend on our common stock.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table reflects the weighted average assumptions used to estimate the fair value of options granted during the periods presented.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:79%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expected term (in years)</font></div><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expected volatility</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">74.42</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">78.67</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Risk free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expected dividend yield</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Fair value of common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">12.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">9.68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For information about our employee stock purchase plan, see Note 13 to the Consolidated Financial Statements.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">See Note 3 of our audited consolidated financial statements beginning on page F-1 of this Annual Report on Form 10-K for a description of recent accounting pronouncements applicable to our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">JOBS Act</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The JOBS Act permits an &#8220;emerging growth company&#8221;, such as us, to take advantage of an extended transition </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">92</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected to &#8220;opt out&#8221; of this provision and, as a result, we will comply with new or revised accounting standards when they are required to be adopted by public companies that are not emerging growth companies.</font></div><div><a name="s940C06565A7754E4B0AECE3209F34293"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Consolidated Results of Operations</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Comparison of the years ended </font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#32;and </font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">2017</font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table sets forth our selected consolidated statements of operations data for the periods indicated (in thousands):</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:77%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Net product revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7,065</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cost of product sales</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,588</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Gross margin</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,477</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10,099</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">16,832</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">95,618</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">31,698</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">105,717</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">48,530</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(100,240</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(48,530</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other (income) expense:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Interest (income) expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,776</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">607</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other (income) expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(358</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(235</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total other (income) expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,418</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">372</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(106,658</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(48,902</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Net product revenues</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net product revenues related to sales of XHANCE were </font><font style="font-family:Arial;font-size:10pt;">$7.1</font><font style="font-family:Arial;font-size:10pt;">&#32;million for the </font><font style="font-family:Arial;font-size:10pt;">year ended December 31, 2018</font><font style="font-family:Arial;font-size:10pt;">. We did not record any net product revenues during the </font><font style="font-family:Arial;font-size:10pt;">year ended December 31, 2017</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Cost of product sales</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cost of product sales related to XHANCE were </font><font style="font-family:Arial;font-size:10pt;">$1.6</font><font style="font-family:Arial;font-size:10pt;">&#32;million for the </font><font style="font-family:Arial;font-size:10pt;">year ended December 31, 2018</font><font style="font-family:Arial;font-size:10pt;">. We did not record any cost of product sales during the </font><font style="font-family:Arial;font-size:10pt;">year ended December 31, 2017</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Research and development expense </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research and development expenses were </font><font style="font-family:Arial;font-size:10pt;">$10.1</font><font style="font-family:Arial;font-size:10pt;">&#160;million and </font><font style="font-family:Arial;font-size:10pt;">$16.8</font><font style="font-family:Arial;font-size:10pt;">&#160;million for the years ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively. The </font><font style="font-family:Arial;font-size:10pt;">$6.7</font><font style="font-family:Arial;font-size:10pt;">&#160;million decrease in 2018 was attributable primarily to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a $6.5&#160;million decrease in regulatory and medical affairs expenses, including payroll and administrative expenses, as a result of a shift in departmental focus from research and development to commercialization activities as a result of the FDA approval of XHANCE in September 2017; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a $3.0 million decrease related to the substantial completion of the preparation of contract manufacturing capabilities prior to the receipt of FDA approval of XHANCE in September of 2017 in anticipation of the expected commercial launch of XHANCE in the U.S. in 2018.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">These decreases were offset by:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a $3.0 million increase in clinical expenses related to the preparation for and initiation of our clinical trials of XHANCE for a follow-on indication for the treatment of chronic sinusitis and FDA-mandated pediatric studies.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Selling general and administrative expense</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Selling, general and administrative expenses were </font><font style="font-family:Arial;font-size:10pt;">$95.6</font><font style="font-family:Arial;font-size:10pt;">&#32;million and </font><font style="font-family:Arial;font-size:10pt;">$31.7</font><font style="font-family:Arial;font-size:10pt;">&#160;million for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively. The $</font><font style="font-family:Arial;font-size:10pt;">63.9</font><font style="font-family:Arial;font-size:10pt;">&#32;million increase was due primarily to:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">93</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a $37.3&#160;million increase in sales and marketing expenses related to our preparation for and support of the commercial launch of XHANCE in the U.S. for the treatment of nasal polyps, of which:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$22.2 million related to the deployment of our contract sales force and our nurse educator team;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$15.1 million related primarily to marketing expenses for XHANCE;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a $12.4&#160;million increase in payroll-related expenses due to increases in headcount;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a $6.5&#160;million increase in regulatory and medical affairs expenses, including payroll-related and administrative expenses, as a result of a shift in departmental focus from research and development to commercialization activities as a result of the FDA approval of XHANCE in September 2017;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a $1.6&#160;million increase in facilities expense, professional fees and consultancy expenses to support our expanding infrastructure to prepare for and support the commercial launch of XHANCE and operate as a public company; and</font></div></td></tr></table><div style="line-height:120%;padding-left:24px;padding-bottom:10px;padding-top:10px;"><font style="padding-bottom:10px;padding-top:10px;font-family:Arial;font-size:10pt;padding-right:24px;">&#9642;</font><font style="font-family:Arial;font-size:10pt;">a $3.7&#160;million increase in stock-based compensation expense.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Interest (income) expense, net</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Interest expense, net, was </font><font style="font-family:Arial;font-size:10pt;">$6.8</font><font style="font-family:Arial;font-size:10pt;">&#32;million and </font><font style="font-family:Arial;font-size:10pt;">$0.6</font><font style="font-family:Arial;font-size:10pt;">&#160;million for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively. The increase in interest expense, net, for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;was related to </font><font style="font-family:Arial;font-size:10pt;">$9.2</font><font style="font-family:Arial;font-size:10pt;">&#32;million in interest expense on our long-term debt which was issued in December 2017, offset by </font><font style="font-family:Arial;font-size:10pt;">$2.5</font><font style="font-family:Arial;font-size:10pt;">&#32;million in interest income. Interest income increased </font><font style="font-family:Arial;font-size:10pt;">$2.2</font><font style="font-family:Arial;font-size:10pt;">&#32;million during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, as compared to the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:10pt;">&#32;as a result of higher cash balances. Interest expense for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:10pt;">&#32;was related to our convertible notes, which were converted to shares of preferred stock in March&#160;2017. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Other (income) expense, net</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other income, net, was </font><font style="font-family:Arial;font-size:10pt;">$0.4</font><font style="font-family:Arial;font-size:10pt;">&#160;million and </font><font style="font-family:Arial;font-size:10pt;">$0.2</font><font style="font-family:Arial;font-size:10pt;">&#160;million for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively. The income in both periods was attributable primarily to grant eligible research and development expenses incurred by OptiNose AS, our Norwegian subsidiary.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Since inception, we have incurred significant net losses and expect to continue to incur net losses for the foreseeable future. We incurred net losses of </font><font style="font-family:Arial;font-size:10pt;">$106.7 million</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$48.9 million</font><font style="font-family:Arial;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively. As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, we had an accumulated deficit of </font><font style="font-family:Arial;font-size:10pt;">$317.9 million</font><font style="font-family:Arial;font-size:10pt;">.  We have funded our operations primarily through the sale of stock and the issuance of debt, as well as through licensing revenues received under the terms of the AVP-825 License Agreement and revenues from sales of XHANCE. As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, we had $</font><font style="font-family:Arial;font-size:10pt;">201.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in cash and cash equivalents. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table shows a summary of our cash flows for the periods indicated (in thousands):</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:78%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Net cash used in operating activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(91,817</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(35,680</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Net cash used in investing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1,690</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(2,406</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Net cash provided by financing activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">59,579</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">236,125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Effects of exchange rates on cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">64</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Net (decrease) increase in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(33,864</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">198,028</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Operating activities</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash used in operating activities increased by </font><font style="font-family:Arial;font-size:10pt;">$56.1</font><font style="font-family:Arial;font-size:10pt;">&#160;million, from </font><font style="font-family:Arial;font-size:10pt;">$35.7 million</font><font style="font-family:Arial;font-size:10pt;">&#32;for the </font><font style="font-family:Arial;font-size:10pt;">year ended</font><font style="font-family:Arial;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:10pt;">&#32;to </font><font style="font-family:Arial;font-size:10pt;">$91.8 million</font><font style="font-family:Arial;font-size:10pt;">&#32;for the </font><font style="font-family:Arial;font-size:10pt;">year ended</font><font style="font-family:Arial;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">. The increase in cash used in operating activities was attributable primarily to the increase in our net loss from&#160;</font><font style="font-family:Arial;font-size:10pt;">$48.9 million</font><font style="font-family:Arial;font-size:10pt;">&#160;for the&#160;year ended&#160;</font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:10pt;">&#160;to&#160;</font><font style="font-family:Arial;font-size:10pt;">$106.7 million</font><font style="font-family:Arial;font-size:10pt;">&#160;for the&#160;year ended&#160;</font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">. The increase in net loss is primarily related increased in expenses related to our preparation for and ongoing efforts to support the commercial launch of XHANCE. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">94</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Investing activities</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash used in investing activities decreased </font><font style="font-family:Arial;font-size:10pt;">$0.7</font><font style="font-family:Arial;font-size:10pt;">&#160;million from </font><font style="font-family:Arial;font-size:10pt;">$2.4 million</font><font style="font-family:Arial;font-size:10pt;">&#32;for the </font><font style="font-family:Arial;font-size:10pt;">year ended</font><font style="font-family:Arial;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:10pt;">&#32;to </font><font style="font-family:Arial;font-size:10pt;">$1.7 million</font><font style="font-family:Arial;font-size:10pt;">&#32;for the </font><font style="font-family:Arial;font-size:10pt;">year ended</font><font style="font-family:Arial;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">. The decrease was related primarily to a decrease in equipment purchases related to our preparation for the commercial launch of XHANCE.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Financing activities</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash provided by financing activities was </font><font style="font-family:Arial;font-size:10pt;">$59.6 million</font><font style="font-family:Arial;font-size:10pt;">&#32;for the </font><font style="font-family:Arial;font-size:10pt;">year ended</font><font style="font-family:Arial;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, driven primarily by net proceeds to us of $59.9 million as a result of of the Offering of 5,750,000 shares of our common stock at a price of $22.25 per share, which consisted of 2,875,000 shares of our common stock sold by us and 2,875,000 shares of our common stock sold by certain stockholders. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash provided by financing activities was </font><font style="font-family:Arial;font-size:10pt;">$236.1 million</font><font style="font-family:Arial;font-size:10pt;">&#32;for the </font><font style="font-family:Arial;font-size:10pt;">year ended</font><font style="font-family:Arial;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:10pt;">, driven primarily by the receipt of $36.4 million in net proceeds from the sale of our Series D Preferred Stock, </font><font style="font-family:Arial;font-size:10pt;">$125.5 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in net proceeds from our IPO and </font><font style="font-family:Arial;font-size:10pt;">$71.9 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in net proceeds from the issuance of the Notes.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Senior Secured Note Purchase Agreement </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In December 2017, we entered into a Note Purchase Agreement with Athyrium Opportunities III Acquisition LP, as collateral agent (the Collateral Agent) and the purchasers party thereto (the Purchasers) that provides for the issuance of up to </font><font style="font-family:Arial;font-size:10pt;">$100.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;of senior secured notes (the Notes) of which </font><font style="font-family:Arial;font-size:10pt;">$75.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;of the Notes were issued on December 29, 2017, of which $50.0 million were issued by OptiNose AS and $25 million were issued by OptiNose US, Inc. (the Issuers). The remaining $25.0 million of Notes (the Delayed Draw Notes), may be issued by OptiNose US, Inc. and sold to the Purchasers between April 1, 2019 and August 14, 2019, subject to achieving trailing four quarter net revenues (as calculated pursuant to the terms of the Note Purchase Agreement) of $15.0 million and a pro forma ratio of total debt to trailing four quarter net revenues not exceeding 6.50 to 1.00, and certain other conditions.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The unpaid principal amount under the Notes is due and payable on June 29, 2023 (the Maturity Date). The Notes bear interest at a per annum rate of three-month LIBOR rate (subject to a 1.0% floor) plus 9.0%. The Issuers are required to make quarterly interest-only payments until the Maturity Date. In addition, the Issuers paid an upfront fee of 1% of the aggregate principal amount of the Notes on the Closing Date. We are also required to pay an exit fee of 2% of any principal payments (whether mandatory, voluntary or at maturity) made throughout the term of the Note Purchase Agreement. Subject to certain exceptions, the Issuers are required to make mandatory prepayments of the Notes, with the proceeds of assets sales extraordinary receipts and prohibited debt issuances and upon the occurrence of a change of control. In addition, the Issuers may make voluntary prepayments of the Notes, in whole or in part. All mandatory and voluntary prepayments of the Notes are subject to the payment of prepayment premiums as follows: (i) if prepayment occurs prior to the second anniversary of the applicable date of issuance, an amount equal to the amount by which (a) the present value of 102% of the principal prepaid plus all interest that would have accrued on such principal through such second anniversary exceeds (b) the amount of principal prepaid, (ii) if prepayment occurs on or after the second anniversary of the applicable date of issuance but prior to the third anniversary of such issuance, an amount equal to 2% of the principal prepaid, and (iii) if prepayment occurs on or after the third anniversary of the applicable date of issuance but prior to the fourth anniversary of such issuance, an amount equal to 1% of the principal prepaid. No prepayment premium is due on any principal prepaid after the fourth anniversary of the applicable date of issuance of any Notes.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Note Purchase Agreement contains affirmative and negative covenants customary for financings of this type, including limitations on our and our subsidiaries&#8217; ability, among other things, to incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, grant certain license rights to our products, technology and other intellectual property rights, pay dividends and distributions, repay junior indebtedness and enter into affiliate transactions, in each case, subject to certain exceptions. In addition, the Note Purchase Agreement contains financial covenants requiring us to maintain at all times (i) at least $10 million of cash and cash equivalents and (ii) following the issuance of the Delayed Draw Notes or upon entering into certain exclusive licenses of XHANCE, a total debt to trailing four quarter XHANCE net revenue ratio of not more than 6.50 to 1.00 initially, and thereafter declining quarterly by equal half-steps to a ratio of not more than 3.00 to 1.00. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Projected 2019 operating expenses</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We expect that our total GAAP operating expenses (consisting of selling, general &amp; administrative expenses and research &amp; development expenses) for 2018 will be between $135.0 - $142.0 million of which $10 - $12 million is </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">95</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">expected to be stock-based compensation. Total GAAP operating expenses excluding stock-based compensation are expected to be in the range from $125 - $130 million. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Future funding requirements</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We expect to continue to incur significant expenses in connection with our ongoing activities, particularly as we:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">internalize and expand our commercial infrastructure to support the sales and marketing for XHANCE;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">maintain and expand our sales force;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">continue advertising and other promotional activities to support the commercialization of XHANCE;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">continue to provide co-pay and other patient affordability programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">continue clinical development activities for XHANCE, including FDA-mandated pediatric studies and clinical trials for a follow-on indication for the treatment of chronic sinusitis;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">hire additional staff and add operational, financial and information systems to execute our business plan; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">maintain, expand and protect our patent portfolio; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">continue to contract to manufacture XHANCE and our other product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">service our debt obligations under the Notes issued in December 2017;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">continue research and development activities for additional product candidates; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">maintain infrastructure necessary to operate as a publicly traded commercial-stage company. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the success of our commercialization of XHANCE for the treatment of nasal polyps including, among other things, patient and physician acceptance of XHANCE and our ability to obtain adequate insurance coverage and reimbursement for XHANCE; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the cost of commercialization activities for XHANCE, including product manufacturing, distribution, marketing and sales; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">net product revenues received from sales of XHANCE;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the costs and timing of internalizing and expanding our sales force;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the level of co-pay assistance and other patient affordability programs offered for XHANCE; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">our clinical development plans for XHANCE, including FDA-mandated pediatric studies and clinical trials for the supplemental indication for the treatment of chronic sinusitis; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the outcome, timing and cost of the regulatory approval process of XHANCE for chronic sinusitis by the FDA, including the potential for the FDA to require that we perform more studies and clinical trials than those that we currently expect; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the costs involved in preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">fluctuations in the three-month LIBOR-based floating interest rate of our Notes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the initiation, progress, timing, costs and results of clinical trials and other research and development related to additional product candidates; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the extent to which we in-license, acquire or otherwise partner in development of other products, product candidates or technologies. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Although it is difficult to predict our future liquidity requirements, we believe that existing cash and cash equivalents at December 31, 2018 will be sufficient to meet our debt service obligations under our Notes, and to carry out our </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">96</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">planned development and commercial activities into the fourth quarter of 2020. Additional capital, secured in the future through equity or debt financings, partnerships, collaborations, or other sources, may not be available on a timely basis, on favorable terms, or at all, and such capital, if raised, may not be sufficient to meet our debt service obligations, including repayment, or enable us to continue to implement our long-term business strategy. If additional capital is not secured when required, we may need to delay or curtail our operations until such funding is received. If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition and results of operations could be materially adversely affected and we may need to delay or curtail our operations until such funding is received. Additionally, we may never become profitable, or if we do, we may not be able to sustain profitability on a recurring basis. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Contractual obligations and commitments </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes our contractual obligations at </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;(in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Less than 1 year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">1-3 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">3-5 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">More than 5 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Operating leases</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,630</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Long-term debt</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">117,229</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8,958</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">17,965</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">90,306</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Purchase obligations</font><font style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#160;(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,335</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">122,692</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">12,923</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">19,463</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">90,306</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></font><font style="font-family:Arial;font-size:8pt;">Reflects obligations pursuant to our office leases in Yardley, Pennsylvania, Ewing, New Jersey, Oslo, Norway and Swindon, England and leases of certain other equipment.</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></font><font style="font-family:Arial;font-size:8pt;">Reflects principal, interest obligations and exit fees pursuant to the Note Purchase Agreement entered into on December 29, 2017. The Notes bear interest at </font><font style="font-family:Arial;font-size:8pt;">9.0%</font><font style="font-family:Arial;font-size:8pt;">&#32;plus the three-month LIBOR rate, subject to a </font><font style="font-family:Arial;font-size:8pt;">1.0%</font><font style="font-family:Arial;font-size:8pt;">&#32;floor. We are required to make quarterly, interest only payments until the maturity date. Interest amounts included above are calculated at the quarterly rate as of </font><font style="font-family:Arial;font-size:8pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:8pt;">&#32;of 11.8125%. </font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3) </sup></font><font style="font-family:Arial;font-size:8pt;">Reflects non-cancellable services under an agreement we entered into in November 2017 with a contract sales organization for the recruitment, deployment and management of a contract sales force to market XHANCE in the U.S. Subject to certain limited exceptions, we could not terminate this agreement until after the first anniversary of the deployment of the sales force (which occurred in March 2018). In December 2018, as a result of our decision to manage the sales force directly, we terminated the agreement effective April 1, 2019. We estimate the expenses related to the remaining non-cancellable services to be approximately $2.3 million. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Off-balance sheet arrangements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="sF38D7AECF2A751CF8D0C9016DFA1272A"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ITEM 7A. QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="sD2EC1E6E15A053DAAAC52584A157C92A"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The information required by Item 8 including the financial statements and notes thereto, and report of the independent registered public accounting firm thereon, are included in this Form 10-K as set forth in the &#8220;Index to Consolidated Financial Statements&#8221; on page F-1.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="s38E97CB35D285B2D9AE0A9E35C26D8D2"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Not applicable.</font></div><div><a name="s73D75ADD19095ED5880BEB9839E93006"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ITEM 9A. CONTROLS AND PROCEDURES</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Act, refers to controls and procedures that are designed to ensure that information required to be disclosed by a</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">97</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to a company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our Chief Executive Officer and our Chief Financial Officer evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a 15(e) and 15d 15(e) under the Exchange Act, as of the end of the period covered by this report. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Management's Report on Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance of the reliability of financial reporting and of the preparation of financial statements for external reporting purposes, in accordance with U.S. generally accepted accounting principles.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Internal control over financial reporting includes policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect transactions and disposition of assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with the authorization of its management and directors; and (3) provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on its financial statements.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of the effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures included in such controls may deteriorate.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our management has assessed the effectiveness of our internal control over financial reporting as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">. In making this assessment, management used the criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework (2013). These criteria are in the areas of control environment, risk assessment, control activities, information and communication, and monitoring. Management&#8217;s assessment included extensive documentation, evaluating and testing the design and operating effectiveness of its internal controls over financial reporting.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Based on management&#8217;s processes and assessment, as described above, management has concluded that, as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, our internal control over financial reporting was effective.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Attestation Report of the Registered Public Accounting Firm</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">due to an exemption established by the JOBS Act for &#8220;emerging growth companies.</font><font style="font-family:inherit;font-size:10pt;">&#8221;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">98</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">There were no changes in our internal control over financial reporting that occurred during our the quarter ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div><a name="s63DB44EE979353DEBC569EB62FB27E8B"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ITEM 9B. OTHER INFORMATION</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">None.</font></div><div><a name="s7B0D5AFED3A05884B20B099CFAA9FB78"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PART III</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="s3CD940376DD251739BD6CC2654CA967F"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The information required by this item is incorporated by reference to our Proxy Statement for the </font><font style="font-family:Arial;font-size:10pt;">2019</font><font style="font-family:Arial;font-size:10pt;">&#32;Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of the fiscal year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our Board has adopted a written Code Conduct applicable to all officers, directors and employees, which is available on our website (www.optinose.com) under "Corporate Governance" within the &#8220;Investors&#8221; section. We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding amendment to, or waiver from, a provision of this Code and by posting such information on the website address and location specified above.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="sF531A5A9BF855DC58B2AF72099DD6F60"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ITEM 11. EXECUTIVE COMPENSATION</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The information required by this item is incorporated by reference to our Proxy Statement for the </font><font style="font-family:Arial;font-size:10pt;">2019</font><font style="font-family:Arial;font-size:10pt;">&#32;Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of the fiscal year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="s481E20F9765B53229B2A7EBB09DBDFB8"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The information required by this item is incorporated by reference to our Proxy Statement for the </font><font style="font-family:Arial;font-size:10pt;">2019</font><font style="font-family:Arial;font-size:10pt;">&#32;Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of the fiscal year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="sD2F00FC2BCA354E5A2A3E469CD521D92"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The information required by this item is incorporated by reference to our Proxy Statement for the </font><font style="font-family:Arial;font-size:10pt;">2019</font><font style="font-family:Arial;font-size:10pt;">&#32;Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of the fiscal year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="sDA87DC37D53B5975BFBE4C764F8B2BD4"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The information required by this item is incorporated by reference to our Proxy Statement for the </font><font style="font-family:Arial;font-size:10pt;">2019</font><font style="font-family:Arial;font-size:10pt;">&#32;Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of the fiscal year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="sA0F92E279724560FAB661EA8B02682E2"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PART IV</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="sFC512B1C65885524A24D66D58ABF0C29"></a></div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a) (1)&#160; Consolidated Financial Statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Consolidated Financial Statements are filed as part of this report. See the Index to the Consolidated Financial Statements on page&#160;F-1.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;(2)&#160; Consolidated Financial Statement Schedule.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">99</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Schedules are omitted because they are not applicable, or are not required, or because the information is included in the Consolidated Financial Statements and Notes thereto.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3)&#160;The exhibits listed under Item&#160;15(b), which are incorporated herein by reference, are filed or furnished as  part of this report or are incorporated into this report by reference.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160; Exhibits.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:51%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:8%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Incorporated by Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Exhibit</font></div><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Exhibit Description</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Date</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Filed Herewith</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">2.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917005928/a2233286zex-2_1.htm"><font style="font-family:Arial;font-size:8pt;">Exchange Agreement, dated as of June 7, 2010, by and among the Registrant, OptiNose AS and the other signatories thereto (the Registrant hereby agrees to furnish supplementally a copy of any omitted schedules to the SEC upon request)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">9/18/17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">2.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1494650/000110465917062762/a17-15165_17ex3d1.htm"><font style="font-family:Arial;font-size:8pt;">Fourth Amended and Restated Certificate of Incorporation of OptiNose,&#160;Inc. </font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10/18/17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1494650/000110465917062762/a17-15165_17ex3d2.htm"><font style="font-family:Arial;font-size:8pt;">Amended and Restated Bylaws of OptiNose,&#160;Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10/18/17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917006175/a2233379zex-4_1.htm"><font style="font-family:Arial;font-size:8pt;">Form of Common Stock Certificate.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">S-1/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10/3/17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">4.2</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917005928/a2233286zex-4_2.htm"><font style="font-family:Arial;font-size:8pt;">Second Amended and Restated Registration Rights Agreement, dated March&#160;24, 2017, by and among the Registrant and certain of its stockholders.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">9/18/17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">4.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">4.3</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917005928/a2233286zex-4_4.htm"><font style="font-family:Arial;font-size:8pt;">Form of Warrant issued by the Registrant on June&#160;7, 2010.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">9/18/17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">4.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">4.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917006175/a2233379zex-4_6.htm"><font style="font-family:Arial;font-size:8pt;">Stockholders&#8217; Agreement, dated October 2, 2017, by and among OptiNose, Inc. and certain of its stockholders.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">S-1/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10/3/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">4.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">4.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917006300/a2233453zex-4_7.htm"><font style="font-family:Arial;font-size:8pt;">First Amendment to the Second Amended and Restated Registration Rights Agreement, dated October 2, 2017, by and among the Registrant and certain of its stockholders.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">S-1/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10/11/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">4.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="formindemnificationagreeme.htm"><font style="font-family:Arial;font-size:8pt;">Form of Indemnification Agreement.</font></a><font style="font-family:Arial;font-size:8pt;">+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">x</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1494650/000110465917062762/a17-15165_17ex10d1.htm#Exhibit10_1_031446"><font style="font-family:Arial;font-size:8pt;">Employment Agreement, dated October 12, 2017, between OptiNose US, Inc. and Peter K. Miller.</font></a><font style="font-family:Arial;font-size:8pt;">+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10/18/17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1494650/000110465917062762/a17-15165_17ex10d2.htm#Exhibit10_2_030414"><font style="font-family:Arial;font-size:8pt;">Employment Agreement, dated October 12, 2017, between OptiNose US, Inc. and Ramy A. Mahmoud</font></a><font style="font-family:Arial;font-size:8pt;">.+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10/18/17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1494650/000110465917062762/a17-15165_17ex10d3.htm#Exhibit10_3_030306"><font style="font-family:Arial;font-size:8pt;">Employment Agreement, dated October 12, 2017, between OptiNose US, Inc. and Thomas&#160;E. Gibbs</font></a><font style="font-family:Arial;font-size:8pt;">.+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10/18/17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1494650/000110465917062762/a17-15165_17ex10d4.htm#Exhibit10_4_030414"><font style="font-family:Arial;font-size:8pt;">Employment Agreement, dated October 12, 2017, between OptiNose US, Inc. and Keith&#160;A. Goldan.</font></a><font style="font-family:Arial;font-size:8pt;">+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10/18/17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1494650/000110465917062762/a17-15165_17ex10d5.htm#Exhibit10_5_030644"><font style="font-family:Arial;font-size:8pt;">Employment Agreement, dated October 12, 2017, between OptiNose US, Inc. and Michael&#160;F. Marino</font></a><font style="font-family:Arial;font-size:8pt;">.+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10/18/17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917006175/a2233379zex-10_7.htm"><font style="font-family:Arial;font-size:8pt;">Amended and Restated 2010 Stock Incentive Plan</font></a><font style="font-family:Arial;font-size:8pt;">.+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">S-1/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10/3/17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917006175/a2233379zex-10_8.htm"><font style="font-family:Arial;font-size:8pt;">Form of Non-Qualified Stock Option Agreement Granted Under the 2010 Stock Incentive Plan (Relating to Success Pool Grants).</font></a><font style="font-family:Arial;font-size:8pt;">+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">S-1/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10/3/17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917006175/a2233379zex-10_9.htm"><font style="font-family:Arial;font-size:8pt;">Form of Non-Qualified Stock Option Agreement Granted Under the 2010 Stock Incentive Plan (Relating to Option Pool Grants).</font></a><font style="font-family:Arial;font-size:8pt;">+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">S-1/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10/3/17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917006175/a2233379zex-10_10.htm"><font style="font-family:Arial;font-size:8pt;">Form of Non-Qualified Stock Option Agreement Granted Under the 2010 Stock Incentive Plan</font></a><font style="font-family:Arial;font-size:8pt;">.+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">S-1/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10/3/17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917005928/a2233286zex-10_11.htm"><font style="font-family:Arial;font-size:8pt;">License Agreement, dated as of July&#160;1, 2013, by and between OptiNose AS and Avanir Pharmaceuticals,&#160;Inc</font></a><font style="font-family:Arial;font-size:8pt;">.&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">9/18/17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917005928/a2233286zex-10_12.htm"><font style="font-family:Arial;font-size:8pt;">First Amendment of License Agreement, dated as of April&#160;25, 2014, by and between OptiNose US,&#160;Inc. and Avanir Pharmaceuticals,&#160;Inc.</font></a><font style="font-family:Arial;font-size:8pt;">&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">9/18/17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.13</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917005928/a2233286zex-10_13.htm"><font style="font-family:Arial;font-size:8pt;">Amendment to License Agreement, dated as of August&#160;6, 2015, by and between OptiNose AS and Avanir Pharmaceuticals,&#160;Inc.</font></a><font style="font-family:Arial;font-size:8pt;">&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">9/18/17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.13</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.14</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917005928/a2233286zex-10_14.htm"><font style="font-family:Arial;font-size:8pt;">Supply Agreement, dated July&#160;1, 2017, by and between Hovione Inter&#160;Ltd and OptiNose US,&#160;Inc., OptiNose UK,&#160;Ltd and OptiNose AS.</font></a><font style="font-family:Arial;font-size:8pt;">&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">9/18/17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.14</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917005928/a2233286zex-10_15.htm"><font style="font-family:Arial;font-size:8pt;">Manufacture and Supply Agreement, dated as of August&#160;18, 2017, by and among OptiNose US,&#160;Inc., OptiNose UK&#160;Ltd. and OptiNose AS and Contract Pharmaceuticals Limited Canada.</font></a><font style="font-family:Arial;font-size:8pt;">&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">9/18/17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">100</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:51%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:8%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917005928/a2233286zex-10_16.htm"><font style="font-family:Arial;font-size:8pt;">Manufacturing Services Agreement, dated as of August&#160;31, 2017, by and among OptiNose US,&#160;Inc., OptiNose UK&#160;Ltd. and OptiNose AS and Ximedica,&#160;LLC.</font></a><font style="font-family:Arial;font-size:8pt;">&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">9/18/17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917006175/a2233379zex-10_17.htm"><font style="font-family:Arial;font-size:8pt;">Form of Non-Qualified Stock Option Agreement Under the Amended and Restated 2010 Stock Incentive Plan</font></a><font style="font-family:Arial;font-size:8pt;">+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">S-1/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10/3/17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1494650/000104746917006175/a2233379zex-10_18.htm"><font style="font-family:Arial;font-size:8pt;">2017 Employee Stock Purchase Plan.</font></a><font style="font-family:Arial;font-size:8pt;">+</font></div><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">S-1/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10/3/17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.19</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1494650/000149465018000025/optinose_athyriumxnotepurc.htm"><font style="font-family:Arial;font-size:8pt;">Note Purchase Agreement dated December 29, 2017, among OptiNose AS and OptiNose US, Inc., as the Issuers, OptiNose, Inc. as Parent and a Guarantor, and Athyrium Opportunities III Acquisition LP, as Collateral Agent and a Purchaser</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3/13/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.19</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">10.20</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit1020_optn-vtmopnass.htm"><font style="font-family:Arial;font-size:8pt;">Manufacturing Services Agreement, dated December 21, 2018, by and among OptiNose US, Inc., OptiNose UK Ltd. and Optinose AS and Advance Mold &amp; Manufacturing, Inc. d/b/a Vision Technical Molding</font></a><font style="font-family:Arial;font-size:8pt;">.&#8224;&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">x</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">21.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="listofsubsidiariesex211.htm"><font style="font-family:Arial;font-size:8pt;">List of Subsidiaries</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">x</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">23.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="auditorconsent10-kex231.htm"><font style="font-family:Arial;font-size:8pt;">Consent of Ernst&#160;&amp; Young&#160;LLP, independent registered public accounting firm.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">x</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">31.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="optn12-31x201810xkex311.htm"><font style="font-family:Arial;font-size:8pt;">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15a-14(a) under the Exchange Act.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">x</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="optn12-31x201810xkex312.htm"><font style="font-family:Arial;font-size:8pt;">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15a-14(a) under the Exchange Act.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">x</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">32.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="optn12-31x201810xkex321.htm"><font style="font-family:Arial;font-size:8pt;">Certification Pursuant to 18 U.S.C. Section 1350 of principal executive officer and principal financial officer.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">x</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">32.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="optn12-31x201810xkex322.htm"><font style="font-family:Arial;font-size:8pt;">Certification Pursuant to 18 U.S.C. Section 1350 of principal executive officer and principal financial officer.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">x</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">101.INS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">XBRL Instance Document. </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">x</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">101.SCH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">XBRL Taxonomy Extension Schema Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">x</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">101.CAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">XBRL Taxonomy Extension Calculation Linkbase Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">x</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">101.DEF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">XBRL Taxonomy Extension Definition Linkbase Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">x</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">101.LAB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">XBRL Taxonomy Extension Label Linkbase Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">x</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">XBRL Taxonomy Extension Presentation Linkbase Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">x</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8224;</font></div></td><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment granted pursuant to Rule&#160;406 under the Securities Act of 1933.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#8224;&#8224;</font></div></td><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment pursuant to Rule&#160;406 under the Securities Act of 1933.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">+</font></div></td><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Indicates management contract or compensatory plan.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="sCDFBD0BE9787560388D04689BD755E8B"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ITEM 16. FORM 10-K SUMMARY</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Not applicable. </font></div><div><a name="s255B684B0C785025863CCCF06A095A1C"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">101</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized in the capacities and on the date indicated. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.0703125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:55%;"></td><td style="width:4%;"></td><td style="width:5%;"></td><td style="width:4%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:23%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OPTINOSE,&#160;INC.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Date:  March 6, 2019</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/&#160;PETER K. MILLER</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Name:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Peter K. Miller</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Title:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:26%;"></td><td style="width:1%;"></td><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">Signature</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">Title</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">/s/ PETER K. MILLER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Chief Executive Officer and Director (Principal Executive Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">March&#160;6, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Peter K. Miller</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">/s/ KEITH A. GOLDAN</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Chief Financial Officer (Principal Finance Officer and Principal Accounting Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">March&#160;6, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Keith A. Goldan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">/s/ JOSEPH C. SCODARI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Chairman of the Board of Directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">March&#160;6, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Joseph C. Scodari</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">/s/ ROBERT P. O'NEIL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">March&#160;6, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Robert P. O'Neil</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">/s/ SRIRAM VENKATARAMAN</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">March&#160;6, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Sriram Venkataraman</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">/s/ WILLIAM F. DOYLE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">March&#160;6, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">William F. Doyle</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">/s/ JOSHUA  A. TAMAROFF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">March&#160;6, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Joshua A. Tamaroff</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">/s/ WILHELMUS GROENHUYSEN</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">March&#160;6, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Wilhelmus Groenhuysen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">/s/ SANDRA L. HELTON</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">March&#160;6, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Sandra L. Helton</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><a name="s7F1F88971F3357AC9FF3C9837FE32D42"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">102</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:91%;"></td><td style="width:1%;"></td><td style="width:8%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Audited Consolidated Financial Statements</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sD9442FE1C23D58EE9865B6EA23B078F9"><font style="font-family:Arial;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sD9442FE1C23D58EE9865B6EA23B078F9">F-2</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sBACEA074DB7551F5BF3F1DE6FCC5880C"><font style="font-family:Arial;font-size:10pt;">Consolidated Balance Sheets as of December&#160;31, 2018 and 2017</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sBACEA074DB7551F5BF3F1DE6FCC5880C">F-3</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sD155342634A65FD3B30A92A14E5A1DE1"><font style="font-family:Arial;font-size:10pt;">Consolidated Statements of Operations for the years ended December&#160;31, 2018 and 2017</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sD155342634A65FD3B30A92A14E5A1DE1">F-4</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s6802CB5A0D9F5099A80CA2EE6840D794"><font style="font-family:Arial;font-size:10pt;">Consolidated Statements of Comprehensive Loss for the years ended December&#160;31, 2018 and 2017</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s6802CB5A0D9F5099A80CA2EE6840D794">F-5</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sFE8B9A1AF59C57B8885B9077F6B25190"><font style="font-family:Arial;font-size:10pt;">Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) for the years ended December&#160;31, 2018 and 2017</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sFE8B9A1AF59C57B8885B9077F6B25190">F-6</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s31F5847F7B935F6FAAB315740DBC013F"><font style="font-family:Arial;font-size:10pt;">Consolidated Statements of Cash Flows for the years ended December&#160;31, 2018 and 2017</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s31F5847F7B935F6FAAB315740DBC013F">F-7</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s7F805493F00F57A9977E8226BF080CE8"><font style="font-family:Arial;font-size:10pt;">Notes to Consolidated Financial Statements</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s7F805493F00F57A9977E8226BF080CE8">F-8</a></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">F-1</font></div></div><hr style="page-break-after:always"><div><a name="sD9442FE1C23D58EE9865B6EA23B078F9"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">To the Shareholders and Board of Directors and of OptiNose,&#160;Inc.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Opinion on the Financial Statements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have audited the accompanying consolidated balance sheets of OptiNose, Inc. (the Company) as of December 31, 2018 and 2017, the related consolidated statements of operations, comprehensive loss, redeemable convertible preferred stock and stockholders&#8217; equity (deficit) and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2018 and 2017, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Basis for Opinion</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Ernst &amp; Young LLP</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have served as the Company&#8217;s auditor since 2016.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Philadelphia, Pennsylvania</font></div><div style="line-height:120%;padding-bottom:157px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">March 6, 2019</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">F-2</font></div></div><hr style="page-break-after:always"><div><a name="sBACEA074DB7551F5BF3F1DE6FCC5880C"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OptiNose, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Consolidated Balance Sheets</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:79%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Current assets:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">200,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">234,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Accounts receivable, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,310</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Grants and other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">242</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7,132</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,013</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,183</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,254</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">212,857</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">238,167</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,884</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">248</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">405</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">216,989</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">241,136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Liabilities and stockholders' equity</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Current liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7,116</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,893</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">18,421</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8,698</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Deferred other income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">160</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">186</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">25,697</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">14,777</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Long-term debt, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">72,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">71,863</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">181</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">98,378</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">86,640</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Commitments and contingencies (Note 11)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Stockholders' equity:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Common stock, $0.001 par value; 200,000,000 December 31, 2018 and 2017; 41,227,530 and 37,802,556 shares issued and outstanding at December 31, 2018 and December&#160;31, 2017, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">436,554</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">365,838</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(317,927</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(211,269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(57</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(111</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total stockholders' equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">118,611</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">154,496</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total liabilities and stockholders' equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">216,989</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">241,136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">See accompanying notes to consolidated financial statements</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">F-3</font></div></div><hr style="page-break-after:always"><div><a name="sD155342634A65FD3B30A92A14E5A1DE1"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OptiNose,&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Consolidated Statements of Operations</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:76%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Net product revenues</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7,065</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cost of product sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,588</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Gross margin</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,477</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Operating expenses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Research and development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10,099</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">16,832</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Selling, general and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">95,618</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">31,698</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total operating expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">105,717</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">48,530</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(100,240</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(48,530</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other (income) expense:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Grant and other income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(406</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(162</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Interest income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(2,453</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(303</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">9,229</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">910</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign currency (gains) losses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(106,658</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(48,902</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Deemed dividend</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">11,969</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Accretion to redemption value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,096</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Net loss attributable to common stockholders</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(106,658</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(61,967</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Net loss per share of common stock, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(2.68</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(5.63</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average common shares outstanding, basic and diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">39,765,983</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10,999,121</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">See accompanying notes to consolidated financial statements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">F-4</font></div></div><hr style="page-break-after:always"><div><a name="s6802CB5A0D9F5099A80CA2EE6840D794"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OptiNose,&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Consolidated Statements of Comprehensive Loss</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:78%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended<br>December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(106,658</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(48,902</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other comprehensive (loss) income:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign currency translation adjustment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Comprehensive loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(106,604</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(48,914</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">See accompanying notes to consolidated financial statements</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">F-5</font></div></div><hr style="page-break-after:always"><div><a name="sFE8B9A1AF59C57B8885B9077F6B25190"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OptiNose,&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Stockholders' Equity (Deficit)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands, except share data)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="31"></td></tr><tr><td style="width:21%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">&#160;</font></div></td><td colspan="6" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Redeemable</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Convertible Preferred</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Stockholders' Equity (Deficit)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Paid -in</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Capital</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Deficit</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Comprehensive</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Loss</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Stockholders'</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Equity (Deficit)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">Balance at January 1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">6,875,514</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">168,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">4,067,717</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">(151,102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">(99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">(151,197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">Conversion of convertible debt to Series&#160;C-2 preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">687,474</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">19,527</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">Sale of Series&#160;D preferred stock, net of issuance costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">1,117,578</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">36,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">Stock compensation expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">5,096</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">5,096</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">Accretion of Series&#160;C, Series&#160;C-1&#160;&amp; Series&#160;D preferred stock to redemption value</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">1,096</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">(1,096</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">(1,096</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">Accretion of Series&#160;C, Series&#160;C-1, Series&#160;C-2&#160;&amp; Series&#160;D preferred stock in lieu of 8% dividend</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">11,969</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">(704</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">(11,265</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">(11,969</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">Sale of common stock upon consummation of initial public offering, net of issuance costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">8,625,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">125,462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">125,471</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">Reclassification of redeemable convertible preferred stock upon consummation of initial public offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">(8,680,566</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">(237,259</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">25,068,556</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">237,234</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">237,259</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">Exercise of stock options, net of shares withheld for income taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">41,283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">(154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">(154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">Foreign currency translation adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">(12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">(12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">(48,902</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">(48,902</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">Balance at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">37,802,556</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">38</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">365,838</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">(211,269</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">(111</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">154,496</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">Stock compensation expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">8,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">8,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">Sale of common stock, net of issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">2,875,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">59,914</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">59,917</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">Exercise of common stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">482,190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">1,418</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">1,418</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">Exercise of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">14,647</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">Issuance of common stock under employee stock purchase plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">53,137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">739</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">739</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">Foreign currency translation adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">54</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">54</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">(106,658</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">(106,658</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">Balance at December&#160;31, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">41,227,530</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">41</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">436,554</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">(317,927</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">(57</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">118,611</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">See accompanying notes to consolidated financial statements</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">F-6</font></div></div><hr style="page-break-after:always"><div><a name="s31F5847F7B935F6FAAB315740DBC013F"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OptiNose,&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Consolidated Statements of Cash Flows</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:79%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended<br>December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Operating activities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(106,658</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(48,902</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Adjustments to reconcile net loss to net cash used in operating activities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">539</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">166</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,096</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Amortization of debt discount and issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">404</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">198</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(2,310</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Grants and other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(196</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">337</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(762</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,358</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(4,698</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(2,013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,171</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">392</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Accrued expenses and other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,688</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(91,817</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(35,680</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Investing activities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Purchases of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1,690</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(2,406</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cash used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1,690</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(2,406</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Financing activities:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Proceeds from the sale of Series&#160;D preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">36,712</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Proceeds from the issuance of common stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">63,969</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">138,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Proceeds from the issuance of common stock under employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">739</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Proceeds from long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">75,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Proceeds from the exercise of stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,488</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Payments of withholdings on shares withheld for income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(70</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(288</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cash paid for financing costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(6,547</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(13,433</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">59,579</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">236,125</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Effects of exchange rate changes on cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">64</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Net (decrease) increase in cash, cash equivalents and restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(33,864</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">198,028</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cash, cash equivalents and restricted cash at beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">234,875</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">36,847</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cash, cash equivalents and restricted cash at end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">201,011</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">234,875</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Supplemental disclosure of cash flow information:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cash paid for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8,253</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Supplemental disclosure of noncash financing activities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Deemed dividend</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">11,969</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Accretion to redemption value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,096</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Fixed asset purchases within accounts payable and accrued expenses</font></div><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">146</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Fixed asset additions acquired through tenant allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">361</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Financing costs within accounts payable and accrued expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,454</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Conversion of convertible notes payable and accrued interest into Series&#160;C-2 preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">19,527</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Conversion of redeemable convertible preferred stock into common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">237,259</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">See accompanying notes to consolidated financial statements</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">F-7</font></div></div><hr style="page-break-after:always"><div><a name="s7F805493F00F57A9977E8226BF080CE8"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OptiNose,&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="s0F898869552E5D60B97835AA72294821"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1. Organization and Description of Business</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">OptiNose,&#160;Inc. (the Company) was incorporated in Delaware in May 2010 (inception) and has facilities in Yardley, Pennsylvania, Ewing, New Jersey, Oslo, Norway and Swindon, England. The Company's predecessor entity, OptiNose AS, was formed under the laws of Norway in September 2000. In 2010, OptiNose AS became a wholly-owned subsidiary of the Company as part of an internal reorganization.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company is a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's first commercial product, XHANCE</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;(fluticasone propionate) nasal spray, 93 mcg, is a therapeutic utilizing its proprietary Optinose Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE was approved by the United States (US) Food and Drug Administration (FDA) in September 2017 for the treatment of nasal polyps in patients 18&#160;years of age or older, and&#160;XHANCE was launched commercially in the US in March 2018.</font></div><div><a name="s37AEF26EDC92571695B13BC1B881F41C"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2. Liquidity</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Since inception, the Company's operations have focused on organization and staffing, business planning, raising capital, establishing an intellectual property portfolio, conducting preclinical studies and clinical trials, pursuing regulatory approvals and most recently, preparing for and launching XHANCE. As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company had cash and cash equivalents of </font><font style="font-family:Arial;font-size:10pt;">$200,990</font><font style="font-family:Arial;font-size:10pt;">. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On June 11, 2018, the Company and certain stockholders closed an underwritten public offering (the Offering) of </font><font style="font-family:Arial;font-size:10pt;">5,750,000</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of Company common stock (Common Stock) at a price of </font><font style="font-family:Arial;font-size:10pt;">$22.25</font><font style="font-family:Arial;font-size:10pt;">&#32;per share. The Offering consisted of </font><font style="font-family:Arial;font-size:10pt;">2,875,000</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of Common Stock sold by the Company and </font><font style="font-family:Arial;font-size:10pt;">2,875,000</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of Common Stock sold by certain stockholders. As a result of the Offering, the Company received </font><font style="font-family:Arial;font-size:10pt;">$59,917</font><font style="font-family:Arial;font-size:10pt;">&#32;in net proceeds, after deducting discounts and commissions of </font><font style="font-family:Arial;font-size:10pt;">$3,678</font><font style="font-family:Arial;font-size:10pt;">&#32;and offering expenses of approximately </font><font style="font-family:Arial;font-size:10pt;">$373</font><font style="font-family:Arial;font-size:10pt;">&#32;payable by the Company.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company will likely require additional capital in the future through equity or debt financings, partnerships, collaborations, or other sources in order to meet the debt service obligations under the Company's outstanding senior secured notes (Senior Secured Notes), including repayment, and to carry out the Company's planned development and commercial activities. If additional capital is not secured when required, the Company may need to delay or curtail its operations until such funding is received. The Company is subject to a number of risks similar to other life sciences companies, including, but not limited to, successful discovery, development and commercialization of its products and product candidates, raising additional capital, the development by its competitors of new technological innovations, protection of proprietary technology and market acceptance of the Company's products.</font></div><div><a name="sA7C947C2CA355D2D8E9759E1CBF32FD8"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3. Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Basis of presentation</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The accompanying consolidated financial statements have been prepared in conformity with US generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Principles of consolidation</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The consolidated financial statements include the accounts of OptiNose,&#160;Inc. and its wholly-owned subsidiaries, OptiNose US,&#160;Inc., OptiNose AS and OptiNose UK&#160;Ltd. All inter-company balances and transactions have been eliminated in consolidation.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">F-8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OptiNose,&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Use of estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Stock Split</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On October 10, 2017, the Company&#160;effected a </font><font style="font-family:Arial;font-size:10pt;">2.8879</font><font style="font-family:Arial;font-size:10pt;">-for-1 reclassification, or stock split, of the Company's common stock in connection with its initial public offering, or the IPO. All common share and per share amounts in these consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to reflect the stock split. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of credit risk</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and accounts receivable.The Company generally invests its cash in deposits with high credit quality financial institutions. Additionally, the Company performs periodic evaluations of the relative credit standing of these financial institutions.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has exposure to credit risk in accounts receivable from sales of product. XHANCE is sold to wholesale pharmaceutical distributors and preferred pharmacy network partners, who, in turn, sell XHANCE to pharmacies, hospitals and other customers.&#160;</font><font style="font-family:Arial;font-size:10pt;">Four</font><font style="font-family:Arial;font-size:10pt;">&#32;customers represent approximately </font><font style="font-family:Arial;font-size:10pt;">90%</font><font style="font-family:Arial;font-size:10pt;">&#32;of the Company's accounts receivable at </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;">&#32;customers represent approximately </font><font style="font-family:Arial;font-size:10pt;">94%</font><font style="font-family:Arial;font-size:10pt;">&#32;of the Company's net product sales for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Cash and cash equivalents</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All highly liquid investments purchased with an original maturity date of three months or less at the date of purchase are considered to be cash equivalents. The Company maintains its cash and cash equivalent balances at foreign and domestic financial institutions. Bank deposits with Norwegian banks are insured up to approximately 2,000 Norwegian krone by the Norwegian Banks' Guarantee Fund. Bank deposits with US banks are insured up to $250 by the Federal Deposits Insurance Corporation. The Company had uninsured cash balances of </font><font style="font-family:Arial;font-size:10pt;">$199,507</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$233,772</font><font style="font-family:Arial;font-size:10pt;">&#32;at </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Fair value of financial instruments</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company measures certain assets and liabilities at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The FASB accounting guidance outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company uses quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of the inputs as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level&#160;1&#160;&#8212; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level&#160;2&#160;&#8212; Valuations based on observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">F-9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OptiNose,&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level&#160;3&#160;&#8212; Valuations based on inputs that are unobservable and models that are significant to the overall fair value measurement.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">At </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, the Company's financial instruments included cash and cash equivalents, accounts receivable, grants receivable, accounts payable, and accrued expenses. The carrying amounts reported in the Company's financial statements for these instruments approximates their respective fair values because of the short-term nature of these instruments.  In addition, at </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company believes the carrying value of debt approximates fair value as the interest rates are reflective of the rate the Company could obtain on debt with similar terms and conditions. At </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, there were no financial assets or liabilities measured at fair value on a recurring basis.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Accounts receivable</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounts receivable primarily relates to amounts due from customers, which are typically due within 31 to 61 days. The Company analyzes accounts that are past due for collectability. Given the nature and historical collectability of the Company&#8217;s accounts receivable, an allowance for doubtful accounts was not deemed necessary at&#160;</font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prior to receiving FDA approval for XHANCE in September 2017, inventory purchases were expensed as incurred and recorded as a component of research and development expense. Subsequent to receiving FDA approval, inventories are stated at the lower of cost or net realizable value. Costs of inventories, which include amounts related to materials and manufacturing overhead, are determined on a first-in, first-out basis. An assessment of the recoverability of capitalized inventory is performed during each reporting period and any excess and obsolete inventories are written down to their estimated net realizable value in the period in which the impairment is first identified. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Property and equipment</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Property and equipment is recorded at cost less accumulated depreciation. Significant additions or improvements are capitalized, and expenditures for repairs and maintenance are charged to expense as incurred. Gains and losses on disposal of assets are included in the consolidated statements of operations. Depreciation is calculated on a straight-line basis over the estimated useful lives of the respective assets.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The estimated useful lives of property and equipment are as follows:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:53%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Computer equipment</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2-3 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Software</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Machinery &amp; production equipment</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5-10 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Furniture &amp; fixtures</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3-5 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Leasehold improvements</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Shorter of lease term or useful life</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Long lived assets</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated. Impairment charges are recognized at the amount by which the carrying amount of an asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell. The Company did </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;">t recognize any impairment or disposition of long-lived assets for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">F-10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OptiNose,&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Revenue recognition</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company accounts for revenue in accordance with ASC Topic 606, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Arial;font-size:10pt;">, which was adopted on January 1, 2018. This standard applies to all contracts with customers, with the exception of contracts that are within the scope of other standards, such as leases, insurance and financial instruments. Under ASC Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to be entitled in exchange for those goods or services.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company performs the following five steps to recognize revenue under ASC Topic 606: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only recognizes revenue when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that will be transferred to the customer. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Net Product Revenues</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company sells XHANCE to preferred pharmacy network partners and wholesalers in the US (collectively, Customers). These Customers subsequently resell the Company&#8217;s products to healthcare providers, patients and other retail pharmacies. In addition to agreements with Customers, the Company enters into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts for the purchase of the Company&#8217;s products.  </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company recognizes revenue from product sales at the point the Customer obtains control of the product, which generally occurs upon delivery. The transaction price that is recognized as revenue for products includes an estimate of variable consideration which is described below. Payment terms with Customers do not exceed one year and, therefore, the Company does not account for a financing component in its arrangements. The Company expenses incremental costs of obtaining a contract with a Customer (for example, sales commissions) when incurred as the period of benefit is less than one year. Shipping and handling costs for product shipments to Customers are recorded as selling, general and administrative expenses.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Transaction Price, including Estimates of Variable Consideration</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue from products is recognized at the estimated net sales price (transaction price), which includes estimates of variable consideration. The Company includes estimated amounts in the transaction price to the extent it is determined probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The Company&#8217;s estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of its anticipated performance and all information (historical, current and forecasted) that is reasonably available.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Components of Variable Consideration</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Components of variable consideration include provider chargebacks and discounts, trade discounts and allowances, product returns, government rebates, third-party payor rebates, sales order management fees and other incentives, such as voluntary patient assistance and other allowances that are offered within contracts between the Company and its Customers, payors and other indirect customers relating to the Company&#8217;s sale of products. Those components, as described below, are based on the amounts earned, or to be claimed, on the related sales and are presented as reductions of accounts receivable (if the amount is payable to the Customer) or as a current liability (if the amount is payable to a party other than the Customer). The Company considers all relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">F-11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OptiNose,&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;text-decoration:underline;">Variable Consideration - Accounts Receivable Reductions</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Provider Chargebacks and Discounts.</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:10pt;">Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from the Company.&#160;Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers.&#160;These components of variable consideration are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable.&#160;Reserves for chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel inventories at each reporting period-end that the Company expects will be sold to qualified healthcare providers, as well as chargebacks that Customers have claimed, but for which the Company has not yet issued a credit.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-24px;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Trade Discounts and Allowances.</font><font style="font-family:Arial;font-size:10pt;">&#32;&#32;The Company generally provides Customers with discounts that include incentive fees which are explicitly stated in the Company&#8217;s contracts. These discounts are recorded as a reduction of revenue and accounts receivable in the period in which the related product revenue is recognized. In addition, the Company reimburses (through discounts and allowances) its Customers for sales order management, data and distribution services.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:6px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-6px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;text-decoration:underline;">Variable Consideration - Current Liabilities</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Product Returns.</font><font style="font-family:Arial;font-size:10pt;">&#32;&#32;Consistent with industry practice, the Company has a product returns policy that provides Customers a right of return for product purchased within a specified period prior to and subsequent to the product&#8217;s expiration date. The right of return lapses upon shipment of the goods to a patient. The Company estimates the amount of its products that may be returned and presents this amount as a reduction of revenue in the period the related product revenue is recognized, in addition to establishing a liability. The Company considers several factors in the estimation process, including expiration dates of product shipped to preferred pharmacy network partners and wholesalers, inventory levels within the distribution channel, product shelf life, prescription trends and other relevant factors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Government Rebates</font><font style="font-family:Arial;font-size:10pt;">.  The Company is subject to discount obligations under state Medicaid programs and Medicare. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. For Medicaid, accruals are based on estimates of future Medicaid beneficiary utilization applied to the Medicaid unit rebate formula established by the Center for Medicaid and Medicare Services. The Medicare Part&#160;D prescription drug benefit mandates manufacturers to fund approximately 50% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. To estimate the cost to the Company of this Medicare coverage gap responsibility, the Company estimates the number of patients in the prescription drug coverage gap for whom it will owe an additional liability under the Medicare Part D program. The Company&#8217;s liability for these rebates consists of estimates of claims for the current quarter and estimated future claims that will be made for product that has been recognized as revenue but remains in the distribution channel inventories at the end of the reporting period.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Payor Rebates.</font><font style="font-family:Arial;font-size:10pt;">&#32;&#32;The Company contracts with certain third-party payors, primarily health insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. These rebates are based on contractual percentages applied to the amount of product prescribed to patients who are covered by the plan or the organization with which it contracts. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Other Incentives.</font><font style="font-family:Arial;font-size:10pt;">&#32;&#32;Other incentives that the Company offers include voluntary patient assistance programs, such as co-pay assistance programs, which are intended to provide financial assistance to qualified commercially insured patients with prescription drug co-payments required by payors and coupon programs for cash payors.&#160;The calculation of the accruals for this assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">F-12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OptiNose,&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-left:60px;padding-bottom:10px;padding-top:10px;text-align:left;"><font style="font-family:Arial;font-size:10pt;">that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Licensing Revenues</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Through December 31, 2017, the Company's revenues had been generated pursuant to the terms of a single license agreement (the AVP-825 License Agreement) with Avanir Pharmaceuticals,&#160;Inc. (Avanir) (Note&#160;7). The AVP-825 License Agreement included licensed rights to patented technology, non-refundable up-front payment, research services, and regulatory and sales milestones as well as royalty payments. Through </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, under the terms of the AVP-825 License Agreement, the Company received aggregate cash payments of </font><font style="font-family:Arial;font-size:10pt;">$70,000</font><font style="font-family:Arial;font-size:10pt;">&#32;in connection with the initial signing and the achievement of certain development milestones. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On December 10, 2018, the Company received written notice from Avanir of its election to terminate the AVP-825 License Agreement.&#160;As a result, the AVP-825 License Agreement is expected to terminate on March 10, 2019. We do not expect to receive any additional proceeds from the AVP-825 License Agreement.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prior to the receipt of notice of termination of the License Agreement, the Company analyzed the performance obligations under the AVP-825 License Agreement, the consideration received to date and the consideration the Company could have received in the future as part of its analysis related to ASU 2014-09. The consideration received to date, which included an upfront payment, research and development funding and development milestone payments was recognized in prior years and the Company&#8217;s performance obligations pursuant to the arrangement have been completed. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Advertising expenses</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company expenses the costs of advertising, including promotional expenses, as incurred.  Advertising expenses were </font><font style="font-family:Arial;font-size:10pt;">$9,767</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">and</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">$1,833</font><font style="font-family:Arial;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">and</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Research and development</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research and development costs are expensed as incurred. Research and development costs consist primarily of device development, clinical trial related costs and regulatory related costs. The Company enters into agreements with contract research organizations (CROs) to facilitate, coordinate and perform agreed upon research and development activities for the Company's clinical trials. These CRO contracts typically call for the payment of fees for services at the initiation of the contract and/or upon the achievement of certain clinical trial milestones. The Company prepays certain CRO fees whereby the prepayments are recorded as a current or non-current prepaid asset and are amortized into research and development expense over the period of time the contracted research and development services were performed. The Company's CRO contracts generally also included other fees such as project management and pass through fees whereby the Company expenses these costs as incurred, using the Company's best estimate. Pass through fees include, but are not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous costs. Pass through fees incurred are based on the amount of work completed for the clinical trials and are monitored through reporting provided by the Company's CROs.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based compensation</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company measures and recognizes compensation expense for all stock options awarded to employees and nonemployees and shares issued under the employee stock purchase plan based on the estimated fair value of the awards on the respective grant dates. The Company uses the Black-Scholes option pricing model to value its stock option awards and shares issued under the employee stock purchase plan. The Company recognizes compensation expense for time-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company recognizes compensation expense for performance based awards when the performance condition is probable of achievement. Stock-based awards issued to nonemployees are revalued at each reporting period until the award vests. The Company accounts for forfeitures of stock option awards as they occur.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">F-13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OptiNose,&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Estimating the fair value of options and shares issued under the employee stock purchase plan requires the input of subjective assumptions, including the estimated fair value of the Company's common stock, the expected life of the options, stock price volatility, the risk-free interest rate and expected dividends. The assumptions used in the Company's Black-Scholes option-pricing model represent management's best estimates and involve a number of variables, uncertainties and assumptions and the application of management's judgment, as they are inherently subjective.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Income taxes</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, the Company has concluded that a full valuation allowance is necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest or penalties in the accompanying consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Grant income</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Government grants are agreements that provide cost reimbursement for certain research and development activities over a contractually defined period. Income from government grants is recognized in the period in which related costs are incurred, provided that the conditions under which government grants were provided have been met and only perfunctory obligations are outstanding. Grant income received in excess of costs incurred is recognized as deferred other income.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Net income (loss) per common share</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Basic net income (loss) per common share is determined by dividing net income (loss) applicable to common stockholders by the weighted average common shares outstanding during the period. For the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, the outstanding common stock options and common stock warrants have been excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted net loss per share are the same.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Diluted net loss per common share for the periods presented do not reflect the following potential common shares, as the effect would be antidilutive:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:76%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,182,873</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,141,367</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Common stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,866,831</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,890,489</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Employee stock purchase plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">31,892</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8,081,596</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,031,856</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Recent accounting pronouncements</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In August 2018, the FASB issued ASU No. 2018-15,&#160;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</font><font style="font-family:Arial;font-size:10pt;">.&#160; ASU 2018-15 requires that certain implementation costs incurred in a cloud computing arrangement be deferred and recognized over the term of the arrangement. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on its results of operations, financial position and cash flows and related disclosures.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">F-14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OptiNose,&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In August 2018, the FASB issued ASU No. 2018-13,&#160;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:Arial;font-size:10pt;">.&#160; ASU 2018-13 resulted in certain modifications to fair value measurement disclosures, primarily related to level 3 fair value measurements. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on its disclosures.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09,&#160;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Stock&#160;Compensation - Scope of Modification Accounting</font><font style="font-family:Arial;font-size:10pt;">.&#160; ASU 2017-09 provides guidance on which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The new standard is effective for fiscal years beginning after December 15, 2017. The adoption of ASU 2017-09 did not have a material impact on the Company&#8217;s results of operations, financial position, cash flows and related disclosures.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230). </font><font style="font-family:Arial;font-size:10pt;">ASU No. 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The new standard is effective for fiscal years beginning after December 15, 2017. The Company adopted ASU 2016-18 in the first quarter of 2018, and the guidance has been retrospectively applied to all periods presented. The restricted cash balance included in prepaid expenses and other assets was </font><font style="font-family:Arial;font-size:10pt;">$21</font><font style="font-family:Arial;font-size:10pt;">&#32;as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02,</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#160;Leases (Topic 842)</font><font style="font-family:Arial;font-size:10pt;">. The FASB issued the update to require the recognition of lease assets and liabilities on the balance sheet of lessees. The standard will be effective for fiscal years beginning after December&#160;15, 2018, with early adoption permitted. The ASU requires a modified retrospective transition method with the option to elect a package of practical expedients. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following are other key disclosures, as well as determinations made and actions taken by the Company, related to the adoption of ASC 842:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Elected the optional modified retrospective transition method as of January 1, 2019; therefore prior period amounts will not be restated;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Established and implemented key implementation controls to ensure the Company meets the new reporting and disclosure requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Elected the following transition practical expedients:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to not reassess lease identification, lease classification and initial indirect costs related to those leases entered into prior to the adoption of ASC 842;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to not separate lease and non-lease components for our office lease portfolio;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Made policy elections as of January 1, 2019:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to not apply the recognition and measurement requirements to leases with an initial term of one year or less;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to apply the portfolio approach for the development of the discount rate related to leases with similar characteristics;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to keep leases with an immaterial right-of-use asset at inception, off the balance sheet and recognize this expense on a straight-line basis in the consolidated statements of operations;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">While we continue to assess all the effects of adoption, the Company believes the most significant effect relates to the recognition of right-of-use assets and corresponding liabilities on its consolidated balance sheet, primarily related to its existing facility operating leases, and providing new disclosures with regards to the Company&#8217;s leasing activities.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">F-15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OptiNose,&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09,&#160;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Arial;font-size:10pt;">, or ASU-2014-09, which replaced numerous requirements in US&#160;GAAP, including industry-specific requirements. This guidance provides a five-step model to be applied to all contracts with customers, with an underlying principle that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The new standard also defines accounting for certain costs related to origination and fulfillment of contracts with customers, including whether such costs should be capitalized.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This statement requires extensive quantitative and qualitative disclosures covering the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including disclosures on significant judgments made when applying the guidance and assets recognized from costs incurred to obtain or fulfill a contract. The guidance was effective for annual reporting periods beginning after December&#160;15, 2017, and interim periods within that reporting period. An entity could elect to apply the guidance under one of the following two methods: (i)&#160;retrospectively to each prior reporting period presented&#160;&#8212; referred to as the full retrospective method or (ii)&#160;retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings&#160;&#8212; referred to as the modified retrospective method.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company assessed the impact that ASU No. 2014-09 had on its financial statements and related disclosures. Through the January 1, 2018 adoption date, the Company has derived its revenues from a single licensing agreement with Avanir (the AVP-825 License Agreement). The consideration the Company has received to date includes an upfront payment, research and development funding and development milestone payments. The Company analyzed the performance obligations under the AVP-825 License Agreement as well as the consideration received to date as part of its analysis of the impact of ASU 2014-09 on this arrangement. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company adopted ASU 2014-09 on January 1, 2018 using the modified retrospective transition method. No transition adjustments were recognized as a result of the adoption. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. </font></div><div><a name="sd93665efde6a4a789e7ecbb7e3a03b69"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">4. Inventory</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Inventory consisted of the following: </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,969</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,385</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Work-in-process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,344</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">628</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,819</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7,132</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s7915C84163A556E2A682BBC94CE86D71"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5. Property and Equipment</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Property and equipment, net, consisted of:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Computer equipment and software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">833</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">389</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">89</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Machinery and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,723</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">609</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">28</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Construction in process</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">481</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,035</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,919</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1,151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,884</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,564</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">F-16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OptiNose,&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Depreciation expense was </font><font style="font-family:Arial;font-size:10pt;">$535</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">and </font><font style="font-family:Arial;font-size:10pt;">$164</font><font style="font-family:Arial;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively.  In addition, depreciation expense of </font><font style="font-family:Arial;font-size:10pt;">$322</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$10</font><font style="font-family:Arial;font-size:10pt;">&#32;is included within inventory and prepaid expenses and other assets, respectively, as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, which represents depreciation expense related to equipment involved in the manufacturing process. </font></div><div><a name="sC94552DF94905053B920B364F226072A"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6. Accrued Expenses</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accrued expenses consisted of:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Contract sales organization expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,482</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,432</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Selling, general and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,812</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Research and development expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">933</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">80</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Bonus expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Payroll and benefit expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">564</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">448</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Employee contributions withheld</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Product revenue allowances</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,856</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">435</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">314</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">18,421</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8,698</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s7C2592A3AF6D54B983AFC619DF1DCBE0"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7. AVP-825 License Agreement</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In July 2013, the Company's wholly owned subsidiary, OptiNose AS, entered into the AVP-825 License Agreement with Avanir for the exclusive right to sell AVP-825 (now marketed as Onzetra</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;Xsail</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">), a product combining a low-dose powder form of sumatriptan with the Company's EDS technology platform, for the acute treatment of migraines in adults and any follow-on products under development that consist of a formulation that contains triptans as the sole active ingredient. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Through </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, under the terms of the AVP-825 License Agreement, the Company received aggregate cash payments of </font><font style="font-family:Arial;font-size:10pt;">$70,000</font><font style="font-family:Arial;font-size:10pt;">&#32;in connection with the initial signing and the achievement of certain development milestones. The Company did </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;">t recognize any licensing revenue during the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On December 10, 2018, the Company received written notice from Avanir of its election to terminate the AVP-825 License Agreement.&#160;As a result, the AVP-825 License Agreement is expected to terminate on March 10, 2019.&#160;Upon termination, the Company may elect to continue to commercialize Onzetra Xsail itself or through a new licensee.&#160; We do not expect to receive any additional proceeds from the AVP-825 License Agreement.</font></div><div><a name="s888610ce975e430a8939c91509843a2a"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">8. Convertible Notes</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On September&#160;30, 2015, the Company entered into a Senior Secured Convertible Note Purchase Agreement (Notes) with various existing stockholders. The Notes provided the Company with up to </font><font style="font-family:Arial;font-size:10pt;">$30,000</font><font style="font-family:Arial;font-size:10pt;">&#32;in capital available in </font><font style="font-family:Arial;font-size:10pt;">two</font><font style="font-family:Arial;font-size:10pt;">&#32;separate tranches.The first tranche of </font><font style="font-family:Arial;font-size:10pt;">$15,000</font><font style="font-family:Arial;font-size:10pt;">&#32;closed on September&#160;30, 2015. The second tranche of up to </font><font style="font-family:Arial;font-size:10pt;">$15,000</font><font style="font-family:Arial;font-size:10pt;">&#32;was available to the Company until March&#160;30, 2017 but was never drawn. The Notes bore an annual interest rate of </font><font style="font-family:Arial;font-size:10pt;">17%</font><font style="font-family:Arial;font-size:10pt;">&#32;and were scheduled to mature on September&#160;30, 2020 if not otherwise converted to Series C-2 shares. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On March&#160;24, 2017, in connection with the Series&#160;D Financing, the Notes and associated accrued interest and back end fees thereon totaling </font><font style="font-family:Arial;font-size:10pt;">$19,527</font><font style="font-family:Arial;font-size:10pt;">&#32;converted into </font><font style="font-family:Arial;font-size:10pt;">687,474</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of Series&#160;C-2 preferred stock at a per share conversion price of approximately </font><font style="font-family:Arial;font-size:10pt;">$28.40</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company recorded interest expense of </font><font style="font-family:Arial;font-size:10pt;">$862</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:10pt;">&#32;in conjunction with the Notes. Total coupon interest on the Notes and back end fees was </font><font style="font-family:Arial;font-size:10pt;">$743</font><font style="font-family:Arial;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:10pt;">. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">F-17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OptiNose,&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The front-end fees of </font><font style="font-family:Arial;font-size:10pt;">$450</font><font style="font-family:Arial;font-size:10pt;">&#32;were recorded as debt discount at issuance and were amortized to interest expense over the </font><font style="font-family:Arial;font-size:10pt;">18 months</font><font style="font-family:Arial;font-size:10pt;">&#32;loan conversion period. During the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:10pt;">, the Company recorded a total of </font><font style="font-family:Arial;font-size:10pt;">$75</font><font style="font-family:Arial;font-size:10pt;">&#32;of interest expense related to the front end fees. Additionally, back end fees of </font><font style="font-family:Arial;font-size:10pt;">$450</font><font style="font-family:Arial;font-size:10pt;">&#32;were amortized to interest expense over the </font><font style="font-family:Arial;font-size:10pt;">18 months</font><font style="font-family:Arial;font-size:10pt;">&#32;loan conversion period of which </font><font style="font-family:Arial;font-size:10pt;">$90</font><font style="font-family:Arial;font-size:10pt;">&#32;was recorded as interest expense and as an increase in the carrying amount of the Notes during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:10pt;">. The Company also incurred </font><font style="font-family:Arial;font-size:10pt;">$265</font><font style="font-family:Arial;font-size:10pt;">&#32;in debt issuance costs during the year ended December&#160;31, 2015 which were amortized to interest expense over the </font><font style="font-family:Arial;font-size:10pt;">18 months</font><font style="font-family:Arial;font-size:10pt;">&#32;loan conversion period.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;and 2017, </font><font style="font-family:Arial;font-size:10pt;">none</font><font style="font-family:Arial;font-size:10pt;">&#32;of the Notes were outstanding. </font></div><div><a name="s48EE273847A35B71A26D0CFB3B92CC54"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">9. Long-term Debt</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On December 29, 2017, the Company entered into a Senior Secured Note Purchase Agreement (the Senior Secured Notes) with Athyrium Opportunities III Acquisition LP. The Senior Secured Notes provided the Company with up to </font><font style="font-family:Arial;font-size:10pt;">$100,000</font><font style="font-family:Arial;font-size:10pt;">&#32;in capital, of which </font><font style="font-family:Arial;font-size:10pt;">$75,000</font><font style="font-family:Arial;font-size:10pt;">&#32;was issued immediately. The remaining </font><font style="font-family:Arial;font-size:10pt;">$25,000</font><font style="font-family:Arial;font-size:10pt;">&#32;(the Delayed Draw Notes) may be issued between April 1, 2019 and August 14, 2019, subject to the Company achieving trailing </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;">&#32;quarter net revenues (as calculated pursuant to the terms of the Note Purchase Agreement)  of </font><font style="font-family:Arial;font-size:10pt;">$15,000</font><font style="font-family:Arial;font-size:10pt;">&#32;and a pro forma ratio of total debt to trailing </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;">&#32;quarter net revenues not exceeding </font><font style="font-family:Arial;font-size:10pt;">6.50</font><font style="font-family:Arial;font-size:10pt;">&#32;to 1.00, and certain other conditions.  </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Senior Secured Notes bear interest at </font><font style="font-family:Arial;font-size:10pt;">9.0%</font><font style="font-family:Arial;font-size:10pt;">&#32;plus the three-month London Inter-bank Offered Rate (LIBOR) rate, subject to a </font><font style="font-family:Arial;font-size:10pt;">1.0%</font><font style="font-family:Arial;font-size:10pt;">&#32;floor and are scheduled to mature on June 29, 2023. The interest rate was </font><font style="font-family:Arial;font-size:10pt;">11.8125%</font><font style="font-family:Arial;font-size:10pt;">&#32;at </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">. The Senior Secured Notes bore front-end fees of </font><font style="font-family:Arial;font-size:10pt;">1%</font><font style="font-family:Arial;font-size:10pt;">&#32;of the aggregate principal amount, which were paid at issuance. The Company is also required to pay an exit fee of </font><font style="font-family:Arial;font-size:10pt;">2%</font><font style="font-family:Arial;font-size:10pt;">&#32;of any principal payments (whether mandatory, voluntary, or at maturity) made throughout the term of the Note Purchase Agreement. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company is required to make quarterly, interest only payments until the maturity date. The Company may make voluntary prepayments of the Senior Secured Notes, in whole or in part, and subject to certain exceptions, is required to make mandatory prepayments upon the occurrence of certain events as defined in the agreement, including, the occurrence of a change of control.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#32;All mandatory and voluntary prepayments of the Senior Secured Notes are subject to the payment of prepayment premiums as follows: (i) if prepayment occurs prior to the second anniversary of the applicable date of issuance, an amount equal to the amount by which (a) the present value of </font><font style="font-family:Arial;font-size:10pt;">102%</font><font style="font-family:Arial;font-size:10pt;">&#32;of the principal prepaid plus all interest that would have accrued on such principal through such second anniversary exceeds (b) the amount of principal prepaid, (ii) if prepayment occurs on or after the second anniversary of the applicable date of issuance but prior to the third anniversary of such issuance, an amount equal to </font><font style="font-family:Arial;font-size:10pt;">2%</font><font style="font-family:Arial;font-size:10pt;">&#32;of the principal prepaid, and (iii) if prepayment occurs on or after the third anniversary of the applicable date of issuance but prior to the fourth anniversary of such issuance, an amount equal to </font><font style="font-family:Arial;font-size:10pt;">1%</font><font style="font-family:Arial;font-size:10pt;">&#32;of the principal prepaid. </font><font style="font-family:Arial;font-size:10pt;">No</font><font style="font-family:Arial;font-size:10pt;">&#32;prepayment premium is due on any principal prepaid after the fourth anniversary of the applicable date of issuance of any Senior Secured Notes.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Senior Secured Notes are secured by a pledge of substantially&#160;all of the Company&#8217;s assets and contains affirmative and negative covenants customary for financings of this type, including limitations on the Company&#8217;s and its subsidiaries&#8217; ability to, among other things, incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, grant certain license rights related to the Company's products, technology and other intellectual property rights, pay dividends and distributions, repay junior indebtedness and enter into affiliate transactions, in each case, subject to certain exceptions.  In addition, the Senior Secured Notes contains financial covenants requiring the Company to maintain (i) at least </font><font style="font-family:Arial;font-size:10pt;">$10,000</font><font style="font-family:Arial;font-size:10pt;">&#32;of cash and cash equivalents and (ii) following the issuance of the Delayed Draw Notes or upon entering into certain exclusive licenses of XHANCE, a total debt to trailing </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;">&#32;quarter net revenue ratio of less than </font><font style="font-family:Arial;font-size:10pt;">6.50</font><font style="font-family:Arial;font-size:10pt;">&#32;to 1.00 initially, and thereafter declining quarterly by equal half-steps to a ratio of less than </font><font style="font-family:Arial;font-size:10pt;">3.00</font><font style="font-family:Arial;font-size:10pt;">&#32;to 1.00. As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company was in compliance with the covenants.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company recorded interest expense of </font><font style="font-family:Arial;font-size:10pt;">$9,229</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$48</font><font style="font-family:Arial;font-size:10pt;">&#32;during the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively, in conjunction with the Senior Secured Notes. Interest expense included total coupon interest, back </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">F-18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OptiNose,&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">end fees, front end fees and the amortization of debt issuance costs. The front-end fees of </font><font style="font-family:Arial;font-size:10pt;">$1,000</font><font style="font-family:Arial;font-size:10pt;">&#32;were recorded as debt discount at issuance and are being amortized to interest expense over the </font><font style="font-family:Arial;font-size:10pt;">5.5</font><font style="font-family:Arial;font-size:10pt;">&#32;year term of the loan. Additionally, back end fees of </font><font style="font-family:Arial;font-size:10pt;">$2,000</font><font style="font-family:Arial;font-size:10pt;">&#32;are being amortized to interest expense and are recorded as an increase in the carrying amount throughout the term of the Senior Secured Notes. The Company also incurred </font><font style="font-family:Arial;font-size:10pt;">$2,181</font><font style="font-family:Arial;font-size:10pt;">&#32;in debt issuance costs during the year ended December&#160;31, 2017 which are also being amortized to interest expense over the term of the Senior Secured Notes.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, the long-term debt balance is comprised of the following:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:77%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Face amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">75,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">75,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Front end fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(872</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(999</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1,902</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(2,139</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Back end fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">274</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">72,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">71,863</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="sA58E1459DED05C6AA50C275A0D3ED58D"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">10. Employee Benefit Plans</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For US employees, the Company maintains a defined contribution 401(k) retirement plan, which covers all employees. Employees are eligible to participate in the plan on the first of the month following their date of hire. Under the 401(k)&#160;retirement plan, participating employees may defer up to </font><font style="font-family:Arial;font-size:10pt;">100%</font><font style="font-family:Arial;font-size:10pt;">&#32;of their pre-tax salary, but not more than statutory limits. In October 2017, the Company adopted a 401(k) matching program for its US employees. The Company matches </font><font style="font-family:Arial;font-size:10pt;">100%</font><font style="font-family:Arial;font-size:10pt;">&#32;of the first </font><font style="font-family:Arial;font-size:10pt;">3%</font><font style="font-family:Arial;font-size:10pt;">&#32;of participating employee contributions and </font><font style="font-family:Arial;font-size:10pt;">50%</font><font style="font-family:Arial;font-size:10pt;">&#32;of the next </font><font style="font-family:Arial;font-size:10pt;">2%</font><font style="font-family:Arial;font-size:10pt;">&#32;of participating employee contributions, subject to applicable IRC limits. The Company incurred costs of  $</font><font style="font-family:Arial;font-size:10pt;">645</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$230</font><font style="font-family:Arial;font-size:10pt;">&#32;related to the Company match applicable to employee contributions for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">. The Company's contributions are made in cash. The Company's common stock is not currently an investment option available to participants in the 401(k) retirement plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For Norway and UK employees, the Company maintains defined contribution pension plans which meet statutory requirements of those jurisdictions. The Company incurred costs of $</font><font style="font-family:Arial;font-size:10pt;">81</font><font style="font-family:Arial;font-size:10pt;">&#32;and $</font><font style="font-family:Arial;font-size:10pt;">56</font><font style="font-family:Arial;font-size:10pt;">&#32;related to the pension plans for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div><a name="sA2B5ABC1E2385CFAB92EBC563C769035"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">11. Commitments and Contingencies</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company leases office space under </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;">&#32;operating leases and has leases for certain other equipment. Rent expense is recognized as incurred.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following is a schedule of future minimum annual payments as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;under operating lease agreements:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:89%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">For the years ending December 31:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,630</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,107</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">391</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total future minimum lease payments as of December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,128</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Rent expense related to leases of office space was $</font><font style="font-family:Arial;font-size:10pt;">831</font><font style="font-family:Arial;font-size:10pt;">&#32;and $</font><font style="font-family:Arial;font-size:10pt;">689</font><font style="font-family:Arial;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">F-19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OptiNose,&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In January 2018, the Company amended its existing office lease agreement for the Company&#8217;s headquarters in Yardley, PA (the Lease Amendment). Under the terms of the Lease Amendment, the Company&#8217;s leased office space was increased from approximately </font><font style="font-family:Arial;font-size:10pt;">20,050</font><font style="font-family:Arial;font-size:10pt;">&#32;square feet to approximately </font><font style="font-family:Arial;font-size:10pt;">30,000</font><font style="font-family:Arial;font-size:10pt;">&#32;square feet, and the term of the lease was extended from March 31, 2018 to May 31, 2021 (the Extended Term), with an option to renew the lease for an additional </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;">-year term.&#160;The Company&#8217;s rent payments during the Extended Term will be approximately </font><font style="font-family:Arial;font-size:10pt;">$2,750</font><font style="font-family:Arial;font-size:10pt;">&#32;in the aggregate, and the Company will also be required to pay its proportionate share of certain operating costs and property taxes applicable to the leased premises.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Purchase commitments</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In November 2017, the Company entered into an agreement with a contract sales organization for the recruitment, deployment and management of a contract sales force to market XHANCE in the US. Subject to certain limited exceptions, the Company could not terminate this agreement until after the first anniversary of the deployment of the sales force (which occurred in March 2018). In December 2018, as a result of the Company's decision to manage its sales force directly, the Company terminated the agreement effective April 1, 2019 and accrued an early termination fee of </font><font style="font-family:Arial;font-size:10pt;">$691</font><font style="font-family:Arial;font-size:10pt;">. The Company estimates the expenses related to the remaining non-cancellable services, all of which will be provided in 2019, to be approximately </font><font style="font-family:Arial;font-size:10pt;">$2,335</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company had </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;">&#32;other material outstanding non-cancellable purchase commitments related to inventory and other goods and services, including pre-commercial manufacturing scale-up and sales and marketing activities.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Employment agreements</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has entered into employment contracts with its officers and certain employees that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Litigation</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. There are no matters currently outstanding.</font></div><div><a name="sBCF77807F24659BC9313A9127DAEEFAA"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12. Stockholders' equity</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Common stock</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In October 2017, the Company increased the number of authorized common shares from </font><font style="font-family:Arial;font-size:10pt;">10,624,486</font><font style="font-family:Arial;font-size:10pt;">&#32;to </font><font style="font-family:Arial;font-size:10pt;">200,000,000</font><font style="font-family:Arial;font-size:10pt;">&#32;and completed an initial public offering (IPO) of its common stock, selling </font><font style="font-family:Arial;font-size:10pt;">8,625,000</font><font style="font-family:Arial;font-size:10pt;">&#32;shares at </font><font style="font-family:Arial;font-size:10pt;">$16.00</font><font style="font-family:Arial;font-size:10pt;">&#32;per share.  As a result of the IPO, the Company received </font><font style="font-family:Arial;font-size:10pt;">$125,471</font><font style="font-family:Arial;font-size:10pt;">&#32;in net proceeds, after deducting discounts and commissions of </font><font style="font-family:Arial;font-size:10pt;">$9,660</font><font style="font-family:Arial;font-size:10pt;">&#32;and offering expenses of approximately </font><font style="font-family:Arial;font-size:10pt;">$2,869</font><font style="font-family:Arial;font-size:10pt;">&#32;payable by the Company. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On June 11, 2018, the Company and certain stockholders closed the Offering of </font><font style="font-family:Arial;font-size:10pt;">5,750,000</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of Common Stock at a price of </font><font style="font-family:Arial;font-size:10pt;">$22.25</font><font style="font-family:Arial;font-size:10pt;">&#32;per share. The Offering consisted of </font><font style="font-family:Arial;font-size:10pt;">2,875,000</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of Common Stock sold by the Company and </font><font style="font-family:Arial;font-size:10pt;">2,875,000</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of Common Stock sold by certain stockholders. As a result of the Offering, the Company received </font><font style="font-family:Arial;font-size:10pt;">$59,917</font><font style="font-family:Arial;font-size:10pt;">&#32;in net proceeds, after deducting discounts and commissions of </font><font style="font-family:Arial;font-size:10pt;">$3,678</font><font style="font-family:Arial;font-size:10pt;">&#32;and offering expenses of approximately </font><font style="font-family:Arial;font-size:10pt;">$373</font><font style="font-family:Arial;font-size:10pt;">&#32;payable by the Company.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Each share of common stock entitles the holder to </font><font style="font-family:Arial;font-size:10pt;">one</font><font style="font-family:Arial;font-size:10pt;">&#32;vote on all matters submitted to a vote of the Company&#8217;s stockholders. Subject to preferences that may apply to any outstanding preferred stock, holders of common stock are entitled to receive ratably any dividends that the Company&#8217;s board of directors may declare out of funds legally available for that purpose on a non-cumulative basis. </font><font style="font-family:Arial;font-size:10pt;">No</font><font style="font-family:Arial;font-size:10pt;">&#32;dividends had been declared through </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Common stock warrants</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company had </font><font style="font-family:Arial;font-size:10pt;">1,866,831</font><font style="font-family:Arial;font-size:10pt;">&#32;warrants outstanding to purchase shares of the Company's common stock with an exercise price of </font><font style="font-family:Arial;font-size:10pt;">$8.16</font><font style="font-family:Arial;font-size:10pt;">. The warrants expire on November 1, 2020.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">F-20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OptiNose,&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Redeemable convertible preferred stock</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the year ended December&#160;31, 2017, the Company sold </font><font style="font-family:Arial;font-size:10pt;">1,117,578</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of Series&#160;D Preferred Stock at a per share purchase price of </font><font style="font-family:Arial;font-size:10pt;">$32.85</font><font style="font-family:Arial;font-size:10pt;">, resulting in gross proceeds to the Company of </font><font style="font-family:Arial;font-size:10pt;">$36,712</font><font style="font-family:Arial;font-size:10pt;">&#32;(the Series&#160;D Financing). In connection with the Series&#160;D Financing, the Company's existing convertible notes and associated accrued interest and back end fees thereon totaling </font><font style="font-family:Arial;font-size:10pt;">$19,527</font><font style="font-family:Arial;font-size:10pt;">&#32;converted into </font><font style="font-family:Arial;font-size:10pt;">687,474</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of Series&#160;C-2 Preferred Stock at a per share conversion price of approximately </font><font style="font-family:Arial;font-size:10pt;">$28.40</font><font style="font-family:Arial;font-size:10pt;">&#32;(Note&#160;8).</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upon consummation of the IPO in October 2017, all of the outstanding shares of the Company's redeemable convertible preferred stock were converted into an aggregate of </font><font style="font-family:Arial;font-size:10pt;">25,068,556</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of common stock. In connection with the IPO, </font><font style="font-family:Arial;font-size:10pt;">5,000,000</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of preferred stock, with a par value of </font><font style="font-family:Arial;font-size:10pt;">$0.001</font><font style="font-family:Arial;font-size:10pt;">&#32;per share, were authorized for issuance. As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;">&#32;preferred stock was issued or outstanding.</font></div><div><a name="s7A518F55C7BA58DF9B055ABEBDD98DA6"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">13. Stock-based compensation</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company issues stock-based awards pursuant to its 2010 Stock Incentive Plan. Effective as of October 12, 2017, the Company's 2010 Stock Incentive Plan was amended and restated (A&amp;R Plan). The A&amp;R Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units, deferred stock units, performance shares, stock appreciation rights and other equity-based awards. The Company's employees, officers, directors and other persons are eligible to receive awards under the A&amp;R Plan. As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">8,406,547</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of the Company's common stock were authorized to be issued under the A&amp;R Plan, and </font><font style="font-family:Arial;font-size:10pt;">1,635,295</font><font style="font-family:Arial;font-size:10pt;">&#160;shares were reserved for future awards under the A&amp;R Plan. The number of shares of the Company's common stock authorized under the A&amp;R Plan will automatically increase on January&#160;1st of each year, commencing on January&#160;1, 2018 and continuing until the expiration of the A&amp;R Plan, in an amount equal to </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;">&#32;percent of the total number of shares of the Company's common stock outstanding on December&#160;31</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">st</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;of the preceding calendar year, subject to the discretion of the Company's board of directors or compensation committee to determine a lesser number of shares shall be added for such year.&#160;</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The amount, terms of grants, and exercisability provisions are determined and set by the Company's board of directors or compensation committee. The Company measures employee stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. Stock-based awards issued to non-employees are revalued until the award vests. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Stock options</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has issued service-based and performance-based stock options that generally have a contractual life of up to </font><font style="font-family:Arial;font-size:10pt;">10</font><font style="font-family:Arial;font-size:10pt;">&#160;years and may be exercisable in cash or as otherwise determined by the board of directors. Vesting generally occurs over a period of not greater than </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;">&#32;years. Performance-based options may vest upon the achievement of certain milestones in connection with the Company's development programs. Additionally, the Company has issued stock options in excess of the fair market value of Common Stock on the issuance date that were only exercisable upon a change in control or upon or after an initial public offering. As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, all of the performance conditions related to performance-based stock options issued by the Company have been achieved.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">F-21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OptiNose,&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes the activity related to stock option grants to employees and nonemployees for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:62%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">exercise price</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">contractual life</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Outstanding at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,251,589</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">9.34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.67</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">472,792</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">19.36</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(491,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(49,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">9.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Outstanding at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,182,873</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.60</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.48</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Exercisable at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,804,999</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.09</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Vested and expected to vest at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,182,873</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.60</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.48</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, stock options to purchase </font><font style="font-family:Arial;font-size:10pt;">472,792</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of common stock were granted to employees that generally vest over </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;">&#32;years. The options had an estimated weighted average grant date fair value of </font><font style="font-family:Arial;font-size:10pt;">$12.85</font><font style="font-family:Arial;font-size:10pt;">. The grant date fair value of each option grant was estimated at the time of grant using the Black-Scholes option-pricing model. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The total aggregate intrinsic value of stock options exercised during the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">and</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">&#32;was </font><font style="font-family:Arial;font-size:10pt;">$9,255</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">and </font><font style="font-family:Arial;font-size:10pt;">$435</font><font style="font-family:Arial;font-size:10pt;">, respectively. The aggregate intrinsic value of stock options outstanding and stock options exercisable as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;was </font><font style="font-family:Arial;font-size:10pt;">$8,470</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$8,028</font><font style="font-family:Arial;font-size:10pt;">, respectively. At </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, the unrecognized compensation cost related to unvested stock options expected to vest was </font><font style="font-family:Arial;font-size:10pt;">$20,405</font><font style="font-family:Arial;font-size:10pt;">. This unrecognized compensation will be recognized over an estimated weighted-average amortization period of </font><font style="font-family:Arial;font-size:10pt;">2.7 years</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">2017 Employee Stock Purchase Plan </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company's 2017 Employee Stock Purchase Plan (the 2017 Plan) became effective on October 12, 2017. As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">,&#160;</font><font style="font-family:Arial;font-size:10pt;">522,420</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of the Company's common stock were authorized to be issued pursuant to purchase rights granted to its employees or to employees of any of its participating affiliates under the 2017 Plan. 469,283 shares of the Company's common stock were reserved for future issuance under the 2017 Plan. The number of shares of the Company's common stock that may be issued pursuant to rights granted under the 2017 Plan shall automatically increase on January&#160;1st of each year, commencing on January&#160;1, 2018 and continuing until the expiration of the 2017 Plan, in an amount equal to </font><font style="font-family:Arial;font-size:10pt;">one</font><font style="font-family:Arial;font-size:10pt;">&#32;percent of the total number of shares of the Company's common stock outstanding on December&#160;31st of the preceding calendar year, subject to the discretion of the board of directors or compensation committee to determine a lesser number of shares shall be added for such year.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Under the 2017 Plan, eligible employees can purchase the Company&#8217;s common stock through accumulated payroll deductions at such times as are established by the administrator. The 2017 Plan is administered by the compensation committee. Under the 2017 Plan, eligible employees may purchase the Company&#8217;s common stock at 85% of the lesser of the average high and low sales price of the Company's common stock on (i) the first trading day of the relevant offering period and (ii) on the last trading day of the relevant offering period (or, if the relevant offering period has multiple purchase periods, the last trading day of the relevant purchase period). Eligible employees may contribute up to 15% of their eligible compensation. Under the 2017 Plan, a participant may not accrue rights to purchase more than $25 worth of the Company&#8217;s common stock for each calendar year in which such right is outstanding.&#160;</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Effective October 12, 2017, employees who elected to participate in the 2017 Plan commenced payroll withholdings that accumulated through June 30, 2018.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">F-22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OptiNose,&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Beginning on January 1, 2018, employees who elected to participate in the 2017 Plan commenced payroll withholdings that accumulate during the following six month offering periods each calendar year while the Purchase Plan is effective:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">January 1 through June 30, and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">July 1 through December 31.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">At the end of each offering period, shares of the Company&#8217;s common stock may be purchased at 85% of the lesser of the average of the high and low sales price of the Company&#8217;s common stock on (i) the first trading day of the relevant offering period and (ii) the last trading day of the relevant offering period (or, if the relevant offering period has multiple purchase periods, the last trading day of the relevant purchase period). In accordance with the guidance in ASC 718-50 &#8211;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#160;Compensation &#8211; Stock Compensation</font><font style="font-family:Arial;font-size:10pt;">, the ability to purchase shares of the Company&#8217;s common stock at the lower of the price on the first day of the offering period or the last day of the offering period (i.e. the purchase date) represents an option and, therefore, the 2017 Plan is a compensatory plan under this guidance. Accordingly, stock-based compensation expense is determined based on the option&#8217;s grant-date fair value as estimated by applying the Black Scholes option-pricing model and is recognized over the requisite service period of the option. The Company has recognized stock-based compensation expense of </font><font style="font-family:Arial;font-size:10pt;">$446</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">and</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">$106</font><font style="font-family:Arial;font-size:10pt;">&#32;during the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively, related to the 2017 Plan.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based compensation expense</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company recorded stock-based compensation expense in the following expense categories of its accompanying consolidated statements of operations for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;and  </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:79%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cost of product sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">989</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,288</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7,545</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,808</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8,543</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,096</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition, stock-based compensation expense of </font><font style="font-family:Arial;font-size:10pt;">$99</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$2</font><font style="font-family:Arial;font-size:10pt;">&#32;is included within inventory and prepaid expenses and other assets, respectively, as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, which represents the total stock-based compensation expense incurred related to employees involved in the manufacturing process of finished goods and samples during the period.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company utilized the Black-Scholes valuation model for estimating the fair value of stock options granted and the option component of the 2017 Plan. The Company calculated the fair value of each option grant and the option component of the 2017 Plan on the respective dates of grant using the following weighted average assumptions: </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:73%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2010 A&amp;R Stock Incentive Plan</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017 Employee Stock Purchase Plan</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Risk free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expected term (in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.95</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.64</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">74.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">80.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Annual dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Option valuation methods, including Black-Scholes, require the input of subjective assumptions, which are discussed below.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The expected term of employee options is determined using the "simplified" method, as prescribed in SEC's Staff Accounting Bulletin (SAB) No.&#160;107, whereby the expected life equals the arithmetic average of the </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">F-23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OptiNose,&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:10px;padding-top:10px;"><font style="font-family:Arial;font-size:10pt;">vesting term and the original contractual term of the option due to the Company's lack of sufficient historical data. The expected term of nonemployee options is equal to the contractual term.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The expected volatility is based on historical volatilities of similar entities within the Company's industry which were commensurate with the expected term assumption as described in SAB No.&#160;107.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The risk-free interest rate is based on the interest rate payable on US Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The expected dividend yield is </font><font style="font-family:Arial;font-size:10pt;">0%</font><font style="font-family:Arial;font-size:10pt;">&#32;because the Company has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.</font></div></td></tr></table><div><a name="sA5C009CB85D45A4CB15978815F39DFAC"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">14. Income taxes</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Tax Cuts and Jobs Act (TCJA) was enacted on December 22, 2017 with most changes effective January 1, 2018. Among other changes, the TCJA significantly lowered the US corporate income tax rate from 35% to 21% as of January 1, 2018. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse. As a result of the reduction in the US corporate income tax rate, the Company revalued its net deferred tax assets at December&#160;31, 2017. Due to the full valuation allowance on the Company's deferred tax assets, no tax expense or benefit associated with the re-measurement was recognized in the Company's consolidated statement of operations for the year ended December&#160;31, 2017. The change in the US corporate tax rate is also included in the Company&#8217;s deferred tax table.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The TCJA provided for a one-time transition tax on the deemed repatriation of post-1986 undistributed foreign subsidiary earnings and profits (E&amp;P). As the Company's foreign subsidiaries did not have accumulated E&amp;P, the Company did not record any income tax expense related to the transition tax.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Due to the timing of and the substantial changes made by the TCJA, the Staff of the Securities and Exchange Commission (SEC) issued Staff Accounting Bulletin No. 118 (SAB 118), which provides registrants a measurement period to report the impact of the new US tax law.&#160;During the measurement period, provisional amounts for the effects of the law are recorded to the extent a reasonable estimate can be made.&#160;To the extent that all information necessary is not available, prepared or analyzed, companies may recognize provisional estimated amounts for a period of up to one year following enactment of the TCJA. Accordingly, the Company recorded a preliminary estimate of the impact of the TCJA and the re-measurement of its deferred tax assets and liabilities in 2017. The Company finalized its analysis of the impact of the TCJA and recorded the adjustment, which was not material, in 2018.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Income taxes have been recorded on the following book income (loss) before income tax expense:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:67%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Domestic operations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(146,247</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(30,463</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">39,589</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(18,439</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Loss before provision for income taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(106,658</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(48,902</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">F-24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OptiNose,&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A reconciliation of income tax expense (benefit) at the US federal statutory income tax rate and the income tax provision in the financial statements is as follows: </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:54%;"></td><td style="width:22%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Income tax expense at statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">21.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Permanent items</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Foreign rate differential</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(4.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Impact of foreign operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(7.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;State taxes, net of federal benefit</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Tax rate changes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(15.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Foreign exchange and other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Change in valuation allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(16.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(16.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Effective income tax rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Tax rate changes includes the impact of the reduction in the US tax rate in 2017 under the TCJA and a reduction in the Norway tax rate in both 2017 and 2018.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The principal components of the Company&#8217;s deferred tax assets and liabilities are as follows: </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.44054580896686%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:55%;"></td><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Deferred tax assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,674</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">972</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Prepaid licensing arrangement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">11,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">55</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Interest expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,267</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">783</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Stock compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,493</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,701</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Research and development credits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,485</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,485</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Net operating losses </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">32,548</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">29,636</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;Total deferred tax assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">53,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">35,632</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Deferred tax liabilities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Fixed assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(409</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;Total deferred tax liabilities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(409</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Less: Valuation allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(52,620</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(35,632</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total net deferred tax assets (liabilities)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During 2018, our wholly-owned subsidiary in Norway licensed certain intellectual property rights related to XHANCE to our US subsidiary. While this transaction did not result in any gain or loss in the condensed consolidated statements of operations, the transaction generated taxable income in both Norway and the US. Norway tax loss carryforwards were utilized to offset the taxable income in Norway and the income reduced the current year US taxable loss.  There were no cash taxes associated with the transaction.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The TCJA, in addition to the changes indicated above, contained other provisions that may have a future impact on the Company. The provisions include limitations on the deductibility of interest based on the amount of adjusted taxable income, the deferral of research and development deductions, the acceleration of deductions related to fixed asset </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">F-25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA071692F10A856EE9C9C70B526949937"><font style="font-family:Arial;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OptiNose,&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">additions, changes to the utilization of net operating loss carry forwards and changes in the carry forward period, and global intangible low-taxed income provisions that subject foreign subsidiary income that exceeds an allowable return to current US taxation.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company had foreign net operating loss (NOL) carry forwards of </font><font style="font-family:Arial;font-size:10pt;">$50,513</font><font style="font-family:Arial;font-size:10pt;">&#32;primarily from its operations in Norway. As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company had federal and state NOLs of </font><font style="font-family:Arial;font-size:10pt;">$86,574</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$57,017</font><font style="font-family:Arial;font-size:10pt;">, respectively. These domestic NOL carry forwards may be subject to an annual limitation in the event of cumulative changes in the ownership interests of significant stockholders over a three&#8209;year period in excess of 50%. This could limit the amount of NOLs that the Company can utilize annually to offset future domestic taxable income, if any. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The federal NOL generated in 2018 has an indefinite carry forward period. The federal NOLs generated prior to 2018 will expire from 2030 through 2037. Some state NOLs will not expire while other state NOLs expire over various periods depending on the rules of the jurisdiction in which they were generated. The earliest state NOL expiration is in 2028.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ASC 740 requires the establishment of a valuation allowance to reduce deferred tax assets if, based on the weight of the available positive and negative evidence it is more likely than not that all or a portion of the deferred tax assets will not be realized. There is insufficient positive evidence to overcome the negative evidence attributable to the Company&#8217;s cumulative operating losses. Consequently, the Company established a full valuation allowance against its net deferred tax assets at </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively, because the Company&#8217;s management was unable to conclude that it is more likely than not that these assets will be fully realized. The Company had a net increase in its valuation allowance of </font><font style="font-family:Arial;font-size:10pt;">$16,988</font><font style="font-family:Arial;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company files income tax returns in Norway, the UK, the US, and various states. The Company is subject to examination by federal, state and foreign jurisdictions. The Company&#8217;s tax years in the US are open under statute from inception to present. All open years may be examined to the extent that tax credits or net operating loss carryforwards are used in future periods. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s policy is to record interest and penalties related to uncertain tax positions in income tax expense.  As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company had </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;">&#32;accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#8217;s statement of operations. </font></div><div><a name="sBAB14227CF505BE19EC98261C4632A5B"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">15. Related-party transactions</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Debt and equity transactions</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All of the Company's convertible debt (see Note&#160;8) was issued to holders of the Company's convertible preferred stock.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the year ended December&#160;31, 2018 and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, the Company reimbursed Avista Capital Holdings, LP and related parties </font><font style="font-family:Arial;font-size:10pt;">$51</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$157</font><font style="font-family:Arial;font-size:10pt;">, respectively in expenses, primarily related to legal fees incurred in conjunction with the Company's Offering of Common Stock in June 2018, the IPO in October 2017 and the issuance of Series D redeemable convertible preferred stock March 2017.  </font></div><div><a name="sc640c7da071043208e4a49660e0f392a"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">16. Subsequent events</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On January 31, 2019, OptiNose AS, a wholly owned subsidiary of the Company, entered into a license agreement (the Inexia License Agreement) with Inexia Limited (Inexia).</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Under the terms of the Inexia License Agreement, Inexia paid the Company a </font><font style="font-family:Arial;font-size:10pt;">$500</font><font style="font-family:Arial;font-size:10pt;">&#32;upfront payment. For each product developed under the Inexia License Agreement, the Company is eligible to receive up to </font><font style="font-family:Arial;font-size:10pt;">$8,000</font><font style="font-family:Arial;font-size:10pt;">&#32;of development milestone payments and up to </font><font style="font-family:Arial;font-size:10pt;">$37,000</font><font style="font-family:Arial;font-size:10pt;">&#32;of sales milestone payments. In addition, the Company is eligible to receive tiered, low-to-mid single digit royalties based on net sales of any products successfully developed and commercialized under the Inexia License Agreement.  Other than the upfront payment, the Company does not anticipate the receipt of any milestone or royalty payments from Inexia in the near term. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">F-26</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>formindemnificationagreeme.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD45D454C373E5180943092DEF0126380"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">INDEMNIFICATION AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Indemnification Agreement (this &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Agreement</font><font style="font-family:inherit;font-size:10pt;">&#8221;) is made as of __________, 201___ by and between OptiNose,&#160;Inc., a Delaware corporation (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Corporation</font><font style="font-family:inherit;font-size:10pt;">&#8221;), in its own name and on behalf of its direct and indirect subsidiaries, and __________________, an individual (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Indemnitee</font><font style="font-family:inherit;font-size:10pt;">&#8221;).  This Agreement supersedes and replaces any and all previous Agreements between the Corporation and Indemnitee covering the subject matter of this Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">RECITALS</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:inherit;font-size:10pt;">, directors, officers, employees, controlling persons, fiduciaries and other agents (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Representatives</font><font style="font-family:inherit;font-size:10pt;">&#8221;) in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming litigation relating to, among other things, matters that traditionally would have been brought only against the corporation or business enterprise itself;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:inherit;font-size:10pt;">, the Board of Directors of the Company (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Board</font><font style="font-family:inherit;font-size:10pt;">&#8221;) believes that highly competent persons have become more reluctant to serve corporations as Representatives unless they are provided with adequate protection through insurance and adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation or business enterprise;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:inherit;font-size:10pt;">, the Board has determined that the increased difficulty in attracting and retaining highly competent persons is detrimental to the best interests of the Corporation and its stockholders and that the Corporation should act to assure such persons that there will be increased certainty of protection against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the Corporation;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:inherit;font-size:10pt;">, it is reasonable, prudent and necessary for the Corporation contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Corporation free from undue concern regarding such risks;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:inherit;font-size:10pt;">, (a)&#160;the Amended and Restated Bylaws of the Corporation (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Bylaws</font><font style="font-family:inherit;font-size:10pt;">&#8221;) require indemnification of the officers and directors of the Corporation, (b)&#160;Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware, as it may be amended from time to time (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">DGCL</font><font style="font-family:inherit;font-size:10pt;">&#8221;) and (c)&#160;the Bylaws and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive and thereby contemplate that contracts may be entered into between the Corporation and its Representatives with respect to indemnification;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:inherit;font-size:10pt;">, this Agreement is a supplement to and in furtherance of the Bylaws and any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefore, nor to diminish or abrogate any rights of Indemnitee thereunder; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:inherit;font-size:10pt;">, (a)&#160;Indemnitee does not regard the protection available under the Bylaws and insurance as adequate in the present circumstances, (b)&#160;Indemnitee may not be willing to serve or continue to serve as a Representative without adequate protection, (c)&#160;the Corporation desires Indemnitee to serve or continue to serve in such capacity and (d)&#160;Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Corporation on the condition that he/she be so indemnified.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">AGREEMENT</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOW, THEREFORE</font><font style="font-family:inherit;font-size:10pt;">, in consideration of the premises and the covenants contained herein, the Corporation and Indemnitee do hereby covenant and agree as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:10pt;padding-right:84px;">Section 1.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Definitions</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;As used in this Agreement:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Agreement</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall have the meaning ascribed to such term in the Preamble hereto.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Beneficial Owner</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall have the meaning given to such term in Rule 13d-3 under the Exchange Act (as defined below); provided, however, that Beneficial Owner shall exclude any Person otherwise becoming a Beneficial Owner by reason of the stockholders of the Corporation approving a merger of the Corporation with another entity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Board</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall have the meaning ascribed to such term in the Recitals hereto.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Bylaws</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall have the meaning ascribed to such term in the Recitals hereto.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Certificate of Incorporation</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean the Fourth Amended and Restated Certificate of Incorporation of the Corporation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Change in Control</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">i.&#160;&#160;&#160;&#160;Acquisition of Stock by Third Party.  Any Person (as defined below), other than the Sponsor Entities (as defined below), is or becomes the Beneficial Owner (as defined below), directly or indirectly, of securities of the Corporation representing fifteen percent (15%) or more of the combined voting power of the Corporation&#8217;s then outstanding securities, unless the change in relative Beneficial Ownership of the Corporation&#8217;s securities by any Person results solely from a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ii.&#160;&#160;&#160;&#160;Change in Board of Directors.  During any period of two (2) consecutive years (not including any period prior to the execution of this Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a person who has entered into an agreement with the Corporation to effect a transaction described herein) whose election by the Board or nomination for election by the Corporation&#8217;s stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Board;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">iii.&#160;&#160;&#160;&#160;Corporate Transactions.  The effective date of a merger or consolidation of the Corporation with any other entity, other than a merger or consolidation which would result in the voting securities of the Corporation outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity in any such transaction) more than fifty percent (50%) of the combined voting power of the voting securities of such surviving entity outstanding immediately after such merger or consolidation and with the power to elect at least a majority of the board of directors or other governing body of such Surviving Entity;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">iv.&#160;&#160;&#160;&#160;Liquidation.  The approval by the stockholders of the Corporation of a complete liquidation of the Corporation or an agreement for the sale or disposition by the Corporation of all or substantially all of the Corporation&#8217;s assets; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">v.&#160;&#160;&#160;&#160;Other Events.  There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act (as defined below), whether or not the Corporation is then subject to such reporting requirement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Corporate Status</font><font style="font-family:inherit;font-size:10pt;">&#8221; describes the status of an individual who is or was a Representative of an Enterprise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Corporation</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall have the meaning ascribed to such term in the Preamble hereto.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">DGCL</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall have the meaning ascribed to such term in the Recitals hereto.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Enterprise</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean the Corporation and any other Person, employee benefit plan, joint venture or other enterprise of which Indemnitee is or was serving at the request of the Corporation as a Representative.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exchange Act</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean the Securities Exchange Act of 1934, as amended from time to time, and the rules&#160;and regulations thereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Expenses</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall include all reasonable costs, expenses, fees and charges, including, without limitation, attorneys&#8217; fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding. Expenses also shall include, without limitation, (i)&#160;expenses incurred in connection with any appeal resulting from any Proceeding, including, without limitation, the premium, security for, and other costs relating to any cost bond, supersedes bond, or other appeal bond or its equivalent, (ii)&#160;for purposes of Section&#160;12(d)&#160;only, expenses incurred by Indemnitee in connection with the interpretation, enforcement or defense of Indemnitee&#8217;s rights under this Agreement, by litigation or otherwise, (iii)&#160;any federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement (on a grossed up basis), (iv) excise taxes and penalties under the Employee Retirement Income Security Act of 1974, and (v)&#160;any interest, assessments or other charges in respect of the foregoing.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Indemnitee</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall have the meaning ascribed to such term in the Preamble hereto.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Indemnity Obligations</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean all obligations of the Corporation to Indemnitee under this Agreement, including, without limitation, the Corporation&#8217;s obligations to provide indemnification to Indemnitee and advance Expenses to Indemnitee under this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Independent Counsel</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five (5)&#160;years has been, retained to represent: (i)&#160;the Corporation or Indemnitee in any matter material to either such party (other than with respect to matters concerning the Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements) or (ii)&#160;any other party to the Proceeding giving rise to a claim for indemnification hereunder; </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:10pt;">, that the term &#8220;Independent Counsel&#8221; shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Corporation or Indemnitee in an action to determine Indemnitee&#8217;s rights under this Agreement.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Liabilities</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean all claims, liabilities, damages, losses, judgments, orders, fines, penalties and other amounts payable in connection with, arising out of, in respect of, relating to or occurring as a direct or indirect consequence of, any Proceeding, including, without limitation, amounts paid in whole or partial settlement of any Proceeding, all Expenses incurred in complying with any judgment, order or decree issued or entered in connection with any Proceeding or any settlement agreement, stipulation or consent decree entered into or issued in settlement of any Proceeding, and any consequential damages resulting from any Proceeding or the settlement, judgment, or result thereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Person</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean any individual, corporation, partnership, limited partnership, limited liability company, trust, governmental agency or body or any other legal entity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Proceeding</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall include any threatened, pending or completed action, claim, suit, counterclaim, cross claim, arbitration, mediation, alternate dispute resolution mechanism, formal or informal hearing, inquiry or investigation,  administrative hearing or any other actual, threatened or completed judicial, administrative or arbitration proceeding (including, without limitation, any such proceeding under the Securities Act of 1933, as amended, or the Exchange Act or any other federal law, state law, statute or regulation), whether brought in the right of the Corporation or otherwise, and whether of a civil, criminal, administrative legislative or investigative nature, including any appeal therefrom, in which Indemnitee was, is or will be, or is threatened to be, involved as a party, potential party, non-party witness or otherwise (i)&#160;by reason of the fact that Indemnitee is or was a Representative of the Corporation, (ii)&#160;by reason of any actual or alleged action taken by Indemnitee (or a failure to take action by Indemnitee) or of any action (or failure to act) on Indemnitee&#8217;s part while acting as Representative of the Corporation or (iii)&#160;by reason of the fact that Indemnitee is or was serving at the request of the Corporation as a Representative of another Person, whether or not serving in such capacity at the time any liability or Expense is incurred for which indemnification, reimbursement, or advancement of Expenses can be provided under this Agreement.  If the Indemnitee believes in good faith that a given situation may lead to or culminate in the institution of a Proceeding, this shall be considered a Proceeding under this paragraph.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Representative</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall have the meaning ascribed to such term in the Recitals hereto.&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Sponsor Entities</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean funds affiliated with Avista Capital Partners and any of their respective Affiliates who beneficially own shares of common stock, par value $0.001 per share, of the Corporation, and any securities into which such shares of common stock shall have been changed or any securities resulting from any reclassification or recapitalization of such shares of common stock from time to time; </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:10pt;">, that neither the Corporation nor any of its subsidiaries shall be considered Sponsor Entities hereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Submission Date</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall have the meaning ascribed to such term in Section&#160;11(a).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;For the purpose hereof, references to &#8220;fines&#8221; shall include any excise tax assessed with respect to any employee benefit plan; references to &#8220;serving at the request of the Corporation&#8221; shall include any service as a Representative of the Corporation which imposes duties on, or involves services by, such Representative with respect to an employee benefit plan, its participants or beneficiaries; and a Person who acted in good faith and in a manner he/she reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in manner &#8220;not opposed to the best interests of the Corporation&#8221; as referred to in this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 2.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Indemnity in Third-Party Proceedings</font><font style="font-family:inherit;font-size:10pt;">. The Corporation shall indemnify and hold harmless Indemnitee, to the fullest extent permitted by applicable law, from and against all Liabilities and Expenses suffered or incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection with or as a consequence of any Proceeding (other than any Proceeding brought by or in the right of the Corporation to procure a judgment in its favor which </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">shall be governed by the provisions set forth in Section&#160;3 below), if Indemnitee acted in good faith and in a manner he/she reasonably believed to be in, or not opposed to, the best interests of the Corporation and, in the case of a criminal proceeding, had no reasonable cause to believe that his conduct was unlawful. For the avoidance of doubt, a finding, admission or stipulation that an Indemnitee has not met such applicable standard of conduct or that Indemnitee acted with gross negligence or recklessness shall not, of itself, be a defense to any action pursuant to this Agreement or create a presumption that such Indemnitee has failed to meet the standard of conduct required for indemnification in this Section&#160;2.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 3.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Indemnity in Proceedings by or in the Right of the Corporation</font><font style="font-family:inherit;font-size:10pt;">. The Corporation shall indemnify and hold harmless Indemnitee, to the fullest extent permitted by applicable law, from and against all Liabilities and Expenses suffered or incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection with or as a consequence of any Proceeding brought by or in the right of the Corporation to procure a judgment in its favor, or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he/she reasonably believed to be in, or not opposed, to the best interests of the Corporation. No indemnification for Liabilities and Expenses shall be made under this Section&#160;3 in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudged by a court to be liable to the Corporation, unless and only to the extent that the Delaware Court of Chancery or any court in which the Proceeding was brought shall determine upon application that, despite the adjudication of liability, but in view of all the circumstances of the case,&#160;Indemnitee is fairly and reasonably entitled to indemnification for such Liabilities and Expenses which the Court of Chancery or such other court shall deem proper. For the avoidance of doubt, a finding, admission or stipulation that an Indemnitee has not met such applicable standard of conduct or that Indemnitee acted with gross negligence or recklessness shall not, of itself, be a defense to any action pursuant to this Agreement or create a presumption that such Indemnitee has failed to meet the standard of conduct required for indemnification in this Section&#160;3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 4.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Indemnification for Expenses of a Party Who is Wholly or Partly Successful</font><font style="font-family:inherit;font-size:10pt;">. Notwithstanding any other provisions of this Agreement, and without limiting the rights of Indemnitee under any other provision hereof, to the extent that Indemnitee is a party to (or a participant in) any Proceeding and is successful on the merits or otherwise (including, without limitation, settlement thereof), as to one or more but less than all claims, issues or matters in such Proceeding, in whole or in part, then the Corporation shall indemnify Indemnitee, to the fullest extent permitted by applicable law, against all Liabilities and Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf, in connection with or as a consequence of each successfully resolved claim, issue or matter. For purposes of this Section&#160;4 and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 5.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Partial Indemnification</font><font style="font-family:inherit;font-size:10pt;">. If Indemnitee is entitled under any provision of this Agreement to indemnification by the Corporation for some or a portion of Expenses, but not, however, for the total amount thereof, the Corporation shall nevertheless indemnify Indemnitee for the portion thereof to which Indemnitee is entitled.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 6.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Indemnification for Expenses of a Witness</font><font style="font-family:inherit;font-size:10pt;">. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of Indemnitee&#8217;s Corporate Status, a witness in any Proceeding to which Indemnitee is not a party,&#160;Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Liabilities and Expenses suffered or incurred by him or on his behalf in connection therewith.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 7.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Additional Indemnification</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Notwithstanding any limitation in Sections 2, 3, 4 or 5, the Corporation shall indemnify Indemnitee to the fullest extent permitted by applicable law if Indemnitee is a party to, or threatened to be made a party to, any Proceeding (including, without limitation, a Proceeding by or in the right of the Corporation to procure a judgment in its favor), by reason of Indemnitee&#8217;s Corporate Status.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;For purposes of Section 7(a), the meaning of the phrase &#8220;to the fullest extent permitted by applicable law&#8221; shall include, but not be limited to: </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;to the fullest extent permitted by the provision of the DGCL that authorizes or contemplates additional indemnification by agreement, or the corresponding provision of any amendment to, or replacement of, the DGCL, and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;to the fullest extent authorized or permitted by any amendments to, or replacements of, the DGCL adopted after the date of this Agreement that increase the extent to which a corporation may indemnify its officers and directors.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 8.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exclusions</font><font style="font-family:inherit;font-size:10pt;">. Notwithstanding any provision in this Agreement, the Corporation shall not be obligated under this Agreement to make any indemnification payment in connection with any claim involving Indemnitee: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;subject to Section 14, for (i) an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Corporation within the meaning of Section 16(b) of the Exchange Act (as defined in Section 1(a) hereof) or similar provisions of state statutory law or common law, (ii) any reimbursement of the Corporation by the Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by the Indemnitee from the sale of securities of the Corporation, as required in each case under the Exchange Act (including any such reimbursements that arise from an accounting restatement of the Corporation pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Sarbanes-Oxley Act</font><font style="font-family:inherit;font-size:10pt;">&#8221;), or the payment to the Corporation of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 306 of the Sarbanes-Oxley Act) or (iii) any reimbursement of the Corporation by Indemnitee of any compensation pursuant to any compensation recoupment or clawback policy adopted by the Board or the compensation committee of the Board to comply with stock exchange listing requirements implementing Section 10D of the Exchange Act; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;except as provided in Section 13(d) of this Agreement, in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Corporation or its directors, officers, employees or other indemnitees, unless (i) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation or (ii) the Corporation provides the indemnification, in its sole discretion, pursuant to the powers vested in the Corporation under applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 9.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Advances of Expenses</font><font style="font-family:inherit;font-size:10pt;">. Notwithstanding any provision of this Agreement to the contrary (other than Section 13(d)), the Corporation shall advance, to the fullest extent permitted by law, Expenses incurred by Indemnitee in connection with any Proceeding (or part of any Proceeding) not initiated by Indemnitee or any Proceeding initiated by Indemnitee with the prior approval of the Board, and such advancement shall be made within ten (10)&#160;days after the receipt by the Corporation of a statement or statements requesting such advances from time to time, whether prior to, or after, final disposition of any Proceeding. Advances shall be unsecured and interest free. Indemnitee shall be entitled to continue to receive advancement of Expenses pursuant to this Section 9 unless and until the matter of Indemnitee&#8217;s entitlement to indemnification hereunder has been finally adjudicated by court order or judgment from which no further right or appeal exists. Advances shall be made without regard to Indemnitee&#8217;s ability to repay Expenses and without regard to Indemnitee&#8217;s ultimate entitlement to indemnification under the other provisions of this Agreement. In accordance with Section 13(d), advances shall include any and all Expenses incurred pursuing an action to enforce this right of advancement, including, without limitation, Expenses incurred preparing and forwarding statements to the Corporation to support the advances claimed. Indemnitee shall qualify for advances upon the execution and delivery to the Corporation of this Agreement, which shall constitute an undertaking, providing that Indemnitee undertakes to repay the amounts advanced (without interest) to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Corporation.  No other form of undertaking shall be required other than the execution of this Agreement.  This Section 9 shall not apply to any claim made by Indemnitee for which indemnity is excluded pursuant to Section 8.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 10.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Procedure for Notification and Defense of Claim</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Indemnitee shall notify the Corporation in writing of any Proceeding with respect to which Indemnitee intends to seek indemnification or advancement of Expenses hereunder as soon as reasonably practicable following the receipt by Indemnitee of written notice thereof. The written notification to the Corporation shall include a description of the nature of the Proceeding and the facts underlying the Proceeding. To obtain indemnification under this Agreement,&#160;Indemnitee shall submit to the Corporation a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification following the final disposition of such Proceeding. Any delay or failure by Indemnitee to notify the Corporation hereunder will not relieve the Corporation from any liability which it may have to Indemnitee hereunder or otherwise than under this Agreement, nor shall such delay or failure constitute a waiver by Indemnitee of any rights under this Agreement.  The Secretary of the Corporation shall, promptly upon receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested indemnification. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;In the event Indemnitee seeks indemnification and/or advancement of Expenses with respect to any Proceeding,&#160;Indemnitee may, at Indemnitee&#8217;s option, (i)&#160;retain legal counsel selected by Indemnitee and approved by the Corporation (which approval shall not to be unreasonably withheld, conditioned or delayed) to defend Indemnitee in such Proceeding, at the sole expense of the Corporation or (ii)&#160;have the Corporation assume the defense of Indemnitee in the Proceeding, in which case the Corporation shall assume the defense of such Proceeding with legal counsel selected by the Corporation and approved by Indemnitee (which approval shall not be unreasonably withheld, conditioned or delayed) within ten (10)&#160;days of the Corporation&#8217;s receipt of written notice of Indemnitee&#8217;s election to cause the Corporation to do so. If the Corporation is required to assume the defense of any such Proceeding, it shall engage legal counsel for such defense, and shall be solely responsible for all Expenses of such legal counsel and otherwise of such defense. Such legal counsel may represent both Indemnitee and the Corporation (and/or any other party or parties entitled to be indemnified by the Corporation with respect to such matter) unless, in the reasonable opinion of legal counsel to Indemnitee, there is a conflict of interest between Indemnitee and the Corporation (or any other such party or parties) or there are legal defenses available to Indemnitee that are not available to the Corporation (or any such other party or parties). Notwithstanding either party&#8217;s assumption of responsibility for defense of a Proceeding, each party shall have the right to engage separate legal counsel at its own expense. The party having responsibility for defense of a Proceeding shall provide the other party and its legal counsel with all copies of pleadings and material correspondence relating to the Proceeding. Indemnitee and the Corporation shall reasonably cooperate in the defense of any Proceeding with respect to which indemnification is sought hereunder, regardless of whether the Corporation or Indemnitee assumes the defense thereof. Indemnitee may not settle or compromise any Proceeding without the prior written consent of the Corporation (which consent shall not be unreasonably withheld, conditioned or delayed). The Corporation may not settle or compromise any Proceeding without the prior written consent of Indemnitee (which consent shall not be unreasonably withheld, conditioned or delayed).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 11.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Procedure Upon Application for Indemnification</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Upon receipt of a written request by Indemnitee for indemnification pursuant to Section&#160;10(a) (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Submission Date</font><font style="font-family:inherit;font-size:10pt;">&#8221;), if any determination by the Corporation is required by applicable law with respect to Indemnitee&#8217;s ultimate entitlement to indemnification, such determination shall be made (i) if a Change in Control shall have occurred, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee; or (ii) if a Change in Control shall not have occurred, (A) by a majority vote of the Disinterested Directors, even though less than a quorum of the Board, (B) by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum of the Board, (C) if there are no such Disinterested Directors or, if such Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee or (D) if so directed by the Board, by the stockholders of the </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporation. If it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten (10) days after such determination. Indemnitee shall cooperate with the Person(s)&#160;making such determination with respect to Indemnitee&#8217;s entitlement to indemnification, including, without limitation, providing to such Person(s), upon reasonable advance request, any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any Expenses incurred by Indemnitee in so cooperating with the Person(s)&#160;making such determination shall be borne by the Corporation (irrespective of the determination as to Indemnitee&#8217;s entitlement to indemnification) and the Corporation hereby indemnifies and agrees to hold Indemnitee harmless therefrom. The Corporation will not deny any written request for indemnification hereunder made in good faith by Indemnitee unless a determination as to Indemnitee&#8217;s entitlement to such indemnification described in this Section&#160;11(a)&#160;has been made. The Corporation agrees to pay Expenses of the Independent Counsel referred to above and to fully indemnify the Independent Counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;In the event that the determination of entitlement to indemnification is to be made by the Independent Counsel pursuant to Section&#160;11(a)&#160;hereof, the Independent Counsel shall be selected as provided in this Section&#160;11(b).  If a Change in Control has not occurred, the Independent Counsel shall be selected by the Board, and the Corporation shall give written notice to Indemnitee advising Indemnitee of the identity of the Independent Counsel so selected.  If a Change in Control has occurred, the Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Board, in which event the preceding sentence shall apply), and Indemnitee shall give written notice to the Corporation advising it of the identity of the Independent Counsel so selected.  In either event, Indemnitee or the Corporation, as the case may be, may, within ten (10) days after such written notice of selection shall have been given, deliver to the Corporation or to Indemnitee, as the case may be, a written objection to such selection; </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:10pt;">, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of &#8220;Independent Counsel&#8221; as defined in Section&#160;1(a) of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion.  Absent a proper and timely objection, the person so selected shall act as Independent Counsel.  If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or the Delaware Court of Chancery has determined that such objection is without merit.  If, within twenty (20) days after the later of submission by Indemnitee of a written request for indemnification pursuant to Section&#160;10(a) hereof and the final disposition of the Proceeding, no Independent Counsel shall have been selected and not objected to, either the Corporation or Indemnitee may petition the Delaware Court of Chancery for resolution of any objection which shall have been made by the Corporation or Indemnitee to the other's selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by such court or by such other person as such court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section&#160;11(a) hereof.  Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 13(a) of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 12.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Presumptions and Effect of Certain Proceedings</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;In making a determination with respect to entitlement to indemnification hereunder, the Person(s)&#160;making such determination shall, to the fullest extent permitted by law, presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section&#160;10(a)&#160;of this Agreement, and the Corporation shall, to the fullest extent permitted by law, have the burden of proof to overcome that presumption with clear and convincing evidence in connection with the making by any Person(s)&#160;of any determination contrary to that presumption. Neither the failure of the Corporation (including, without limitation, by its directors or independent legal counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the applicable standard of conduct, nor an actual determination by the Corporation (including, without limitation, by its directors or independent legal counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Subject to Section&#160;12(e), if the Person(s)&#160;empowered or selected under Section&#160;10 hereof to determine whether Indemnitee is entitled to indemnification shall not have made a determination within sixty (60) days after receipt by the Corporation of the request therefore, the requisite determination of entitlement to indemnification shall, to the fullest extent permitted by law, be deemed to have been made and Indemnitee shall be entitled to such indemnification, absent a prohibition of such indemnification under applicable law; </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:10pt;">, that such sixty (60) day period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if (i)&#160;the determination is to be made by the Independent Counsel and there is an objection to the selection of the Independent Counsel and (ii)&#160;the Person(s) making such determination requires such additional time for the obtaining or evaluating of documentation and/or information relating thereto; and provided, further, that the foregoing provisions of this Section 12(b) shall not apply (i) if the determination of entitlement to indemnification is to be made by the stockholders pursuant to Section 11(a) of this Agreement and if </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(</font><font style="font-family:inherit;font-size:10pt;">A) within fifteen (15) days after receipt by the Corporation of the request for such determination the Board has resolved to submit such determination to the stockholders for their consideration at an annual meeting thereof to be held within seventy-five (75) days after such receipt and such determination is made thereat, or (B) a special meeting of stockholders is called within fifteen (15) days after such receipt for the purpose of making such determination, such meeting is held for such purpose within sixty (60) days after having been so called and such determination is made thereat. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">nolo contendere</font><font style="font-family:inherit;font-size:10pt;">&#32;or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he/she reasonably believed to be in, or not opposed to, the best interests of the Corporation or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that Indemnitee&#8217;s conduct was unlawful.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Reliance as Safe Harbor</font><font style="font-family:inherit;font-size:10pt;">. For purposes of any determination of good faith,&#160;Indemnitee shall be deemed to have acted in good faith if Indemnitee&#8217;s action is based on the records or books of account of the Enterprise, including financial statements, or on information supplied to Indemnitee by the officers of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise, or on information or records given or reports made to the Enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by the Enterprise. The provisions of this Section&#160;12(d)&#160;shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Actions of Others</font><font style="font-family:inherit;font-size:10pt;">. The knowledge and/or actions, or failure to act, of any Representative (other than Indemnitee) of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 13.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Remedies of Indemnitee</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Subject to Section&#160;12(d), in the event that (i)&#160;a determination is made pursuant to Section&#160;11 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii)&#160;advancement of Expenses is not timely made pursuant to Section&#160;9 of this Agreement, (iii)&#160;no determination of entitlement to indemnification shall have been made pursuant to Section&#160;11(a)&#160;of this Agreement within ninety (90) days after the Submission Date, (iv)&#160;payment of indemnification is not made pursuant to Section&#160;4, 5, 6 or 11(a)&#160;of this Agreement within ten (10)&#160;days after receipt by the Corporation of a written </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">request therefore, (v)&#160;payment of indemnification pursuant to Section&#160;2, 3 or 7 of this Agreement is not made within ten (10)&#160;days after a determination has been made that Indemnitee is entitled to indemnification or (vi)&#160;in the event that the Corporation or any other person takes or threatens to take any action to declare this Agreement void or unenforceable, or institutes any litigation or other action or Proceeding designed to deny, or to recover from,&#160;Indemnitee, the benefits provided or intended to be provided to Indemnitee hereunder,&#160;Indemnitee shall be entitled to an adjudication by a court of Indemnitee&#8217;s entitlement to such indemnification and/or advancement of Expenses. Alternatively,&#160;Indemnitee, at Indemnitee&#8217;s option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules&#160;of the American Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within one hundred and eighty (180) days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 13(a). The Corporation shall not oppose Indemnitee&#8217;s right to seek any such adjudication or award in arbitration.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;In the event that a determination shall have been made pursuant to Section&#160;11&#160;of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section&#160;13 shall be conducted in all respects as a </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">de novo</font><font style="font-family:inherit;font-size:10pt;">&#32;trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant to this Section&#160;13, the Corporation shall have the burden of proving by clear and convincing evidence Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;If a determination shall have been made pursuant to Section&#160;11&#160;of this Agreement that Indemnitee is entitled to indemnification, the Corporation shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section&#160;13, absent (i)&#160;a misstatement by the Indemnitee of a material fact, or an omission by the Indemnitee of a material fact necessary to make the Indemnitee&#8217;s statement not materially misleading, in connection with the request for indemnification, or (ii)&#160;a prohibition of such indemnification under applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;The Corporation shall, to the fullest extent not prohibited by law, be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section&#160;13 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Corporation is bound by all the provisions of this Agreement. It is the intent of the Corporation that, to the fullest extent permitted by law, Indemnitee not be required to incur legal fees or other Expenses associated with the interpretation, enforcement or defense of Indemnitee&#8217;s rights under this Agreement by litigation or otherwise because the cost and expense thereof would substantially detract from the benefits intended to be extended to Indemnitee hereunder. In addition, the Corporation shall, to the fullest extent permitted by law, indemnify Indemnitee against any and all such Expenses and, if requested by Indemnitee, shall (within ten (10)&#160;days after receipt by the Corporation of a written request therefore) advance, to the fullest extent not prohibited by law, such Expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advancement of Expenses from the Corporation under this Agreement or under any directors&#8217; and officers&#8217; liability insurance policies maintained by the Corporation if, in the case of indemnification, Indemnitee is wholly successful on the underlying claims; if Indemnitee is not wholly successful on the underlying claims, then such indemnification shall be only in connection with each successfully resolved claim, issue or matter, or otherwise as permitted by law, whichever is greater.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification under this Agreement shall be required to be made prior to the final disposition of the Proceeding; </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">provided,</font><font style="font-family:inherit;font-size:10pt;">&#32;that in absence of any such determination with respect to such Proceeding, the Corporation shall pay Liabilities and advance Expenses with respect to such Proceeding as if Indemnitee has been determined to be entitled to indemnification and advancement of Expenses with respect to such Proceeding.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 14.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Non-Exclusivity; Survival of Rights; Insurance; Subrogation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;The rights of indemnification and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Certificate of Incorporation, the Bylaws, any agreement, a vote of stockholders, a resolution of directors or otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in Indemnitee&#8217;s Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in applicable law, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the Certificate of Incorporation, the Bylaws and/or this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;The Corporation hereby acknowledges that Indemnitee may have certain rights to indemnification, advancement of Expenses and/or insurance provided by one or more Persons with whom or which Indemnitee may be associated (including, without limitation, any Sponsor Entity). The Corporation hereby acknowledges and agrees that (i)&#160;the Corporation shall be the indemnitor of first resort with respect to any Proceeding, Expense, Liability or matter that is the subject of the Indemnity Obligations, (ii)&#160;the Corporation shall be primarily liable for all Indemnity Obligations and any indemnification afforded to Indemnitee in respect of any Proceeding, Expense, Liability or matter that is the subject of Indemnity Obligations, whether created by law, organizational or constituent documents, contract (including, without limitation, this Agreement) or otherwise, (iii)&#160;any obligation of any other Persons with whom or which Indemnitee may be associated (including, without limitation, any Sponsor Entity) to indemnify Indemnitee and/or advance Expenses to Indemnitee in respect of any proceeding shall be secondary to the obligations of the Corporation hereunder, (iv)&#160;the Corporation shall be required to indemnify Indemnitee and advance Expenses to Indemnitee hereunder to the fullest extent provided herein without regard to any rights Indemnitee may have against any other Person with whom or which Indemnitee may be associated (including, without limitation, any Sponsor Entity) or insurer of any such Person and (v)&#160;the Corporation irrevocably waives, relinquishes and releases any other Person with whom or which Indemnitee may be associated (including, without limitation, any Sponsor Entity) from any claim of contribution, subrogation or any other recovery of any kind in respect of amounts paid by the Corporation hereunder. In the event that any other Person with whom or which Indemnitee may be associated (including, without limitation, any Sponsor Entity) or their insurers advances or extinguishes any liability or loss which is the subject of any Indemnity Obligation owed by the Corporation or payable under any insurance policy provided under this Agreement, such payor shall have a right of subrogation against the Corporation or its insurer or insurers for all amounts so paid which would otherwise be payable by the Corporation or its insurer or insurers under this Agreement. In no event will payment of an Indemnity Obligation of the Corporation under this Agreement by any other Person with whom or which Indemnitee may be associated (including, without limitation, any Sponsor Entity) or their insurers, affect the obligations of the Corporation hereunder or shift primary liability for any Indemnity Obligation to any other Person with whom or which Indemnitee may be associated (including, without limitation, any Sponsor Entity). Any indemnification and/or insurance or advancement of Expenses provided by any other Person with whom or which Indemnitee may be associated (including, without limitation, any Sponsor Entity), with respect to any liability arising as a result of Indemnitee&#8217;s Corporate Status or capacity as an officer or director of any Person, is specifically in excess of any Indemnity Obligation of the Corporation or valid and any collectible insurance (including, without limitation, any malpractice insurance or professional errors and omissions insurance) provided by the Corporation under this Agreement, and any obligation to provide indemnification and/or insurance or advance Expenses provided by any other Person with whom or which Indemnitee may be associated (including, without limitation, any Sponsor Entity) shall be reduced </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">by any amount that Indemnitee collects from the Corporation as an indemnification payment or advancement of Expenses pursuant to this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;The Corporation shall use its best efforts to obtain and maintain in full force and effect an insurance policy or policies providing liability insurance for Representatives of the Corporation or of any other Enterprise, and Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such Representative under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Corporation maintains an insurance policy or policies providing liability insurance for Representatives of the Corporation or of any other Enterprise, the Corporation shall give prompt notice of the commencement of such Proceeding to the insurers in accordance with the procedures set forth in the respective policy or policies. The Corporation shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies.  In the event of a Change in Control or the Corporation&#8217;s becoming insolvent, the Corporation shall maintain in force any and all insurance policies then maintained by the Corporation in providing insurance (directors&#8217; and officers&#8217; liability, fiduciary, employment practices or otherwise) in respect of Indemnitee for a period of six years thereafter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;In the event of any payment under this Agreement, the Corporation shall not be subrogated to, and hereby waives any rights to be subrogated to, any rights of recovery of Indemnitee, including, without limitation, rights of indemnification provided to Indemnitee from any other Person or entity with whom Indemnitee may be associated (including, without limitation, any Sponsor Entity) as well as any rights to contribution that might otherwise exist; </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:10pt;">, that the Corporation shall be subrogated to the extent of any such payment of all rights of recovery of Indemnitee under insurance policies of the Corporation or any of its subsidiaries, and the Indemnitee shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Corporation to brings suit to enforce such rights.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;The indemnification and contribution provided for in this Agreement will remain in full force and effect regardless of any investigation made by or on behalf of Indemnitee.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 15.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Duration of Agreement; Not Employment Contract</font><font style="font-family:inherit;font-size:10pt;">. This Agreement shall continue until and terminate upon the latest of: (a)&#160;ten (10)&#160;years after the date that Indemnitee shall have ceased to serve as a Representative of the Corporation or any other Enterprise and (b)&#160;one (1)&#160;year after the final termination of any Proceeding then pending in respect of which Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any proceeding commenced by Indemnitee pursuant to Section&#160;13 of this Agreement relating thereto. This Agreement shall be binding upon the Corporation and its successors and assigns and shall inure to the benefit of Indemnitee and Indemnitee&#8217;s heirs, executors and administrators. The Corporation shall require and cause any direct or indirect successor (whether by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Corporation, by written agreement, expressly or to assume and agree to perform this agreement in the same manner and to the same extent that the Corporation would be required to perform if no such succession had taken place.&#160; This Agreement shall not be deemed an employment contract between the Corporation (or any of its subsidiaries or any Enterprise) and Indemnitee. Indemnitee specifically acknowledges that Indemnitee&#8217;s employment with the Corporation (or any of its subsidiaries or any Enterprise), if any, is at will, and Indemnitee may be discharged at any time for any reason, with or without cause, except as may be otherwise provided in any written employment contract between Indemnitee and the Corporation (or any of its subsidiaries or any Enterprise), other applicable formal severance policies duly adopted by the Board, or, with respect to service as a Representative of the Corporation, by the Certificate of Incorporation, Bylaws and the DGCL.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 16.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:10pt;">. If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a)&#160;the validity, legality and enforceability of the remaining provisions of this Agreement (including, without limitation, each portion of any Section&#160;of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">permitted by law; (b)&#160;such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c)&#160;to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any Section&#160;of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 17.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Enforcement</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;The Corporation expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve as a Representative of the Corporation, and the Corporation acknowledges that Indemnitee is relying upon this Agreement in serving or continuing to serve as a Representative of the Corporation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof; </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:10pt;">, that this Agreement is a supplement to and in furtherance of the Bylaws and applicable law, and shall not be deemed a substitute therefore, nor to diminish or abrogate any rights of Indemnitee thereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; The Corporation shall not seek from a court, or agree to, a &#8220;bar order&#8221; which would have the effect of prohibiting or limiting the Indemnitee&#8217;s right to receive advancement of expenses under this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 18.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Modification and Waiver</font><font style="font-family:inherit;font-size:10pt;">. No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by the parties thereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing waiver. The failure of any party to enforce any of the provisions of this Agreement shall in no way be construed as a waiver of such provisions and shall not affect the right of such party thereafter to enforce each and every provision of this Agreement in accordance with its terms.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 19.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:10pt;">. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given if (a)&#160;delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, (b)&#160;mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed, (c)&#160;mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have been directed or (d)&#160;sent by facsimile transmission, with receipt of oral confirmation that such transmission has been received:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;If to Indemnitee, at the address indicated on the signature page&#160;of this Agreement, or such other address as Indemnitee shall provide to the Corporation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#010000;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;If to the Corporation to:</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OptiNose,&#160;Inc.</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1020 Stony Hill Road, Suite&#160;300</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Yardley, Pennsylvania 19067</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Attn: Chief Legal Officer</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Facsimile: (267) 395-2119</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or to any other address as may have been furnished to Indemnitee by the Corporation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 20.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Contribution</font><font style="font-family:inherit;font-size:10pt;">. To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Corporation, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">13</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of the Proceeding in order to reflect (a)&#160;the relative benefits received by the Corporation and Indemnitee as a result of the event(s)&#160;and/or transaction(s)&#160;giving cause to such Proceeding; and/or (b)&#160;the relative fault of the Corporation (and its directors, officers, employees and agents) and Indemnitee in connection with such event(s)&#160;and/or transaction(s).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 21.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Applicable Law and Consent to Jurisdiction</font><font style="font-family:inherit;font-size:10pt;">. This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section 13(a), the Corporation and Indemnitee hereby irrevocably and unconditionally (a)&#160;agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware Court of Chancery, and not in any other state or federal court in the United States of America or any court in any other country, (b)&#160;consent to submit to the exclusive jurisdiction of the Delaware Court of Chancery for purposes of any action or proceeding arising out of or in connection with this Agreement, (c)&#160;waive any objection to the laying of venue of any such action or proceeding in the Delaware Court of Chancery and (d)&#160;waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court of Chancery has been brought in an improper or inconvenient forum.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 22.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Counterparts</font><font style="font-family:inherit;font-size:10pt;">. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.&#160; Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 23.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Third-Party Beneficiaries</font><font style="font-family:inherit;font-size:10pt;">. The Sponsor Entities are intended third-party beneficiaries of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 24.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Miscellaneous</font><font style="font-family:inherit;font-size:10pt;">. Use of the masculine pronoun shall be deemed to include usage of the feminine pronoun where appropriate. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[SIGNATURE PAGE FOLLOWS]</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">14</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><a name="sA20F19AFB5BD54FC99BC1B996D491F1E"></a></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and year first above written.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OPTINOSE,&#160;INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:  Peter Miller</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:  Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[Signature Page&#160;to Indemnification Agreement]</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">INDEMNITEE:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[Signature Page&#160;to Indemnification Agreement]</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">16</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Schedule to Exhibit 10.1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following directors and executive officers are parties to an Indemnification Agreement with the Company, each of which are substantially identical in all material respects to the representative Indemnification Agreement filed herewith as Exhibit&#160;10.1 except as to the name of the signatory and the date of each signatory&#8217;s Indemnification Agreement, which are listed below. The actual Indemnification Agreements are omitted pursuant to Instruction 2 to Item 601 of Regulation S-K.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:51%;"></td><td style="width:4%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">INDEMNITEE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">DATE</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Peter K. Miller</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 2, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ramy A. Mahmoud, M.D., M.P.H.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 2, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thomas E. Gibbs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 2, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Keith A. Goldan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 2, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Michael F. Marino</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 2, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William F. Doyle</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 1, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sriram Venkataraman</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 29, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Joshua A. Tamaroff</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 29, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Joseph C. Scodari</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 5, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wilhelmus Groenhuysen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 5, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sandra K. Helton</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 22, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Robert P. O'Neil</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 7, 2018</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">17</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>3
<FILENAME>exhibit1020_optn-vtmopnass.htm
<DESCRIPTION>EXHIBIT 10.20
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s6430E83F8A02206317BF4E9702B80DB0"></a></div><div><div style="line-height:150%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.20</font></div><div style="line-height:150%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div><div style="line-height:150%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;MANUFACTURING SERVICES AGREEMENT FOR SUBASSEMBLY</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(does not apply to cap)</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Manufacturing Services Agreement (this &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), dated as of December 21, 2018 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Effective Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;), is by and among, on the one hand, OptiNose US, Inc., duly organized and existing under the laws of Delaware and having offices located at 1020 Stony Hill Road, Suite 300, Yardley, PA 19067 (referred to herein as "</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OptiNose US</font><font style="font-family:inherit;font-size:12pt;">"), OptiNose UK Ltd. duly organized and existing under the laws of England and having offices located at Hunts Rise, South Marston Park, Wiltshire, SN3 4TG, England (referred to herein as "OptiNose UK"), and OptiNose AS, duly organized and existing under the laws of Norway and having offices located at Gaustadall&#233;en 21, 0349 Oslo, Norway (referred to herein as "</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OptiNose Norway</font><font style="font-family:inherit;font-size:12pt;">", and collectively with OptiNose US and OptiNose UK, &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OptiNose</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and, on the other hand, and Advance Mold &amp; Manufacturing, Inc., d/b/a Vision Technical Molding, a Connecticut corporation having offices located at 71 Utopia Road, Manchester, CT 06042 (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">VTM</font><font style="font-family:inherit;font-size:12pt;">&#8221;).    </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, VTM is a device development and manufacturing company skilled in the design, development, manufacture and assembly of medical devices and delivery systems and of their components; </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, VTM and OptiNose previously entered into a Molded Parts Agreement dated October 24, 2017 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Molded Parts Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;) whereby VTM molded various product components and product cap for OptiNose; </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, concurrent with the execution of this Agreement, the parties shall enter into an amendment to the Molded Parts Agreement whereby the parties will remove VTM&#8217;s future manufacture for OptiNose of various product components thereunder (other than the product cap noted therein); and</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, OptiNose desires to retain VTM to assemble and supply DSAs (as defined herein) for use by OptiNose in the subsequent production of Finished Product (as defined herein) under FDA and other regulations for the benefit of patients.  </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In consideration of the mutual covenants and agreements hereinafter set forth, the parties agree as follows:</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE I</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DEFINITIONS</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***].</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Action</font><font style="font-family:inherit;font-size:12pt;">&#8221;&#160;shall have the meaning set forth in Section 12.03.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Affiliate</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, another Person. The term </font></div><div><br></div><div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;control&#8221; (including the terms &#8220;controlled by&#8221; and &#8220;under common control with&#8221;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;&#160;shall have the meaning set forth in the preamble. </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Approved Vendor List</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean the list of vendors approved in writing by OptiNose and VTM to provide the Inventory or services specified in the Bill of Materials for a DSA.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Bill of Materials</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean the Inventory and OptiNose Components that comprise the DSA, as set forth in the Specifications.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Binding Period&#8221; </font><font style="font-family:inherit;font-size:12pt;">shall have the meeting set forth in Section 2.07.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#8220;Capacity&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;means the facility space, equipment, utilities, maintenance capabilities, infrastructure, human capital, and other capabilities in sufficient volume needed to manufacture DSAs, except for the OptiNose Equipment.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Confidential Information</font><font style="font-family:inherit;font-size:12pt;">&#8221;&#160;means any information that is treated as confidential by a Disclosing Party, whether tangible or intangible, including, without limitation, any and all specification information, techniques, discoveries, inventions, processes, know-how, patent applications and related information, inventor certificates, trade names, trade secrets, methods of production, technology, other proprietary information, other intellectual property, information pertaining to business operations and strategies, and information pertaining to pricing, and marketing of Finished Product or Inventory. Confidential Information shall not include information that: (a) is already known to the Receiving Party without restriction on use or disclosure prior to receipt of such information from the Disclosing Party; (b) is or becomes generally known by the public other than by breach of this Agreement by, or other wrongful act of, the Receiving Party; (c) is developed by the Receiving Party independently of, and without reference to, any Confidential Information of the Disclosing Party; or (d) is received by the Receiving Party from a third party who is not under any obligation to the Disclosing Party to maintain the confidentiality of such information.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Defaulting Party&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;shall have the meaning set forth in Section 15.02.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Defective Product</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any DSA that fails to conform to the Specifications, Quality Agreement or applicable Laws or that contains a Latent Defect or Patent Defect.   </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Deliverables</font><font style="font-family:inherit;font-size:12pt;">&#8221;&#160;means all documents, work product and other materials that are delivered to OptiNose hereunder or prepared by or on behalf of VTM in the course of performing the services under this Agreement.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Disclosing Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;&#160;means a party that discloses Confidential Information under this Agreement. </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;DSA&#8221; </font><font style="font-family:inherit;font-size:12pt;">means a device subassembly manufactured under this Agreement.    </font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Effective Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall have the meaning set forth in the preamble of this Agreement.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***].</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;FDA&#8221; </font><font style="font-family:inherit;font-size:12pt;">means the U.S. Food &amp; Drug Administration.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Excess Inventory</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean any DSA, partially completed DSA or Inventory (in each instance, to the extent procured by or on-order with VTM) that is not required for consumption to satisfy the next [***] of demand for DSAs under the then-current Forecast.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FD&amp;C Act</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Federal Food, Drug, and Cosmetic Act, as amended, and includes the rules, regulations and guidances promulgated thereunder (including, without limitation, current Good Manufacturing Practices).</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Finished Product&#8221; </font><font style="font-family:inherit;font-size:12pt;">means the full saleable product unit for XHANCE</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(formerly known as OPN-375) including without limitation active ingredient, delivery system, container closure system, and market package.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Forecast&#8221; </font><font style="font-family:inherit;font-size:12pt;">shall have the meeting set forth in Section 2.07.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Force Majeure Event</font><font style="font-family:inherit;font-size:12pt;">&#8221;&#160;shall have the meaning set forth in Section 17.01.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Intellectual Property Rights</font><font style="font-family:inherit;font-size:12pt;">&#8221;&#160;means all (a) patents, patent disclosures and inventions (whether patentable or not), (b) trademarks, service marks, trade dress, trade names, logos, corporate names and domain names, together with all of the goodwill associated therewith, (c) copyrights and copyrightable works (including computer programs), mask works, and rights in data and databases, (d) trade secrets, know-how and other confidential information, and (e) all other intellectual property rights, in each case whether registered or unregistered and including all applications for, and renewals or extensions of, such rights, and all similar or equivalent rights or forms of protection in any part of the world. </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Inventory</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean any materials, parts, components and inputs needed for VTM to manufacture the DSAs in accordance with the Specifications, whether made by VTM or procured from a third-party. (other than OptiNose Components) that are procured by or on-order with VTM in accordance with the applicable Lead Time for use in the manufacture of DSAs pursuant to a Purchase Order or Forecast from OptiNose, which may include (unless the context requires otherwise) Special Inventory and Minimum Order Inventory.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Inventory Procurement Lead Time</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean, with respect to any particular item of Inventory, the longer of (a) the lead time to obtain such Inventory as recorded on VTM&#8217;s system of record or (b) the actual lead time.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Latent Defect</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a defect where any DSA fails to conform to the Specifications, Quality Agreement or applicable Laws, which could not reasonably have been discovered upon receipt and physical inspection of the DSA by OptiNose or its designee.</font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Law</font><font style="font-family:inherit;font-size:12pt;">&#8221;&#160;means any statute (including without limitation the FD&amp;C Act), law, ordinance, regulation, rule, code, order, constitution, treaty, common law, judgment, decree, other requirement or guidance, or rule of law of any federal, state, local or foreign government or political subdivision thereof, or any arbitrator, court or tribunal of competent jurisdiction that is applicable: (a) to the obligations of VTM in supplying OptiNose with the DSAs, and  performing any related activities under other terms of this Agreement, or (b) to the obligations of OptiNose.  </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Lead Time</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean the Inventory Procurement Lead Time plus the manufacturing cycle time required from the delivery of the Inventory at VTM&#8217;s facility to the completion of the manufacture, assembly and test processes for the DSA.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Long Lead Time Inventory</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean Inventory with Lead Times exceeding the period covered by the accepted Purchase Orders for the DSA.  </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Losses</font><font style="font-family:inherit;font-size:12pt;">&#8221;&#160;means all losses, damages, liabilities, deficiencies, actions, judgments, interest, awards, penalties, fines, costs or expenses of whatever kind, including reasonable attorneys&#8217; fees and the cost of enforcing any right to indemnification hereunder and the cost of pursuing any insurance providers.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Minimum Order Inventory</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean Inventory purchased in excess of requirements for Purchase Orders and Forecast because of minimum lot sizes required by the vendor.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NDA</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a new drug application filed with the FDA.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Obsolete Inventory</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean any partially completed DSA or Inventory that is any of the following: (a) removed from the Bill of Materials for a DSA by an engineering change; or (b) no longer on an active Bill of Materials for a DSA.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OptiNose</font><font style="font-family:inherit;font-size:12pt;">&#8221;&#160;shall have the meaning set forth in the preamble.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;OptiNose Components&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;shall mean the consigned inventory that has the meaning set forth in Section 2.02(a).</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;OptiNose Equipment&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;means equipment (i) that can be used only for production of DSA&#8217;s under this Agreement or (ii) that OptiNose desires to have dedicated solely to the production of DSA&#8217;s under this Agreement. </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;OptiNose Indemnitee&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;shall have the meeting set forth in Section 12.02.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OptiNose Information</font><font style="font-family:inherit;font-size:12pt;">&#8221;&#160;means any documents, data, know-how, trade secrets, methodologies, software and other information (Confidential Information or otherwise) provided to VTM by or on behalf of OptiNose or developed by VTM on behalf of OptiNose, including without limitation computer programs, reports and specifications.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OptiNose Supply Relationship Manager</font><font style="font-family:inherit;font-size:12pt;">&#8221;&#160;shall have the meaning set forth in Section 7.01(a)</font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Patent Defect</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any instance where any DSA fails to conform to the Specifications, Quality Agreement or applicable Laws, where such failure is or was discoverable upon reasonable physical inspection upon receipt by OptiNose or its designee.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Person</font><font style="font-family:inherit;font-size:12pt;">&#8221;&#160;means an individual, corporation, partnership, joint venture, limited liability company, governmental authority, unincorporated organization, trust, association or other entity.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Production Materials</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean materials that are consumed in the production processes to manufacture DSAs including without limitation, [***]; Production Materials do not include any such production materials that have been specified by OptiNose.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Purchase Order</font><font style="font-family:inherit;font-size:12pt;">&#8221;&#160;shall have the meaning set forth in Section 2.09(a).</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Quality Agreement&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;means that Quality Agreement between OptiNose and VTM to be entered between the parties related to production of the DSAs.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Quantitative Defect&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;means any instance in which VTM has delivered a quantity that is [***] less than, or [***] greater than, the quantity stated in any invoice or bill of lading.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Receiving Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;&#160;means a party that receives or acquires Confidential Information directly or indirectly under this Agreement.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Special Inventory</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean any mutually agreed Inventory acquired by VTM to support flexibility, demand requirements, safety stock or pricing discounts.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Specifications&#8221; </font><font style="font-family:inherit;font-size:12pt;">shall mean the procedures, standards, quality control and other data and requirements for each DSA, which shall include, without limitation: Bills of Materials, designs, schematics, assembly drawings, process documentation, specifications according to the Device Master Record for the DSA, current revision number, and an Approved Vendor List.  </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Standard Cost</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean, as applicable, (a) the quoted cost of Inventory represented on the Bill of Materials current at the time such Inventory is acquired; or (b) the value of any services required to be performed hereunder on work-in-progress at the time such services are performed.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Term</font><font style="font-family:inherit;font-size:12pt;">&#8221;&#160;shall have the meaning set forth in Section 14.01.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">VTM</font><font style="font-family:inherit;font-size:12pt;">&#8221;&#160;shall have the meaning set forth in the preamble. </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">VTM Supply Relationship Manager</font><font style="font-family:inherit;font-size:12pt;">&#8221;&#160;shall have the meaning set forth in Section 6.01(a).</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">VTM Equipment</font><font style="font-family:inherit;font-size:12pt;">&#8221;&#160;means any and all equipment, systems, or facilities owned or leased, by or on behalf of VTM and made available for either direct or indirect performance by VTM under this Agreement.  </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">VTM Personnel</font><font style="font-family:inherit;font-size:12pt;">&#8221;&#160;means all employees, contractors, and consultants, engaged by VTM to perform under this Agreement.  </font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:46px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">VTM Tools</font><font style="font-family:inherit;font-size:12pt;">&#8221;&#160;means all documents, data, know-how, methodologies, software and other information provided by or used by VTM in connection with performance by VTM under this Agreement, in any case developed or acquired by VTM independently of this Agreement and of other services performed by VTM for OptiNose prior to or after the date hereof.    </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE II</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">MANUFACTURE AND SUPPLY OF DSAS</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 2.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Manufacture and Supply</font><font style="font-family:inherit;font-size:12pt;">.  During the Term and subject to the terms and conditions set forth herein, VTM shall procure Inventory and manufacture and assemble DSAs in compliance with the Specifications, Quality Agreement, applicable Laws and the other terms of this Agreement and deliver them to OptiNose or its designee.  Delivery of the DSAs shall be EXW (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Ex-Works</font><font style="font-family:inherit;font-size:12pt;">&#8221;) VTM&#8217;s manufacturing facility 71 Utopia Road, Manchester, CT 06042 (INCOTERMS 2000); [***] shall arrange for the DSAs to be picked up by a carrier identified and paid by [***] or its designee.  During the Term, VTM shall use [***] to ensure that it has the Capacity to meet all of OptiNose&#8217;s requirements for DSAs in a timely manner based on the applicable Forecast under this Agreement; provided that if new or additional OptiNose Equipment is required, VTM will inform OptiNose with sufficient lead time for such OptiNose Equipment to be acquired by OptiNose [***] and qualified for use under this Agreement taking into account normal equipment malfunctions and breakdowns not preventable through normal maintenance; Capacity metrics will be agreed upon and equipment will be initiated if projected utilization for the following year exceeds [***], or if OptiNose deems to initiate a project for business continuity. </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 2.02</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Inputs for Supply of DSA&#8217;s</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">OptiNose is responsible for negotiation of agreements and payment to third parties for the items listed on Exhibit B (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Third Party Components</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and was responsible for the agreements and payment for the Pre-Existing Inventory (as defined in Exhibit A) listed on Exhibit B (collectively with the Third Party Components, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OptiNose Components</font><font style="font-family:inherit;font-size:12pt;">&#8221;), in each instance for use in the manufacture of DSAs.  </font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">OptiNose will manage the relationship with suppliers of the OptiNose Components identified in Exhibit B, placing orders for Third Party Components, arranging delivery to VTM of the OptiNose Components at OptiNose&#8217;s cost, and ensuring that such suppliers perform in accordance with requirements of OptiNose.  VTM shall manage suppliers of the OptiNose Components within VTM&#8217;s quality systems as appropriate to ensure compliance with the quality agreements referenced in this Section 2.02(b).  OptiNose may initiate the addition or replacement of suppliers for each OptiNose Component upon [***] written notice to VTM and will work with VTM to execute such addition or replacement according to relevant OptiNose and VTM procedures at OptiNose&#8217;s expense. </font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If the suppliers of the OptiNose Components cause the assembly line at VTM to halt production due to lack of OptiNose Components, and if VTM has provided OptiNose at least [***] advance written notice of VTM&#8217;s projected or actual shortage of such OptiNose Components, then subject to the following sentence, VTM may invoice OptiNose for the reasonable costs incurred by VTM for such idle VTM operator time, which shall not exceed $[***]per week for [***] shift, or $[***] per week if running [***] shifts, in the aggregate, for which VTM shall provide OptiNose with a detailed breakdown of such costs and which shall solely include the compensation of the operators (and not any other overhead, facility costs, or profit of VTM), such amount to be the sole amount payable by OptiNose with respect to such idle time.  If OptiNose provides VTM with at [***] prior written notice of any such lack of OptiNose Components then VTM shall use its [***] efforts to reassign its staff and otherwise mitigate its costs, which shall be deducted from any amounts due by OptiNose to VTM for such lack of OptiNose Components.  </font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If any time after [***] VTM&#8217;s production of DSA requires less operators than anticipated or no operators at all, and then an increase in demand requires operators to be retrained to manufacture and assemble the DSAs, (1) OptiNose shall pay for such retraining at a rate [***], and (2) OptiNose must provide at least [***] prior written notice before VTM shall be required to effectuate such an increase. </font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">At OptiNose&#8217;s request, VTM shall warehouse up to [***] pallets of the OptiNose Components listed on Exhibit B. The parties will mutually agree to any additional warehousing and associated cost.  Notwithstanding the foregoing, VTM shall at OptiNose&#8217;s request warehouse [***] any and all OptiNose Components that VTM previously manufactured for OptiNose pursuant to the Molded Parts Agreement.</font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">[***] is responsible for the negotiation, payment, purchase, and delivery to VTM of all Inventory, but not the OptiNose Components.  Appropriate agreements and documentation of quality related requirements will also be the responsibility of [***]. </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 2.03</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Specifications</font><font style="font-family:inherit;font-size:12pt;">.  The Specifications may be amended in accordance with the terms of this Agreement, the Quality Agreement, or as required by the FDA or other similar regulatory authority, and by the written agreement of the parties. VTM shall not make changes to the Specifications without OptiNose&#8217;s prior written approval as provided for in the Quality Agreement.  </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 2.04</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Validation and Other Services</font><font style="font-family:inherit;font-size:12pt;">.  Before manufacturing DSAs under this Agreement, VTM will have completed validation necessary and appropriate for such manufacture in accordance with the Specifications, applicable protocols- and the other requirements of this Agreement and the Quality Agreement.</font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:8px;padding-top:18px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 2.05</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Engineering Changes</font><font style="font-family:inherit;font-size:12pt;">.  Either party may request that VTM incorporate engineering changes into the DSAs or Specifications by providing a written description of the proposed engineering change sufficient to permit the parties to evaluate the feasibility and cost of the proposed change.  VTM shall proceed with engineering changes when the parties have agreed in writing upon the changes to the Specifications, delivery schedule and adjustments to the Pricing, [***].  In all instances VTM shall use [***] to incorporate engineering changes requested by OptiNose.</font></div><div style="line-height:150%;padding-top:8px;text-align:justify;text-indent:125px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 2.06</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Pricing</font><font style="font-family:inherit;font-size:12pt;">.   </font></div><div style="line-height:150%;padding-top:8px;text-align:justify;padding-left:125px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">[***], the initial pricing for all DSAs and any associated services for such calendar year shall be the respective column as set forth on Exhibit A based on the [***] Forecast in such calendar year. At the end of each calendar year, if the actual volume of DSA production would have resulted in a lower applicable price per unit had the pricing been based on such respective column (i.e. if the pricing was initially based at the beginning of such calendar year on the [***] column but [***] DSA were actually assembled during such calendar year, then the pricing will be based solely on the [***] column in Exhibit A), then VTM shall apply the appropriate credit due OptiNose against future production until the full credit has been issued (if the amount of the credit is over [***], the credit will be applied [***]), while in the event the actual volume of DSA production would have resulted in a higher applicable price per unit had the pricing been based on such respective column (i.e. if the pricing was initially based at the beginning of such calendar year on the [***] column but [***] DSA were actually assembled during such calendar year, then the pricing will be based solely on the [***] column in Exhibit A), then VTM shall invoice OptiNose for the appropriate amount. Notwithstanding the foregoing, for the calendar year 2019 the charge shall be based on the column [***] set forth in Exhibit A less any credit due to OptiNose per Exhibit A, and [***].  [***].</font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">VTM will use [***] to engage in continuous improvement processes with respect to the manufacture of the DSAs and any such resulting cost reductions shall be applied to lower the pricing set forth in Exhibit A hereto.  [***]. Additionally, the price may be adjusted prospectively for any costs directly related to any changes in the Specifications and/or levels of service requested by OptiNose and agreed to by VTM, in writing.  VTM shall provide sufficient documentation to support any price adjustment in accordance with this Section [***].  &#160;&#160;&#160;&#160;</font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Commencing on [***] and [***] thereafter, during the Term of this Agreement, the unit price of each DSA shall be increased or decreased, which adjustment shall become effective on January 1 and July 1, respectively, of the applicable calendar year, by the [***] provided, that, with respect to price increases of [***], (A) VTM shall have used [***] to negate, defer or reduce proposed [***] cost increases, and (B) the parties shall have discussed in good faith such increases and VTM shall have provided OptiNose with reasonable documentation to explain and support such increase or </font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">decrease.  [***]. This pricing review may be triggered immediately if the price of [***] increases or decreases by more [***] at any time between the scheduled review periods, in which case such change will not be considered for any price change to be implemented under the preceding sentence in this Section 2.06(c).</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 2.07</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Forecasts</font><font style="font-family:inherit;font-size:12pt;">.  Commencing on January 1, 2019, OptiNose shall provide VTM with a non-binding, rolling [***] forecast of its DSA requirements by month to VTM (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Forecast</font><font style="font-family:inherit;font-size:12pt;">&#8221;).   The portion of the Forecast for the first [***] period shall be binding (a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Binding Period</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and the remaining [***] shall be for planning purposes and not binding (a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Non-Binding Period</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  OptiNose shall place Purchase Orders for the Binding Period of the Forecast in accordance with Section 2.09 of this Agreement.  The Forecast shall be updated [***] by OptiNose no later than the [***] day of each calendar month with the Binding Period updated with each Forecast to include the new [***] of the going forward [***] rolling forecast.  VTM shall participate in periodic sales and operations planning meetings with OptiNose and other suppliers as OptiNose [***] deems appropriate.  VTM shall provide OptiNose monthly inventory reports of DSAs, OptiNose Components and all other Inventory inventoried by VTM solely for the manufacture of DSAs.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 2.08</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Use of Forecasts</font><font style="font-family:inherit;font-size:12pt;">.  VTM will reference the latest available Forecasts when ordering Inventory (excluding the OptiNose Components which shall be ordered by OptiNose) necessary or appropriate to fulfill the forecasted DSA requirements, taking into account necessary lead times, volume-based pricing, the applicable Inventory&#8217; expiration periods, the Binding Period, and any Purchase Orders for DSAs outside the Binding Period.  VTM may purchase such Inventory (including minimum quantities required by suppliers) on the basis of OptiNose&#8217;s most recent Forecasts for the applicable Binding Period and, further, the Forecast for the longer period in the case of such Inventory having a longer lead time than [***].  Notwithstanding anything contained in this Agreement to the contrary and other than as set forth in Section 3.09(d), in no case shall VTM maintain more than a [***] supply of Inventory (other than OptiNose Components) based on the then [***] rolling forecast without OptiNose&#8217;s prior written consent.  Beginning on July 1, 2020 and on an annual basis thereafter, if less than [***] DSAs are assembled over the prior [***] period (and such shortage is due to OptiNose ordering less than this amount and not due to any production delays attributable to VTM or otherwise), OptiNose will pay a fee equal to the number of DSAs below [***] not assembled over the relevant [***] period multiplied by [***] of the assembly fee set forth in Exhibit A (for example, if only [***] DSAs were assembled during the relevant [***] period then the amount due is $[***] ([***] multiplied by $[***] ([***] of $[***]))]. </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 2.09</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Purchase Orders</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The terms and conditions contained in this Agreement shall prevail over any terms and conditions of any Purchase Order, acknowledgment form or other form instrument exchanged by the </font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">parties.  OptiNose shall submit purchase orders specifying: (a) the number of units of DSAs to be manufactured, (b) the price (determined in accordance with Exhibit A hereto) and (c) the expected delivery date (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Purchase Orders</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  Unless otherwise agreed, a Purchase Order shall not request a shipment date sooner than [***] days from the date of the Purchase Order unless agreed to separately by both parties.  VTM shall confirm acceptance of Purchase Orders and projected dates of shipment within [***] days of receiving a Purchase Order.   Failure of VTM to confirm any Purchase Order within the [***] day period shall be deemed to be acceptance of such Purchase Order, price and delivery.</font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">For any Binding Period, OptiNose shall submit Purchase Orders that aggregately meet at least [***] of the Forecast for such Binding Period, and VTM shall fulfill such Purchase Orders.  If the Purchase Orders for a month in the Binding Period in aggregate exceed the Forecast for such month by an amount between [***], VTM shall supply such excess under this Agreement, provided, however, that, in any consecutive [***] in a Binding Period, VTM shall not be required to supply DSAs in aggregate in excess of [***]. If such Purchase Orders in aggregate exceed the Forecast for such month in the Binding Period by more than [***], VTM shall use [***] to fill such orders, but shall not be in breach of this Agreement if VTM does not accept such portion of the order in excess of such [***], as applicable.  VTM shall promptly advise OptiNose to what extent VTM can fulfill such excess amount above [***], as applicable, which amount shall be considered part of the accepted Purchase Order hereunder. </font></div><div style="line-height:150%;padding-bottom:8px;padding-top:18px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 2.10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Release of DSAs</font><font style="font-family:inherit;font-size:12pt;">.  Upon completion of manufacture and associated testing documentation [***] and before shipping each batch, VTM shall send batch documentation, prepared pursuant to the Quality Agreement, to OptiNose&#8217;s designee for review and approval.  If OptiNose or its designee advises VTM of any issues or concerns regarding such batch documentation in accordance with this Agreement, VTM shall promptly rectify any such issue or concern and reissue updated batch documentation for review and approval within the time periods set forth in the Quality Agreement. Upon OptiNose&#8217;s (or OptiNose&#8217;s designee) receipt of complete batch documentation for such shipment, OptiNose&#8217;s designee shall, within the time period set forth in the Quality Agreement, review and respond as to whether the batch is approved for shipment.  [***]. </font></div><div style="line-height:150%;padding-bottom:8px;padding-top:18px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 2.11</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Non- or late Deliveries</font><font style="font-family:inherit;font-size:12pt;">.  In the event that VTM is unable to make delivery by a ready to ship date specified in the applicable Purchase Order, VTM shall immediately notify OptiNose (and any designee of OptiNose) of such delay and provide the date of availability for the shipment.  If VTM fails to deliver the DSAs in the quantities ordered in any Purchase Order within [***] of the date specified in such Purchase Order, then in addition to, and without waiver or limitation of any of its other rights hereunder, at law or in equity,   in all instances VTM shall use [***] to timely deliver DSAs even if there were prior delays in the OptiNose Components due to [***]. </font><font style="font-family:inherit;font-size:11pt;">I</font><font style="font-family:inherit;font-size:12pt;">f shipment of Product is more than [***] late from the most recent agreed upon shipping date pursuant to the </font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:8px;padding-top:18px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">accepted Purchase Order, then promptly following OPN&#8217;s written request for expedited shipping, VTM shall be responsible for the cost of such expedited shipping over and above standard shipping costs for that shipment, but only if the reason for such expedited shipping is attributable to a cause within VTM&#8217;s reasonable control. In the event that there is an actual or anticipated delay in shipping beyond [***] or other project delay due to events within VTM&#8217;s control, OPN may request an immediate escalation of the issue to VTM&#8217;s senior management at the subsidiary level (e.g., Vice-President, Precision Plastics), and failing resolution of the issue in [***], to Flex&#8217;s senior management at the corporate level (e.g., President, Medical Segment).  Failing resolution at such point, the matter shall be further escalated pursuant to Exhibit D attached hereto after each [***] period.</font></div><div style="line-height:150%;padding-bottom:8px;padding-top:18px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 2.12</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Manager Meetings.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;The parties shall meet periodically [***] at meetings to be organized by the OptiNose Supply Relationship Manager and the VTM Supply Relationship Manager to discuss, agree upon, and oversee implementation of initiatives to plan Capacity and OptiNose Equipment requirements, improve the DSA manufacturing process to improve quality and to reduce cost and price for the benefit of both parties.  Participants in such meetings will be agreed to by the parties.  For each such agreed initiative, the parties shall agree on the capital and expense to implement the initiative, the party to provide funds for such capital and expense, the expected cost savings to result, and an equitable sharing of the cost and other benefits from the initiative after recoupment of the funds provided for the initiative (which sharing shall take into account a reasonable return on investment for the party providing the funds to implement such initiative).  Additionally, promptly following the execution of this Agreement, the parties shall use [***] to agree upon reporting metrics, which shall include but are not limited to [***].</font></div><div style="line-height:150%;padding-bottom:8px;padding-top:18px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE III</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EQUIPMENT, INVENTORY AND WORK IN PROGRESS</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 3.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OptiNose Equipment</font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a) &#160;&#160;&#160;&#160;VTM acknowledges that the OptiNose Equipment [***], is owned by OptiNose and that OptiNose may place identifying tags on the OptiNose Equipment confirming and providing notice of OptiNose&#8217;s ownership.  VTM shall not permit [***] and shall only use the OptiNose Equipment for the manufacture of the DSAs hereunder or other activities for OptiNose. VTM hereby disclaims any interest, to the extent it has any, in the OptiNose Equipment and agrees to execute and deliver any agreements or other documents evidencing OptiNose&#8217;s ownership of such OptiNose Equipment.   In the event that any OptiNose Equipment is to be shipped from VTM to OptiNose or any third party, [***] shall be responsible for all reasonable packing and shipping costs related thereto.</font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b) &#160;&#160;&#160;&#160;VTM shall, [***], maintain the OptiNose Equipment in good working order (including maintenance and repair in the ordinary course and calibration, if needed) such that the OptiNose </font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Equipment enables VTM to produce DSAs according to the Specifications and otherwise in accordance with this Agreement.  OptiNose shall be responsible for [***].  </font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c) &#160;&#160;&#160;&#160;At OptiNose&#8217;s written request, VTM shall make available at VTM&#8217;s facility such OptiNose Equipment as OptiNose may designate, [***], and VTM shall provide [***] at [***] in transitioning such OptiNose Equipment  to OptiNose [***].  </font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 3.02</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Inventory and Work In Progress</font><font style="font-family:inherit;font-size:12pt;">.  The parties acknowledge that the OptiNose Components are significant inputs to the DSAs by value and that the OptiNose Components will be the property of OptiNose at all times that such OptiNose Components are in VTM&#8217;s possession.  [***], VTM shall not [***].  </font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 3.03</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Bailment Agreements</font><font style="font-family:inherit;font-size:12pt;">.  VTM agrees to enter a bailment agreement with OptiNose in the form reasonably acceptable to both parties for the OptiNose Equipment, and the OptiNose Components. </font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 3.04</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Inventory.  Authorization</font><font style="font-family:inherit;font-size:12pt;">. OptiNose&#8217;s accepted Purchase Orders and each Forecast shall constitute authorization for VTM to procure, without OptiNose&#8217;s prior approval, but subject to the [***] limitation set forth in Section 2.08: (a) Inventory to manufacture the DSAs covered by such Purchase Orders and Forecast based on the applicable Lead Times, including Long Lead Time Inventory; (b) Minimum Order Inventory reasonably required to support OptiNose&#8217;s Purchase Orders and Forecast; and (c) any Special Inventory which is separately authorized in writing by OptiNose.  </font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:132px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 3.05</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Supply Chain Management. Purchases from Approved Vendor List</font><font style="font-family:inherit;font-size:12pt;">. VTM shall maintain an Approved Vendor List.  VTM shall purchase Inventory required to manufacture the DSA only from vendors listed on such Approved Vendor List.</font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 3.06</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Vendor Warranties for Inventory</font><font style="font-family:inherit;font-size:12pt;">.  To the extent VTM actually receives from a vendor of Inventory or services the benefit arising from said vendor&#8217;s warranty obligations related to its Inventory or services, including OptiNose Components, VTM shall transfer such benefit to OptiNose (without any actual liability for such vendor&#8217;s warranty obligations) related to the following warranties with regard to the Inventory or services: (i) conformance of the Inventory or services with the vendor&#8217;s specifications; (ii) that the Inventory or services shall be free from defects in design, materials, or workmanship; (iii) that the Inventory or services shall comply with environmental regulations and all other applicable Laws; and (iv) that the Inventory or services shall not infringe the intellectual property rights of third parties.  Nothing contained in this Section 3.06 is intended to limit the warranties provided by VTM under Section 4.02 of this Agreement or any other obligation of VTM under this Agreement. </font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 3.07</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OptiNose Responsibility for Inventory</font><font style="font-family:inherit;font-size:12pt;">. Subject to the other terms of this Section 3, OptiNose is financially responsible under the conditions provided in this Agreement for all Inventory purchased by VTM under this Section 3 that can only be used for manufacturing the DSAs.  VTM agrees to maintain sufficient level of Inventory to manufacture the DSAs in accordance with the Forecast and Purchase Orders and the terms of this Agreement; provided, that in the event such Inventory is not used in connection with the manufacture of DSA then VTM shall use [***] to return or utilize such Inventory and if they are unable to do so OptiNose shall reimburse VTM for such Inventory, as the case may be.</font></div><div style="line-height:150%;padding-bottom:8px;text-align:left;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 3.08</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Quantity Increases and Shipment Schedule Changes</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:150%;padding-left:0px;padding-bottom:8px;text-align:justify;text-indent:48px;"><font style="padding-bottom:8px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(a)</font><font style="font-family:inherit;font-size:12pt;">For any accepted Purchase Order, OptiNose may request an increase in the quantity of DSAs ordered.  All DSA quantity increases in excess of the amount set forth in such Purchase Order (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Excess Request</font><font style="font-family:inherit;font-size:12pt;">&#8221;) shall require VTM&#8217;s approval, which is subject to Inventory, OptiNose Component and capacity availability. VTM shall use [***] to meet any DSA quantity increases in an Excess Request.</font></div><div style="line-height:150%;padding-left:0px;padding-bottom:8px;text-align:justify;text-indent:48px;"><font style="padding-bottom:8px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(b)</font><font style="font-family:inherit;font-size:12pt;">For any accepted Purchase Order, OptiNose may request a reschedule of the expected delivery date set forth in the applicable Purchase Order not to exceed [***] days.  All DSA reschedules in excess of [***] days require VTM&#8217;s approval, which, in its reasonable discretion, may or may not be granted.  If VTM agrees to accept a reschedule of any length of time, and if there are extra costs to meet such reschedule, then OptiNose shall be liable for such extra costs, provided, that VTM provides OptiNose advance notice of such costs and OptiNose elects to proceed with such reschedule.  </font></div><div style="line-height:150%;padding-left:0px;padding-bottom:8px;text-align:justify;text-indent:48px;"><font style="padding-bottom:8px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(c)</font><font style="font-family:inherit;font-size:12pt;">Any delays in the normal production or interruption in the workflow process caused by OptiNose&#8217;s changes to the Specifications shall be considered a reschedule of any affected Purchase Orders for purposes of this Section 3.08 for the period of such delay.  </font></div><div style="line-height:150%;padding-left:0px;padding-bottom:8px;text-align:justify;text-indent:48px;"><font style="padding-bottom:8px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(d)</font><font style="font-family:inherit;font-size:12pt;">Cancellations.  OptiNose may not cancel all or any portion of DSA quantity of an accepted Purchase Order without VTM&#8217;s prior written approval, which, in its [***], may or may not be granted; provided, however, that any reduction of the DSAs ordered in an accepted Purchase Order which reduction is equal to or less than [***] shall not require VTM&#8217;s approval and shall not be subject to the other terms and conditions of this Section 3.08; and, provided, further, that VTM will not withhold its approval of any cancellation in the event VTM is able to utilize the production capability that would have been utilized to produce product or otherwise provide services for another customer.   </font></div><div style="line-height:150%;padding-bottom:8px;text-align:left;text-indent:132px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 3.09</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Excess and Obsolete Inventory</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:150%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">OptiNose shall be responsible for the following:  </font></div><div style="line-height:150%;padding-left:0px;padding-bottom:8px;text-align:justify;text-indent:48px;"><font style="padding-bottom:8px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">a.</font><font style="font-family:inherit;font-size:12pt;">Excess Inventory.  When applicable, VTM shall report the Excess Inventory to OptiNose on a monthly basis.  VTM shall advise whether such Excess Inventory was due to a decrease within the first [***] period of a Forecast in DSA production hereunder or due to VTM&#8217;s purchase of Inventory </font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">13</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-left:0px;padding-bottom:8px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">beyond the amount reasonably necessary for the next [***] of demand for DSAs under the then-current Forecast. Such Excess Inventory reports shall be deemed agreed to by OptiNose, unless OptiNose provides a written objection within [***] days of the end of the calendar month in which such report is received by OptiNose.  Upon notice from VTM to OptiNose of any Excess Inventory pursuant to a report, VTM shall attempt to cancel or amend any pending orders for such inventory to the extent such inventory is not reasonably likely to be necessary for any Forecasts hereunder or otherwise for VTM to comply with its obligations hereunder.</font></div><div style="line-height:150%;padding-left:0px;padding-bottom:8px;text-align:justify;text-indent:48px;"><font style="padding-bottom:8px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">b.</font><font style="font-family:inherit;font-size:12pt;">Purchase of Excess Inventory.  OptiNose shall pay VTM for Excess Inventory, as identified by VTM in each monthly report, and not objected to by OptiNose or returned/cancelled by VTM, in each instance pursuant to the process set forth above in Section 3.09(a), at a price equal to (as applicable) the price from the price list set forth in Exhibit A for any finished DSAs, the proportionate amount of such price for any partially completed DSAs, or the listed price for individual components, in each instance such price to be the price in existence at the time such Excess Inventory was acquired, used or completed; provided that if any such completed DSAs, partially completed DSAs or other Excess Inventory are subsequently utilized by VTM for the manufacture and supply of DSAs under this Agreement, VTM shall provide OptiNose a credit for the amount previously paid by OptiNose for such completed DSA, partially completed DSA or other Excess Inventory pursuant to this Section 3.09(b); [***].  In connection with any payments made by OptiNose to VTM pursuant to this Section 3.09(b), at VTM&#8217;s discretion and OptiNose&#8217;s request (1) VTM shall safely store such Excess Inventory at the rate to be mutually agreed to by the parties, and/or (2) OptiNose can, [***], have some or all of such Excess Inventory stored by a third party for VTM&#8217;s potential future use. </font></div><div style="line-height:150%;padding-left:0px;padding-bottom:8px;text-align:justify;text-indent:48px;"><font style="padding-bottom:8px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">c.</font><font style="font-family:inherit;font-size:12pt;">Obsolete Inventory. When applicable, VTM shall report the Obsolete Inventory to OptiNose on a monthly basis.  OptiNose&#8217;s failure to object to VTM&#8217;s Obsolete Inventory report (or failure to deny its responsibility for such inventory) within [***] days of the end of the calendar month in which such report is received by OptiNose shall constitute its acceptance of VTM&#8217;s Obsolete Inventory report.  After a validation period, which shall not exceed [***] from the date of such report, OptiNose shall purchase the Obsolete Inventory (and pay in accordance with Section 2 of this Agreement) at a price equal to (as applicable) the price from the price list set forth in Exhibit A for any finished DSAs, the proportionate amount of such price for any partially completed DSAs, or the listed price for individual components.      </font></div><div style="line-height:150%;padding-left:0px;padding-bottom:8px;text-align:justify;text-indent:48px;"><font style="padding-bottom:8px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">d.</font><font style="font-family:inherit;font-size:12pt;">Notwithstanding the foregoing in Sections 3.09(a), (b) and (c) above, for those OptiNose Components set forth on Exhibit C, the [***] period noted in Sections 3.09(a) and (b) shall instead be [***] with respect to the items set forth in Exhibit C for which VTM shall also be required to maintain at least [***] but not more than [***] of available inventory at all times.</font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">14</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-left:0px;padding-bottom:8px;text-align:justify;text-indent:48px;"><font style="padding-bottom:8px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">e.</font><font style="font-family:inherit;font-size:12pt;">Prior to invoicing OptiNose for the amounts due pursuant to Section this 3.09, VTM shall use [***] for a period not to exceed [***] to return for refund unused Inventory from Excess Inventory and Obsolete Inventory and to otherwise mitigate the amounts payable by OptiNose.  OptiNose shall submit payment for the amounts identified and invoiced pursuant to this Section 3.09 in accordance with the terms for payment set forth above in Section 2.  At OptiNose&#8217;s discretion, VTM shall ship the Excess Inventory and Obsolete Inventory to OptiNose promptly following said payment by OptiNose, or destroy such Excess Inventory and Obsolete Inventory, at [***].  [***].  </font></div><div style="line-height:150%;padding-left:0px;padding-bottom:8px;text-align:justify;text-indent:48px;"><font style="padding-bottom:8px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">f.</font><font style="font-family:inherit;font-size:12pt;">For changes (including cancellation and reschedules) that are not consistent with Sections 3.08 or 3.09, [***] shall be responsible for any vendor cancellation charges incurred.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ARTICLE IV</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DEFECTIVE PRODUCT</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 4.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notification of Defective Product.</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;OptiNose or its designee shall notify VTM within: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:12pt;padding-left:132px;"><font style="font-family:inherit;font-size:12pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***] days after receiving a shipment of DSAs if it determines that such shipment contains a Quantitative Defect,    </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:12pt;padding-left:132px;"><font style="font-family:inherit;font-size:12pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***] days after receiving a shipment of DSAs if it determines that such shipment contains a Patent Defect, and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:12pt;padding-left:132px;"><font style="font-family:inherit;font-size:12pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***] days after OptiNose becomes aware of a Latent Defect.</font></div></td></tr></table><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">OptiNose or its designee shall provide VTM a sample of what it alleges contains a Latent or Patent Defect, subject to compliance with the foregoing notice requirements and the provisions of Section 4.02, below.   </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 4.02</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Resolution of Defective Product.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Patent Defect and Latent Defect</font><font style="font-family:inherit;font-size:12pt;">. VTM warrants and covenants that: (i) for a period of [***] from invoice date, such DSAs shall be free from defects in workmanship;  (ii) be manufactured and delivered in accordance with the terms of this Agreement, the Specifications, and the Quality Agreement, (iii) it shall perform its obligations under this Agreement using personnel of required skill, experience and qualifications and in a professional and workmanlike manner in accordance with generally recognized industry standards, (iv) it is in compliance with, and shall perform under this Agreement in compliance with, all applicable Laws, and (v) OptiNose will receive good and valid title to all DSAs, free and clear of all encumbrances and liens of any kind (collectively, the &#8220;Warranty&#8221;). </font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Notwithstanding anything else in this Agreement, this Warranty does not apply to, and VTM makes no representations or warranties whatsoever with respect to any of: (i) defects resulting from adherence to the Specifications, or any written instructions provided by or on behalf of OptiNose; (ii) the design of the DSAs; (iii) DSAs that have been abused, damaged, altered or misused or </font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">mishandled by any person or entity after title passes to OptiNose; or (iv) defects resulting from tooling, designs or written instructions produced or supplied by OptiNose.</font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Upon any failure of a DSA to comply with this Warranty, VTM shall, [***]; provided that OptiNose&#8217;s inspection or approval shall not excuse Supplier&#8217;s responsibility with respect to Latent Defects.  [***] shall bear all of the risk, and shipping costs, associated with DSAs that have been returned to VTM for which there is no defect found under the Warranty.</font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">OptiNose or its designee must obtain a Returned Material Authorization (RMA) Number from VTM prior to returning any DSA. The RMA must be indicated on the return package as notice to VTM&#8217;s Shipping Department to accept shipment. Any package not so marked will be returned at [***] expense. [***] is responsible for risk of loss and all costs associated with the return to VTM of the DSAs; provided that [***] shall reimburse [***] for such costs if it is determined that the DSA is non-conforming.  For purposes of this Agreement, a DSA shall be deemed to be &#8220;non-conforming&#8221; if it does not meet the Specifications or the other requirements of this Warranty. If OptiNose and VTM are unable to agree as to whether a DSA is conforming, then after [***] to resolve the disagreement, and subject to, and without waiver or limitation of OptiNose&#8217;s and/or VTM&#8217;s rights and remedies hereunder, at law and/or in equity, either party may submit a sample of such DSA to a mutually agreed upon independent third party testing laboratory which is an expert in the industry and which will expertly apply the agreed upon testing protocol in order to determine whether the DSA is conforming or non-conforming.  The independent laboratory&#8217;s results shall be final and binding for purposes of determining whether payment is owed (but not for purposes of any pending or potential product liability litigation which shall be governed by Article XII). If the parties or the independent laboratory determine that the DSA was non-conforming, then in addition to, and without waiver or limitation of OptiNose&#8217;s rights and remedies hereunder, at law and/or in equity, OptiNose shall [***].  If the parties or the independent laboratory determine the DSA was conforming, OptiNose shall [***].  Unless otherwise agreed to by the parties in writing, the costs associated with testing and review of a DSA pursuant to this Section shall be borne by [***].</font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The above warranties are given in lieu of any other representation or warranty, express or implied, and including but not limited to the implied warranty of merchantability or fitness for a particular purpose. </font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Quantitative Defect</font><font style="font-family:inherit;font-size:12pt;">.  If OptiNose believes that a shipment of DSAs hereunder has a Quantitative Defect, OptiNose shall notify VTM within the applicable period.  If VTM agrees with such Quantitative Defect, VTM will promptly, and in no event more than [***] days, ship sufficient DSAs at OptiNose&#8217;s direction to remedy such Quantitative Defect. If VTM does not agree with OptiNose&#8217;s determination that such shipment has a Quantitative Defect, then after [***] to resolve the disagreement, and subject to, and without waiver or limitation of OptiNose&#8217;s and/or VTM&#8217;s rights and </font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">16</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">remedies hereunder, at law and/or in equity, VTM may require a mutually agreed upon independent third party to determine whether the shipment had a Quantitative Defect.  The independent party&#8217;s results shall be final and binding for purposes of determining whether VTM is obligated to ship additional DSAs, and the costs of such independent third party shall be borne by [***]. If such results indicate that the shipment had a Quantitative Defect, OptiNose shall be entitled to [***].     </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE V</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">RECORDS AND REGULATORY MATTERS</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 5.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Recordkeeping</font><font style="font-family:inherit;font-size:12pt;">.  VTM shall maintain true and accurate books, records, inventory of Inventory and finished DSAs, test and laboratory data, reports and all other information relating to Manufacturing under this Agreement, including all information required to be maintained by all Law.  Such information shall be maintained for the period specified in the Quality Agreement or longer if required under Law.  VTM shall provide or make such information available to OptiNose upon request and shall notify and provide OptiNose with advance notice and opportunity to obtain such information at the end of the retention period.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 5.02</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Regulatory Compliance</font><font style="font-family:inherit;font-size:12pt;">.  VTM will be responsible to maintain all permits and licenses required by any Law with respect to the facility and its equipment for the manufacture and delivery of DSAs and will manufacture and deliver the DSAs in accordance with the requirements of this Agreement, including the Quality Agreement, the Specifications and applicable Laws.  In addition, during the Term, at OptiNose&#8217;s request VTM will provide [***] assistance [***] with all regulatory matters relating to the manufacturing of the DSAs and services under this Agreement.  Each Party intends and commits to cooperate to satisfy all Law within the scope of its respective responsibilities under this Agreement.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 5.03</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Regulatory Correspondence</font><font style="font-family:inherit;font-size:12pt;">.   VTM shall notify OptiNose in accordance with the Quality Agreement of any notice, correspondence, and the result of any inspection(s) by or with the FDA or any Regulatory Authority (including without limitation any 483, warning letter, or similar correspondence) concerning an actual or potential regulatory deficiency, noncompliance or problem that directly or indirectly relates to the manufacturing of the DSAs or any of the services provided by VTM under this Agreement.  VTM shall notify OptiNose in accordance with the Quality Agreement of any other notice or correspondence, and the result of any inspection(s), with the FDA or any Regulatory Authority that is reasonably likely to impact or directly relates to the manufacture of DSAs or other performance under this Agreement.  In all of the foregoing notifications, VTM shall provide OptiNose with copies of any such notices, correspondences, or results of inspection in accordance with the Quality Agreement subject to any other customer confidentiality requirements of VTM; provided VTM shall attempt to reasonably redact any such other customer confidential information in order to provide OptiNose with such information. Furthermore, VTM shall send a draft </font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">17</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">to OptiNose of all correspondence VTM intends to send to any Regulatory Authority with any substantial relation to DSAs. For all correspondence with a Regulatory Authority related directly to DSAs that is in response to any 483, warning letter, regulatory deficiency or other problem relating to the manufacture of DSAs, VTM shall consult with, and reasonably consider the input of, OptiNose on the draft correspondence before such correspondence is sent to the Regulatory Authorities.  Regarding all interactions with Regulatory Authorities, both parties shall make [***] to act expeditiously in cooperating with each other and responding to Regulatory Authorities. </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 5.04</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Governmental Inspections and Requests</font><font style="font-family:inherit;font-size:12pt;">.  VTM shall as soon as [***] in accordance with the Quality Agreement inform OptiNose in writing of any inspection, notice or request for inspection, and other regulatory action, by any regulatory agency relating to the manufacture of DSAs and/or, in the case of a facility to the extent related to VTM&#8217;s manufacturing, packaging, testing and storage of DSAs at such facility, so that OptiNose has as much advance notice as possible to enable it to, as applicable and relevant, participate in preparation and/or strategy regarding and/or attend the inspection.  VTM shall permit the OptiNose&#8217;s representatives to be present during any such inspection related to DSAs ([***]), including being present at any inspection of the facility to the extent such inspection is related to VTM&#8217;s manufacturing, packaging, testing or storage of the DSAs.  As provided in Section 5.03, VTM will provide OptiNose with the results of all regulatory inspection or audits related to the DSAs after VTM&#8217;s receipt of such results in accordance with the Quality Agreement.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 5.05</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Recall</font><font style="font-family:inherit;font-size:12pt;">.  In the event VTM believes a recall, field alert, product withdrawal or field correction may be necessary with respect to any DSA provided under this Agreement, VTM shall as soon as practicable notify OptiNose in writing.  VTM will not act to initiate a recall, field alert, product withdrawal or field correction with respect to the DSAs.  In the event OptiNose believes a recall, field alert, product withdrawal or field correction may be necessary with respect to any DSA provided under this Agreement, OptiNose shall immediately notify VTM in writing and VTM shall provide [***] cooperation and assistance to OptiNose.  The cost of any recall, field alert, product withdrawal or field correction, and any assistance in connection therewith, shall be borne by [***].  For avoidance of doubt and subject to applicable Laws, OptiNose shall have the ultimate and final authority to initiate a field alert or recall of the Finished Product.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 5.06</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Inspections and Audits by OptiNose</font><font style="font-family:inherit;font-size:12pt;">.  [***], representatives of OptiNose shall have access upon [***] prior notice to VTM&#8217;s facility where it manufactures DSAs for the purpose of: (a) conducting inspections of such facility and VTM&#8217;s maintenance and usage of the equipment utilized in the manufacture of the DSAs, (b) performing quality control and quality assurance (including without limitation cGMP) audits (c) witnessing the manufacture, storage or transportation of the DSAs or the Inventory, (d) verifying the storage of the OptiNose Components, and (d) requiring cycle counts by VTM (and adjustments to inventory as necessary).  OptiNose shall have access to the </font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">18</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">results of any tests performed by VTM relating to DSAs and Inventory and the processes or the Inventory that VTM&#8217;s purchases directly from a third party used in their manufacture.  Such inspections shall not relieve VTM of any of its obligations under this Agreement or create new obligations on the part of OptiNose.  This right of inspection can be exercised [***] (and as often as necessary for cause), subject to a written notice to VTM given in accordance with the time periods specified in the Quality Agreement, or at any time for cause.  VTM shall permit such inspection during normal business hours at reasonable and mutually acceptable times [***].  At all times, OptiNose&#8217;s representatives shall be accompanied by VTM personnel and follow all site reasonable health and safety policies of VTM.  Each inspection, audit and witnessing shall be subject, at all times, to VTM&#8217;s confidentiality and non-disclosure obligations to its other third party customers.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE VI</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ADDITIONAL VTM OBLIGATIONS</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 6.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">VTM shall:</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">appoint a VTM employee to serve as a primary contact with respect to this Agreement and who will have the expertise and authority to act on behalf of VTM in connection with matters pertaining to this Agreement (the </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;VTM Supply Relationship Manager</font><font style="font-family:inherit;font-size:12pt;">&#8221;);</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">[***] maintain the same VTM Supply Relationship Manager throughout the Term, however VTM has the right to replace the VTM Supply Relationship Manager [***];</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">before the date on which the services under this Agreement are to start, obtain, and at all times during the Term maintain, all necessary licenses and consents and comply with all Laws;</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">prior to any VTM Personnel performing any services hereunder: (i) ensure that such VTM Personnel are suitably trained, skilled, experienced and qualified to perform such services; and (ii) ensure that such VTM Personnel have the legal right to work in the United States; and</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">maintain complete and accurate records relating to the provision of services under this Agreement, including records of the time spent and Inventory and OptiNose Components used by VTM in providing such services in such form as [***] shall [***]. During the Term and for a period of [***] thereafter, upon OptiNose&#8217;s written request, VTM shall allow OptiNose or OptiNose&#8217;s representative to inspect and make copies of such manufacturing and quality records  in connection with the provision of the services under this Agreement; provided that any such inspection shall take place during regular business hours no more than [***] (which limit shall not include any inspections for cause) and OptiNose provides VTM with [***] advance written notice.  </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 6.02</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">VTM is responsible for all VTM Personnel and for the payment of their compensation, including, if applicable, withholding of income taxes, and the payment and </font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">19</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">withholding of social security and other payroll taxes, unemployment insurance, workers&#8217; compensation insurance payments and disability benefits.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 6.03</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">VTM acknowledges that time is of the essence with respect to VTM&#8217;s obligations hereunder and that prompt and timely performance of all such obligations is strictly required.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 6.04</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The obligations of VTM under this Agreement shall be performed fully within the facility located at 71 and 20 Utopia Road, Manchester, CT 06042 United States, unless approved in writing in advance by OptiNose.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 6.05</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Upon VTM&#8217;s receipt of OptiNose Components, VTM shall promptly inspect such OptiNose Components in accordance with the applicable inspection criteria provided by OptiNose and ensure that such OptiNose Components provided by each such supplier meets the applicable specifications for such OptiNose Components.  VTM shall do such inspection within [***] days of its receipt of such OptiNose Components.  Should the OptiNose Components fail any such inspection or should VTM identify any issues with the OptiNose Components, VTM shall provide OptiNose and the applicable supplier of such OptiNose Components notice of such failure and/or issue within [***] day. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ARTICLE VII</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ADDITIONAL OPTINOSE&#8217;S OBLIGATIONS</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 7.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">OptiNose shall:</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">appoint an OptiNose employee to serve as the primary contact with respect to this Agreement and who will have the expertise and authority to act on behalf of OptiNose with respect to matters pertaining to this Agreement (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OptiNose Supply Relationship Manager</font><font style="font-family:inherit;font-size:12pt;">&#8221;); </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">respond [***] to any VTM request to provide direction, information, approvals, authorizations or decisions that are reasonably necessary for VTM to perform in accordance with this Agreement;</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">provide such information as VTM may reasonably request and OptiNose considers [***] necessary in order to perform under this Agreement;  </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">obtain and maintain all necessary licenses and consents and comply with all Law to the extent necessary for OptiNose&#8217;s performance under the Agreement; and</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">obtain and maintain throughout the term of this Agreement insurance on the OptiNose Equipment in [***] amounts and coverage.  </font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">20</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE VIII</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br>          </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">FEES AND EXPENSES; PAYMENT TERMS</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 8.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">VTM shall issue invoices to OptiNose upon delivery to OptiNose in accordance with Section 2.01 of DSAs with pricing pursuant to Exhibit A for such DSAs produced, and OptiNose shall pay all properly invoiced amounts due to VTM within [***] days after the date of the invoice except for any amounts disputed by OptiNose in good faith (subject to OptiNose&#8217;s match process for Purchase Order, invoice and receipt). VTM shall provide, for OptiNose&#8217;s review and prior written approval, statements of work with budgetary allowances for any services not required to be provided by VTM at its costs by the quality agreement or this Agreement. VTM will provide invoices to those services if incurred. All payments hereunder shall be in US dollars and made by check or wire transfer.  The provisions of this Agreement shall govern over any terms and conditions listed on any invoice or Purchase Order. A service fee of [***]% per month will be added to all accounts more than [***] days past due, and [***] is responsible for all collection and attorneys&#8217; fees and costs required to collect unpaid amounts.  </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 8.02</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">[***] shall be responsible for all sales, use and excise taxes, and any other similar taxes, duties and charges of any kind imposed by any federal, state or local governmental entity on any amounts payable to VTM.  [***]. In no event shall [***] pay or be responsible for any taxes imposed on, or with respect to, [***] income, revenues, gross receipts, personnel or real or personal property or other assets.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE IX</font><font style="font-family:inherit;font-size:10pt;"><br></font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">INTELLECTUAL PROPERTY RIGHTS; OWNERSHIP</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 9.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Except as set forth in Section 9.03, OptiNose is, and shall be, the sole and exclusive owner of all right, title and interest in and to any Intellectual Property Rights generated in connection with VTM&#8217;s performance under this Agreement, and to any of the Deliverables, including all Intellectual Property Rights therein. VTM agrees, and will cause its VTM Personnel to agree, that with respect to any Intellectual Property Rights or Deliverables that may qualify as &#8220;work made for hire&#8221; as defined in 17 U.S.C. &#167;101, such Intellectual Property Rights and Deliverables are hereby deemed a &#8220;work made for hire&#8221; for OptiNose. To the extent that any of the Intellectual Property Rights or Deliverables hereunder do not immediately vest in OptiNose or do not constitute a &#8220;work made for hire&#8221;, VTM hereby irrevocably assigns on behalf of itself and all VTM Personnel, and, [***], shall cause the VTM Personnel to irrevocably assign to OptiNose, in each case without additional consideration, all right, title and interest throughout the world in and to such Intellectual Property Rights and Deliverables, including all Intellectual Property Rights therein. VTM hereby waives on behalf of itself and all VTM Personnel, and, [***], shall cause the VTM Personnel to irrevocably waive, to the extent permitted by applicable Law, any and all claims VTM and/or such VTM Personnel </font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">21</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">may now or hereafter have in any jurisdiction to so-called &#8220;moral rights&#8221; or rights of droit moral with respect to such Intellectual Property Rights and Deliverables.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 9.02</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Upon the request of OptiNose, VTM shall, and shall cause the VTM Personnel to, promptly take such further actions, including execution and delivery of all appropriate instruments of conveyance, as may be necessary to assist OptiNose to prosecute, register, perfect or record its rights in or to any Deliverables.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 9.03</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">VTM and its licensors are, and shall remain, the sole and exclusive owners of all right, title and interest in and to the VTM Tools, including all Intellectual Property Rights therein. VTM represents and warrants that the DSAs delivered hereunder shall not incorporate any VTM Tools, and that OptiNose can use and/or sell the DSAs without the requirement of any approval and/or license from VTM</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 9.04</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">OptiNose and its licensors are, and shall remain, the sole and exclusive owner of all right, title and interest in and to the OptiNose Information, including all Intellectual Property Rights therein. VTM shall have no right or license to use any OptiNose Information, except solely during the Term of the Agreement to the extent necessary to perform under this Agreement. All other rights in and to the OptiNose Information are expressly reserved by OptiNose.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE X</font><font style="font-family:inherit;font-size:10pt;"><br></font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CONFIDENTIAL INFORMATION</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 10.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Receiving Party agrees: </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">not to disclose or otherwise make available Confidential Information of the Disclosing Party to any third party without the prior written consent of the Disclosing Party; </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">provided, however</font><font style="font-family:inherit;font-size:12pt;">, that the Receiving Party may disclose the Confidential Information of the Disclosing Party to its Affiliates, and their officers, employees, consultants and legal advisors who have a &#8220;need to know&#8221;, who have been apprised of this restriction and who are themselves bound by nondisclosure obligations at least as restrictive as those set forth in this Article X, provided, that, the Receiving Party shall be responsible for any disclosure or use of Confidential Information by such persons or entities that is contrary to the terms of this Agreement;</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">to use the Confidential Information of the Disclosing Party only for the purposes of performing its obligations under the Agreement or, in the case of OptiNose, to make use of the services under this Agreement and Deliverables; and</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#32;to promptly notify the Disclosing Party in the event it becomes aware of any loss or disclosure of any of the Confidential Information of the Disclosing Party.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 10.02</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If the Receiving Party becomes legally compelled to disclose any Confidential Information, the Receiving Party shall provide: (i) prompt written notice of such </font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">22</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">requirement so that the Disclosing Party may seek, at its sole cost and expense, a protective order or other remedy; and (ii) [***] assistance, [***], in opposing such disclosure or seeking a protective order or other limitations on disclosure. If, after providing such notice and assistance as required herein, the Receiving Party remains required by Law to disclose any Confidential Information, the Receiving Party shall disclose no more than that portion of the Confidential Information which, on the advice of the Receiving Party&#8217;s legal counsel, the Receiving Party is legally required to disclose and, upon the Disclosing Party&#8217;s request, shall use commercially reasonable efforts to obtain assurances from the applicable court or agency that such Confidential Information will be afforded confidential treatment.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ARTICLE XI</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">REPRESENTATIONS AND WARRANTIES</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 11.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each party further represents and warrants to the other party that:</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">it is duly organized, validly existing and in good standing as a corporation or other entity as represented herein under the laws and regulations of its jurisdiction of incorporation, organization or chartering;</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">it has the full right, power and authority to enter into this Agreement, to grant the rights and licenses granted hereunder and to perform its obligations hereunder; </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the execution of this Agreement by its representative whose signature is set forth at the end hereof has been duly authorized by all necessary corporate action of the party; </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">when executed and delivered by such party, this Agreement will constitute the legal, valid and binding obligation of such party, enforceable against such party in accordance with its terms; and</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">it will comply at all times with the provisions of applicable Laws of the United States (and, as applicable, analogous such laws in any other territories where regulatory approval is sought) regarding debarment and will upon request certify in writing to the other parties that none of its employees nor any person providing services in connection with this Agreement have been debarred under the provisions of such laws.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 11.02</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">VTM further represents and warrants to OptiNose that:</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">it shall perform the services under this Agreement using personnel of required skill, experience and qualifications and in a professional and workmanlike manner in accordance with generally recognized industry standards for similar services and shall devote adequate resources to meet its obligations under this Agreement;</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">it is in compliance with, and shall perform under this Agreement in compliance with, all applicable Laws;</font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">23</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Upon delivery of DSAs to OptiNose in accordance with Section 2.1, OptiNose will receive good and valid title to all Deliverables, free and clear of all encumbrances and liens of any kind;</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the DSAs provided under this Agreement shall be manufactured and delivered in strict compliance with the terms of this Agreement, including (i) the Specifications; (ii) all Laws relating to the manufacture of the DSAs, including without limitation the FD&amp;C Act and cGMPs; and (iii) the Quality Agreement; and </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">as of the date hereof, there are no pending or, to VTM&#8217;s knowledge, threatened claims, litigation or other proceedings pending against VTM by any third party, in each case, excluding any infringement or claim, litigation or other proceedings to the extent arising out of (x) any OptiNose Information or any instruction, information, designs, specifications or other materials provided by OptiNose to VTM, (y) use of the Deliverables in combination with any materials or equipment not supplied or specified by VTM, if the infringement would have been avoided by the use of the Deliverables not so combined, and (z) any modifications or changes made to the Deliverables by or on behalf of any Person other than VTM.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 11.03</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">EXCEPT FOR THE EXPRESS WARRANTIES IN THIS AGREEMENT, EACH PARTY HEREBY DISCLAIMS ALL WARRANTIES, EITHER EXPRESS, IMPLIED, STATUTORY, OR OTHERWISE UNDER THIS AGREEMENT, INCLUDING ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE XII<br></font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">INDEMNIFICATION</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 12.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">OptiNose acknowledges that VTM has no control over, and is not responsible for, the manner in which the DSAs will be used or otherwise dealt with by OptiNose. OptiNose shall defend, indemnify and hold VTM and VTM&#8217;s Affiliates and their officers, directors, employees, agents, successors and permitted assigns (each, a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">VTM Indemnitee</font><font style="font-family:inherit;font-size:12pt;">&#8221;) harmless from and against any and all third party suits, claims, losses, demands, liabilities, damages, costs and expenses (including reasonable attorneys&#8217; fees) (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Losses</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and agree to assume all responsibility for any and all actions, claims, or demands arising out of or in any way connected with, and any and all amounts which VTM and/or OptiNose becomes obligated to pay, caused by or resulting directly or indirectly from the use or operation of the DSAs, including any intellectual property claims, except to the extent VTM is required to indemnity OptiNose for such Loss pursuant to Section 12.02. </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 12.02</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">VTM agrees to defend, indemnify and hold harmless OptiNose and OptiNose&#8217;s Affiliates and their officers, directors, employees, agents, successors and permitted assigns (each, an &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OptiNose Indemnitee</font><font style="font-family:inherit;font-size:12pt;">&#8221;) from and against, any and all Losses as follows: (a) any </font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">24</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">actual or alleged injury or damage to any person (including death) or property caused, or alleged to be caused, by a DSA sold by VTM to OptiNose hereunder, but solely to the extent such injury or damage has been caused by the breach by VTM of its Warranty set forth in Article IV, including but not limited to the failure of the DSA to conform to the Specifications; and (b) any actual or alleged infringement or misappropriation of the intellectual property rights (including any industrial design rights, database rights or any other form of intangible or business property rights) of any third party, but solely to the extent that such infringement or misappropriation is caused by a process, VTM Tools, or Production Materials that VTM elects to use to manufacture, assemble or test the DSAs; however, VTM shall not have any obligation to indemnify OptiNose if such claim would not have arisen but for VTM&#8217;s manufacture, assembly or test of the DSA in accordance with the Specifications.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 12.03</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The party seeking indemnification hereunder shall promptly notify the indemnifying party in writing of any third party claim, suit, action or proceeding (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Action</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and cooperate with the indemnifying party [***]. The indemnifying party shall immediately take control of the defense and investigation of such Action and shall employ counsel of its choice to handle and defend the same, [***]. The indemnifying party shall not settle any Action in a manner that adversely affects the rights of the indemnified party without the indemnified party&#8217;s prior written consent.  The indemnified party&#8217;s failure to perform any obligations under this Section 12.3 shall not relieve the indemnifying party of its obligations under this Section 12.3 except to the extent that the indemnifying party can demonstrate that it has been materially prejudiced as a result of such failure. The indemnified party may participate in and observe the proceedings [***].</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE XIII</font><font style="font-family:inherit;font-size:10pt;"><br>        </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">LIMITATION OF LIABILITY</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 13.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">EXCEPT AS OTHERWISE PROVIDED IN SECTION 13.02, IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER OR TO ANY THIRD PARTY FOR ANY LOSS OF USE, REVENUE OR PROFIT OR FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY, SPECIAL OR PUNITIVE DAMAGES WHETHER ARISING OUT OF BREACH OF CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. FURTHERMORE, EXCEPT WITH RESPECT TO THE EQUITABLE EXCEPTIONS, IN NO EVENT WILL VTM BE LIABLE FOR THE VALUE OF THE INTERNAL TIME OF OPTINOSE&#8217;S EMPLOYEES TO REMEDY A BREACH.    </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 13.02</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The exclusions and limitations in Section 13.01 shall not apply to the following (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Equitable Exceptions</font><font style="font-family:inherit;font-size:12pt;">&#8221;):</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">damages or other liabilities arising out of or relating to a party&#8217;s failure to comply with its obligations under Article IX (Intellectual Property Rights; Ownership); </font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">25</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">damages or other liabilities arising out of or relating to a party&#8217;s failure to comply with its obligations under Article X (Confidentiality);</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">a party&#8217;s indemnification obligations under Article XII (Indemnification); and</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">damages or other liabilities arising out of or relating to a party&#8217;s gross negligence, willful misconduct or intentional acts. </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">EXCEPT WITH RESPECT TO THE EQUITABLE EXCEPTIONS ABOVE AND NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, VTM&#8217;S TOTAL LIABILITY TO OPTINOSE HEREUNDER SHALL BE SUBJECT TO AN AGGREGATE CAP IN ACCORDANCE WITH THE FOLLOWING: [***].  </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 13.03</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Double Recovery</font><font style="font-family:inherit;font-size:12pt;">.  Notwithstanding OptiNose&#8217;s rights under the Molded Parts Agreement, in the event of a dispute of a claim under either this Agreement or the Molded Parts Agreement, OptiNose is only entitled to recover under this Agreement with respect to the DSAs, and the Molded Parts Agreement with respect to the cap covered thereunder.  Further, notwithstanding the preceding sentence, if there are any disputes or claims regarding Pre-Existing Inventory that OptiNose purchased from VTM prior to the date of this Agreement and such Pre-Existing Inventory would not be covered under this Agreement for any claims or disputes related thereto, then the parties agree and acknowledge that OptiNose maintains any and all rights set forth in the Molded Parts Agreements regarding such Pre-Existing Inventory.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE XIV</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">TERM</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 14.01</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;&#32;This Agreement shall commence as of the Effective Date and shall expire at 11:59PM on October 24, 2021, unless sooner terminated pursuant to Article XV. After the expiration of the initial term hereunder, this Agreement shall be automatically renewed for separate but successive one-year terms unless either party provides written notice to the other party that it does not intend to renew this Agreement ninety (90) days or more prior to the end of any term.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE XV</font><font style="font-family:inherit;font-size:10pt;"><br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TERMINATION; EFFECT OF TERMINATION</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 15.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">OptiNose, in its sole discretion, may terminate this Agreement: </font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">[***]; </font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">by providing VTM written notice if VTM fails an inspection or suffers a hold, 483, warning letter, or other disciplinary action by the FDA or any other government authority and VTM fails to cure such inspection shortcoming, or remove or resolve such hold or disciplinary action in such a manner that the VTM facility passes re-inspection by the FDA or government authority and/or is free of the hold or disciplinary action, in good standing with FDA or such other government authority, </font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">26</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">and is lawfully able to and does resume timely and conforming manufacture and delivery of OptiNose&#8217;s DSAs requirements in accordance with this Agreement within thirty days of such original inspection, or imposition of the hold or disciplinary action; or</font></div><div style="line-height:150%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">by providing VTM written notice if VTM fails to gain recommendation for approval by FDA to manufacture DSAs in accordance with this Agreement (with such recommendation being either unqualified or with any qualifications resolved to FDA&#8217;s acknowledged satisfaction) in a manner that does not delay such approval by the FDA.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 15.02</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Either party may terminate this Agreement, effective upon written notice to the other party (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Defaulting Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;), if the Defaulting Party: </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">materially breaches this Agreement, and such breach is incapable of cure, or with respect to a material breach capable of cure, the Defaulting Party does not cure such breach within [***] days after receipt of written notice of such breach.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">(i) becomes insolvent or admits its inability to pay its debts generally as they become due; (ii) becomes subject, voluntarily or involuntarily, to any proceeding under any domestic or foreign bankruptcy or insolvency law, which is not fully stayed within seven business days or is not dismissed or vacated within forty-five days after filing; (iii) is dissolved or liquidated or takes any corporate action for such purpose; (iv) makes a general assignment for the benefit of creditors; or (v) has a receiver, trustee, custodian or similar agent appointed by order of any court of competent jurisdiction to take charge of or sell any material portion of its property or business.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 15.03</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Upon expiration or termination of this Agreement for any reason:</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">OptiNose shall have the right at any time after a notice of termination has been given or an event has occurred which, with the passage of time, will cause this Agreement to terminate to require VTM, as soon as reasonably practicable and in no more than [***] days from the effective date of termination, to make available for removal by OptiNose or its designee [***]:  (i) all DSAs, all Inventory, all partially completed DSAs, all Deliverables and all OptiNose Information ([***]), and (ii) all OptiNose Equipment.  Upon payment, as applicable, all of the foregoing items for removal shall be made available at the facility, [***], claims and encumbrances, and VTM shall provide [***] cooperation and assistance to OptiNose upon OptiNose&#8217;s written request [***] in transitioning the manufacture of DSAs and related services under this Agreement to an alternate supplier.  [***].</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each party shall (i) return to the other party all documents and tangible materials (and any copies) containing, reflecting, incorporating or based on the other party&#8217;s Confidential Information, (ii) if the other party requests, use [***] efforts to permanently erase all of the other party&#8217;s Confidential Information from its computer systems, and (iii) certify in writing to the other party that it has complied with the requirements of this clause; </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">provided, however</font><font style="font-family:inherit;font-size:12pt;">, that OptiNose may retain copies of any Confidential Information of VTM incorporated in the Deliverables or to the extent necessary to allow </font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">27</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">it to make full use of the DSAs and any Deliverables; and </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">provided further, however, </font><font style="font-family:inherit;font-size:12pt;">that VTM shall retain such documents and tangible materials as are required to be maintained by VTM under Law.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">In no event shall OptiNose be liable for [***].</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 15.04</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The rights and obligations of the parties set forth in this Section 15.04 and Article I, Sections 5.01, 5.03, 5.04, 5.05, 5.06 and 6.01(e), Article IX, Article X, Article XI, Article XII, Article XIII, Section 15.03, Article XVI and Article XVIII, and any right or obligation of the parties in this Agreement which, by its nature, should survive termination or expiration of this Agreement, will survive any such termination or expiration of this Agreement.  For purposes of clarity, in no event shall any termination or expiration of this Agreement excuse either party from any breach or violation of this Agreement or other obligation that occurred prior to such termination or expiration and, in each such case, full legal and equitable remedies shall remain available to address such issues.  </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE XVI</font><font style="font-family:inherit;font-size:10pt;"><br></font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">INSURANCE</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 16.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#32;At all times during the Term and for a period of at least [***] thereafter, VTM shall procure and maintain, at its sole cost and expense, at least the following types and amounts of insurance coverage:</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Commercial General Liability/ Completed Operation Liability with limits no less than $[***] per occurrence, including bodily injury and property damage and products, which policy will include contractual liability coverage insuring the activities of VTM under this Agreement;</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Worker&#8217;s Compensation with employer&#8217;s liability limits no less [***];</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Errors and Omissions and/or Professional Liability with limits no less than $[***] per occurrence; and</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Umbrella Liability with limits no less than $[***] per occurrence and $[***] in the aggregate providing excess coverage of the primary Commercial General Liability, including Products/Completed Operations Liability.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 16.02</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">All insurance policies required pursuant to this Article XVI shall:</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">be issued by an insurance company or insurance companies having an A.M. Best Rating of [***] or better;</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">provide that such insurance be primary insurance and any similar insurance in the name of and/or for the benefit of OptiNose shall be excess and non-contributory; provided, however, this provision shall not apply to the insurance required by Section 16.01(b); and</font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">28</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">name OptiNose and OptiNose&#8217;s Affiliates, including, in each case, all successors and permitted assigns, as Additional Insureds; provided, however, this provision shall not apply to the insurance required by Section 16.01(b). </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 16.03</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Upon the written request of OptiNose, VTM shall provide OptiNose with copies of the certificates of insurance for all insurance coverage required by this Article XVI, and shall not do anything to invalidate such insurance. This Article XVI shall not be construed in any manner as waiving, restricting or limiting the liability of either party for any obligations imposed under this Agreement (including but not limited to, any provisions requiring a party hereto to indemnify, defend and hold the other harmless under this Agreement).</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE XVII</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">FORCE MAJEURE</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 17.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">No party shall be liable or responsible to the other party, nor be deemed to have defaulted under or breached this Agreement, for any failure or delay in fulfilling or performing any term of this Agreement, when and to the extent such failure or delay is caused by or results from acts beyond the affected party&#8217;s reasonable control, including, without limitation:</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;padding-left:102px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">acts of God;</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;padding-left:102px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">flood, fire or explosion;</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;padding-left:102px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">war, invasion, riot or other civil unrest;</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;padding-left:102px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">actions, embargoes or blockades in effect on or after the date of this Agreement;</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;padding-left:102px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">national or regional emergency;</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;padding-left:102px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">strikes, labor stoppages or slowdowns or other industrial disturbances; or</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;padding-left:102px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">compliance with any law or governmental order, rule, regulation or direction, or any action taken by a governmental or public authority, including but not limited to imposing an embargo, export or import restriction, quota or other restriction or prohibition, or failing to grant a necessary license or consent;</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;(each of the foregoing, a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Force Majeure Event</font><font style="font-family:inherit;font-size:12pt;">&#8221;). A party whose performance is affected by a Force Majeure Event shall give notice to the other party, stating the period of time the occurrence is expected to continue and shall use [***] to end the failure or delay and minimize the effects of such Force Majeure Event.</font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">29</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 17.02</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">During the Force Majeure Event, the non-affected party may similarly suspend its performance obligations until such time as the affected party resumes performance.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 17.03</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The non-affected party may terminate this Agreement if such failure or delay continues for a period of [***] days or more and, [***]. </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE XVIII</font><font style="font-family:inherit;font-size:10pt;"><br></font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">MISCELLANEOUS</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 18.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each party shall, upon the reasonable request, promptly execute such documents and perform such acts as may be necessary to give full effect to the terms of this Agreement.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 18.02</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The relationship between the parties is that of independent contractors. Nothing contained in this Agreement shall be construed as creating any agency, partnership, joint venture or other form of joint enterprise, employment or fiduciary relationship between the parties, and neither party shall have authority to contract for or bind the other party in any manner whatsoever.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 18.03</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Neither party shall issue or release any announcement, statement, press release or other publicity or marketing materials relating to this Agreement, or otherwise use the other party&#8217;s trademarks, service marks, trade names, logos, symbols or brand names, in each case, without the prior written consent of the other party, except to the extent necessary pursuant to any applicable securities exchange rule.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 18.04</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in writing and shall be deemed to have been given (a) when delivered by hand (with written confirmation of receipt); (b) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); or (c) on the third day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such communications must be sent to the respective parties at the addresses indicated below (or at such other address for a party as shall be specified in a notice given in accordance with this Section 18.04.)  </font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">30</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.62655601659752%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If to VTM:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">VTM, LLC</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attn:  Chief Executive Officer</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">71 Utopia Road</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Manchester, CT 06042 </font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Flex Health Solutions</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6201 America Center Drive</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">San Jose, CA </font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attn: Medical, General Counsel</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If to OptiNose:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">OptiNose US, Inc.  <br>Attn: Chief Executive Officer  <br>1020 Stony Hill Road, Suite 300 <br>Yardley, PA 19067</font></div><div style="padding-bottom:6px;padding-top:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">To OptiNose UK:   </font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:inherit;font-size:12pt;">OptiNose UK, Ltd. <br>Hunts Rise <br>South Marston Park, Wiltshire <br>SN3 4TG, England <br>Attention: Chief Executive Officer</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">To OptiNose Norway:    <br>OptiNose AS</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:inherit;font-size:12pt;">Gaustadall&#233;en 210349</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:inherit;font-size:12pt;">Oslo, Norway       <br>Attention: Chief Executive Officer</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></td></tr></table></div></div><div style="line-height:150%;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In each instance, with cc to:</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;OptiNose US, Inc.</font></div><div style="line-height:150%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attn: Chief Legal Officer</font></div><div style="line-height:150%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1020 Stony Hill Road, Suite 300</font></div><div style="line-height:150%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Yardley, PA 19067</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 18.05</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">For purposes of this Agreement, (a) the words &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the words &#8220;without limitation&#8221;; (b) the word &#8220;or&#8221; is not exclusive; and (c) the words &#8220;herein,&#8221; &#8220;hereof,&#8221; &#8220;hereby,&#8221; &#8220;hereto&#8221; and &#8220;hereunder&#8221; refer to this Agreement as a whole. Unless the context otherwise requires, references herein: (x) to Sections and Exhibits refer to the Sections of, and Exhibits attached to, this Agreement; and (y) to a statute means such statute as amended from time to time and includes any successor legislation thereto and any regulations promulgated thereunder. This Agreement shall be construed without regard to any </font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">31</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">presumption or rule requiring construction or interpretation against the party drafting an instrument or causing any instrument to be drafted. The Schedules, Exhibits and Statements of Work referred to herein shall be construed with, and as an integral part of, this Agreement to the same extent as if they were set forth verbatim herein.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 18.06</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Agreement, together with all Exhibits and any other documents incorporated herein by reference, constitutes the sole and entire agreement of the parties to this Agreement with respect to the subject matter contained herein, and supersedes all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter.  For purposes of clarity, this Agreement shall not supersede the development agreements and other related project work between the parties not otherwise covered by this Agreement. </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 18.07</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Neither party may assign, transfer or delegate any or all of its rights or obligations under this Agreement (including without limitation to any subcontractors), without the prior written consent of the other party, which consent shall not be unreasonably withheld or delayed; </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">provided, that</font><font style="font-family:inherit;font-size:12pt;">, upon prior written notice to the other party, either party may assign the Agreement to an Affiliate of such party or to a successor of all or substantially all of the assets of such party through merger, reorganization, consolidation or acquisition; provided further, that, notwithstanding the foregoing, VTM may not make such an assignment without OptiNose&#8217;s prior written consent, not to be unreasonably withheld. No assignment shall relieve the assigning party of any of its obligations hereunder. Any attempted assignment, transfer or other conveyance in violation of the foregoing shall be null and void. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 18.08</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Agreement is for the sole benefit of the parties hereto and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other Person any legal or equitable right, benefit or remedy of any nature whatsoever, under or by reason of this Agreement.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 18.09</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 18.10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Agreement may only be amended, modified or supplemented by an agreement in writing signed by each party hereto. No waiver by any party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the party so waiving. Except as otherwise set forth in this Agreement, no failure to exercise, or delay in exercising, any rights, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.</font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">32</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 18.11</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. Upon such determination that any term or other provision is invalid, illegal or unenforceable, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the greatest extent possible.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 18.12</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Agreement shall be governed by and interpreted in accordance with the laws of the State of New York, exclusive of conflict or choice-of-law rules, except to the extent there may be any conflict between the laws of the State of New York and the Incoterms of the International Chamber of Commerce, 2010 edition, in which case the Incoterms shall be controlling.  The parties specifically agree that the 1980 United Nations Convention on Contracts for the International Sale of Goods, as may be amended from time to time, shall not apply to this Agreement.  The parties hereby consent to the personal and exclusive jurisdiction and venue of the New York state courts and the federal courts located in New York, New York.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 18.13</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Any controversy, claim, or dispute arising out of or relating to this order and not resolved by agreement of the parties shall be resolved in Arbitration in New York, New York. The decision and award of the arbitrator(s) shall be final and binding and may be entered in any court having jurisdiction thereof. The parties will pay their respective attorneys&#8217; fees and equally share all other costs and expenses of the arbitration proceedings.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 18.14</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Notwithstanding the foregoing, except with respect to enforcing claims for injunctive or equitable relief, any dispute, claim or controversy arising out of or relating in any way to this Agreement, any other aspect of the relationship between VTM and OptiNose or their respective affiliates and subsidiaries, the interpretation, application, enforcement, breach, termination or validity thereof (including, without limitation, any claim of inducement of this Agreement by fraud and a determination of the scope or applicability of this agreement to arbitrate), or its subject matter (collectively, &#8220;Disputes&#8221;) shall be determined by binding arbitration before one arbitrator.  The arbitration shall be administered by JAMS conducted in accordance with the expedited procedures set forth in the JAMS Comprehensive Arbitration Rules and Procedures as those Rules exist on the Effective Date of this Agreement, including Rules 16.1 and 16.2 of those Rules.  Notwithstanding anything to the contrary in this Agreement, the Federal Arbitration Act shall govern the arbitrability of all Disputes.  The arbitration shall be held in New York, New York and it shall be conducted in the English language.  The parties shall maintain the confidential nature of the arbitration proceeding and any award, including the hearing, except as may be necessary to prepare for or conduct the arbitration hearing on the merits, or except as may be necessary in connection with a court application for a </font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">33</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">preliminary remedy, a judicial challenge to an award or its enforcement, or unless otherwise required by law or judicial decision.  The arbitrator shall have authority to award compensatory damages only and shall not award any punitive, exemplary, or multiple damages and the parties waive any right to recover any such damages.  Judgment on any award in arbitration may be entered in any court of competent jurisdiction.  Notwithstanding the above, each party shall have recourse to any court of competent jurisdiction to enforce claims for injunctive and other equitable relief.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 18.15</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">IN THE EVENT OF ANY DISPUTE BETWEEN THE PARTIES, WHETHER IT RESULTS IN PROCEEDINGS IN ANY COURT IN ANY JURISDICTION OR IN ARBITRATION, THE PARTIES HEREBY KNOWINGLY AND VOLUNTARILY, AND HAVING HAD AN OPPORTUNITY TO CONSULT WITH COUNSEL, WAIVE ALL RIGHTS TO TRIAL BY JURY, AND AGREE THAT ANY AND ALL MATTERS SHALL BE DECIDED BY A JUDGE OR ARBITRATOR WITHOUT A JURY TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW.  To the extent applicable, in the event of any lawsuit between the parties arising out of or related to this Agreement, the parties agree to prepare and to timely file in the applicable court a mutual consent to waive any statutory or other requirements for a trial by jury.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 18.16</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each party acknowledges that a breach by a party of Article IX (Intellectual Property Rights; Ownership) or Article X (Confidentiality) may cause the non-breaching party irreparable damages, for which an award of damages would not be adequate compensation and agrees that, in the event of such breach or threatened breach, the non-breaching party will be entitled to seek equitable relief, including a restraining order, injunctive relief, specific performance and any other relief that may be available from any court, in addition to any other remedy to which the non-breaching party may be entitled at law or in equity. Such remedies shall not be deemed to be exclusive but shall be in addition to all other remedies available at law or in equity, subject to any express exclusions or limitations in this Agreement to the contrary.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 18.17</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">In the event that any action, suit, or other legal or administrative proceeding is instituted or commenced by either party hereto against the other party arising out of or related to this Agreement, the prevailing party shall be entitled to recover its reasonable attorneys&#8217; fees and court costs from the non-prevailing party.</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 18.18</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.  </font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 18.19</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">[***].</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[Signature Page Follows]</font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">34</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.1701244813278%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ADVANCE MOLD &amp; MANUFACTURING, INC.</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: </font><font style="font-family:inherit;font-size:12pt;">&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Fabio Scagliarini</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Fabio Scagliarini</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Its: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">General Manager</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OPTINOSE US, INC.</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: </font><font style="font-family:inherit;font-size:12pt;">&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Peter Miller</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:   Peter Miller   </font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Its:   Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OPTINOSE UK LTD.</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: </font><font style="font-family:inherit;font-size:12pt;">&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Ricci Whitlow</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:    Ricci Whitlow</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Its:   VP, Tech Ops</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OPTINOSE AS</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: </font><font style="font-family:inherit;font-size:12pt;">&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Peter Miller</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:   Peter Miller   </font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Its:   Chief Executive Officer</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">35</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT A</font></div><div style="line-height:150%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PRICING</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">***************</font></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">36</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:150%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT B</font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">37</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OPTINOSE COMPONENTS</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">38</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:150%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT C</font></div><div style="line-height:150%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OPTINOSE COMPONENTS WITH ADDITIONAL STORAGE TIME</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">39</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:150%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT D</font></div><div style="line-height:150%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ESCALATION MATRIX</font></div><div style="line-height:150%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:150%;text-align:center;"><img src="exhibit1020optnvtmopn_image1.gif" alt="exhibit1020optnvtmopn_image1.gif" style="height:398px;width:236px;"></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">40</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div></div><div><br></div><div style="line-height:150%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:150%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">41</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>listofsubsidiariesex211.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sC947DC523CB558CEAF8E1A392792C54B"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Exhibit 21.1</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OPTINOSE, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">LIST OF SUBSIDIARIES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Jurisdiction of Incorporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Percent Owned</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">OptiNose US, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">100%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Optinose AS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Norway</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">100%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Optinose UK, Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United Kingdom</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">100%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>auditorconsent10-kex231.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7AF45296BB50544982E4F6153190D1AB"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Exhibit 23.1</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Consent of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;">We consent to the incorporation by reference in the following Registration Statements:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;">Registration Statement (Form S-8 No. 333-221047) pertaining to the Amended and Restated 2010 Stock Incentive Plan and the 2017 Employee Stock Purchase Plan of OptiNose, Inc.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;">Registration Statement (Form S-8 No. 333-223617) pertaining to the Amended and Restated 2010 Stock Incentive Plan and the 2017 Employee Stock Purchase Plan of OptiNose, Inc.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;">Registration Statement (Form S-3 No. 333-228122) of OptiNose, Inc.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;">of our report dated March 6, 2019, with respect to the consolidated financial statements of OptiNose, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2018.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:480px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Ernst &amp; Young LLP</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Philadelphia, Pennsylvania</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">March 6, </font><font style="font-family:Arial;font-size:10pt;">2019</font><font style="font-family:Arial;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>optn12-31x201810xkex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sB154582D146550659CCFD22ADF2E1361"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 302 OF THE</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">I, Peter K. Miller, certify that:</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1. &#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K of OptiNose, Inc.;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2. &#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3. &#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4. &#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a. &#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">b.     Designed such&#160;internal control over financial reporting, or caused such&#160;internal control over financial reporting&#160;to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">c. &#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">d. &#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5. &#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a. &#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">b. &#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:41%;"></td><td style="width:3%;"></td><td style="width:56%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Date: March 6, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">/s/ Peter K. Miller</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Peter K. Miller</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>optn12-31x201810xkex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s3DBB4512957E591083C8C79D3ACAFB9C"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OFFICER PURSUANT TO  SECTION 302 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">I, Keith A. Goldan, certify that:</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1. &#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K of OptiNose, Inc.;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2. &#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3. &#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4. &#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a. &#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">b.     Designed such&#160;internal control over financial reporting, or caused such&#160;internal control over financial reporting&#160;to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">c. &#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">d. &#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5. &#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a. &#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">b. &#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:41%;"></td><td style="width:3%;"></td><td style="width:56%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Date: March 6, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">/s/ Keith A. Goldan</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Principal Financial Officer and Principal Accounting Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>optn12-31x201810xkex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s1D02E33CB75E5954A07528B886CA2537"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OFFICER PURSUANT TO 18 U.S.C</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">SECTION 1350, AS ADOPTED PURSUANTTO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">I, Peter K. Miller, Chief Executive Officer of OptiNose, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:77px;"></td><td style="width:605px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the Annual Report on Form 10-K of the Company for the year ended December 31, 2018 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:77px;"></td><td style="width:605px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:41%;"></td><td style="width:3%;"></td><td style="width:56%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Date: March 6, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">/s/ Peter K. Miller</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Peter K. Miller</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>optn12-31x201810xkex322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s307896B89B885C3080CE54FE06664D8E"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OFFICER PURSUANT TO U.S.C SECTION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1350, AS ADOPTED PURSUANT TO </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">I, Keith A. Goldan, Chief Financial Officer of OptiNose, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:77px;"></td><td style="width:605px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the Annual Report on Form 10-K of the Company for the year ended December&#160;31, 2018 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:77px;"></td><td style="width:605px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:41%;"></td><td style="width:3%;"></td><td style="width:56%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Date: March 6, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">/s/ Keith A. Goldan</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Keith A. Goldan</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Principal Financial Officer and Principal Accounting Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>10
<FILENAME>optn-20181231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:92CA4AAD513B5459BA6728875DAF5C81,x:a637564b7cc447b495246895b7ebb0f1-->
<xbrli:xbrl xmlns:acec="http://fasb.org/dis/acec/2018-01-31" xmlns:ap="http://fasb.org/dis/ap/2018-01-31" xmlns:aro="http://fasb.org/dis/aro/2018-01-31" xmlns:bc="http://fasb.org/dis/bc/2018-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2018-01-31" xmlns:cc="http://fasb.org/dis/cc/2018-01-31" xmlns:cce="http://fasb.org/dis/cce/2018-01-31" xmlns:codification-part="http://fasb.org/codification-part/2018-01-31" xmlns:com="http://fasb.org/stm/com/2018-01-31" xmlns:con="http://fasb.org/dis/con/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2018-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2018-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2018-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2018-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2018-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2017-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2017-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2017-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2017-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2018-01-31" xmlns:debt="http://fasb.org/dis/debt/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2018-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2018-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2018-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:diha="http://fasb.org/dis/diha/2018-01-31" xmlns:disops="http://fasb.org/dis/disops/2018-01-31" xmlns:dr="http://fasb.org/dis/dr/2018-01-31" xmlns:edco="http://fasb.org/dis/edco/2018-01-31" xmlns:ei="http://fasb.org/dis/ei/2018-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2018-01-31" xmlns:eps="http://fasb.org/dis/eps/2018-01-31" xmlns:equity="http://fasb.org/dis/equity/2018-01-31" xmlns:ero="http://fasb.org/dis/ero/2018-01-31" xmlns:eui="http://fasb.org/dis/eui/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2018-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2018-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2018-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2018-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2018-01-31" xmlns:foct="http://fasb.org/dis/foct/2018-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2018-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2018-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2018-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2018-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2018-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2018-01-31" xmlns:guar="http://fasb.org/dis/guar/2018-01-31" xmlns:hco="http://fasb.org/dis/hco/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2018-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2018-01-31" xmlns:ides="http://fasb.org/dis/ides/2018-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2018-01-31" xmlns:inv="http://fasb.org/dis/inv/2018-01-31" xmlns:invco="http://fasb.org/dis/invco/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2018-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:lea="http://fasb.org/dis/lea/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:ni="http://fasb.org/dis/ni/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:nt="http://fasb.org/dis/nt/2018-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2018-01-31" xmlns:oi="http://fasb.org/dis/oi/2018-01-31" xmlns:optn="http://www.optinose.com/20181231" xmlns:otherexp="http://fasb.org/dis/otherexp/2018-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2018-01-31" xmlns:pay="http://fasb.org/dis/pay/2018-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2018-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2018-01-31" xmlns:rd="http://fasb.org/dis/rd/2018-01-31" xmlns:re="http://fasb.org/dis/re/2018-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:regop="http://fasb.org/dis/regop/2018-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2018-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2018-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2018-01-31" xmlns:ru="http://fasb.org/dis/ru/2018-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2018-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2018-01-31" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2018-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2018-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2018-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2018-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2018-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2018-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2018-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2018-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2018-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2018-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2018-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2018-01-31" xmlns:se="http://fasb.org/dis/se/2018-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2018-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2018-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2018-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2018-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2018-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2018-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2018-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2018-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2018-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2018-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2018-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2018-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2018-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2018-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:soc="http://fasb.org/stm/soc/2018-01-31" xmlns:soi="http://fasb.org/stm/soi/2018-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2018-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2018-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2018-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2018-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2018-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2018-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2018-01-31" xmlns:spc="http://fasb.org/stm/spc/2018-01-31" xmlns:sr="http://fasb.org/dis/sr/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:srt-all="http://fasb.org/srt-all/2018-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2018-01-31" xmlns:srt-std="http://fasb.org/srt-std/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:te="http://fasb.org/dis/te/2018-01-31" xmlns:tin-part="http://fasb.org/tin-part/2018-01-31" xmlns:ts="http://fasb.org/dis/ts/2018-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2018-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2018-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2018-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="optn-20181231.xsd" xlink:type="simple" />
	<xbrli:context id="FD2018Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1Mar1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Jun29">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesC2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">optn:RedeemableConvertiblePreferredStockSeriesC2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemablePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesDMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">optn:RedeemableConvertiblePreferredStockSeriesDMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">optn:RedeemableConvertiblePreferredStockSeriesCC1C2DMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">optn:RedeemableConvertiblePreferredStockSeriesCC1C2DMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesCC1DMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">optn:RedeemableConvertiblePreferredStockSeriesCC1DMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemablePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemablePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">optn:RedeemableConvertiblePreferredStockSeriesCC1C2DMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesCC1DMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">optn:RedeemableConvertiblePreferredStockSeriesCC1DMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">optn:RedeemableConvertiblePreferredStockSeriesCC1C2DMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesCC1DMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">optn:RedeemableConvertiblePreferredStockSeriesCC1DMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesC2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">optn:RedeemableConvertiblePreferredStockSeriesC2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Jun11_us-gaap_SubsidiarySaleOfStockAxis_optn_PublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">optn:PublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Jun11_us-gaap_SubsidiarySaleOfStockAxis_optn_PublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">optn:PublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-11</xbrli:startDate>
			<xbrli:endDate>2018-06-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Jun11_srt_CounterpartyNameAxis_optn_CertainStockholdersMember_us-gaap_SubsidiarySaleOfStockAxis_optn_PublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">optn:CertainStockholdersMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">optn:PublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-11</xbrli:startDate>
			<xbrli:endDate>2018-06-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Jun11_srt_CounterpartyNameAxis_optn_TheCompanyMember_us-gaap_SubsidiarySaleOfStockAxis_optn_PublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">optn:TheCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">optn:PublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-11</xbrli:startDate>
			<xbrli:endDate>2018-06-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_optn_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">optn:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_optn_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">optn:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Oct10">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-10</xbrli:startDate>
			<xbrli:endDate>2017-10-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_optn_ComputerEquipmentandSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">optn:ComputerEquipmentandSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_optn_ComputerEquipmentandSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">optn:ComputerEquipmentandSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Jul1-Dec31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-07-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Sep30_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-09-30</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Mar24_us-gaap_DebtConversionByUniqueDescriptionAxis_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesC2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">optn:ConversionofConvertiblenotesintoSeriesC2PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">optn:RedeemableConvertiblePreferredStockSeriesC2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-24</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_DebtInstrumentAxis_optn_TrancheTwoMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:TrancheTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar24_us-gaap_DebtConversionByUniqueDescriptionAxis_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesC2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">optn:ConversionofConvertiblenotesintoSeriesC2PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">optn:RedeemableConvertiblePreferredStockSeriesC2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-24</xbrli:startDate>
			<xbrli:endDate>2017-03-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_DebtInstrumentAxis_optn_TrancheOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:TrancheOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar24_us-gaap_DebtConversionByUniqueDescriptionAxis_optn_SeriesDFinancingMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">optn:SeriesDFinancingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-24</xbrli:startDate>
			<xbrli:endDate>2017-03-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Dec29_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementDelayedDrawNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementDelayedDrawNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-29</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Dec29_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-29</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementDelayedDrawNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementDelayedDrawNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Dec29_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementDelayedDrawNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementDelayedDrawNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-29</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFourMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q2Apr1-Aug14_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementDelayedDrawNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementDelayedDrawNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-08-14</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">optn:NotePurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_optn_DefinedContributionPlanTranchesAxisAxis_optn_DefinedContributionPlanTrancheTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="optn:DefinedContributionPlanTranchesAxisAxis">optn:DefinedContributionPlanTrancheTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_optn_DefinedContributionPlanTranchesAxisAxis_optn_DefinedContributionPlanTrancheOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="optn:DefinedContributionPlanTranchesAxisAxis">optn:DefinedContributionPlanTrancheOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Jan31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Nov30_us-gaap_OtherCommitmentsAxis_optn_MarketSalesforceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">optn:MarketSalesforceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-11-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Nov30_srt_RangeAxis_srt_MaximumMember_us-gaap_OtherCommitmentsAxis_optn_MarketSalesforceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">optn:MarketSalesforceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-11-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Oct1-Oct31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Oct1-Oct31_us-gaap_ConversionOfStockByUniqueDescriptionAxis_optn_ConversionatConsummationofIPOMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">optn:ConversionatConsummationofIPOMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_DebtConversionByUniqueDescriptionAxis_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesC2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">optn:ConversionofConvertiblenotesintoSeriesC2PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">optn:RedeemableConvertiblePreferredStockSeriesC2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Oct31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_DebtConversionByUniqueDescriptionAxis_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesC2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">optn:ConversionofConvertiblenotesintoSeriesC2PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">optn:RedeemableConvertiblePreferredStockSeriesC2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_DebtConversionByUniqueDescriptionAxis_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">optn:ConversionofConvertiblenotesintoSeriesC2PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesDMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">optn:RedeemableConvertiblePreferredStockSeriesDMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Oct31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesDMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">optn:RedeemableConvertiblePreferredStockSeriesDMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Oct1-Oct31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Oct31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">optn:ServiceBasedStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">optn:ServiceBasedStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">optn:ServiceBasedStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">optn:ServiceBasedStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PlanNameAxis_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">optn:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_PlanNameAxis_optn_AmendedandRestated2010StockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">optn:AmendedandRestated2010StockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_PlanNameAxis_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">optn:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PlanNameAxis_optn_AmendedandRestated2010StockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">optn:AmendedandRestated2010StockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">optn:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_RelatedPartyTransactionAxis_optn_FeesForIPOAndSeriesDConvertibleStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_InvestorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">optn:FeesForIPOAndSeriesDConvertibleStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RelatedPartyTransactionAxis_optn_FeesForIPOAndSeriesDConvertibleStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_InvestorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">optn:FeesForIPOAndSeriesDConvertibleStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1Jan31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001494650</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="sqft">
		<xbrli:measure>utreg:sqft</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="quarter">
		<xbrli:measure>optn:quarter</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="tranche">
		<xbrli:measure>optn:tranche</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="customers">
		<xbrli:measure>optn:customers</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="vote">
		<xbrli:measure>optn:vote</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="lease">
		<xbrli:measure>optn:lease</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2018Q4YTD" id="Fact-E60B45979D34E2616F97DED0B864729B">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2018Q4YTD" id="Fact-0B75F6975495C98A6D62DED0B864D1F1">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2018Q4YTD" id="Fact-61FC39E949F422224131DED0B8662053">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2018Q4YTD" id="Fact-9CF31D26385076732359DED0B8677680">2018</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2018Q4YTD" id="Fact-7242C6B3E84FDF32EA5EDED0B866DBE7">2018-12-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2018Q4YTD" id="Fact-2129DC7CB719FDDD19FADED0B869A3D2">10-K</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2018Q4YTD" id="Fact-8A9746FD0FA276D7FD24DED0B868613B">0001494650</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2019Q1Mar1" decimals="INF" id="Fact-62D4206F8DCA20E6D985DED0B866E2F7" unitRef="shares">41264422</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2018Q4YTD" id="Fact-0EE6B459E2EC5B970124DED0B8662077">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityEmergingGrowthCompany contextRef="FD2018Q4YTD" id="Fact-471D5BF82698861D06D6DED7366E7CDA">true</dei:EntityEmergingGrowthCompany>
	<dei:EntityExTransitionPeriod contextRef="FD2018Q4YTD" id="Fact-BE446490CFC62A2F571EDED7582469D8">true</dei:EntityExTransitionPeriod>
	<dei:EntityFilerCategory contextRef="FD2018Q4YTD" id="Fact-D5BE5647399B9D747B11DED0B8670EBF">Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityPublicFloat contextRef="I2018Q2Jun29" decimals="-5" id="Fact-E87AC3A4A9412B79E49DDED0B868BF45" unitRef="usd">682400000</dei:EntityPublicFloat>
	<dei:EntityRegistrantName contextRef="FD2018Q4YTD" id="Fact-D2FC5DA1C14755720D71DED0B8656CCF">OptiNose, Inc.</dei:EntityRegistrantName>
	<dei:EntityShellCompany contextRef="FD2018Q4YTD" id="Fact-A2E085E5C91CC467D727DED77B41DF2F">false</dei:EntityShellCompany>
	<dei:EntitySmallBusiness contextRef="FD2018Q4YTD" id="Fact-9B51D02C285E3DCB7DAFDED70F5CB8DF">true</dei:EntitySmallBusiness>
	<dei:EntityVoluntaryFilers contextRef="FD2018Q4YTD" id="Fact-97E47FB38F5F78CB65C9DED0B868CAD2">No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef="FD2018Q4YTD" id="Fact-FBAA6C1F7AA6C5B4543ADED0B86890B7">No</dei:EntityWellKnownSeasonedIssuer>
	<optn:AccruedProductAllowancesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-3DD56FC5BF5CDE3A998DE2FFB7A4DD82" unitRef="usd">0</optn:AccruedProductAllowancesCurrent>
	<optn:AccruedProductAllowancesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-CEEDA7252464D9A3F5F0E2FF782AD32D" unitRef="usd">2856000</optn:AccruedProductAllowancesCurrent>
	<optn:AccruedResearchandDevelopmentCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-4246379F439D3E0C12CBDED0B82B19F9" unitRef="usd">80000</optn:AccruedResearchandDevelopmentCurrent>
	<optn:AccruedResearchandDevelopmentCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-B4F7113493CCC334B0ABDED0B83BDD2C" unitRef="usd">933000</optn:AccruedResearchandDevelopmentCurrent>
	<optn:AccruedSalesOrganizationExpensesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-966EEE1551628931AB183A6132C15D9D" unitRef="usd">1432000</optn:AccruedSalesOrganizationExpensesCurrent>
	<optn:AccruedSalesOrganizationExpensesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-6A89FA4F7FEA31604C273A6132C16BAF" unitRef="usd">4482000</optn:AccruedSalesOrganizationExpensesCurrent>
	<optn:AccruedSellingGeneralandAdministrativeCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-6434F4B51202591B1219DED0B82B946F" unitRef="usd">2031000</optn:AccruedSellingGeneralandAdministrativeCurrent>
	<optn:AccruedSellingGeneralandAdministrativeCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-A5E0500514EC19D17F29E2F73D0B61B7" unitRef="usd">4812000</optn:AccruedSellingGeneralandAdministrativeCurrent>
	<optn:CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease contextRef="FI2018Q4_us-gaap_PlanNameAxis_optn_AmendedandRestated2010StockIncentivePlanMember" decimals="INF" id="Fact-0DE2181940F775FE2F8ADED0B84B4515" unitRef="number">0.04</optn:CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease>
	<optn:ConcentrationRiskNumberofClients contextRef="FI2018Q4_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember" decimals="INF" id="Fact-1A8E4518AB878C9385993A5C76A0E897" unitRef="customers">4</optn:ConcentrationRiskNumberofClients>
	<optn:ConcentrationRiskNumberofClients contextRef="FI2018Q4_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember" decimals="INF" id="Fact-9B7B352B078B02CE9BB93A5C76BB226A" unitRef="customers">4</optn:ConcentrationRiskNumberofClients>
	<optn:DebtDiscountAmortizationPeriod contextRef="FD2017Q4YTD" id="Fact-E14A387A41315FDAF18EDED0B82B1176">P5Y6M</optn:DebtDiscountAmortizationPeriod>
	<optn:DebtInstrumentCouponInterestandFees contextRef="FD2017Q4YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-3" id="Fact-DA011A11085F5F3DA41CE313BCF8098F" unitRef="usd">743000</optn:DebtInstrumentCouponInterestandFees>
	<optn:DebtInstrumentCovenantCashandCashEquivalents contextRef="I2017Q4Dec29_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-43D35BB62D5D3548F4FDDED0B82B9ACD" unitRef="usd">10000000</optn:DebtInstrumentCovenantCashandCashEquivalents>
	<optn:DebtInstrumentFeeAmountBackEnd contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-9B2461BDEF70F32C831DE33631E97BA6" unitRef="usd">1000</optn:DebtInstrumentFeeAmountBackEnd>
	<optn:DebtInstrumentFeeAmountBackEnd contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-B6884F99F7BFB37F7C20DED0B8797D87" unitRef="usd">274000</optn:DebtInstrumentFeeAmountBackEnd>
	<optn:DebtInstrumentFeeAmountFrontEnd contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-6319D6D727C409021419E3362B93A0CE" unitRef="usd">999000</optn:DebtInstrumentFeeAmountFrontEnd>
	<optn:DebtInstrumentFeeAmountFrontEnd contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-A06732D028395EE51D45DED0B81C7638" unitRef="usd">872000</optn:DebtInstrumentFeeAmountFrontEnd>
	<optn:DebtInstrumentFeeExitFee contextRef="I2017Q4Dec29_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="2" id="Fact-E53E2CF514EEA3493F16DED0B82B0EB2" unitRef="number">0.02</optn:DebtInstrumentFeeExitFee>
	<optn:DebtInstrumentFeeUpfrontFee contextRef="I2017Q4Dec29_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="INF" id="Fact-BA9CD48272484E765CE3DED0B84B05E8" unitRef="number">0.01</optn:DebtInstrumentFeeUpfrontFee>
	<optn:DebtInstrumentFeesCapitalizedtoPrincipal contextRef="FI2017Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-3" id="Fact-65C2C4F5551BC2F61B79E31779CFDEB8" unitRef="usd">90000</optn:DebtInstrumentFeesCapitalizedtoPrincipal>
	<optn:DebtInstrumentInterestRateFloor contextRef="I2017Q4Dec29_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember" decimals="INF" id="Fact-EE25AE0ED250C109E51DDED0B82B1DC1" unitRef="number">0.01</optn:DebtInstrumentInterestRateFloor>
	<optn:DebtInstrumentLoanConversionPeriod contextRef="D2015Q3Sep30_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" id="Fact-8CA084940146BB3E3DB1E317156578F0">P18M</optn:DebtInstrumentLoanConversionPeriod>
	<optn:DebtInstrumentPrepaymentFee contextRef="I2017Q4Dec29_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFourMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="INF" id="Fact-4314FEFF17DA6F46B5C2DED0B83BAE9B" unitRef="number">0</optn:DebtInstrumentPrepaymentFee>
	<optn:DebtInstrumentPrepaymentFee contextRef="I2017Q4Dec29_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="INF" id="Fact-0830D571E5F163DB3F3EDED0B83BE99D" unitRef="number">0.01</optn:DebtInstrumentPrepaymentFee>
	<optn:DebtInstrumentPrepaymentFee contextRef="I2017Q4Dec29_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="INF" id="Fact-38337F0F01768B0249F2DED0B82BB9FA" unitRef="number">0.02</optn:DebtInstrumentPrepaymentFee>
	<optn:DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses contextRef="FD2017Q4YTD" decimals="-3" id="Fact-EA38BC1CBFB731D557ABDF2C9C2982C4" unitRef="usd">0</optn:DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses>
	<optn:DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses contextRef="FD2018Q4YTD" decimals="-3" id="Fact-8ED4A2924405E23B5B71DF2C9ADB556E" unitRef="usd">146000</optn:DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses>
	<optn:DeferredTaxAssetsInterestExpense contextRef="FI2017Q4" decimals="-3" id="Fact-9DB8FC88D5D0BA308FFDDED0B81CF25F" unitRef="usd">783000</optn:DeferredTaxAssetsInterestExpense>
	<optn:DeferredTaxAssetsInterestExpense contextRef="FI2018Q4" decimals="-3" id="Fact-FE8B4850082585032D63DED0B8701AF8" unitRef="usd">1267000</optn:DeferredTaxAssetsInterestExpense>
	<optn:DeferredTaxAssetsPrepaidLicenseArrangement contextRef="FI2017Q4" decimals="-3" id="Fact-672793F30410549924343A64983D2E8E" unitRef="usd">0</optn:DeferredTaxAssetsPrepaidLicenseArrangement>
	<optn:DeferredTaxAssetsPrepaidLicenseArrangement contextRef="FI2018Q4" decimals="-3" id="Fact-DB85FA3810B1E4BAD01F3A64983DFA82" unitRef="usd">11562000</optn:DeferredTaxAssetsPrepaidLicenseArrangement>
	<optn:DevelopmentMilestoneEligibility contextRef="I2019Q1Jan31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-3" id="Fact-87CAF7F664DD7ADAE6F2EE66C6F347BA" unitRef="usd">8000000</optn:DevelopmentMilestoneEligibility>
	<optn:EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent contextRef="FD2017Q4YTD" decimals="3" id="Fact-5E85800D90F9B6AC8380EE599EF79CD5" unitRef="number">-0.006</optn:EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent>
	<optn:EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent contextRef="FD2018Q4YTD" decimals="3" id="Fact-ED270913C6F1D65B309DEE599EE41C3B" unitRef="number">0.000</optn:EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent>
	<optn:EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent contextRef="FD2017Q4YTD" decimals="3" id="Fact-D196C011DBF95B852E3DEE577C702992" unitRef="number">0.000</optn:EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent>
	<optn:EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent contextRef="FD2018Q4YTD" decimals="3" id="Fact-63BC2E8E43022857D379EE577C826834" unitRef="number">-0.072</optn:EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent>
	<optn:FutureRentExpense contextRef="FI2018Q4" decimals="-3" id="Fact-E444D76CF505C123DEEDDED0B83B02CB" unitRef="usd">2750000</optn:FutureRentExpense>
	<optn:GrantandOtherIncome contextRef="FD2017Q4YTD" decimals="-3" id="Fact-241C05CB03884545D764DED0B83BCC99" unitRef="usd">162000</optn:GrantandOtherIncome>
	<optn:GrantandOtherIncome contextRef="FD2018Q4YTD" decimals="-3" id="Fact-5ABA69F090891E7C797FDED0B85CC08B" unitRef="usd">406000</optn:GrantandOtherIncome>
	<optn:IncreaseDecreaseInGrantsandOtherReceivables contextRef="FD2017Q4YTD" decimals="-3" id="Fact-988F9BB844875846FFF1DED0B8635A71" unitRef="usd">-337000</optn:IncreaseDecreaseInGrantsandOtherReceivables>
	<optn:IncreaseDecreaseInGrantsandOtherReceivables contextRef="FD2018Q4YTD" decimals="-3" id="Fact-954720B0F2E9921001BEDED0B83B473A" unitRef="usd">196000</optn:IncreaseDecreaseInGrantsandOtherReceivables>
	<optn:IncreaseDecreaseinDepositsandOtherAssets contextRef="FD2017Q4YTD" decimals="-3" id="Fact-80D7B709C368948F20F0DED0B83B205D" unitRef="usd">-2358000</optn:IncreaseDecreaseinDepositsandOtherAssets>
	<optn:IncreaseDecreaseinDepositsandOtherAssets contextRef="FD2018Q4YTD" decimals="-3" id="Fact-1779D887E871D56DA450DED0B85DC3BA" unitRef="usd">762000</optn:IncreaseDecreaseinDepositsandOtherAssets>
	<optn:InterestExpenseDebtBackEndFees contextRef="FD2017Q4YTD" decimals="-3" id="Fact-151009984490434440BBDED0B82B13FA" unitRef="usd">2000000</optn:InterestExpenseDebtBackEndFees>
	<optn:InterestExpenseDebtFrontEndFees contextRef="FD2017Q4YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-3" id="Fact-323B652C758522D5E075E3143B51E793" unitRef="usd">75000</optn:InterestExpenseDebtFrontEndFees>
	<optn:NumberOfOperatingLeases contextRef="FD2018Q4YTD" decimals="INF" id="Fact-0B2E8559D914A6E65C76DED0B83B1725" unitRef="lease">4</optn:NumberOfOperatingLeases>
	<optn:NumberOfTrailingQuarters contextRef="I2017Q4Dec29_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementDelayedDrawNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="INF" id="Fact-2838D4D40652E6AE7494DED0B82BD87C" unitRef="quarter">4</optn:NumberOfTrailingQuarters>
	<optn:NumberofTranches contextRef="FI2015Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-D8BA390DBCD3A675B1B0E30D01CBC902" unitRef="tranche">2</optn:NumberofTranches>
	<optn:ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan contextRef="FD2017Q4YTD" decimals="-3" id="Fact-EED96F055D20F56501BEDF2BE3122D91" unitRef="usd">0</optn:ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan>
	<optn:ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan contextRef="FD2018Q4YTD" decimals="-3" id="Fact-B0469283068678239C51DF2BE1F47EFA" unitRef="usd">739000</optn:ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan>
	<optn:SaleofStockDiscounts contextRef="D2018Q2Jun11_us-gaap_SubsidiarySaleOfStockAxis_optn_PublicOfferingMember" decimals="-3" id="Fact-757426C694CF6D21E982EE2E8E460C69" unitRef="usd">3678000</optn:SaleofStockDiscounts>
	<optn:SaleofStockDiscountsandCommissions contextRef="D2017Q4Oct1-Oct31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="-3" id="Fact-6E4723099E67C50DE009DED0B81C384E" unitRef="usd">9660000</optn:SaleofStockDiscountsandCommissions>
	<optn:SaleofStockDiscountsandCommissions contextRef="D2018Q2Jun11_us-gaap_SubsidiarySaleOfStockAxis_optn_PublicOfferingMember" decimals="-3" id="Fact-E72C0FF6135B2087FC48E2B593AE50CC" unitRef="usd">3678000</optn:SaleofStockDiscountsandCommissions>
	<optn:SalesMilestoneEligibility contextRef="I2019Q1Jan31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-3" id="Fact-B5CBB742AACE513BA659EE66C6F3B2B7" unitRef="usd">37000000</optn:SalesMilestoneEligibility>
	<optn:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember" decimals="INF" id="Fact-CEFB8F4B303C248B2FE5DED0B83B2DDE" unitRef="number">0.01</optn:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear>
	<optn:StockIssuedDuringPeriodValueWarrantsExercised contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-C064F8D8E9CF1508F685DF056314EC53" unitRef="shares">14647</optn:StockIssuedDuringPeriodValueWarrantsExercised>
	<optn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesDMember" decimals="INF" id="Fact-BC8F64E854696DF28988DED0B81C865D" unitRef="shares">1117578</optn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
	<optn:TotalDebttoTrailingQuarterNetSalesRatio contextRef="D2017Q4Dec29_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementDelayedDrawNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="2" id="Fact-66CB8DE014D228CE6084DED0B82B90F9" unitRef="number">3.00</optn:TotalDebttoTrailingQuarterNetSalesRatio>
	<optn:TotalDebttoTrailingQuarterNetSalesRatio contextRef="D2017Q4Dec29_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementDelayedDrawNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="2" id="Fact-F9D43C47BC335248C5C9DED0B82BFFE4" unitRef="number">6.50</optn:TotalDebttoTrailingQuarterNetSalesRatio>
	<optn:TotalDebttoTrailingQuarterNetSalesRatio contextRef="D2019Q2Apr1-Aug14_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementDelayedDrawNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember" decimals="2" id="Fact-88A47590C8B96C959C07DED0B83BABB8" unitRef="number">6.50</optn:TotalDebttoTrailingQuarterNetSalesRatio>
	<optn:UpfrontLicenseFeeReceivable contextRef="I2019Q1Jan31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-3" id="Fact-3379C6A70CD3467D62F1EE65F99F93F6" unitRef="usd">500000</optn:UpfrontLicenseFeeReceivable>
	<optn:VotePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-5C6CBDF725472C7B676BDED0B82B1614" unitRef="vote">1</optn:VotePerShare>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-F337912B206F2ED6E974DED0B86B68E6" unitRef="usd">5893000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-0A66735C383118CE7F71DED0B81CA7C9" unitRef="usd">7116000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-ABD29BD19DE2D2C3EED7DEF14D53EE6C" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-E81D5FFF9F8A27703056DEF14B7D2B1E" unitRef="usd">2310000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccruedBonusesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-51D278459B0E8B8C1811DED0B83BA5B2" unitRef="usd">4163000</us-gaap:AccruedBonusesCurrent>
	<us-gaap:AccruedBonusesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-60DD655AF5FEDF02146FDED0B82B293A" unitRef="usd">3635000</us-gaap:AccruedBonusesCurrent>
	<us-gaap:AccruedEmployeeBenefitsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-CF61FB2EBF8EA729F40BDED0B82BA58C" unitRef="usd">448000</us-gaap:AccruedEmployeeBenefitsCurrent>
	<us-gaap:AccruedEmployeeBenefitsCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-EC33C45CA7522D4CC1D7DED0B83B6BAB" unitRef="usd">564000</us-gaap:AccruedEmployeeBenefitsCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-C29FC1BDACDBD44EFAD1DED0B83B890E" unitRef="usd">8698000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-6120BD7F309FD8F2FBA1DED0B83B9C59" unitRef="usd">18421000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2017Q4" decimals="-3" id="Fact-9CDD0017A4C9A7F7946EDED0B86C8DAE" unitRef="usd">355000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2018Q4" decimals="-3" id="Fact-4E5251810027261058CCDED0B86D865A" unitRef="usd">1151000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4" decimals="-3" id="Fact-72B9D15A4529DE0A082DDED0B83B4918" unitRef="usd">-111000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q4" decimals="-3" id="Fact-0BDE1E0FA30759F8A845DED0B81CFAA4" unitRef="usd">-57000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2017Q4" decimals="-3" id="Fact-86F65AEC73FD66149117DED0B82B0C7F" unitRef="usd">365838000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2018Q4" decimals="-3" id="Fact-AB6422A17D9E435E475CDED0B83BA666" unitRef="usd">436554000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember" decimals="-3" id="Fact-B2CCA21D79F8CAC56E59DED0B84B2DAB" unitRef="usd">11969000</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-70894A8A93C858ADE89BDED0B87819F0" unitRef="usd">704000</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-CA42FF8E662884563401DED0B81C21D2" unitRef="usd">11265000</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesCC1DMember" decimals="-3" id="Fact-AEBD3D7445BBABD70C56DED0B83B5089" unitRef="usd">1096000</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesCC1DMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-9D845BB74A239AE36188DED0B8603C5B" unitRef="usd">1096000</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q4YTD" decimals="-3" id="Fact-2444BD16E37DD7305739DED0B82B4A14" unitRef="usd">5096000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-FB57BF254251816ECAECDED0B85BA1D8" unitRef="usd">5096000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q4YTD" decimals="-3" id="Fact-FE5B85EA4D0E8BFF8A21DF010C11CF92" unitRef="usd">8645000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-93B950A558384623A4ABDF0106B79E6B" unitRef="usd">8645000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdvertisingExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-C935F14A42AD97A0528AE2D243AB34E1" unitRef="usd">1833000</us-gaap:AdvertisingExpense>
	<us-gaap:AdvertisingExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-3BF1EE60DD62FD86DDEFDED0B871A9F4" unitRef="usd">9767000</us-gaap:AdvertisingExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-3CBA444E43E66A6C7DF1DED0B85D1292" unitRef="usd">5096000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" decimals="-3" id="Fact-EDFCA1FB6BDA9BD36A32EE3C82069EB4" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-4F1A0EF359094EA68062DED0B85E9A34" unitRef="usd">3808000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-87C4AA1E5085C7F9F328DED0B81C78BE" unitRef="usd">1288000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember" decimals="-3" id="Fact-BC8DA124D5FDF480B933EE3AC1063B7B" unitRef="usd">106000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-973BAE8E47C32F3FB56EDED0B85FB6CD" unitRef="usd">8543000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" decimals="-3" id="Fact-6F0C3DC65E4D66BEE84BEE3C7B9E062C" unitRef="usd">9000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-A8FE6896EEB298CEEE44DED0B864005F" unitRef="usd">7545000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_InventoriesMember" decimals="-3" id="Fact-24B2F49CEB1A3ECE1E9FEE3E3645DC8A" unitRef="usd">99000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" decimals="-3" id="Fact-873DFF75DD73F27B4933EE3E354038D6" unitRef="usd">2000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-6ADB1500FCDCF2169AE5DED0B867838A" unitRef="usd">989000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember" decimals="-3" id="Fact-B2DE902902E3F5064FB7DED0B86050CC" unitRef="usd">446000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AmortizationOfDebtDiscountPremium contextRef="FD2017Q4YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-65346A7EEE15C46C8493DED0B82B7469" unitRef="usd">1000000</us-gaap:AmortizationOfDebtDiscountPremium>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2017Q4YTD" decimals="-3" id="Fact-1C3C997716EEE2444AA7DED0B83BB00F" unitRef="usd">198000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2018Q4YTD" decimals="-3" id="Fact-69FAB3AA50F96C1EB17ADED0B83BBFEB" unitRef="usd">404000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD" decimals="0" id="Fact-0DB57A4AD566AAD8C498DED0B85D5B99" unitRef="shares">4031856</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_optn_EmployeeStockPurchasePlanMember" decimals="0" id="Fact-9E0251213A7A290E6D39E2E32FDEFC75" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-7B3ECA3F664FB6FD9851DED0B85D1578" unitRef="shares">2141367</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="0" id="Fact-7B9B64D11DB9B95E0528DED0B84BED32" unitRef="shares">1890489</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD" decimals="0" id="Fact-2608F65E64553C3664E6DED0B8669E48" unitRef="shares">8081596</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_optn_EmployeeStockPurchasePlanMember" decimals="0" id="Fact-E81441F8AC7FE2000D8DE2E32C8FBFCD" unitRef="shares">31892</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-E7E8C2DF40DFD26BD35DEE1F48B06A51" unitRef="shares">6182873</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="0" id="Fact-13891630B04A064B3070EE1F48CF1DBA" unitRef="shares">1866831</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AreaOfRealEstateProperty contextRef="FI2018Q4" decimals="-1" id="Fact-AF17C77A2E46BA741729DED0B84B730E" unitRef="sqft">20050</us-gaap:AreaOfRealEstateProperty>
	<us-gaap:AreaOfRealEstateProperty contextRef="I2018Q1Jan31" decimals="-4" id="Fact-2E13E75A00604584E1DFDED0B83B4BA5" unitRef="sqft">30000</us-gaap:AreaOfRealEstateProperty>
	<us-gaap:Assets contextRef="FI2017Q4" decimals="-3" id="Fact-73755DFD1B49AC42EF7EDED0B83B24B4" unitRef="usd">241136000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2018Q4" decimals="-3" id="Fact-ADFDF0FEA9EE65218D01DED0B83BB2C7" unitRef="usd">216989000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-40D2267BC5F135EE3024DED0B83B9554" unitRef="usd">238167000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-052ABB6DA698A786163BDED0B83B6645" unitRef="usd">212857000</us-gaap:AssetsCurrent>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-3" id="Fact-31DB431C6655657C4E5849EBDB26CB75" unitRef="usd">36847000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="-3" id="Fact-57125018C51CD0A4C93ADED0B83B552F" unitRef="usd">234875000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q4" decimals="-3" id="Fact-07EBD1E81160DCFF285EDED0B868416C" unitRef="usd">201011000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2017Q4YTD" decimals="-3" id="Fact-C04805BD4F5F7AE1AD8DDED0B8603E61" unitRef="usd">198028000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2018Q4YTD" decimals="-3" id="Fact-48A76A760311A204DAE2DED0B8651056" unitRef="usd">-33864000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="-3" id="Fact-4ED4F1C0947296907061DED0B8775E0D" unitRef="usd">234854000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2018Q4" decimals="-3" id="Fact-3BCE062F19F505B78AA5DED0B81C9D6E" unitRef="usd">200990000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashUninsuredAmount contextRef="FI2017Q4" decimals="-3" id="Fact-458A6B39F37F133F0628DED0B877E248" unitRef="usd">233772000</us-gaap:CashUninsuredAmount>
	<us-gaap:CashUninsuredAmount contextRef="FI2018Q4" decimals="-3" id="Fact-850F7337744F6741D37DDED0B81CA8A1" unitRef="usd">199507000</us-gaap:CashUninsuredAmount>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2018Q4" decimals="INF" id="Fact-071709713523DF4CE680DED0B82B3522" unitRef="usdPerShare">8.16</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-B07CCAE6103486AD4C74DED0B83B64FE" unitRef="shares">1866831</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2017Q4" id="Fact-2B523227CAC3FFFEC84CDED0B84B01D7" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2018Q4" id="Fact-4BD5CF5CCFD6B02FFD28DED0B86FFE2E" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2018Q4_us-gaap_PlanNameAxis_optn_AmendedandRestated2010StockIncentivePlanMember" decimals="INF" id="Fact-C503BA425CCEC48060C6DED0B83B145A" unitRef="shares">1635295</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockDividendsPerShareDeclared contextRef="FD2018Q4YTD" decimals="INF" id="Fact-1830B5F7371FD821B511DED0B82B4602" unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-620A71A1C20E311E48C5DED0B85BC63A" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-2205F3F3C97DA53E92E5DED0B84BB9AA" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="INF" id="Fact-E7D22183C56441AF914CDED0B82B28F8" unitRef="shares">10624486</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q4" decimals="INF" id="Fact-6D151EB6015BFC6E52A3DED0B84BB5E7" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2018Q4" decimals="INF" id="Fact-B92BD427FE3B0D616837DED0B84BB026" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="I2017Q4Oct31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="INF" id="Fact-54F698AE291BA40E1B5EDED0B82B17B6" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2017Q4" decimals="INF" id="Fact-8B73C3BAA5092394C73CDED0B84B39A2" unitRef="shares">41227530</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-E76D984B5E9E3412D913DED0B84B03B9" unitRef="shares">41227530</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-B03F2A937CBD8BC2A2FDDED0B83B5404" unitRef="shares">37802556</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-6B669299CBEC1C2BDB47DED0B84B964E" unitRef="shares">37802556</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2017Q4" decimals="-3" id="Fact-7B1B4B98598CF93E343BDED0B82BED2A" unitRef="usd">38000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2018Q4" decimals="-3" id="Fact-357F24F37659D0FFDFFFDED0B84B28F2" unitRef="usd">41000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2017Q4YTD" decimals="-3" id="Fact-AD54138EF3B1123EB6E5DED0B82B6F3F" unitRef="usd">-48914000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2018Q4YTD" decimals="-3" id="Fact-4A1766CF67E2B19E5EB3DED0B82B486E" unitRef="usd">-106604000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2018Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember" decimals="2" id="Fact-4700A742E15AEBA7117A3A5977E259A7" unitRef="number">0.90</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2018Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember" decimals="2" id="Fact-CDCF8F97CC55E442A08E3A5A67F44658" unitRef="number">0.94</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ContractWithCustomerLiabilityCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-356B289F041866BDF918DED0B86E94D1" unitRef="usd">186000</us-gaap:ContractWithCustomerLiabilityCurrent>
	<us-gaap:ContractWithCustomerLiabilityCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-285A2D61A91DB7FB8C97DED0B83B901F" unitRef="usd">160000</us-gaap:ContractWithCustomerLiabilityCurrent>
	<us-gaap:ContractualObligation contextRef="I2017Q4Nov30_us-gaap_OtherCommitmentsAxis_optn_MarketSalesforceMember" decimals="-3" id="Fact-FBF970440C5E8A710F19DED0B83B6B76" unitRef="usd">2335000</us-gaap:ContractualObligation>
	<us-gaap:ConversionOfStockAmountIssued1 contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D79B09F0776B7906DC2BDF2A02643FD8" unitRef="usd">237259000</us-gaap:ConversionOfStockAmountIssued1>
	<us-gaap:ConversionOfStockAmountIssued1 contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesC2Member" decimals="-3" id="Fact-5D7174AC3777C85C488EDF2A024E8B18" unitRef="usd">19527000</us-gaap:ConversionOfStockAmountIssued1>
	<us-gaap:ConversionOfStockAmountIssued1 contextRef="FD2018Q4YTD" decimals="-3" id="Fact-FA532A6F5D8B98759296DED0B84BF6D4" unitRef="usd">0</us-gaap:ConversionOfStockAmountIssued1>
	<us-gaap:ConversionOfStockAmountIssued1 contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesC2Member" decimals="-3" id="Fact-530AAE3FBFA1529B40C6DED0B85E7C14" unitRef="usd">0</us-gaap:ConversionOfStockAmountIssued1>
	<us-gaap:ConversionOfStockSharesIssued1 contextRef="D2017Q4Oct1-Oct31_us-gaap_ConversionOfStockByUniqueDescriptionAxis_optn_ConversionatConsummationofIPOMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-7C9BE0CFDF797999C436DED0B82B210F" unitRef="shares">25068556</us-gaap:ConversionOfStockSharesIssued1>
	<us-gaap:ConvertibleDebt contextRef="FI2017Q4" decimals="INF" id="Fact-D846EF7C7A8ABC2B6AB8E32F6ECEC462" unitRef="usd">0</us-gaap:ConvertibleDebt>
	<us-gaap:ConvertibleDebt contextRef="FI2018Q4" decimals="INF" id="Fact-13ED1B26B70E966E0290E33099F45DA7" unitRef="usd">0</us-gaap:ConvertibleDebt>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F63528D88F3A9EA3F3D84A35B6E0E9DB" unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2018Q4YTD" decimals="-3" id="Fact-EDD161F6E19FAC77E2FA4A35B6EFEC34" unitRef="usd">1588000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="D2017Q1Mar24_us-gaap_DebtConversionByUniqueDescriptionAxis_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesC2Member" decimals="INF" id="Fact-7EFFB43E31D680B38C50E3112BCA3115" unitRef="shares">687474</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
	<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="FD2018Q4YTD_us-gaap_DebtConversionByUniqueDescriptionAxis_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesC2Member" decimals="INF" id="Fact-19A6EC2E931CBFFA7934DED0B84B8D3C" unitRef="shares">687474</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
	<us-gaap:DebtConversionOriginalDebtAmount1 contextRef="D2017Q1Mar24_us-gaap_DebtConversionByUniqueDescriptionAxis_optn_SeriesDFinancingMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-3" id="Fact-4B80CBB26001C29CE958E31040693E33" unitRef="usd">19527000</us-gaap:DebtConversionOriginalDebtAmount1>
	<us-gaap:DebtConversionOriginalDebtAmount1 contextRef="FD2018Q4YTD_us-gaap_DebtConversionByUniqueDescriptionAxis_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember" decimals="-3" id="Fact-2A6BF19D8CB7C7771586DED0B83B0BBF" unitRef="usd">19527000</us-gaap:DebtConversionOriginalDebtAmount1>
	<us-gaap:DebtInstrumentCarryingAmount contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-3BD325D23437FAB7B0EEE33627F53377" unitRef="usd">75000000</us-gaap:DebtInstrumentCarryingAmount>
	<us-gaap:DebtInstrumentCarryingAmount contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-4D2CCCAFB407D410AD9CDED0B878774B" unitRef="usd">75000000</us-gaap:DebtInstrumentCarryingAmount>
	<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="FI2018Q4_us-gaap_DebtConversionByUniqueDescriptionAxis_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesC2Member" decimals="2" id="Fact-954A58F0F74635E25BD5DED0B83B46A3" unitRef="usdPerShare">28.40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
	<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="I2017Q1Mar24_us-gaap_DebtConversionByUniqueDescriptionAxis_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesC2Member" decimals="2" id="Fact-F6825BFCB582B99B8E6BE3127C269E6D" unitRef="usdPerShare">28.40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_optn_TrancheOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-FB212CD7D9EA3C46792DE30D31D20FDF" unitRef="usd">15000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2015Q3_us-gaap_DebtInstrumentAxis_optn_TrancheTwoMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-5AB1C214591F99E9F01AE30D5DC064E7" unitRef="usd">15000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2015Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-4EDB2FCE4432AEE730F1E30C9A5790B8" unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2017Q4Dec29_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="INF" id="Fact-78BE18341296468E52DDDED0B82BEE8E" unitRef="usd">75000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-1CDC4C442EEDDD29E7F0E30D736FDE30" unitRef="number">0.17</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="INF" id="Fact-3F46D75413CE284BB0CEDED0B82B3581" unitRef="number">0.118125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2017Q4Dec29_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="INF" id="Fact-0158BC31F1A49C72FD17DED0B82BDD04" unitRef="number">0.09</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="D2017Q4Dec29_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="INF" id="Fact-418559DDE0DA963A5954DED0B82B5BB7" unitRef="number">1.02</us-gaap:DebtInstrumentRedemptionPricePercentage>
	<us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount contextRef="I2017Q4Dec29_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementDelayedDrawNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="INF" id="Fact-23D5DDEE8ED7D056F850DED0B82BE35E" unitRef="usd">25000000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
	<us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount contextRef="I2017Q4Dec29_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="INF" id="Fact-CDCA026A193FB3C84B95DED0B82BC3D1" unitRef="usd">100000000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
	<us-gaap:DeferredFinanceCostsGross contextRef="FI2017Q4" decimals="-3" id="Fact-E0AC0AA972688FDF30BEDED0B82BD5C0" unitRef="usd">2181000</us-gaap:DeferredFinanceCostsGross>
	<us-gaap:DeferredFinanceCostsNet contextRef="FI2015Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-3" id="Fact-BA96FA09BACB31D7FBD650057C2FF73E" unitRef="usd">450000</us-gaap:DeferredFinanceCostsNet>
	<us-gaap:DeferredFinanceCostsNet contextRef="FI2015Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-3" id="Fact-1401034ED343A8F53904E317C784A758" unitRef="usd">265000</us-gaap:DeferredFinanceCostsNet>
	<us-gaap:DeferredIncomeTaxLiabilities contextRef="FI2017Q4" decimals="-3" id="Fact-84B63ECC847AED673103DED0B87A9A1C" unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilities>
	<us-gaap:DeferredIncomeTaxLiabilities contextRef="FI2018Q4" decimals="-3" id="Fact-25DED8F5C032EFF74F16DED0B82B68FE" unitRef="usd">409000</us-gaap:DeferredIncomeTaxLiabilities>
	<us-gaap:DeferredOfferingCosts contextRef="I2018Q2Jun11_us-gaap_SubsidiarySaleOfStockAxis_optn_PublicOfferingMember" decimals="-3" id="Fact-C4CBDA1865289637B257E2B5AE2F8A21" unitRef="usd">373000</us-gaap:DeferredOfferingCosts>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2017Q4" decimals="-3" id="Fact-46A85BBC7E348600AEBDDED0B81C0419" unitRef="usd">35632000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2018Q4" decimals="-3" id="Fact-735B67C71FB64EF041E7DED0B81CFF9C" unitRef="usd">53029000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="FI2017Q4" decimals="-3" id="Fact-17192B76E42BDF645DD1DED0B879FB3E" unitRef="usd">2485000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
	<us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="FI2018Q4" decimals="-3" id="Fact-F218D0FCE548EE9F184ADED0B82B5ACD" unitRef="usd">2485000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
	<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="FI2017Q4" decimals="-3" id="Fact-A011C34E15DE129E4569DED0B8786DE4" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
	<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="FI2018Q4" decimals="-3" id="Fact-49B54B3A98C40F3DE097DED0B86EFD3C" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2017Q4" decimals="-3" id="Fact-E1EAD78D3760C53BFB28DED0B81C0B92" unitRef="usd">29636000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2018Q4" decimals="-3" id="Fact-6047A14AE357245F8596DED0B81C095C" unitRef="usd">32548000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="FI2017Q4" decimals="-3" id="Fact-C88CB960752B99CC357ADED0B81CC6C3" unitRef="usd">55000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
	<us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="FI2018Q4" decimals="-3" id="Fact-606C0F030BEDD5248DA2DED0B81C4D03" unitRef="usd">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpense contextRef="FI2017Q4" decimals="-3" id="Fact-D9B447C7445DBE01EAA0DED0B86F0DA6" unitRef="usd">972000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpense contextRef="FI2018Q4" decimals="-3" id="Fact-4F247231E53FF5FA990ADED0B8772F7D" unitRef="usd">1674000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="FI2017Q4" decimals="-3" id="Fact-57C4EEEC58687C6204B3DED0B86EE0A6" unitRef="usd">1701000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="FI2018Q4" decimals="-3" id="Fact-7C5744761B53C12B33F5DED0B87A1F51" unitRef="usd">3493000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2017Q4" decimals="-3" id="Fact-BA6B7982E72ABCBDBB7DDED0B81CA388" unitRef="usd">35632000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2018Q4" decimals="-3" id="Fact-F0DCE9286275BD043B0DDED0B8776F7C" unitRef="usd">52620000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="FI2017Q4" decimals="-3" id="Fact-D2B9F12166338D3C34FADED0B81C9DDD" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
	<us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="FI2018Q4" decimals="-3" id="Fact-BB7FE158AF5522B31346DED0B8715915" unitRef="usd">409000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2017Q4YTD" decimals="-3" id="Fact-1D759D949D62E8BF439AEE8CC84CDCA6" unitRef="usd">230000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember" decimals="-3" id="Fact-FC4B80543DB05681A89CDED0B81CDEC1" unitRef="usd">56000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2018Q4YTD" decimals="-3" id="Fact-6939C5BAE93EEC2CB275DED0B82B2815" unitRef="usd">645000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember" decimals="-3" id="Fact-0B7017FC654601ED68BADED0B82BE33A" unitRef="usd">81000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch contextRef="FD2018Q4YTD_optn_DefinedContributionPlanTranchesAxisAxis_optn_DefinedContributionPlanTrancheOneMember" decimals="2" id="Fact-8962FD44864B31FBDDA6DED0B82BFA16" unitRef="number">1.00</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
	<us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch contextRef="FD2018Q4YTD_optn_DefinedContributionPlanTranchesAxisAxis_optn_DefinedContributionPlanTrancheTwoMember" decimals="2" id="Fact-215C8F83569E1CC164F8DED0B82BF245" unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
	<us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent contextRef="FD2018Q4YTD" decimals="INF" id="Fact-1EDF2F5025A2CA1300F9DED0B82BCDAF" unitRef="number">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
	<us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent contextRef="FD2018Q4YTD_optn_DefinedContributionPlanTranchesAxisAxis_optn_DefinedContributionPlanTrancheOneMember" decimals="INF" id="Fact-A960C8D8E3943B549C7ADED0B81CF343" unitRef="number">0.03</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
	<us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent contextRef="FD2018Q4YTD_optn_DefinedContributionPlanTranchesAxisAxis_optn_DefinedContributionPlanTrancheTwoMember" decimals="INF" id="Fact-9102E34EC19932A6074FDED0B82BA48F" unitRef="number">0.02</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
	<us-gaap:Depreciation contextRef="FD2017Q4YTD" decimals="-3" id="Fact-9AA46E9187DCEDF09109DED0B863D884" unitRef="usd">164000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2018Q4YTD" decimals="-3" id="Fact-60CF3B7D8D4FDA947185DED0B83BA974" unitRef="usd">535000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2018Q4YTD_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember" decimals="-3" id="Fact-7547884AB3F99B4B3B3AE2F5227EA6A1" unitRef="usd">322000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2018Q4YTD_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" decimals="-3" id="Fact-E091B0558A80A4920C79E2F5218BBD56" unitRef="usd">10000</us-gaap:Depreciation>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2017Q4YTD" decimals="-3" id="Fact-E5ADB88C8A18529B7F56DED0B84B102A" unitRef="usd">166000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2018Q4YTD" decimals="-3" id="Fact-58C4AF5F67664E75D804DED0B83B80F1" unitRef="usd">539000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q4YTD" decimals="2" id="Fact-0A235488A5D3874B4F78DED0B83BF5E7" unitRef="usdPerShare">-5.63</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2018Q4YTD" decimals="2" id="Fact-0CD34DB7020D31CFB8ABDED0B81C863F" unitRef="usdPerShare">-2.68</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q4YTD" decimals="2" id="Fact-7C8AE6B02B835085EA0CDED0B84B5C6B" unitRef="usdPerShare">-5.63</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2018Q4YTD" decimals="2" id="Fact-18B50EB67F52272FCCA3DED0B82B83AD" unitRef="usdPerShare">-2.68</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2017Q4YTD" decimals="-3" id="Fact-FF06125AF64BC062779EDED0B83B94A2" unitRef="usd">-11000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2018Q4YTD" decimals="-3" id="Fact-373CEB689BDB7BB03911DED0B83B4A62" unitRef="usd">64000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2017Q4YTD" decimals="1" id="Fact-1B6BD768786F992957F53A62FAC19950" unitRef="number">0.0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2018Q4YTD" decimals="1" id="Fact-F6F0349E646A4C76E2573A62FAB86893" unitRef="number">0.0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2017Q4YTD" decimals="INF" id="Fact-4DA2FC934CBE4A513780DED0B8623848" unitRef="number">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2018Q4YTD" decimals="INF" id="Fact-5E454B242AEED50C05DBDED0B84BB010" unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2017Q4YTD" decimals="3" id="Fact-C74F15EFAC1DCCBF93ECDED0B84BE517" unitRef="number">-0.167</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2018Q4YTD" decimals="3" id="Fact-ABDC68F5D3AFF067BD98DED0B84B5FEA" unitRef="number">-0.162</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="FD2017Q4YTD" decimals="3" id="Fact-B7326D1C86FBCA2CC75FDED0B82B5978" unitRef="number">-0.154</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="FD2018Q4YTD" decimals="3" id="Fact-836A9A109DFBF861C529DED0B81CAE17" unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2017Q4YTD" decimals="3" id="Fact-E52B5DFD81B5167D9081DED0B82B659D" unitRef="number">-0.042</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2018Q4YTD" decimals="3" id="Fact-CF3851EC67997F5C0866DED0B81CC6BE" unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="FD2017Q4YTD" decimals="3" id="Fact-11DDC324AA7817F7B132DED0B867C065" unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="FD2018Q4YTD" decimals="3" id="Fact-F56BD5A8AD760CE117A6DED0B81CF90B" unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2017Q4YTD" decimals="3" id="Fact-E6E217C4CF1941D95DC3DED0B84B8EA5" unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2018Q4YTD" decimals="3" id="Fact-FB27E4D8C984428045B6DED0B81C3AEB" unitRef="number">0.039</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" id="Fact-8EA7A1892F0B2086356FDED0B85B4346">P2Y8M11D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="FI2018Q4_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" decimals="-3" id="Fact-70A73C187A4B9DFBE2ADDED0B84B72D8" unitRef="usd">20405000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2017Q4YTD" decimals="-3" id="Fact-4078F2245E4E3122409FDED0B861F8D7" unitRef="usd">73000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2018Q4YTD" decimals="-3" id="Fact-DA8C0A8BEAC02220206CDED0B83B33C4" unitRef="usd">-48000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="FD2017Q4YTD" decimals="INF" id="Fact-E5A89480E9C227DF3D76E2DA2A77DA12" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="FD2018Q4YTD" decimals="INF" id="Fact-8BC257C99D3BFEE59B693A5EBA349110" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GrossProfit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-555FF667B8C4301B763DDED9C77FB80E" unitRef="usd">0</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-0C8CA55BCAAC2BDBFB6FDED9C6E80D05" unitRef="usd">5477000</us-gaap:GrossProfit>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="FD2017Q4YTD" decimals="-3" id="Fact-4F4AF739B4CBD54AD9CEDED0B865DCD9" unitRef="usd">-30463000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="FD2018Q4YTD" decimals="-3" id="Fact-31F617706A26259039E3DED0B863E0DA" unitRef="usd">-146247000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B0B6D0DA54A1EE3421FADED0B863F01D" unitRef="usd">-18439000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="FD2018Q4YTD" decimals="-3" id="Fact-658C18C82855CE8833DFDED0B83BAA48" unitRef="usd">39589000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B24419D9371ACC8731B6DED0B86B4B9E" unitRef="usd">-48902000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2018Q4YTD" decimals="-3" id="Fact-7AD84F6732332CD23EA3DED0B86480F5" unitRef="usd">-106658000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F383C88B91A1990E3A39DED0B83BEDD5" unitRef="usd">392000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2018Q4YTD" decimals="-3" id="Fact-B935788B432FEB94100BDED0B83B040E" unitRef="usd">3171000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2017Q4YTD" decimals="-3" id="Fact-1371CFDC032B995C625FDF2B8A928C84" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2018Q4YTD" decimals="-3" id="Fact-DD6E9DCDC97378954478DF2B895273E3" unitRef="usd">2310000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-00DF8AD77E9AD0862D96DED0B83BDC68" unitRef="usd">6688000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-03578B78F50C12E51EF7DED0B82B597F" unitRef="usd">10150000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2017Q4YTD" decimals="-3" id="Fact-46E458A1460AAA5696EEDED0B83B7A4E" unitRef="usd">2013000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2018Q4YTD" decimals="-3" id="Fact-CFBAA7608EE0ECCFB5C9DED0B85D213C" unitRef="usd">4698000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:InterestExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-45387D0A8B70C5085518DED0B82B4AB6" unitRef="usd">910000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-84911289642A87553E1DDED0B84B5DCF" unitRef="usd">9229000</us-gaap:InterestExpense>
	<us-gaap:InterestExpenseDebt contextRef="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-459DB929192C34CDFA36DED0B82B4C7A" unitRef="usd">48000</us-gaap:InterestExpenseDebt>
	<us-gaap:InterestExpenseDebt contextRef="FD2017Q4YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-3" id="Fact-7BEEA495BB4667945809E31359A010C8" unitRef="usd">862000</us-gaap:InterestExpenseDebt>
	<us-gaap:InterestExpenseDebt contextRef="FD2018Q4YTD_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-E564C9037FDD11409FB2E33456A4BC6A" unitRef="usd">9229000</us-gaap:InterestExpenseDebt>
	<us-gaap:InterestPaidNet contextRef="FD2017Q4YTD" decimals="0" id="Fact-338113F6B25524003067DF2C7191A7EC" unitRef="usd">0</us-gaap:InterestPaidNet>
	<us-gaap:InterestPaidNet contextRef="FD2018Q4YTD" decimals="-3" id="Fact-1C0C6423A9853C015F53DF2C71D00D8A" unitRef="usd">8253000</us-gaap:InterestPaidNet>
	<us-gaap:InterestPayableCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-AB3480622E19A7F70A1DDED0B83B119E" unitRef="usd">45000</us-gaap:InterestPayableCurrent>
	<us-gaap:InterestPayableCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-C17D76A181FE51D61F95DED0B82B047D" unitRef="usd">345000</us-gaap:InterestPayableCurrent>
	<us-gaap:InventoryFinishedGoods contextRef="FI2017Q4" decimals="-3" id="Fact-461A97496ED0C6C36F2DE2ECB34CBFDD" unitRef="usd">0</us-gaap:InventoryFinishedGoods>
	<us-gaap:InventoryFinishedGoods contextRef="FI2018Q4" decimals="-3" id="Fact-AF66E6354258FBDB54C3E2ECB34CB102" unitRef="usd">2819000</us-gaap:InventoryFinishedGoods>
	<us-gaap:InventoryGross contextRef="FI2017Q4" decimals="-3" id="Fact-30EA040EB67CA0E54E22E2ECD02179D1" unitRef="usd">2013000</us-gaap:InventoryGross>
	<us-gaap:InventoryGross contextRef="FI2018Q4" decimals="-3" id="Fact-2E3F8D976E4C4437DEE3E2ECD01DBB35" unitRef="usd">7132000</us-gaap:InventoryGross>
	<us-gaap:InventoryNet contextRef="FI2017Q4" decimals="-3" id="Fact-07AB52551D425C3E5474DED0B83BDA14" unitRef="usd">2013000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2018Q4" decimals="-3" id="Fact-49F14C3396135061E92ADED0B83BB244" unitRef="usd">7132000</us-gaap:InventoryNet>
	<us-gaap:InventoryRawMaterials contextRef="FI2017Q4" decimals="-3" id="Fact-D0E9837A1F22883C1D31E2EC7F0D6C1C" unitRef="usd">1385000</us-gaap:InventoryRawMaterials>
	<us-gaap:InventoryRawMaterials contextRef="FI2018Q4" decimals="-3" id="Fact-D1B42891CF9CBA5EDB17E2EC7F045BD0" unitRef="usd">1969000</us-gaap:InventoryRawMaterials>
	<us-gaap:InventoryWorkInProcess contextRef="FI2017Q4" decimals="-3" id="Fact-BC53FFC3741CD87DD7ECE2EC9BCEE127" unitRef="usd">628000</us-gaap:InventoryWorkInProcess>
	<us-gaap:InventoryWorkInProcess contextRef="FI2018Q4" decimals="-3" id="Fact-DF796171A22BDB00F86EE2EC9BC54719" unitRef="usd">2344000</us-gaap:InventoryWorkInProcess>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2017Q4YTD" decimals="-3" id="Fact-FC651DA8FF00A5C99913DED0B86F9993" unitRef="usd">303000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2018Q4YTD" decimals="-3" id="Fact-EE5AAB9582CF316022FCDED0B8679CF9" unitRef="usd">2453000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="FI2018Q4" id="Fact-8B82C953F9BD10BA3275DED0B83B826B">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
	<us-gaap:Liabilities contextRef="FI2017Q4" decimals="-3" id="Fact-5C3BBD1195D3F99139F9DED0B82B9A27" unitRef="usd">86640000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2018Q4" decimals="-3" id="Fact-B2AF05E3E43247BBD48CDED0B860F449" unitRef="usd">98378000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-393CBB8F756717ABEBACDED0B87138A8" unitRef="usd">241136000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2018Q4" decimals="-3" id="Fact-1D6E98E26C225EA31CA4DED0B82B7EA4" unitRef="usd">216989000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-16F3283571EE320F5C17DED0B82B4FCC" unitRef="usd">14777000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-C966919CE560288595D1DED0B82B1ACF" unitRef="usd">25697000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesSubjectToCompromiseEarlyContractTerminationFees contextRef="I2017Q4Nov30_srt_RangeAxis_srt_MaximumMember_us-gaap_OtherCommitmentsAxis_optn_MarketSalesforceMember" decimals="-3" id="Fact-A7FD9FE71AD6CE7E60BEDED0B83B27A2" unitRef="usd">691000</us-gaap:LiabilitiesSubjectToCompromiseEarlyContractTerminationFees>
	<us-gaap:LongTermDebt contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-3C0627F3033C486DDB76E3363560E34E" unitRef="usd">71863000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-FF6D4F5458943FE38B38DED0B8708E75" unitRef="usd">72500000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-9D6AA51393C43BC6DC71DEED7567D870" unitRef="usd">71863000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-C2E499559834AEA15A77DED0B85D6C29" unitRef="usd">72500000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-27E7901871185B1B2920DED0B84B61C8" unitRef="usd">236125000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-29092F2913D21933D2C7DED0B85F4510" unitRef="usd">59579000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-34E001B469BA56D9F694DED0B85AD176" unitRef="usd">-2406000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-60CFB01F41E19B4F3B76DED0B862C74A" unitRef="usd">-1690000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-74C976DF912E89E847C8DED0B84B5069" unitRef="usd">-35680000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-A45619E09D6DA3C58122DED0B8628E07" unitRef="usd">-91817000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD" decimals="-3" id="Fact-03458DFFFE3815E8FAE1DED0B81CBEBE" unitRef="usd">-48902000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-BA7981C5C411612F5559DED0B81CB769" unitRef="usd">-48902000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q4YTD" decimals="-3" id="Fact-142FD80207490B552DC1DED0B86000BC" unitRef="usd">-106658000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-DC509743E99013EC697ADF02DDBD9D4E" unitRef="usd">-106658000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F3B97AEE9BFB3FCEA05CDED0B82B40DD" unitRef="usd">-61967000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2018Q4YTD" decimals="-3" id="Fact-D6C7C9BF33B0F6F97A6BDED0B81CB2E6" unitRef="usd">-106658000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 contextRef="FD2017Q4YTD" decimals="-3" id="Fact-07598078281075C11279DF2C9F6D91E6" unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
	<us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 contextRef="FD2018Q4YTD" decimals="-3" id="Fact-869C1F8EE93E667E8482DF2C9E4E88E2" unitRef="usd">361000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
	<us-gaap:OperatingExpenses contextRef="FD2017Q4YTD" decimals="-3" id="Fact-09B9B4EAF00E49FE7C67DED0B864BE55" unitRef="usd">48530000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2018Q4YTD" decimals="-3" id="Fact-51686FC1AB4C8FC0B123DED0B83B3486" unitRef="usd">105717000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q4YTD" decimals="-3" id="Fact-E739548C9A547EC3B672DED0B85B34A5" unitRef="usd">-48530000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q4YTD" decimals="-3" id="Fact-89B6DC448B980EDFE2BEDED0B8784D81" unitRef="usd">-100240000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2018Q4" decimals="-3" id="Fact-686908DCFD3B56276DEEDED0B83BD3B5" unitRef="usd">3128000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-0BF5DD954E6EFB8ED0C5DED0B83BD587" unitRef="usd">1630000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2018Q4" decimals="-3" id="Fact-05A680DE866E55C70C68EE287503CFD1" unitRef="usd">391000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2018Q4" decimals="-3" id="Fact-B05D986CDEA5E60144F9EE2821617A97" unitRef="usd">1107000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2017Q4YTD" decimals="-3" id="Fact-68BDA4AE9062D69D5190DED0B82B2BD7" unitRef="usd">689000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2018Q4YTD" decimals="-3" id="Fact-6FDF4A13EB4658516691DED0B83B535E" unitRef="usd">831000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" decimals="-3" id="Fact-73D8A7D4EACE5989DE6EDED0B85A28DA" unitRef="usd">86574000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember" decimals="-3" id="Fact-032EA3B4349945372AD0DED0B85C08A6" unitRef="usd">50513000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" decimals="-3" id="Fact-7C5894EF4B163651C6B1DED0B85BA6AE" unitRef="usd">57017000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-E77BAF226863344A1197DED0B83B3423" unitRef="usd">314000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-B2FD2BA0B7D5D6854D1CDED0B82B7903" unitRef="usd">435000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-60A5D1A95A81E6E87CB8DED0B83BD2D2" unitRef="usd">1254000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-2B1BB9451854E42B2960DED0B83B5002" unitRef="usd">2183000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-B95506AB2B34FCF043A3DED0B82BC926" unitRef="usd">405000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-9E9ED534A68F8CCA82F7DED0B81CCF76" unitRef="usd">248000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="FD2017Q4YTD" decimals="-3" id="Fact-C06CBB65182DD7E33BE8DED0B82BEFFA" unitRef="usd">-12000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-E4DA6CEF95CC68E31520DED0B84B69AF" unitRef="usd">-12000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="FD2018Q4YTD" decimals="-3" id="Fact-62EFA00523FA162EF6EEDF02D48CAFA7" unitRef="usd">54000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-9D85FEE9288D1D6464D4DF02D3020781" unitRef="usd">54000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2017Q4YTD" decimals="-3" id="Fact-0A0B3F3FDE038A9F9D57DED0B82B9673" unitRef="usd">-12000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2018Q4YTD" decimals="-3" id="Fact-94ACEEA8933D46C1E2E6DED0B82BA26D" unitRef="usd">54000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-AFD9DDFFCA9D0F5D4A07E2FFB5A071C9" unitRef="usd">185000</us-gaap:OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent>
	<us-gaap:OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-F6FA6BA7EBA754BAC57BE2FF77C025C9" unitRef="usd">359000</us-gaap:OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent>
	<us-gaap:OtherLiabilities contextRef="FI2017Q4" decimals="-3" id="Fact-EEE4903D2CEE53362018DEED7564C9C8" unitRef="usd">0</us-gaap:OtherLiabilities>
	<us-gaap:OtherLiabilities contextRef="FI2018Q4" decimals="-3" id="Fact-330E8E8667BB5AD81090DEED7486A5C4" unitRef="usd">181000</us-gaap:OtherLiabilities>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-70D3E6FA595E0FCFF95ADF2A027AC90A" unitRef="usd">2454000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-11C9A0A8BEF169A4F227DED0B83BF2F5" unitRef="usd">0</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:PaymentsOfFinancingCosts contextRef="FD2017Q4YTD" decimals="-3" id="Fact-098DD70CA6CAD10E2EB7DF2A0256016C" unitRef="usd">13433000</us-gaap:PaymentsOfFinancingCosts>
	<us-gaap:PaymentsOfFinancingCosts contextRef="FD2018Q4YTD" decimals="-3" id="Fact-632F1B32581B6B8E58C7DED0B863497B" unitRef="usd">6547000</us-gaap:PaymentsOfFinancingCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="D2017Q4Oct1-Oct31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="-3" id="Fact-337D81854AD8E9573113DED0B82B7041" unitRef="usd">2869000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2017Q4YTD" decimals="-3" id="Fact-A81B528CA413F6A49E69DF2A0276CA77" unitRef="usd">288000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2018Q4YTD" decimals="-3" id="Fact-EFBCF71059C533D6B497DED0B862DF53" unitRef="usd">70000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2017Q4YTD" decimals="-3" id="Fact-8CF8DA44B05F3AC9D80FDED0B865FD96" unitRef="usd">2406000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2018Q4YTD" decimals="-3" id="Fact-911D2DE26705C702ADDEDED0B83B75CD" unitRef="usd">1690000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockDividendRatePercentage contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember" decimals="INF" id="Fact-A78D777AFE1F5E3955E5DED0B86FC412" unitRef="number">0.08</us-gaap:PreferredStockDividendRatePercentage>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="I2017Q4Oct31" decimals="INF" id="Fact-34E9E838AC5C582D53BDDED0B82B7D9B" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="I2017Q4Oct31" decimals="INF" id="Fact-CCA3CF2CFA6547751DE0DED0B84B93B1" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-00EFBCC1A9320F96AB8BDED0B83BCA65" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-AF23A3509C7B955DCF4FDED0B83B696C" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="D2017Q4Oct1-Oct31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="-3" id="Fact-A664BACB74B00915F37DDED0B81C7CC5" unitRef="usd">125471000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2017Q4YTD" decimals="-3" id="Fact-76D5106CC791180390C7DED0B83B5DDF" unitRef="usd">138000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2018Q4YTD" decimals="-3" id="Fact-1F792D596E4748DAB36BDED0B85F51AB" unitRef="usd">63969000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2017Q4YTD" decimals="-3" id="Fact-5B737E45F3BBCD681A68DF2A02523759" unitRef="usd">75000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2018Q4YTD" decimals="-3" id="Fact-5E1D54F414EDF74BF790DED0B84B0C87" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfRedeemablePreferredStock contextRef="FD2017Q4YTD" decimals="-3" id="Fact-31CB71F7608401FA28FADF2A0248FBD5" unitRef="usd">36712000</us-gaap:ProceedsFromIssuanceOfRedeemablePreferredStock>
	<us-gaap:ProceedsFromIssuanceOfRedeemablePreferredStock contextRef="FD2018Q4YTD" decimals="-3" id="Fact-D4674C6C235CBF2B64C6DED0B83B358A" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfRedeemablePreferredStock>
	<us-gaap:ProceedsFromIssuanceOfRedeemablePreferredStock contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesDMember" decimals="-3" id="Fact-5277D5E10A5D3CA42E09DED0B82B6C63" unitRef="usd">36712000</us-gaap:ProceedsFromIssuanceOfRedeemablePreferredStock>
	<us-gaap:ProceedsFromLicenseFeesReceived contextRef="D2018Q1Jul1-Dec31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember" decimals="-3" id="Fact-24CAD0F7610F40936068DED0B83B30FA" unitRef="usd">70000000</us-gaap:ProceedsFromLicenseFeesReceived>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D0E08DFC0B0339742F63DF2A0281086C" unitRef="usd">134000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2018Q4YTD" decimals="-3" id="Fact-792D7F1EE6FFF4C55939DED0B8631840" unitRef="usd">1488000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4" decimals="-3" id="Fact-8F2F9EAB51FF59443F66DED0B862644E" unitRef="usd">2919000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_optn_ComputerEquipmentandSoftwareMember" decimals="-3" id="Fact-6D07412A7A50FAF737F0DED0B82B3EE7" unitRef="usd">307000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" decimals="-3" id="Fact-3B2654573C261E10C55CE2F40046F80E" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-BA4FF3D9C523CABDFCF2DED0B87A33B5" unitRef="usd">89000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-663248C54DB18B6EFA4FDED0B86E5685" unitRef="usd">28000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" decimals="-3" id="Fact-64694995DB7BC92BCA71DED0B8712A95" unitRef="usd">2495000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4" decimals="-3" id="Fact-7D87703615BB44CE5458DED0B86C62BB" unitRef="usd">5035000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_optn_ComputerEquipmentandSoftwareMember" decimals="-3" id="Fact-08A18F04D78C32C996ADDED0B86C6F41" unitRef="usd">833000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" decimals="-3" id="Fact-3DDD68DF39D6A06E71ABE2F3FAF8D86A" unitRef="usd">481000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-756BCFE418B231A20D10DED0B86D021C" unitRef="usd">389000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-8DA2B28224BF40E1ABAFDED0B871BDD5" unitRef="usd">609000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" decimals="-3" id="Fact-D722571CDE9A7B9BFE81DED0B82B94C1" unitRef="usd">2723000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2017Q4" decimals="-3" id="Fact-AAB2A4E68949F05C0EB1DED0B84B7352" unitRef="usd">2564000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2018Q4" decimals="-3" id="Fact-4C81FE07986AFF1DE715DED0B85A9748" unitRef="usd">3884000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" id="Fact-EC4350080D5779080693E2D6E281E933">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" id="Fact-2858A891519F01DE78F6DED0B83B509C">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" id="Fact-9E2B9F80E991A63C465BDED0B862F3EA">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" id="Fact-50BEA3EA7FB2C1A9FF33DED0B82B5F95">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" id="Fact-9466A71001AA991622FDDED0B82B1D39">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" id="Fact-9573ABB168AC9E2CEFD2DED0B86D41F0">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" id="Fact-B885459DB64E20587632DED0B86DAE14">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PurchaseObligation contextRef="FI2018Q4" decimals="INF" id="Fact-79111F58AECB3E5E73D6DED0B83BF7AC" unitRef="usd">0</us-gaap:PurchaseObligation>
	<us-gaap:ReceivablesNetCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-D51340D68122A4F8372CDED0B82B56DE" unitRef="usd">46000</us-gaap:ReceivablesNetCurrent>
	<us-gaap:ReceivablesNetCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-825EB8E2454E323D8228DED0B82B1BB1" unitRef="usd">242000</us-gaap:ReceivablesNetCurrent>
	<us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="FD2017Q4YTD_us-gaap_RelatedPartyTransactionAxis_optn_FeesForIPOAndSeriesDConvertibleStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_InvestorMember" decimals="-3" id="Fact-88C534FB29530BC7720FDED0B81C620C" unitRef="usd">157000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
	<us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="FD2018Q4YTD_us-gaap_RelatedPartyTransactionAxis_optn_FeesForIPOAndSeriesDConvertibleStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_InvestorMember" decimals="-3" id="Fact-27A4BF99C8A8C854D83950388743A169" unitRef="usd">51000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
	<us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="FD2017Q4YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember" decimals="INF" id="Fact-383790B840A7D93F89F3E305CC82EA9F" unitRef="usd">0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
	<us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="FD2018Q4YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember" decimals="INF" id="Fact-3A6EA7D8214261CB080ADED0B83BED8A" unitRef="usd">0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-BB4061C063935B7EA73DDED0B83B96E4" unitRef="usd">16832000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-C01D81DEBDE2692353ADDED0B83BFA9A" unitRef="usd">10099000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RestrictedCash contextRef="FI2017Q4" decimals="-3" id="Fact-50C97AE01CCD629024FB4A3DF7B2D167" unitRef="usd">21000</us-gaap:RestrictedCash>
	<us-gaap:RestrictedCash contextRef="FI2018Q4" decimals="-3" id="Fact-4CA54759A576D342BD39E2DE02BF782C" unitRef="usd">21000</us-gaap:RestrictedCash>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q4" decimals="-3" id="Fact-D310490A4C3A51C98B30DED0B83B1F9C" unitRef="usd">-211269000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q4" decimals="-3" id="Fact-354CD2729682961BBA75DED0B865CEEF" unitRef="usd">-317927000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2017Q4YTD" decimals="-3" id="Fact-04F57AE32611F535E97FDED9BF42A4EB" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q4YTD" decimals="-3" id="Fact-23C114EF05BC59170F47DED9BD71B9C9" unitRef="usd">7065000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" decimals="0" id="Fact-780EA0E52A87E9B158FB49FA943FB815" unitRef="usd">70000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:Revenues contextRef="D2019Q2Apr1-Aug14_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementDelayedDrawNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember" decimals="-3" id="Fact-3E21488FB6694410ACA6DED0B82B9223" unitRef="usd">15000000</us-gaap:Revenues>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2018Q2Jun11_us-gaap_SubsidiarySaleOfStockAxis_optn_PublicOfferingMember" decimals="-3" id="Fact-F0C43A605338DB3B09BEE2B57C4FE2C5" unitRef="usd">59917000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2017Q4Oct1-Oct31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="INF" id="Fact-FFE98EC412A8C612A88ADED0B82B8EDF" unitRef="shares">8625000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2018Q2Jun11_srt_CounterpartyNameAxis_optn_CertainStockholdersMember_us-gaap_SubsidiarySaleOfStockAxis_optn_PublicOfferingMember" decimals="INF" id="Fact-DBE598978E3D9CCD152BE2B55EE839F1" unitRef="shares">2875000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2018Q2Jun11_srt_CounterpartyNameAxis_optn_TheCompanyMember_us-gaap_SubsidiarySaleOfStockAxis_optn_PublicOfferingMember" decimals="INF" id="Fact-53AD312E6E539FC56A7AE2B52ED113BF" unitRef="shares">2875000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2018Q2Jun11_us-gaap_SubsidiarySaleOfStockAxis_optn_PublicOfferingMember" decimals="INF" id="Fact-C0AD40F3AC595C00A1AD65EB96055B2E" unitRef="shares">5750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesDMember" decimals="INF" id="Fact-D2875DA7061A1AA50097DED0B82B3D9C" unitRef="shares">1117578</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockPricePerShare contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesDMember" decimals="2" id="Fact-D4CAB66BE6A8EBAE7034DED0B82B5358" unitRef="usdPerShare">32.85</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2017Q4Oct31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="2" id="Fact-286DD6795EF75DC19099DED0B82BBAEB" unitRef="usdPerShare">16.00</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2018Q2Jun11_us-gaap_SubsidiarySaleOfStockAxis_optn_PublicOfferingMember" decimals="INF" id="Fact-038EB3FA769FFEFFCE9CE2B512B72F27" unitRef="usdPerShare">22.25</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-3849779C6BD95C4D68A5DED0B84BA523" unitRef="usd">31698000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-E653C112C42BA8BBB958DED0B864A2C4" unitRef="usd">95618000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q4YTD" decimals="-3" id="Fact-AF7CA89C05C7B2928A58DED0B86193A7" unitRef="usd">5096000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2018Q4YTD" decimals="-3" id="Fact-A002CD5A5D901563E1D9DED0B861848E" unitRef="usd">8543000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" id="Fact-F185A0E7AD26B402F7CADED0B84B2AA7">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_optn_AmendedandRestated2010StockIncentivePlanMember" id="Fact-048F341D03FFA64AC8F8DED0B85E286A">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2018Q4YTD" decimals="INF" id="Fact-38C63227195D8EF6183CDED0B83BABC6" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-FCD527FB0119B987A430DED0B81C8DA7" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember" decimals="INF" id="Fact-D6134A4AAF683457696BDED0B862811B" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-BCA1BFBB0B7654C0F210DED0B81C999E" unitRef="number">0.0274</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember" decimals="4" id="Fact-D4E271454FADA71F1BE7DED0B87919AC" unitRef="number">0.0153</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-6C34D7BE42E8D94B1A92DED0B81C5830" unitRef="number">0.7442</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember" decimals="4" id="Fact-C325DD5095092CF732B5DED0B86E9823" unitRef="number">0.8040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2018Q4_us-gaap_PlanNameAxis_optn_AmendedandRestated2010StockIncentivePlanMember" decimals="INF" id="Fact-9B90277664131F3D3066DED0B84BE72A" unitRef="shares">8406547</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2018Q4_us-gaap_PlanNameAxis_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember" decimals="INF" id="Fact-2831A25C8EDD3FAB9F20DED0B84B98EF" unitRef="shares">522420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2018Q4_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" decimals="INF" id="Fact-91CF2918227BA55F8C3BDED0B83B7BC7" unitRef="shares">3804999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2018Q4_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" decimals="2" id="Fact-015218C94BAD98A3F0CBDED0B81C27F8" unitRef="usdPerShare">8.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" decimals="-3" id="Fact-6DB4559286E39BD0E71CDED0B84B5994" unitRef="usd">435000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" decimals="-3" id="Fact-1400E32AC0BDB6DEF1AEDED0B84B80C6" unitRef="usd">9255000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" decimals="INF" id="Fact-B5E6A7E4541CAAE4AE22DED0B83BBA5D" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" decimals="INF" id="Fact-8AED3B1E7D36FD7F134BDED0B81CD1F3" unitRef="shares">49854</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" decimals="INF" id="Fact-CA7B73C367B8C94B6B86DED0B84BD0B6" unitRef="shares">472792</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" decimals="2" id="Fact-5814D964D08B593F5A55DED0B84BFE8C" unitRef="usdPerShare">12.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2018Q4_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" decimals="-3" id="Fact-3F8B0A3E3D1AD0461F22DED0B83BE76E" unitRef="usd">8470000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" decimals="INF" id="Fact-5C43E23B60703CC4D879DED0B82B0611" unitRef="shares">6251589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2018Q4_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" decimals="0" id="Fact-1468CE703D586DE1F0C8DED0B82BD72C" unitRef="shares">6182873</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q4_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" decimals="2" id="Fact-60174CFBD99487A82E22DED0B84B87F6" unitRef="usdPerShare">9.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2018Q4_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" decimals="2" id="Fact-DD912E1FC89FDA816D16DED0B860636F" unitRef="usdPerShare">10.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="FI2018Q4_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" decimals="INF" id="Fact-EF3310E8E25ED8034A45DED0B82B5A54" unitRef="shares">6182873</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="FI2018Q4_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" decimals="2" id="Fact-9FDF5B09DFD768504346DED0B84BC394" unitRef="usdPerShare">10.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" decimals="2" id="Fact-B175E43668BA0F780EEFDED0B81CCEA6" unitRef="usdPerShare">3.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" decimals="2" id="Fact-14AE8C93B8A964FE0098DED0B83B0E0A" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" decimals="2" id="Fact-A7CDD3F0B8965F47A402DED0B81CB6FD" unitRef="usdPerShare">9.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" decimals="2" id="Fact-041F3860EE3E362664C0DED0B84BE848" unitRef="usdPerShare">19.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_optn_AmendedandRestated2010StockIncentivePlanMember" id="Fact-2C31E746D783B53B5989DED0B84BD188">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-17A3E68A5E9249621FF0DED0B81C1C5D">P5Y345D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember" id="Fact-505D87D0AEA7A65A6378DED0B871BE43">P7M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2018Q4_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" decimals="-3" id="Fact-E6B861EF4DDCFFE0D90FDED0B85BAD4B" unitRef="usd">8028000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" id="Fact-C11DCC98D836E5CB3E11DED0B82BFA35">P5Y1M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" id="Fact-3A1A3754AF537348997DDED0B84B6E68">P6Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" id="Fact-5EDBD261855AA39B6FD9DED0B84BDF2F">P6Y5M22D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" id="Fact-C9672B3F0DC9344CDF18DED0B81CDCDA">P6Y5M22D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharesOutstanding contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-E6701FF69C50AC069F3CDED0B84BBBFC" unitRef="shares">4067717</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-78995DC2C27F0954C82FDED0B82B0A2C" unitRef="shares">37802556</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-A8917013C48D2A5EAD0BDF02E6EE2483" unitRef="shares">41227530</us-gaap:SharesOutstanding>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesC2Member" decimals="INF" id="Fact-9438EFE22F5A67DDA75ADED0B83B9801" unitRef="shares">687474</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemablePreferredStockMember" decimals="INF" id="Fact-A8248654C3F23582C115DED0B82BC2A9" unitRef="shares">8680566</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-47DB1BE25808425E3515DED0B82BFCE2" unitRef="shares">25068556</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-641FE7AD6816C1E1A16BDF06DD57BF63" unitRef="shares">53137</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-E50D83D00E61B156FE3CDED0B84B89AB" unitRef="shares">8625000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-7C69E15F669360CDFA40DF01D96B2375" unitRef="shares">2875000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-FE195082F32574D50672DED0B84BA257" unitRef="shares">41283</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_optn_ServiceBasedStockOptionsMember" decimals="INF" id="Fact-115A5EC0720CEB5B8DAFDED0B84B78AD" unitRef="shares">491654</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-938177ECDA989F5BA700DF023CD0DAE3" unitRef="shares">482190</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-1C130061FC66C13FFC1FDED0B83B9E76" unitRef="usd">237259000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesC2Member" decimals="-3" id="Fact-C897BC735BB83C6B1DF4DED0B83B5118" unitRef="usd">19527000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemablePreferredStockMember" decimals="-3" id="Fact-416E32F7B36F19F07A2DDED0B82B356A" unitRef="usd">-237259000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-929B6C0A43A0C9524DDADED0B81C00C9" unitRef="usd">237234000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-31CE71D3E2EE68EE6D35DED0B879C6CC" unitRef="usd">25000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan contextRef="FD2018Q4YTD" decimals="-3" id="Fact-E337E36A69657070AAEBDF069FFFA0C1" unitRef="usd">739000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-2B998D83B428862E7E45DF069FEFEC65" unitRef="usd">739000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q4YTD" decimals="-3" id="Fact-21EE05A2744501075CA3DED0B83BAF4F" unitRef="usd">125471000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-4757752ECB0B72F937B9DED0B83BE01F" unitRef="usd">125462000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-B951DF7EFCFE49E11E46DED0B82B75CA" unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD" decimals="-3" id="Fact-FA2B6221CDA8127C40B9DF01E2A89296" unitRef="usd">59917000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-C5D55CD8DAB13676EFDDDF01DD0A8FA0" unitRef="usd">59914000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-7A2BCBDE5ADD4DD5D20FDF01DA93549F" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2017Q4YTD" decimals="-3" id="Fact-15181DE9E7B8E814A7C1DED0B84BF125" unitRef="usd">-154000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-E1292A5A373F0DA316C7DED0B82BF632" unitRef="usd">-154000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q4YTD" decimals="-3" id="Fact-54480AF7A53B5512DDA0DF0242081F29" unitRef="usd">1418000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-E292B3E645CBA2B2AC58DF023EE4DF94" unitRef="usd">1418000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-2F67C34319EC7EEEF836DED0B84B6C70" unitRef="usd">154496000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4" decimals="-3" id="Fact-A04D7CE1DEF233E6BC3BDED0B82B5450" unitRef="usd">118611000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4" decimals="-3" id="Fact-FC2E90E1F12AE4D556D9DED0B82B10E2" unitRef="usd">-151197000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-C0CDAC7B6DA1DADDED33DED0B84B47E4" unitRef="usd">-99000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-4EB645A4C4B40222D753DED0B81C220D" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-A90C62895BC5A987466EDED0B82B33AF" unitRef="usd">4000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-10C9B7995C7907AD97C3DED0B82B27B8" unitRef="usd">-151102000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4" decimals="-3" id="Fact-CFEE84FAE2AB3BD58D8CDED0B870B124" unitRef="usd">154496000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-625AE0E899A19F10711CDED0B84B7C79" unitRef="usd">-111000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-881E8C614BC375540AB4DED0B83BEFE5" unitRef="usd">365838000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-2298E5725716E9EB13B4DED0B82B65A2" unitRef="usd">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-7DC51EC36B3357613C27DED0B84B2DD7" unitRef="usd">-211269000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4" decimals="-3" id="Fact-1BA81CC0DF5C62859A3ADF02EE9B98BF" unitRef="usd">118611000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-180BE44CD33C819625FEDF02ED1E26F2" unitRef="usd">-57000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-A9400316CC75179258A0DF02E9A8FA39" unitRef="usd">436554000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-644A7EFEFDFB73BCB5FCDF02E804C25D" unitRef="usd">41000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-4D73EB410825EC1A3770DF02EB4D447D" unitRef="usd">-317927000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="D2017Q4Oct10" decimals="4" id="Fact-5004BB3103BEB464A94DDED0B870926D" unitRef="number">2.8879</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
	<us-gaap:TemporaryEquityAccretionToRedemptionValue contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember" decimals="-3" id="Fact-8941C96D6846AB3EB8C4DED0B83BF0A5" unitRef="usd">11969000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
	<us-gaap:TemporaryEquityAccretionToRedemptionValue contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesCC1DMember" decimals="-3" id="Fact-9F4C5D4813CD46E8D76BDED0B81CCEFE" unitRef="usd">1096000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
	<us-gaap:TemporaryEquityAccretionToRedemptionValue contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember" decimals="-3" id="Fact-91BC84009998E4F52CADDED0B83B0AA8" unitRef="usd">0</us-gaap:TemporaryEquityAccretionToRedemptionValue>
	<us-gaap:TemporaryEquityAccretionToRedemptionValue contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesCC1DMember" decimals="-3" id="Fact-3DD3E92A7EBD222D8C16DED0B860EA1B" unitRef="usd">0</us-gaap:TemporaryEquityAccretionToRedemptionValue>
	<us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="FD2017Q4YTD" decimals="-3" id="Fact-697ED2BBD6FED76FFD66DED0B84BAEAD" unitRef="usd">1096000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
	<us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="FD2018Q4YTD" decimals="-3" id="Fact-11B5A831DC09257E46E0DED0B86BB718" unitRef="usd">0</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
	<us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemablePreferredStockMember" decimals="-3" id="Fact-E06BC8D3842DFDE08FA7DED0B82B9B0F" unitRef="usd">168173000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
	<us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemablePreferredStockMember" decimals="-3" id="Fact-D2364FA8F50C2DA38123DED0B8721C26" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
	<us-gaap:TemporaryEquityDividendsAdjustment contextRef="FD2017Q4YTD" decimals="-3" id="Fact-47D2080DBA265CC5DE3CDED0B87884DB" unitRef="usd">11969000</us-gaap:TemporaryEquityDividendsAdjustment>
	<us-gaap:TemporaryEquityDividendsAdjustment contextRef="FD2018Q4YTD" decimals="-3" id="Fact-340D53BE3E38AE637DD5DED0B84BC454" unitRef="usd">0</us-gaap:TemporaryEquityDividendsAdjustment>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemablePreferredStockMember" decimals="INF" id="Fact-7BF0C846EB0A90C14E6DDED0B81C74FB" unitRef="shares">6875514</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemablePreferredStockMember" decimals="INF" id="Fact-7C0E7A996EACF6A758F6DED0B81CA8D6" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_optn_RedeemableConvertiblePreferredStockSeriesDMember" decimals="-3" id="Fact-8909C6906248EEBD3E75DED0B82B92B3" unitRef="usd">36494000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
	<us-gaap:UnamortizedDebtIssuanceExpense contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-D88124B0D2C49549DA35E3362EBC3C4A" unitRef="usd">2139000</us-gaap:UnamortizedDebtIssuanceExpense>
	<us-gaap:UnamortizedDebtIssuanceExpense contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_optn_NotePurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-CFCB5678DB692C4DD3DDDED0B84B4EFF" unitRef="usd">1902000</us-gaap:UnamortizedDebtIssuanceExpense>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="FI2018Q4" decimals="INF" id="Fact-9AAFBAE2A48CBBFB0FB8DED0B861D8EB" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="FD2018Q4YTD" decimals="-3" id="Fact-BD7D4AC250CD32BEEFEADED0B86A7C44" unitRef="usd">16988000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2017Q4YTD" decimals="0" id="Fact-D3EE1644EECF23017620DED0B84BB974" unitRef="shares">10999121</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2018Q4YTD" decimals="0" id="Fact-EECB7526A8E50D399589DED0B84BE27C" unitRef="shares">39765983</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2017Q4YTD" decimals="0" id="Fact-E6E3D2C19E4FB3A163AFDED0B86E6ADF" unitRef="shares">10999121</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2018Q4YTD" decimals="0" id="Fact-570953A5AC548D5E531CDED0B84B4C50" unitRef="shares">39765983</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<optn:FutureLiquidityTextBlock contextRef="FD2018Q4YTD" id="Fact-0F1618217BF547E6A986DED0B83B2EE8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Liquidity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Since inception, the Company's operations have focused on organization and staffing, business planning, raising capital, establishing an intellectual property portfolio, conducting preclinical studies and clinical trials, pursuing regulatory approvals and most recently, preparing for and launching XHANCE. As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company had cash and cash equivalents of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$200,990&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;On June 11, 2018, the Company and certain stockholders closed an underwritten public offering (the Offering) of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5,750,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of Company common stock (Common Stock) at a price of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$22.25&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per share. The Offering consisted of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,875,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of Common Stock sold by the Company and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,875,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of Common Stock sold by certain stockholders. As a result of the Offering, the Company received &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$59,917&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in net proceeds, after deducting discounts and commissions of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$3,678&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and offering expenses of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$373&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; payable by the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company will likely require additional capital in the future through equity or debt financings, partnerships, collaborations, or other sources in order to meet the debt service obligations under the Company's outstanding senior secured notes (Senior Secured Notes), including repayment, and to carry out the Company's planned development and commercial activities. If additional capital is not secured when required, the Company may need to delay or curtail its operations until such funding is received. The Company is subject to a number of risks similar to other life sciences companies, including, but not limited to, successful discovery, development and commercialization of its products and product candidates, raising additional capital, the development by its competitors of new technological innovations, protection of proprietary technology and market acceptance of the Company's products.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</optn:FutureLiquidityTextBlock>
	<us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="FD2018Q4YTD" id="Fact-D5E17C26D2CB41777596DED0B82B0200">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Accrued Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Accrued expenses consisted of:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Contract sales organization expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;4,482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,432&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Selling, general and administrative expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;4,812&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Research and development expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;933&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Bonus expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;3,635&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;4,163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Payroll and benefit expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;564&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;448&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Employee contributions withheld&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;359&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;185&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Product revenue allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,856&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;345&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;435&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;314&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;18,421&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;8,698&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
	<us-gaap:AdvertisingCostsPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-895C00583B76BE9A3ADADED0B879CABB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Advertising expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company expenses the costs of advertising, including promotional expenses, as incurred. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-607E3ADD5645810F422949F6CEBCF586">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The accompanying consolidated financial statements have been prepared in conformity with US generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-F0EDBAD9ACC647941BC8DED0B87008B1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;All highly liquid investments purchased with an original maturity date of three months or less at the date of purchase are considered to be cash equivalents. The Company maintains its cash and cash equivalent balances at foreign and domestic financial institutions.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-BBDF1BCC9A26B60262E8DED0B83B5D86">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company leases office space under &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; operating leases and has leases for certain other equipment. Rent expense is recognized as incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following is a schedule of future minimum annual payments as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; under operating lease agreements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:89%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;For the years ending December 31:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,630&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,107&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;391&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Total future minimum lease payments as of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;3,128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Rent expense related to leases of office space was $&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;831&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and $&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;689&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In January 2018, the Company amended its existing office lease agreement for the Company&amp;#8217;s headquarters in Yardley, PA (the Lease Amendment). Under the terms of the Lease Amendment, the Company&amp;#8217;s leased office space was increased from approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;20,050&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; square feet to approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;30,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; square feet, and the term of the lease was extended from March 31, 2018 to May 31, 2021 (the Extended Term), with an option to renew the lease for an additional &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;-year term.&amp;#160;The Company&amp;#8217;s rent payments during the Extended Term will be approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$2,750&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in the aggregate, and the Company will also be required to pay its proportionate share of certain operating costs and property taxes applicable to the leased premises.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Purchase commitments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In November 2017, the Company entered into an agreement with a contract sales organization for the recruitment, deployment and management of a contract sales force to market XHANCE in the US. Subject to certain limited exceptions, the Company could not terminate this agreement until after the first anniversary of the deployment of the sales force (which occurred in March 2018). In December 2018, as a result of the Company's decision to manage its sales force directly, the Company terminated the agreement effective April 1, 2019 and accrued an early termination fee of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$691&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The Company estimates the expenses related to the remaining non-cancellable services, all of which will be provided in 2019, to be approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$2,335&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company had &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; other material outstanding non-cancellable purchase commitments related to inventory and other goods and services, including pre-commercial manufacturing scale-up and sales and marketing activities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Employment agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company has entered into employment contracts with its officers and certain employees that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. There are no matters currently outstanding.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="FD2018Q4YTD" id="Fact-3005350739B0181296B73A547915577C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Concentration of credit risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and accounts receivable.The Company generally invests its cash in deposits with high credit quality financial institutions. Additionally, the Company performs periodic evaluations of the relative credit standing of these financial institutions.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-C3E7177474C6457B7FC4DED0B81CCC31">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Principles of consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The consolidated financial statements include the accounts of OptiNose,&amp;#160;Inc. and its wholly-owned subsidiaries, OptiNose US,&amp;#160;Inc., OptiNose AS and OptiNose UK&amp;#160;Ltd. All inter-company balances and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-6B917C5953EB257F66B5E30ADBCEB13B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Convertible Notes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;On September&amp;#160;30, 2015, the Company entered into a Senior Secured Convertible Note Purchase Agreement (Notes) with various existing stockholders. The Notes provided the Company with up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$30,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in capital available in &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; separate tranches.The first tranche of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$15,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; closed on September&amp;#160;30, 2015. The second tranche of up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$15,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; was available to the Company until March&amp;#160;30, 2017 but was never drawn. The Notes bore an annual interest rate of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;17%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and were scheduled to mature on September&amp;#160;30, 2020 if not otherwise converted to Series C-2 shares. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;On March&amp;#160;24, 2017, in connection with the Series&amp;#160;D Financing, the Notes and associated accrued interest and back end fees thereon totaling &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$19,527&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; converted into &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;687,474&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of Series&amp;#160;C-2 preferred stock at a per share conversion price of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$28.40&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company recorded interest expense of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$862&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;during the year ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in conjunction with the Notes. Total coupon interest on the Notes and back end fees was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$743&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; during the year ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The front-end fees of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$450&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; were recorded as debt discount at issuance and were amortized to interest expense over the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;18 months&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; loan conversion period. During the year ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company recorded a total of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$75&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of interest expense related to the front end fees. Additionally, back end fees of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$450&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; were amortized to interest expense over the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;18 months&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; loan conversion period of which &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$90&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; was recorded as interest expense and as an increase in the carrying amount of the Notes during the year ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The Company also incurred &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$265&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in debt issuance costs during the year ended December&amp;#160;31, 2015 which were amortized to interest expense over the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;18 months&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; loan conversion period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and 2017, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;none&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the Notes were outstanding.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Long-term Debt&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;On December 29, 2017, the Company entered into a Senior Secured Note Purchase Agreement (the Senior Secured Notes) with Athyrium Opportunities III Acquisition LP. The Senior Secured Notes provided the Company with up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$100,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in capital, of which &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$75,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; was issued immediately. The remaining &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$25,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; (the Delayed Draw Notes) may be issued between April 1, 2019 and August 14, 2019, subject to the Company achieving trailing &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; quarter net revenues (as calculated pursuant to the terms of the Note Purchase Agreement)  of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$15,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and a pro forma ratio of total debt to trailing &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; quarter net revenues not exceeding &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;6.50&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; to 1.00, and certain other conditions.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Senior Secured Notes bear interest at &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;9.0%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; plus the three-month London Inter-bank Offered Rate (LIBOR) rate, subject to a &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1.0%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; floor and are scheduled to mature on June 29, 2023. The interest rate was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;11.8125%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; at &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The Senior Secured Notes bore front-end fees of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the aggregate principal amount, which were paid at issuance. The Company is also required to pay an exit fee of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of any principal payments (whether mandatory, voluntary, or at maturity) made throughout the term of the Note Purchase Agreement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company is required to make quarterly, interest only payments until the maturity date. The Company may make voluntary prepayments of the Senior Secured Notes, in whole or in part, and subject to certain exceptions, is required to make mandatory prepayments upon the occurrence of certain events as defined in the agreement, including, the occurrence of a change of control.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; All mandatory and voluntary prepayments of the Senior Secured Notes are subject to the payment of prepayment premiums as follows: (i) if prepayment occurs prior to the second anniversary of the applicable date of issuance, an amount equal to the amount by which (a) the present value of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;102%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the principal prepaid plus all interest that would have accrued on such principal through such second anniversary exceeds (b) the amount of principal prepaid, (ii) if prepayment occurs on or after the second anniversary of the applicable date of issuance but prior to the third anniversary of such issuance, an amount equal to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the principal prepaid, and (iii) if prepayment occurs on or after the third anniversary of the applicable date of issuance but prior to the fourth anniversary of such issuance, an amount equal to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the principal prepaid. &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; prepayment premium is due on any principal prepaid after the fourth anniversary of the applicable date of issuance of any Senior Secured Notes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Senior Secured Notes are secured by a pledge of substantially&amp;#160;all of the Company&amp;#8217;s assets and contains affirmative and negative covenants customary for financings of this type, including limitations on the Company&amp;#8217;s and its subsidiaries&amp;#8217; ability to, among other things, incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, grant certain license rights related to the Company's products, technology and other intellectual property rights, pay dividends and distributions, repay junior indebtedness and enter into affiliate transactions, in each case, subject to certain exceptions.  In addition, the Senior Secured Notes contains financial covenants requiring the Company to maintain (i) at least &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$10,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of cash and cash equivalents and (ii) following the issuance of the Delayed Draw Notes or upon entering into certain exclusive licenses of XHANCE, a total debt to trailing &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; quarter net revenue ratio of less than &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;6.50&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; to 1.00 initially, and thereafter declining quarterly by equal half-steps to a ratio of less than &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3.00&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; to 1.00. As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company was in compliance with the covenants.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company recorded interest expense of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$9,229&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$48&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; during the years ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively, in conjunction with the Senior Secured Notes. Interest expense included total coupon interest, back end fees, front end fees and the amortization of debt issuance costs. The front-end fees of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; were recorded as debt discount at issuance and are being amortized to interest expense over the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5.5&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; year term of the loan. Additionally, back end fees of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$2,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; are being amortized to interest expense and are recorded as an increase in the carrying amount throughout the term of the Senior Secured Notes. The Company also incurred &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$2,181&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in debt issuance costs during the year ended December&amp;#160;31, 2017 which are also being amortized to interest expense over the term of the Senior Secured Notes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the long-term debt balance is comprised of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:77%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Face amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;75,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;75,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Front end fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(872&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(999&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(1,902&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(2,139&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Back end fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;72,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;71,863&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2018Q4YTD" id="Fact-65A3752A1BAF1CF7C4E5DED0B84BA3A0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company issues stock-based awards pursuant to its 2010 Stock Incentive Plan. Effective as of October 12, 2017, the Company's 2010 Stock Incentive Plan was amended and restated (A&amp;amp;R Plan). The A&amp;amp;R Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units, deferred stock units, performance shares, stock appreciation rights and other equity-based awards. The Company's employees, officers, directors and other persons are eligible to receive awards under the A&amp;amp;R Plan. As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;8,406,547&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of the Company's common stock were authorized to be issued under the A&amp;amp;R Plan, and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,635,295&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;shares were reserved for future awards under the A&amp;amp;R Plan. The number of shares of the Company's common stock authorized under the A&amp;amp;R Plan will automatically increase on January&amp;#160;1st of each year, commencing on January&amp;#160;1, 2018 and continuing until the expiration of the A&amp;amp;R Plan, in an amount equal to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; percent of the total number of shares of the Company's common stock outstanding on December&amp;#160;31&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;st&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the preceding calendar year, subject to the discretion of the Company's board of directors or compensation committee to determine a lesser number of shares shall be added for such year.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The amount, terms of grants, and exercisability provisions are determined and set by the Company's board of directors or compensation committee. The Company measures employee stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. Stock-based awards issued to non-employees are revalued until the award vests. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company has issued service-based and performance-based stock options that generally have a contractual life of up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;years and may be exercisable in cash or as otherwise determined by the board of directors. Vesting generally occurs over a period of not greater than &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; years. Performance-based options may vest upon the achievement of certain milestones in connection with the Company's development programs. Additionally, the Company has issued stock options in excess of the fair market value of Common Stock on the issuance date that were only exercisable upon a change in control or upon or after an initial public offering. As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, all of the performance conditions related to performance-based stock options issued by the Company have been achieved.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following table summarizes the activity related to stock option grants to employees and nonemployees for the years ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.22027290448344%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;exercise price&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;contractual life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Outstanding at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6,251,589&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;9.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6.67&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;472,792&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;19.36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(491,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;3.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(49,854&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;9.67&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Outstanding at December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6,182,873&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;10.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Exercisable at December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;3,804,999&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;8.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;5.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Vested and expected to vest at December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6,182,873&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;10.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;During the year ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, stock options to purchase &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;472,792&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of common stock were granted to employees that generally vest over &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; years. The options had an estimated weighted average grant date fair value of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$12.85&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The grant date fair value of each option grant was estimated at the time of grant using the Black-Scholes option-pricing model. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The total aggregate intrinsic value of stock options exercised during the years ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;and&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$9,255&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$435&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively. The aggregate intrinsic value of stock options outstanding and stock options exercisable as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$8,470&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$8,028&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively. At &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the unrecognized compensation cost related to unvested stock options expected to vest was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$20,405&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. This unrecognized compensation will be recognized over an estimated weighted-average amortization period of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2.7 years&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;2017 Employee Stock Purchase Plan &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company's 2017 Employee Stock Purchase Plan (the 2017 Plan) became effective on October 12, 2017. As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;522,420&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of the Company's common stock were authorized to be issued pursuant to purchase rights granted to its employees or to employees of any of its participating affiliates under the 2017 Plan. 469,283 shares of the Company's common stock were reserved for future issuance under the 2017 Plan. The number of shares of the Company's common stock that may be issued pursuant to rights granted under the 2017 Plan shall automatically increase on January&amp;#160;1st of each year, commencing on January&amp;#160;1, 2018 and continuing until the expiration of the 2017 Plan, in an amount equal to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; percent of the total number of shares of the Company's common stock outstanding on December&amp;#160;31st of the preceding calendar year, subject to the discretion of the board of directors or compensation committee to determine a lesser number of shares shall be added for such year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Under the 2017 Plan, eligible employees can purchase the Company&amp;#8217;s common stock through accumulated payroll deductions at such times as are established by the administrator. The 2017 Plan is administered by the compensation committee. Under the 2017 Plan, eligible employees may purchase the Company&amp;#8217;s common stock at 85% of the lesser of the average high and low sales price of the Company's common stock on (i) the first trading day of the relevant offering period and (ii) on the last trading day of the relevant offering period (or, if the relevant offering period has multiple purchase periods, the last trading day of the relevant purchase period). Eligible employees may contribute up to 15% of their eligible compensation. Under the 2017 Plan, a participant may not accrue rights to purchase more than $25 worth of the Company&amp;#8217;s common stock for each calendar year in which such right is outstanding.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Effective October 12, 2017, employees who elected to participate in the 2017 Plan commenced payroll withholdings that accumulated through June 30, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Beginning on January 1, 2018, employees who elected to participate in the 2017 Plan commenced payroll withholdings that accumulate during the following six month offering periods each calendar year while the Purchase Plan is effective:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;January 1 through June 30, and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;July 1 through December 31.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;At the end of each offering period, shares of the Company&amp;#8217;s common stock may be purchased at 85% of the lesser of the average of the high and low sales price of the Company&amp;#8217;s common stock on (i) the first trading day of the relevant offering period and (ii) the last trading day of the relevant offering period (or, if the relevant offering period has multiple purchase periods, the last trading day of the relevant purchase period). In accordance with the guidance in ASC 718-50 &amp;#8211;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;&amp;#160;Compensation &amp;#8211; Stock Compensation&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the ability to purchase shares of the Company&amp;#8217;s common stock at the lower of the price on the first day of the offering period or the last day of the offering period (i.e. the purchase date) represents an option and, therefore, the 2017 Plan is a compensatory plan under this guidance. Accordingly, stock-based compensation expense is determined based on the option&amp;#8217;s grant-date fair value as estimated by applying the Black Scholes option-pricing model and is recognized over the requisite service period of the option. The Company has recognized stock-based compensation expense of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$446&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;and&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$106&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; during the years ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively, related to the 2017 Plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-based compensation expense&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company recorded stock-based compensation expense in the following expense categories of its accompanying consolidated statements of operations for the years ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and  &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:79%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Cost of product sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;989&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,288&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;7,545&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;3,808&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;8,543&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;5,096&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In addition, stock-based compensation expense of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$99&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$2&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; is included within inventory and prepaid expenses and other assets, respectively, as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which represents the total stock-based compensation expense incurred related to employees involved in the manufacturing process of finished goods and samples during the period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company utilized the Black-Scholes valuation model for estimating the fair value of stock options granted and the option component of the 2017 Plan. The Company calculated the fair value of each option grant and the option component of the 2017 Plan on the respective dates of grant using the following weighted average assumptions: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2010 A&amp;amp;R Stock Incentive Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2017 Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Risk free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2.74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1.53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Expected term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;5.95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;0.64&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;74.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;80.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Annual dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;0.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;0.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Option valuation methods, including Black-Scholes, require the input of subjective assumptions, which are discussed below.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The expected term of employee options is determined using the "simplified" method, as prescribed in SEC's Staff Accounting Bulletin (SAB) No.&amp;#160;107, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company's lack of sufficient historical data. The expected term of nonemployee options is equal to the contractual term.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The expected volatility is based on historical volatilities of similar entities within the Company's industry which were commensurate with the expected term assumption as described in SAB No.&amp;#160;107.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The risk-free interest rate is based on the interest rate payable on US Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The expected dividend yield is &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; because the Company has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-886F68444495A7DCB5A3DED0B81CB244">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net income (loss) per common share&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2018Q4YTD" id="Fact-64653B84607FC9EEE9B4DED0B86F2F89">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair value of financial instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company measures certain assets and liabilities at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The FASB accounting guidance outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company uses quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of the inputs as follows:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Level&amp;#160;1&amp;#160;&amp;#8212; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Level&amp;#160;2&amp;#160;&amp;#8212; Valuations based on observable inputs (other than Level&amp;#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Level&amp;#160;3&amp;#160;&amp;#8212; Valuations based on inputs that are unobservable and models that are significant to the overall fair value measurement.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;At &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company's financial instruments included cash and cash equivalents, accounts receivable, grants receivable, accounts payable, and accrued expenses. The carrying amounts reported in the Company's financial statements for these instruments approximates their respective fair values because of the short-term nature of these instruments.  In addition, at &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company believes the carrying value of debt approximates fair value as the interest rates are reflective of the rate the Company could obtain on debt with similar terms and conditions. At &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, there were no financial assets or liabilities measured at fair value on a recurring basis.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-52A066A39978C30ACC87DED0B81C8A5F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Long lived assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated. Impairment charges are recognized at the amount by which the carrying amount of an asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-A17A61E814EC4BC6A1C9DED0B85AC33C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Income taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Tax Cuts and Jobs Act (TCJA) was enacted on December 22, 2017 with most changes effective January 1, 2018. Among other changes, the TCJA significantly lowered the US corporate income tax rate from 35% to 21% as of January 1, 2018. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse. As a result of the reduction in the US corporate income tax rate, the Company revalued its net deferred tax assets at December&amp;#160;31, 2017. Due to the full valuation allowance on the Company's deferred tax assets, no tax expense or benefit associated with the re-measurement was recognized in the Company's consolidated statement of operations for the year ended December&amp;#160;31, 2017. The change in the US corporate tax rate is also included in the Company&amp;#8217;s deferred tax table.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The TCJA provided for a one-time transition tax on the deemed repatriation of post-1986 undistributed foreign subsidiary earnings and profits (E&amp;amp;P). As the Company's foreign subsidiaries did not have accumulated E&amp;amp;P, the Company did not record any income tax expense related to the transition tax.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Due to the timing of and the substantial changes made by the TCJA, the Staff of the Securities and Exchange Commission (SEC) issued Staff Accounting Bulletin No. 118 (SAB 118), which provides registrants a measurement period to report the impact of the new US tax law.&amp;#160;During the measurement period, provisional amounts for the effects of the law are recorded to the extent a reasonable estimate can be made.&amp;#160;To the extent that all information necessary is not available, prepared or analyzed, companies may recognize provisional estimated amounts for a period of up to one year following enactment of the TCJA. Accordingly, the Company recorded a preliminary estimate of the impact of the TCJA and the re-measurement of its deferred tax assets and liabilities in 2017. The Company finalized its analysis of the impact of the TCJA and recorded the adjustment, which was not material, in 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Income taxes have been recorded on the following book income (loss) before income tax expense:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Domestic operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(146,247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(30,463&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Foreign operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;39,589&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(18,439&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Loss before provision for income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(106,658&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(48,902&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;A reconciliation of income tax expense (benefit) at the US federal statutory income tax rate and the income tax provision in the financial statements is as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:54%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:22%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Income tax expense at statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;21.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Permanent items&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Foreign rate differential&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(4.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Impact of foreign operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(7.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;State taxes, net of federal benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;3.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Tax rate changes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(15.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Foreign exchange and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Change in valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(16.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Effective income tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;0.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;0.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Tax rate changes includes the impact of the reduction in the US tax rate in 2017 under the TCJA and a reduction in the Norway tax rate in both 2017 and 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The principal components of the Company&amp;#8217;s deferred tax assets and liabilities are as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.44054580896686%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,674&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;972&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Prepaid licensing arrangement&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;11,562&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,267&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;783&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Stock compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;3,493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,701&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Research and development credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,485&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,485&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Net operating losses &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;32,548&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;29,636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;53,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;35,632&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Fixed assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(409&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(409&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Less: Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(52,620&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(35,632&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Total net deferred tax assets (liabilities)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;During 2018, our wholly-owned subsidiary in Norway licensed certain intellectual property rights related to XHANCE to our US subsidiary. While this transaction did not result in any gain or loss in the condensed consolidated statements of operations, the transaction generated taxable income in both Norway and the US. Norway tax loss carryforwards were utilized to offset the taxable income in Norway and the income reduced the current year US taxable loss.  There were no cash taxes associated with the transaction.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The TCJA, in addition to the changes indicated above, contained other provisions that may have a future impact on the Company. The provisions include limitations on the deductibility of interest based on the amount of adjusted taxable income, the deferral of research and development deductions, the acceleration of deductions related to fixed asset additions, changes to the utilization of net operating loss carry forwards and changes in the carry forward period, and global intangible low-taxed income provisions that subject foreign subsidiary income that exceeds an allowable return to current US taxation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company had foreign net operating loss (NOL) carry forwards of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$50,513&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; primarily from its operations in Norway. As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company had federal and state NOLs of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$86,574&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$57,017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively. These domestic NOL carry forwards may be subject to an annual limitation in the event of cumulative changes in the ownership interests of significant stockholders over a three&amp;#8209;year period in excess of 50%. This could limit the amount of NOLs that the Company can utilize annually to offset future domestic taxable income, if any. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The federal NOL generated in 2018 has an indefinite carry forward period. The federal NOLs generated prior to 2018 will expire from 2030 through 2037. Some state NOLs will not expire while other state NOLs expire over various periods depending on the rules of the jurisdiction in which they were generated. The earliest state NOL expiration is in 2028.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;ASC 740 requires the establishment of a valuation allowance to reduce deferred tax assets if, based on the weight of the available positive and negative evidence it is more likely than not that all or a portion of the deferred tax assets will not be realized. There is insufficient positive evidence to overcome the negative evidence attributable to the Company&amp;#8217;s cumulative operating losses. Consequently, the Company established a full valuation allowance against its net deferred tax assets at &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively, because the Company&amp;#8217;s management was unable to conclude that it is more likely than not that these assets will be fully realized. The Company had a net increase in its valuation allowance of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$16,988&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; during the year ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company files income tax returns in Norway, the UK, the US, and various states. The Company is subject to examination by federal, state and foreign jurisdictions. The Company&amp;#8217;s tax years in the US are open under statute from inception to present. All open years may be examined to the extent that tax credits or net operating loss carryforwards are used in future periods. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company&amp;#8217;s policy is to record interest and penalties related to uncertain tax positions in income tax expense.  As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company had &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&amp;#8217;s statement of operations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-BE7EEFA60AD92A526B39DED0B8716E68">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:InventoryDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-C9B74F8B38CA706D2F7BE2E984FE5DB1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Inventory consisted of the following: &lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,969&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,385&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Work-in-process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,344&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;628&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,819&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;7,132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
	<us-gaap:InventoryPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-6D15617234930E09EF2DDED0B81C8858">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Prior to receiving FDA approval for XHANCE in September 2017, inventory purchases were expensed as incurred and recorded as a component of research and development expense. Subsequent to receiving FDA approval, inventories are stated at the lower of cost or net realizable value. Costs of inventories, which include amounts related to materials and manufacturing overhead, are determined on a first-in, first-out basis. An assessment of the recoverability of capitalized inventory is performed during each reporting period and any excess and obsolete inventories are written down to their estimated net realizable value in the period in which the impairment is first identified. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
	<us-gaap:NatureOfOperations contextRef="FD2018Q4YTD" id="Fact-F89AF1F029CE4C4FFDB5DED0B81CA648">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Organization and Description of Business&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;OptiNose,&amp;#160;Inc. (the Company) was incorporated in Delaware in May 2010 (inception) and has facilities in Yardley, Pennsylvania, Ewing, New Jersey, Oslo, Norway and Swindon, England. The Company's predecessor entity, OptiNose AS, was formed under the laws of Norway in September 2000. In 2010, OptiNose AS became a wholly-owned subsidiary of the Company as part of an internal reorganization.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company is a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's first commercial product, XHANCE&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; (fluticasone propionate) nasal spray, 93 mcg, is a therapeutic utilizing its proprietary Optinose Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE was approved by the United States (US) Food and Drug Administration (FDA) in September 2017 for the treatment of nasal polyps in patients 18&amp;#160;years of age or older, and&amp;#160;XHANCE was launched commercially in the US in March 2018.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-9A603E31B5E66FB3F950DED0B81C1E28">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent accounting pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In August 2018, the FASB issued ASU No. 2018-15,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&amp;#160; ASU 2018-15 requires that certain implementation costs incurred in a cloud computing arrangement be deferred and recognized over the term of the arrangement. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on its results of operations, financial position and cash flows and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In August 2018, the FASB issued ASU No. 2018-13,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&amp;#160; ASU 2018-13 resulted in certain modifications to fair value measurement disclosures, primarily related to level 3 fair value measurements. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on its disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In May 2017, the FASB issued ASU No. 2017-09,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Stock&amp;#160;Compensation - Scope of Modification Accounting&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&amp;#160; ASU 2017-09 provides guidance on which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The new standard is effective for fiscal years beginning after December 15, 2017. The adoption of ASU 2017-09 did not have a material impact on the Company&amp;#8217;s results of operations, financial position, cash flows and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In November 2016, the FASB issued ASU No. 2016-18, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Statement of Cash Flows (Topic 230). &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;ASU No. 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The new standard is effective for fiscal years beginning after December 15, 2017. The Company adopted ASU 2016-18 in the first quarter of 2018, and the guidance has been retrospectively applied to all periods presented. The restricted cash balance included in prepaid expenses and other assets was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$21&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In February 2016, the FASB issued ASU 2016-02,&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;&amp;#160;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The FASB issued the update to require the recognition of lease assets and liabilities on the balance sheet of lessees. The standard will be effective for fiscal years beginning after December&amp;#160;15, 2018, with early adoption permitted. The ASU requires a modified retrospective transition method with the option to elect a package of practical expedients. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following are other key disclosures, as well as determinations made and actions taken by the Company, related to the adoption of ASC 842:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Elected the optional modified retrospective transition method as of January 1, 2019; therefore prior period amounts will not be restated;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Established and implemented key implementation controls to ensure the Company meets the new reporting and disclosure requirements;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Elected the following transition practical expedients:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#9702;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;to not reassess lease identification, lease classification and initial indirect costs related to those leases entered into prior to the adoption of ASC 842;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#9702;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;to not separate lease and non-lease components for our office lease portfolio;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Made policy elections as of January 1, 2019:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#9702;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;to not apply the recognition and measurement requirements to leases with an initial term of one year or less;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#9702;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;to apply the portfolio approach for the development of the discount rate related to leases with similar characteristics;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#9702;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;to keep leases with an immaterial right-of-use asset at inception, off the balance sheet and recognize this expense on a straight-line basis in the consolidated statements of operations;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;While we continue to assess all the effects of adoption, the Company believes the most significant effect relates to the recognition of right-of-use assets and corresponding liabilities on its consolidated balance sheet, primarily related to its existing facility operating leases, and providing new disclosures with regards to the Company&amp;#8217;s leasing activities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In May 2014, the FASB issued ASU No. 2014-09,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, or ASU-2014-09, which replaced numerous requirements in US&amp;#160;GAAP, including industry-specific requirements. This guidance provides a five-step model to be applied to all contracts with customers, with an underlying principle that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The new standard also defines accounting for certain costs related to origination and fulfillment of contracts with customers, including whether such costs should be capitalized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;This statement requires extensive quantitative and qualitative disclosures covering the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including disclosures on significant judgments made when applying the guidance and assets recognized from costs incurred to obtain or fulfill a contract. The guidance was effective for annual reporting periods beginning after December&amp;#160;15, 2017, and interim periods within that reporting period. An entity could elect to apply the guidance under one of the following two methods: (i)&amp;#160;retrospectively to each prior reporting period presented&amp;#160;&amp;#8212; referred to as the full retrospective method or (ii)&amp;#160;retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings&amp;#160;&amp;#8212; referred to as the modified retrospective method.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company assessed the impact that ASU No. 2014-09 had on its financial statements and related disclosures. Through the January 1, 2018 adoption date, the Company has derived its revenues from a single licensing agreement with Avanir (the AVP-825 License Agreement). The consideration the Company has received to date includes an upfront payment, research and development funding and development milestone payments. The Company analyzed the performance obligations under the AVP-825 License Agreement as well as the consideration received to date as part of its analysis of the impact of ASU 2014-09 on this arrangement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company adopted ASU 2014-09 on January 1, 2018 using the modified retrospective transition method. No transition adjustments were recognized as a result of the adoption. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-FAF70EE3567D61FAAE8DDED0B82BCEF7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following is a schedule of future minimum annual payments as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; under operating lease agreements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:89%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;For the years ending December 31:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,630&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,107&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;391&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Total future minimum lease payments as of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;3,128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-E80AC551E849E7099108DED0B81C9080">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The accompanying consolidated financial statements have been prepared in conformity with US generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Principles of consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The consolidated financial statements include the accounts of OptiNose,&amp;#160;Inc. and its wholly-owned subsidiaries, OptiNose US,&amp;#160;Inc., OptiNose AS and OptiNose UK&amp;#160;Ltd. All inter-company balances and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock Split&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;On October 10, 2017, the Company&amp;#160;effected a &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2.8879&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;-for-1 reclassification, or stock split, of the Company's common stock in connection with its initial public offering, or the IPO. All common share and per share amounts in these consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to reflect the stock split. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Concentration of credit risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and accounts receivable.The Company generally invests its cash in deposits with high credit quality financial institutions. Additionally, the Company performs periodic evaluations of the relative credit standing of these financial institutions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company has exposure to credit risk in accounts receivable from sales of product. XHANCE is sold to wholesale pharmaceutical distributors and preferred pharmacy network partners, who, in turn, sell XHANCE to pharmacies, hospitals and other customers.&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Four&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; customers represent approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;90%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the Company's accounts receivable at &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; customers represent approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;94%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the Company's net product sales for the year ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;All highly liquid investments purchased with an original maturity date of three months or less at the date of purchase are considered to be cash equivalents. The Company maintains its cash and cash equivalent balances at foreign and domestic financial institutions. Bank deposits with Norwegian banks are insured up to approximately 2,000 Norwegian krone by the Norwegian Banks' Guarantee Fund. Bank deposits with US banks are insured up to $250 by the Federal Deposits Insurance Corporation. The Company had uninsured cash balances of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$199,507&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$233,772&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; at &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair value of financial instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company measures certain assets and liabilities at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The FASB accounting guidance outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company uses quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of the inputs as follows:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Level&amp;#160;1&amp;#160;&amp;#8212; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Level&amp;#160;2&amp;#160;&amp;#8212; Valuations based on observable inputs (other than Level&amp;#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Level&amp;#160;3&amp;#160;&amp;#8212; Valuations based on inputs that are unobservable and models that are significant to the overall fair value measurement.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;At &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company's financial instruments included cash and cash equivalents, accounts receivable, grants receivable, accounts payable, and accrued expenses. The carrying amounts reported in the Company's financial statements for these instruments approximates their respective fair values because of the short-term nature of these instruments.  In addition, at &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company believes the carrying value of debt approximates fair value as the interest rates are reflective of the rate the Company could obtain on debt with similar terms and conditions. At &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, there were no financial assets or liabilities measured at fair value on a recurring basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Accounts receivable primarily relates to amounts due from customers, which are typically due within 31 to 61 days. The Company analyzes accounts that are past due for collectability. Given the nature and historical collectability of the Company&amp;#8217;s accounts receivable, an allowance for doubtful accounts was not deemed necessary at&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Prior to receiving FDA approval for XHANCE in September 2017, inventory purchases were expensed as incurred and recorded as a component of research and development expense. Subsequent to receiving FDA approval, inventories are stated at the lower of cost or net realizable value. Costs of inventories, which include amounts related to materials and manufacturing overhead, are determined on a first-in, first-out basis. An assessment of the recoverability of capitalized inventory is performed during each reporting period and any excess and obsolete inventories are written down to their estimated net realizable value in the period in which the impairment is first identified. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Property and equipment is recorded at cost less accumulated depreciation. Significant additions or improvements are capitalized, and expenditures for repairs and maintenance are charged to expense as incurred. Gains and losses on disposal of assets are included in the consolidated statements of operations. Depreciation is calculated on a straight-line basis over the estimated useful lives of the respective assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The estimated useful lives of property and equipment are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Computer equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2-3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Machinery &amp;amp; production equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;5-10 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Furniture &amp;amp; fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;3-5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Shorter of lease term or useful life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Long lived assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated. Impairment charges are recognized at the amount by which the carrying amount of an asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell. The Company did &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;t recognize any impairment or disposition of long-lived assets for the years ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company accounts for revenue in accordance with ASC Topic 606, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which was adopted on January 1, 2018. This standard applies to all contracts with customers, with the exception of contracts that are within the scope of other standards, such as leases, insurance and financial instruments. Under ASC Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to be entitled in exchange for those goods or services.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company performs the following five steps to recognize revenue under ASC Topic 606: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only recognizes revenue when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that will be transferred to the customer. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;text-decoration:underline;"&gt;Net Product Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company sells XHANCE to preferred pharmacy network partners and wholesalers in the US (collectively, Customers). These Customers subsequently resell the Company&amp;#8217;s products to healthcare providers, patients and other retail pharmacies. In addition to agreements with Customers, the Company enters into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts for the purchase of the Company&amp;#8217;s products.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company recognizes revenue from product sales at the point the Customer obtains control of the product, which generally occurs upon delivery. The transaction price that is recognized as revenue for products includes an estimate of variable consideration which is described below. Payment terms with Customers do not exceed one year and, therefore, the Company does not account for a financing component in its arrangements. The Company expenses incremental costs of obtaining a contract with a Customer (for example, sales commissions) when incurred as the period of benefit is less than one year. Shipping and handling costs for product shipments to Customers are recorded as selling, general and administrative expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;text-decoration:underline;"&gt;Transaction Price, including Estimates of Variable Consideration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Revenue from products is recognized at the estimated net sales price (transaction price), which includes estimates of variable consideration. The Company includes estimated amounts in the transaction price to the extent it is determined probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The Company&amp;#8217;s estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of its anticipated performance and all information (historical, current and forecasted) that is reasonably available.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Components of Variable Consideration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Components of variable consideration include provider chargebacks and discounts, trade discounts and allowances, product returns, government rebates, third-party payor rebates, sales order management fees and other incentives, such as voluntary patient assistance and other allowances that are offered within contracts between the Company and its Customers, payors and other indirect customers relating to the Company&amp;#8217;s sale of products. Those components, as described below, are based on the amounts earned, or to be claimed, on the related sales and are presented as reductions of accounts receivable (if the amount is payable to the Customer) or as a current liability (if the amount is payable to a party other than the Customer). The Company considers all relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:12px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Variable Consideration - Accounts Receivable Reductions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:60px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#9702;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;text-decoration:underline;"&gt;Provider Chargebacks and Discounts.&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from the Company.&amp;#160;Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers.&amp;#160;These components of variable consideration are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable.&amp;#160;Reserves for chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel inventories at each reporting period-end that the Company expects will be sold to qualified healthcare providers, as well as chargebacks that Customers have claimed, but for which the Company has not yet issued a credit.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#9702;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:24px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-24px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;text-decoration:underline;"&gt;Trade Discounts and Allowances.&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;  The Company generally provides Customers with discounts that include incentive fees which are explicitly stated in the Company&amp;#8217;s contracts. These discounts are recorded as a reduction of revenue and accounts receivable in the period in which the related product revenue is recognized. In addition, the Company reimburses (through discounts and allowances) its Customers for sales order management, data and distribution services.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:12px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:6px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-6px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Variable Consideration - Current Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:60px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#9702;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;text-decoration:underline;"&gt;Product Returns.&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;  Consistent with industry practice, the Company has a product returns policy that provides Customers a right of return for product purchased within a specified period prior to and subsequent to the product&amp;#8217;s expiration date. The right of return lapses upon shipment of the goods to a patient. The Company estimates the amount of its products that may be returned and presents this amount as a reduction of revenue in the period the related product revenue is recognized, in addition to establishing a liability. The Company considers several factors in the estimation process, including expiration dates of product shipped to preferred pharmacy network partners and wholesalers, inventory levels within the distribution channel, product shelf life, prescription trends and other relevant factors.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:60px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#9702;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;text-decoration:underline;"&gt;Government Rebates&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  The Company is subject to discount obligations under state Medicaid programs and Medicare. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. For Medicaid, accruals are based on estimates of future Medicaid beneficiary utilization applied to the Medicaid unit rebate formula established by the Center for Medicaid and Medicare Services. The Medicare Part&amp;#160;D prescription drug benefit mandates manufacturers to fund approximately 50% of the Medicare Part&amp;#160;D insurance coverage gap for prescription drugs sold to eligible patients. To estimate the cost to the Company of this Medicare coverage gap responsibility, the Company estimates the number of patients in the prescription drug coverage gap for whom it will owe an additional liability under the Medicare Part D program. The Company&amp;#8217;s liability for these rebates consists of estimates of claims for the current quarter and estimated future claims that will be made for product that has been recognized as revenue but remains in the distribution channel inventories at the end of the reporting period.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:60px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#9702;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;text-decoration:underline;"&gt;Payor Rebates.&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;  The Company contracts with certain third-party payors, primarily health insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. These rebates are based on contractual percentages applied to the amount of product prescribed to patients who are covered by the plan or the organization with which it contracts. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:60px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#9702;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;text-decoration:underline;"&gt;Other Incentives.&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;  Other incentives that the Company offers include voluntary patient assistance programs, such as co-pay assistance programs, which are intended to provide financial assistance to qualified commercially insured patients with prescription drug co-payments required by payors and coupon programs for cash payors.&amp;#160;The calculation of the accruals for this assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;text-decoration:underline;"&gt;Licensing Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Through December 31, 2017, the Company's revenues had been generated pursuant to the terms of a single license agreement (the AVP-825 License Agreement) with Avanir Pharmaceuticals,&amp;#160;Inc. (Avanir) (Note&amp;#160;7). The AVP-825 License Agreement included licensed rights to patented technology, non-refundable up-front payment, research services, and regulatory and sales milestones as well as royalty payments. Through &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, under the terms of the AVP-825 License Agreement, the Company received aggregate cash payments of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$70,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in connection with the initial signing and the achievement of certain development milestones. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;On December 10, 2018, the Company received written notice from Avanir of its election to terminate the AVP-825 License Agreement.&amp;#160;As a result, the AVP-825 License Agreement is expected to terminate on March 10, 2019. We do not expect to receive any additional proceeds from the AVP-825 License Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Prior to the receipt of notice of termination of the License Agreement, the Company analyzed the performance obligations under the AVP-825 License Agreement, the consideration received to date and the consideration the Company could have received in the future as part of its analysis related to ASU 2014-09. The consideration received to date, which included an upfront payment, research and development funding and development milestone payments was recognized in prior years and the Company&amp;#8217;s performance obligations pursuant to the arrangement have been completed. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Advertising expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company expenses the costs of advertising, including promotional expenses, as incurred.  Advertising expenses were &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$9,767&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;and&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1,833&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;and&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Research and development costs are expensed as incurred. Research and development costs consist primarily of device development, clinical trial related costs and regulatory related costs. The Company enters into agreements with contract research organizations (CROs) to facilitate, coordinate and perform agreed upon research and development activities for the Company's clinical trials. These CRO contracts typically call for the payment of fees for services at the initiation of the contract and/or upon the achievement of certain clinical trial milestones. The Company prepays certain CRO fees whereby the prepayments are recorded as a current or non-current prepaid asset and are amortized into research and development expense over the period of time the contracted research and development services were performed. The Company's CRO contracts generally also included other fees such as project management and pass through fees whereby the Company expenses these costs as incurred, using the Company's best estimate. Pass through fees include, but are not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous costs. Pass through fees incurred are based on the amount of work completed for the clinical trials and are monitored through reporting provided by the Company's CROs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company measures and recognizes compensation expense for all stock options awarded to employees and nonemployees and shares issued under the employee stock purchase plan based on the estimated fair value of the awards on the respective grant dates. The Company uses the Black-Scholes option pricing model to value its stock option awards and shares issued under the employee stock purchase plan. The Company recognizes compensation expense for time-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company recognizes compensation expense for performance based awards when the performance condition is probable of achievement. Stock-based awards issued to nonemployees are revalued at each reporting period until the award vests. The Company accounts for forfeitures of stock option awards as they occur.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Estimating the fair value of options and shares issued under the employee stock purchase plan requires the input of subjective assumptions, including the estimated fair value of the Company's common stock, the expected life of the options, stock price volatility, the risk-free interest rate and expected dividends. The assumptions used in the Company's Black-Scholes option-pricing model represent management's best estimates and involve a number of variables, uncertainties and assumptions and the application of management's judgment, as they are inherently subjective.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company has concluded that a full valuation allowance is necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest or penalties in the accompanying consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Grant income&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Government grants are agreements that provide cost reimbursement for certain research and development activities over a contractually defined period. Income from government grants is recognized in the period in which related costs are incurred, provided that the conditions under which government grants were provided have been met and only perfunctory obligations are outstanding. Grant income received in excess of costs incurred is recognized as deferred other income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net income (loss) per common share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Basic net income (loss) per common share is determined by dividing net income (loss) applicable to common stockholders by the weighted average common shares outstanding during the period. For the years ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the outstanding common stock options and common stock warrants have been excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted net loss per share are the same.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Diluted net loss per common share for the periods presented do not reflect the following potential common shares, as the effect would be antidilutive:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.73684210526315%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:76%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6,182,873&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,141,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,866,831&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,890,489&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;31,892&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;8,081,596&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;4,031,856&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent accounting pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In August 2018, the FASB issued ASU No. 2018-15,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&amp;#160; ASU 2018-15 requires that certain implementation costs incurred in a cloud computing arrangement be deferred and recognized over the term of the arrangement. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on its results of operations, financial position and cash flows and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In August 2018, the FASB issued ASU No. 2018-13,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&amp;#160; ASU 2018-13 resulted in certain modifications to fair value measurement disclosures, primarily related to level 3 fair value measurements. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on its disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In May 2017, the FASB issued ASU No. 2017-09,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Stock&amp;#160;Compensation - Scope of Modification Accounting&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&amp;#160; ASU 2017-09 provides guidance on which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The new standard is effective for fiscal years beginning after December 15, 2017. The adoption of ASU 2017-09 did not have a material impact on the Company&amp;#8217;s results of operations, financial position, cash flows and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In November 2016, the FASB issued ASU No. 2016-18, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Statement of Cash Flows (Topic 230). &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;ASU No. 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The new standard is effective for fiscal years beginning after December 15, 2017. The Company adopted ASU 2016-18 in the first quarter of 2018, and the guidance has been retrospectively applied to all periods presented. The restricted cash balance included in prepaid expenses and other assets was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$21&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In February 2016, the FASB issued ASU 2016-02,&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;&amp;#160;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The FASB issued the update to require the recognition of lease assets and liabilities on the balance sheet of lessees. The standard will be effective for fiscal years beginning after December&amp;#160;15, 2018, with early adoption permitted. The ASU requires a modified retrospective transition method with the option to elect a package of practical expedients. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following are other key disclosures, as well as determinations made and actions taken by the Company, related to the adoption of ASC 842:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Elected the optional modified retrospective transition method as of January 1, 2019; therefore prior period amounts will not be restated;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Established and implemented key implementation controls to ensure the Company meets the new reporting and disclosure requirements;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Elected the following transition practical expedients:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#9702;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;to not reassess lease identification, lease classification and initial indirect costs related to those leases entered into prior to the adoption of ASC 842;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#9702;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;to not separate lease and non-lease components for our office lease portfolio;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Made policy elections as of January 1, 2019:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#9702;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;to not apply the recognition and measurement requirements to leases with an initial term of one year or less;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#9702;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;to apply the portfolio approach for the development of the discount rate related to leases with similar characteristics;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#9702;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;to keep leases with an immaterial right-of-use asset at inception, off the balance sheet and recognize this expense on a straight-line basis in the consolidated statements of operations;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;While we continue to assess all the effects of adoption, the Company believes the most significant effect relates to the recognition of right-of-use assets and corresponding liabilities on its consolidated balance sheet, primarily related to its existing facility operating leases, and providing new disclosures with regards to the Company&amp;#8217;s leasing activities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In May 2014, the FASB issued ASU No. 2014-09,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, or ASU-2014-09, which replaced numerous requirements in US&amp;#160;GAAP, including industry-specific requirements. This guidance provides a five-step model to be applied to all contracts with customers, with an underlying principle that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The new standard also defines accounting for certain costs related to origination and fulfillment of contracts with customers, including whether such costs should be capitalized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;This statement requires extensive quantitative and qualitative disclosures covering the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including disclosures on significant judgments made when applying the guidance and assets recognized from costs incurred to obtain or fulfill a contract. The guidance was effective for annual reporting periods beginning after December&amp;#160;15, 2017, and interim periods within that reporting period. An entity could elect to apply the guidance under one of the following two methods: (i)&amp;#160;retrospectively to each prior reporting period presented&amp;#160;&amp;#8212; referred to as the full retrospective method or (ii)&amp;#160;retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings&amp;#160;&amp;#8212; referred to as the modified retrospective method.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company assessed the impact that ASU No. 2014-09 had on its financial statements and related disclosures. Through the January 1, 2018 adoption date, the Company has derived its revenues from a single licensing agreement with Avanir (the AVP-825 License Agreement). The consideration the Company has received to date includes an upfront payment, research and development funding and development milestone payments. The Company analyzed the performance obligations under the AVP-825 License Agreement as well as the consideration received to date as part of its analysis of the impact of ASU 2014-09 on this arrangement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company adopted ASU 2014-09 on January 1, 2018 using the modified retrospective transition method. No transition adjustments were recognized as a result of the adoption. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
	<us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-1B6182C640E2F62E5526DED0B82BC7D9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Employee Benefit Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;For US employees, the Company maintains a defined contribution 401(k) retirement plan, which covers all employees. Employees are eligible to participate in the plan on the first of the month following their date of hire. Under the 401(k)&amp;#160;retirement plan, participating employees may defer up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of their pre-tax salary, but not more than statutory limits. In October 2017, the Company adopted a 401(k) matching program for its US employees. The Company matches &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the first &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of participating employee contributions and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the next &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of participating employee contributions, subject to applicable IRC limits. The Company incurred costs of  $&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;645&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$230&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; related to the Company match applicable to employee contributions for the years ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The Company's contributions are made in cash. The Company's common stock is not currently an investment option available to participants in the 401(k) retirement plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;For Norway and UK employees, the Company maintains defined contribution pension plans which meet statutory requirements of those jurisdictions. The Company incurred costs of $&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;81&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and $&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;56&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; related to the pension plans for the years ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-A53B8A065282FD3F6BE7DED0B82BE232">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Property and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Property and equipment, net, consisted of:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Computer equipment and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;833&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;307&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;389&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Machinery and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,723&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,495&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;609&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Construction in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;481&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;5,035&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,919&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(1,151&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(355&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;3,884&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,564&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Depreciation expense was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$535&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$164&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively.  In addition, depreciation expense of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$322&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$10&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; is included within inventory and prepaid expenses and other assets, respectively, as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which represents depreciation expense related to equipment involved in the manufacturing process.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-30C11DEBF973C44793E9DED0B81C8B61">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Property and equipment is recorded at cost less accumulated depreciation. Significant additions or improvements are capitalized, and expenditures for repairs and maintenance are charged to expense as incurred. Gains and losses on disposal of assets are included in the consolidated statements of operations. Depreciation is calculated on a straight-line basis over the estimated useful lives of the respective assets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="FD2018Q4YTD" id="Fact-2526D8047729042D712BDED0B878C416">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The estimated useful lives of property and equipment are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Computer equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2-3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Machinery &amp;amp; production equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;5-10 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Furniture &amp;amp; fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;3-5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Shorter of lease term or useful life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Property and equipment, net, consisted of:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Computer equipment and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;833&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;307&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;389&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Machinery and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,723&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,495&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;609&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Construction in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;481&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;5,035&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,919&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(1,151&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(355&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;3,884&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,564&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-8DADED4EDE4AF69D4F78DED0B81CCD2C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Related-party transactions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Debt and equity transactions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;All of the Company's convertible debt (see Note&amp;#160;8) was issued to holders of the Company's convertible preferred stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;During the year ended December&amp;#160;31, 2018 and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company reimbursed Avista Capital Holdings, LP and related parties &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$51&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$157&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively in expenses, primarily related to legal fees incurred in conjunction with the Company's Offering of Common Stock in June 2018, the IPO in October 2017 and the issuance of Series D redeemable convertible preferred stock March 2017.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="FD2018Q4YTD" id="Fact-8D55191E72B63C82E129DED0B81C821D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Research and development costs are expensed as incurred. Research and development costs consist primarily of device development, clinical trial related costs and regulatory related costs. The Company enters into agreements with contract research organizations (CROs) to facilitate, coordinate and perform agreed upon research and development activities for the Company's clinical trials. These CRO contracts typically call for the payment of fees for services at the initiation of the contract and/or upon the achievement of certain clinical trial milestones. The Company prepays certain CRO fees whereby the prepayments are recorded as a current or non-current prepaid asset and are amortized into research and development expense over the period of time the contracted research and development services were performed. The Company's CRO contracts generally also included other fees such as project management and pass through fees whereby the Company expenses these costs as incurred, using the Company's best estimate. Pass through fees include, but are not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous costs. Pass through fees incurred are based on the amount of work completed for the clinical trials and are monitored through reporting provided by the Company's CROs.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-F8B7A76A60ABBB6D5FF1DED0B83B2BE9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;AVP-825 License Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In July 2013, the Company's wholly owned subsidiary, OptiNose AS, entered into the AVP-825 License Agreement with Avanir for the exclusive right to sell AVP-825 (now marketed as Onzetra&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; Xsail&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;), a product combining a low-dose powder form of sumatriptan with the Company's EDS technology platform, for the acute treatment of migraines in adults and any follow-on products under development that consist of a formulation that contains triptans as the sole active ingredient. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Through &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, under the terms of the AVP-825 License Agreement, the Company received aggregate cash payments of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$70,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in connection with the initial signing and the achievement of certain development milestones. The Company did &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;t recognize any licensing revenue during the years ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;On December 10, 2018, the Company received written notice from Avanir of its election to terminate the AVP-825 License Agreement.&amp;#160;As a result, the AVP-825 License Agreement is expected to terminate on March 10, 2019.&amp;#160;Upon termination, the Company may elect to continue to commercialize Onzetra Xsail itself or through a new licensee.&amp;#160; We do not expect to receive any additional proceeds from the AVP-825 License Agreement.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
	<us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-43D8D02D8B9C2798EA13E2CF078B30B9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company accounts for revenue in accordance with ASC Topic 606, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which was adopted on January 1, 2018. This standard applies to all contracts with customers, with the exception of contracts that are within the scope of other standards, such as leases, insurance and financial instruments. Under ASC Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to be entitled in exchange for those goods or services.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company performs the following five steps to recognize revenue under ASC Topic 606: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only recognizes revenue when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that will be transferred to the customer. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;text-decoration:underline;"&gt;Net Product Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company sells XHANCE to preferred pharmacy network partners and wholesalers in the US (collectively, Customers). These Customers subsequently resell the Company&amp;#8217;s products to healthcare providers, patients and other retail pharmacies. In addition to agreements with Customers, the Company enters into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts for the purchase of the Company&amp;#8217;s products.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company recognizes revenue from product sales at the point the Customer obtains control of the product, which generally occurs upon delivery. The transaction price that is recognized as revenue for products includes an estimate of variable consideration which is described below. Payment terms with Customers do not exceed one year and, therefore, the Company does not account for a financing component in its arrangements. The Company expenses incremental costs of obtaining a contract with a Customer (for example, sales commissions) when incurred as the period of benefit is less than one year. Shipping and handling costs for product shipments to Customers are recorded as selling, general and administrative expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;text-decoration:underline;"&gt;Transaction Price, including Estimates of Variable Consideration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Revenue from products is recognized at the estimated net sales price (transaction price), which includes estimates of variable consideration. The Company includes estimated amounts in the transaction price to the extent it is determined probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The Company&amp;#8217;s estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of its anticipated performance and all information (historical, current and forecasted) that is reasonably available.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Components of Variable Consideration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Components of variable consideration include provider chargebacks and discounts, trade discounts and allowances, product returns, government rebates, third-party payor rebates, sales order management fees and other incentives, such as voluntary patient assistance and other allowances that are offered within contracts between the Company and its Customers, payors and other indirect customers relating to the Company&amp;#8217;s sale of products. Those components, as described below, are based on the amounts earned, or to be claimed, on the related sales and are presented as reductions of accounts receivable (if the amount is payable to the Customer) or as a current liability (if the amount is payable to a party other than the Customer). The Company considers all relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:12px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Variable Consideration - Accounts Receivable Reductions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:60px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#9702;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;text-decoration:underline;"&gt;Provider Chargebacks and Discounts.&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from the Company.&amp;#160;Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers.&amp;#160;These components of variable consideration are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable.&amp;#160;Reserves for chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel inventories at each reporting period-end that the Company expects will be sold to qualified healthcare providers, as well as chargebacks that Customers have claimed, but for which the Company has not yet issued a credit.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#9702;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:24px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-24px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;text-decoration:underline;"&gt;Trade Discounts and Allowances.&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;  The Company generally provides Customers with discounts that include incentive fees which are explicitly stated in the Company&amp;#8217;s contracts. These discounts are recorded as a reduction of revenue and accounts receivable in the period in which the related product revenue is recognized. In addition, the Company reimburses (through discounts and allowances) its Customers for sales order management, data and distribution services.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:12px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:6px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-6px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Variable Consideration - Current Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:60px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#9702;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;text-decoration:underline;"&gt;Product Returns.&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;  Consistent with industry practice, the Company has a product returns policy that provides Customers a right of return for product purchased within a specified period prior to and subsequent to the product&amp;#8217;s expiration date. The right of return lapses upon shipment of the goods to a patient. The Company estimates the amount of its products that may be returned and presents this amount as a reduction of revenue in the period the related product revenue is recognized, in addition to establishing a liability. The Company considers several factors in the estimation process, including expiration dates of product shipped to preferred pharmacy network partners and wholesalers, inventory levels within the distribution channel, product shelf life, prescription trends and other relevant factors.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:60px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#9702;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;text-decoration:underline;"&gt;Government Rebates&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.  The Company is subject to discount obligations under state Medicaid programs and Medicare. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. For Medicaid, accruals are based on estimates of future Medicaid beneficiary utilization applied to the Medicaid unit rebate formula established by the Center for Medicaid and Medicare Services. The Medicare Part&amp;#160;D prescription drug benefit mandates manufacturers to fund approximately 50% of the Medicare Part&amp;#160;D insurance coverage gap for prescription drugs sold to eligible patients. To estimate the cost to the Company of this Medicare coverage gap responsibility, the Company estimates the number of patients in the prescription drug coverage gap for whom it will owe an additional liability under the Medicare Part D program. The Company&amp;#8217;s liability for these rebates consists of estimates of claims for the current quarter and estimated future claims that will be made for product that has been recognized as revenue but remains in the distribution channel inventories at the end of the reporting period.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:60px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#9702;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;text-decoration:underline;"&gt;Payor Rebates.&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;  The Company contracts with certain third-party payors, primarily health insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. These rebates are based on contractual percentages applied to the amount of product prescribed to patients who are covered by the plan or the organization with which it contracts. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:60px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#9702;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;text-decoration:underline;"&gt;Other Incentives.&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;  Other incentives that the Company offers include voluntary patient assistance programs, such as co-pay assistance programs, which are intended to provide financial assistance to qualified commercially insured patients with prescription drug co-payments required by payors and coupon programs for cash payors.&amp;#160;The calculation of the accruals for this assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;text-decoration:underline;"&gt;Licensing Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Through December 31, 2017, the Company's revenues had been generated pursuant to the terms of a single license agreement (the AVP-825 License Agreement) with Avanir Pharmaceuticals,&amp;#160;Inc. (Avanir) (Note&amp;#160;7). The AVP-825 License Agreement included licensed rights to patented technology, non-refundable up-front payment, research services, and regulatory and sales milestones as well as royalty payments. Through &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, under the terms of the AVP-825 License Agreement, the Company received aggregate cash payments of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$70,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in connection with the initial signing and the achievement of certain development milestones. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;On December 10, 2018, the Company received written notice from Avanir of its election to terminate the AVP-825 License Agreement.&amp;#160;As a result, the AVP-825 License Agreement is expected to terminate on March 10, 2019. We do not expect to receive any additional proceeds from the AVP-825 License Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Prior to the receipt of notice of termination of the License Agreement, the Company analyzed the performance obligations under the AVP-825 License Agreement, the consideration received to date and the consideration the Company could have received in the future as part of its analysis related to ASU 2014-09. The consideration received to date, which included an upfront payment, research and development funding and development milestone payments was recognized in prior years and the Company&amp;#8217;s performance obligations pursuant to the arrangement have been completed. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
	<us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="FD2018Q4YTD" id="Fact-395B4032AA1D144CD2DEDED0B83B741C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Accrued expenses consisted of:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Contract sales organization expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;4,482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,432&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Selling, general and administrative expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;4,812&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Research and development expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;933&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Bonus expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;3,635&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;4,163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Payroll and benefit expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;564&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;448&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Employee contributions withheld&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;359&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;185&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Product revenue allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,856&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;345&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;435&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;314&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;18,421&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;8,698&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="FD2018Q4YTD" id="Fact-F963F04F1C992898C35CDED0B81CACEF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Diluted net loss per common share for the periods presented do not reflect the following potential common shares, as the effect would be antidilutive:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.73684210526315%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:76%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6,182,873&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,141,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,866,831&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,890,489&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;31,892&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;8,081,596&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;4,031,856&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
	<us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="FD2018Q4YTD" id="Fact-0A2C12CA88B669AAA152DED0B82B63CB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the long-term debt balance is comprised of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:77%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Face amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;75,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;75,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Front end fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(872&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(999&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(1,902&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(2,139&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Back end fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;72,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;71,863&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
	<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="FD2018Q4YTD" id="Fact-9C2E1048DA94277E4939DED0B85DB51C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The principal components of the Company&amp;#8217;s deferred tax assets and liabilities are as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.44054580896686%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,674&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;972&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Prepaid licensing arrangement&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;11,562&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,267&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;783&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Stock compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;3,493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,701&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Research and development credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,485&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,485&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Net operating losses &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;32,548&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;29,636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;53,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;35,632&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Fixed assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(409&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(409&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Less: Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(52,620&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(35,632&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Total net deferred tax assets (liabilities)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2018Q4YTD" id="Fact-F500EF97A3A0DE29E5EFDED0B85C2593">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;A reconciliation of income tax expense (benefit) at the US federal statutory income tax rate and the income tax provision in the financial statements is as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:54%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:22%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Income tax expense at statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;21.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Permanent items&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Foreign rate differential&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(4.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Impact of foreign operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(7.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;State taxes, net of federal benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;3.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Tax rate changes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(15.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Foreign exchange and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&amp;#160;Change in valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(16.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Effective income tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;0.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;0.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2018Q4YTD" id="Fact-57C46627FD1D9884CEACDED0B83B67CC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company recorded stock-based compensation expense in the following expense categories of its accompanying consolidated statements of operations for the years ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and  &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:79%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Cost of product sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;989&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,288&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;7,545&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;3,808&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;8,543&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;5,096&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="FD2018Q4YTD" id="Fact-041F338866A2AD3CB850DED0B8626981">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Income taxes have been recorded on the following book income (loss) before income tax expense:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Domestic operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(146,247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(30,463&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Foreign operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;39,589&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(18,439&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Loss before provision for income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(106,658&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(48,902&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
	<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="FD2018Q4YTD" id="Fact-97F8A81D4B3529960ACFE2EA59FE3F85">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Inventory consisted of the following: &lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,969&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1,385&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Work-in-process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,344&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;628&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,819&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;7,132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2,013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2018Q4YTD" id="Fact-18B71F277476845002E4DED0B84B15EE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.22027290448344%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;exercise price&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;contractual life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Outstanding at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6,251,589&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;9.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6.67&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;472,792&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;19.36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(491,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;3.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;(49,854&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;9.67&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Outstanding at December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6,182,873&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;10.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Exercisable at December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;3,804,999&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;8.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;5.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Vested and expected to vest at December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6,182,873&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;10.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;6.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2018Q4YTD" id="Fact-5E7822B5C6C53ED5F330DED0B84BD749">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company calculated the fair value of each option grant and the option component of the 2017 Plan on the respective dates of grant using the following weighted average assumptions: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2010 A&amp;amp;R Stock Incentive Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2017 Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Risk free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2.74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1.53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Expected term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;5.95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;0.64&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;74.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;80.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Annual dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;0.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;0.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company calculated the fair value of each option grant and the option component of the 2017 Plan on the respective dates of grant using the following weighted average assumptions: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2010 A&amp;amp;R Stock Incentive Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2017 Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Risk free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;2.74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;1.53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Expected term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;5.95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;0.64&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;74.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;80.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;Annual dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;0.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;0.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2018Q4YTD" id="Fact-9963725AE5CDA7806367DED0B81CF49E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company measures and recognizes compensation expense for all stock options awarded to employees and nonemployees and shares issued under the employee stock purchase plan based on the estimated fair value of the awards on the respective grant dates. The Company uses the Black-Scholes option pricing model to value its stock option awards and shares issued under the employee stock purchase plan. The Company recognizes compensation expense for time-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company recognizes compensation expense for performance based awards when the performance condition is probable of achievement. Stock-based awards issued to nonemployees are revalued at each reporting period until the award vests. The Company accounts for forfeitures of stock option awards as they occur.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Estimating the fair value of options and shares issued under the employee stock purchase plan requires the input of subjective assumptions, including the estimated fair value of the Company's common stock, the expected life of the options, stock price volatility, the risk-free interest rate and expected dividends. The assumptions used in the Company's Black-Scholes option-pricing model represent management's best estimates and involve a number of variables, uncertainties and assumptions and the application of management's judgment, as they are inherently subjective.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-84E0E65F69BC6AEC9647DED0B82B7FD3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Stockholders' equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In October 2017, the Company increased the number of authorized common shares from &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10,624,486&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;200,000,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and completed an initial public offering (IPO) of its common stock, selling &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;8,625,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares at &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$16.00&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per share.  As a result of the IPO, the Company received &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$125,471&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in net proceeds, after deducting discounts and commissions of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$9,660&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and offering expenses of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$2,869&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; payable by the Company. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;On June 11, 2018, the Company and certain stockholders closed the Offering of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5,750,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of Common Stock at a price of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$22.25&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per share. The Offering consisted of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,875,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of Common Stock sold by the Company and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,875,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of Common Stock sold by certain stockholders. As a result of the Offering, the Company received &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$59,917&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in net proceeds, after deducting discounts and commissions of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$3,678&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and offering expenses of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$373&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; payable by the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Each share of common stock entitles the holder to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; vote on all matters submitted to a vote of the Company&amp;#8217;s stockholders. Subject to preferences that may apply to any outstanding preferred stock, holders of common stock are entitled to receive ratably any dividends that the Company&amp;#8217;s board of directors may declare out of funds legally available for that purpose on a non-cumulative basis. &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; dividends had been declared through &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company had &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,866,831&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; warrants outstanding to purchase shares of the Company's common stock with an exercise price of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$8.16&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The warrants expire on November 1, 2020.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Redeemable convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;During the year ended December&amp;#160;31, 2017, the Company sold &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,117,578&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of Series&amp;#160;D Preferred Stock at a per share purchase price of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$32.85&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, resulting in gross proceeds to the Company of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$36,712&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; (the Series&amp;#160;D Financing). In connection with the Series&amp;#160;D Financing, the Company's existing convertible notes and associated accrued interest and back end fees thereon totaling &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$19,527&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; converted into &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;687,474&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of Series&amp;#160;C-2 Preferred Stock at a per share conversion price of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$28.40&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; (Note&amp;#160;8).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Upon consummation of the IPO in October 2017, all of the outstanding shares of the Company's redeemable convertible preferred stock were converted into an aggregate of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;25,068,556&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of common stock. In connection with the IPO, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5,000,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of preferred stock, with a par value of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$0.001&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per share, were authorized for issuance. As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; preferred stock was issued or outstanding.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2018Q4YTD" id="Fact-99503EC997C321B9E6D8EE630967BDA0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Subsequent events&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;On January 31, 2019, OptiNose AS, a wholly owned subsidiary of the Company, entered into a license agreement (the Inexia License Agreement) with Inexia Limited (Inexia).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Under the terms of the Inexia License Agreement, Inexia paid the Company a &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$500&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; upfront payment. For each product developed under the Inexia License Agreement, the Company is eligible to receive up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$8,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of development milestone payments and up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$37,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of sales milestone payments. In addition, the Company is eligible to receive tiered, low-to-mid single digit royalties based on net sales of any products successfully developed and commercialized under the Inexia License Agreement.  Other than the upfront payment, the Company does not anticipate the receipt of any milestone or royalty payments from Inexia in the near term.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="FD2018Q4YTD" id="Fact-1D7279E8234444B704E749F85BD0A700">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Accounts receivable primarily relates to amounts due from customers, which are typically due within 31 to 61 days. The Company analyzes accounts that are past due for collectability. Given the nature and historical collectability of the Company&amp;#8217;s accounts receivable, an allowance for doubtful accounts was not deemed necessary at&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
	<us-gaap:UseOfEstimates contextRef="FD2018Q4YTD" id="Fact-8D8945B4EE8DBB04CD79DED0B8702FFE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>optn-20181231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.optinose.com/20181231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:optn="http://www.optinose.com/20181231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="optn-20181231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="optn-20181231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="optn-20181231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="optn-20181231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccruedExpenses" roleURI="http://www.optinose.com/role/AccruedExpenses">
        <link:definition>2119100 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.optinose.com/role/AccruedExpensesDetails">
        <link:definition>2419402 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.optinose.com/role/AccruedExpensesTables">
        <link:definition>2319301 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Avp825LicenseAgreement" roleURI="http://www.optinose.com/role/Avp825LicenseAgreement">
        <link:definition>2122100 - Disclosure - AVP-825 License Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Avp825LicenseAgreementDetails" roleURI="http://www.optinose.com/role/Avp825LicenseAgreementDetails">
        <link:definition>2422401 - Disclosure - AVP-825 License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.optinose.com/role/CommitmentsAndContingencies">
        <link:definition>2134100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" roleURI="http://www.optinose.com/role/CommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails">
        <link:definition>2434403 - Disclosure - Commitments and Contingencies (Future Minimum Lease Payments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesLeasesDetails" roleURI="http://www.optinose.com/role/CommitmentsAndContingenciesLeasesDetails">
        <link:definition>2434402 - Disclosure - Commitments and Contingencies (Leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesPurchaseCommitmentsDetails" roleURI="http://www.optinose.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetails">
        <link:definition>2434404 - Disclosure - Commitments and Contingencies (Purchase Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.optinose.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2334301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.optinose.com/role/ConsolidatedBalanceSheets">
        <link:definition>1002000 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.optinose.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002001 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.optinose.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1006000 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholders" roleURI="http://www.optinose.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholders">
        <link:definition>1005000 - Statement - Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders'</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersParenthetical" roleURI="http://www.optinose.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersParenthetical">
        <link:definition>1005001 - Statement - Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveIncomeAndLoss" roleURI="http://www.optinose.com/role/ConsolidatedStatementsOfComprehensiveIncomeAndLoss">
        <link:definition>1004000 - Statement - Consolidated Statements of Comprehensive Income and Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfOperations" roleURI="http://www.optinose.com/role/ConsolidatedStatementsOfOperations">
        <link:definition>1003000 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleNotes" roleURI="http://www.optinose.com/role/ConvertibleNotes">
        <link:definition>2125100 - Disclosure - Convertible Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleNotesNarrativeDetails" roleURI="http://www.optinose.com/role/ConvertibleNotesNarrativeDetails">
        <link:definition>2425401 - Disclosure - Convertible Notes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformationDocument" roleURI="http://www.optinose.com/role/DocumentAndEntityInformationDocument">
        <link:definition>0001000 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.optinose.com/role/EmployeeBenefitPlans">
        <link:definition>2131100 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansDetails" roleURI="http://www.optinose.com/role/EmployeeBenefitPlansDetails">
        <link:definition>2431401 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.optinose.com/role/IncomeTaxes">
        <link:definition>2137100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.optinose.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2437405 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.optinose.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>2437404 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.optinose.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>2437403 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails" roleURI="http://www.optinose.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails">
        <link:definition>2437402 - Disclosure - Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.optinose.com/role/IncomeTaxesTables">
        <link:definition>2337301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.optinose.com/role/Inventory">
        <link:definition>2110100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.optinose.com/role/InventoryDetails">
        <link:definition>2410402 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.optinose.com/role/InventoryTables">
        <link:definition>2310301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Liquidity" roleURI="http://www.optinose.com/role/Liquidity">
        <link:definition>2104100 - Disclosure - Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiquidityDetails" roleURI="http://www.optinose.com/role/LiquidityDetails">
        <link:definition>2404401 - Disclosure - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.optinose.com/role/LongTermDebt">
        <link:definition>2128100 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNarrativeDetails" roleURI="http://www.optinose.com/role/LongTermDebtNarrativeDetails">
        <link:definition>2428402 - Disclosure - Long-Term Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduleOfLongTermDebtDetails" roleURI="http://www.optinose.com/role/LongTermDebtScheduleOfLongTermDebtDetails">
        <link:definition>2428403 - Disclosure - Long-Term Debt - Schedule of Long Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtTables" roleURI="http://www.optinose.com/role/LongTermDebtTables">
        <link:definition>2328301 - Disclosure - Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndDescriptionOfBusiness" roleURI="http://www.optinose.com/role/OrganizationAndDescriptionOfBusiness">
        <link:definition>2101100 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipment" roleURI="http://www.optinose.com/role/PropertyAndEquipment">
        <link:definition>2116100 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentDetails" roleURI="http://www.optinose.com/role/PropertyAndEquipmentDetails">
        <link:definition>2416402 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentTables" roleURI="http://www.optinose.com/role/PropertyAndEquipmentTables">
        <link:definition>2316301 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.optinose.com/role/RelatedPartyTransactions">
        <link:definition>2138100 - Disclosure - Related-party transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.optinose.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2438401 - Disclosure - Related-party transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.optinose.com/role/StockBasedCompensation">
        <link:definition>2136100 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationBlackScholesPricingModelOptionsDetails" roleURI="http://www.optinose.com/role/StockBasedCompensationBlackScholesPricingModelOptionsDetails">
        <link:definition>2436407 - Disclosure - Stock-based Compensation - Black-Scholes pricing model options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationEmployeeStockPurchasePlanDetails" roleURI="http://www.optinose.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails">
        <link:definition>2436405 - Disclosure - Stock-based Compensation - Employee stock purchase plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.optinose.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2436402 - Disclosure - Stock-based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationServiceBasedStockOptionsDetails" roleURI="http://www.optinose.com/role/StockBasedCompensationServiceBasedStockOptionsDetails">
        <link:definition>2436403 - Disclosure - Stock-based Compensation - Service-based stock options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://www.optinose.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>2436406 - Disclosure - Stock-based Compensation - Stock-based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.optinose.com/role/StockBasedCompensationTables">
        <link:definition>2336301 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.optinose.com/role/StockholdersEquity">
        <link:definition>2135100 - Disclosure - Stockholders' equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCommonStockDetails" roleURI="http://www.optinose.com/role/StockholdersEquityCommonStockDetails">
        <link:definition>2435402 - Disclosure - Stockholders' equity - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.optinose.com/role/StockholdersEquityDetails">
        <link:definition>2435405 - Disclosure - Stockholders' equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityWarrantsDetails" roleURI="http://www.optinose.com/role/StockholdersEquityWarrantsDetails">
        <link:definition>2435403 - Disclosure - Stockholders' equity - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.optinose.com/role/SubsequentEvents">
        <link:definition>2140100 - Disclosure - Subsequent events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.optinose.com/role/SubsequentEventsDetails">
        <link:definition>2440401 - Disclosure - Subsequent events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2107100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesAntidilutiveSharesExcludedFromEarningsPerShareDetails" roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesAntidilutiveSharesExcludedFromEarningsPerShareDetails">
        <link:definition>2407407 - Disclosure - Summary of Significant Accounting Policies - Antidilutive shares excluded from earnings per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails">
        <link:definition>2407404 - Disclosure - Summary of Significant Accounting Policies - Concentration Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2207201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <link:definition>2407405 - Disclosure - Summary of Significant Accounting Policies - Property and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2307302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="optn_AccruedProductAllowancesCurrent" name="AccruedProductAllowancesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="optn_AccruedResearchandDevelopmentCurrent" name="AccruedResearchandDevelopmentCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="optn_AccruedSalesOrganizationExpensesCurrent" name="AccruedSalesOrganizationExpensesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="optn_AccruedSellingGeneralandAdministrativeCurrent" name="AccruedSellingGeneralandAdministrativeCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="optn_AmendedandRestated2010StockIncentivePlanMember" name="AmendedandRestated2010StockIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="optn_CertainStockholdersMember" name="CertainStockholdersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease" name="CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="optn_ComputerEquipmentandSoftwareMember" name="ComputerEquipmentandSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="optn_ConcentrationRiskNumberofClients" name="ConcentrationRiskNumberofClients" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="optn_ConversionatConsummationofIPOMember" name="ConversionatConsummationofIPOMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember" name="ConversionofConvertiblenotesintoSeriesC2PreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="optn_DebtDiscountAmortizationPeriod" name="DebtDiscountAmortizationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="optn_DebtInstrumentCouponInterestandFees" name="DebtInstrumentCouponInterestandFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="optn_DebtInstrumentCovenantCashandCashEquivalents" name="DebtInstrumentCovenantCashandCashEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="optn_DebtInstrumentFeeAmountBackEnd" name="DebtInstrumentFeeAmountBackEnd" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="optn_DebtInstrumentFeeAmountFrontEnd" name="DebtInstrumentFeeAmountFrontEnd" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="optn_DebtInstrumentFeeExitFee" name="DebtInstrumentFeeExitFee" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="optn_DebtInstrumentFeeUpfrontFee" name="DebtInstrumentFeeUpfrontFee" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="optn_DebtInstrumentFeesCapitalizedtoPrincipal" name="DebtInstrumentFeesCapitalizedtoPrincipal" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="optn_DebtInstrumentInterestRateFloor" name="DebtInstrumentInterestRateFloor" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="optn_DebtInstrumentLoanConversionPeriod" name="DebtInstrumentLoanConversionPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="optn_DebtInstrumentPrepaymentFee" name="DebtInstrumentPrepaymentFee" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses" name="DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="optn_DeferredTaxAssetsInterestExpense" name="DeferredTaxAssetsInterestExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="optn_DeferredTaxAssetsPrepaidLicenseArrangement" name="DeferredTaxAssetsPrepaidLicenseArrangement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="optn_DefinedContributionPlanTrancheOneMember" name="DefinedContributionPlanTrancheOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="optn_DefinedContributionPlanTrancheTwoMember" name="DefinedContributionPlanTrancheTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="optn_DefinedContributionPlanTranchesAxisAxis" name="DefinedContributionPlanTranchesAxisAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="optn_DefinedContributionPlanTranchesAxisDomain" name="DefinedContributionPlanTranchesAxisDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="optn_DevelopmentMilestoneEligibility" name="DevelopmentMilestoneEligibility" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="optn_DocumentandEntityInformationAbstract" name="DocumentandEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent" name="EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent" name="EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="optn_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="optn_FeesForIPOAndSeriesDConvertibleStockMember" name="FeesForIPOAndSeriesDConvertibleStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="optn_FutureLiquidityTextBlock" name="FutureLiquidityTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="optn_FutureRentExpense" name="FutureRentExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="optn_GrantandOtherIncome" name="GrantandOtherIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="optn_IncreaseDecreaseInGrantsandOtherReceivables" name="IncreaseDecreaseInGrantsandOtherReceivables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="optn_IncreaseDecreaseinDepositsandOtherAssets" name="IncreaseDecreaseinDepositsandOtherAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="optn_InterestExpenseDebtBackEndFees" name="InterestExpenseDebtBackEndFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="optn_InterestExpenseDebtFrontEndFees" name="InterestExpenseDebtFrontEndFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="optn_MarketSalesforceMember" name="MarketSalesforceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="optn_NotePurchaseAgreementDelayedDrawNotesMember" name="NotePurchaseAgreementDelayedDrawNotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="optn_NotePurchaseAgreementMember" name="NotePurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="optn_NumberOfOperatingLeases" name="NumberOfOperatingLeases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="optn_NumberOfTrailingQuarters" name="NumberOfTrailingQuarters" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="optn_NumberofTranches" name="NumberofTranches" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan" name="ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="optn_PublicOfferingMember" name="PublicOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="optn_RedeemableConvertiblePreferredStockSeriesC2Member" name="RedeemableConvertiblePreferredStockSeriesC2Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember" name="RedeemableConvertiblePreferredStockSeriesCC1C2DMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="optn_RedeemableConvertiblePreferredStockSeriesCC1DMember" name="RedeemableConvertiblePreferredStockSeriesCC1DMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="optn_RedeemableConvertiblePreferredStockSeriesDMember" name="RedeemableConvertiblePreferredStockSeriesDMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="optn_SaleofStockDiscounts" name="SaleofStockDiscounts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="optn_SaleofStockDiscountsandCommissions" name="SaleofStockDiscountsandCommissions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="optn_SalesMilestoneEligibility" name="SalesMilestoneEligibility" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="optn_SeriesDFinancingMember" name="SeriesDFinancingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="optn_ServiceBasedStockOptionsMember" name="ServiceBasedStockOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear" name="SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="optn_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="optn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="optn_TheCompanyMember" name="TheCompanyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="optn_TotalDebttoTrailingQuarterNetSalesRatio" name="TotalDebttoTrailingQuarterNetSalesRatio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="optn_TrancheOneMember" name="TrancheOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="optn_TrancheTwoMember" name="TrancheTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember" name="TwoThousandSeventeenEmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="optn_UpfrontLicenseFeeReceivable" name="UpfrontLicenseFeeReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="optn_VotePerShare" name="VotePerShare" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>optn-20181231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.optinose.com/role/AccruedExpenses" xlink:href="optn-20181231.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/AccruedExpensesDetails" xlink:href="optn-20181231.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/AccruedExpensesTables" xlink:href="optn-20181231.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/Avp825LicenseAgreement" xlink:href="optn-20181231.xsd#Avp825LicenseAgreement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/Avp825LicenseAgreementDetails" xlink:href="optn-20181231.xsd#Avp825LicenseAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/CommitmentsAndContingencies" xlink:href="optn-20181231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/CommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" xlink:href="optn-20181231.xsd#CommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/CommitmentsAndContingenciesLeasesDetails" xlink:href="optn-20181231.xsd#CommitmentsAndContingenciesLeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetails" xlink:href="optn-20181231.xsd#CommitmentsAndContingenciesPurchaseCommitmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/CommitmentsAndContingenciesTables" xlink:href="optn-20181231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedBalanceSheets" xlink:href="optn-20181231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="optn-20181231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="optn-20181231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholders" xlink:href="optn-20181231.xsd#ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholders" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersParenthetical" xlink:href="optn-20181231.xsd#ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedStatementsOfComprehensiveIncomeAndLoss" xlink:href="optn-20181231.xsd#ConsolidatedStatementsOfComprehensiveIncomeAndLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedStatementsOfOperations" xlink:href="optn-20181231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConvertibleNotes" xlink:href="optn-20181231.xsd#ConvertibleNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConvertibleNotesNarrativeDetails" xlink:href="optn-20181231.xsd#ConvertibleNotesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/DocumentAndEntityInformationDocument" xlink:href="optn-20181231.xsd#DocumentAndEntityInformationDocument" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/EmployeeBenefitPlans" xlink:href="optn-20181231.xsd#EmployeeBenefitPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/EmployeeBenefitPlansDetails" xlink:href="optn-20181231.xsd#EmployeeBenefitPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxes" xlink:href="optn-20181231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxesNarrativeDetails" xlink:href="optn-20181231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="optn-20181231.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="optn-20181231.xsd#IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails" xlink:href="optn-20181231.xsd#IncomeTaxesScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxesTables" xlink:href="optn-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/Inventory" xlink:href="optn-20181231.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/InventoryDetails" xlink:href="optn-20181231.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/InventoryTables" xlink:href="optn-20181231.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/Liquidity" xlink:href="optn-20181231.xsd#Liquidity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/LiquidityDetails" xlink:href="optn-20181231.xsd#LiquidityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/LongTermDebt" xlink:href="optn-20181231.xsd#LongTermDebt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/LongTermDebtNarrativeDetails" xlink:href="optn-20181231.xsd#LongTermDebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/LongTermDebtScheduleOfLongTermDebtDetails" xlink:href="optn-20181231.xsd#LongTermDebtScheduleOfLongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/LongTermDebtTables" xlink:href="optn-20181231.xsd#LongTermDebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="optn-20181231.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/PropertyAndEquipment" xlink:href="optn-20181231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/PropertyAndEquipmentDetails" xlink:href="optn-20181231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/PropertyAndEquipmentTables" xlink:href="optn-20181231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/RelatedPartyTransactions" xlink:href="optn-20181231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/RelatedPartyTransactionsDetails" xlink:href="optn-20181231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockBasedCompensation" xlink:href="optn-20181231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockBasedCompensationBlackScholesPricingModelOptionsDetails" xlink:href="optn-20181231.xsd#StockBasedCompensationBlackScholesPricingModelOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:href="optn-20181231.xsd#StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockBasedCompensationNarrativeDetails" xlink:href="optn-20181231.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" xlink:href="optn-20181231.xsd#StockBasedCompensationServiceBasedStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:href="optn-20181231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockBasedCompensationTables" xlink:href="optn-20181231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockholdersEquity" xlink:href="optn-20181231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockholdersEquityCommonStockDetails" xlink:href="optn-20181231.xsd#StockholdersEquityCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockholdersEquityDetails" xlink:href="optn-20181231.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockholdersEquityWarrantsDetails" xlink:href="optn-20181231.xsd#StockholdersEquityWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SubsequentEvents" xlink:href="optn-20181231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SubsequentEventsDetails" xlink:href="optn-20181231.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="optn-20181231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesAntidilutiveSharesExcludedFromEarningsPerShareDetails" xlink:href="optn-20181231.xsd#SummaryOfSignificantAccountingPoliciesAntidilutiveSharesExcludedFromEarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:href="optn-20181231.xsd#SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="optn-20181231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="optn-20181231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:href="optn-20181231.xsd#SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="optn-20181231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/AccruedExpenses" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="locator" />
    <link:loc xlink:href="optn-20181231.xsd#optn_AccruedResearchandDevelopmentCurrent" xlink:label="loc_optn_AccruedResearchandDevelopmentCurrent_d14296bf-c0c4-462f-da89-d362231153b3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_optn_AccruedResearchandDevelopmentCurrent_d14296bf-c0c4-462f-da89-d362231153b3" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_AccruedSellingGeneralandAdministrativeCurrent" xlink:label="loc_optn_AccruedSellingGeneralandAdministrativeCurrent_b4389b87-e894-d885-c343-d362230187a1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_optn_AccruedSellingGeneralandAdministrativeCurrent_b4389b87-e894-d885-c343-d362230187a1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent_853bd7d0-a1a5-045b-6078-0f9a7e4e9e80" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_AccruedBonusesCurrent_853bd7d0-a1a5-045b-6078-0f9a7e4e9e80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d9354686-0832-bbe3-9389-140489c487e8" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d9354686-0832-bbe3-9389-140489c487e8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_84c97d53-d75c-0fec-d05e-498cb2460450" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_InterestPayableCurrent_84c97d53-d75c-0fec-d05e-498cb2460450" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_282c42f6-247d-2d65-69d2-2b392778c0ef" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_282c42f6-247d-2d65-69d2-2b392778c0ef" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_AccruedProductAllowancesCurrent" xlink:label="loc_optn_AccruedProductAllowancesCurrent_b1692024-59cc-5a25-337e-d36222d8489e" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_optn_AccruedProductAllowancesCurrent_b1692024-59cc-5a25-337e-d36222d8489e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_0ecff572-4427-028e-de1a-032fc8792eed" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_0ecff572-4427-028e-de1a-032fc8792eed" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_AccruedSalesOrganizationExpensesCurrent" xlink:label="loc_optn_AccruedSalesOrganizationExpensesCurrent_0744847BD48F5AB65A1E3A6121E814D9" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_optn_AccruedSalesOrganizationExpensesCurrent_0744847BD48F5AB65A1E3A6121E814D9" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.optinose.com/role/AccruedExpensesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/Avp825LicenseAgreement" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/Avp825LicenseAgreementDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/CommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_f67237f3-7c78-8a5c-b7b3-17f1eb0b017a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_f67237f3-7c78-8a5c-b7b3-17f1eb0b017a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_39e76369-4fdc-9d5f-860a-45d0795e5fb0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_39e76369-4fdc-9d5f-860a-45d0795e5fb0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_ccaff3fc-3d87-e58a-0083-69dda0c10f9d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_ccaff3fc-3d87-e58a-0083-69dda0c10f9d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.optinose.com/role/CommitmentsAndContingenciesLeasesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_e66dfde8-0121-7642-0551-40d4c5bfd655" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_e66dfde8-0121-7642-0551-40d4c5bfd655" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_5212eab8-bedb-997a-101c-3c3b65fbee4f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_ReceivablesNetCurrent_5212eab8-bedb-997a-101c-3c3b65fbee4f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_79aabdc0-b963-1fd1-4e81-8c0801b1ebca" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_OtherAssetsCurrent_79aabdc0-b963-1fd1-4e81-8c0801b1ebca" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1beea529-7ff9-f264-77a3-b82530469f83" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1beea529-7ff9-f264-77a3-b82530469f83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaap_OtherLiabilities_b7c80bbc-e033-5d39-6a1b-ed85fbc903f7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_OtherLiabilities_b7c80bbc-e033-5d39-6a1b-ed85fbc903f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_fcfc6b17-bfc5-2ebc-3fc1-751aa446a572" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_fcfc6b17-bfc5-2ebc-3fc1-751aa446a572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_df284507-8ac7-eed1-41db-05e81b70be6d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_df284507-8ac7-eed1-41db-05e81b70be6d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.optinose.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_007d9109-9595-5f2c-7482-78ac7c9eb888" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_007d9109-9595-5f2c-7482-78ac7c9eb888" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6ec8bc8e-bcd9-36ad-d8ae-2c2fa1dfd920" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6ec8bc8e-bcd9-36ad-d8ae-2c2fa1dfd920" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan" xlink:label="loc_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan_07C4CD0B1B1AEE7A45559DBFE1E2EC4A" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan_07C4CD0B1B1AEE7A45559DBFE1E2EC4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_60ab1096-bf53-5d61-76bd-431fe857fc03" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_60ab1096-bf53-5d61-76bd-431fe857fc03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_706d3cc5-3df5-1e1a-5067-c02728407eb6" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_706d3cc5-3df5-1e1a-5067-c02728407eb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_43305c85-41ff-3d0f-c464-dc8983363bce" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_43305c85-41ff-3d0f-c464-dc8983363bce" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_8bd1a974-560d-3f84-e984-727058b1874b" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_8bd1a974-560d-3f84-e984-727058b1874b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b11c1cb0-596b-4c3d-0283-76cef67837c7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b11c1cb0-596b-4c3d-0283-76cef67837c7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1b3da715-8d28-869a-fc9e-cb75bcd8d652" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1b3da715-8d28-869a-fc9e-cb75bcd8d652" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_IncreaseDecreaseInGrantsandOtherReceivables" xlink:label="loc_optn_IncreaseDecreaseInGrantsandOtherReceivables_0370a770-823f-c1b0-2dbe-d36223702bc1" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_optn_IncreaseDecreaseInGrantsandOtherReceivables_0370a770-823f-c1b0-2dbe-d36223702bc1" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_IncreaseDecreaseinDepositsandOtherAssets" xlink:label="loc_optn_IncreaseDecreaseinDepositsandOtherAssets_252ae327-9f10-5bb0-11d3-d362234a4fb2" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_optn_IncreaseDecreaseinDepositsandOtherAssets_252ae327-9f10-5bb0-11d3-d362234a4fb2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_334f1d33-7cae-7fd2-9d83-bb387fc2f3dd" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_334f1d33-7cae-7fd2-9d83-bb387fc2f3dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a39d2ee-656d-ead5-a676-41794b4da8f4" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a39d2ee-656d-ead5-a676-41794b4da8f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d76eef5-dce5-0152-632e-9bab39da698c" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d76eef5-dce5-0152-632e-9bab39da698c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_e0089888-8677-d95e-95e6-00fe630f2dcb" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_e0089888-8677-d95e-95e6-00fe630f2dcb" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.optinose.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholders" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/ConsolidatedStatementsOfComprehensiveIncomeAndLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b087c8bb-e0f6-4c7f-883c-027f52d32745" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b087c8bb-e0f6-4c7f-883c-027f52d32745" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.optinose.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_5fcda05e-5b0d-7f20-111d-115dec47eebc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_InvestmentIncomeInterest_5fcda05e-5b0d-7f20-111d-115dec47eebc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_a56b34b7-57ab-a07c-7f03-8366849a14f0" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_InterestExpense_a56b34b7-57ab-a07c-7f03-8366849a14f0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_743ecb1a-adc1-2b63-ff24-350f33c715bd" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_743ecb1a-adc1-2b63-ff24-350f33c715bd" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_GrantandOtherIncome" xlink:label="loc_optn_GrantandOtherIncome_DDA5B1EE967736F08774DEE18E976C93" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_optn_GrantandOtherIncome_DDA5B1EE967736F08774DEE18E976C93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_693c47dd-e6fa-9c85-6a65-7baa26f76b5e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_693c47dd-e6fa-9c85-6a65-7baa26f76b5e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_df00e688-c7aa-f044-9cba-c48e7c14e35b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_GrossProfit_df00e688-c7aa-f044-9cba-c48e7c14e35b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c604cfe-da19-5194-72b6-98be0130cfb7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_df00e688-c7aa-f044-9cba-c48e7c14e35b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c604cfe-da19-5194-72b6-98be0130cfb7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1c65a201-fd8e-32d7-dad9-c6d1d5719594" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_df00e688-c7aa-f044-9cba-c48e7c14e35b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1c65a201-fd8e-32d7-dad9-c6d1d5719594" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:label="loc_us-gaap_TemporaryEquityDividendsAdjustment_f88276ac-6615-3b05-6c2e-9e44dc6148fd" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:to="loc_us-gaap_TemporaryEquityDividendsAdjustment_f88276ac-6615-3b05-6c2e-9e44dc6148fd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_98db377b-8b8a-f78c-cff8-12ecd6a66f77" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_98db377b-8b8a-f78c-cff8-12ecd6a66f77" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.optinose.com/role/ConvertibleNotes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/ConvertibleNotesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/DocumentAndEntityInformationDocument" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/EmployeeBenefitPlans" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/EmployeeBenefitPlansDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c003e837-c7c9-cd10-ae74-916131fdc333" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c003e837-c7c9-cd10-ae74-916131fdc333" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_d96675b6-7cb7-72db-4336-242d9d77a55c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_d96675b6-7cb7-72db-4336-242d9d77a55c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_b4dece9a-8c95-7770-52f2-bc14b57aa839" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_b4dece9a-8c95-7770-52f2-bc14b57aa839" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DeferredTaxAssetsInterestExpense" xlink:label="loc_optn_DeferredTaxAssetsInterestExpense_ec9c3b1e-65a4-7212-6e36-ded0c7e31464" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_optn_DeferredTaxAssetsInterestExpense_ec9c3b1e-65a4-7212-6e36-ded0c7e31464" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_9a653a3a-e258-968f-49ea-6112d232a0c6" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_9a653a3a-e258-968f-49ea-6112d232a0c6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_8cc5c29a-fc27-b861-be5d-a8aecede9ea0" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_8cc5c29a-fc27-b861-be5d-a8aecede9ea0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_877d9548-0a6d-f5af-1e31-5b1edfc4107e" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_877d9548-0a6d-f5af-1e31-5b1edfc4107e" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DeferredTaxAssetsPrepaidLicenseArrangement" xlink:label="loc_optn_DeferredTaxAssetsPrepaidLicenseArrangement_79B825E27E6257F877DF3A68834D7CC3" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_optn_DeferredTaxAssetsPrepaidLicenseArrangement_79B825E27E6257F877DF3A68834D7CC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_5ca8e732-540c-5527-8ee3-c835dafc5838" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c003e837-c7c9-cd10-ae74-916131fdc333" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_5ca8e732-540c-5527-8ee3-c835dafc5838" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4ed01819-014a-ce74-957e-ddc9b0c1d62e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5ca8e732-540c-5527-8ee3-c835dafc5838" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4ed01819-014a-ce74-957e-ddc9b0c1d62e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d9af76c3-a64a-3b37-1d7d-4e9be8c70af6" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c003e837-c7c9-cd10-ae74-916131fdc333" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d9af76c3-a64a-3b37-1d7d-4e9be8c70af6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.optinose.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_51d18bf0-0823-2940-9470-e9bbca486da6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_51d18bf0-0823-2940-9470-e9bbca486da6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_481cad45-a7f9-b179-4730-79d0ba87d4ce" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_481cad45-a7f9-b179-4730-79d0ba87d4ce" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2159a283-2879-8644-198d-34cde06e5374" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2159a283-2879-8644-198d-34cde06e5374" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d23dd313-f50b-59fa-fd80-0dbe24277535" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d23dd313-f50b-59fa-fd80-0dbe24277535" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_7ffe16d1-cedd-985f-c95d-65ae6fa8d756" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_7ffe16d1-cedd-985f-c95d-65ae6fa8d756" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_082942cb-e31f-ff03-a943-7f4739f70da9" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_082942cb-e31f-ff03-a943-7f4739f70da9" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent" xlink:label="loc_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent_7C0876117EDFD85F23CBEE59982FD1C0" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent_7C0876117EDFD85F23CBEE59982FD1C0" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent" xlink:label="loc_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent_597F6D3C554BCE72322EEE5771A4A8E1" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent_597F6D3C554BCE72322EEE5771A4A8E1" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.optinose.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e6f9d43e-fcd6-745d-b634-9ed4792095b2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e6f9d43e-fcd6-745d-b634-9ed4792095b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_a4e74316-f31b-80bc-a44a-3464e9dcdb33" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_a4e74316-f31b-80bc-a44a-3464e9dcdb33" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.optinose.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_c874fd7d-1c88-8feb-a9e1-2ace184ce14d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_aec9630a-9e19-cd8f-8217-90be7ac55d44" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_c874fd7d-1c88-8feb-a9e1-2ace184ce14d" xlink:to="loc_us-gaap_InventoryRawMaterials_aec9630a-9e19-cd8f-8217-90be7ac55d44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_9a39fd9b-6ecf-21de-0dc6-98f2a03e9440" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_c874fd7d-1c88-8feb-a9e1-2ace184ce14d" xlink:to="loc_us-gaap_InventoryWorkInProcess_9a39fd9b-6ecf-21de-0dc6-98f2a03e9440" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_4e166bbb-377c-800b-7f59-05671dfec1ab" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_c874fd7d-1c88-8feb-a9e1-2ace184ce14d" xlink:to="loc_us-gaap_InventoryFinishedGoods_4e166bbb-377c-800b-7f59-05671dfec1ab" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.optinose.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/Liquidity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/LiquidityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/LongTermDebt" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/LongTermDebtNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/LongTermDebtScheduleOfLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_88b8f1df-ff6f-5cd6-e45f-5878f70c11d5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_88b8f1df-ff6f-5cd6-e45f-5878f70c11d5" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentFeeAmountFrontEnd" xlink:label="loc_optn_DebtInstrumentFeeAmountFrontEnd_5032fb29-94da-8880-8cfc-d36222a83b02" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:to="loc_optn_DebtInstrumentFeeAmountFrontEnd_5032fb29-94da-8880-8cfc-d36222a83b02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_a73af488-e519-8a85-854a-8b8e1b665875" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_a73af488-e519-8a85-854a-8b8e1b665875" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentFeeAmountBackEnd" xlink:label="loc_optn_DebtInstrumentFeeAmountBackEnd_c069fd0e-5669-1cf5-ec79-d36222f51bd5" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:to="loc_optn_DebtInstrumentFeeAmountBackEnd_c069fd0e-5669-1cf5-ec79-d36222f51bd5" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.optinose.com/role/LongTermDebtTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/OrganizationAndDescriptionOfBusiness" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_78662f7f-2a6a-5d68-ba8a-7947ed287be5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_78662f7f-2a6a-5d68-ba8a-7947ed287be5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a08cda9-11b3-e7ac-3fc9-3a23c67d9b96" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a08cda9-11b3-e7ac-3fc9-3a23c67d9b96" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.optinose.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/StockBasedCompensationBlackScholesPricingModelOptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/StockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/StockholdersEquityCommonStockDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/StockholdersEquityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/StockholdersEquityWarrantsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/SubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/SubsequentEventsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesAntidilutiveSharesExcludedFromEarningsPerShareDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>optn-20181231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.optinose.com/role/AccruedExpenses" xlink:href="optn-20181231.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/AccruedExpensesDetails" xlink:href="optn-20181231.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/AccruedExpensesTables" xlink:href="optn-20181231.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/Avp825LicenseAgreement" xlink:href="optn-20181231.xsd#Avp825LicenseAgreement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/Avp825LicenseAgreementDetails" xlink:href="optn-20181231.xsd#Avp825LicenseAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/CommitmentsAndContingencies" xlink:href="optn-20181231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/CommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" xlink:href="optn-20181231.xsd#CommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/CommitmentsAndContingenciesLeasesDetails" xlink:href="optn-20181231.xsd#CommitmentsAndContingenciesLeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetails" xlink:href="optn-20181231.xsd#CommitmentsAndContingenciesPurchaseCommitmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/CommitmentsAndContingenciesTables" xlink:href="optn-20181231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedBalanceSheets" xlink:href="optn-20181231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="optn-20181231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="optn-20181231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholders" xlink:href="optn-20181231.xsd#ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholders" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersParenthetical" xlink:href="optn-20181231.xsd#ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedStatementsOfComprehensiveIncomeAndLoss" xlink:href="optn-20181231.xsd#ConsolidatedStatementsOfComprehensiveIncomeAndLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedStatementsOfOperations" xlink:href="optn-20181231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConvertibleNotes" xlink:href="optn-20181231.xsd#ConvertibleNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConvertibleNotesNarrativeDetails" xlink:href="optn-20181231.xsd#ConvertibleNotesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/DocumentAndEntityInformationDocument" xlink:href="optn-20181231.xsd#DocumentAndEntityInformationDocument" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/EmployeeBenefitPlans" xlink:href="optn-20181231.xsd#EmployeeBenefitPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/EmployeeBenefitPlansDetails" xlink:href="optn-20181231.xsd#EmployeeBenefitPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxes" xlink:href="optn-20181231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxesNarrativeDetails" xlink:href="optn-20181231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="optn-20181231.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="optn-20181231.xsd#IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails" xlink:href="optn-20181231.xsd#IncomeTaxesScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxesTables" xlink:href="optn-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/Inventory" xlink:href="optn-20181231.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/InventoryDetails" xlink:href="optn-20181231.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/InventoryTables" xlink:href="optn-20181231.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/Liquidity" xlink:href="optn-20181231.xsd#Liquidity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/LiquidityDetails" xlink:href="optn-20181231.xsd#LiquidityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/LongTermDebt" xlink:href="optn-20181231.xsd#LongTermDebt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/LongTermDebtNarrativeDetails" xlink:href="optn-20181231.xsd#LongTermDebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/LongTermDebtScheduleOfLongTermDebtDetails" xlink:href="optn-20181231.xsd#LongTermDebtScheduleOfLongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/LongTermDebtTables" xlink:href="optn-20181231.xsd#LongTermDebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="optn-20181231.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/PropertyAndEquipment" xlink:href="optn-20181231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/PropertyAndEquipmentDetails" xlink:href="optn-20181231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/PropertyAndEquipmentTables" xlink:href="optn-20181231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/RelatedPartyTransactions" xlink:href="optn-20181231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/RelatedPartyTransactionsDetails" xlink:href="optn-20181231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockBasedCompensation" xlink:href="optn-20181231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockBasedCompensationBlackScholesPricingModelOptionsDetails" xlink:href="optn-20181231.xsd#StockBasedCompensationBlackScholesPricingModelOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:href="optn-20181231.xsd#StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockBasedCompensationNarrativeDetails" xlink:href="optn-20181231.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" xlink:href="optn-20181231.xsd#StockBasedCompensationServiceBasedStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:href="optn-20181231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockBasedCompensationTables" xlink:href="optn-20181231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockholdersEquity" xlink:href="optn-20181231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockholdersEquityCommonStockDetails" xlink:href="optn-20181231.xsd#StockholdersEquityCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockholdersEquityDetails" xlink:href="optn-20181231.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockholdersEquityWarrantsDetails" xlink:href="optn-20181231.xsd#StockholdersEquityWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SubsequentEvents" xlink:href="optn-20181231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SubsequentEventsDetails" xlink:href="optn-20181231.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="optn-20181231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesAntidilutiveSharesExcludedFromEarningsPerShareDetails" xlink:href="optn-20181231.xsd#SummaryOfSignificantAccountingPoliciesAntidilutiveSharesExcludedFromEarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:href="optn-20181231.xsd#SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="optn-20181231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="optn-20181231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:href="optn-20181231.xsd#SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="optn-20181231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/AccruedExpenses" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/AccruedExpensesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/AccruedExpensesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/Avp825LicenseAgreement" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/Avp825LicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_DCF337EC6438068C2A83E3007C5A0379" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636FA198625FBABF6C1BE3007C5994FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_DCF337EC6438068C2A83E3007C5A0379" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636FA198625FBABF6C1BE3007C5994FB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_13AA8922EDCAD5E99845E3007C59479C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636FA198625FBABF6C1BE3007C5994FB" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_13AA8922EDCAD5E99845E3007C59479C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8F255C682D030E45E9FBE3007C599AE1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_13AA8922EDCAD5E99845E3007C59479C" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8F255C682D030E45E9FBE3007C599AE1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8F255C682D030E45E9FBE3007C599AE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_13AA8922EDCAD5E99845E3007C59479C" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8F255C682D030E45E9FBE3007C599AE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_F5130ADFF20F3F9857A3E3007C5AAE03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8F255C682D030E45E9FBE3007C599AE1" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_F5130ADFF20F3F9857A3E3007C5AAE03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_D9CCEE5990A657563A29E3007C5A2113" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_DCF337EC6438068C2A83E3007C5A0379" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_D9CCEE5990A657563A29E3007C5A2113" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0D103484BFC8238345B1E3007C5BAA88" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_DCF337EC6438068C2A83E3007C5A0379" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0D103484BFC8238345B1E3007C5BAA88" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.optinose.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/CommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/CommitmentsAndContingenciesLeasesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_671B31586B7BE4F3FAB8EDA0AAF6F2A5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_D05ABEFE9BDF55111716EDA0AAF37AA4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_671B31586B7BE4F3FAB8EDA0AAF6F2A5" xlink:to="loc_us-gaap_OtherCommitmentsTable_D05ABEFE9BDF55111716EDA0AAF37AA4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_F7E960FD0A7C2C161C7BEDA0AAF473BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_D05ABEFE9BDF55111716EDA0AAF37AA4" xlink:to="loc_srt_RangeAxis_F7E960FD0A7C2C161C7BEDA0AAF473BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_481E481DFA95FBD6CF65EDA0AAF4F1C2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_F7E960FD0A7C2C161C7BEDA0AAF473BF" xlink:to="loc_srt_RangeMember_481E481DFA95FBD6CF65EDA0AAF4F1C2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_481E481DFA95FBD6CF65EDA0AAF4F1C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_F7E960FD0A7C2C161C7BEDA0AAF473BF" xlink:to="loc_srt_RangeMember_481E481DFA95FBD6CF65EDA0AAF4F1C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_B5199EC6646A73B255FEEDA0AAF586CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_481E481DFA95FBD6CF65EDA0AAF4F1C2" xlink:to="loc_srt_MaximumMember_B5199EC6646A73B255FEEDA0AAF586CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaap_OtherCommitmentsAxis_4E43DAB4682BAF794D3BEDA0AAF55C20" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_D05ABEFE9BDF55111716EDA0AAF37AA4" xlink:to="loc_us-gaap_OtherCommitmentsAxis_4E43DAB4682BAF794D3BEDA0AAF55C20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_B36285375B3C81982779EDA0AAF5CEBB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_4E43DAB4682BAF794D3BEDA0AAF55C20" xlink:to="loc_us-gaap_OtherCommitmentsDomain_B36285375B3C81982779EDA0AAF5CEBB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_B36285375B3C81982779EDA0AAF5CEBB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_4E43DAB4682BAF794D3BEDA0AAF55C20" xlink:to="loc_us-gaap_OtherCommitmentsDomain_B36285375B3C81982779EDA0AAF5CEBB" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_MarketSalesforceMember" xlink:label="loc_optn_MarketSalesforceMember_C25661FFF2D45B33A31AEDA0AAF68E13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_B36285375B3C81982779EDA0AAF5CEBB" xlink:to="loc_optn_MarketSalesforceMember_C25661FFF2D45B33A31AEDA0AAF68E13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:label="loc_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_F3656547B17011C3CECDEDA0AAF71768" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_671B31586B7BE4F3FAB8EDA0AAF6F2A5" xlink:to="loc_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_F3656547B17011C3CECDEDA0AAF71768" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_24387F6DD1C8C2C32DEDEDA0AAF6FBB8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_671B31586B7BE4F3FAB8EDA0AAF6F2A5" xlink:to="loc_us-gaap_ContractualObligation_24387F6DD1C8C2C32DEDEDA0AAF6FBB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_29B2F0DADA87EB1740A8EDA0AAF73329" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_671B31586B7BE4F3FAB8EDA0AAF6F2A5" xlink:to="loc_us-gaap_PurchaseObligation_29B2F0DADA87EB1740A8EDA0AAF73329" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.optinose.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3938029DB74A51988EF549EBE88433E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296" xlink:to="loc_us-gaap_StatementTable_3938029DB74A51988EF549EBE88433E3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_458E600641048CE895C649EBE8857D2E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3938029DB74A51988EF549EBE88433E3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_458E600641048CE895C649EBE8857D2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_951F111F8D4F9293DB9049EBE885C4FE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_458E600641048CE895C649EBE8857D2E" xlink:to="loc_us-gaap_ClassOfStockDomain_951F111F8D4F9293DB9049EBE885C4FE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_951F111F8D4F9293DB9049EBE885C4FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_458E600641048CE895C649EBE8857D2E" xlink:to="loc_us-gaap_ClassOfStockDomain_951F111F8D4F9293DB9049EBE885C4FE" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember" xlink:label="loc_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember_1930E1355F1E60A98EC149EBE88569E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_951F111F8D4F9293DB9049EBE885C4FE" xlink:to="loc_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember_1930E1355F1E60A98EC149EBE88569E4" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_RedeemableConvertiblePreferredStockSeriesCC1DMember" xlink:label="loc_optn_RedeemableConvertiblePreferredStockSeriesCC1DMember_D360F52CDA85DC60BAF449EBE8859746" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_951F111F8D4F9293DB9049EBE885C4FE" xlink:to="loc_optn_RedeemableConvertiblePreferredStockSeriesCC1DMember_D360F52CDA85DC60BAF449EBE8859746" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_RedeemableConvertiblePreferredStockSeriesC2Member" xlink:label="loc_optn_RedeemableConvertiblePreferredStockSeriesC2Member_A0FEDA46561C0B8E184449EBE886DC89" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_951F111F8D4F9293DB9049EBE885C4FE" xlink:to="loc_optn_RedeemableConvertiblePreferredStockSeriesC2Member_A0FEDA46561C0B8E184449EBE886DC89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C41EB5DC2028AF99FFD649EBE886CA65" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C41EB5DC2028AF99FFD649EBE886CA65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_D42F49C14EB623F649BA49EBE88812BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C41EB5DC2028AF99FFD649EBE886CA65" xlink:to="loc_us-gaap_NetIncomeLoss_D42F49C14EB623F649BA49EBE88812BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B5DE6D288B88D23325E549EBE888F87E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C41EB5DC2028AF99FFD649EBE886CA65" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B5DE6D288B88D23325E549EBE888F87E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_E9A14022DF6FCEC041B049EBE888D056" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B5DE6D288B88D23325E549EBE888F87E" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_E9A14022DF6FCEC041B049EBE888D056" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_12DB8353F58C84AE3B7449EBE889EA52" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B5DE6D288B88D23325E549EBE888F87E" xlink:to="loc_us-gaap_ShareBasedCompensation_12DB8353F58C84AE3B7449EBE889EA52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_E51C4C09F2B8DB11CEF549EBE8897A08" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B5DE6D288B88D23325E549EBE888F87E" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_E51C4C09F2B8DB11CEF549EBE8897A08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04BAA57205C6347D4FC549EBE889DB6F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B5DE6D288B88D23325E549EBE888F87E" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04BAA57205C6347D4FC549EBE889DB6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_F0BEC61FE4F59CAEA00849EBE88929D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04BAA57205C6347D4FC549EBE889DB6F" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_F0BEC61FE4F59CAEA00849EBE88929D2" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_IncreaseDecreaseInGrantsandOtherReceivables" xlink:label="loc_optn_IncreaseDecreaseInGrantsandOtherReceivables_330B065D3D3C6956DFAC49EBE88A0645" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04BAA57205C6347D4FC549EBE889DB6F" xlink:to="loc_optn_IncreaseDecreaseInGrantsandOtherReceivables_330B065D3D3C6956DFAC49EBE88A0645" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_IncreaseDecreaseinDepositsandOtherAssets" xlink:label="loc_optn_IncreaseDecreaseinDepositsandOtherAssets_2F9ABFF791AB1F9FC3E349EBE88A8076" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04BAA57205C6347D4FC549EBE889DB6F" xlink:to="loc_optn_IncreaseDecreaseinDepositsandOtherAssets_2F9ABFF791AB1F9FC3E349EBE88A8076" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_E0633646B44358C7289E49EBE88A3CA4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04BAA57205C6347D4FC549EBE889DB6F" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_E0633646B44358C7289E49EBE88A3CA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_CA70F0590D209152F81749EBE88A5734" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04BAA57205C6347D4FC549EBE889DB6F" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_CA70F0590D209152F81749EBE88A5734" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_599910982139B2ABEC7349EBE88A1489" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04BAA57205C6347D4FC549EBE889DB6F" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_599910982139B2ABEC7349EBE88A1489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6091196D3068291415D649EBE88A1CD4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C41EB5DC2028AF99FFD649EBE886CA65" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6091196D3068291415D649EBE88A1CD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7C3DE1AD885346A325E49EBE88A4D81" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7C3DE1AD885346A325E49EBE88A4D81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_DCEA5234B6000742D36F49EBE88B90AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7C3DE1AD885346A325E49EBE88A4D81" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_DCEA5234B6000742D36F49EBE88B90AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6245F955084E06EA66E349EBE88BB0DD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7C3DE1AD885346A325E49EBE88A4D81" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6245F955084E06EA66E349EBE88BB0DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_0EADA54A34D9B3B7316749EBE88BBE30" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_0EADA54A34D9B3B7316749EBE88BBE30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0266380FFCE0FAA7C74449EBE88C39C8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0266380FFCE0FAA7C74449EBE88C39C8" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan" xlink:label="loc_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan_82D58AA84D186F79509F49EBE88C04A5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A" xlink:to="loc_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan_82D58AA84D186F79509F49EBE88C04A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2F5B8245A7A99916D46E49EBE88C5345" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2F5B8245A7A99916D46E49EBE88C5345" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_CCDB6EBE1F6EE0EE28C949EBE88C1B2F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_CCDB6EBE1F6EE0EE28C949EBE88C1B2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B7710DC936BCA1BCA3BE49EBE88C8B0B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B7710DC936BCA1BCA3BE49EBE88C8B0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_8364BFCE2451817E57A149EBE88C5974" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_8364BFCE2451817E57A149EBE88C5974" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_BCD55EF6A729886FCB0249EBE88D1814" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_BCD55EF6A729886FCB0249EBE88D1814" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_972709892096A82D22D249EBE88DBA69" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_972709892096A82D22D249EBE88DBA69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2E1ED88ABCA15347015649EBE88D8BCC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2E1ED88ABCA15347015649EBE88D8BCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5283CA7C95F0E343AD0B49EBE88DD841" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5283CA7C95F0E343AD0B49EBE88DD841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_65452D1522887234A08049EBE88E84D7" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_65452D1522887234A08049EBE88E84D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_207BB562F194617EB27949EBE88DDCB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_65452D1522887234A08049EBE88E84D7" xlink:to="loc_us-gaap_InterestPaidNet_207BB562F194617EB27949EBE88DDCB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_626C2DEE1F0404F3C9D649F2541B0F5C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_626C2DEE1F0404F3C9D649F2541B0F5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_CFD9DFAD9494EEE32AC549EBE88E2A3C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_626C2DEE1F0404F3C9D649F2541B0F5C" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_CFD9DFAD9494EEE32AC549EBE88E2A3C" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses" xlink:label="loc_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses_31C21F78CC59A38BB73949EBE88E4E8F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_626C2DEE1F0404F3C9D649F2541B0F5C" xlink:to="loc_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses_31C21F78CC59A38BB73949EBE88E4E8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_74FD09FC49171C7AF60649EBE88E3232" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_626C2DEE1F0404F3C9D649F2541B0F5C" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_74FD09FC49171C7AF60649EBE88E3232" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_31AE8E50EF69CAB6C0D649EBE88E6CE7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_626C2DEE1F0404F3C9D649F2541B0F5C" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_31AE8E50EF69CAB6C0D649EBE88E6CE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_59A7EA860DEBA505F7D249EBE88EAB1B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_626C2DEE1F0404F3C9D649F2541B0F5C" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_59A7EA860DEBA505F7D249EBE88EAB1B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.optinose.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholders" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_B2E6917114CA9893ADA349EC16095736" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_0937F1DBFB225F6C505449EC1609931D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_B2E6917114CA9893ADA349EC16095736" xlink:to="loc_us-gaap_StatementTable_0937F1DBFB225F6C505449EC1609931D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A082A5C3D7703A98492249EC16099EC2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0937F1DBFB225F6C505449EC1609931D" xlink:to="loc_us-gaap_StatementClassOfStockAxis_A082A5C3D7703A98492249EC16099EC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B038BFEAF8152A1CDE8A49EC16091F8C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A082A5C3D7703A98492249EC16099EC2" xlink:to="loc_us-gaap_ClassOfStockDomain_B038BFEAF8152A1CDE8A49EC16091F8C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B038BFEAF8152A1CDE8A49EC16091F8C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A082A5C3D7703A98492249EC16099EC2" xlink:to="loc_us-gaap_ClassOfStockDomain_B038BFEAF8152A1CDE8A49EC16091F8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemablePreferredStockMember" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_8CF973D87069AFC606E749EC16093D6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B038BFEAF8152A1CDE8A49EC16091F8C" xlink:to="loc_us-gaap_RedeemablePreferredStockMember_8CF973D87069AFC606E749EC16093D6D" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_RedeemableConvertiblePreferredStockSeriesC2Member" xlink:label="loc_optn_RedeemableConvertiblePreferredStockSeriesC2Member_FAA5690321DA5948C60F49EC16099BE3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B038BFEAF8152A1CDE8A49EC16091F8C" xlink:to="loc_optn_RedeemableConvertiblePreferredStockSeriesC2Member_FAA5690321DA5948C60F49EC16099BE3" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_RedeemableConvertiblePreferredStockSeriesDMember" xlink:label="loc_optn_RedeemableConvertiblePreferredStockSeriesDMember_4D097EB4B25C8669CF3349EC1609375E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B038BFEAF8152A1CDE8A49EC16091F8C" xlink:to="loc_optn_RedeemableConvertiblePreferredStockSeriesDMember_4D097EB4B25C8669CF3349EC1609375E" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_RedeemableConvertiblePreferredStockSeriesCC1DMember" xlink:label="loc_optn_RedeemableConvertiblePreferredStockSeriesCC1DMember_81E6A5C9E21664CFD6FB49EC1609FBEF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B038BFEAF8152A1CDE8A49EC16091F8C" xlink:to="loc_optn_RedeemableConvertiblePreferredStockSeriesCC1DMember_81E6A5C9E21664CFD6FB49EC1609FBEF" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember" xlink:label="loc_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember_7A02AA3A2DBE5964377F49EC1609AC4F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B038BFEAF8152A1CDE8A49EC16091F8C" xlink:to="loc_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember_7A02AA3A2DBE5964377F49EC1609AC4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_445FDF25BBFD4D62CD8149EC16099B9E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0937F1DBFB225F6C505449EC1609931D" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_445FDF25BBFD4D62CD8149EC16099B9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6D0A07EB06558C16646549EC16099A9E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_445FDF25BBFD4D62CD8149EC16099B9E" xlink:to="loc_us-gaap_EquityComponentDomain_6D0A07EB06558C16646549EC16099A9E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6D0A07EB06558C16646549EC16099A9E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_445FDF25BBFD4D62CD8149EC16099B9E" xlink:to="loc_us-gaap_EquityComponentDomain_6D0A07EB06558C16646549EC16099A9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_8FDD6FC0721455D284FB49EC16091A95" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6D0A07EB06558C16646549EC16099A9E" xlink:to="loc_us-gaap_CommonStockMember_8FDD6FC0721455D284FB49EC16091A95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_DD2627379C2BD35940BC49EC16099B08" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6D0A07EB06558C16646549EC16099A9E" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_DD2627379C2BD35940BC49EC16099B08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_40BCD399E0FA8934C88749EC16098F17" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6D0A07EB06558C16646549EC16099A9E" xlink:to="loc_us-gaap_RetainedEarningsMember_40BCD399E0FA8934C88749EC16098F17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_63868E2D78C90943FEE049EC16094101" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6D0A07EB06558C16646549EC16099A9E" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_63868E2D78C90943FEE049EC16094101" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B2E6917114CA9893ADA349EC16095736" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_EE614D846FFDFD6EB07349EC16095FB6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_EE614D846FFDFD6EB07349EC16095FB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_A0C2600FDFEBA788B9A849EC1609F198" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_A0C2600FDFEBA788B9A849EC1609F198" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_46A93FAFDE582B3AE38149EC160997A6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_SharesOutstanding_46A93FAFDE582B3AE38149EC160997A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7981EB001D4E2F785BB849EC16182128" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7981EB001D4E2F785BB849EC16182128" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_65016156BD6368F6D8C049EC161869A5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_65016156BD6368F6D8C049EC161869A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_782424077FFB12FA261549EC1618F019" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_782424077FFB12FA261549EC1618F019" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_optn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_E4138EE5067B27416B8A49EC1618C404" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_optn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_E4138EE5067B27416B8A49EC1618C404" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_FD0D65199F8A33DE2F6749EC16187A3D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_FD0D65199F8A33DE2F6749EC16187A3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC31829D6727EB27094749EC1618951B" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC31829D6727EB27094749EC1618951B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_19A46AD4DAD8C1A9BB2A49EC16184EF3" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_19A46AD4DAD8C1A9BB2A49EC16184EF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_05D6FF046E7AAD6AEB9D49EC16180838" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_05D6FF046E7AAD6AEB9D49EC16180838" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_optn_StockIssuedDuringPeriodValueWarrantsExercised_858DE034CF75669DE68149EC16186951" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_optn_StockIssuedDuringPeriodValueWarrantsExercised_858DE034CF75669DE68149EC16186951" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_BDF9A94B58BA85C18BAD49EC1618C77F" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_BDF9A94B58BA85C18BAD49EC1618C77F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_359CC5D11822882198E749EC1618B550" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_359CC5D11822882198E749EC1618B550" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_FD85824972D9395CE5C549EC16183021" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_FD85824972D9395CE5C549EC16183021" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_BC2DA16AD9E90CE3DAAF49EC16183BF1" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_BC2DA16AD9E90CE3DAAF49EC16183BF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_02CD92079390681CA4C749EC16187077" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_02CD92079390681CA4C749EC16187077" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_40B0698CE5E5D2176ADB49EC1618A519" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_40B0698CE5E5D2176ADB49EC1618A519" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_D3A70EA98E085CE87E0549EC16186059" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_D3A70EA98E085CE87E0549EC16186059" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_AEF3219121C51ABB8FF949EC1618D5EA" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_NetIncomeLoss_AEF3219121C51ABB8FF949EC1618D5EA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.optinose.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_E64BF16648FF7239512549EC15F943A3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_A572A60EF6EBFBBC7D0749EC15F96926" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_E64BF16648FF7239512549EC15F943A3" xlink:to="loc_us-gaap_StatementTable_A572A60EF6EBFBBC7D0749EC15F96926" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_06E4355AC3FB5F6ACD8F49EC15F9636F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_A572A60EF6EBFBBC7D0749EC15F96926" xlink:to="loc_us-gaap_StatementClassOfStockAxis_06E4355AC3FB5F6ACD8F49EC15F9636F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_989ED6889D8B7F115C3A49EC15F94C29_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_06E4355AC3FB5F6ACD8F49EC15F9636F" xlink:to="loc_us-gaap_ClassOfStockDomain_989ED6889D8B7F115C3A49EC15F94C29_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_989ED6889D8B7F115C3A49EC15F94C29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_06E4355AC3FB5F6ACD8F49EC15F9636F" xlink:to="loc_us-gaap_ClassOfStockDomain_989ED6889D8B7F115C3A49EC15F94C29" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember" xlink:label="loc_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember_B18A1E1372A2F9D37F5249EC15F92B5A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_989ED6889D8B7F115C3A49EC15F94C29" xlink:to="loc_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember_B18A1E1372A2F9D37F5249EC15F92B5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_C1BC47BCDFEC40D56CE749EC15F98014" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E64BF16648FF7239512549EC15F943A3" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_C1BC47BCDFEC40D56CE749EC15F98014" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.optinose.com/role/ConsolidatedStatementsOfComprehensiveIncomeAndLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/ConvertibleNotes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/ConvertibleNotesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_D4D91B622BB69A68A64DEE277A1DA10A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_us-gaap_DebtInstrumentTable_D4D91B622BB69A68A64DEE277A1DA10A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_AF1363B627735B1BFEB5EE277A1D1EB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_D4D91B622BB69A68A64DEE277A1DA10A" xlink:to="loc_us-gaap_StatementClassOfStockAxis_AF1363B627735B1BFEB5EE277A1D1EB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D44916B0C36D671B6670EE277A1E9E2B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_AF1363B627735B1BFEB5EE277A1D1EB2" xlink:to="loc_us-gaap_ClassOfStockDomain_D44916B0C36D671B6670EE277A1E9E2B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D44916B0C36D671B6670EE277A1E9E2B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_AF1363B627735B1BFEB5EE277A1D1EB2" xlink:to="loc_us-gaap_ClassOfStockDomain_D44916B0C36D671B6670EE277A1E9E2B" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_RedeemableConvertiblePreferredStockSeriesC2Member" xlink:label="loc_optn_RedeemableConvertiblePreferredStockSeriesC2Member_CC6DE46B917F37F25201EE277A1EC3E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_D44916B0C36D671B6670EE277A1E9E2B" xlink:to="loc_optn_RedeemableConvertiblePreferredStockSeriesC2Member_CC6DE46B917F37F25201EE277A1EC3E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_CABB2C200E989304A4FEEE277A1E21D8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_D4D91B622BB69A68A64DEE277A1DA10A" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_CABB2C200E989304A4FEEE277A1E21D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_F1DD0AAE31D7BE6727BEEE277A1FE5B7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_CABB2C200E989304A4FEEE277A1E21D8" xlink:to="loc_us-gaap_DebtConversionNameDomain_F1DD0AAE31D7BE6727BEEE277A1FE5B7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_F1DD0AAE31D7BE6727BEEE277A1FE5B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_CABB2C200E989304A4FEEE277A1E21D8" xlink:to="loc_us-gaap_DebtConversionNameDomain_F1DD0AAE31D7BE6727BEEE277A1FE5B7" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_SeriesDFinancingMember" xlink:label="loc_optn_SeriesDFinancingMember_BE00CEF2409F020FB5ABEE277A1F4CE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_F1DD0AAE31D7BE6727BEEE277A1FE5B7" xlink:to="loc_optn_SeriesDFinancingMember_BE00CEF2409F020FB5ABEE277A1F4CE0" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember" xlink:label="loc_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember_8A0E92E76D4543C23C58EE277A1F143D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_F1DD0AAE31D7BE6727BEEE277A1FE5B7" xlink:to="loc_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember_8A0E92E76D4543C23C58EE277A1F143D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0F54E19DCA48C9FA2980EE277A1F9EF0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_D4D91B622BB69A68A64DEE277A1DA10A" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0F54E19DCA48C9FA2980EE277A1F9EF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1B25DD6175671F9BBE68EE277A1F4513_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0F54E19DCA48C9FA2980EE277A1F9EF0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1B25DD6175671F9BBE68EE277A1F4513_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1B25DD6175671F9BBE68EE277A1F4513" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0F54E19DCA48C9FA2980EE277A1F9EF0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1B25DD6175671F9BBE68EE277A1F4513" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_61D95DD1DA84031AB88CEE277A200563" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1B25DD6175671F9BBE68EE277A1F4513" xlink:to="loc_us-gaap_ConvertibleDebtMember_61D95DD1DA84031AB88CEE277A200563" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_129D278547486ABB5779EE277A200F1F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_D4D91B622BB69A68A64DEE277A1DA10A" xlink:to="loc_us-gaap_DebtInstrumentAxis_129D278547486ABB5779EE277A200F1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1E0EE3EEACFA5B6CFD75EE277A206234_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_129D278547486ABB5779EE277A200F1F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1E0EE3EEACFA5B6CFD75EE277A206234_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1E0EE3EEACFA5B6CFD75EE277A206234" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_129D278547486ABB5779EE277A200F1F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1E0EE3EEACFA5B6CFD75EE277A206234" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_TrancheOneMember" xlink:label="loc_optn_TrancheOneMember_3C5DC079B33B82E0C4B0EE277A20C6A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1E0EE3EEACFA5B6CFD75EE277A206234" xlink:to="loc_optn_TrancheOneMember_3C5DC079B33B82E0C4B0EE277A20C6A0" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_TrancheTwoMember" xlink:label="loc_optn_TrancheTwoMember_6AA00B99D2451B110462EE277A21AC84" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1E0EE3EEACFA5B6CFD75EE277A206234" xlink:to="loc_optn_TrancheTwoMember_6AA00B99D2451B110462EE277A21AC84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_E5D26641F1B8FBBA90F4EE277A215459" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_E5D26641F1B8FBBA90F4EE277A215459" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_NumberofTranches" xlink:label="loc_optn_NumberofTranches_29D9C8BC01FFDDB65A9BEE277A21BB37" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_optn_NumberofTranches_29D9C8BC01FFDDB65A9BEE277A21BB37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3111D59DE8B03F10E70CEE277A22324D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3111D59DE8B03F10E70CEE277A22324D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_1C3CE0A79C01EA2D212CEE277A22CBB2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_1C3CE0A79C01EA2D212CEE277A22CBB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_935BD629949B0EB4DAC6EE277A22B3AB" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_935BD629949B0EB4DAC6EE277A22B3AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_F952947920A516676629EE277A229DF1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_F952947920A516676629EE277A229DF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_6039A408D5D773920114EE277A22694B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_us-gaap_InterestExpenseDebt_6039A408D5D773920114EE277A22694B" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentCouponInterestandFees" xlink:label="loc_optn_DebtInstrumentCouponInterestandFees_84E217AF4CBA328EB288EE277A22B600" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_optn_DebtInstrumentCouponInterestandFees_84E217AF4CBA328EB288EE277A22B600" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentLoanConversionPeriod" xlink:label="loc_optn_DebtInstrumentLoanConversionPeriod_9F36D36886558CD69D05EE277A23F57E" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_optn_DebtInstrumentLoanConversionPeriod_9F36D36886558CD69D05EE277A23F57E" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_InterestExpenseDebtBackEndFees" xlink:label="loc_optn_InterestExpenseDebtBackEndFees_3D0E583B2FDA6BAE44A5EE277A2310BA" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_optn_InterestExpenseDebtBackEndFees_3D0E583B2FDA6BAE44A5EE277A2310BA" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_InterestExpenseDebtFrontEndFees" xlink:label="loc_optn_InterestExpenseDebtFrontEndFees_9DD4A1D325C2A397F925EE277A23918F" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_optn_InterestExpenseDebtFrontEndFees_9DD4A1D325C2A397F925EE277A23918F" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentFeesCapitalizedtoPrincipal" xlink:label="loc_optn_DebtInstrumentFeesCapitalizedtoPrincipal_0EF913099A882C57AA41EE277A231F5D" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_optn_DebtInstrumentFeesCapitalizedtoPrincipal_0EF913099A882C57AA41EE277A231F5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_CE038317D98BFD1A0B99EE277A238483" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_CE038317D98BFD1A0B99EE277A238483" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_EBA1671792F66B600F06EE277A2355B5" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_us-gaap_ConvertibleDebt_EBA1671792F66B600F06EE277A2355B5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.optinose.com/role/DocumentAndEntityInformationDocument" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/EmployeeBenefitPlans" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_35551AFD9A0F444F8097E32FECE95EE8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable_B0C25850575DA2998E7AE32FECE75146" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_35551AFD9A0F444F8097E32FECE95EE8" xlink:to="loc_us-gaap_DefinedContributionPlanTable_B0C25850575DA2998E7AE32FECE75146" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DefinedContributionPlanTranchesAxisAxis" xlink:label="loc_optn_DefinedContributionPlanTranchesAxisAxis_EBF4E41618FDDFFAE771E32FECE76C86" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_B0C25850575DA2998E7AE32FECE75146" xlink:to="loc_optn_DefinedContributionPlanTranchesAxisAxis_EBF4E41618FDDFFAE771E32FECE76C86" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DefinedContributionPlanTranchesAxisDomain" xlink:label="loc_optn_DefinedContributionPlanTranchesAxisDomain_5BDC90359213ED2CBFB0E32FECE7FD10_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_optn_DefinedContributionPlanTranchesAxisAxis_EBF4E41618FDDFFAE771E32FECE76C86" xlink:to="loc_optn_DefinedContributionPlanTranchesAxisDomain_5BDC90359213ED2CBFB0E32FECE7FD10_default" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DefinedContributionPlanTranchesAxisDomain" xlink:label="loc_optn_DefinedContributionPlanTranchesAxisDomain_5BDC90359213ED2CBFB0E32FECE7FD10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_optn_DefinedContributionPlanTranchesAxisAxis_EBF4E41618FDDFFAE771E32FECE76C86" xlink:to="loc_optn_DefinedContributionPlanTranchesAxisDomain_5BDC90359213ED2CBFB0E32FECE7FD10" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DefinedContributionPlanTrancheOneMember" xlink:label="loc_optn_DefinedContributionPlanTrancheOneMember_084221B77E2EA2EECD9EE32FECE763B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_optn_DefinedContributionPlanTranchesAxisDomain_5BDC90359213ED2CBFB0E32FECE7FD10" xlink:to="loc_optn_DefinedContributionPlanTrancheOneMember_084221B77E2EA2EECD9EE32FECE763B4" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DefinedContributionPlanTrancheTwoMember" xlink:label="loc_optn_DefinedContributionPlanTrancheTwoMember_F37D82FEB14C56712AEEE32FECE89D83" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_optn_DefinedContributionPlanTranchesAxisDomain_5BDC90359213ED2CBFB0E32FECE7FD10" xlink:to="loc_optn_DefinedContributionPlanTrancheTwoMember_F37D82FEB14C56712AEEE32FECE89D83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_4A148FFB18F2719DE762E32FECE896D9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_B0C25850575DA2998E7AE32FECE75146" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_4A148FFB18F2719DE762E32FECE896D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_A5694646F464AC290D7BE32FECE8CD9B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_4A148FFB18F2719DE762E32FECE896D9" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_A5694646F464AC290D7BE32FECE8CD9B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_A5694646F464AC290D7BE32FECE8CD9B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_4A148FFB18F2719DE762E32FECE896D9" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_A5694646F464AC290D7BE32FECE8CD9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_D1548A5BDE59C85499E9E32FECE91493" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_A5694646F464AC290D7BE32FECE8CD9B" xlink:to="loc_us-gaap_ForeignPlanMember_D1548A5BDE59C85499E9E32FECE91493" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_EB9BBB25970D7B89A357E32FECE96BB7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_35551AFD9A0F444F8097E32FECE95EE8" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_EB9BBB25970D7B89A357E32FECE96BB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_AD3E7BBF0DABA3C80246E32FECE9C271" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_35551AFD9A0F444F8097E32FECE95EE8" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_AD3E7BBF0DABA3C80246E32FECE9C271" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_FB44C0E4E86903858388E32FECEA9FC9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_35551AFD9A0F444F8097E32FECE95EE8" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_FB44C0E4E86903858388E32FECEA9FC9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.optinose.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_B6320A86D7BE6E3AC205EE277924309B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_9E8D88C3114903E6A336EE2779200E87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B6320A86D7BE6E3AC205EE277924309B" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_9E8D88C3114903E6A336EE2779200E87" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_BF3C185C95E9A01C765BEE2779219A56" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_9E8D88C3114903E6A336EE2779200E87" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_BF3C185C95E9A01C765BEE2779219A56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_A256433012B40B414CFEEE277923BDD1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_BF3C185C95E9A01C765BEE2779219A56" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_A256433012B40B414CFEEE277923BDD1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_A256433012B40B414CFEEE277923BDD1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_BF3C185C95E9A01C765BEE2779219A56" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_A256433012B40B414CFEEE277923BDD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_0B90A592B0ADBA88899CEE277923AD7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_A256433012B40B414CFEEE277923BDD1" xlink:to="loc_us-gaap_ForeignCountryMember_0B90A592B0ADBA88899CEE277923AD7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_A580E0C38D7CAF00CC30EE2779245CA9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_A256433012B40B414CFEEE277923BDD1" xlink:to="loc_us-gaap_DomesticCountryMember_A580E0C38D7CAF00CC30EE2779245CA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_4E811A208684A28C6A3EEE27792425DF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_A256433012B40B414CFEEE277923BDD1" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_4E811A208684A28C6A3EEE27792425DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_A7FD314097B23FB797B5EE277925E145" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B6320A86D7BE6E3AC205EE277924309B" xlink:to="loc_us-gaap_OperatingLossCarryforwards_A7FD314097B23FB797B5EE277925E145" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_728844566B032BD51E95EE2779258E3C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B6320A86D7BE6E3AC205EE277924309B" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_728844566B032BD51E95EE2779258E3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_FC78E5BF73E6F6055568EE277925E0D5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B6320A86D7BE6E3AC205EE277924309B" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_FC78E5BF73E6F6055568EE277925E0D5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.optinose.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/InventoryDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/Liquidity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/LiquidityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_66D8A074820D76C4909549EC15CA85E1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_373962FAAFE8D434E7D949EC15CAF327" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_66D8A074820D76C4909549EC15CA85E1" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_373962FAAFE8D434E7D949EC15CAF327" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_C2C7CA9273560FD59F4F49EC15CA5650" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_373962FAAFE8D434E7D949EC15CAF327" xlink:to="loc_srt_CounterpartyNameAxis_C2C7CA9273560FD59F4F49EC15CA5650" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B9AC1D0F36CDACFA955949EC15CA9330_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_C2C7CA9273560FD59F4F49EC15CA5650" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B9AC1D0F36CDACFA955949EC15CA9330_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B9AC1D0F36CDACFA955949EC15CA9330" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_C2C7CA9273560FD59F4F49EC15CA5650" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B9AC1D0F36CDACFA955949EC15CA9330" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_TheCompanyMember" xlink:label="loc_optn_TheCompanyMember_83BC6DB74C91CB873CE849EC15CAD733" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B9AC1D0F36CDACFA955949EC15CA9330" xlink:to="loc_optn_TheCompanyMember_83BC6DB74C91CB873CE849EC15CAD733" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_CertainStockholdersMember" xlink:label="loc_optn_CertainStockholdersMember_3F0878B0C2FD58630BA949EC15CA512D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B9AC1D0F36CDACFA955949EC15CA9330" xlink:to="loc_optn_CertainStockholdersMember_3F0878B0C2FD58630BA949EC15CA512D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_D7A51CC253C5C5A7B35449EC15CA4382" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_373962FAAFE8D434E7D949EC15CAF327" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_D7A51CC253C5C5A7B35449EC15CA4382" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A1C4154318731688113549EC15CA784A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_D7A51CC253C5C5A7B35449EC15CA4382" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A1C4154318731688113549EC15CA784A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A1C4154318731688113549EC15CA784A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_D7A51CC253C5C5A7B35449EC15CA4382" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A1C4154318731688113549EC15CA784A" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_PublicOfferingMember" xlink:label="loc_optn_PublicOfferingMember_FE1C284D4CC0DE7696AA49EC15CA0F47" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A1C4154318731688113549EC15CA784A" xlink:to="loc_optn_PublicOfferingMember_FE1C284D4CC0DE7696AA49EC15CA0F47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_4DEB93CF05216141CA1349EC15CAA26B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_66D8A074820D76C4909549EC15CA85E1" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_4DEB93CF05216141CA1349EC15CAA26B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_BB6999A36BFBB11B6CE749EC15CAD8FA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_66D8A074820D76C4909549EC15CA85E1" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_BB6999A36BFBB11B6CE749EC15CAD8FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_81ED5B3579A01025908549EC15CA6EDD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_66D8A074820D76C4909549EC15CA85E1" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_81ED5B3579A01025908549EC15CA6EDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_A190BD44D307171A931549EC15CA85FD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_66D8A074820D76C4909549EC15CA85E1" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_A190BD44D307171A931549EC15CA85FD" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_SaleofStockDiscountsandCommissions" xlink:label="loc_optn_SaleofStockDiscountsandCommissions_B11F8FD88411CC0644444A43E925FD76" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_66D8A074820D76C4909549EC15CA85E1" xlink:to="loc_optn_SaleofStockDiscountsandCommissions_B11F8FD88411CC0644444A43E925FD76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_2B060E9B61EF6C3F839849EC15CA4BEC" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_66D8A074820D76C4909549EC15CA85E1" xlink:to="loc_us-gaap_DeferredOfferingCosts_2B060E9B61EF6C3F839849EC15CA4BEC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.optinose.com/role/LongTermDebt" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/LongTermDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_E3BF2294A42F9F2397EEE32FED0A4951" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_us-gaap_DebtInstrumentTable_E3BF2294A42F9F2397EEE32FED0A4951" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_A9600D4CFD60A6103C2FE32FED0BE989" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_E3BF2294A42F9F2397EEE32FED0A4951" xlink:to="loc_us-gaap_StatementScenarioAxis_A9600D4CFD60A6103C2FE32FED0BE989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_0389B6FA8520C2F93650E32FED0BCFA2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_A9600D4CFD60A6103C2FE32FED0BE989" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_0389B6FA8520C2F93650E32FED0BCFA2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_0389B6FA8520C2F93650E32FED0BCFA2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_A9600D4CFD60A6103C2FE32FED0BE989" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_0389B6FA8520C2F93650E32FED0BCFA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_559435A66FB573072FEDE32FED0B5A29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_0389B6FA8520C2F93650E32FED0BCFA2" xlink:to="loc_us-gaap_ScenarioForecastMember_559435A66FB573072FEDE32FED0B5A29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_325B1ECDCD214338BA53E32FED0C6170" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_E3BF2294A42F9F2397EEE32FED0A4951" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_325B1ECDCD214338BA53E32FED0C6170" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_80A78079BAA1D2384DC6E32FED0CD1CE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_325B1ECDCD214338BA53E32FED0C6170" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_80A78079BAA1D2384DC6E32FED0CD1CE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_80A78079BAA1D2384DC6E32FED0CD1CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_325B1ECDCD214338BA53E32FED0C6170" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_80A78079BAA1D2384DC6E32FED0CD1CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_85EE23E961F9DFDB221CE32FED0CFD81" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_80A78079BAA1D2384DC6E32FED0CD1CE" xlink:to="loc_us-gaap_SeniorNotesMember_85EE23E961F9DFDB221CE32FED0CFD81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2A4FFA355E897E74BB93E32FED0C955A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_E3BF2294A42F9F2397EEE32FED0A4951" xlink:to="loc_us-gaap_DebtInstrumentAxis_2A4FFA355E897E74BB93E32FED0C955A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6171733DB07667B0068DE32FED0DA6F6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2A4FFA355E897E74BB93E32FED0C955A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6171733DB07667B0068DE32FED0DA6F6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6171733DB07667B0068DE32FED0DA6F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2A4FFA355E897E74BB93E32FED0C955A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6171733DB07667B0068DE32FED0DA6F6" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_NotePurchaseAgreementMember" xlink:label="loc_optn_NotePurchaseAgreementMember_74CB2D5DD7F15CD79697E32FED0D0EA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6171733DB07667B0068DE32FED0DA6F6" xlink:to="loc_optn_NotePurchaseAgreementMember_74CB2D5DD7F15CD79697E32FED0D0EA5" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_NotePurchaseAgreementDelayedDrawNotesMember" xlink:label="loc_optn_NotePurchaseAgreementDelayedDrawNotesMember_5D2C8839800CF0845607E32FED0D0469" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6171733DB07667B0068DE32FED0DA6F6" xlink:to="loc_optn_NotePurchaseAgreementDelayedDrawNotesMember_5D2C8839800CF0845607E32FED0D0469" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_E82D8472D329942198AFE32FED0DAB11" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_E3BF2294A42F9F2397EEE32FED0A4951" xlink:to="loc_us-gaap_VariableRateAxis_E82D8472D329942198AFE32FED0DAB11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_4144C335F38B6D0D81E9E32FED0E15A7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_E82D8472D329942198AFE32FED0DAB11" xlink:to="loc_us-gaap_VariableRateDomain_4144C335F38B6D0D81E9E32FED0E15A7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_4144C335F38B6D0D81E9E32FED0E15A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_E82D8472D329942198AFE32FED0DAB11" xlink:to="loc_us-gaap_VariableRateDomain_4144C335F38B6D0D81E9E32FED0E15A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_124C7A3FCC9D059B2208E32FED0E3946" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_4144C335F38B6D0D81E9E32FED0E15A7" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_124C7A3FCC9D059B2208E32FED0E3946" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_25E2E0B836273CFE2514E32FED0F8D2B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_E3BF2294A42F9F2397EEE32FED0A4951" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_25E2E0B836273CFE2514E32FED0F8D2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8D695C99D457AAAAE2BAE32FED0F731E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_25E2E0B836273CFE2514E32FED0F8D2B" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8D695C99D457AAAAE2BAE32FED0F731E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8D695C99D457AAAAE2BAE32FED0F731E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_25E2E0B836273CFE2514E32FED0F8D2B" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8D695C99D457AAAAE2BAE32FED0F731E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_0CCE640BEEDDC00611D3E32FED109FD9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8D695C99D457AAAAE2BAE32FED0F731E" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_0CCE640BEEDDC00611D3E32FED109FD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_B4CDA917284763D6FA7CE32FED108EAB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8D695C99D457AAAAE2BAE32FED0F731E" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_B4CDA917284763D6FA7CE32FED108EAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_AC74B6D63D6815138417E32FED105B7D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8D695C99D457AAAAE2BAE32FED0F731E" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_AC74B6D63D6815138417E32FED105B7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_3ED64B00BCC82569866AE32FED10ED51" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8D695C99D457AAAAE2BAE32FED0F731E" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_3ED64B00BCC82569866AE32FED10ED51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_84701357E6DBF7F966E9E32FED115FAA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_E3BF2294A42F9F2397EEE32FED0A4951" xlink:to="loc_srt_RangeAxis_84701357E6DBF7F966E9E32FED115FAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_C81CAD7B980D6B6D651EE32FED11947E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_84701357E6DBF7F966E9E32FED115FAA" xlink:to="loc_srt_RangeMember_C81CAD7B980D6B6D651EE32FED11947E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_C81CAD7B980D6B6D651EE32FED11947E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_84701357E6DBF7F966E9E32FED115FAA" xlink:to="loc_srt_RangeMember_C81CAD7B980D6B6D651EE32FED11947E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_6F9C3A9FB4740C1C1C66E32FED1207B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_C81CAD7B980D6B6D651EE32FED11947E" xlink:to="loc_srt_MinimumMember_6F9C3A9FB4740C1C1C66E32FED1207B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_56C15077D3A5AA936F5AE32FED121F69" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_56C15077D3A5AA936F5AE32FED121F69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_460A0365C0CEBC681265E32FED13DFA0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_460A0365C0CEBC681265E32FED13DFA0" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_NumberOfTrailingQuarters" xlink:label="loc_optn_NumberOfTrailingQuarters_A33EC4DC7AD280DB6616E32FED13CD4B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_optn_NumberOfTrailingQuarters_A33EC4DC7AD280DB6616E32FED13CD4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_B0A915D97DD011475899E33379963A2E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_us-gaap_Revenues_B0A915D97DD011475899E33379963A2E" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_TotalDebttoTrailingQuarterNetSalesRatio" xlink:label="loc_optn_TotalDebttoTrailingQuarterNetSalesRatio_E130D08B68A03757C045E32FED133A02" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_optn_TotalDebttoTrailingQuarterNetSalesRatio_E130D08B68A03757C045E32FED133A02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_C404A7F96EF39EEEB9F9E32FED148428" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_C404A7F96EF39EEEB9F9E32FED148428" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentInterestRateFloor" xlink:label="loc_optn_DebtInstrumentInterestRateFloor_725D171E99DD5A009B9EE32FED149D5E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_optn_DebtInstrumentInterestRateFloor_725D171E99DD5A009B9EE32FED149D5E" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentFeeUpfrontFee" xlink:label="loc_optn_DebtInstrumentFeeUpfrontFee_DC9F2AE28CC3BD6216F6E32FED157102" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_optn_DebtInstrumentFeeUpfrontFee_DC9F2AE28CC3BD6216F6E32FED157102" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentFeeExitFee" xlink:label="loc_optn_DebtInstrumentFeeExitFee_5F9B145128CA98853EA4E32FED15B09D" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_optn_DebtInstrumentFeeExitFee_5F9B145128CA98853EA4E32FED15B09D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_834665F2BF2630A807FEE32FED15F85F" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_834665F2BF2630A807FEE32FED15F85F" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentPrepaymentFee" xlink:label="loc_optn_DebtInstrumentPrepaymentFee_D7C4EB5E70F35963B042E32FED154C95" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_optn_DebtInstrumentPrepaymentFee_D7C4EB5E70F35963B042E32FED154C95" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentCovenantCashandCashEquivalents" xlink:label="loc_optn_DebtInstrumentCovenantCashandCashEquivalents_3CE30D7802798C93D035E32FED15E260" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_optn_DebtInstrumentCovenantCashandCashEquivalents_3CE30D7802798C93D035E32FED15E260" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_85EEC673325196C95919E32FED16F873" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_us-gaap_InterestExpenseDebt_85EEC673325196C95919E32FED16F873" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_B9C433A0BE44B65A696DE32FED16EF35" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_B9C433A0BE44B65A696DE32FED16EF35" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtDiscountAmortizationPeriod" xlink:label="loc_optn_DebtDiscountAmortizationPeriod_0D3464BEE039A14182FAE32FED16A0D2" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_optn_DebtDiscountAmortizationPeriod_0D3464BEE039A14182FAE32FED16A0D2" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_InterestExpenseDebtBackEndFees" xlink:label="loc_optn_InterestExpenseDebtBackEndFees_B0F46A3663A2B200094DE32FED171B88" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_optn_InterestExpenseDebtBackEndFees_B0F46A3663A2B200094DE32FED171B88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_3CD00922277B3A07C766E32FED17F260" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_3CD00922277B3A07C766E32FED17F260" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_87483361ABB4CF7BED3DE32FED17730E" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_87483361ABB4CF7BED3DE32FED17730E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.optinose.com/role/LongTermDebtScheduleOfLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_855D1AFB83FE984EE6C1E32FECF6B6D5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_06C71A2D720E951451EAE32FECF32106" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_855D1AFB83FE984EE6C1E32FECF6B6D5" xlink:to="loc_us-gaap_DebtInstrumentTable_06C71A2D720E951451EAE32FECF32106" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1FEB20CB7AC7C74CD2AFE32FECF472B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_06C71A2D720E951451EAE32FECF32106" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1FEB20CB7AC7C74CD2AFE32FECF472B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6D2743E78A4738670198E32FECF4CAD9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1FEB20CB7AC7C74CD2AFE32FECF472B7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6D2743E78A4738670198E32FECF4CAD9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6D2743E78A4738670198E32FECF4CAD9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1FEB20CB7AC7C74CD2AFE32FECF472B7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6D2743E78A4738670198E32FECF4CAD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_C0D8D6295CD6D7C6F6EAE32FECF48CCB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6D2743E78A4738670198E32FECF4CAD9" xlink:to="loc_us-gaap_SeniorNotesMember_C0D8D6295CD6D7C6F6EAE32FECF48CCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_58857BCA14F3A135DC78E32FECF5A00E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_06C71A2D720E951451EAE32FECF32106" xlink:to="loc_us-gaap_DebtInstrumentAxis_58857BCA14F3A135DC78E32FECF5A00E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_778C1D1CF9117F160788E32FECF5061A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_58857BCA14F3A135DC78E32FECF5A00E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_778C1D1CF9117F160788E32FECF5061A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_778C1D1CF9117F160788E32FECF5061A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_58857BCA14F3A135DC78E32FECF5A00E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_778C1D1CF9117F160788E32FECF5061A" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_NotePurchaseAgreementMember" xlink:label="loc_optn_NotePurchaseAgreementMember_7D36E7F860B6E77772F1E32FECF6223A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_778C1D1CF9117F160788E32FECF5061A" xlink:to="loc_optn_NotePurchaseAgreementMember_7D36E7F860B6E77772F1E32FECF6223A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_04F3493B3978362B122DE32FECF6D95A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_855D1AFB83FE984EE6C1E32FECF6B6D5" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_04F3493B3978362B122DE32FECF6D95A" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentFeeAmountFrontEnd" xlink:label="loc_optn_DebtInstrumentFeeAmountFrontEnd_E16F6C109135D3ADD62BE32FECF69342" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_855D1AFB83FE984EE6C1E32FECF6B6D5" xlink:to="loc_optn_DebtInstrumentFeeAmountFrontEnd_E16F6C109135D3ADD62BE32FECF69342" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_EFBB8953B2F61B839F46E32FECF72117" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_855D1AFB83FE984EE6C1E32FECF6B6D5" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_EFBB8953B2F61B839F46E32FECF72117" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentFeeAmountBackEnd" xlink:label="loc_optn_DebtInstrumentFeeAmountBackEnd_FCB281C124B220FD50C7E32FECF79B55" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_855D1AFB83FE984EE6C1E32FECF6B6D5" xlink:to="loc_optn_DebtInstrumentFeeAmountBackEnd_FCB281C124B220FD50C7E32FECF79B55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_4E62AABED537A3DEE7A5E32FECF712EC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_855D1AFB83FE984EE6C1E32FECF6B6D5" xlink:to="loc_us-gaap_LongTermDebt_4E62AABED537A3DEE7A5E32FECF712EC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.optinose.com/role/LongTermDebtTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/OrganizationAndDescriptionOfBusiness" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2AF2EA129C57E7CC1D65E2AA3CDCF396" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_86C85939240313CC3FF3E2AA3CDA56EC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2AF2EA129C57E7CC1D65E2AA3CDCF396" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_86C85939240313CC3FF3E2AA3CDA56EC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_C4FCE4D3103D180DF1C5E2F5DA2E91B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_86C85939240313CC3FF3E2AA3CDA56EC" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_C4FCE4D3103D180DF1C5E2F5DA2E91B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_28D9D6276A600FA7F2A1E2F5DA42078F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_C4FCE4D3103D180DF1C5E2F5DA2E91B2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_28D9D6276A600FA7F2A1E2F5DA42078F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_28D9D6276A600FA7F2A1E2F5DA42078F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_C4FCE4D3103D180DF1C5E2F5DA2E91B2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_28D9D6276A600FA7F2A1E2F5DA42078F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_B8F4B900137ACC10E1A3E2F60BE4142B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_28D9D6276A600FA7F2A1E2F5DA42078F" xlink:to="loc_us-gaap_InventoriesMember_B8F4B900137ACC10E1A3E2F60BE4142B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_4AC0EF5CB443DA5C42C0E2F632A7DAC4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_28D9D6276A600FA7F2A1E2F5DA42078F" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_4AC0EF5CB443DA5C42C0E2F632A7DAC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_672628BD005509B41852E2AA3CDAD807" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_86C85939240313CC3FF3E2AA3CDA56EC" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_672628BD005509B41852E2AA3CDAD807" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E19FB0B4F7AEA7938AC4E2AA3CDA7528_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_672628BD005509B41852E2AA3CDAD807" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E19FB0B4F7AEA7938AC4E2AA3CDA7528_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E19FB0B4F7AEA7938AC4E2AA3CDA7528" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_672628BD005509B41852E2AA3CDAD807" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E19FB0B4F7AEA7938AC4E2AA3CDA7528" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_ComputerEquipmentandSoftwareMember" xlink:label="loc_optn_ComputerEquipmentandSoftwareMember_99492370606CA5255037E2AA3CDB6E06" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E19FB0B4F7AEA7938AC4E2AA3CDA7528" xlink:to="loc_optn_ComputerEquipmentandSoftwareMember_99492370606CA5255037E2AA3CDB6E06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_73A74079B9CFA506997EE2AA3CDB13E2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E19FB0B4F7AEA7938AC4E2AA3CDA7528" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_73A74079B9CFA506997EE2AA3CDB13E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_D67547A0DDF942294638E2AA3CDBC78D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E19FB0B4F7AEA7938AC4E2AA3CDA7528" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_D67547A0DDF942294638E2AA3CDBC78D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_81D9560F1543BC8DB202E2AA3CDC69EC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E19FB0B4F7AEA7938AC4E2AA3CDA7528" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_81D9560F1543BC8DB202E2AA3CDC69EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_33936D9E9738B224B2B4E2F43CFE412A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E19FB0B4F7AEA7938AC4E2AA3CDA7528" xlink:to="loc_us-gaap_ConstructionInProgressMember_33936D9E9738B224B2B4E2F43CFE412A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8073C0606F8BB0280906E2AA3CDC4FD2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2AF2EA129C57E7CC1D65E2AA3CDCF396" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8073C0606F8BB0280906E2AA3CDC4FD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_55CF6FDD4A1812AB8777E2AA3CDC2387" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2AF2EA129C57E7CC1D65E2AA3CDCF396" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_55CF6FDD4A1812AB8777E2AA3CDC2387" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1023972EE7975FDF47AEE2AA3CDCF73D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2AF2EA129C57E7CC1D65E2AA3CDCF396" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1023972EE7975FDF47AEE2AA3CDCF73D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_7A9D1EC2EDCAD32DD18CE2AA3CDDADD6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2AF2EA129C57E7CC1D65E2AA3CDCF396" xlink:to="loc_us-gaap_Depreciation_7A9D1EC2EDCAD32DD18CE2AA3CDDADD6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.optinose.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_AA131C9521C8746B2E4DDED0E1466CDA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1D3B242B769F2F786705DED0E1467E92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_AA131C9521C8746B2E4DDED0E1466CDA" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1D3B242B769F2F786705DED0E1467E92" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A66DAB60A00B810A35D6DED0E14632B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1D3B242B769F2F786705DED0E1467E92" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A66DAB60A00B810A35D6DED0E14632B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_110A1AD603C88C8B128ADED0E1466204_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A66DAB60A00B810A35D6DED0E14632B3" xlink:to="loc_us-gaap_RelatedPartyDomain_110A1AD603C88C8B128ADED0E1466204_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_110A1AD603C88C8B128ADED0E1466204" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A66DAB60A00B810A35D6DED0E14632B3" xlink:to="loc_us-gaap_RelatedPartyDomain_110A1AD603C88C8B128ADED0E1466204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_2151AA7F0F0AE741086BDED0E14613B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_110A1AD603C88C8B128ADED0E1466204" xlink:to="loc_us-gaap_InvestorMember_2151AA7F0F0AE741086BDED0E14613B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1FEF78D659F2FB739B03DED0E1464240" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1D3B242B769F2F786705DED0E1467E92" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1FEF78D659F2FB739B03DED0E1464240" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_DB3574E3E53561B14404DED0E146C0E2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1FEF78D659F2FB739B03DED0E1464240" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_DB3574E3E53561B14404DED0E146C0E2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_DB3574E3E53561B14404DED0E146C0E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1FEF78D659F2FB739B03DED0E1464240" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_DB3574E3E53561B14404DED0E146C0E2" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_FeesForIPOAndSeriesDConvertibleStockMember" xlink:label="loc_optn_FeesForIPOAndSeriesDConvertibleStockMember_10F842CE5D369E0F333CDED0E1467276" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_DB3574E3E53561B14404DED0E146C0E2" xlink:to="loc_optn_FeesForIPOAndSeriesDConvertibleStockMember_10F842CE5D369E0F333CDED0E1467276" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_23B3C6AC55D1EC9DE50DDED0E146F9DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_AA131C9521C8746B2E4DDED0E1466CDA" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_23B3C6AC55D1EC9DE50DDED0E146F9DD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.optinose.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/StockBasedCompensationBlackScholesPricingModelOptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34F010247A13980E44E2DED0E16CAA7C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1EC04BB994CA81EC7389DED0E1693DB4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34F010247A13980E44E2DED0E16CAA7C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1EC04BB994CA81EC7389DED0E1693DB4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2DFC559A472692FA0E08DED0E16A36D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1EC04BB994CA81EC7389DED0E1693DB4" xlink:to="loc_us-gaap_AwardTypeAxis_2DFC559A472692FA0E08DED0E16A36D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8D4197EAF6AE10444DC6DED0E16A0512_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2DFC559A472692FA0E08DED0E16A36D1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8D4197EAF6AE10444DC6DED0E16A0512_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8D4197EAF6AE10444DC6DED0E16A0512" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2DFC559A472692FA0E08DED0E16A36D1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8D4197EAF6AE10444DC6DED0E16A0512" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_D5675AF0825B42876391DED0E16A2CD8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8D4197EAF6AE10444DC6DED0E16A0512" xlink:to="loc_us-gaap_EmployeeStockOptionMember_D5675AF0825B42876391DED0E16A2CD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_FF11D96EB8B2DACDF45CDED0E16B91A6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1EC04BB994CA81EC7389DED0E1693DB4" xlink:to="loc_us-gaap_PlanNameAxis_FF11D96EB8B2DACDF45CDED0E16B91A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_E8F70B7A5078C1093BD9DED0E16B87C9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_FF11D96EB8B2DACDF45CDED0E16B91A6" xlink:to="loc_us-gaap_PlanNameDomain_E8F70B7A5078C1093BD9DED0E16B87C9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_E8F70B7A5078C1093BD9DED0E16B87C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_FF11D96EB8B2DACDF45CDED0E16B91A6" xlink:to="loc_us-gaap_PlanNameDomain_E8F70B7A5078C1093BD9DED0E16B87C9" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:label="loc_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_E6689088424171956D98DED0E16CA51A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_E8F70B7A5078C1093BD9DED0E16B87C9" xlink:to="loc_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_E6689088424171956D98DED0E16CA51A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F6F13E9609F44DEDA1F6DED0E16D9EFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34F010247A13980E44E2DED0E16CAA7C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F6F13E9609F44DEDA1F6DED0E16D9EFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_CA5B7054E902B388B455DED0E16D9411" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34F010247A13980E44E2DED0E16CAA7C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_CA5B7054E902B388B455DED0E16D9411" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_92DA9D4D48A770E1FDADDED0E16DE85F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34F010247A13980E44E2DED0E16CAA7C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_92DA9D4D48A770E1FDADDED0E16DE85F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_984E333ED2A30FB7B7C0DED0E16E1C4D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34F010247A13980E44E2DED0E16CAA7C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_984E333ED2A30FB7B7C0DED0E16E1C4D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.optinose.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F298FB8722C96AB6A9BDED0E533F93A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_151A91DFCA107EB088EADED0E5314519" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F298FB8722C96AB6A9BDED0E533F93A" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_151A91DFCA107EB088EADED0E5314519" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_751D5E4CB7CF1034EFD5DED0E5322404" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_151A91DFCA107EB088EADED0E5314519" xlink:to="loc_us-gaap_PlanNameAxis_751D5E4CB7CF1034EFD5DED0E5322404" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_CC5935168C0A2FB76A8FDED0E532C5E9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_751D5E4CB7CF1034EFD5DED0E5322404" xlink:to="loc_us-gaap_PlanNameDomain_CC5935168C0A2FB76A8FDED0E532C5E9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_CC5935168C0A2FB76A8FDED0E532C5E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_751D5E4CB7CF1034EFD5DED0E5322404" xlink:to="loc_us-gaap_PlanNameDomain_CC5935168C0A2FB76A8FDED0E532C5E9" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:label="loc_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_5F48BA7D503E341095BDDED0E532A5B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_CC5935168C0A2FB76A8FDED0E532C5E9" xlink:to="loc_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_5F48BA7D503E341095BDDED0E532A5B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_07F89B38977DA6BB3F23DED0E533C0DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F298FB8722C96AB6A9BDED0E533F93A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_07F89B38977DA6BB3F23DED0E533C0DF" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear" xlink:label="loc_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear_A53FDABAE9B58130E2F6DED0E534C79E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F298FB8722C96AB6A9BDED0E533F93A" xlink:to="loc_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear_A53FDABAE9B58130E2F6DED0E534C79E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4EE9F68B89DA7703C6EFDED0E534C6A2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F298FB8722C96AB6A9BDED0E533F93A" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4EE9F68B89DA7703C6EFDED0E534C6A2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.optinose.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34105EB09F634D47D47AEE2779AB5E26" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34105EB09F634D47D47AEE2779AB5E26" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_C14E8928F1DBC2EC531FEE2779ACE7AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34105EB09F634D47D47AEE2779AB5E26" xlink:to="loc_us-gaap_PlanNameAxis_C14E8928F1DBC2EC531FEE2779ACE7AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_667DCDACA6C90148F794EE2779ACD04F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_C14E8928F1DBC2EC531FEE2779ACE7AE" xlink:to="loc_us-gaap_PlanNameDomain_667DCDACA6C90148F794EE2779ACD04F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_667DCDACA6C90148F794EE2779ACD04F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_C14E8928F1DBC2EC531FEE2779ACE7AE" xlink:to="loc_us-gaap_PlanNameDomain_667DCDACA6C90148F794EE2779ACD04F" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_AmendedandRestated2010StockIncentivePlanMember" xlink:label="loc_optn_AmendedandRestated2010StockIncentivePlanMember_7AF41417315B2758D3DDEE2779ACA4F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_667DCDACA6C90148F794EE2779ACD04F" xlink:to="loc_optn_AmendedandRestated2010StockIncentivePlanMember_7AF41417315B2758D3DDEE2779ACA4F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_237D112B1F4C6E0D0505EE2779AC237B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34105EB09F634D47D47AEE2779AB5E26" xlink:to="loc_us-gaap_AwardTypeAxis_237D112B1F4C6E0D0505EE2779AC237B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4376ECA03173966C71CCEE2779AD0DDE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_237D112B1F4C6E0D0505EE2779AC237B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4376ECA03173966C71CCEE2779AD0DDE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4376ECA03173966C71CCEE2779AD0DDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_237D112B1F4C6E0D0505EE2779AC237B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4376ECA03173966C71CCEE2779AD0DDE" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_ServiceBasedStockOptionsMember" xlink:label="loc_optn_ServiceBasedStockOptionsMember_49AB1FCC21826FB6CC8DEE2779AD426F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4376ECA03173966C71CCEE2779AD0DDE" xlink:to="loc_optn_ServiceBasedStockOptionsMember_49AB1FCC21826FB6CC8DEE2779AD426F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_894C0242A21EA209B337EE2779AE4CF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_894C0242A21EA209B337EE2779AE4CF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2E3FD04E097B5F21CEABEE2779AE92DA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2E3FD04E097B5F21CEABEE2779AE92DA" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease" xlink:label="loc_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease_F2D30316B3E609F6B2A4EE2779AEC07D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:to="loc_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease_F2D30316B3E609F6B2A4EE2779AEC07D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A28B72502242D5D11094EE2779AE1E23" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A28B72502242D5D11094EE2779AE1E23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_86D207A1179C57B7D757EE2779AE7EC4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_86D207A1179C57B7D757EE2779AE7EC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_CD729B35ACA56BD8F32BEE2779AF3367" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_CD729B35ACA56BD8F32BEE2779AF3367" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_82B4DD8EE2FB389FBBECEE2779AF0C22" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_82B4DD8EE2FB389FBBECEE2779AF0C22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_03765D345F4DC0BFB86DEE2779AFE8F3" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_03765D345F4DC0BFB86DEE2779AFE8F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_61751BBF974201E672F0EE2779AFB54D" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_61751BBF974201E672F0EE2779AFB54D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5DF2795524508D2D39CBEE2779AFD9EB" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5DF2795524508D2D39CBEE2779AFD9EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_CDD82D03AEA052733C9FEE2779B057CF" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_CDD82D03AEA052733C9FEE2779B057CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_486B8688F2F77C00C52CEE2779B063E8" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_486B8688F2F77C00C52CEE2779B063E8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.optinose.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7502628F37CDB786F501DED0E56D3AE6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7DF0D47A8FBAFCB7B8B3DED0E56CF7C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7502628F37CDB786F501DED0E56D3AE6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7DF0D47A8FBAFCB7B8B3DED0E56CF7C7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_87B29F8C84377D6C9D50DED0E56D846D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7DF0D47A8FBAFCB7B8B3DED0E56CF7C7" xlink:to="loc_us-gaap_AwardTypeAxis_87B29F8C84377D6C9D50DED0E56D846D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4B9F7EFFA71CED3BF65DDED0E56D4E83_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_87B29F8C84377D6C9D50DED0E56D846D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4B9F7EFFA71CED3BF65DDED0E56D4E83_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4B9F7EFFA71CED3BF65DDED0E56D4E83" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_87B29F8C84377D6C9D50DED0E56D846D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4B9F7EFFA71CED3BF65DDED0E56D4E83" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_ServiceBasedStockOptionsMember" xlink:label="loc_optn_ServiceBasedStockOptionsMember_E76AC36BF46BB74F5878DED0E56DBD53" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4B9F7EFFA71CED3BF65DDED0E56D4E83" xlink:to="loc_optn_ServiceBasedStockOptionsMember_E76AC36BF46BB74F5878DED0E56DBD53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2BD86E0F0F17D8875F2EDED0E56ED494" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7502628F37CDB786F501DED0E56D3AE6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2BD86E0F0F17D8875F2EDED0E56ED494" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1D1C82611F0171D3104BDED0E56E5948" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2BD86E0F0F17D8875F2EDED0E56ED494" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1D1C82611F0171D3104BDED0E56E5948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_B55FE515419EE3E66207DED0E56E1E0E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2BD86E0F0F17D8875F2EDED0E56ED494" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_B55FE515419EE3E66207DED0E56E1E0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A1BD84E7970F880580BDDED0E56E0E6D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2BD86E0F0F17D8875F2EDED0E56ED494" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A1BD84E7970F880580BDDED0E56E0E6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2A89BD924DBDFFD7FD93DED0E56F1FD4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2BD86E0F0F17D8875F2EDED0E56ED494" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2A89BD924DBDFFD7FD93DED0E56F1FD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_307511807118457BD14FDED0E56F6C29" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2BD86E0F0F17D8875F2EDED0E56ED494" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_307511807118457BD14FDED0E56F6C29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_414AF0326CAD587A832BDED0E56F048D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7502628F37CDB786F501DED0E56D3AE6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_414AF0326CAD587A832BDED0E56F048D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F74680DD484BF121D169DED0E56F2D40" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7502628F37CDB786F501DED0E56D3AE6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F74680DD484BF121D169DED0E56F2D40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7F9B81D20648910B8BA2DED0E56FCB4C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7502628F37CDB786F501DED0E56D3AE6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7F9B81D20648910B8BA2DED0E56FCB4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21A80D64D4B3F4233E22DED0E56FD7C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7F9B81D20648910B8BA2DED0E56FCB4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21A80D64D4B3F4233E22DED0E56FD7C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8B929ADF7E51A8FA5A9FDED0E5702CEA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7F9B81D20648910B8BA2DED0E56FCB4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8B929ADF7E51A8FA5A9FDED0E5702CEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40A0C686E36813D71FC7DED0E57002BA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7F9B81D20648910B8BA2DED0E56FCB4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40A0C686E36813D71FC7DED0E57002BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4C5EA7CF481677FBFA5BDED0E5707E24" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7F9B81D20648910B8BA2DED0E56FCB4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4C5EA7CF481677FBFA5BDED0E5707E24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_86DA28CC08F1EF232582DED0E5703972" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7F9B81D20648910B8BA2DED0E56FCB4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_86DA28CC08F1EF232582DED0E5703972" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0DBDBC06725553A2FF70DED0E5718639" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7502628F37CDB786F501DED0E56D3AE6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0DBDBC06725553A2FF70DED0E5718639" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_D29ACDC7D47CFBA40E8CDED0E571CFF1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7502628F37CDB786F501DED0E56D3AE6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_D29ACDC7D47CFBA40E8CDED0E571CFF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_04A3F1B7BFC78C01C227DED0E571F102" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7502628F37CDB786F501DED0E56D3AE6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_04A3F1B7BFC78C01C227DED0E571F102" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0861AE86047380744C6ADED0E572B7B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_04A3F1B7BFC78C01C227DED0E571F102" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0861AE86047380744C6ADED0E572B7B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_61E161D0D0490B590196DED0E57265C2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_04A3F1B7BFC78C01C227DED0E571F102" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_61E161D0D0490B590196DED0E57265C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_67DEACCFFA01773310A1DED0E5724B5C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_04A3F1B7BFC78C01C227DED0E571F102" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_67DEACCFFA01773310A1DED0E5724B5C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.optinose.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CC80909C1355A9A13DD1EE27796ED152" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_96CDCBA3AC71BF26F8B8EE27796CBE39" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CC80909C1355A9A13DD1EE27796ED152" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_96CDCBA3AC71BF26F8B8EE27796CBE39" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5936FFC843DEFD3099D5EE27796C509E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_96CDCBA3AC71BF26F8B8EE27796CBE39" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5936FFC843DEFD3099D5EE27796C509E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8FBA88A58E9C65B47F54EE27796DD10E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5936FFC843DEFD3099D5EE27796C509E" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8FBA88A58E9C65B47F54EE27796DD10E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8FBA88A58E9C65B47F54EE27796DD10E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5936FFC843DEFD3099D5EE27796C509E" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8FBA88A58E9C65B47F54EE27796DD10E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_CCB0F47F80C9D4E42718EE3CC81C6F58" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8FBA88A58E9C65B47F54EE27796DD10E" xlink:to="loc_us-gaap_CostOfSalesMember_CCB0F47F80C9D4E42718EE3CC81C6F58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2E9587624D3AC616CAAAEE27796D491A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8FBA88A58E9C65B47F54EE27796DD10E" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2E9587624D3AC616CAAAEE27796D491A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ABB4BF1FF6107EA9143EEE27796E28D6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8FBA88A58E9C65B47F54EE27796DD10E" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ABB4BF1FF6107EA9143EEE27796E28D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_3B4A87CC98C0F2C254F8EE3EDB47D89D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8FBA88A58E9C65B47F54EE27796DD10E" xlink:to="loc_us-gaap_InventoriesMember_3B4A87CC98C0F2C254F8EE3EDB47D89D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_6E4C24EAC54176391EC1EE3F3C9D4D46" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8FBA88A58E9C65B47F54EE27796DD10E" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_6E4C24EAC54176391EC1EE3F3C9D4D46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_CE2D567A435A50C618FDEE27796E0472" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CC80909C1355A9A13DD1EE27796ED152" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_CE2D567A435A50C618FDEE27796E0472" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.optinose.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/StockholdersEquity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/StockholdersEquityCommonStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_11911169C4A98A6D0136EE2779D4863E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_11911169C4A98A6D0136EE2779D4863E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_63F2B149BFE4B5C5F8AAEE2FFC55A1E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_11911169C4A98A6D0136EE2779D4863E" xlink:to="loc_srt_CounterpartyNameAxis_63F2B149BFE4B5C5F8AAEE2FFC55A1E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6C1E117C230A12A01047EE2FFC6972D2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_63F2B149BFE4B5C5F8AAEE2FFC55A1E8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6C1E117C230A12A01047EE2FFC6972D2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6C1E117C230A12A01047EE2FFC6972D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_63F2B149BFE4B5C5F8AAEE2FFC55A1E8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6C1E117C230A12A01047EE2FFC6972D2" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_TheCompanyMember" xlink:label="loc_optn_TheCompanyMember_7B227CFD92EFDF5CF06DEE2FFCAD010A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6C1E117C230A12A01047EE2FFC6972D2" xlink:to="loc_optn_TheCompanyMember_7B227CFD92EFDF5CF06DEE2FFCAD010A" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_CertainStockholdersMember" xlink:label="loc_optn_CertainStockholdersMember_C6810B03AB9A471B1CA9EE2FFCC45841" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6C1E117C230A12A01047EE2FFC6972D2" xlink:to="loc_optn_CertainStockholdersMember_C6810B03AB9A471B1CA9EE2FFCC45841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_E5D21DC4F973326387B8EE2779D5705D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_11911169C4A98A6D0136EE2779D4863E" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_E5D21DC4F973326387B8EE2779D5705D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A2466CD58C57C2C8BE33EE2779D5E946_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_E5D21DC4F973326387B8EE2779D5705D" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A2466CD58C57C2C8BE33EE2779D5E946_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A2466CD58C57C2C8BE33EE2779D5E946" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_E5D21DC4F973326387B8EE2779D5705D" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A2466CD58C57C2C8BE33EE2779D5E946" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_5E416BCBA94C9F06CA4AEE2779D5CD31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A2466CD58C57C2C8BE33EE2779D5E946" xlink:to="loc_us-gaap_IPOMember_5E416BCBA94C9F06CA4AEE2779D5CD31" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_PublicOfferingMember" xlink:label="loc_optn_PublicOfferingMember_C969E5FAB1C9155CA0F2EE2FFC93DE5C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A2466CD58C57C2C8BE33EE2779D5E946" xlink:to="loc_optn_PublicOfferingMember_C969E5FAB1C9155CA0F2EE2FFC93DE5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6B37FDE88B6BC968760BEE2779D5F39D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_11911169C4A98A6D0136EE2779D4863E" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6B37FDE88B6BC968760BEE2779D5F39D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_F6A1839CFB0B6EEE6914EE2779D5646A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6B37FDE88B6BC968760BEE2779D5F39D" xlink:to="loc_us-gaap_ClassOfStockDomain_F6A1839CFB0B6EEE6914EE2779D5646A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_F6A1839CFB0B6EEE6914EE2779D5646A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6B37FDE88B6BC968760BEE2779D5F39D" xlink:to="loc_us-gaap_ClassOfStockDomain_F6A1839CFB0B6EEE6914EE2779D5646A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1246A7E8A78F36EE660CEE2779D6C1B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_F6A1839CFB0B6EEE6914EE2779D5646A" xlink:to="loc_us-gaap_CommonStockMember_1246A7E8A78F36EE660CEE2779D6C1B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_89885CA622C5834EA505EE2779D69FDD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_89885CA622C5834EA505EE2779D69FDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_DA41BB369D5953E8D427EE2779D6C537" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_DA41BB369D5953E8D427EE2779D6C537" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_513A5CB269BF5E1B3547EE2779D74B00" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_513A5CB269BF5E1B3547EE2779D74B00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_05D6A719B5B197242C9EEE2779D74A4D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_05D6A719B5B197242C9EEE2779D74A4D" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_SaleofStockDiscountsandCommissions" xlink:label="loc_optn_SaleofStockDiscountsandCommissions_593DECBF95C2098DA571EE2779D75C65" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:to="loc_optn_SaleofStockDiscountsandCommissions_593DECBF95C2098DA571EE2779D75C65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_31F6B946CF88E2A9CA97EE2779D700B8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_31F6B946CF88E2A9CA97EE2779D700B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1A13B98DC005F1FDB2E0EE2FFB7FFA66" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1A13B98DC005F1FDB2E0EE2FFB7FFA66" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_SaleofStockDiscounts" xlink:label="loc_optn_SaleofStockDiscounts_C9129DEDDA2DC11E37BAEE2FFB8C99AC" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:to="loc_optn_SaleofStockDiscounts_C9129DEDDA2DC11E37BAEE2FFB8C99AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_A745EA91226A6239C427EE2FFC438F87" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:to="loc_us-gaap_DeferredOfferingCosts_A745EA91226A6239C427EE2FFC438F87" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_VotePerShare" xlink:label="loc_optn_VotePerShare_F3E3995AD4F01E6D9ED5EE2779D7B353" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:to="loc_optn_VotePerShare_F3E3995AD4F01E6D9ED5EE2779D7B353" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_EF6A3D38536AED148D4CEE2779D81811" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_EF6A3D38536AED148D4CEE2779D81811" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.optinose.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_492E3F553A97A255C6A0EE2779BFB3D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_492E3F553A97A255C6A0EE2779BFB3D1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_A76D135D657B69C4A0CFEE2779BF7ED8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_492E3F553A97A255C6A0EE2779BFB3D1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_A76D135D657B69C4A0CFEE2779BF7ED8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F8F3FF4725B5B2B22A6DEE2779C07A3B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_A76D135D657B69C4A0CFEE2779BF7ED8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F8F3FF4725B5B2B22A6DEE2779C07A3B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F8F3FF4725B5B2B22A6DEE2779C07A3B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_A76D135D657B69C4A0CFEE2779BF7ED8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F8F3FF4725B5B2B22A6DEE2779C07A3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_28110431BCCBACF7B564EE2779C0F9A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F8F3FF4725B5B2B22A6DEE2779C07A3B" xlink:to="loc_us-gaap_IPOMember_28110431BCCBACF7B564EE2779C0F9A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_67B8A2549839D28A196AEE2779C02B1B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_492E3F553A97A255C6A0EE2779BFB3D1" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_67B8A2549839D28A196AEE2779C02B1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_7B58DD15CA35278DEF8BEE2779C00BBE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_67B8A2549839D28A196AEE2779C02B1B" xlink:to="loc_us-gaap_DebtConversionNameDomain_7B58DD15CA35278DEF8BEE2779C00BBE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_7B58DD15CA35278DEF8BEE2779C00BBE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_67B8A2549839D28A196AEE2779C02B1B" xlink:to="loc_us-gaap_DebtConversionNameDomain_7B58DD15CA35278DEF8BEE2779C00BBE" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember" xlink:label="loc_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember_8774504C38A32998666EEE2779C1CF6C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_7B58DD15CA35278DEF8BEE2779C00BBE" xlink:to="loc_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember_8774504C38A32998666EEE2779C1CF6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_1148F9FC08FCB54E62F2EE2779C11BF4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_492E3F553A97A255C6A0EE2779BFB3D1" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_1148F9FC08FCB54E62F2EE2779C11BF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_4CC3037C41B7172CA8E0EE2779C15178_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_1148F9FC08FCB54E62F2EE2779C11BF4" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_4CC3037C41B7172CA8E0EE2779C15178_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_4CC3037C41B7172CA8E0EE2779C15178" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_1148F9FC08FCB54E62F2EE2779C11BF4" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_4CC3037C41B7172CA8E0EE2779C15178" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_ConversionatConsummationofIPOMember" xlink:label="loc_optn_ConversionatConsummationofIPOMember_8C9E5F4D7A5DA6FDBE06EE2779C1971D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4CC3037C41B7172CA8E0EE2779C15178" xlink:to="loc_optn_ConversionatConsummationofIPOMember_8C9E5F4D7A5DA6FDBE06EE2779C1971D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3004EC8ADFE45F0DDF52EE2779C20093" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_492E3F553A97A255C6A0EE2779BFB3D1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3004EC8ADFE45F0DDF52EE2779C20093" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_C12A27A9B498DEAE47E8EE2779C28F02_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3004EC8ADFE45F0DDF52EE2779C20093" xlink:to="loc_us-gaap_ClassOfStockDomain_C12A27A9B498DEAE47E8EE2779C28F02_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_C12A27A9B498DEAE47E8EE2779C28F02" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3004EC8ADFE45F0DDF52EE2779C20093" xlink:to="loc_us-gaap_ClassOfStockDomain_C12A27A9B498DEAE47E8EE2779C28F02" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_RedeemableConvertiblePreferredStockSeriesDMember" xlink:label="loc_optn_RedeemableConvertiblePreferredStockSeriesDMember_CD8F801782993399BA84EE2779C21BDC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_C12A27A9B498DEAE47E8EE2779C28F02" xlink:to="loc_optn_RedeemableConvertiblePreferredStockSeriesDMember_CD8F801782993399BA84EE2779C21BDC" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_RedeemableConvertiblePreferredStockSeriesC2Member" xlink:label="loc_optn_RedeemableConvertiblePreferredStockSeriesC2Member_17031026590148028D24EE2779C2C8EE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_C12A27A9B498DEAE47E8EE2779C28F02" xlink:to="loc_optn_RedeemableConvertiblePreferredStockSeriesC2Member_17031026590148028D24EE2779C2C8EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_52B2D6AFA8606F35A076EE2779C397B6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_C12A27A9B498DEAE47E8EE2779C28F02" xlink:to="loc_us-gaap_CommonStockMember_52B2D6AFA8606F35A076EE2779C397B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_11793B513610616D9045EE2779C37872" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_11793B513610616D9045EE2779C37872" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_B7A9398995BE40FFD216EE2779C38D3D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_B7A9398995BE40FFD216EE2779C38D3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_93165E0E5F4F00BDEAE1EE2779C3792F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_93165E0E5F4F00BDEAE1EE2779C3792F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_1A6557EB8AC12D0C0240EE2779C39BDE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_1A6557EB8AC12D0C0240EE2779C39BDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_E072B3861FFE84128A2AEE2779C41D5E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_E072B3861FFE84128A2AEE2779C41D5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4B67B52E0DBA43EFC322EE2779C4015B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4B67B52E0DBA43EFC322EE2779C4015B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_2D9CC30AABC59A4BEADFEE2779C49A1C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_2D9CC30AABC59A4BEADFEE2779C49A1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_E67A202D3692AE6681B6EE2779C4BC24" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_E67A202D3692AE6681B6EE2779C4BC24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2EAB776FBE44EC8D4B31EE2779C5BAC8" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2EAB776FBE44EC8D4B31EE2779C5BAC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1DF071B8F977BE2B05BEEE2779C5D0D4" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1DF071B8F977BE2B05BEEE2779C5D0D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_EBE77D9022BD2202462EEE2779C5D0D9" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_EBE77D9022BD2202462EEE2779C5D0D9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.optinose.com/role/StockholdersEquityWarrantsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/SubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_2913392D6FBE355623DAEE2778897909" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_ED3D4BD162FD6C7B2946EE277887A4F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_2913392D6FBE355623DAEE2778897909" xlink:to="loc_us-gaap_SubsequentEventTable_ED3D4BD162FD6C7B2946EE277887A4F7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_C3D2B19DBBF19FE5F656EE2778880446" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_ED3D4BD162FD6C7B2946EE277887A4F7" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_C3D2B19DBBF19FE5F656EE2778880446" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6E1E14E8B38E41D043C8EE277888B044_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_C3D2B19DBBF19FE5F656EE2778880446" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6E1E14E8B38E41D043C8EE277888B044_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6E1E14E8B38E41D043C8EE277888B044" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_C3D2B19DBBF19FE5F656EE2778880446" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6E1E14E8B38E41D043C8EE277888B044" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_26E8B17C60BF71EC5505EE2778889AAE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6E1E14E8B38E41D043C8EE277888B044" xlink:to="loc_us-gaap_SubsequentEventMember_26E8B17C60BF71EC5505EE2778889AAE" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_UpfrontLicenseFeeReceivable" xlink:label="loc_optn_UpfrontLicenseFeeReceivable_BD448601167075F38647EE65F98FFB59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2913392D6FBE355623DAEE2778897909" xlink:to="loc_optn_UpfrontLicenseFeeReceivable_BD448601167075F38647EE65F98FFB59" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DevelopmentMilestoneEligibility" xlink:label="loc_optn_DevelopmentMilestoneEligibility_3306B2E67EE748C14F8BEE696391F280" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2913392D6FBE355623DAEE2778897909" xlink:to="loc_optn_DevelopmentMilestoneEligibility_3306B2E67EE748C14F8BEE696391F280" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_SalesMilestoneEligibility" xlink:label="loc_optn_SalesMilestoneEligibility_BC312FC32ECC400B9A9CEE68B8826FBF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2913392D6FBE355623DAEE2778897909" xlink:to="loc_optn_SalesMilestoneEligibility_BC312FC32ECC400B9A9CEE68B8826FBF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.optinose.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesAntidilutiveSharesExcludedFromEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6E5C6FA9B5FDE5AA102449EC157C7390" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_168254F27DD5F108CF4749EC157C0DDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6E5C6FA9B5FDE5AA102449EC157C7390" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_168254F27DD5F108CF4749EC157C0DDE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4F4E37DE4D8BDA09793249EC157C263D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_168254F27DD5F108CF4749EC157C0DDE" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4F4E37DE4D8BDA09793249EC157C263D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3AE9A6DA41343A852E8949EC157C9D85_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4F4E37DE4D8BDA09793249EC157C263D" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3AE9A6DA41343A852E8949EC157C9D85_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3AE9A6DA41343A852E8949EC157C9D85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4F4E37DE4D8BDA09793249EC157C263D" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3AE9A6DA41343A852E8949EC157C9D85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_BFFBE80176A7DD925D1249EC157C2FF2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3AE9A6DA41343A852E8949EC157C9D85" xlink:to="loc_us-gaap_EmployeeStockOptionMember_BFFBE80176A7DD925D1249EC157C2FF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_181C376E4D25E88FFAF149EC157CB902" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3AE9A6DA41343A852E8949EC157C9D85" xlink:to="loc_us-gaap_WarrantMember_181C376E4D25E88FFAF149EC157CB902" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_EmployeeStockPurchasePlanMember" xlink:label="loc_optn_EmployeeStockPurchasePlanMember_D3D96737AD2726E30E4349EC157C38E4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3AE9A6DA41343A852E8949EC157C9D85" xlink:to="loc_optn_EmployeeStockPurchasePlanMember_D3D96737AD2726E30E4349EC157C38E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E71E9F1CBEA5603CA10849EC157C3149" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6E5C6FA9B5FDE5AA102449EC157C7390" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E71E9F1CBEA5603CA10849EC157C3149" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_50F9AE28564AA1538B063A5963C22379" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_0ED8F02B087A85DAB2F73A5963C29876" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_50F9AE28564AA1538B063A5963C22379" xlink:to="loc_us-gaap_ConcentrationRiskTable_0ED8F02B087A85DAB2F73A5963C29876" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_A67D82C541408E9108123A59CC8B6303" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_0ED8F02B087A85DAB2F73A5963C29876" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_A67D82C541408E9108123A59CC8B6303" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2DA05ADE5B312AA619613A5B035EA1F3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_A67D82C541408E9108123A59CC8B6303" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2DA05ADE5B312AA619613A5B035EA1F3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2DA05ADE5B312AA619613A5B035EA1F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_A67D82C541408E9108123A59CC8B6303" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2DA05ADE5B312AA619613A5B035EA1F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_459563E6AFC1BD9B61653A59ECCF8722" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2DA05ADE5B312AA619613A5B035EA1F3" xlink:to="loc_us-gaap_AccountsReceivableMember_459563E6AFC1BD9B61653A59ECCF8722" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_39DADDA3E35C9CF2F7AB3A5ACD01CC6E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2DA05ADE5B312AA619613A5B035EA1F3" xlink:to="loc_us-gaap_SalesRevenueNetMember_39DADDA3E35C9CF2F7AB3A5ACD01CC6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_3C535A2567C70236B7843A5977C3365D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_50F9AE28564AA1538B063A5963C22379" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_3C535A2567C70236B7843A5977C3365D" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_ConcentrationRiskNumberofClients" xlink:label="loc_optn_ConcentrationRiskNumberofClients_40D2E4430D14C4C8B0873A5C1C6675B5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_50F9AE28564AA1538B063A5963C22379" xlink:to="loc_optn_ConcentrationRiskNumberofClients_40D2E4430D14C4C8B0873A5C1C6675B5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_509E73EA91AE291E2CC349FAC3981526" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1577EC264AA30057FCDB49FAC3986A7B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_509E73EA91AE291E2CC349FAC3981526" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1577EC264AA30057FCDB49FAC3986A7B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_B92B516A99FC4E1090AF49FAFBAE8001" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1577EC264AA30057FCDB49FAC3986A7B" xlink:to="loc_srt_ProductOrServiceAxis_B92B516A99FC4E1090AF49FAFBAE8001" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D25848861728B4C0DD1649FAFBB0B9AD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_B92B516A99FC4E1090AF49FAFBAE8001" xlink:to="loc_srt_ProductsAndServicesDomain_D25848861728B4C0DD1649FAFBB0B9AD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D25848861728B4C0DD1649FAFBB0B9AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_B92B516A99FC4E1090AF49FAFBAE8001" xlink:to="loc_srt_ProductsAndServicesDomain_D25848861728B4C0DD1649FAFBB0B9AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_527CB3E899C7F2DF3A0B49FB316E77F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D25848861728B4C0DD1649FAFBB0B9AD" xlink:to="loc_us-gaap_LicenseMember_527CB3E899C7F2DF3A0B49FB316E77F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2263D9EEBED494C302D049FA8191CAAE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_509E73EA91AE291E2CC349FAC3981526" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2263D9EEBED494C302D049FA8191CAAE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_BE33700B616D89A78724E2AA3D16A0AE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_344C0CEE3B427FCC5FD0E2AA3D1372F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_BE33700B616D89A78724E2AA3D16A0AE" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_344C0CEE3B427FCC5FD0E2AA3D1372F3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12B7ECD74C114325D637E2AA3D135AF7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_344C0CEE3B427FCC5FD0E2AA3D1372F3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12B7ECD74C114325D637E2AA3D135AF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E3B24A36FD3F661377FFE2AA3D149144_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12B7ECD74C114325D637E2AA3D135AF7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E3B24A36FD3F661377FFE2AA3D149144_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E3B24A36FD3F661377FFE2AA3D149144" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12B7ECD74C114325D637E2AA3D135AF7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E3B24A36FD3F661377FFE2AA3D149144" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_13DEBD804C225DF2585EE2AA3D141BF3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E3B24A36FD3F661377FFE2AA3D149144" xlink:to="loc_us-gaap_ComputerEquipmentMember_13DEBD804C225DF2585EE2AA3D141BF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7246EDE6A20DE6C0E2C0E2AA3D14B822" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E3B24A36FD3F661377FFE2AA3D149144" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7246EDE6A20DE6C0E2C0E2AA3D14B822" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_02405C8157574794803CE2AA3D14190D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E3B24A36FD3F661377FFE2AA3D149144" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_02405C8157574794803CE2AA3D14190D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_E2131D5F41914B1A2A5CE2AA3D15E75A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E3B24A36FD3F661377FFE2AA3D149144" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_E2131D5F41914B1A2A5CE2AA3D15E75A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_01D6E3F9E052F9B6C1A9E2AA3D15C4FD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_344C0CEE3B427FCC5FD0E2AA3D1372F3" xlink:to="loc_srt_RangeAxis_01D6E3F9E052F9B6C1A9E2AA3D15C4FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3158B71E2E33E8D83F77E2AA3D15131F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_01D6E3F9E052F9B6C1A9E2AA3D15C4FD" xlink:to="loc_srt_RangeMember_3158B71E2E33E8D83F77E2AA3D15131F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3158B71E2E33E8D83F77E2AA3D15131F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_01D6E3F9E052F9B6C1A9E2AA3D15C4FD" xlink:to="loc_srt_RangeMember_3158B71E2E33E8D83F77E2AA3D15131F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_C3FF342138212D8A3245E2AA3D15F914" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3158B71E2E33E8D83F77E2AA3D15131F" xlink:to="loc_srt_MinimumMember_C3FF342138212D8A3245E2AA3D15F914" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_5CE46347CF8F33BF4D7AE2AA3D157AC4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3158B71E2E33E8D83F77E2AA3D15131F" xlink:to="loc_srt_MaximumMember_5CE46347CF8F33BF4D7AE2AA3D157AC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_D0C75350EC8CAECB5DB3E2AA3D16A9DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_BE33700B616D89A78724E2AA3D16A0AE" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_D0C75350EC8CAECB5DB3E2AA3D16A9DE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>optn-20181231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_50AF7AE89E7562E5002EEDA0AAD68925_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_50AF7AE89E7562E5002EEDA0AAD68925" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_50AF7AE89E7562E5002EEDA0AAD68925" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_50AF7AE89E7562E5002EEDA0AAD68925" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_50AF7AE89E7562E5002EEDA0AAD68925" xlink:type="arc" />
    <link:label id="lab_optn_NumberOfOperatingLeases_029E1D48B89401621572EDA0AADA0FE9_terseLabel_en-US" xlink:label="lab_optn_NumberOfOperatingLeases_029E1D48B89401621572EDA0AADA0FE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating leases</link:label>
    <link:label id="lab_optn_NumberOfOperatingLeases_029E1D48B89401621572EDA0AADA0FE9_label_en-US" xlink:label="lab_optn_NumberOfOperatingLeases_029E1D48B89401621572EDA0AADA0FE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Operating Leases</link:label>
    <link:label id="lab_optn_NumberOfOperatingLeases_029E1D48B89401621572EDA0AADA0FE9_documentation_en-US" xlink:label="lab_optn_NumberOfOperatingLeases_029E1D48B89401621572EDA0AADA0FE9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Operating Leases</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_NumberOfOperatingLeases" xlink:label="loc_optn_NumberOfOperatingLeases_029E1D48B89401621572EDA0AADA0FE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_NumberOfOperatingLeases_029E1D48B89401621572EDA0AADA0FE9" xlink:to="lab_optn_NumberOfOperatingLeases_029E1D48B89401621572EDA0AADA0FE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_99C2FF4BE30ECF465CFBEDA0AADAFA3C_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_99C2FF4BE30ECF465CFBEDA0AADAFA3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_99C2FF4BE30ECF465CFBEDA0AADAFA3C_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_99C2FF4BE30ECF465CFBEDA0AADAFA3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_99C2FF4BE30ECF465CFBEDA0AADAFA3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_99C2FF4BE30ECF465CFBEDA0AADAFA3C" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet_99C2FF4BE30ECF465CFBEDA0AADAFA3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_9CA4510C273F8D685A3CEDA0AADB7460_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty_9CA4510C273F8D685A3CEDA0AADB7460" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of real estate property</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_9CA4510C273F8D685A3CEDA0AADB7460_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty_9CA4510C273F8D685A3CEDA0AADB7460" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_9CA4510C273F8D685A3CEDA0AADB7460" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty_9CA4510C273F8D685A3CEDA0AADB7460" xlink:to="lab_us-gaap_AreaOfRealEstateProperty_9CA4510C273F8D685A3CEDA0AADB7460" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_6E8C00A610B6ABF80EB6EDA0AADBD3D7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_6E8C00A610B6ABF80EB6EDA0AADBD3D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_6E8C00A610B6ABF80EB6EDA0AADBD3D7_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_6E8C00A610B6ABF80EB6EDA0AADBD3D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_6E8C00A610B6ABF80EB6EDA0AADBD3D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_6E8C00A610B6ABF80EB6EDA0AADBD3D7" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_6E8C00A610B6ABF80EB6EDA0AADBD3D7" xlink:type="arc" />
    <link:label id="lab_optn_FutureRentExpense_80230E05889D68D0C9A8EE84641E4059_terseLabel_en-US" xlink:label="lab_optn_FutureRentExpense_80230E05889D68D0C9A8EE84641E4059" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future rent expense</link:label>
    <link:label id="lab_optn_FutureRentExpense_80230E05889D68D0C9A8EE84641E4059_label_en-US" xlink:label="lab_optn_FutureRentExpense_80230E05889D68D0C9A8EE84641E4059" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Rent Expense</link:label>
    <link:label id="lab_optn_FutureRentExpense_80230E05889D68D0C9A8EE84641E4059_documentation_en-US" xlink:label="lab_optn_FutureRentExpense_80230E05889D68D0C9A8EE84641E4059" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Rent Expense</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_FutureRentExpense" xlink:label="loc_optn_FutureRentExpense_80230E05889D68D0C9A8EE84641E4059" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_FutureRentExpense_80230E05889D68D0C9A8EE84641E4059" xlink:to="lab_optn_FutureRentExpense_80230E05889D68D0C9A8EE84641E4059" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_68B9889CEF1ADABEEA89EE277B6BA334_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_68B9889CEF1ADABEEA89EE277B6BA334" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_68B9889CEF1ADABEEA89EE277B6BA334" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_68B9889CEF1ADABEEA89EE277B6BA334" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_68B9889CEF1ADABEEA89EE277B6BA334" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_46E0E03A5253BFD003D4EE277B6C9551_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_46E0E03A5253BFD003D4EE277B6C9551" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_46E0E03A5253BFD003D4EE277B6C9551_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_46E0E03A5253BFD003D4EE277B6C9551" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_46E0E03A5253BFD003D4EE277B6C9551" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_46E0E03A5253BFD003D4EE277B6C9551" xlink:to="lab_us-gaap_AssetsAbstract_46E0E03A5253BFD003D4EE277B6C9551" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_C3B04091E48F27C34240EE277B6C296C_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_C3B04091E48F27C34240EE277B6C296C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_C3B04091E48F27C34240EE277B6C296C_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_C3B04091E48F27C34240EE277B6C296C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_C3B04091E48F27C34240EE277B6C296C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C3B04091E48F27C34240EE277B6C296C" xlink:to="lab_us-gaap_AssetsCurrentAbstract_C3B04091E48F27C34240EE277B6C296C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_003FA4CE7F32955B978BEE277B6C122C_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_003FA4CE7F32955B978BEE277B6C122C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_003FA4CE7F32955B978BEE277B6C122C_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_003FA4CE7F32955B978BEE277B6C122C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_003FA4CE7F32955B978BEE277B6C122C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_003FA4CE7F32955B978BEE277B6C122C" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue_003FA4CE7F32955B978BEE277B6C122C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_8D531E97167211E8259FEE277B6DB020_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_8D531E97167211E8259FEE277B6DB020" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_8D531E97167211E8259FEE277B6DB020_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_8D531E97167211E8259FEE277B6DB020" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8D531E97167211E8259FEE277B6DB020" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_8D531E97167211E8259FEE277B6DB020" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_8D531E97167211E8259FEE277B6DB020" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_88ABA2751F48FE49C340EE277B6D36D7_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_88ABA2751F48FE49C340EE277B6D36D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grants and other receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_88ABA2751F48FE49C340EE277B6D36D7_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_88ABA2751F48FE49C340EE277B6D36D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_88ABA2751F48FE49C340EE277B6D36D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent_88ABA2751F48FE49C340EE277B6D36D7" xlink:to="lab_us-gaap_ReceivablesNetCurrent_88ABA2751F48FE49C340EE277B6D36D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_0CB01A648E9A5AED704FEE277B6D1CA5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_0CB01A648E9A5AED704FEE277B6D1CA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_0CB01A648E9A5AED704FEE277B6D1CA5_label_en-US" xlink:label="lab_us-gaap_InventoryNet_0CB01A648E9A5AED704FEE277B6D1CA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_0CB01A648E9A5AED704FEE277B6D1CA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_0CB01A648E9A5AED704FEE277B6D1CA5" xlink:to="lab_us-gaap_InventoryNet_0CB01A648E9A5AED704FEE277B6D1CA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_C0E0D51E740BCC798ED1EE277B6D3DF5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_C0E0D51E740BCC798ED1EE277B6D3DF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_C0E0D51E740BCC798ED1EE277B6D3DF5_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_C0E0D51E740BCC798ED1EE277B6D3DF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_C0E0D51E740BCC798ED1EE277B6D3DF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_C0E0D51E740BCC798ED1EE277B6D3DF5" xlink:to="lab_us-gaap_OtherAssetsCurrent_C0E0D51E740BCC798ED1EE277B6D3DF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_A61BC6D9DA8953091236EE277B6D872E_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_A61BC6D9DA8953091236EE277B6D872E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_A61BC6D9DA8953091236EE277B6D872E_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_A61BC6D9DA8953091236EE277B6D872E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_A61BC6D9DA8953091236EE277B6D872E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_A61BC6D9DA8953091236EE277B6D872E" xlink:to="lab_us-gaap_AssetsCurrent_A61BC6D9DA8953091236EE277B6D872E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_454F861A09F031632EE0EE277B6E06E7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_454F861A09F031632EE0EE277B6E06E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_454F861A09F031632EE0EE277B6E06E7_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_454F861A09F031632EE0EE277B6E06E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_454F861A09F031632EE0EE277B6E06E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_454F861A09F031632EE0EE277B6E06E7" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_454F861A09F031632EE0EE277B6E06E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_DD27EFB01A35748528B6EE277B6E48F8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_DD27EFB01A35748528B6EE277B6E48F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_DD27EFB01A35748528B6EE277B6E48F8_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_DD27EFB01A35748528B6EE277B6E48F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_DD27EFB01A35748528B6EE277B6E48F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_DD27EFB01A35748528B6EE277B6E48F8" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_DD27EFB01A35748528B6EE277B6E48F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_988C20B77B27BFE1F70FEE277B6E3336_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_988C20B77B27BFE1F70FEE277B6E3336" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_988C20B77B27BFE1F70FEE277B6E3336_label_en-US" xlink:label="lab_us-gaap_Assets_988C20B77B27BFE1F70FEE277B6E3336" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_988C20B77B27BFE1F70FEE277B6E3336" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_988C20B77B27BFE1F70FEE277B6E3336" xlink:to="lab_us-gaap_Assets_988C20B77B27BFE1F70FEE277B6E3336" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39A5C0E26F1760730259EE277B6E6B3D_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39A5C0E26F1760730259EE277B6E6B3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39A5C0E26F1760730259EE277B6E6B3D_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39A5C0E26F1760730259EE277B6E6B3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39A5C0E26F1760730259EE277B6E6B3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39A5C0E26F1760730259EE277B6E6B3D" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39A5C0E26F1760730259EE277B6E6B3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_5AA18A09D0B97207A783EE277B6EC90E_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_5AA18A09D0B97207A783EE277B6EC90E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_5AA18A09D0B97207A783EE277B6EC90E_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_5AA18A09D0B97207A783EE277B6EC90E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5AA18A09D0B97207A783EE277B6EC90E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5AA18A09D0B97207A783EE277B6EC90E" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_5AA18A09D0B97207A783EE277B6EC90E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_B450A228CBEEB56CFBDAEE277B6F9F33_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_B450A228CBEEB56CFBDAEE277B6F9F33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_B450A228CBEEB56CFBDAEE277B6F9F33_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_B450A228CBEEB56CFBDAEE277B6F9F33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_B450A228CBEEB56CFBDAEE277B6F9F33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_B450A228CBEEB56CFBDAEE277B6F9F33" xlink:to="lab_us-gaap_AccountsPayableCurrent_B450A228CBEEB56CFBDAEE277B6F9F33" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_7404A74EA3CF7FFA2A45EE277B6F762A_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_7404A74EA3CF7FFA2A45EE277B6F762A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_7404A74EA3CF7FFA2A45EE277B6F762A_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_7404A74EA3CF7FFA2A45EE277B6F762A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7404A74EA3CF7FFA2A45EE277B6F762A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7404A74EA3CF7FFA2A45EE277B6F762A" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_7404A74EA3CF7FFA2A45EE277B6F762A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_D57EDBA3985B8CA4C91AEE8A14C7266C_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_D57EDBA3985B8CA4C91AEE8A14C7266C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred other income</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_D57EDBA3985B8CA4C91AEE8A14C7266C_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_D57EDBA3985B8CA4C91AEE8A14C7266C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_D57EDBA3985B8CA4C91AEE8A14C7266C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent_D57EDBA3985B8CA4C91AEE8A14C7266C" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent_D57EDBA3985B8CA4C91AEE8A14C7266C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_133588E68CCFD0744467EE277B6FCF6E_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_133588E68CCFD0744467EE277B6FCF6E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_133588E68CCFD0744467EE277B6FCF6E_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_133588E68CCFD0744467EE277B6FCF6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_133588E68CCFD0744467EE277B6FCF6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_133588E68CCFD0744467EE277B6FCF6E" xlink:to="lab_us-gaap_LiabilitiesCurrent_133588E68CCFD0744467EE277B6FCF6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_EE9AF27ABACCFAB944A0EE277B6F9040_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_EE9AF27ABACCFAB944A0EE277B6F9040" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_EE9AF27ABACCFAB944A0EE277B6F9040_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_EE9AF27ABACCFAB944A0EE277B6F9040" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_EE9AF27ABACCFAB944A0EE277B6F9040" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_EE9AF27ABACCFAB944A0EE277B6F9040" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_EE9AF27ABACCFAB944A0EE277B6F9040" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilities_D0D47B4E4C476B28CC25EE277B70D541_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilities_D0D47B4E4C476B28CC25EE277B70D541" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilities_D0D47B4E4C476B28CC25EE277B70D541_label_en-US" xlink:label="lab_us-gaap_OtherLiabilities_D0D47B4E4C476B28CC25EE277B70D541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaap_OtherLiabilities_D0D47B4E4C476B28CC25EE277B70D541" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilities_D0D47B4E4C476B28CC25EE277B70D541" xlink:to="lab_us-gaap_OtherLiabilities_D0D47B4E4C476B28CC25EE277B70D541" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_FE86873E0B7B69A0B58BEE277B70D008_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_FE86873E0B7B69A0B58BEE277B70D008" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_FE86873E0B7B69A0B58BEE277B70D008_label_en-US" xlink:label="lab_us-gaap_Liabilities_FE86873E0B7B69A0B58BEE277B70D008" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_FE86873E0B7B69A0B58BEE277B70D008" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_FE86873E0B7B69A0B58BEE277B70D008" xlink:to="lab_us-gaap_Liabilities_FE86873E0B7B69A0B58BEE277B70D008" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_E80798CFFAF05A6216ACEE277B70A799_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_E80798CFFAF05A6216ACEE277B70A799" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_E80798CFFAF05A6216ACEE277B70A799_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_E80798CFFAF05A6216ACEE277B70A799" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_E80798CFFAF05A6216ACEE277B70A799" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_E80798CFFAF05A6216ACEE277B70A799" xlink:to="lab_us-gaap_CommitmentsAndContingencies_E80798CFFAF05A6216ACEE277B70A799" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9044B0A411289A771704EE277B70DE21_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9044B0A411289A771704EE277B70DE21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9044B0A411289A771704EE277B70DE21_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9044B0A411289A771704EE277B70DE21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9044B0A411289A771704EE277B70DE21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9044B0A411289A771704EE277B70DE21" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9044B0A411289A771704EE277B70DE21" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_B1BD49B5C4835CB6EF60EE277B70A752_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_B1BD49B5C4835CB6EF60EE277B70A752" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; 200,000,000 December 31, 2018 and 2017; 41,227,530 and 37,802,556 shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_B1BD49B5C4835CB6EF60EE277B70A752_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_B1BD49B5C4835CB6EF60EE277B70A752" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_B1BD49B5C4835CB6EF60EE277B70A752" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_B1BD49B5C4835CB6EF60EE277B70A752" xlink:to="lab_us-gaap_CommonStockValue_B1BD49B5C4835CB6EF60EE277B70A752" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_CA19345BB9C030F6C8F2EE277B704F25_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_CA19345BB9C030F6C8F2EE277B704F25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_CA19345BB9C030F6C8F2EE277B704F25_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_CA19345BB9C030F6C8F2EE277B704F25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_CA19345BB9C030F6C8F2EE277B704F25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_CA19345BB9C030F6C8F2EE277B704F25" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_CA19345BB9C030F6C8F2EE277B704F25" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_423A469E9003432DE685EE277B71D8BC_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_423A469E9003432DE685EE277B71D8BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_423A469E9003432DE685EE277B71D8BC_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_423A469E9003432DE685EE277B71D8BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_423A469E9003432DE685EE277B71D8BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_423A469E9003432DE685EE277B71D8BC" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_423A469E9003432DE685EE277B71D8BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3BB7D52AF49168CA8F06EE277B71B23D_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3BB7D52AF49168CA8F06EE277B71B23D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3BB7D52AF49168CA8F06EE277B71B23D_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3BB7D52AF49168CA8F06EE277B71B23D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3BB7D52AF49168CA8F06EE277B71B23D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3BB7D52AF49168CA8F06EE277B71B23D" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3BB7D52AF49168CA8F06EE277B71B23D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_BDDDAE01EF1AEE1A8E8AEE277B713145_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_BDDDAE01EF1AEE1A8E8AEE277B713145" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_BDDDAE01EF1AEE1A8E8AEE277B713145_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_BDDDAE01EF1AEE1A8E8AEE277B713145" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_BDDDAE01EF1AEE1A8E8AEE277B713145" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_BDDDAE01EF1AEE1A8E8AEE277B713145" xlink:to="lab_us-gaap_StockholdersEquity_BDDDAE01EF1AEE1A8E8AEE277B713145" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_C16BFF6674D598002EE8EE277B712473_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_C16BFF6674D598002EE8EE277B712473" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_C16BFF6674D598002EE8EE277B712473_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_C16BFF6674D598002EE8EE277B712473" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_C16BFF6674D598002EE8EE277B712473" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_C16BFF6674D598002EE8EE277B712473" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_C16BFF6674D598002EE8EE277B712473" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A0F028FD2A2C3266073ADED0E563E4B2_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A0F028FD2A2C3266073ADED0E563E4B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A0F028FD2A2C3266073ADED0E563E4B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A0F028FD2A2C3266073ADED0E563E4B2" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A0F028FD2A2C3266073ADED0E563E4B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_BA6DD5EE8EB7D3133017DED0E5637AEC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_BA6DD5EE8EB7D3133017DED0E5637AEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_BA6DD5EE8EB7D3133017DED0E5637AEC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_BA6DD5EE8EB7D3133017DED0E5637AEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_BA6DD5EE8EB7D3133017DED0E5637AEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_BA6DD5EE8EB7D3133017DED0E5637AEC" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_BA6DD5EE8EB7D3133017DED0E5637AEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_02B3358A242C744B5101DED0E563CC67_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_02B3358A242C744B5101DED0E563CC67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of allocated stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_02B3358A242C744B5101DED0E563CC67_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_02B3358A242C744B5101DED0E563CC67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_02B3358A242C744B5101DED0E563CC67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_02B3358A242C744B5101DED0E563CC67" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_02B3358A242C744B5101DED0E563CC67" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C5617ACB43036880F2FBDED0E5643EE6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C5617ACB43036880F2FBDED0E5643EE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of fair value options using Black-Scholes pricing model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C5617ACB43036880F2FBDED0E5643EE6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C5617ACB43036880F2FBDED0E5643EE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C5617ACB43036880F2FBDED0E5643EE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C5617ACB43036880F2FBDED0E5643EE6" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C5617ACB43036880F2FBDED0E5643EE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_9137D7F7C5D4BCAAB855EE2779CF8FC9_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_9137D7F7C5D4BCAAB855EE2779CF8FC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_9137D7F7C5D4BCAAB855EE2779CF8FC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_9137D7F7C5D4BCAAB855EE2779CF8FC9" xlink:to="lab_us-gaap_EquityAbstract_9137D7F7C5D4BCAAB855EE2779CF8FC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_F527DBF600BE4AAB0A02EE2779D0C0DD_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_F527DBF600BE4AAB0A02EE2779D0C0DD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_F527DBF600BE4AAB0A02EE2779D0C0DD_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_F527DBF600BE4AAB0A02EE2779D0C0DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_F527DBF600BE4AAB0A02EE2779D0C0DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_F527DBF600BE4AAB0A02EE2779D0C0DD" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_F527DBF600BE4AAB0A02EE2779D0C0DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A4E320B16F5A5881C40FEE2779D04F62_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A4E320B16F5A5881C40FEE2779D04F62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrant exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A4E320B16F5A5881C40FEE2779D04F62_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A4E320B16F5A5881C40FEE2779D04F62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A4E320B16F5A5881C40FEE2779D04F62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A4E320B16F5A5881C40FEE2779D04F62" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A4E320B16F5A5881C40FEE2779D04F62" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_AACA6470E60A1726B0EADED0E463CE2B_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_AACA6470E60A1726B0EADED0E463CE2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_AACA6470E60A1726B0EADED0E463CE2B_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_AACA6470E60A1726B0EADED0E463CE2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_AACA6470E60A1726B0EADED0E463CE2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_AACA6470E60A1726B0EADED0E463CE2B" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_AACA6470E60A1726B0EADED0E463CE2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_28B453B992872B6EFDA2DED0E4CC39AD_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_28B453B992872B6EFDA2DED0E4CC39AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_28B453B992872B6EFDA2DED0E4CC39AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_28B453B992872B6EFDA2DED0E4CC39AD" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_28B453B992872B6EFDA2DED0E4CC39AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_05ABF16B71C397390FBFDED0E4CD5CF2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_05ABF16B71C397390FBFDED0E4CD5CF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_05ABF16B71C397390FBFDED0E4CD5CF2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_05ABF16B71C397390FBFDED0E4CD5CF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_05ABF16B71C397390FBFDED0E4CD5CF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_05ABF16B71C397390FBFDED0E4CD5CF2" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_05ABF16B71C397390FBFDED0E4CD5CF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_A5A831807B8EB1E88707DED0E4CD1FC8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_A5A831807B8EB1E88707DED0E4CD1FC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_A5A831807B8EB1E88707DED0E4CD1FC8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_A5A831807B8EB1E88707DED0E4CD1FC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_A5A831807B8EB1E88707DED0E4CD1FC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_A5A831807B8EB1E88707DED0E4CD1FC8" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_A5A831807B8EB1E88707DED0E4CD1FC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4EED51EB4B46B23EF7FFDED0E4CDD727_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4EED51EB4B46B23EF7FFDED0E4CDD727" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4EED51EB4B46B23EF7FFDED0E4CDD727_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4EED51EB4B46B23EF7FFDED0E4CDD727" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4EED51EB4B46B23EF7FFDED0E4CDD727" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4EED51EB4B46B23EF7FFDED0E4CDD727" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4EED51EB4B46B23EF7FFDED0E4CDD727" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_619B38B5A87379062681DED0E3127926_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_619B38B5A87379062681DED0E3127926" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_619B38B5A87379062681DED0E3127926" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_619B38B5A87379062681DED0E3127926" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_619B38B5A87379062681DED0E3127926" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C1F933D2CDF9784CC21DDED0E312021F_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C1F933D2CDF9784CC21DDED0E312021F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C1F933D2CDF9784CC21DDED0E312021F_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C1F933D2CDF9784CC21DDED0E312021F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C1F933D2CDF9784CC21DDED0E312021F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C1F933D2CDF9784CC21DDED0E312021F" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C1F933D2CDF9784CC21DDED0E312021F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73C57EAC3BE9FCC4C5443A5961300C44_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73C57EAC3BE9FCC4C5443A5961300C44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73C57EAC3BE9FCC4C5443A5961300C44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73C57EAC3BE9FCC4C5443A5961300C44" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73C57EAC3BE9FCC4C5443A5961300C44" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTable_0ED8F02B087A85DAB2F73A5963C29876_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_0ED8F02B087A85DAB2F73A5963C29876" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_0ED8F02B087A85DAB2F73A5963C29876_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_0ED8F02B087A85DAB2F73A5963C29876" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_0ED8F02B087A85DAB2F73A5963C29876" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable_0ED8F02B087A85DAB2F73A5963C29876" xlink:to="lab_us-gaap_ConcentrationRiskTable_0ED8F02B087A85DAB2F73A5963C29876" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_A67D82C541408E9108123A59CC8B6303_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_A67D82C541408E9108123A59CC8B6303" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_A67D82C541408E9108123A59CC8B6303_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_A67D82C541408E9108123A59CC8B6303" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_A67D82C541408E9108123A59CC8B6303" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_A67D82C541408E9108123A59CC8B6303" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_A67D82C541408E9108123A59CC8B6303" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_2DA05ADE5B312AA619613A5B035EA1F3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_2DA05ADE5B312AA619613A5B035EA1F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_2DA05ADE5B312AA619613A5B035EA1F3_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_2DA05ADE5B312AA619613A5B035EA1F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2DA05ADE5B312AA619613A5B035EA1F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2DA05ADE5B312AA619613A5B035EA1F3" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_2DA05ADE5B312AA619613A5B035EA1F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_459563E6AFC1BD9B61653A59ECCF8722_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_459563E6AFC1BD9B61653A59ECCF8722" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_459563E6AFC1BD9B61653A59ECCF8722_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_459563E6AFC1BD9B61653A59ECCF8722" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_459563E6AFC1BD9B61653A59ECCF8722" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_459563E6AFC1BD9B61653A59ECCF8722" xlink:to="lab_us-gaap_AccountsReceivableMember_459563E6AFC1BD9B61653A59ECCF8722" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueNetMember_39DADDA3E35C9CF2F7AB3A5ACD01CC6E_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember_39DADDA3E35C9CF2F7AB3A5ACD01CC6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Revenue, Net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_39DADDA3E35C9CF2F7AB3A5ACD01CC6E_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember_39DADDA3E35C9CF2F7AB3A5ACD01CC6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Net [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_39DADDA3E35C9CF2F7AB3A5ACD01CC6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember_39DADDA3E35C9CF2F7AB3A5ACD01CC6E" xlink:to="lab_us-gaap_SalesRevenueNetMember_39DADDA3E35C9CF2F7AB3A5ACD01CC6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_50F9AE28564AA1538B063A5963C22379_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_50F9AE28564AA1538B063A5963C22379" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_50F9AE28564AA1538B063A5963C22379_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_50F9AE28564AA1538B063A5963C22379" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_50F9AE28564AA1538B063A5963C22379" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_50F9AE28564AA1538B063A5963C22379" xlink:to="lab_us-gaap_ConcentrationRiskLineItems_50F9AE28564AA1538B063A5963C22379" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_3C535A2567C70236B7843A5977C3365D_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_3C535A2567C70236B7843A5977C3365D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_3C535A2567C70236B7843A5977C3365D_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_3C535A2567C70236B7843A5977C3365D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_3C535A2567C70236B7843A5977C3365D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_3C535A2567C70236B7843A5977C3365D" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_3C535A2567C70236B7843A5977C3365D" xlink:type="arc" />
    <link:label id="lab_optn_ConcentrationRiskNumberofClients_40D2E4430D14C4C8B0873A5C1C6675B5_terseLabel_en-US" xlink:label="lab_optn_ConcentrationRiskNumberofClients_40D2E4430D14C4C8B0873A5C1C6675B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk, number of clients</link:label>
    <link:label id="lab_optn_ConcentrationRiskNumberofClients_40D2E4430D14C4C8B0873A5C1C6675B5_label_en-US" xlink:label="lab_optn_ConcentrationRiskNumberofClients_40D2E4430D14C4C8B0873A5C1C6675B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Number of Clients</link:label>
    <link:label id="lab_optn_ConcentrationRiskNumberofClients_40D2E4430D14C4C8B0873A5C1C6675B5_documentation_en-US" xlink:label="lab_optn_ConcentrationRiskNumberofClients_40D2E4430D14C4C8B0873A5C1C6675B5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration Risk, Number of Clients</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_ConcentrationRiskNumberofClients" xlink:label="loc_optn_ConcentrationRiskNumberofClients_40D2E4430D14C4C8B0873A5C1C6675B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_ConcentrationRiskNumberofClients_40D2E4430D14C4C8B0873A5C1C6675B5" xlink:to="lab_optn_ConcentrationRiskNumberofClients_40D2E4430D14C4C8B0873A5C1C6675B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_AF911E9C02E4C37CE54ADED0E4801A39_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_AF911E9C02E4C37CE54ADED0E4801A39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_AF911E9C02E4C37CE54ADED0E4801A39_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_AF911E9C02E4C37CE54ADED0E4801A39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Disclosure [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_AF911E9C02E4C37CE54ADED0E4801A39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_AF911E9C02E4C37CE54ADED0E4801A39" xlink:to="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_AF911E9C02E4C37CE54ADED0E4801A39" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8717DD30C2C9D3082ADFDED0E4C270E1_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8717DD30C2C9D3082ADFDED0E4C270E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8717DD30C2C9D3082ADFDED0E4C270E1_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8717DD30C2C9D3082ADFDED0E4C270E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8717DD30C2C9D3082ADFDED0E4C270E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8717DD30C2C9D3082ADFDED0E4C270E1" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8717DD30C2C9D3082ADFDED0E4C270E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_F7586EC8716D23092E20DED0E61021E0_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_F7586EC8716D23092E20DED0E61021E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_F7586EC8716D23092E20DED0E61021E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_F7586EC8716D23092E20DED0E61021E0" xlink:to="lab_us-gaap_DebtDisclosureAbstract_F7586EC8716D23092E20DED0E61021E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_4980010336C74AE50881DED0E611B3C3_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_4980010336C74AE50881DED0E611B3C3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_4980010336C74AE50881DED0E611B3C3_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_4980010336C74AE50881DED0E611B3C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_4980010336C74AE50881DED0E611B3C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_4980010336C74AE50881DED0E611B3C3" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_4980010336C74AE50881DED0E611B3C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_6333ABC4A03C9A1A2CE549EC15AB3F71_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_6333ABC4A03C9A1A2CE549EC15AB3F71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock split conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_6333ABC4A03C9A1A2CE549EC15AB3F71_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_6333ABC4A03C9A1A2CE549EC15AB3F71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_6333ABC4A03C9A1A2CE549EC15AB3F71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_6333ABC4A03C9A1A2CE549EC15AB3F71" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_6333ABC4A03C9A1A2CE549EC15AB3F71" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashUninsuredAmount_193877AD714780ACB9C649EC15AB36D7_terseLabel_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount_193877AD714780ACB9C649EC15AB36D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, uninsured amount</link:label>
    <link:label id="lab_us-gaap_CashUninsuredAmount_193877AD714780ACB9C649EC15AB36D7_label_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount_193877AD714780ACB9C649EC15AB36D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Uninsured Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaap_CashUninsuredAmount_193877AD714780ACB9C649EC15AB36D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashUninsuredAmount_193877AD714780ACB9C649EC15AB36D7" xlink:to="lab_us-gaap_CashUninsuredAmount_193877AD714780ACB9C649EC15AB36D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6AFE410E2EE2A52F3BB449EC15AB1596_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6AFE410E2EE2A52F3BB449EC15AB1596" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on sale of equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6AFE410E2EE2A52F3BB449EC15AB1596_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6AFE410E2EE2A52F3BB449EC15AB1596" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6AFE410E2EE2A52F3BB449EC15AB1596" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6AFE410E2EE2A52F3BB449EC15AB1596" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6AFE410E2EE2A52F3BB449EC15AB1596" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdvertisingExpense_CE41B30AF0B2E3971ADA49EC15ABEFD5_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense_CE41B30AF0B2E3971ADA49EC15ABEFD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_CE41B30AF0B2E3971ADA49EC15ABEFD5_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense_CE41B30AF0B2E3971ADA49EC15ABEFD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_CE41B30AF0B2E3971ADA49EC15ABEFD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense_CE41B30AF0B2E3971ADA49EC15ABEFD5" xlink:to="lab_us-gaap_AdvertisingExpense_CE41B30AF0B2E3971ADA49EC15ABEFD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCash_9C25AA710C2D083B89EC49EC15AB13F2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash_9C25AA710C2D083B89EC49EC15AB13F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_9C25AA710C2D083B89EC49EC15AB13F2_label_en-US" xlink:label="lab_us-gaap_RestrictedCash_9C25AA710C2D083B89EC49EC15AB13F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_9C25AA710C2D083B89EC49EC15AB13F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash_9C25AA710C2D083B89EC49EC15AB13F2" xlink:to="lab_us-gaap_RestrictedCash_9C25AA710C2D083B89EC49EC15AB13F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_1577EC264AA30057FCDB49FAC3986A7B_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_1577EC264AA30057FCDB49FAC3986A7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_1577EC264AA30057FCDB49FAC3986A7B_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_1577EC264AA30057FCDB49FAC3986A7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1577EC264AA30057FCDB49FAC3986A7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1577EC264AA30057FCDB49FAC3986A7B" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_1577EC264AA30057FCDB49FAC3986A7B" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_B92B516A99FC4E1090AF49FAFBAE8001_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_B92B516A99FC4E1090AF49FAFBAE8001" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_B92B516A99FC4E1090AF49FAFBAE8001_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_B92B516A99FC4E1090AF49FAFBAE8001" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_B92B516A99FC4E1090AF49FAFBAE8001" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_B92B516A99FC4E1090AF49FAFBAE8001" xlink:to="lab_srt_ProductOrServiceAxis_B92B516A99FC4E1090AF49FAFBAE8001" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_D25848861728B4C0DD1649FAFBB0B9AD_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_D25848861728B4C0DD1649FAFBB0B9AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_D25848861728B4C0DD1649FAFBB0B9AD_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_D25848861728B4C0DD1649FAFBB0B9AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D25848861728B4C0DD1649FAFBB0B9AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_D25848861728B4C0DD1649FAFBB0B9AD" xlink:to="lab_srt_ProductsAndServicesDomain_D25848861728B4C0DD1649FAFBB0B9AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseMember_527CB3E899C7F2DF3A0B49FB316E77F5_verboseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember_527CB3E899C7F2DF3A0B49FB316E77F5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_527CB3E899C7F2DF3A0B49FB316E77F5_label_en-US" xlink:label="lab_us-gaap_LicenseMember_527CB3E899C7F2DF3A0B49FB316E77F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_527CB3E899C7F2DF3A0B49FB316E77F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember_527CB3E899C7F2DF3A0B49FB316E77F5" xlink:to="lab_us-gaap_LicenseMember_527CB3E899C7F2DF3A0B49FB316E77F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_509E73EA91AE291E2CC349FAC3981526_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_509E73EA91AE291E2CC349FAC3981526" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_509E73EA91AE291E2CC349FAC3981526_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_509E73EA91AE291E2CC349FAC3981526" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_509E73EA91AE291E2CC349FAC3981526" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_509E73EA91AE291E2CC349FAC3981526" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_509E73EA91AE291E2CC349FAC3981526" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2263D9EEBED494C302D049FA8191CAAE_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2263D9EEBED494C302D049FA8191CAAE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2263D9EEBED494C302D049FA8191CAAE_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2263D9EEBED494C302D049FA8191CAAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2263D9EEBED494C302D049FA8191CAAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2263D9EEBED494C302D049FA8191CAAE" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2263D9EEBED494C302D049FA8191CAAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_EC1C5EA1D3BAE52B143EE32FECE63A70_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_EC1C5EA1D3BAE52B143EE32FECE63A70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_EC1C5EA1D3BAE52B143EE32FECE63A70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_EC1C5EA1D3BAE52B143EE32FECE63A70" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_EC1C5EA1D3BAE52B143EE32FECE63A70" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_B0C25850575DA2998E7AE32FECE75146_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable_B0C25850575DA2998E7AE32FECE75146" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_B0C25850575DA2998E7AE32FECE75146_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable_B0C25850575DA2998E7AE32FECE75146" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable_B0C25850575DA2998E7AE32FECE75146" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTable_B0C25850575DA2998E7AE32FECE75146" xlink:to="lab_us-gaap_DefinedContributionPlanTable_B0C25850575DA2998E7AE32FECE75146" xlink:type="arc" />
    <link:label id="lab_optn_DefinedContributionPlanTranchesAxisAxis_EBF4E41618FDDFFAE771E32FECE76C86_terseLabel_en-US" xlink:label="lab_optn_DefinedContributionPlanTranchesAxisAxis_EBF4E41618FDDFFAE771E32FECE76C86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan Tranches Axis [Axis]</link:label>
    <link:label id="lab_optn_DefinedContributionPlanTranchesAxisAxis_EBF4E41618FDDFFAE771E32FECE76C86_label_en-US" xlink:label="lab_optn_DefinedContributionPlanTranchesAxisAxis_EBF4E41618FDDFFAE771E32FECE76C86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan Tranches Axis [Axis]</link:label>
    <link:label id="lab_optn_DefinedContributionPlanTranchesAxisAxis_EBF4E41618FDDFFAE771E32FECE76C86_documentation_en-US" xlink:label="lab_optn_DefinedContributionPlanTranchesAxisAxis_EBF4E41618FDDFFAE771E32FECE76C86" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan Tranches Axis [Axis]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_DefinedContributionPlanTranchesAxisAxis" xlink:label="loc_optn_DefinedContributionPlanTranchesAxisAxis_EBF4E41618FDDFFAE771E32FECE76C86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DefinedContributionPlanTranchesAxisAxis_EBF4E41618FDDFFAE771E32FECE76C86" xlink:to="lab_optn_DefinedContributionPlanTranchesAxisAxis_EBF4E41618FDDFFAE771E32FECE76C86" xlink:type="arc" />
    <link:label id="lab_optn_DefinedContributionPlanTranchesAxisDomain_5BDC90359213ED2CBFB0E32FECE7FD10_terseLabel_en-US" xlink:label="lab_optn_DefinedContributionPlanTranchesAxisDomain_5BDC90359213ED2CBFB0E32FECE7FD10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan Tranches Axis [Domain]</link:label>
    <link:label id="lab_optn_DefinedContributionPlanTranchesAxisDomain_5BDC90359213ED2CBFB0E32FECE7FD10_label_en-US" xlink:label="lab_optn_DefinedContributionPlanTranchesAxisDomain_5BDC90359213ED2CBFB0E32FECE7FD10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan Tranches Axis [Domain]</link:label>
    <link:label id="lab_optn_DefinedContributionPlanTranchesAxisDomain_5BDC90359213ED2CBFB0E32FECE7FD10_documentation_en-US" xlink:label="lab_optn_DefinedContributionPlanTranchesAxisDomain_5BDC90359213ED2CBFB0E32FECE7FD10" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Defined Contribution Plan Tranches Axis [Axis]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_DefinedContributionPlanTranchesAxisDomain" xlink:label="loc_optn_DefinedContributionPlanTranchesAxisDomain_5BDC90359213ED2CBFB0E32FECE7FD10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DefinedContributionPlanTranchesAxisDomain_5BDC90359213ED2CBFB0E32FECE7FD10" xlink:to="lab_optn_DefinedContributionPlanTranchesAxisDomain_5BDC90359213ED2CBFB0E32FECE7FD10" xlink:type="arc" />
    <link:label id="lab_optn_DefinedContributionPlanTrancheOneMember_084221B77E2EA2EECD9EE32FECE763B4_terseLabel_en-US" xlink:label="lab_optn_DefinedContributionPlanTrancheOneMember_084221B77E2EA2EECD9EE32FECE763B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Tranche One</link:label>
    <link:label id="lab_optn_DefinedContributionPlanTrancheOneMember_084221B77E2EA2EECD9EE32FECE763B4_label_en-US" xlink:label="lab_optn_DefinedContributionPlanTrancheOneMember_084221B77E2EA2EECD9EE32FECE763B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Tranche One [Member]</link:label>
    <link:label id="lab_optn_DefinedContributionPlanTrancheOneMember_084221B77E2EA2EECD9EE32FECE763B4_documentation_en-US" xlink:label="lab_optn_DefinedContributionPlanTrancheOneMember_084221B77E2EA2EECD9EE32FECE763B4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Tranche One [Member]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_DefinedContributionPlanTrancheOneMember" xlink:label="loc_optn_DefinedContributionPlanTrancheOneMember_084221B77E2EA2EECD9EE32FECE763B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DefinedContributionPlanTrancheOneMember_084221B77E2EA2EECD9EE32FECE763B4" xlink:to="lab_optn_DefinedContributionPlanTrancheOneMember_084221B77E2EA2EECD9EE32FECE763B4" xlink:type="arc" />
    <link:label id="lab_optn_DefinedContributionPlanTrancheTwoMember_F37D82FEB14C56712AEEE32FECE89D83_terseLabel_en-US" xlink:label="lab_optn_DefinedContributionPlanTrancheTwoMember_F37D82FEB14C56712AEEE32FECE89D83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Tranche Two</link:label>
    <link:label id="lab_optn_DefinedContributionPlanTrancheTwoMember_F37D82FEB14C56712AEEE32FECE89D83_label_en-US" xlink:label="lab_optn_DefinedContributionPlanTrancheTwoMember_F37D82FEB14C56712AEEE32FECE89D83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Tranche Two [Member]</link:label>
    <link:label id="lab_optn_DefinedContributionPlanTrancheTwoMember_F37D82FEB14C56712AEEE32FECE89D83_documentation_en-US" xlink:label="lab_optn_DefinedContributionPlanTrancheTwoMember_F37D82FEB14C56712AEEE32FECE89D83" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Tranche Two [Member]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_DefinedContributionPlanTrancheTwoMember" xlink:label="loc_optn_DefinedContributionPlanTrancheTwoMember_F37D82FEB14C56712AEEE32FECE89D83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DefinedContributionPlanTrancheTwoMember_F37D82FEB14C56712AEEE32FECE89D83" xlink:to="lab_optn_DefinedContributionPlanTrancheTwoMember_F37D82FEB14C56712AEEE32FECE89D83" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_4A148FFB18F2719DE762E32FECE896D9_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis_4A148FFB18F2719DE762E32FECE896D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_4A148FFB18F2719DE762E32FECE896D9_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis_4A148FFB18F2719DE762E32FECE896D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_4A148FFB18F2719DE762E32FECE896D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_4A148FFB18F2719DE762E32FECE896D9" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis_4A148FFB18F2719DE762E32FECE896D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_A5694646F464AC290D7BE32FECE8CD9B_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain_A5694646F464AC290D7BE32FECE8CD9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_A5694646F464AC290D7BE32FECE8CD9B_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain_A5694646F464AC290D7BE32FECE8CD9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_A5694646F464AC290D7BE32FECE8CD9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_A5694646F464AC290D7BE32FECE8CD9B" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain_A5694646F464AC290D7BE32FECE8CD9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignPlanMember_D1548A5BDE59C85499E9E32FECE91493_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember_D1548A5BDE59C85499E9E32FECE91493" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Plan</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_D1548A5BDE59C85499E9E32FECE91493_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember_D1548A5BDE59C85499E9E32FECE91493" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_D1548A5BDE59C85499E9E32FECE91493" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember_D1548A5BDE59C85499E9E32FECE91493" xlink:to="lab_us-gaap_ForeignPlanMember_D1548A5BDE59C85499E9E32FECE91493" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_35551AFD9A0F444F8097E32FECE95EE8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_35551AFD9A0F444F8097E32FECE95EE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_35551AFD9A0F444F8097E32FECE95EE8_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_35551AFD9A0F444F8097E32FECE95EE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_35551AFD9A0F444F8097E32FECE95EE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_35551AFD9A0F444F8097E32FECE95EE8" xlink:to="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_35551AFD9A0F444F8097E32FECE95EE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_EB9BBB25970D7B89A357E32FECE96BB7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_EB9BBB25970D7B89A357E32FECE96BB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum annual contributions per employee</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_EB9BBB25970D7B89A357E32FECE96BB7_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_EB9BBB25970D7B89A357E32FECE96BB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_EB9BBB25970D7B89A357E32FECE96BB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_EB9BBB25970D7B89A357E32FECE96BB7" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_EB9BBB25970D7B89A357E32FECE96BB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_AD3E7BBF0DABA3C80246E32FECE9C271_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_AD3E7BBF0DABA3C80246E32FECE9C271" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employer matching contribution</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_AD3E7BBF0DABA3C80246E32FECE9C271_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_AD3E7BBF0DABA3C80246E32FECE9C271" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_AD3E7BBF0DABA3C80246E32FECE9C271" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_AD3E7BBF0DABA3C80246E32FECE9C271" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_AD3E7BBF0DABA3C80246E32FECE9C271" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_FB44C0E4E86903858388E32FECEA9FC9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_FB44C0E4E86903858388E32FECEA9FC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined contribution plan, cost</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_FB44C0E4E86903858388E32FECEA9FC9_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_FB44C0E4E86903858388E32FECEA9FC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_FB44C0E4E86903858388E32FECEA9FC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized_FB44C0E4E86903858388E32FECEA9FC9" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized_FB44C0E4E86903858388E32FECEA9FC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_EA769D5C535A1B2F47DF3A562348AFE3_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_EA769D5C535A1B2F47DF3A562348AFE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_EA769D5C535A1B2F47DF3A562348AFE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_EA769D5C535A1B2F47DF3A562348AFE3" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_EA769D5C535A1B2F47DF3A562348AFE3" xlink:type="arc" />
    <link:label id="lab_optn_AccruedSalesOrganizationExpensesCurrent_4ABA373BAA220A642AE43A61356F72B3_terseLabel_en-US" xlink:label="lab_optn_AccruedSalesOrganizationExpensesCurrent_4ABA373BAA220A642AE43A61356F72B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract sales organization expenses</link:label>
    <link:label id="lab_optn_AccruedSalesOrganizationExpensesCurrent_4ABA373BAA220A642AE43A61356F72B3_label_en-US" xlink:label="lab_optn_AccruedSalesOrganizationExpensesCurrent_4ABA373BAA220A642AE43A61356F72B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Sales Organization Expenses, Current</link:label>
    <link:label id="lab_optn_AccruedSalesOrganizationExpensesCurrent_4ABA373BAA220A642AE43A61356F72B3_documentation_en-US" xlink:label="lab_optn_AccruedSalesOrganizationExpensesCurrent_4ABA373BAA220A642AE43A61356F72B3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Sales Organization Expenses, Current</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_AccruedSalesOrganizationExpensesCurrent" xlink:label="loc_optn_AccruedSalesOrganizationExpensesCurrent_4ABA373BAA220A642AE43A61356F72B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_AccruedSalesOrganizationExpensesCurrent_4ABA373BAA220A642AE43A61356F72B3" xlink:to="lab_optn_AccruedSalesOrganizationExpensesCurrent_4ABA373BAA220A642AE43A61356F72B3" xlink:type="arc" />
    <link:label id="lab_optn_AccruedSellingGeneralandAdministrativeCurrent_CEB32936B7CA1801F95A3A562348D49C_terseLabel_en-US" xlink:label="lab_optn_AccruedSellingGeneralandAdministrativeCurrent_CEB32936B7CA1801F95A3A562348D49C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_optn_AccruedSellingGeneralandAdministrativeCurrent_CEB32936B7CA1801F95A3A562348D49C_label_en-US" xlink:label="lab_optn_AccruedSellingGeneralandAdministrativeCurrent_CEB32936B7CA1801F95A3A562348D49C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Selling, General and Administrative, Current</link:label>
    <link:label id="lab_optn_AccruedSellingGeneralandAdministrativeCurrent_CEB32936B7CA1801F95A3A562348D49C_documentation_en-US" xlink:label="lab_optn_AccruedSellingGeneralandAdministrativeCurrent_CEB32936B7CA1801F95A3A562348D49C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Selling, General and Administrative, Current</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_AccruedSellingGeneralandAdministrativeCurrent" xlink:label="loc_optn_AccruedSellingGeneralandAdministrativeCurrent_CEB32936B7CA1801F95A3A562348D49C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_AccruedSellingGeneralandAdministrativeCurrent_CEB32936B7CA1801F95A3A562348D49C" xlink:to="lab_optn_AccruedSellingGeneralandAdministrativeCurrent_CEB32936B7CA1801F95A3A562348D49C" xlink:type="arc" />
    <link:label id="lab_optn_AccruedResearchandDevelopmentCurrent_EE4A946C661162B7201A3A56234846E9_terseLabel_en-US" xlink:label="lab_optn_AccruedResearchandDevelopmentCurrent_EE4A946C661162B7201A3A56234846E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_optn_AccruedResearchandDevelopmentCurrent_EE4A946C661162B7201A3A56234846E9_label_en-US" xlink:label="lab_optn_AccruedResearchandDevelopmentCurrent_EE4A946C661162B7201A3A56234846E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research and Development, Current</link:label>
    <link:label id="lab_optn_AccruedResearchandDevelopmentCurrent_EE4A946C661162B7201A3A56234846E9_documentation_en-US" xlink:label="lab_optn_AccruedResearchandDevelopmentCurrent_EE4A946C661162B7201A3A56234846E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Research and Development, Current</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_AccruedResearchandDevelopmentCurrent" xlink:label="loc_optn_AccruedResearchandDevelopmentCurrent_EE4A946C661162B7201A3A56234846E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_AccruedResearchandDevelopmentCurrent_EE4A946C661162B7201A3A56234846E9" xlink:to="lab_optn_AccruedResearchandDevelopmentCurrent_EE4A946C661162B7201A3A56234846E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_5DFE4564918B093356183A562348C429_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent_5DFE4564918B093356183A562348C429" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bonus expense</link:label>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_5DFE4564918B093356183A562348C429_label_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent_5DFE4564918B093356183A562348C429" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Bonuses, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent_5DFE4564918B093356183A562348C429" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrent_5DFE4564918B093356183A562348C429" xlink:to="lab_us-gaap_AccruedBonusesCurrent_5DFE4564918B093356183A562348C429" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_FF06CEA79771AAAA22D53A56234823F9_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent_FF06CEA79771AAAA22D53A56234823F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payroll and benefit expenses</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_FF06CEA79771AAAA22D53A56234823F9_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent_FF06CEA79771AAAA22D53A56234823F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_FF06CEA79771AAAA22D53A56234823F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent_FF06CEA79771AAAA22D53A56234823F9" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent_FF06CEA79771AAAA22D53A56234823F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_799A4A068357F7A141373A5623485C84_terseLabel_en-US" xlink:label="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_799A4A068357F7A141373A5623485C84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee contributions withheld</link:label>
    <link:label id="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_799A4A068357F7A141373A5623485C84_label_en-US" xlink:label="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_799A4A068357F7A141373A5623485C84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Employee-related Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_799A4A068357F7A141373A5623485C84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_799A4A068357F7A141373A5623485C84" xlink:to="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_799A4A068357F7A141373A5623485C84" xlink:type="arc" />
    <link:label id="lab_optn_AccruedProductAllowancesCurrent_4C4D2482CDB9BEFB9D353A5623486D11_terseLabel_en-US" xlink:label="lab_optn_AccruedProductAllowancesCurrent_4C4D2482CDB9BEFB9D353A5623486D11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenue allowances</link:label>
    <link:label id="lab_optn_AccruedProductAllowancesCurrent_4C4D2482CDB9BEFB9D353A5623486D11_label_en-US" xlink:label="lab_optn_AccruedProductAllowancesCurrent_4C4D2482CDB9BEFB9D353A5623486D11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Product Allowances, Current</link:label>
    <link:label id="lab_optn_AccruedProductAllowancesCurrent_4C4D2482CDB9BEFB9D353A5623486D11_documentation_en-US" xlink:label="lab_optn_AccruedProductAllowancesCurrent_4C4D2482CDB9BEFB9D353A5623486D11" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Product Allowances, Current</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_AccruedProductAllowancesCurrent" xlink:label="loc_optn_AccruedProductAllowancesCurrent_4C4D2482CDB9BEFB9D353A5623486D11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_AccruedProductAllowancesCurrent_4C4D2482CDB9BEFB9D353A5623486D11" xlink:to="lab_optn_AccruedProductAllowancesCurrent_4C4D2482CDB9BEFB9D353A5623486D11" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPayableCurrent_92C550B9A6828DEF29333A56234818DA_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_92C550B9A6828DEF29333A56234818DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_92C550B9A6828DEF29333A56234818DA_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_92C550B9A6828DEF29333A56234818DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_92C550B9A6828DEF29333A56234818DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent_92C550B9A6828DEF29333A56234818DA" xlink:to="lab_us-gaap_InterestPayableCurrent_92C550B9A6828DEF29333A56234818DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_B5EBC9D7BA30CC25997E3A5623485707_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_B5EBC9D7BA30CC25997E3A5623485707" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_B5EBC9D7BA30CC25997E3A5623485707_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_B5EBC9D7BA30CC25997E3A5623485707" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_B5EBC9D7BA30CC25997E3A5623485707" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_B5EBC9D7BA30CC25997E3A5623485707" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_B5EBC9D7BA30CC25997E3A5623485707" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_B9DC6DCE2D71567BA6EC3A562348F2F4_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_B9DC6DCE2D71567BA6EC3A562348F2F4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_B9DC6DCE2D71567BA6EC3A562348F2F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_B9DC6DCE2D71567BA6EC3A562348F2F4" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_B9DC6DCE2D71567BA6EC3A562348F2F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_5EC7E2F2EAC455E61966DED0E555DB70_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract_5EC7E2F2EAC455E61966DED0E555DB70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_5EC7E2F2EAC455E61966DED0E555DB70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_5EC7E2F2EAC455E61966DED0E555DB70" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract_5EC7E2F2EAC455E61966DED0E555DB70" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_1BFAD5A726C82DF45BFDDED0E55502F2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_1BFAD5A726C82DF45BFDDED0E55502F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AVP-825 License Agreement</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_1BFAD5A726C82DF45BFDDED0E55502F2_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_1BFAD5A726C82DF45BFDDED0E55502F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_1BFAD5A726C82DF45BFDDED0E55502F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_1BFAD5A726C82DF45BFDDED0E55502F2" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_1BFAD5A726C82DF45BFDDED0E55502F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_42F01E582F49B475CA59E2E97313C256_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_42F01E582F49B475CA59E2E97313C256" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_42F01E582F49B475CA59E2E97313C256" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_42F01E582F49B475CA59E2E97313C256" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_42F01E582F49B475CA59E2E97313C256" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterials_6E2907E74A8B192D9446E2EB278E0EB5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials_6E2907E74A8B192D9446E2EB278E0EB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_6E2907E74A8B192D9446E2EB278E0EB5_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials_6E2907E74A8B192D9446E2EB278E0EB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_6E2907E74A8B192D9446E2EB278E0EB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials_6E2907E74A8B192D9446E2EB278E0EB5" xlink:to="lab_us-gaap_InventoryRawMaterials_6E2907E74A8B192D9446E2EB278E0EB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcess_6C60FD318B845C7FDA2EE2EB27971C35_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_6C60FD318B845C7FDA2EE2EB27971C35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_6C60FD318B845C7FDA2EE2EB27971C35_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_6C60FD318B845C7FDA2EE2EB27971C35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_6C60FD318B845C7FDA2EE2EB27971C35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess_6C60FD318B845C7FDA2EE2EB27971C35" xlink:to="lab_us-gaap_InventoryWorkInProcess_6C60FD318B845C7FDA2EE2EB27971C35" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoods_5C3E83E04DC038DA4CB9E2EB27AC170A_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_5C3E83E04DC038DA4CB9E2EB27AC170A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_5C3E83E04DC038DA4CB9E2EB27AC170A_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_5C3E83E04DC038DA4CB9E2EB27AC170A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_5C3E83E04DC038DA4CB9E2EB27AC170A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods_5C3E83E04DC038DA4CB9E2EB27AC170A" xlink:to="lab_us-gaap_InventoryFinishedGoods_5C3E83E04DC038DA4CB9E2EB27AC170A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryGross_193A20968806E6D4113DE2EB27BA6551_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross_193A20968806E6D4113DE2EB27BA6551" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryGross_193A20968806E6D4113DE2EB27BA6551_label_en-US" xlink:label="lab_us-gaap_InventoryGross_193A20968806E6D4113DE2EB27BA6551" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_193A20968806E6D4113DE2EB27BA6551" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross_193A20968806E6D4113DE2EB27BA6551" xlink:to="lab_us-gaap_InventoryGross_193A20968806E6D4113DE2EB27BA6551" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0A4B181B45119DE1334A49EC15AB13B7_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0A4B181B45119DE1334A49EC15AB13B7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0A4B181B45119DE1334A49EC15AB13B7_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0A4B181B45119DE1334A49EC15AB13B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_0A4B181B45119DE1334A49EC15AB13B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_0A4B181B45119DE1334A49EC15AB13B7" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0A4B181B45119DE1334A49EC15AB13B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_01761B868992AF4711EB49EC15AB8020_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_01761B868992AF4711EB49EC15AB8020" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of antidilutive shares excluded from earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_01761B868992AF4711EB49EC15AB8020_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_01761B868992AF4711EB49EC15AB8020" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_01761B868992AF4711EB49EC15AB8020" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_01761B868992AF4711EB49EC15AB8020" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_01761B868992AF4711EB49EC15AB8020" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_301D1A5B10F30CAD9165E2E984E05C85_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_301D1A5B10F30CAD9165E2E984E05C85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_301D1A5B10F30CAD9165E2E984E05C85_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_301D1A5B10F30CAD9165E2E984E05C85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_301D1A5B10F30CAD9165E2E984E05C85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_301D1A5B10F30CAD9165E2E984E05C85" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_301D1A5B10F30CAD9165E2E984E05C85" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0B89AED08451107A1FED49F6CE7FCE92_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0B89AED08451107A1FED49F6CE7FCE92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0B89AED08451107A1FED49F6CE7FCE92_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0B89AED08451107A1FED49F6CE7FCE92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0B89AED08451107A1FED49F6CE7FCE92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0B89AED08451107A1FED49F6CE7FCE92" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0B89AED08451107A1FED49F6CE7FCE92" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_68932D5E3C353E3310BF49EC15BA45A9_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_68932D5E3C353E3310BF49EC15BA45A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_68932D5E3C353E3310BF49EC15BA45A9_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_68932D5E3C353E3310BF49EC15BA45A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_68932D5E3C353E3310BF49EC15BA45A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_68932D5E3C353E3310BF49EC15BA45A9" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_68932D5E3C353E3310BF49EC15BA45A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_E2EED529F84C0BDF296049EC15BAF382_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_E2EED529F84C0BDF296049EC15BAF382" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_E2EED529F84C0BDF296049EC15BAF382_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_E2EED529F84C0BDF296049EC15BAF382" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_E2EED529F84C0BDF296049EC15BAF382" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_E2EED529F84C0BDF296049EC15BAF382" xlink:to="lab_us-gaap_UseOfEstimates_E2EED529F84C0BDF296049EC15BAF382" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_F843AF1F94015A291E4049EC15BA8E2C_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_F843AF1F94015A291E4049EC15BA8E2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of credit risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_F843AF1F94015A291E4049EC15BA8E2C_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_F843AF1F94015A291E4049EC15BA8E2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_F843AF1F94015A291E4049EC15BA8E2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_F843AF1F94015A291E4049EC15BA8E2C" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_F843AF1F94015A291E4049EC15BA8E2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3625DCD49E1DE018A26049EC15BA5C3C_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3625DCD49E1DE018A26049EC15BA5C3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3625DCD49E1DE018A26049EC15BA5C3C_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3625DCD49E1DE018A26049EC15BA5C3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3625DCD49E1DE018A26049EC15BA5C3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3625DCD49E1DE018A26049EC15BA5C3C" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3625DCD49E1DE018A26049EC15BA5C3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_3699E45783239570E74B49EC15BA07E9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_3699E45783239570E74B49EC15BA07E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of financial instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_3699E45783239570E74B49EC15BA07E9_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_3699E45783239570E74B49EC15BA07E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3699E45783239570E74B49EC15BA07E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3699E45783239570E74B49EC15BA07E9" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_3699E45783239570E74B49EC15BA07E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_C02EF176131CA33D5C1049F85BC011BF_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_C02EF176131CA33D5C1049F85BC011BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_C02EF176131CA33D5C1049F85BC011BF_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_C02EF176131CA33D5C1049F85BC011BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and Other Accounts Receivable, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_C02EF176131CA33D5C1049F85BC011BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_C02EF176131CA33D5C1049F85BC011BF" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_C02EF176131CA33D5C1049F85BC011BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_FF503274E2D69D01DDBF49EC15BA0BD0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_FF503274E2D69D01DDBF49EC15BA0BD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_FF503274E2D69D01DDBF49EC15BA0BD0_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_FF503274E2D69D01DDBF49EC15BA0BD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_FF503274E2D69D01DDBF49EC15BA0BD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_FF503274E2D69D01DDBF49EC15BA0BD0" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_FF503274E2D69D01DDBF49EC15BA0BD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6EA46F82D729F57BA76D49EC15BA4EB7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6EA46F82D729F57BA76D49EC15BA4EB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6EA46F82D729F57BA76D49EC15BA4EB7_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6EA46F82D729F57BA76D49EC15BA4EB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6EA46F82D729F57BA76D49EC15BA4EB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6EA46F82D729F57BA76D49EC15BA4EB7" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6EA46F82D729F57BA76D49EC15BA4EB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1F134D0B93B49495A0DE49EC15BAE05C_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1F134D0B93B49495A0DE49EC15BAE05C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1F134D0B93B49495A0DE49EC15BAE05C_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1F134D0B93B49495A0DE49EC15BAE05C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1F134D0B93B49495A0DE49EC15BAE05C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1F134D0B93B49495A0DE49EC15BAE05C" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1F134D0B93B49495A0DE49EC15BAE05C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0DF75CAC48FCE8A7326B49EC15BA10AE_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0DF75CAC48FCE8A7326B49EC15BA10AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0DF75CAC48FCE8A7326B49EC15BA10AE_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0DF75CAC48FCE8A7326B49EC15BA10AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0DF75CAC48FCE8A7326B49EC15BA10AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0DF75CAC48FCE8A7326B49EC15BA10AE" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0DF75CAC48FCE8A7326B49EC15BA10AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_EB55BF458F87A32B67E549EC15BAA517_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock_EB55BF458F87A32B67E549EC15BAA517" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising expenses</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_EB55BF458F87A32B67E549EC15BAA517_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock_EB55BF458F87A32B67E549EC15BAA517" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_EB55BF458F87A32B67E549EC15BAA517" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock_EB55BF458F87A32B67E549EC15BAA517" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock_EB55BF458F87A32B67E549EC15BAA517" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_6A3B6DE6881F1E85C77849EC15BA9279_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_6A3B6DE6881F1E85C77849EC15BA9279" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_6A3B6DE6881F1E85C77849EC15BA9279_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_6A3B6DE6881F1E85C77849EC15BA9279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_6A3B6DE6881F1E85C77849EC15BA9279" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_6A3B6DE6881F1E85C77849EC15BA9279" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_6A3B6DE6881F1E85C77849EC15BA9279" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_12D3DC12FAB3224DACD549EC15BAB2C7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_12D3DC12FAB3224DACD549EC15BAB2C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_12D3DC12FAB3224DACD549EC15BAB2C7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_12D3DC12FAB3224DACD549EC15BAB2C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_12D3DC12FAB3224DACD549EC15BAB2C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_12D3DC12FAB3224DACD549EC15BAB2C7" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_12D3DC12FAB3224DACD549EC15BAB2C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_3510B581FC2AF9565D8C49EC15BAC54B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_3510B581FC2AF9565D8C49EC15BAC54B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_3510B581FC2AF9565D8C49EC15BAC54B_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_3510B581FC2AF9565D8C49EC15BAC54B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_3510B581FC2AF9565D8C49EC15BAC54B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_3510B581FC2AF9565D8C49EC15BAC54B" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_3510B581FC2AF9565D8C49EC15BAC54B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_DC7E9623F7CA9AB3EBC549EC15BA7F1D_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_DC7E9623F7CA9AB3EBC549EC15BA7F1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per common share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_DC7E9623F7CA9AB3EBC549EC15BA7F1D_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_DC7E9623F7CA9AB3EBC549EC15BA7F1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_DC7E9623F7CA9AB3EBC549EC15BA7F1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_DC7E9623F7CA9AB3EBC549EC15BA7F1D" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_DC7E9623F7CA9AB3EBC549EC15BA7F1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_426FF730253B655D6B4549EC15BA6E3C_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_426FF730253B655D6B4549EC15BA6E3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_426FF730253B655D6B4549EC15BA6E3C_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_426FF730253B655D6B4549EC15BA6E3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_426FF730253B655D6B4549EC15BA6E3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_426FF730253B655D6B4549EC15BA6E3C" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_426FF730253B655D6B4549EC15BA6E3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_168254F27DD5F108CF4749EC157C0DDE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_168254F27DD5F108CF4749EC157C0DDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_168254F27DD5F108CF4749EC157C0DDE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_168254F27DD5F108CF4749EC157C0DDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_168254F27DD5F108CF4749EC157C0DDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_168254F27DD5F108CF4749EC157C0DDE" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_168254F27DD5F108CF4749EC157C0DDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4F4E37DE4D8BDA09793249EC157C263D_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4F4E37DE4D8BDA09793249EC157C263D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4F4E37DE4D8BDA09793249EC157C263D_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4F4E37DE4D8BDA09793249EC157C263D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4F4E37DE4D8BDA09793249EC157C263D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4F4E37DE4D8BDA09793249EC157C263D" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4F4E37DE4D8BDA09793249EC157C263D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3AE9A6DA41343A852E8949EC157C9D85_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3AE9A6DA41343A852E8949EC157C9D85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3AE9A6DA41343A852E8949EC157C9D85_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3AE9A6DA41343A852E8949EC157C9D85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3AE9A6DA41343A852E8949EC157C9D85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3AE9A6DA41343A852E8949EC157C9D85" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3AE9A6DA41343A852E8949EC157C9D85" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_BFFBE80176A7DD925D1249EC157C2FF2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_BFFBE80176A7DD925D1249EC157C2FF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_BFFBE80176A7DD925D1249EC157C2FF2_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_BFFBE80176A7DD925D1249EC157C2FF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_BFFBE80176A7DD925D1249EC157C2FF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_BFFBE80176A7DD925D1249EC157C2FF2" xlink:to="lab_us-gaap_EmployeeStockOptionMember_BFFBE80176A7DD925D1249EC157C2FF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_181C376E4D25E88FFAF149EC157CB902_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_181C376E4D25E88FFAF149EC157CB902" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_181C376E4D25E88FFAF149EC157CB902_label_en-US" xlink:label="lab_us-gaap_WarrantMember_181C376E4D25E88FFAF149EC157CB902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_181C376E4D25E88FFAF149EC157CB902" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_181C376E4D25E88FFAF149EC157CB902" xlink:to="lab_us-gaap_WarrantMember_181C376E4D25E88FFAF149EC157CB902" xlink:type="arc" />
    <link:label id="lab_optn_EmployeeStockPurchasePlanMember_D3D96737AD2726E30E4349EC157C38E4_terseLabel_en-US" xlink:label="lab_optn_EmployeeStockPurchasePlanMember_D3D96737AD2726E30E4349EC157C38E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_optn_EmployeeStockPurchasePlanMember_D3D96737AD2726E30E4349EC157C38E4_label_en-US" xlink:label="lab_optn_EmployeeStockPurchasePlanMember_D3D96737AD2726E30E4349EC157C38E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_optn_EmployeeStockPurchasePlanMember_D3D96737AD2726E30E4349EC157C38E4_documentation_en-US" xlink:label="lab_optn_EmployeeStockPurchasePlanMember_D3D96737AD2726E30E4349EC157C38E4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_EmployeeStockPurchasePlanMember" xlink:label="loc_optn_EmployeeStockPurchasePlanMember_D3D96737AD2726E30E4349EC157C38E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_EmployeeStockPurchasePlanMember_D3D96737AD2726E30E4349EC157C38E4" xlink:to="lab_optn_EmployeeStockPurchasePlanMember_D3D96737AD2726E30E4349EC157C38E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6E5C6FA9B5FDE5AA102449EC157C7390_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6E5C6FA9B5FDE5AA102449EC157C7390" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6E5C6FA9B5FDE5AA102449EC157C7390_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6E5C6FA9B5FDE5AA102449EC157C7390" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6E5C6FA9B5FDE5AA102449EC157C7390" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6E5C6FA9B5FDE5AA102449EC157C7390" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6E5C6FA9B5FDE5AA102449EC157C7390" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E71E9F1CBEA5603CA10849EC157C3149_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E71E9F1CBEA5603CA10849EC157C3149" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securites excluded from computation of earnings per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E71E9F1CBEA5603CA10849EC157C3149_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E71E9F1CBEA5603CA10849EC157C3149" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E71E9F1CBEA5603CA10849EC157C3149" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E71E9F1CBEA5603CA10849EC157C3149" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E71E9F1CBEA5603CA10849EC157C3149" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_7307BDA10D5D3A8DDAFA49EBE8846D42_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_7307BDA10D5D3A8DDAFA49EBE8846D42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_7307BDA10D5D3A8DDAFA49EBE8846D42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7307BDA10D5D3A8DDAFA49EBE8846D42" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_7307BDA10D5D3A8DDAFA49EBE8846D42" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_3938029DB74A51988EF549EBE88433E3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_3938029DB74A51988EF549EBE88433E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_3938029DB74A51988EF549EBE88433E3_label_en-US" xlink:label="lab_us-gaap_StatementTable_3938029DB74A51988EF549EBE88433E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3938029DB74A51988EF549EBE88433E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_3938029DB74A51988EF549EBE88433E3" xlink:to="lab_us-gaap_StatementTable_3938029DB74A51988EF549EBE88433E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_458E600641048CE895C649EBE8857D2E_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_458E600641048CE895C649EBE8857D2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_458E600641048CE895C649EBE8857D2E_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_458E600641048CE895C649EBE8857D2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_458E600641048CE895C649EBE8857D2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_458E600641048CE895C649EBE8857D2E" xlink:to="lab_us-gaap_StatementClassOfStockAxis_458E600641048CE895C649EBE8857D2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_951F111F8D4F9293DB9049EBE885C4FE_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_951F111F8D4F9293DB9049EBE885C4FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_951F111F8D4F9293DB9049EBE885C4FE_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_951F111F8D4F9293DB9049EBE885C4FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_951F111F8D4F9293DB9049EBE885C4FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_951F111F8D4F9293DB9049EBE885C4FE" xlink:to="lab_us-gaap_ClassOfStockDomain_951F111F8D4F9293DB9049EBE885C4FE" xlink:type="arc" />
    <link:label id="lab_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember_1930E1355F1E60A98EC149EBE88569E4_terseLabel_en-US" xlink:label="lab_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember_1930E1355F1E60A98EC149EBE88569E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable Convertible Preferred Stock, Series C, C1, C2, and D</link:label>
    <link:label id="lab_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember_1930E1355F1E60A98EC149EBE88569E4_label_en-US" xlink:label="lab_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember_1930E1355F1E60A98EC149EBE88569E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redeemable Convertible Preferred Stock, Series C, C1, C2, D [Member]</link:label>
    <link:label id="lab_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember_1930E1355F1E60A98EC149EBE88569E4_documentation_en-US" xlink:label="lab_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember_1930E1355F1E60A98EC149EBE88569E4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Redeemable Convertible Preferred Stock, Series C, C1, C2, D [Member]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember" xlink:label="loc_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember_1930E1355F1E60A98EC149EBE88569E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember_1930E1355F1E60A98EC149EBE88569E4" xlink:to="lab_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember_1930E1355F1E60A98EC149EBE88569E4" xlink:type="arc" />
    <link:label id="lab_optn_RedeemableConvertiblePreferredStockSeriesCC1DMember_D360F52CDA85DC60BAF449EBE8859746_terseLabel_en-US" xlink:label="lab_optn_RedeemableConvertiblePreferredStockSeriesCC1DMember_D360F52CDA85DC60BAF449EBE8859746" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable Convertible Preferred Stock, Series C, C1, D</link:label>
    <link:label id="lab_optn_RedeemableConvertiblePreferredStockSeriesCC1DMember_D360F52CDA85DC60BAF449EBE8859746_label_en-US" xlink:label="lab_optn_RedeemableConvertiblePreferredStockSeriesCC1DMember_D360F52CDA85DC60BAF449EBE8859746" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redeemable Convertible Preferred Stock, Series C, C1, D [Member]</link:label>
    <link:label id="lab_optn_RedeemableConvertiblePreferredStockSeriesCC1DMember_D360F52CDA85DC60BAF449EBE8859746_documentation_en-US" xlink:label="lab_optn_RedeemableConvertiblePreferredStockSeriesCC1DMember_D360F52CDA85DC60BAF449EBE8859746" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Redeemable Convertible Preferred Stock, Series C, C1, D [Member]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_RedeemableConvertiblePreferredStockSeriesCC1DMember" xlink:label="loc_optn_RedeemableConvertiblePreferredStockSeriesCC1DMember_D360F52CDA85DC60BAF449EBE8859746" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_RedeemableConvertiblePreferredStockSeriesCC1DMember_D360F52CDA85DC60BAF449EBE8859746" xlink:to="lab_optn_RedeemableConvertiblePreferredStockSeriesCC1DMember_D360F52CDA85DC60BAF449EBE8859746" xlink:type="arc" />
    <link:label id="lab_optn_RedeemableConvertiblePreferredStockSeriesC2Member_A0FEDA46561C0B8E184449EBE886DC89_terseLabel_en-US" xlink:label="lab_optn_RedeemableConvertiblePreferredStockSeriesC2Member_A0FEDA46561C0B8E184449EBE886DC89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable Convertible Preferred Stock, Series C2</link:label>
    <link:label id="lab_optn_RedeemableConvertiblePreferredStockSeriesC2Member_A0FEDA46561C0B8E184449EBE886DC89_label_en-US" xlink:label="lab_optn_RedeemableConvertiblePreferredStockSeriesC2Member_A0FEDA46561C0B8E184449EBE886DC89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redeemable Convertible Preferred Stock, Series C2 [Member]</link:label>
    <link:label id="lab_optn_RedeemableConvertiblePreferredStockSeriesC2Member_A0FEDA46561C0B8E184449EBE886DC89_documentation_en-US" xlink:label="lab_optn_RedeemableConvertiblePreferredStockSeriesC2Member_A0FEDA46561C0B8E184449EBE886DC89" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Redeemable Convertible Preferred Stock, Series C2 [Member]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_RedeemableConvertiblePreferredStockSeriesC2Member" xlink:label="loc_optn_RedeemableConvertiblePreferredStockSeriesC2Member_A0FEDA46561C0B8E184449EBE886DC89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_RedeemableConvertiblePreferredStockSeriesC2Member_A0FEDA46561C0B8E184449EBE886DC89" xlink:to="lab_optn_RedeemableConvertiblePreferredStockSeriesC2Member_A0FEDA46561C0B8E184449EBE886DC89" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296" xlink:to="lab_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C41EB5DC2028AF99FFD649EBE886CA65_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C41EB5DC2028AF99FFD649EBE886CA65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C41EB5DC2028AF99FFD649EBE886CA65_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C41EB5DC2028AF99FFD649EBE886CA65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C41EB5DC2028AF99FFD649EBE886CA65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C41EB5DC2028AF99FFD649EBE886CA65" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C41EB5DC2028AF99FFD649EBE886CA65" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_D42F49C14EB623F649BA49EBE88812BE_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_D42F49C14EB623F649BA49EBE88812BE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_D42F49C14EB623F649BA49EBE88812BE_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_D42F49C14EB623F649BA49EBE88812BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_D42F49C14EB623F649BA49EBE88812BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_D42F49C14EB623F649BA49EBE88812BE" xlink:to="lab_us-gaap_NetIncomeLoss_D42F49C14EB623F649BA49EBE88812BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B5DE6D288B88D23325E549EBE888F87E_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B5DE6D288B88D23325E549EBE888F87E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B5DE6D288B88D23325E549EBE888F87E_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B5DE6D288B88D23325E549EBE888F87E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B5DE6D288B88D23325E549EBE888F87E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B5DE6D288B88D23325E549EBE888F87E" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B5DE6D288B88D23325E549EBE888F87E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_E9A14022DF6FCEC041B049EBE888D056_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_E9A14022DF6FCEC041B049EBE888D056" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_E9A14022DF6FCEC041B049EBE888D056_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_E9A14022DF6FCEC041B049EBE888D056" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_E9A14022DF6FCEC041B049EBE888D056" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_E9A14022DF6FCEC041B049EBE888D056" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_E9A14022DF6FCEC041B049EBE888D056" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_12DB8353F58C84AE3B7449EBE889EA52_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_12DB8353F58C84AE3B7449EBE889EA52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_12DB8353F58C84AE3B7449EBE889EA52_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_12DB8353F58C84AE3B7449EBE889EA52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_12DB8353F58C84AE3B7449EBE889EA52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_12DB8353F58C84AE3B7449EBE889EA52" xlink:to="lab_us-gaap_ShareBasedCompensation_12DB8353F58C84AE3B7449EBE889EA52" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_E51C4C09F2B8DB11CEF549EBE8897A08_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_E51C4C09F2B8DB11CEF549EBE8897A08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_E51C4C09F2B8DB11CEF549EBE8897A08_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_E51C4C09F2B8DB11CEF549EBE8897A08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_E51C4C09F2B8DB11CEF549EBE8897A08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_E51C4C09F2B8DB11CEF549EBE8897A08" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_E51C4C09F2B8DB11CEF549EBE8897A08" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04BAA57205C6347D4FC549EBE889DB6F_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04BAA57205C6347D4FC549EBE889DB6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04BAA57205C6347D4FC549EBE889DB6F_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04BAA57205C6347D4FC549EBE889DB6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04BAA57205C6347D4FC549EBE889DB6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04BAA57205C6347D4FC549EBE889DB6F" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04BAA57205C6347D4FC549EBE889DB6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_F0BEC61FE4F59CAEA00849EBE88929D2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_F0BEC61FE4F59CAEA00849EBE88929D2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_F0BEC61FE4F59CAEA00849EBE88929D2_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_F0BEC61FE4F59CAEA00849EBE88929D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_F0BEC61FE4F59CAEA00849EBE88929D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_F0BEC61FE4F59CAEA00849EBE88929D2" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_F0BEC61FE4F59CAEA00849EBE88929D2" xlink:type="arc" />
    <link:label id="lab_optn_IncreaseDecreaseInGrantsandOtherReceivables_330B065D3D3C6956DFAC49EBE88A0645_negatedTerseLabel_en-US" xlink:label="lab_optn_IncreaseDecreaseInGrantsandOtherReceivables_330B065D3D3C6956DFAC49EBE88A0645" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Grants and other receivables</link:label>
    <link:label id="lab_optn_IncreaseDecreaseInGrantsandOtherReceivables_330B065D3D3C6956DFAC49EBE88A0645_label_en-US" xlink:label="lab_optn_IncreaseDecreaseInGrantsandOtherReceivables_330B065D3D3C6956DFAC49EBE88A0645" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Grants and Other Receivables</link:label>
    <link:label id="lab_optn_IncreaseDecreaseInGrantsandOtherReceivables_330B065D3D3C6956DFAC49EBE88A0645_documentation_en-US" xlink:label="lab_optn_IncreaseDecreaseInGrantsandOtherReceivables_330B065D3D3C6956DFAC49EBE88A0645" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Grants and Other Receivables</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_IncreaseDecreaseInGrantsandOtherReceivables" xlink:label="loc_optn_IncreaseDecreaseInGrantsandOtherReceivables_330B065D3D3C6956DFAC49EBE88A0645" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_IncreaseDecreaseInGrantsandOtherReceivables_330B065D3D3C6956DFAC49EBE88A0645" xlink:to="lab_optn_IncreaseDecreaseInGrantsandOtherReceivables_330B065D3D3C6956DFAC49EBE88A0645" xlink:type="arc" />
    <link:label id="lab_optn_IncreaseDecreaseinDepositsandOtherAssets_2F9ABFF791AB1F9FC3E349EBE88A8076_negatedTerseLabel_en-US" xlink:label="lab_optn_IncreaseDecreaseinDepositsandOtherAssets_2F9ABFF791AB1F9FC3E349EBE88A8076" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_optn_IncreaseDecreaseinDepositsandOtherAssets_2F9ABFF791AB1F9FC3E349EBE88A8076_label_en-US" xlink:label="lab_optn_IncreaseDecreaseinDepositsandOtherAssets_2F9ABFF791AB1F9FC3E349EBE88A8076" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deposits and Other Assets</link:label>
    <link:label id="lab_optn_IncreaseDecreaseinDepositsandOtherAssets_2F9ABFF791AB1F9FC3E349EBE88A8076_documentation_en-US" xlink:label="lab_optn_IncreaseDecreaseinDepositsandOtherAssets_2F9ABFF791AB1F9FC3E349EBE88A8076" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deposits and Other Assets</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_IncreaseDecreaseinDepositsandOtherAssets" xlink:label="loc_optn_IncreaseDecreaseinDepositsandOtherAssets_2F9ABFF791AB1F9FC3E349EBE88A8076" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_IncreaseDecreaseinDepositsandOtherAssets_2F9ABFF791AB1F9FC3E349EBE88A8076" xlink:to="lab_optn_IncreaseDecreaseinDepositsandOtherAssets_2F9ABFF791AB1F9FC3E349EBE88A8076" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_E0633646B44358C7289E49EBE88A3CA4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_E0633646B44358C7289E49EBE88A3CA4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_E0633646B44358C7289E49EBE88A3CA4_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_E0633646B44358C7289E49EBE88A3CA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_E0633646B44358C7289E49EBE88A3CA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_E0633646B44358C7289E49EBE88A3CA4" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_E0633646B44358C7289E49EBE88A3CA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_CA70F0590D209152F81749EBE88A5734_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_CA70F0590D209152F81749EBE88A5734" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_CA70F0590D209152F81749EBE88A5734_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_CA70F0590D209152F81749EBE88A5734" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_CA70F0590D209152F81749EBE88A5734" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_CA70F0590D209152F81749EBE88A5734" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_CA70F0590D209152F81749EBE88A5734" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_599910982139B2ABEC7349EBE88A1489_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_599910982139B2ABEC7349EBE88A1489" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_599910982139B2ABEC7349EBE88A1489_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_599910982139B2ABEC7349EBE88A1489" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_599910982139B2ABEC7349EBE88A1489" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_599910982139B2ABEC7349EBE88A1489" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_599910982139B2ABEC7349EBE88A1489" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6091196D3068291415D649EBE88A1CD4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6091196D3068291415D649EBE88A1CD4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6091196D3068291415D649EBE88A1CD4_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6091196D3068291415D649EBE88A1CD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6091196D3068291415D649EBE88A1CD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6091196D3068291415D649EBE88A1CD4" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6091196D3068291415D649EBE88A1CD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7C3DE1AD885346A325E49EBE88A4D81_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7C3DE1AD885346A325E49EBE88A4D81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7C3DE1AD885346A325E49EBE88A4D81_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7C3DE1AD885346A325E49EBE88A4D81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7C3DE1AD885346A325E49EBE88A4D81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7C3DE1AD885346A325E49EBE88A4D81" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7C3DE1AD885346A325E49EBE88A4D81" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_DCEA5234B6000742D36F49EBE88B90AC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_DCEA5234B6000742D36F49EBE88B90AC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_DCEA5234B6000742D36F49EBE88B90AC_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_DCEA5234B6000742D36F49EBE88B90AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_DCEA5234B6000742D36F49EBE88B90AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_DCEA5234B6000742D36F49EBE88B90AC" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_DCEA5234B6000742D36F49EBE88B90AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6245F955084E06EA66E349EBE88BB0DD_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6245F955084E06EA66E349EBE88BB0DD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6245F955084E06EA66E349EBE88BB0DD_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6245F955084E06EA66E349EBE88BB0DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6245F955084E06EA66E349EBE88BB0DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6245F955084E06EA66E349EBE88BB0DD" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6245F955084E06EA66E349EBE88BB0DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_0EADA54A34D9B3B7316749EBE88BBE30_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_0EADA54A34D9B3B7316749EBE88BBE30" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the sale of Series D preferred stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_0EADA54A34D9B3B7316749EBE88BBE30_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_0EADA54A34D9B3B7316749EBE88BBE30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Redeemable Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_0EADA54A34D9B3B7316749EBE88BBE30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_0EADA54A34D9B3B7316749EBE88BBE30" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_0EADA54A34D9B3B7316749EBE88BBE30" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0266380FFCE0FAA7C74449EBE88C39C8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0266380FFCE0FAA7C74449EBE88C39C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0266380FFCE0FAA7C74449EBE88C39C8_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0266380FFCE0FAA7C74449EBE88C39C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0266380FFCE0FAA7C74449EBE88C39C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0266380FFCE0FAA7C74449EBE88C39C8" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0266380FFCE0FAA7C74449EBE88C39C8" xlink:type="arc" />
    <link:label id="lab_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan_82D58AA84D186F79509F49EBE88C04A5_terseLabel_en-US" xlink:label="lab_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan_82D58AA84D186F79509F49EBE88C04A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan_82D58AA84D186F79509F49EBE88C04A5_label_en-US" xlink:label="lab_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan_82D58AA84D186F79509F49EBE88C04A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock Under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan_82D58AA84D186F79509F49EBE88C04A5_documentation_en-US" xlink:label="lab_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan_82D58AA84D186F79509F49EBE88C04A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock Under Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan" xlink:label="loc_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan_82D58AA84D186F79509F49EBE88C04A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan_82D58AA84D186F79509F49EBE88C04A5" xlink:to="lab_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan_82D58AA84D186F79509F49EBE88C04A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2F5B8245A7A99916D46E49EBE88C5345_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2F5B8245A7A99916D46E49EBE88C5345" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2F5B8245A7A99916D46E49EBE88C5345_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2F5B8245A7A99916D46E49EBE88C5345" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2F5B8245A7A99916D46E49EBE88C5345" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2F5B8245A7A99916D46E49EBE88C5345" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2F5B8245A7A99916D46E49EBE88C5345" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_CCDB6EBE1F6EE0EE28C949EBE88C1B2F_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_CCDB6EBE1F6EE0EE28C949EBE88C1B2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_CCDB6EBE1F6EE0EE28C949EBE88C1B2F_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_CCDB6EBE1F6EE0EE28C949EBE88C1B2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_CCDB6EBE1F6EE0EE28C949EBE88C1B2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_CCDB6EBE1F6EE0EE28C949EBE88C1B2F" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_CCDB6EBE1F6EE0EE28C949EBE88C1B2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B7710DC936BCA1BCA3BE49EBE88C8B0B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B7710DC936BCA1BCA3BE49EBE88C8B0B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments of withholdings on shares withheld for income taxes</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B7710DC936BCA1BCA3BE49EBE88C8B0B_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B7710DC936BCA1BCA3BE49EBE88C8B0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B7710DC936BCA1BCA3BE49EBE88C8B0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B7710DC936BCA1BCA3BE49EBE88C8B0B" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B7710DC936BCA1BCA3BE49EBE88C8B0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_8364BFCE2451817E57A149EBE88C5974_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts_8364BFCE2451817E57A149EBE88C5974" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_8364BFCE2451817E57A149EBE88C5974_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts_8364BFCE2451817E57A149EBE88C5974" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_8364BFCE2451817E57A149EBE88C5974" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts_8364BFCE2451817E57A149EBE88C5974" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts_8364BFCE2451817E57A149EBE88C5974" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_BCD55EF6A729886FCB0249EBE88D1814_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_BCD55EF6A729886FCB0249EBE88D1814" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_BCD55EF6A729886FCB0249EBE88D1814_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_BCD55EF6A729886FCB0249EBE88D1814" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_BCD55EF6A729886FCB0249EBE88D1814" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_BCD55EF6A729886FCB0249EBE88D1814" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_BCD55EF6A729886FCB0249EBE88D1814" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_972709892096A82D22D249EBE88DBA69_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_972709892096A82D22D249EBE88DBA69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effects of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_972709892096A82D22D249EBE88DBA69_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_972709892096A82D22D249EBE88DBA69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_972709892096A82D22D249EBE88DBA69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_972709892096A82D22D249EBE88DBA69" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_972709892096A82D22D249EBE88DBA69" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2E1ED88ABCA15347015649EBE88D8BCC_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2E1ED88ABCA15347015649EBE88D8BCC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2E1ED88ABCA15347015649EBE88D8BCC_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2E1ED88ABCA15347015649EBE88D8BCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2E1ED88ABCA15347015649EBE88D8BCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2E1ED88ABCA15347015649EBE88D8BCC" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2E1ED88ABCA15347015649EBE88D8BCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5283CA7C95F0E343AD0B49EBE88DD841_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5283CA7C95F0E343AD0B49EBE88DD841" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5283CA7C95F0E343AD0B49EBE88DD841_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5283CA7C95F0E343AD0B49EBE88DD841" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5283CA7C95F0E343AD0B49EBE88DD841" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5283CA7C95F0E343AD0B49EBE88DD841" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5283CA7C95F0E343AD0B49EBE88DD841" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7BD06901A5A250C1E0E049EBE88DF3CD_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7BD06901A5A250C1E0E049EBE88DF3CD" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7BD06901A5A250C1E0E049EBE88DF3CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7BD06901A5A250C1E0E049EBE88DF3CD" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7BD06901A5A250C1E0E049EBE88DF3CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_65452D1522887234A08049EBE88E84D7_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_65452D1522887234A08049EBE88E84D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of noncash financing activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_65452D1522887234A08049EBE88E84D7_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_65452D1522887234A08049EBE88E84D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_65452D1522887234A08049EBE88E84D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_65452D1522887234A08049EBE88E84D7" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_65452D1522887234A08049EBE88E84D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_207BB562F194617EB27949EBE88DDCB2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_207BB562F194617EB27949EBE88DDCB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_207BB562F194617EB27949EBE88DDCB2_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_207BB562F194617EB27949EBE88DDCB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_207BB562F194617EB27949EBE88DDCB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_207BB562F194617EB27949EBE88DDCB2" xlink:to="lab_us-gaap_InterestPaidNet_207BB562F194617EB27949EBE88DDCB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_626C2DEE1F0404F3C9D649F2541B0F5C_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_626C2DEE1F0404F3C9D649F2541B0F5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of noncash financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_626C2DEE1F0404F3C9D649F2541B0F5C_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_626C2DEE1F0404F3C9D649F2541B0F5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_626C2DEE1F0404F3C9D649F2541B0F5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_626C2DEE1F0404F3C9D649F2541B0F5C" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_626C2DEE1F0404F3C9D649F2541B0F5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_CFD9DFAD9494EEE32AC549EBE88E2A3C_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_CFD9DFAD9494EEE32AC549EBE88E2A3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_CFD9DFAD9494EEE32AC549EBE88E2A3C_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_CFD9DFAD9494EEE32AC549EBE88E2A3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Accretion to Redemption Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_CFD9DFAD9494EEE32AC549EBE88E2A3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_CFD9DFAD9494EEE32AC549EBE88E2A3C" xlink:to="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_CFD9DFAD9494EEE32AC549EBE88E2A3C" xlink:type="arc" />
    <link:label id="lab_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses_31C21F78CC59A38BB73949EBE88E4E8F_terseLabel_en-US" xlink:label="lab_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses_31C21F78CC59A38BB73949EBE88E4E8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed asset purchases within accounts payable and accrued expenses</link:label>
    <link:label id="lab_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses_31C21F78CC59A38BB73949EBE88E4E8F_label_en-US" xlink:label="lab_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses_31C21F78CC59A38BB73949EBE88E4E8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Offering Costs WIthin Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses_31C21F78CC59A38BB73949EBE88E4E8F_documentation_en-US" xlink:label="lab_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses_31C21F78CC59A38BB73949EBE88E4E8F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Offering Costs WIthin Accounts Payable and Accrued Expenses</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses" xlink:label="loc_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses_31C21F78CC59A38BB73949EBE88E4E8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses_31C21F78CC59A38BB73949EBE88E4E8F" xlink:to="lab_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses_31C21F78CC59A38BB73949EBE88E4E8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_74FD09FC49171C7AF60649EBE88E3232_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_74FD09FC49171C7AF60649EBE88E3232" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed asset additions acquired through tenant allowance</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_74FD09FC49171C7AF60649EBE88E3232_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_74FD09FC49171C7AF60649EBE88E3232" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Fixed Assets Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_74FD09FC49171C7AF60649EBE88E3232" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_74FD09FC49171C7AF60649EBE88E3232" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_74FD09FC49171C7AF60649EBE88E3232" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_31AE8E50EF69CAB6C0D649EBE88E6CE7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_31AE8E50EF69CAB6C0D649EBE88E6CE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing costs within accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_31AE8E50EF69CAB6C0D649EBE88E6CE7_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_31AE8E50EF69CAB6C0D649EBE88E6CE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_31AE8E50EF69CAB6C0D649EBE88E6CE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_31AE8E50EF69CAB6C0D649EBE88E6CE7" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_31AE8E50EF69CAB6C0D649EBE88E6CE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_59A7EA860DEBA505F7D249EBE88EAB1B_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1_59A7EA860DEBA505F7D249EBE88EAB1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible notes payable and accrued interest into Series C-2 preferred stock</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_59A7EA860DEBA505F7D249EBE88EAB1B_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1_59A7EA860DEBA505F7D249EBE88EAB1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Amount Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_59A7EA860DEBA505F7D249EBE88EAB1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountIssued1_59A7EA860DEBA505F7D249EBE88EAB1B" xlink:to="lab_us-gaap_ConversionOfStockAmountIssued1_59A7EA860DEBA505F7D249EBE88EAB1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_E4D4D1BCA15F226E4FEDEE277891196F_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_E4D4D1BCA15F226E4FEDEE277891196F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_E4D4D1BCA15F226E4FEDEE277891196F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_E4D4D1BCA15F226E4FEDEE277891196F" xlink:to="lab_us-gaap_SubsequentEventsAbstract_E4D4D1BCA15F226E4FEDEE277891196F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_7CB8E1BD5BC8C780DE5CEE27789141C7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_7CB8E1BD5BC8C780DE5CEE27789141C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_7CB8E1BD5BC8C780DE5CEE27789141C7_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_7CB8E1BD5BC8C780DE5CEE27789141C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_7CB8E1BD5BC8C780DE5CEE27789141C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_7CB8E1BD5BC8C780DE5CEE27789141C7" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_7CB8E1BD5BC8C780DE5CEE27789141C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4CABE7C7D8212D9E8C88EE2779DEA4F9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4CABE7C7D8212D9E8C88EE2779DEA4F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4CABE7C7D8212D9E8C88EE2779DEA4F9_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4CABE7C7D8212D9E8C88EE2779DEA4F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4CABE7C7D8212D9E8C88EE2779DEA4F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4CABE7C7D8212D9E8C88EE2779DEA4F9" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4CABE7C7D8212D9E8C88EE2779DEA4F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_D4D91B622BB69A68A64DEE277A1DA10A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_D4D91B622BB69A68A64DEE277A1DA10A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_D4D91B622BB69A68A64DEE277A1DA10A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_D4D91B622BB69A68A64DEE277A1DA10A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_D4D91B622BB69A68A64DEE277A1DA10A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_D4D91B622BB69A68A64DEE277A1DA10A" xlink:to="lab_us-gaap_DebtInstrumentTable_D4D91B622BB69A68A64DEE277A1DA10A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_CABB2C200E989304A4FEEE277A1E21D8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_CABB2C200E989304A4FEEE277A1E21D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_CABB2C200E989304A4FEEE277A1E21D8_label_en-US" xlink:label="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_CABB2C200E989304A4FEEE277A1E21D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_CABB2C200E989304A4FEEE277A1E21D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_CABB2C200E989304A4FEEE277A1E21D8" xlink:to="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_CABB2C200E989304A4FEEE277A1E21D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtConversionNameDomain_F1DD0AAE31D7BE6727BEEE277A1FE5B7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionNameDomain_F1DD0AAE31D7BE6727BEEE277A1FE5B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtConversionNameDomain_F1DD0AAE31D7BE6727BEEE277A1FE5B7_label_en-US" xlink:label="lab_us-gaap_DebtConversionNameDomain_F1DD0AAE31D7BE6727BEEE277A1FE5B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_F1DD0AAE31D7BE6727BEEE277A1FE5B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionNameDomain_F1DD0AAE31D7BE6727BEEE277A1FE5B7" xlink:to="lab_us-gaap_DebtConversionNameDomain_F1DD0AAE31D7BE6727BEEE277A1FE5B7" xlink:type="arc" />
    <link:label id="lab_optn_SeriesDFinancingMember_BE00CEF2409F020FB5ABEE277A1F4CE0_terseLabel_en-US" xlink:label="lab_optn_SeriesDFinancingMember_BE00CEF2409F020FB5ABEE277A1F4CE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series D Financing</link:label>
    <link:label id="lab_optn_SeriesDFinancingMember_BE00CEF2409F020FB5ABEE277A1F4CE0_label_en-US" xlink:label="lab_optn_SeriesDFinancingMember_BE00CEF2409F020FB5ABEE277A1F4CE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series D Financing [Member]</link:label>
    <link:label id="lab_optn_SeriesDFinancingMember_BE00CEF2409F020FB5ABEE277A1F4CE0_documentation_en-US" xlink:label="lab_optn_SeriesDFinancingMember_BE00CEF2409F020FB5ABEE277A1F4CE0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series D Financing [Member]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_SeriesDFinancingMember" xlink:label="loc_optn_SeriesDFinancingMember_BE00CEF2409F020FB5ABEE277A1F4CE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_SeriesDFinancingMember_BE00CEF2409F020FB5ABEE277A1F4CE0" xlink:to="lab_optn_SeriesDFinancingMember_BE00CEF2409F020FB5ABEE277A1F4CE0" xlink:type="arc" />
    <link:label id="lab_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember_8A0E92E76D4543C23C58EE277A1F143D_terseLabel_en-US" xlink:label="lab_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember_8A0E92E76D4543C23C58EE277A1F143D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Convertible notes into Series C2 Preferred Stock</link:label>
    <link:label id="lab_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember_8A0E92E76D4543C23C58EE277A1F143D_label_en-US" xlink:label="lab_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember_8A0E92E76D4543C23C58EE277A1F143D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Convertible notes into Series C2 Preferred Stock [Member]</link:label>
    <link:label id="lab_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember_8A0E92E76D4543C23C58EE277A1F143D_documentation_en-US" xlink:label="lab_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember_8A0E92E76D4543C23C58EE277A1F143D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion of Convertible notes into Series C2 Preferred Stock [Member]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember" xlink:label="loc_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember_8A0E92E76D4543C23C58EE277A1F143D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember_8A0E92E76D4543C23C58EE277A1F143D" xlink:to="lab_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember_8A0E92E76D4543C23C58EE277A1F143D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_0F54E19DCA48C9FA2980EE277A1F9EF0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_0F54E19DCA48C9FA2980EE277A1F9EF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_0F54E19DCA48C9FA2980EE277A1F9EF0_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_0F54E19DCA48C9FA2980EE277A1F9EF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0F54E19DCA48C9FA2980EE277A1F9EF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0F54E19DCA48C9FA2980EE277A1F9EF0" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_0F54E19DCA48C9FA2980EE277A1F9EF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_1B25DD6175671F9BBE68EE277A1F4513_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_1B25DD6175671F9BBE68EE277A1F4513" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_1B25DD6175671F9BBE68EE277A1F4513_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_1B25DD6175671F9BBE68EE277A1F4513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1B25DD6175671F9BBE68EE277A1F4513" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1B25DD6175671F9BBE68EE277A1F4513" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_1B25DD6175671F9BBE68EE277A1F4513" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtMember_61D95DD1DA84031AB88CEE277A200563_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember_61D95DD1DA84031AB88CEE277A200563" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_61D95DD1DA84031AB88CEE277A200563_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember_61D95DD1DA84031AB88CEE277A200563" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_61D95DD1DA84031AB88CEE277A200563" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember_61D95DD1DA84031AB88CEE277A200563" xlink:to="lab_us-gaap_ConvertibleDebtMember_61D95DD1DA84031AB88CEE277A200563" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_129D278547486ABB5779EE277A200F1F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_129D278547486ABB5779EE277A200F1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_129D278547486ABB5779EE277A200F1F_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_129D278547486ABB5779EE277A200F1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_129D278547486ABB5779EE277A200F1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_129D278547486ABB5779EE277A200F1F" xlink:to="lab_us-gaap_DebtInstrumentAxis_129D278547486ABB5779EE277A200F1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_1E0EE3EEACFA5B6CFD75EE277A206234_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_1E0EE3EEACFA5B6CFD75EE277A206234" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_1E0EE3EEACFA5B6CFD75EE277A206234_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_1E0EE3EEACFA5B6CFD75EE277A206234" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1E0EE3EEACFA5B6CFD75EE277A206234" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1E0EE3EEACFA5B6CFD75EE277A206234" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_1E0EE3EEACFA5B6CFD75EE277A206234" xlink:type="arc" />
    <link:label id="lab_optn_TrancheOneMember_3C5DC079B33B82E0C4B0EE277A20C6A0_terseLabel_en-US" xlink:label="lab_optn_TrancheOneMember_3C5DC079B33B82E0C4B0EE277A20C6A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_optn_TrancheOneMember_3C5DC079B33B82E0C4B0EE277A20C6A0_label_en-US" xlink:label="lab_optn_TrancheOneMember_3C5DC079B33B82E0C4B0EE277A20C6A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche One [Member]</link:label>
    <link:label id="lab_optn_TrancheOneMember_3C5DC079B33B82E0C4B0EE277A20C6A0_documentation_en-US" xlink:label="lab_optn_TrancheOneMember_3C5DC079B33B82E0C4B0EE277A20C6A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche One [Member]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_TrancheOneMember" xlink:label="loc_optn_TrancheOneMember_3C5DC079B33B82E0C4B0EE277A20C6A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_TrancheOneMember_3C5DC079B33B82E0C4B0EE277A20C6A0" xlink:to="lab_optn_TrancheOneMember_3C5DC079B33B82E0C4B0EE277A20C6A0" xlink:type="arc" />
    <link:label id="lab_optn_TrancheTwoMember_6AA00B99D2451B110462EE277A21AC84_terseLabel_en-US" xlink:label="lab_optn_TrancheTwoMember_6AA00B99D2451B110462EE277A21AC84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_optn_TrancheTwoMember_6AA00B99D2451B110462EE277A21AC84_label_en-US" xlink:label="lab_optn_TrancheTwoMember_6AA00B99D2451B110462EE277A21AC84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche Two [Member]</link:label>
    <link:label id="lab_optn_TrancheTwoMember_6AA00B99D2451B110462EE277A21AC84_documentation_en-US" xlink:label="lab_optn_TrancheTwoMember_6AA00B99D2451B110462EE277A21AC84" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche Two [Member]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_TrancheTwoMember" xlink:label="loc_optn_TrancheTwoMember_6AA00B99D2451B110462EE277A21AC84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_TrancheTwoMember_6AA00B99D2451B110462EE277A21AC84" xlink:to="lab_optn_TrancheTwoMember_6AA00B99D2451B110462EE277A21AC84" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="lab_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_E5D26641F1B8FBBA90F4EE277A215459_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_E5D26641F1B8FBBA90F4EE277A215459" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_E5D26641F1B8FBBA90F4EE277A215459_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_E5D26641F1B8FBBA90F4EE277A215459" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_E5D26641F1B8FBBA90F4EE277A215459" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_E5D26641F1B8FBBA90F4EE277A215459" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_E5D26641F1B8FBBA90F4EE277A215459" xlink:type="arc" />
    <link:label id="lab_optn_NumberofTranches_29D9C8BC01FFDDB65A9BEE277A21BB37_terseLabel_en-US" xlink:label="lab_optn_NumberofTranches_29D9C8BC01FFDDB65A9BEE277A21BB37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_optn_NumberofTranches_29D9C8BC01FFDDB65A9BEE277A21BB37_label_en-US" xlink:label="lab_optn_NumberofTranches_29D9C8BC01FFDDB65A9BEE277A21BB37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Tranches</link:label>
    <link:label id="lab_optn_NumberofTranches_29D9C8BC01FFDDB65A9BEE277A21BB37_documentation_en-US" xlink:label="lab_optn_NumberofTranches_29D9C8BC01FFDDB65A9BEE277A21BB37" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Tranches</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_NumberofTranches" xlink:label="loc_optn_NumberofTranches_29D9C8BC01FFDDB65A9BEE277A21BB37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_NumberofTranches_29D9C8BC01FFDDB65A9BEE277A21BB37" xlink:to="lab_optn_NumberofTranches_29D9C8BC01FFDDB65A9BEE277A21BB37" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3111D59DE8B03F10E70CEE277A22324D_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3111D59DE8B03F10E70CEE277A22324D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3111D59DE8B03F10E70CEE277A22324D_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3111D59DE8B03F10E70CEE277A22324D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3111D59DE8B03F10E70CEE277A22324D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3111D59DE8B03F10E70CEE277A22324D" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3111D59DE8B03F10E70CEE277A22324D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtConversionOriginalDebtAmount1_1C3CE0A79C01EA2D212CEE277A22CBB2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1_1C3CE0A79C01EA2D212CEE277A22CBB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt conversion, original debt amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionOriginalDebtAmount1_1C3CE0A79C01EA2D212CEE277A22CBB2_label_en-US" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1_1C3CE0A79C01EA2D212CEE277A22CBB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Original Debt, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_1C3CE0A79C01EA2D212CEE277A22CBB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionOriginalDebtAmount1_1C3CE0A79C01EA2D212CEE277A22CBB2" xlink:to="lab_us-gaap_DebtConversionOriginalDebtAmount1_1C3CE0A79C01EA2D212CEE277A22CBB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_935BD629949B0EB4DAC6EE277A22B3AB_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_935BD629949B0EB4DAC6EE277A22B3AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt conversion shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_935BD629949B0EB4DAC6EE277A22B3AB_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_935BD629949B0EB4DAC6EE277A22B3AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_935BD629949B0EB4DAC6EE277A22B3AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_935BD629949B0EB4DAC6EE277A22B3AB" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_935BD629949B0EB4DAC6EE277A22B3AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_F952947920A516676629EE277A229DF1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_F952947920A516676629EE277A229DF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt conversion, price per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_F952947920A516676629EE277A229DF1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_F952947920A516676629EE277A229DF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_F952947920A516676629EE277A229DF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_F952947920A516676629EE277A229DF1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_F952947920A516676629EE277A229DF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpenseDebt_6039A408D5D773920114EE277A22694B_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt_6039A408D5D773920114EE277A22694B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, debt</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_6039A408D5D773920114EE277A22694B_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt_6039A408D5D773920114EE277A22694B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_6039A408D5D773920114EE277A22694B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt_6039A408D5D773920114EE277A22694B" xlink:to="lab_us-gaap_InterestExpenseDebt_6039A408D5D773920114EE277A22694B" xlink:type="arc" />
    <link:label id="lab_optn_DebtInstrumentCouponInterestandFees_84E217AF4CBA328EB288EE277A22B600_terseLabel_en-US" xlink:label="lab_optn_DebtInstrumentCouponInterestandFees_84E217AF4CBA328EB288EE277A22B600" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Coupon interest and back end fees</link:label>
    <link:label id="lab_optn_DebtInstrumentCouponInterestandFees_84E217AF4CBA328EB288EE277A22B600_label_en-US" xlink:label="lab_optn_DebtInstrumentCouponInterestandFees_84E217AF4CBA328EB288EE277A22B600" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Coupon Interest and Fees</link:label>
    <link:label id="lab_optn_DebtInstrumentCouponInterestandFees_84E217AF4CBA328EB288EE277A22B600_documentation_en-US" xlink:label="lab_optn_DebtInstrumentCouponInterestandFees_84E217AF4CBA328EB288EE277A22B600" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Coupon Interest and Fees</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentCouponInterestandFees" xlink:label="loc_optn_DebtInstrumentCouponInterestandFees_84E217AF4CBA328EB288EE277A22B600" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DebtInstrumentCouponInterestandFees_84E217AF4CBA328EB288EE277A22B600" xlink:to="lab_optn_DebtInstrumentCouponInterestandFees_84E217AF4CBA328EB288EE277A22B600" xlink:type="arc" />
    <link:label id="lab_optn_DebtInstrumentLoanConversionPeriod_9F36D36886558CD69D05EE277A23F57E_terseLabel_en-US" xlink:label="lab_optn_DebtInstrumentLoanConversionPeriod_9F36D36886558CD69D05EE277A23F57E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan conversion period</link:label>
    <link:label id="lab_optn_DebtInstrumentLoanConversionPeriod_9F36D36886558CD69D05EE277A23F57E_label_en-US" xlink:label="lab_optn_DebtInstrumentLoanConversionPeriod_9F36D36886558CD69D05EE277A23F57E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Loan Conversion Period</link:label>
    <link:label id="lab_optn_DebtInstrumentLoanConversionPeriod_9F36D36886558CD69D05EE277A23F57E_documentation_en-US" xlink:label="lab_optn_DebtInstrumentLoanConversionPeriod_9F36D36886558CD69D05EE277A23F57E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Loan Conversion Period</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentLoanConversionPeriod" xlink:label="loc_optn_DebtInstrumentLoanConversionPeriod_9F36D36886558CD69D05EE277A23F57E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DebtInstrumentLoanConversionPeriod_9F36D36886558CD69D05EE277A23F57E" xlink:to="lab_optn_DebtInstrumentLoanConversionPeriod_9F36D36886558CD69D05EE277A23F57E" xlink:type="arc" />
    <link:label id="lab_optn_InterestExpenseDebtBackEndFees_3D0E583B2FDA6BAE44A5EE277A2310BA_terseLabel_en-US" xlink:label="lab_optn_InterestExpenseDebtBackEndFees_3D0E583B2FDA6BAE44A5EE277A2310BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, back end fees</link:label>
    <link:label id="lab_optn_InterestExpenseDebtBackEndFees_3D0E583B2FDA6BAE44A5EE277A2310BA_label_en-US" xlink:label="lab_optn_InterestExpenseDebtBackEndFees_3D0E583B2FDA6BAE44A5EE277A2310BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Back End Fees</link:label>
    <link:label id="lab_optn_InterestExpenseDebtBackEndFees_3D0E583B2FDA6BAE44A5EE277A2310BA_documentation_en-US" xlink:label="lab_optn_InterestExpenseDebtBackEndFees_3D0E583B2FDA6BAE44A5EE277A2310BA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Back End Fees</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_InterestExpenseDebtBackEndFees" xlink:label="loc_optn_InterestExpenseDebtBackEndFees_3D0E583B2FDA6BAE44A5EE277A2310BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_InterestExpenseDebtBackEndFees_3D0E583B2FDA6BAE44A5EE277A2310BA" xlink:to="lab_optn_InterestExpenseDebtBackEndFees_3D0E583B2FDA6BAE44A5EE277A2310BA" xlink:type="arc" />
    <link:label id="lab_optn_InterestExpenseDebtFrontEndFees_9DD4A1D325C2A397F925EE277A23918F_terseLabel_en-US" xlink:label="lab_optn_InterestExpenseDebtFrontEndFees_9DD4A1D325C2A397F925EE277A23918F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, front end fees</link:label>
    <link:label id="lab_optn_InterestExpenseDebtFrontEndFees_9DD4A1D325C2A397F925EE277A23918F_label_en-US" xlink:label="lab_optn_InterestExpenseDebtFrontEndFees_9DD4A1D325C2A397F925EE277A23918F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Front End Fees</link:label>
    <link:label id="lab_optn_InterestExpenseDebtFrontEndFees_9DD4A1D325C2A397F925EE277A23918F_documentation_en-US" xlink:label="lab_optn_InterestExpenseDebtFrontEndFees_9DD4A1D325C2A397F925EE277A23918F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Front End Fees</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_InterestExpenseDebtFrontEndFees" xlink:label="loc_optn_InterestExpenseDebtFrontEndFees_9DD4A1D325C2A397F925EE277A23918F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_InterestExpenseDebtFrontEndFees_9DD4A1D325C2A397F925EE277A23918F" xlink:to="lab_optn_InterestExpenseDebtFrontEndFees_9DD4A1D325C2A397F925EE277A23918F" xlink:type="arc" />
    <link:label id="lab_optn_DebtInstrumentFeesCapitalizedtoPrincipal_0EF913099A882C57AA41EE277A231F5D_terseLabel_en-US" xlink:label="lab_optn_DebtInstrumentFeesCapitalizedtoPrincipal_0EF913099A882C57AA41EE277A231F5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Back end fees</link:label>
    <link:label id="lab_optn_DebtInstrumentFeesCapitalizedtoPrincipal_0EF913099A882C57AA41EE277A231F5D_label_en-US" xlink:label="lab_optn_DebtInstrumentFeesCapitalizedtoPrincipal_0EF913099A882C57AA41EE277A231F5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fees Capitalized to Principal</link:label>
    <link:label id="lab_optn_DebtInstrumentFeesCapitalizedtoPrincipal_0EF913099A882C57AA41EE277A231F5D_documentation_en-US" xlink:label="lab_optn_DebtInstrumentFeesCapitalizedtoPrincipal_0EF913099A882C57AA41EE277A231F5D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fees Capitalized to Principal</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentFeesCapitalizedtoPrincipal" xlink:label="loc_optn_DebtInstrumentFeesCapitalizedtoPrincipal_0EF913099A882C57AA41EE277A231F5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DebtInstrumentFeesCapitalizedtoPrincipal_0EF913099A882C57AA41EE277A231F5D" xlink:to="lab_optn_DebtInstrumentFeesCapitalizedtoPrincipal_0EF913099A882C57AA41EE277A231F5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_CE038317D98BFD1A0B99EE277A238483_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_CE038317D98BFD1A0B99EE277A238483" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_CE038317D98BFD1A0B99EE277A238483_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_CE038317D98BFD1A0B99EE277A238483" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_CE038317D98BFD1A0B99EE277A238483" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet_CE038317D98BFD1A0B99EE277A238483" xlink:to="lab_us-gaap_DeferredFinanceCostsNet_CE038317D98BFD1A0B99EE277A238483" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebt_EBA1671792F66B600F06EE277A2355B5_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt_EBA1671792F66B600F06EE277A2355B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_EBA1671792F66B600F06EE277A2355B5_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt_EBA1671792F66B600F06EE277A2355B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_EBA1671792F66B600F06EE277A2355B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt_EBA1671792F66B600F06EE277A2355B5" xlink:to="lab_us-gaap_ConvertibleDebt_EBA1671792F66B600F06EE277A2355B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_151A91DFCA107EB088EADED0E5314519_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_151A91DFCA107EB088EADED0E5314519" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_151A91DFCA107EB088EADED0E5314519_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_151A91DFCA107EB088EADED0E5314519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_151A91DFCA107EB088EADED0E5314519" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_151A91DFCA107EB088EADED0E5314519" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_151A91DFCA107EB088EADED0E5314519" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_751D5E4CB7CF1034EFD5DED0E5322404_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_751D5E4CB7CF1034EFD5DED0E5322404" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_751D5E4CB7CF1034EFD5DED0E5322404_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_751D5E4CB7CF1034EFD5DED0E5322404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_751D5E4CB7CF1034EFD5DED0E5322404" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_751D5E4CB7CF1034EFD5DED0E5322404" xlink:to="lab_us-gaap_PlanNameAxis_751D5E4CB7CF1034EFD5DED0E5322404" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_CC5935168C0A2FB76A8FDED0E532C5E9_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_CC5935168C0A2FB76A8FDED0E532C5E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_CC5935168C0A2FB76A8FDED0E532C5E9_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_CC5935168C0A2FB76A8FDED0E532C5E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_CC5935168C0A2FB76A8FDED0E532C5E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_CC5935168C0A2FB76A8FDED0E532C5E9" xlink:to="lab_us-gaap_PlanNameDomain_CC5935168C0A2FB76A8FDED0E532C5E9" xlink:type="arc" />
    <link:label id="lab_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_5F48BA7D503E341095BDDED0E532A5B6_terseLabel_en-US" xlink:label="lab_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_5F48BA7D503E341095BDDED0E532A5B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_5F48BA7D503E341095BDDED0E532A5B6_label_en-US" xlink:label="lab_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_5F48BA7D503E341095BDDED0E532A5B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Seventeen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_5F48BA7D503E341095BDDED0E532A5B6_documentation_en-US" xlink:label="lab_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_5F48BA7D503E341095BDDED0E532A5B6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Seventeen Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:label="loc_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_5F48BA7D503E341095BDDED0E532A5B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_5F48BA7D503E341095BDDED0E532A5B6" xlink:to="lab_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_5F48BA7D503E341095BDDED0E532A5B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F298FB8722C96AB6A9BDED0E533F93A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F298FB8722C96AB6A9BDED0E533F93A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F298FB8722C96AB6A9BDED0E533F93A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F298FB8722C96AB6A9BDED0E533F93A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F298FB8722C96AB6A9BDED0E533F93A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F298FB8722C96AB6A9BDED0E533F93A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F298FB8722C96AB6A9BDED0E533F93A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_07F89B38977DA6BB3F23DED0E533C0DF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_07F89B38977DA6BB3F23DED0E533C0DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized under plan (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_07F89B38977DA6BB3F23DED0E533C0DF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_07F89B38977DA6BB3F23DED0E533C0DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_07F89B38977DA6BB3F23DED0E533C0DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_07F89B38977DA6BB3F23DED0E533C0DF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_07F89B38977DA6BB3F23DED0E533C0DF" xlink:type="arc" />
    <link:label id="lab_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear_A53FDABAE9B58130E2F6DED0E534C79E_terseLabel_en-US" xlink:label="lab_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear_A53FDABAE9B58130E2F6DED0E534C79E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in number of shares issuable each year</link:label>
    <link:label id="lab_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear_A53FDABAE9B58130E2F6DED0E534C79E_label_en-US" xlink:label="lab_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear_A53FDABAE9B58130E2F6DED0E534C79E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Increment Each Year</link:label>
    <link:label id="lab_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear_A53FDABAE9B58130E2F6DED0E534C79E_documentation_en-US" xlink:label="lab_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear_A53FDABAE9B58130E2F6DED0E534C79E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Increment Each Year</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear" xlink:label="loc_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear_A53FDABAE9B58130E2F6DED0E534C79E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear_A53FDABAE9B58130E2F6DED0E534C79E" xlink:to="lab_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear_A53FDABAE9B58130E2F6DED0E534C79E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_4EE9F68B89DA7703C6EFDED0E534C6A2_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_4EE9F68B89DA7703C6EFDED0E534C6A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_4EE9F68B89DA7703C6EFDED0E534C6A2_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_4EE9F68B89DA7703C6EFDED0E534C6A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4EE9F68B89DA7703C6EFDED0E534C6A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_4EE9F68B89DA7703C6EFDED0E534C6A2" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_4EE9F68B89DA7703C6EFDED0E534C6A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3AAC03B87FD253060A8DE2EA59EE0D6F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3AAC03B87FD253060A8DE2EA59EE0D6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3AAC03B87FD253060A8DE2EA59EE0D6F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3AAC03B87FD253060A8DE2EA59EE0D6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3AAC03B87FD253060A8DE2EA59EE0D6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3AAC03B87FD253060A8DE2EA59EE0D6F" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3AAC03B87FD253060A8DE2EA59EE0D6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C8D4497ED51EFE4CBCB649EC1618BF13_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C8D4497ED51EFE4CBCB649EC1618BF13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C8D4497ED51EFE4CBCB649EC1618BF13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C8D4497ED51EFE4CBCB649EC1618BF13" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C8D4497ED51EFE4CBCB649EC1618BF13" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_18ADC5DE4B5C882BDF5C49EC1628D3FF_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_18ADC5DE4B5C882BDF5C49EC1628D3FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive (loss) income:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_18ADC5DE4B5C882BDF5C49EC1628D3FF_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_18ADC5DE4B5C882BDF5C49EC1628D3FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_18ADC5DE4B5C882BDF5C49EC1628D3FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_18ADC5DE4B5C882BDF5C49EC1628D3FF" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_18ADC5DE4B5C882BDF5C49EC1628D3FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7B69BA504FC47506693F49EC16285E3E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7B69BA504FC47506693F49EC16285E3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7B69BA504FC47506693F49EC16285E3E_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7B69BA504FC47506693F49EC16285E3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7B69BA504FC47506693F49EC16285E3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7B69BA504FC47506693F49EC16285E3E" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7B69BA504FC47506693F49EC16285E3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_606891697F56976FA32649EC1628C9C1_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_606891697F56976FA32649EC1628C9C1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_606891697F56976FA32649EC1628C9C1_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_606891697F56976FA32649EC1628C9C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_606891697F56976FA32649EC1628C9C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_606891697F56976FA32649EC1628C9C1" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_606891697F56976FA32649EC1628C9C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_AE8C6FA5FE3510798E61DED0E4D8511B_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_AE8C6FA5FE3510798E61DED0E4D8511B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_AE8C6FA5FE3510798E61DED0E4D8511B_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_AE8C6FA5FE3510798E61DED0E4D8511B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_AE8C6FA5FE3510798E61DED0E4D8511B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_AE8C6FA5FE3510798E61DED0E4D8511B" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_AE8C6FA5FE3510798E61DED0E4D8511B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_B1BEF2659BB904036A3FDEF0AFEC0EFB_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_B1BEF2659BB904036A3FDEF0AFEC0EFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_B1BEF2659BB904036A3FDEF0AFEC0EFB_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_B1BEF2659BB904036A3FDEF0AFEC0EFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_B1BEF2659BB904036A3FDEF0AFEC0EFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_B1BEF2659BB904036A3FDEF0AFEC0EFB" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_B1BEF2659BB904036A3FDEF0AFEC0EFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_0D20E4340C92F860770ADEF0AFECC095_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_0D20E4340C92F860770ADEF0AFECC095" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_0D20E4340C92F860770ADEF0AFECC095_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_0D20E4340C92F860770ADEF0AFECC095" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0D20E4340C92F860770ADEF0AFECC095" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_0D20E4340C92F860770ADEF0AFECC095" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_0D20E4340C92F860770ADEF0AFECC095" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_8A55A0D526C10B0C951EDEF0AFED501D_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_8A55A0D526C10B0C951EDEF0AFED501D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_8A55A0D526C10B0C951EDEF0AFED501D_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_8A55A0D526C10B0C951EDEF0AFED501D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_8A55A0D526C10B0C951EDEF0AFED501D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_8A55A0D526C10B0C951EDEF0AFED501D" xlink:to="lab_us-gaap_CommonStockSharesIssued_8A55A0D526C10B0C951EDEF0AFED501D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0C51109AD635B41E19F9DEF0AFEDC709_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_0C51109AD635B41E19F9DEF0AFEDC709" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0C51109AD635B41E19F9DEF0AFEDC709_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_0C51109AD635B41E19F9DEF0AFEDC709" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0C51109AD635B41E19F9DEF0AFEDC709" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_0C51109AD635B41E19F9DEF0AFEDC709" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_0C51109AD635B41E19F9DEF0AFEDC709" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_A0A5791055D0D42147C8DED0E5258548_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_A0A5791055D0D42147C8DED0E5258548" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_A0A5791055D0D42147C8DED0E5258548_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_A0A5791055D0D42147C8DED0E5258548" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_A0A5791055D0D42147C8DED0E5258548" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_A0A5791055D0D42147C8DED0E5258548" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_A0A5791055D0D42147C8DED0E5258548" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_9E8D88C3114903E6A336EE2779200E87_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_9E8D88C3114903E6A336EE2779200E87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_9E8D88C3114903E6A336EE2779200E87_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_9E8D88C3114903E6A336EE2779200E87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_9E8D88C3114903E6A336EE2779200E87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_9E8D88C3114903E6A336EE2779200E87" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable_9E8D88C3114903E6A336EE2779200E87" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_BF3C185C95E9A01C765BEE2779219A56_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_BF3C185C95E9A01C765BEE2779219A56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_BF3C185C95E9A01C765BEE2779219A56_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_BF3C185C95E9A01C765BEE2779219A56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_BF3C185C95E9A01C765BEE2779219A56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_BF3C185C95E9A01C765BEE2779219A56" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_BF3C185C95E9A01C765BEE2779219A56" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_A256433012B40B414CFEEE277923BDD1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_A256433012B40B414CFEEE277923BDD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_A256433012B40B414CFEEE277923BDD1_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_A256433012B40B414CFEEE277923BDD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_A256433012B40B414CFEEE277923BDD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_A256433012B40B414CFEEE277923BDD1" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_A256433012B40B414CFEEE277923BDD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCountryMember_0B90A592B0ADBA88899CEE277923AD7C_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_0B90A592B0ADBA88899CEE277923AD7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_0B90A592B0ADBA88899CEE277923AD7C_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_0B90A592B0ADBA88899CEE277923AD7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_0B90A592B0ADBA88899CEE277923AD7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_0B90A592B0ADBA88899CEE277923AD7C" xlink:to="lab_us-gaap_ForeignCountryMember_0B90A592B0ADBA88899CEE277923AD7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCountryMember_A580E0C38D7CAF00CC30EE2779245CA9_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_A580E0C38D7CAF00CC30EE2779245CA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_A580E0C38D7CAF00CC30EE2779245CA9_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_A580E0C38D7CAF00CC30EE2779245CA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_A580E0C38D7CAF00CC30EE2779245CA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_A580E0C38D7CAF00CC30EE2779245CA9" xlink:to="lab_us-gaap_DomesticCountryMember_A580E0C38D7CAF00CC30EE2779245CA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_4E811A208684A28C6A3EEE27792425DF_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_4E811A208684A28C6A3EEE27792425DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_4E811A208684A28C6A3EEE27792425DF_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_4E811A208684A28C6A3EEE27792425DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_4E811A208684A28C6A3EEE27792425DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_4E811A208684A28C6A3EEE27792425DF" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_4E811A208684A28C6A3EEE27792425DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_B6320A86D7BE6E3AC205EE277924309B_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_B6320A86D7BE6E3AC205EE277924309B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_B6320A86D7BE6E3AC205EE277924309B_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_B6320A86D7BE6E3AC205EE277924309B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_B6320A86D7BE6E3AC205EE277924309B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B6320A86D7BE6E3AC205EE277924309B" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems_B6320A86D7BE6E3AC205EE277924309B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_A7FD314097B23FB797B5EE277925E145_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_A7FD314097B23FB797B5EE277925E145" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_A7FD314097B23FB797B5EE277925E145_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_A7FD314097B23FB797B5EE277925E145" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_A7FD314097B23FB797B5EE277925E145" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_A7FD314097B23FB797B5EE277925E145" xlink:to="lab_us-gaap_OperatingLossCarryforwards_A7FD314097B23FB797B5EE277925E145" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_728844566B032BD51E95EE2779258E3C_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_728844566B032BD51E95EE2779258E3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance increase (decrease)</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_728844566B032BD51E95EE2779258E3C_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_728844566B032BD51E95EE2779258E3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_728844566B032BD51E95EE2779258E3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_728844566B032BD51E95EE2779258E3C" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_728844566B032BD51E95EE2779258E3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_FC78E5BF73E6F6055568EE277925E0D5_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_FC78E5BF73E6F6055568EE277925E0D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, income tax penalties and interest accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_FC78E5BF73E6F6055568EE277925E0D5_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_FC78E5BF73E6F6055568EE277925E0D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_FC78E5BF73E6F6055568EE277925E0D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_FC78E5BF73E6F6055568EE277925E0D5" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_FC78E5BF73E6F6055568EE277925E0D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_EC62D60FCFEC412F0923E2AA3D13FA72_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_EC62D60FCFEC412F0923E2AA3D13FA72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_EC62D60FCFEC412F0923E2AA3D13FA72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EC62D60FCFEC412F0923E2AA3D13FA72" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_EC62D60FCFEC412F0923E2AA3D13FA72" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_344C0CEE3B427FCC5FD0E2AA3D1372F3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_344C0CEE3B427FCC5FD0E2AA3D1372F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_344C0CEE3B427FCC5FD0E2AA3D1372F3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_344C0CEE3B427FCC5FD0E2AA3D1372F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_344C0CEE3B427FCC5FD0E2AA3D1372F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_344C0CEE3B427FCC5FD0E2AA3D1372F3" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_344C0CEE3B427FCC5FD0E2AA3D1372F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12B7ECD74C114325D637E2AA3D135AF7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12B7ECD74C114325D637E2AA3D135AF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12B7ECD74C114325D637E2AA3D135AF7_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12B7ECD74C114325D637E2AA3D135AF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12B7ECD74C114325D637E2AA3D135AF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12B7ECD74C114325D637E2AA3D135AF7" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12B7ECD74C114325D637E2AA3D135AF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_E3B24A36FD3F661377FFE2AA3D149144_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_E3B24A36FD3F661377FFE2AA3D149144" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_E3B24A36FD3F661377FFE2AA3D149144_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_E3B24A36FD3F661377FFE2AA3D149144" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E3B24A36FD3F661377FFE2AA3D149144" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E3B24A36FD3F661377FFE2AA3D149144" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_E3B24A36FD3F661377FFE2AA3D149144" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComputerEquipmentMember_13DEBD804C225DF2585EE2AA3D141BF3_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_13DEBD804C225DF2585EE2AA3D141BF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_13DEBD804C225DF2585EE2AA3D141BF3_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_13DEBD804C225DF2585EE2AA3D141BF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_13DEBD804C225DF2585EE2AA3D141BF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_13DEBD804C225DF2585EE2AA3D141BF3" xlink:to="lab_us-gaap_ComputerEquipmentMember_13DEBD804C225DF2585EE2AA3D141BF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7246EDE6A20DE6C0E2C0E2AA3D14B822_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7246EDE6A20DE6C0E2C0E2AA3D14B822" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7246EDE6A20DE6C0E2C0E2AA3D14B822_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7246EDE6A20DE6C0E2C0E2AA3D14B822" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7246EDE6A20DE6C0E2C0E2AA3D14B822" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7246EDE6A20DE6C0E2C0E2AA3D14B822" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7246EDE6A20DE6C0E2C0E2AA3D14B822" xlink:type="arc" />
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_02405C8157574794803CE2AA3D14190D_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_02405C8157574794803CE2AA3D14190D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_02405C8157574794803CE2AA3D14190D_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_02405C8157574794803CE2AA3D14190D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_02405C8157574794803CE2AA3D14190D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember_02405C8157574794803CE2AA3D14190D" xlink:to="lab_us-gaap_MachineryAndEquipmentMember_02405C8157574794803CE2AA3D14190D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_E2131D5F41914B1A2A5CE2AA3D15E75A_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_E2131D5F41914B1A2A5CE2AA3D15E75A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_E2131D5F41914B1A2A5CE2AA3D15E75A_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_E2131D5F41914B1A2A5CE2AA3D15E75A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_E2131D5F41914B1A2A5CE2AA3D15E75A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_E2131D5F41914B1A2A5CE2AA3D15E75A" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_E2131D5F41914B1A2A5CE2AA3D15E75A" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_01D6E3F9E052F9B6C1A9E2AA3D15C4FD_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_01D6E3F9E052F9B6C1A9E2AA3D15C4FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_01D6E3F9E052F9B6C1A9E2AA3D15C4FD_label_en-US" xlink:label="lab_srt_RangeAxis_01D6E3F9E052F9B6C1A9E2AA3D15C4FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_01D6E3F9E052F9B6C1A9E2AA3D15C4FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_01D6E3F9E052F9B6C1A9E2AA3D15C4FD" xlink:to="lab_srt_RangeAxis_01D6E3F9E052F9B6C1A9E2AA3D15C4FD" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_3158B71E2E33E8D83F77E2AA3D15131F_terseLabel_en-US" xlink:label="lab_srt_RangeMember_3158B71E2E33E8D83F77E2AA3D15131F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_3158B71E2E33E8D83F77E2AA3D15131F_label_en-US" xlink:label="lab_srt_RangeMember_3158B71E2E33E8D83F77E2AA3D15131F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3158B71E2E33E8D83F77E2AA3D15131F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_3158B71E2E33E8D83F77E2AA3D15131F" xlink:to="lab_srt_RangeMember_3158B71E2E33E8D83F77E2AA3D15131F" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_C3FF342138212D8A3245E2AA3D15F914_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_C3FF342138212D8A3245E2AA3D15F914" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_C3FF342138212D8A3245E2AA3D15F914_label_en-US" xlink:label="lab_srt_MinimumMember_C3FF342138212D8A3245E2AA3D15F914" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_C3FF342138212D8A3245E2AA3D15F914" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_C3FF342138212D8A3245E2AA3D15F914" xlink:to="lab_srt_MinimumMember_C3FF342138212D8A3245E2AA3D15F914" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_5CE46347CF8F33BF4D7AE2AA3D157AC4_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_5CE46347CF8F33BF4D7AE2AA3D157AC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_5CE46347CF8F33BF4D7AE2AA3D157AC4_label_en-US" xlink:label="lab_srt_MaximumMember_5CE46347CF8F33BF4D7AE2AA3D157AC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_5CE46347CF8F33BF4D7AE2AA3D157AC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_5CE46347CF8F33BF4D7AE2AA3D157AC4" xlink:to="lab_srt_MaximumMember_5CE46347CF8F33BF4D7AE2AA3D157AC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_BE33700B616D89A78724E2AA3D16A0AE_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_BE33700B616D89A78724E2AA3D16A0AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_BE33700B616D89A78724E2AA3D16A0AE_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_BE33700B616D89A78724E2AA3D16A0AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_BE33700B616D89A78724E2AA3D16A0AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_BE33700B616D89A78724E2AA3D16A0AE" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_BE33700B616D89A78724E2AA3D16A0AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_D0C75350EC8CAECB5DB3E2AA3D16A9DE_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_D0C75350EC8CAECB5DB3E2AA3D16A9DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_D0C75350EC8CAECB5DB3E2AA3D16A9DE_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_D0C75350EC8CAECB5DB3E2AA3D16A9DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_D0C75350EC8CAECB5DB3E2AA3D16A9DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_D0C75350EC8CAECB5DB3E2AA3D16A9DE" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_D0C75350EC8CAECB5DB3E2AA3D16A9DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_C4FCE4D3103D180DF1C5E2F5DA2E91B2_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_C4FCE4D3103D180DF1C5E2F5DA2E91B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_C4FCE4D3103D180DF1C5E2F5DA2E91B2_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_C4FCE4D3103D180DF1C5E2F5DA2E91B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_C4FCE4D3103D180DF1C5E2F5DA2E91B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_C4FCE4D3103D180DF1C5E2F5DA2E91B2" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_C4FCE4D3103D180DF1C5E2F5DA2E91B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_28D9D6276A600FA7F2A1E2F5DA42078F_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_28D9D6276A600FA7F2A1E2F5DA42078F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_28D9D6276A600FA7F2A1E2F5DA42078F_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_28D9D6276A600FA7F2A1E2F5DA42078F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_28D9D6276A600FA7F2A1E2F5DA42078F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_28D9D6276A600FA7F2A1E2F5DA42078F" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_28D9D6276A600FA7F2A1E2F5DA42078F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoriesMember_B8F4B900137ACC10E1A3E2F60BE4142B_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember_B8F4B900137ACC10E1A3E2F60BE4142B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_B8F4B900137ACC10E1A3E2F60BE4142B_label_en-US" xlink:label="lab_us-gaap_InventoriesMember_B8F4B900137ACC10E1A3E2F60BE4142B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_B8F4B900137ACC10E1A3E2F60BE4142B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember_B8F4B900137ACC10E1A3E2F60BE4142B" xlink:to="lab_us-gaap_InventoriesMember_B8F4B900137ACC10E1A3E2F60BE4142B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_4AC0EF5CB443DA5C42C0E2F632A7DAC4_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_4AC0EF5CB443DA5C42C0E2F632A7DAC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_4AC0EF5CB443DA5C42C0E2F632A7DAC4_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_4AC0EF5CB443DA5C42C0E2F632A7DAC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_4AC0EF5CB443DA5C42C0E2F632A7DAC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_4AC0EF5CB443DA5C42C0E2F632A7DAC4" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_4AC0EF5CB443DA5C42C0E2F632A7DAC4" xlink:type="arc" />
    <link:label id="lab_optn_ComputerEquipmentandSoftwareMember_99492370606CA5255037E2AA3CDB6E06_terseLabel_en-US" xlink:label="lab_optn_ComputerEquipmentandSoftwareMember_99492370606CA5255037E2AA3CDB6E06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_optn_ComputerEquipmentandSoftwareMember_99492370606CA5255037E2AA3CDB6E06_label_en-US" xlink:label="lab_optn_ComputerEquipmentandSoftwareMember_99492370606CA5255037E2AA3CDB6E06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label id="lab_optn_ComputerEquipmentandSoftwareMember_99492370606CA5255037E2AA3CDB6E06_documentation_en-US" xlink:label="lab_optn_ComputerEquipmentandSoftwareMember_99492370606CA5255037E2AA3CDB6E06" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_ComputerEquipmentandSoftwareMember" xlink:label="loc_optn_ComputerEquipmentandSoftwareMember_99492370606CA5255037E2AA3CDB6E06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_ComputerEquipmentandSoftwareMember_99492370606CA5255037E2AA3CDB6E06" xlink:to="lab_optn_ComputerEquipmentandSoftwareMember_99492370606CA5255037E2AA3CDB6E06" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_81D9560F1543BC8DB202E2AA3CDC69EC_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_81D9560F1543BC8DB202E2AA3CDC69EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_81D9560F1543BC8DB202E2AA3CDC69EC_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_81D9560F1543BC8DB202E2AA3CDC69EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_81D9560F1543BC8DB202E2AA3CDC69EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_81D9560F1543BC8DB202E2AA3CDC69EC" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_81D9560F1543BC8DB202E2AA3CDC69EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressMember_33936D9E9738B224B2B4E2F43CFE412A_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_33936D9E9738B224B2B4E2F43CFE412A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in process</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_33936D9E9738B224B2B4E2F43CFE412A_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_33936D9E9738B224B2B4E2F43CFE412A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_33936D9E9738B224B2B4E2F43CFE412A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember_33936D9E9738B224B2B4E2F43CFE412A" xlink:to="lab_us-gaap_ConstructionInProgressMember_33936D9E9738B224B2B4E2F43CFE412A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_8073C0606F8BB0280906E2AA3CDC4FD2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_8073C0606F8BB0280906E2AA3CDC4FD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_8073C0606F8BB0280906E2AA3CDC4FD2_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_8073C0606F8BB0280906E2AA3CDC4FD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8073C0606F8BB0280906E2AA3CDC4FD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_8073C0606F8BB0280906E2AA3CDC4FD2" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_8073C0606F8BB0280906E2AA3CDC4FD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_55CF6FDD4A1812AB8777E2AA3CDC2387_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_55CF6FDD4A1812AB8777E2AA3CDC2387" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_55CF6FDD4A1812AB8777E2AA3CDC2387_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_55CF6FDD4A1812AB8777E2AA3CDC2387" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_55CF6FDD4A1812AB8777E2AA3CDC2387" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_55CF6FDD4A1812AB8777E2AA3CDC2387" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_55CF6FDD4A1812AB8777E2AA3CDC2387" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1023972EE7975FDF47AEE2AA3CDCF73D_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_1023972EE7975FDF47AEE2AA3CDCF73D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1023972EE7975FDF47AEE2AA3CDCF73D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1023972EE7975FDF47AEE2AA3CDCF73D" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_1023972EE7975FDF47AEE2AA3CDCF73D" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_7A9D1EC2EDCAD32DD18CE2AA3CDDADD6_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_7A9D1EC2EDCAD32DD18CE2AA3CDDADD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_7A9D1EC2EDCAD32DD18CE2AA3CDDADD6_label_en-US" xlink:label="lab_us-gaap_Depreciation_7A9D1EC2EDCAD32DD18CE2AA3CDDADD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_7A9D1EC2EDCAD32DD18CE2AA3CDDADD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_7A9D1EC2EDCAD32DD18CE2AA3CDDADD6" xlink:to="lab_us-gaap_Depreciation_7A9D1EC2EDCAD32DD18CE2AA3CDDADD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_ED3D4BD162FD6C7B2946EE277887A4F7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_ED3D4BD162FD6C7B2946EE277887A4F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_ED3D4BD162FD6C7B2946EE277887A4F7_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_ED3D4BD162FD6C7B2946EE277887A4F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_ED3D4BD162FD6C7B2946EE277887A4F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_ED3D4BD162FD6C7B2946EE277887A4F7" xlink:to="lab_us-gaap_SubsequentEventTable_ED3D4BD162FD6C7B2946EE277887A4F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_C3D2B19DBBF19FE5F656EE2778880446_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_C3D2B19DBBF19FE5F656EE2778880446" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_C3D2B19DBBF19FE5F656EE2778880446_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_C3D2B19DBBF19FE5F656EE2778880446" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_C3D2B19DBBF19FE5F656EE2778880446" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_C3D2B19DBBF19FE5F656EE2778880446" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_C3D2B19DBBF19FE5F656EE2778880446" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_6E1E14E8B38E41D043C8EE277888B044_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_6E1E14E8B38E41D043C8EE277888B044" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_6E1E14E8B38E41D043C8EE277888B044_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_6E1E14E8B38E41D043C8EE277888B044" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6E1E14E8B38E41D043C8EE277888B044" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6E1E14E8B38E41D043C8EE277888B044" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_6E1E14E8B38E41D043C8EE277888B044" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_26E8B17C60BF71EC5505EE2778889AAE_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_26E8B17C60BF71EC5505EE2778889AAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_26E8B17C60BF71EC5505EE2778889AAE_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_26E8B17C60BF71EC5505EE2778889AAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_26E8B17C60BF71EC5505EE2778889AAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_26E8B17C60BF71EC5505EE2778889AAE" xlink:to="lab_us-gaap_SubsequentEventMember_26E8B17C60BF71EC5505EE2778889AAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_2913392D6FBE355623DAEE2778897909_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_2913392D6FBE355623DAEE2778897909" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_2913392D6FBE355623DAEE2778897909_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_2913392D6FBE355623DAEE2778897909" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_2913392D6FBE355623DAEE2778897909" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_2913392D6FBE355623DAEE2778897909" xlink:to="lab_us-gaap_SubsequentEventLineItems_2913392D6FBE355623DAEE2778897909" xlink:type="arc" />
    <link:label id="lab_optn_UpfrontLicenseFeeReceivable_BD448601167075F38647EE65F98FFB59_terseLabel_en-US" xlink:label="lab_optn_UpfrontLicenseFeeReceivable_BD448601167075F38647EE65F98FFB59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront license fee receivable</link:label>
    <link:label id="lab_optn_UpfrontLicenseFeeReceivable_BD448601167075F38647EE65F98FFB59_label_en-US" xlink:label="lab_optn_UpfrontLicenseFeeReceivable_BD448601167075F38647EE65F98FFB59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront License Fee Receivable</link:label>
    <link:label id="lab_optn_UpfrontLicenseFeeReceivable_BD448601167075F38647EE65F98FFB59_documentation_en-US" xlink:label="lab_optn_UpfrontLicenseFeeReceivable_BD448601167075F38647EE65F98FFB59" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront License Fee Receivable</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_UpfrontLicenseFeeReceivable" xlink:label="loc_optn_UpfrontLicenseFeeReceivable_BD448601167075F38647EE65F98FFB59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_UpfrontLicenseFeeReceivable_BD448601167075F38647EE65F98FFB59" xlink:to="lab_optn_UpfrontLicenseFeeReceivable_BD448601167075F38647EE65F98FFB59" xlink:type="arc" />
    <link:label id="lab_optn_DevelopmentMilestoneEligibility_3306B2E67EE748C14F8BEE696391F280_terseLabel_en-US" xlink:label="lab_optn_DevelopmentMilestoneEligibility_3306B2E67EE748C14F8BEE696391F280" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development milestone eligibility</link:label>
    <link:label id="lab_optn_DevelopmentMilestoneEligibility_3306B2E67EE748C14F8BEE696391F280_label_en-US" xlink:label="lab_optn_DevelopmentMilestoneEligibility_3306B2E67EE748C14F8BEE696391F280" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Milestone Eligibility</link:label>
    <link:label id="lab_optn_DevelopmentMilestoneEligibility_3306B2E67EE748C14F8BEE696391F280_documentation_en-US" xlink:label="lab_optn_DevelopmentMilestoneEligibility_3306B2E67EE748C14F8BEE696391F280" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development Milestone Eligibility</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_DevelopmentMilestoneEligibility" xlink:label="loc_optn_DevelopmentMilestoneEligibility_3306B2E67EE748C14F8BEE696391F280" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DevelopmentMilestoneEligibility_3306B2E67EE748C14F8BEE696391F280" xlink:to="lab_optn_DevelopmentMilestoneEligibility_3306B2E67EE748C14F8BEE696391F280" xlink:type="arc" />
    <link:label id="lab_optn_SalesMilestoneEligibility_BC312FC32ECC400B9A9CEE68B8826FBF_terseLabel_en-US" xlink:label="lab_optn_SalesMilestoneEligibility_BC312FC32ECC400B9A9CEE68B8826FBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales milestone eligibility</link:label>
    <link:label id="lab_optn_SalesMilestoneEligibility_BC312FC32ECC400B9A9CEE68B8826FBF_label_en-US" xlink:label="lab_optn_SalesMilestoneEligibility_BC312FC32ECC400B9A9CEE68B8826FBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Milestone Eligibility</link:label>
    <link:label id="lab_optn_SalesMilestoneEligibility_BC312FC32ECC400B9A9CEE68B8826FBF_documentation_en-US" xlink:label="lab_optn_SalesMilestoneEligibility_BC312FC32ECC400B9A9CEE68B8826FBF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Milestone Eligibility</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_SalesMilestoneEligibility" xlink:label="loc_optn_SalesMilestoneEligibility_BC312FC32ECC400B9A9CEE68B8826FBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_SalesMilestoneEligibility_BC312FC32ECC400B9A9CEE68B8826FBF" xlink:to="lab_optn_SalesMilestoneEligibility_BC312FC32ECC400B9A9CEE68B8826FBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_C382B9D040C5EDC88243EDA0A957814A_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_C382B9D040C5EDC88243EDA0A957814A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future minimum annual payments, 2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_C382B9D040C5EDC88243EDA0A957814A_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_C382B9D040C5EDC88243EDA0A957814A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_C382B9D040C5EDC88243EDA0A957814A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_C382B9D040C5EDC88243EDA0A957814A" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_C382B9D040C5EDC88243EDA0A957814A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_39E7815FF7C2F66F69D8EE28214D85E9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_39E7815FF7C2F66F69D8EE28214D85E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future minimum annual payments, 2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_39E7815FF7C2F66F69D8EE28214D85E9_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_39E7815FF7C2F66F69D8EE28214D85E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_39E7815FF7C2F66F69D8EE28214D85E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_39E7815FF7C2F66F69D8EE28214D85E9" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_39E7815FF7C2F66F69D8EE28214D85E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_036716696F30CECB884CEE2874F52852_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_036716696F30CECB884CEE2874F52852" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future minimum annual payments, 2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_036716696F30CECB884CEE2874F52852_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_036716696F30CECB884CEE2874F52852" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_036716696F30CECB884CEE2874F52852" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_036716696F30CECB884CEE2874F52852" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_036716696F30CECB884CEE2874F52852" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_466CF593F2EA9646C2ABEDA0A9589A58_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_466CF593F2EA9646C2ABEDA0A9589A58" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum lease payments as of December 31, 2018</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_466CF593F2EA9646C2ABEDA0A9589A58_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_466CF593F2EA9646C2ABEDA0A9589A58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_466CF593F2EA9646C2ABEDA0A9589A58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_466CF593F2EA9646C2ABEDA0A9589A58" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_466CF593F2EA9646C2ABEDA0A9589A58" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_486F322182175BA7486FEE277A28D14E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_486F322182175BA7486FEE277A28D14E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Notes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_486F322182175BA7486FEE277A28D14E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_486F322182175BA7486FEE277A28D14E" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_486F322182175BA7486FEE277A28D14E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_2C52DD0C88A31FCB4496DED0E4C504FD_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_2C52DD0C88A31FCB4496DED0E4C504FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2C52DD0C88A31FCB4496DED0E4C504FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2C52DD0C88A31FCB4496DED0E4C504FD" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_2C52DD0C88A31FCB4496DED0E4C504FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_FE955D6ECF492C20BFE7DED0E54EC74D_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_FE955D6ECF492C20BFE7DED0E54EC74D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_FE955D6ECF492C20BFE7DED0E54EC74D_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_FE955D6ECF492C20BFE7DED0E54EC74D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_FE955D6ECF492C20BFE7DED0E54EC74D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_FE955D6ECF492C20BFE7DED0E54EC74D" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_FE955D6ECF492C20BFE7DED0E54EC74D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_918DC7105D46D9BC4B2149EC14A50ACF_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_918DC7105D46D9BC4B2149EC14A50ACF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_918DC7105D46D9BC4B2149EC14A50ACF_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_918DC7105D46D9BC4B2149EC14A50ACF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_918DC7105D46D9BC4B2149EC14A50ACF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_918DC7105D46D9BC4B2149EC14A50ACF" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_918DC7105D46D9BC4B2149EC14A50ACF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_E1730B1F303C379BAEF249EC14A5415B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_E1730B1F303C379BAEF249EC14A5415B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_E1730B1F303C379BAEF249EC14A5415B_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_E1730B1F303C379BAEF249EC14A5415B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_E1730B1F303C379BAEF249EC14A5415B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_E1730B1F303C379BAEF249EC14A5415B" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_E1730B1F303C379BAEF249EC14A5415B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2D28ACBBFEF51E35F40C49EC14A5491E_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2D28ACBBFEF51E35F40C49EC14A5491E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2D28ACBBFEF51E35F40C49EC14A5491E_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2D28ACBBFEF51E35F40C49EC14A5491E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2D28ACBBFEF51E35F40C49EC14A5491E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2D28ACBBFEF51E35F40C49EC14A5491E" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2D28ACBBFEF51E35F40C49EC14A5491E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitmentsTable_D05ABEFE9BDF55111716EDA0AAF37AA4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable_D05ABEFE9BDF55111716EDA0AAF37AA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_D05ABEFE9BDF55111716EDA0AAF37AA4_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable_D05ABEFE9BDF55111716EDA0AAF37AA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_D05ABEFE9BDF55111716EDA0AAF37AA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable_D05ABEFE9BDF55111716EDA0AAF37AA4" xlink:to="lab_us-gaap_OtherCommitmentsTable_D05ABEFE9BDF55111716EDA0AAF37AA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_4E43DAB4682BAF794D3BEDA0AAF55C20_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis_4E43DAB4682BAF794D3BEDA0AAF55C20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_4E43DAB4682BAF794D3BEDA0AAF55C20_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis_4E43DAB4682BAF794D3BEDA0AAF55C20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaap_OtherCommitmentsAxis_4E43DAB4682BAF794D3BEDA0AAF55C20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis_4E43DAB4682BAF794D3BEDA0AAF55C20" xlink:to="lab_us-gaap_OtherCommitmentsAxis_4E43DAB4682BAF794D3BEDA0AAF55C20" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_B36285375B3C81982779EDA0AAF5CEBB_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain_B36285375B3C81982779EDA0AAF5CEBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_B36285375B3C81982779EDA0AAF5CEBB_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain_B36285375B3C81982779EDA0AAF5CEBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_B36285375B3C81982779EDA0AAF5CEBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain_B36285375B3C81982779EDA0AAF5CEBB" xlink:to="lab_us-gaap_OtherCommitmentsDomain_B36285375B3C81982779EDA0AAF5CEBB" xlink:type="arc" />
    <link:label id="lab_optn_MarketSalesforceMember_C25661FFF2D45B33A31AEDA0AAF68E13_terseLabel_en-US" xlink:label="lab_optn_MarketSalesforceMember_C25661FFF2D45B33A31AEDA0AAF68E13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market Salesforce</link:label>
    <link:label id="lab_optn_MarketSalesforceMember_C25661FFF2D45B33A31AEDA0AAF68E13_label_en-US" xlink:label="lab_optn_MarketSalesforceMember_C25661FFF2D45B33A31AEDA0AAF68E13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Salesforce [Member]</link:label>
    <link:label id="lab_optn_MarketSalesforceMember_C25661FFF2D45B33A31AEDA0AAF68E13_documentation_en-US" xlink:label="lab_optn_MarketSalesforceMember_C25661FFF2D45B33A31AEDA0AAF68E13" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market Salesforce [Member]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_MarketSalesforceMember" xlink:label="loc_optn_MarketSalesforceMember_C25661FFF2D45B33A31AEDA0AAF68E13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_MarketSalesforceMember_C25661FFF2D45B33A31AEDA0AAF68E13" xlink:to="lab_optn_MarketSalesforceMember_C25661FFF2D45B33A31AEDA0AAF68E13" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_671B31586B7BE4F3FAB8EDA0AAF6F2A5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems_671B31586B7BE4F3FAB8EDA0AAF6F2A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_671B31586B7BE4F3FAB8EDA0AAF6F2A5_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems_671B31586B7BE4F3FAB8EDA0AAF6F2A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_671B31586B7BE4F3FAB8EDA0AAF6F2A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_671B31586B7BE4F3FAB8EDA0AAF6F2A5" xlink:to="lab_us-gaap_OtherCommitmentsLineItems_671B31586B7BE4F3FAB8EDA0AAF6F2A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_F3656547B17011C3CECDEDA0AAF71768_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_F3656547B17011C3CECDEDA0AAF71768" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Early contract termination fees</link:label>
    <link:label id="lab_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_F3656547B17011C3CECDEDA0AAF71768_label_en-US" xlink:label="lab_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_F3656547B17011C3CECDEDA0AAF71768" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities Subject to Compromise, Early Contract Termination Fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:label="loc_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_F3656547B17011C3CECDEDA0AAF71768" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_F3656547B17011C3CECDEDA0AAF71768" xlink:to="lab_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_F3656547B17011C3CECDEDA0AAF71768" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractualObligation_24387F6DD1C8C2C32DEDEDA0AAF6FBB8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation_24387F6DD1C8C2C32DEDEDA0AAF6FBB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual obligation</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_24387F6DD1C8C2C32DEDEDA0AAF6FBB8_label_en-US" xlink:label="lab_us-gaap_ContractualObligation_24387F6DD1C8C2C32DEDEDA0AAF6FBB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_24387F6DD1C8C2C32DEDEDA0AAF6FBB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation_24387F6DD1C8C2C32DEDEDA0AAF6FBB8" xlink:to="lab_us-gaap_ContractualObligation_24387F6DD1C8C2C32DEDEDA0AAF6FBB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PurchaseObligation_29B2F0DADA87EB1740A8EDA0AAF73329_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation_29B2F0DADA87EB1740A8EDA0AAF73329" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase obligation</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_29B2F0DADA87EB1740A8EDA0AAF73329_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation_29B2F0DADA87EB1740A8EDA0AAF73329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_29B2F0DADA87EB1740A8EDA0AAF73329" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation_29B2F0DADA87EB1740A8EDA0AAF73329" xlink:to="lab_us-gaap_PurchaseObligation_29B2F0DADA87EB1740A8EDA0AAF73329" xlink:type="arc" />
    <link:label id="lab_optn_AmendedandRestated2010StockIncentivePlanMember_7AF41417315B2758D3DDEE2779ACA4F3_verboseLabel_en-US" xlink:label="lab_optn_AmendedandRestated2010StockIncentivePlanMember_7AF41417315B2758D3DDEE2779ACA4F3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amended and Restated Plan</link:label>
    <link:label id="lab_optn_AmendedandRestated2010StockIncentivePlanMember_7AF41417315B2758D3DDEE2779ACA4F3_label_en-US" xlink:label="lab_optn_AmendedandRestated2010StockIncentivePlanMember_7AF41417315B2758D3DDEE2779ACA4F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amended and Restated 2010 Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_optn_AmendedandRestated2010StockIncentivePlanMember_7AF41417315B2758D3DDEE2779ACA4F3_documentation_en-US" xlink:label="lab_optn_AmendedandRestated2010StockIncentivePlanMember_7AF41417315B2758D3DDEE2779ACA4F3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amended and Restated 2010 Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_AmendedandRestated2010StockIncentivePlanMember" xlink:label="loc_optn_AmendedandRestated2010StockIncentivePlanMember_7AF41417315B2758D3DDEE2779ACA4F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_AmendedandRestated2010StockIncentivePlanMember_7AF41417315B2758D3DDEE2779ACA4F3" xlink:to="lab_optn_AmendedandRestated2010StockIncentivePlanMember_7AF41417315B2758D3DDEE2779ACA4F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_237D112B1F4C6E0D0505EE2779AC237B_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_237D112B1F4C6E0D0505EE2779AC237B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_237D112B1F4C6E0D0505EE2779AC237B_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_237D112B1F4C6E0D0505EE2779AC237B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_237D112B1F4C6E0D0505EE2779AC237B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_237D112B1F4C6E0D0505EE2779AC237B" xlink:to="lab_us-gaap_AwardTypeAxis_237D112B1F4C6E0D0505EE2779AC237B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4376ECA03173966C71CCEE2779AD0DDE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4376ECA03173966C71CCEE2779AD0DDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4376ECA03173966C71CCEE2779AD0DDE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4376ECA03173966C71CCEE2779AD0DDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4376ECA03173966C71CCEE2779AD0DDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4376ECA03173966C71CCEE2779AD0DDE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4376ECA03173966C71CCEE2779AD0DDE" xlink:type="arc" />
    <link:label id="lab_optn_ServiceBasedStockOptionsMember_49AB1FCC21826FB6CC8DEE2779AD426F_verboseLabel_en-US" xlink:label="lab_optn_ServiceBasedStockOptionsMember_49AB1FCC21826FB6CC8DEE2779AD426F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Service Based Stock Options</link:label>
    <link:label id="lab_optn_ServiceBasedStockOptionsMember_49AB1FCC21826FB6CC8DEE2779AD426F_label_en-US" xlink:label="lab_optn_ServiceBasedStockOptionsMember_49AB1FCC21826FB6CC8DEE2779AD426F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service Based Stock Options [Member]</link:label>
    <link:label id="lab_optn_ServiceBasedStockOptionsMember_49AB1FCC21826FB6CC8DEE2779AD426F_documentation_en-US" xlink:label="lab_optn_ServiceBasedStockOptionsMember_49AB1FCC21826FB6CC8DEE2779AD426F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Service Based Stock Options [Member]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_ServiceBasedStockOptionsMember" xlink:label="loc_optn_ServiceBasedStockOptionsMember_49AB1FCC21826FB6CC8DEE2779AD426F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_ServiceBasedStockOptionsMember_49AB1FCC21826FB6CC8DEE2779AD426F" xlink:to="lab_optn_ServiceBasedStockOptionsMember_49AB1FCC21826FB6CC8DEE2779AD426F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2E3FD04E097B5F21CEABEE2779AE92DA_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2E3FD04E097B5F21CEABEE2779AE92DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares reserved for future issuance under plan (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2E3FD04E097B5F21CEABEE2779AE92DA_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2E3FD04E097B5F21CEABEE2779AE92DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2E3FD04E097B5F21CEABEE2779AE92DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2E3FD04E097B5F21CEABEE2779AE92DA" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2E3FD04E097B5F21CEABEE2779AE92DA" xlink:type="arc" />
    <link:label id="lab_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease_F2D30316B3E609F6B2A4EE2779AEC07D_terseLabel_en-US" xlink:label="lab_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease_F2D30316B3E609F6B2A4EE2779AEC07D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Yearly increase in shares reserved for future issuance</link:label>
    <link:label id="lab_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease_F2D30316B3E609F6B2A4EE2779AEC07D_label_en-US" xlink:label="lab_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease_F2D30316B3E609F6B2A4EE2779AEC07D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Yearly Increase</link:label>
    <link:label id="lab_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease_F2D30316B3E609F6B2A4EE2779AEC07D_documentation_en-US" xlink:label="lab_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease_F2D30316B3E609F6B2A4EE2779AEC07D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Yearly Increase</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease" xlink:label="loc_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease_F2D30316B3E609F6B2A4EE2779AEC07D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease_F2D30316B3E609F6B2A4EE2779AEC07D" xlink:to="lab_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease_F2D30316B3E609F6B2A4EE2779AEC07D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A28B72502242D5D11094EE2779AE1E23_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A28B72502242D5D11094EE2779AE1E23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan options contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A28B72502242D5D11094EE2779AE1E23_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A28B72502242D5D11094EE2779AE1E23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A28B72502242D5D11094EE2779AE1E23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A28B72502242D5D11094EE2779AE1E23" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A28B72502242D5D11094EE2779AE1E23" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_86D207A1179C57B7D757EE2779AE7EC4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_86D207A1179C57B7D757EE2779AE7EC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_86D207A1179C57B7D757EE2779AE7EC4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_86D207A1179C57B7D757EE2779AE7EC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_86D207A1179C57B7D757EE2779AE7EC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_86D207A1179C57B7D757EE2779AE7EC4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_86D207A1179C57B7D757EE2779AE7EC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_CD729B35ACA56BD8F32BEE2779AF3367_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_CD729B35ACA56BD8F32BEE2779AF3367" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_CD729B35ACA56BD8F32BEE2779AF3367_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_CD729B35ACA56BD8F32BEE2779AF3367" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_CD729B35ACA56BD8F32BEE2779AF3367" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_CD729B35ACA56BD8F32BEE2779AF3367" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_CD729B35ACA56BD8F32BEE2779AF3367" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_82B4DD8EE2FB389FBBECEE2779AF0C22_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_82B4DD8EE2FB389FBBECEE2779AF0C22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_82B4DD8EE2FB389FBBECEE2779AF0C22_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_82B4DD8EE2FB389FBBECEE2779AF0C22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_82B4DD8EE2FB389FBBECEE2779AF0C22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_82B4DD8EE2FB389FBBECEE2779AF0C22" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_82B4DD8EE2FB389FBBECEE2779AF0C22" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_03765D345F4DC0BFB86DEE2779AFE8F3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_03765D345F4DC0BFB86DEE2779AFE8F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of exercised options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_03765D345F4DC0BFB86DEE2779AFE8F3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_03765D345F4DC0BFB86DEE2779AFE8F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_03765D345F4DC0BFB86DEE2779AFE8F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_03765D345F4DC0BFB86DEE2779AFE8F3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_03765D345F4DC0BFB86DEE2779AFE8F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_61751BBF974201E672F0EE2779AFB54D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_61751BBF974201E672F0EE2779AFB54D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_61751BBF974201E672F0EE2779AFB54D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_61751BBF974201E672F0EE2779AFB54D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_61751BBF974201E672F0EE2779AFB54D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_61751BBF974201E672F0EE2779AFB54D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_61751BBF974201E672F0EE2779AFB54D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5DF2795524508D2D39CBEE2779AFD9EB_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5DF2795524508D2D39CBEE2779AFD9EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of exercisable options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5DF2795524508D2D39CBEE2779AFD9EB_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5DF2795524508D2D39CBEE2779AFD9EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5DF2795524508D2D39CBEE2779AFD9EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5DF2795524508D2D39CBEE2779AFD9EB" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5DF2795524508D2D39CBEE2779AFD9EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_CDD82D03AEA052733C9FEE2779B057CF_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_CDD82D03AEA052733C9FEE2779B057CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_CDD82D03AEA052733C9FEE2779B057CF_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_CDD82D03AEA052733C9FEE2779B057CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_CDD82D03AEA052733C9FEE2779B057CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_CDD82D03AEA052733C9FEE2779B057CF" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_CDD82D03AEA052733C9FEE2779B057CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_486B8688F2F77C00C52CEE2779B063E8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_486B8688F2F77C00C52CEE2779B063E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation, estimated weighted-average amortization period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_486B8688F2F77C00C52CEE2779B063E8_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_486B8688F2F77C00C52CEE2779B063E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_486B8688F2F77C00C52CEE2779B063E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_486B8688F2F77C00C52CEE2779B063E8" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_486B8688F2F77C00C52CEE2779B063E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_9162C3F535405B2DF83249EC15F91A53_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_9162C3F535405B2DF83249EC15F91A53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_9162C3F535405B2DF83249EC15F91A53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_9162C3F535405B2DF83249EC15F91A53" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_9162C3F535405B2DF83249EC15F91A53" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockDividendRatePercentage_C1BC47BCDFEC40D56CE749EC15F98014_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage_C1BC47BCDFEC40D56CE749EC15F98014" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendRatePercentage_C1BC47BCDFEC40D56CE749EC15F98014_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage_C1BC47BCDFEC40D56CE749EC15F98014" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_C1BC47BCDFEC40D56CE749EC15F98014" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendRatePercentage_C1BC47BCDFEC40D56CE749EC15F98014" xlink:to="lab_us-gaap_PreferredStockDividendRatePercentage_C1BC47BCDFEC40D56CE749EC15F98014" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeniorNotesMember_C0D8D6295CD6D7C6F6EAE32FECF48CCB_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember_C0D8D6295CD6D7C6F6EAE32FECF48CCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_C0D8D6295CD6D7C6F6EAE32FECF48CCB_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember_C0D8D6295CD6D7C6F6EAE32FECF48CCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_C0D8D6295CD6D7C6F6EAE32FECF48CCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember_C0D8D6295CD6D7C6F6EAE32FECF48CCB" xlink:to="lab_us-gaap_SeniorNotesMember_C0D8D6295CD6D7C6F6EAE32FECF48CCB" xlink:type="arc" />
    <link:label id="lab_optn_NotePurchaseAgreementMember_7D36E7F860B6E77772F1E32FECF6223A_terseLabel_en-US" xlink:label="lab_optn_NotePurchaseAgreementMember_7D36E7F860B6E77772F1E32FECF6223A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Note Purchase Agreement</link:label>
    <link:label id="lab_optn_NotePurchaseAgreementMember_7D36E7F860B6E77772F1E32FECF6223A_label_en-US" xlink:label="lab_optn_NotePurchaseAgreementMember_7D36E7F860B6E77772F1E32FECF6223A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note Purchase Agreement [Member]</link:label>
    <link:label id="lab_optn_NotePurchaseAgreementMember_7D36E7F860B6E77772F1E32FECF6223A_documentation_en-US" xlink:label="lab_optn_NotePurchaseAgreementMember_7D36E7F860B6E77772F1E32FECF6223A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Note Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_NotePurchaseAgreementMember" xlink:label="loc_optn_NotePurchaseAgreementMember_7D36E7F860B6E77772F1E32FECF6223A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_NotePurchaseAgreementMember_7D36E7F860B6E77772F1E32FECF6223A" xlink:to="lab_optn_NotePurchaseAgreementMember_7D36E7F860B6E77772F1E32FECF6223A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_04F3493B3978362B122DE32FECF6D95A_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_04F3493B3978362B122DE32FECF6D95A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_04F3493B3978362B122DE32FECF6D95A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_04F3493B3978362B122DE32FECF6D95A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_04F3493B3978362B122DE32FECF6D95A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_04F3493B3978362B122DE32FECF6D95A" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount_04F3493B3978362B122DE32FECF6D95A" xlink:type="arc" />
    <link:label id="lab_optn_DebtInstrumentFeeAmountFrontEnd_E16F6C109135D3ADD62BE32FECF69342_negatedTerseLabel_en-US" xlink:label="lab_optn_DebtInstrumentFeeAmountFrontEnd_E16F6C109135D3ADD62BE32FECF69342" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Front end fees</link:label>
    <link:label id="lab_optn_DebtInstrumentFeeAmountFrontEnd_E16F6C109135D3ADD62BE32FECF69342_label_en-US" xlink:label="lab_optn_DebtInstrumentFeeAmountFrontEnd_E16F6C109135D3ADD62BE32FECF69342" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fee Amount, Front End</link:label>
    <link:label id="lab_optn_DebtInstrumentFeeAmountFrontEnd_E16F6C109135D3ADD62BE32FECF69342_documentation_en-US" xlink:label="lab_optn_DebtInstrumentFeeAmountFrontEnd_E16F6C109135D3ADD62BE32FECF69342" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fee Amount, Front End</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentFeeAmountFrontEnd" xlink:label="loc_optn_DebtInstrumentFeeAmountFrontEnd_E16F6C109135D3ADD62BE32FECF69342" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DebtInstrumentFeeAmountFrontEnd_E16F6C109135D3ADD62BE32FECF69342" xlink:to="lab_optn_DebtInstrumentFeeAmountFrontEnd_E16F6C109135D3ADD62BE32FECF69342" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_EFBB8953B2F61B839F46E32FECF72117_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense_EFBB8953B2F61B839F46E32FECF72117" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_EFBB8953B2F61B839F46E32FECF72117_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense_EFBB8953B2F61B839F46E32FECF72117" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_EFBB8953B2F61B839F46E32FECF72117" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense_EFBB8953B2F61B839F46E32FECF72117" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense_EFBB8953B2F61B839F46E32FECF72117" xlink:type="arc" />
    <link:label id="lab_optn_DebtInstrumentFeeAmountBackEnd_FCB281C124B220FD50C7E32FECF79B55_terseLabel_en-US" xlink:label="lab_optn_DebtInstrumentFeeAmountBackEnd_FCB281C124B220FD50C7E32FECF79B55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Back end fees</link:label>
    <link:label id="lab_optn_DebtInstrumentFeeAmountBackEnd_FCB281C124B220FD50C7E32FECF79B55_label_en-US" xlink:label="lab_optn_DebtInstrumentFeeAmountBackEnd_FCB281C124B220FD50C7E32FECF79B55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fee Amount, Back End</link:label>
    <link:label id="lab_optn_DebtInstrumentFeeAmountBackEnd_FCB281C124B220FD50C7E32FECF79B55_documentation_en-US" xlink:label="lab_optn_DebtInstrumentFeeAmountBackEnd_FCB281C124B220FD50C7E32FECF79B55" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fee Amount, Back End</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentFeeAmountBackEnd" xlink:label="loc_optn_DebtInstrumentFeeAmountBackEnd_FCB281C124B220FD50C7E32FECF79B55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DebtInstrumentFeeAmountBackEnd_FCB281C124B220FD50C7E32FECF79B55" xlink:to="lab_optn_DebtInstrumentFeeAmountBackEnd_FCB281C124B220FD50C7E32FECF79B55" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_4E62AABED537A3DEE7A5E32FECF712EC_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_4E62AABED537A3DEE7A5E32FECF712EC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_4E62AABED537A3DEE7A5E32FECF712EC_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_4E62AABED537A3DEE7A5E32FECF712EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_4E62AABED537A3DEE7A5E32FECF712EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_4E62AABED537A3DEE7A5E32FECF712EC" xlink:to="lab_us-gaap_LongTermDebt_4E62AABED537A3DEE7A5E32FECF712EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RedeemablePreferredStockMember_8CF973D87069AFC606E749EC16093D6D_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemablePreferredStockMember_8CF973D87069AFC606E749EC16093D6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_RedeemablePreferredStockMember_8CF973D87069AFC606E749EC16093D6D_label_en-US" xlink:label="lab_us-gaap_RedeemablePreferredStockMember_8CF973D87069AFC606E749EC16093D6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redeemable Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemablePreferredStockMember" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_8CF973D87069AFC606E749EC16093D6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemablePreferredStockMember_8CF973D87069AFC606E749EC16093D6D" xlink:to="lab_us-gaap_RedeemablePreferredStockMember_8CF973D87069AFC606E749EC16093D6D" xlink:type="arc" />
    <link:label id="lab_optn_RedeemableConvertiblePreferredStockSeriesDMember_4D097EB4B25C8669CF3349EC1609375E_terseLabel_en-US" xlink:label="lab_optn_RedeemableConvertiblePreferredStockSeriesDMember_4D097EB4B25C8669CF3349EC1609375E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable Convertible Preferred Stock, Series D</link:label>
    <link:label id="lab_optn_RedeemableConvertiblePreferredStockSeriesDMember_4D097EB4B25C8669CF3349EC1609375E_label_en-US" xlink:label="lab_optn_RedeemableConvertiblePreferredStockSeriesDMember_4D097EB4B25C8669CF3349EC1609375E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redeemable Convertible Preferred Stock, Series D [Member]</link:label>
    <link:label id="lab_optn_RedeemableConvertiblePreferredStockSeriesDMember_4D097EB4B25C8669CF3349EC1609375E_documentation_en-US" xlink:label="lab_optn_RedeemableConvertiblePreferredStockSeriesDMember_4D097EB4B25C8669CF3349EC1609375E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Redeemable Convertible Preferred Stock, Series D [Member]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_RedeemableConvertiblePreferredStockSeriesDMember" xlink:label="loc_optn_RedeemableConvertiblePreferredStockSeriesDMember_4D097EB4B25C8669CF3349EC1609375E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_RedeemableConvertiblePreferredStockSeriesDMember_4D097EB4B25C8669CF3349EC1609375E" xlink:to="lab_optn_RedeemableConvertiblePreferredStockSeriesDMember_4D097EB4B25C8669CF3349EC1609375E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_445FDF25BBFD4D62CD8149EC16099B9E_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_445FDF25BBFD4D62CD8149EC16099B9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_445FDF25BBFD4D62CD8149EC16099B9E_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_445FDF25BBFD4D62CD8149EC16099B9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_445FDF25BBFD4D62CD8149EC16099B9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_445FDF25BBFD4D62CD8149EC16099B9E" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_445FDF25BBFD4D62CD8149EC16099B9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_6D0A07EB06558C16646549EC16099A9E_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_6D0A07EB06558C16646549EC16099A9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_6D0A07EB06558C16646549EC16099A9E_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_6D0A07EB06558C16646549EC16099A9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6D0A07EB06558C16646549EC16099A9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_6D0A07EB06558C16646549EC16099A9E" xlink:to="lab_us-gaap_EquityComponentDomain_6D0A07EB06558C16646549EC16099A9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_8FDD6FC0721455D284FB49EC16091A95_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_8FDD6FC0721455D284FB49EC16091A95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_8FDD6FC0721455D284FB49EC16091A95_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_8FDD6FC0721455D284FB49EC16091A95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_8FDD6FC0721455D284FB49EC16091A95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_8FDD6FC0721455D284FB49EC16091A95" xlink:to="lab_us-gaap_CommonStockMember_8FDD6FC0721455D284FB49EC16091A95" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_DD2627379C2BD35940BC49EC16099B08_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_DD2627379C2BD35940BC49EC16099B08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid -in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_DD2627379C2BD35940BC49EC16099B08_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_DD2627379C2BD35940BC49EC16099B08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_DD2627379C2BD35940BC49EC16099B08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_DD2627379C2BD35940BC49EC16099B08" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_DD2627379C2BD35940BC49EC16099B08" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_40BCD399E0FA8934C88749EC16098F17_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_40BCD399E0FA8934C88749EC16098F17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_40BCD399E0FA8934C88749EC16098F17_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_40BCD399E0FA8934C88749EC16098F17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_40BCD399E0FA8934C88749EC16098F17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_40BCD399E0FA8934C88749EC16098F17" xlink:to="lab_us-gaap_RetainedEarningsMember_40BCD399E0FA8934C88749EC16098F17" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_63868E2D78C90943FEE049EC16094101_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_63868E2D78C90943FEE049EC16094101" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_63868E2D78C90943FEE049EC16094101_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_63868E2D78C90943FEE049EC16094101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_63868E2D78C90943FEE049EC16094101" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_63868E2D78C90943FEE049EC16094101" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_63868E2D78C90943FEE049EC16094101" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_EE614D846FFDFD6EB07349EC16095FB6_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_EE614D846FFDFD6EB07349EC16095FB6" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_EE614D846FFDFD6EB07349EC16095FB6_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_EE614D846FFDFD6EB07349EC16095FB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_EE614D846FFDFD6EB07349EC16095FB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding_EE614D846FFDFD6EB07349EC16095FB6" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding_EE614D846FFDFD6EB07349EC16095FB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_A0C2600FDFEBA788B9A849EC1609F198_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_A0C2600FDFEBA788B9A849EC1609F198" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_A0C2600FDFEBA788B9A849EC1609F198_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_A0C2600FDFEBA788B9A849EC1609F198" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_A0C2600FDFEBA788B9A849EC1609F198" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_A0C2600FDFEBA788B9A849EC1609F198" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_A0C2600FDFEBA788B9A849EC1609F198" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_46A93FAFDE582B3AE38149EC160997A6_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_46A93FAFDE582B3AE38149EC160997A6" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_46A93FAFDE582B3AE38149EC160997A6_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding_46A93FAFDE582B3AE38149EC160997A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_46A93FAFDE582B3AE38149EC160997A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_46A93FAFDE582B3AE38149EC160997A6" xlink:to="lab_us-gaap_SharesOutstanding_46A93FAFDE582B3AE38149EC160997A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7981EB001D4E2F785BB849EC16182128_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7981EB001D4E2F785BB849EC16182128" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7981EB001D4E2F785BB849EC16182128_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7981EB001D4E2F785BB849EC16182128" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7981EB001D4E2F785BB849EC16182128" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7981EB001D4E2F785BB849EC16182128" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7981EB001D4E2F785BB849EC16182128" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_65016156BD6368F6D8C049EC161869A5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_65016156BD6368F6D8C049EC161869A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible securities (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_65016156BD6368F6D8C049EC161869A5_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_65016156BD6368F6D8C049EC161869A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_65016156BD6368F6D8C049EC161869A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_65016156BD6368F6D8C049EC161869A5" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_65016156BD6368F6D8C049EC161869A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_782424077FFB12FA261549EC1618F019_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_782424077FFB12FA261549EC1618F019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible securities</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_782424077FFB12FA261549EC1618F019_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_782424077FFB12FA261549EC1618F019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_782424077FFB12FA261549EC1618F019" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_782424077FFB12FA261549EC1618F019" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_782424077FFB12FA261549EC1618F019" xlink:type="arc" />
    <link:label id="lab_optn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_E4138EE5067B27416B8A49EC1618C404_terseLabel_en-US" xlink:label="lab_optn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_E4138EE5067B27416B8A49EC1618C404" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Series D preferred stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_optn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_E4138EE5067B27416B8A49EC1618C404_label_en-US" xlink:label="lab_optn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_E4138EE5067B27416B8A49EC1618C404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_optn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_E4138EE5067B27416B8A49EC1618C404_documentation_en-US" xlink:label="lab_optn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_E4138EE5067B27416B8A49EC1618C404" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_optn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_E4138EE5067B27416B8A49EC1618C404" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_E4138EE5067B27416B8A49EC1618C404" xlink:to="lab_optn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_E4138EE5067B27416B8A49EC1618C404" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_FD0D65199F8A33DE2F6749EC16187A3D_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_FD0D65199F8A33DE2F6749EC16187A3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Series D preferred stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_FD0D65199F8A33DE2F6749EC16187A3D_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_FD0D65199F8A33DE2F6749EC16187A3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_FD0D65199F8A33DE2F6749EC16187A3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_FD0D65199F8A33DE2F6749EC16187A3D" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_FD0D65199F8A33DE2F6749EC16187A3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC31829D6727EB27094749EC1618951B_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC31829D6727EB27094749EC1618951B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC31829D6727EB27094749EC1618951B_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC31829D6727EB27094749EC1618951B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC31829D6727EB27094749EC1618951B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC31829D6727EB27094749EC1618951B" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC31829D6727EB27094749EC1618951B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_19A46AD4DAD8C1A9BB2A49EC16184EF3_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_19A46AD4DAD8C1A9BB2A49EC16184EF3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise of common stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_19A46AD4DAD8C1A9BB2A49EC16184EF3_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_19A46AD4DAD8C1A9BB2A49EC16184EF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_19A46AD4DAD8C1A9BB2A49EC16184EF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_19A46AD4DAD8C1A9BB2A49EC16184EF3" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_19A46AD4DAD8C1A9BB2A49EC16184EF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_05D6FF046E7AAD6AEB9D49EC16180838_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_05D6FF046E7AAD6AEB9D49EC16180838" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of common stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_05D6FF046E7AAD6AEB9D49EC16180838_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_05D6FF046E7AAD6AEB9D49EC16180838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_05D6FF046E7AAD6AEB9D49EC16180838" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_05D6FF046E7AAD6AEB9D49EC16180838" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_05D6FF046E7AAD6AEB9D49EC16180838" xlink:type="arc" />
    <link:label id="lab_optn_StockIssuedDuringPeriodValueWarrantsExercised_858DE034CF75669DE68149EC16186951_terseLabel_en-US" xlink:label="lab_optn_StockIssuedDuringPeriodValueWarrantsExercised_858DE034CF75669DE68149EC16186951" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of warrants (in shares)</link:label>
    <link:label id="lab_optn_StockIssuedDuringPeriodValueWarrantsExercised_858DE034CF75669DE68149EC16186951_label_en-US" xlink:label="lab_optn_StockIssuedDuringPeriodValueWarrantsExercised_858DE034CF75669DE68149EC16186951" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:label id="lab_optn_StockIssuedDuringPeriodValueWarrantsExercised_858DE034CF75669DE68149EC16186951_documentation_en-US" xlink:label="lab_optn_StockIssuedDuringPeriodValueWarrantsExercised_858DE034CF75669DE68149EC16186951" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_optn_StockIssuedDuringPeriodValueWarrantsExercised_858DE034CF75669DE68149EC16186951" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_StockIssuedDuringPeriodValueWarrantsExercised_858DE034CF75669DE68149EC16186951" xlink:to="lab_optn_StockIssuedDuringPeriodValueWarrantsExercised_858DE034CF75669DE68149EC16186951" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_BDF9A94B58BA85C18BAD49EC1618C77F_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_BDF9A94B58BA85C18BAD49EC1618C77F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_BDF9A94B58BA85C18BAD49EC1618C77F_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_BDF9A94B58BA85C18BAD49EC1618C77F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Ownership Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_BDF9A94B58BA85C18BAD49EC1618C77F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_BDF9A94B58BA85C18BAD49EC1618C77F" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_BDF9A94B58BA85C18BAD49EC1618C77F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_359CC5D11822882198E749EC1618B550_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_359CC5D11822882198E749EC1618B550" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_359CC5D11822882198E749EC1618B550_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_359CC5D11822882198E749EC1618B550" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Ownership Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_359CC5D11822882198E749EC1618B550" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_359CC5D11822882198E749EC1618B550" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_359CC5D11822882198E749EC1618B550" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_FD85824972D9395CE5C549EC16183021_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_FD85824972D9395CE5C549EC16183021" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accretion of preferred stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_FD85824972D9395CE5C549EC16183021" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_FD85824972D9395CE5C549EC16183021" xlink:to="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_FD85824972D9395CE5C549EC16183021" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_BC2DA16AD9E90CE3DAAF49EC16183BF1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_BC2DA16AD9E90CE3DAAF49EC16183BF1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accretion of preferred stock</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_BC2DA16AD9E90CE3DAAF49EC16183BF1_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_BC2DA16AD9E90CE3DAAF49EC16183BF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_BC2DA16AD9E90CE3DAAF49EC16183BF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_BC2DA16AD9E90CE3DAAF49EC16183BF1" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_BC2DA16AD9E90CE3DAAF49EC16183BF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_02CD92079390681CA4C749EC16187077_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_02CD92079390681CA4C749EC16187077" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of common stock upon consummation of initial public offering, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_02CD92079390681CA4C749EC16187077_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_02CD92079390681CA4C749EC16187077" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_02CD92079390681CA4C749EC16187077" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_02CD92079390681CA4C749EC16187077" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_02CD92079390681CA4C749EC16187077" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_40B0698CE5E5D2176ADB49EC1618A519_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_40B0698CE5E5D2176ADB49EC1618A519" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of common stock upon consummation of initial public offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_40B0698CE5E5D2176ADB49EC1618A519_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_40B0698CE5E5D2176ADB49EC1618A519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_40B0698CE5E5D2176ADB49EC1618A519" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_40B0698CE5E5D2176ADB49EC1618A519" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_40B0698CE5E5D2176ADB49EC1618A519" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_D3A70EA98E085CE87E0549EC16186059_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_D3A70EA98E085CE87E0549EC16186059" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_D3A70EA98E085CE87E0549EC16186059_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_D3A70EA98E085CE87E0549EC16186059" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_D3A70EA98E085CE87E0549EC16186059" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_D3A70EA98E085CE87E0549EC16186059" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_D3A70EA98E085CE87E0549EC16186059" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_AEF3219121C51ABB8FF949EC1618D5EA_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_AEF3219121C51ABB8FF949EC1618D5EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_AEF3219121C51ABB8FF949EC1618D5EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_AEF3219121C51ABB8FF949EC1618D5EA" xlink:to="lab_us-gaap_NetIncomeLoss_AEF3219121C51ABB8FF949EC1618D5EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_D5082D21F6FD2A0B284C49EC16182DBC_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_D5082D21F6FD2A0B284C49EC16182DBC" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_D5082D21F6FD2A0B284C49EC16182DBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding_D5082D21F6FD2A0B284C49EC16182DBC" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding_D5082D21F6FD2A0B284C49EC16182DBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_4CEB3A3E6D1729193DFA49EC161864AE_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_4CEB3A3E6D1729193DFA49EC161864AE" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_4CEB3A3E6D1729193DFA49EC161864AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_4CEB3A3E6D1729193DFA49EC161864AE" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_4CEB3A3E6D1729193DFA49EC161864AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_9A84E2F290EDBB4B80DE49EC1618189B_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_9A84E2F290EDBB4B80DE49EC1618189B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_9A84E2F290EDBB4B80DE49EC1618189B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_9A84E2F290EDBB4B80DE49EC1618189B" xlink:to="lab_us-gaap_SharesOutstanding_9A84E2F290EDBB4B80DE49EC1618189B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_C44600E7487187EA1A8A49EC1618D383_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_C44600E7487187EA1A8A49EC1618D383" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_C44600E7487187EA1A8A49EC1618D383" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_C44600E7487187EA1A8A49EC1618D383" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_C44600E7487187EA1A8A49EC1618D383" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_492E3F553A97A255C6A0EE2779BFB3D1_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable_492E3F553A97A255C6A0EE2779BFB3D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_492E3F553A97A255C6A0EE2779BFB3D1_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable_492E3F553A97A255C6A0EE2779BFB3D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_492E3F553A97A255C6A0EE2779BFB3D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_492E3F553A97A255C6A0EE2779BFB3D1" xlink:to="lab_us-gaap_TemporaryEquityByClassOfStockTable_492E3F553A97A255C6A0EE2779BFB3D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_A76D135D657B69C4A0CFEE2779BF7ED8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_A76D135D657B69C4A0CFEE2779BF7ED8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_A76D135D657B69C4A0CFEE2779BF7ED8_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_A76D135D657B69C4A0CFEE2779BF7ED8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_A76D135D657B69C4A0CFEE2779BF7ED8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_A76D135D657B69C4A0CFEE2779BF7ED8" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_A76D135D657B69C4A0CFEE2779BF7ED8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_F8F3FF4725B5B2B22A6DEE2779C07A3B_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_F8F3FF4725B5B2B22A6DEE2779C07A3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_F8F3FF4725B5B2B22A6DEE2779C07A3B_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_F8F3FF4725B5B2B22A6DEE2779C07A3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F8F3FF4725B5B2B22A6DEE2779C07A3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F8F3FF4725B5B2B22A6DEE2779C07A3B" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_F8F3FF4725B5B2B22A6DEE2779C07A3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IPOMember_28110431BCCBACF7B564EE2779C0F9A3_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember_28110431BCCBACF7B564EE2779C0F9A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_28110431BCCBACF7B564EE2779C0F9A3_label_en-US" xlink:label="lab_us-gaap_IPOMember_28110431BCCBACF7B564EE2779C0F9A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_28110431BCCBACF7B564EE2779C0F9A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember_28110431BCCBACF7B564EE2779C0F9A3" xlink:to="lab_us-gaap_IPOMember_28110431BCCBACF7B564EE2779C0F9A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_1148F9FC08FCB54E62F2EE2779C11BF4_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_1148F9FC08FCB54E62F2EE2779C11BF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_1148F9FC08FCB54E62F2EE2779C11BF4_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_1148F9FC08FCB54E62F2EE2779C11BF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_1148F9FC08FCB54E62F2EE2779C11BF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_1148F9FC08FCB54E62F2EE2779C11BF4" xlink:to="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_1148F9FC08FCB54E62F2EE2779C11BF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_4CC3037C41B7172CA8E0EE2779C15178_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain_4CC3037C41B7172CA8E0EE2779C15178" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_4CC3037C41B7172CA8E0EE2779C15178_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain_4CC3037C41B7172CA8E0EE2779C15178" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_4CC3037C41B7172CA8E0EE2779C15178" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4CC3037C41B7172CA8E0EE2779C15178" xlink:to="lab_us-gaap_ConversionOfStockNameDomain_4CC3037C41B7172CA8E0EE2779C15178" xlink:type="arc" />
    <link:label id="lab_optn_ConversionatConsummationofIPOMember_8C9E5F4D7A5DA6FDBE06EE2779C1971D_terseLabel_en-US" xlink:label="lab_optn_ConversionatConsummationofIPOMember_8C9E5F4D7A5DA6FDBE06EE2779C1971D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion at Consummation of IPO</link:label>
    <link:label id="lab_optn_ConversionatConsummationofIPOMember_8C9E5F4D7A5DA6FDBE06EE2779C1971D_label_en-US" xlink:label="lab_optn_ConversionatConsummationofIPOMember_8C9E5F4D7A5DA6FDBE06EE2779C1971D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion at Consummation of IPO [Member]</link:label>
    <link:label id="lab_optn_ConversionatConsummationofIPOMember_8C9E5F4D7A5DA6FDBE06EE2779C1971D_documentation_en-US" xlink:label="lab_optn_ConversionatConsummationofIPOMember_8C9E5F4D7A5DA6FDBE06EE2779C1971D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion at Consummation of IPO [Member]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_ConversionatConsummationofIPOMember" xlink:label="loc_optn_ConversionatConsummationofIPOMember_8C9E5F4D7A5DA6FDBE06EE2779C1971D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_ConversionatConsummationofIPOMember_8C9E5F4D7A5DA6FDBE06EE2779C1971D" xlink:to="lab_optn_ConversionatConsummationofIPOMember_8C9E5F4D7A5DA6FDBE06EE2779C1971D" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:to="lab_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_11793B513610616D9045EE2779C37872_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_11793B513610616D9045EE2779C37872" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sale of Series D preferred stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_11793B513610616D9045EE2779C37872_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_11793B513610616D9045EE2779C37872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_11793B513610616D9045EE2779C37872" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_11793B513610616D9045EE2779C37872" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_11793B513610616D9045EE2779C37872" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_B7A9398995BE40FFD216EE2779C38D3D_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_B7A9398995BE40FFD216EE2779C38D3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_B7A9398995BE40FFD216EE2779C38D3D_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_B7A9398995BE40FFD216EE2779C38D3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_B7A9398995BE40FFD216EE2779C38D3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_B7A9398995BE40FFD216EE2779C38D3D" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_B7A9398995BE40FFD216EE2779C38D3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_93165E0E5F4F00BDEAE1EE2779C3792F_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_93165E0E5F4F00BDEAE1EE2779C3792F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the sale of Series D preferred stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_93165E0E5F4F00BDEAE1EE2779C3792F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_93165E0E5F4F00BDEAE1EE2779C3792F" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_93165E0E5F4F00BDEAE1EE2779C3792F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_2D9CC30AABC59A4BEADFEE2779C49A1C_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1_2D9CC30AABC59A4BEADFEE2779C49A1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued, conversion of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_2D9CC30AABC59A4BEADFEE2779C49A1C_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1_2D9CC30AABC59A4BEADFEE2779C49A1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_2D9CC30AABC59A4BEADFEE2779C49A1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1_2D9CC30AABC59A4BEADFEE2779C49A1C" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1_2D9CC30AABC59A4BEADFEE2779C49A1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_E67A202D3692AE6681B6EE2779C4BC24_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_E67A202D3692AE6681B6EE2779C4BC24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_E67A202D3692AE6681B6EE2779C4BC24_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_E67A202D3692AE6681B6EE2779C4BC24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_E67A202D3692AE6681B6EE2779C4BC24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_E67A202D3692AE6681B6EE2779C4BC24" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_E67A202D3692AE6681B6EE2779C4BC24" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2EAB776FBE44EC8D4B31EE2779C5BAC8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2EAB776FBE44EC8D4B31EE2779C5BAC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2EAB776FBE44EC8D4B31EE2779C5BAC8_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2EAB776FBE44EC8D4B31EE2779C5BAC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2EAB776FBE44EC8D4B31EE2779C5BAC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2EAB776FBE44EC8D4B31EE2779C5BAC8" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2EAB776FBE44EC8D4B31EE2779C5BAC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_1DF071B8F977BE2B05BEEE2779C5D0D4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_1DF071B8F977BE2B05BEEE2779C5D0D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_1DF071B8F977BE2B05BEEE2779C5D0D4_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_1DF071B8F977BE2B05BEEE2779C5D0D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1DF071B8F977BE2B05BEEE2779C5D0D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_1DF071B8F977BE2B05BEEE2779C5D0D4" xlink:to="lab_us-gaap_PreferredStockSharesIssued_1DF071B8F977BE2B05BEEE2779C5D0D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_EBE77D9022BD2202462EEE2779C5D0D9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_EBE77D9022BD2202462EEE2779C5D0D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_EBE77D9022BD2202462EEE2779C5D0D9_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_EBE77D9022BD2202462EEE2779C5D0D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_EBE77D9022BD2202462EEE2779C5D0D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_EBE77D9022BD2202462EEE2779C5D0D9" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_EBE77D9022BD2202462EEE2779C5D0D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_11911169C4A98A6D0136EE2779D4863E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_11911169C4A98A6D0136EE2779D4863E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_11911169C4A98A6D0136EE2779D4863E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_11911169C4A98A6D0136EE2779D4863E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_11911169C4A98A6D0136EE2779D4863E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_11911169C4A98A6D0136EE2779D4863E" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_11911169C4A98A6D0136EE2779D4863E" xlink:type="arc" />
    <link:label id="lab_srt_CounterpartyNameAxis_63F2B149BFE4B5C5F8AAEE2FFC55A1E8_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis_63F2B149BFE4B5C5F8AAEE2FFC55A1E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_63F2B149BFE4B5C5F8AAEE2FFC55A1E8_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis_63F2B149BFE4B5C5F8AAEE2FFC55A1E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_63F2B149BFE4B5C5F8AAEE2FFC55A1E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis_63F2B149BFE4B5C5F8AAEE2FFC55A1E8" xlink:to="lab_srt_CounterpartyNameAxis_63F2B149BFE4B5C5F8AAEE2FFC55A1E8" xlink:type="arc" />
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_6C1E117C230A12A01047EE2FFC6972D2_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_6C1E117C230A12A01047EE2FFC6972D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_6C1E117C230A12A01047EE2FFC6972D2_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_6C1E117C230A12A01047EE2FFC6972D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6C1E117C230A12A01047EE2FFC6972D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6C1E117C230A12A01047EE2FFC6972D2" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain_6C1E117C230A12A01047EE2FFC6972D2" xlink:type="arc" />
    <link:label id="lab_optn_TheCompanyMember_7B227CFD92EFDF5CF06DEE2FFCAD010A_terseLabel_en-US" xlink:label="lab_optn_TheCompanyMember_7B227CFD92EFDF5CF06DEE2FFCAD010A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Company</link:label>
    <link:label id="lab_optn_TheCompanyMember_7B227CFD92EFDF5CF06DEE2FFCAD010A_label_en-US" xlink:label="lab_optn_TheCompanyMember_7B227CFD92EFDF5CF06DEE2FFCAD010A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Company [Member]</link:label>
    <link:label id="lab_optn_TheCompanyMember_7B227CFD92EFDF5CF06DEE2FFCAD010A_documentation_en-US" xlink:label="lab_optn_TheCompanyMember_7B227CFD92EFDF5CF06DEE2FFCAD010A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Company [Member]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_TheCompanyMember" xlink:label="loc_optn_TheCompanyMember_7B227CFD92EFDF5CF06DEE2FFCAD010A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_TheCompanyMember_7B227CFD92EFDF5CF06DEE2FFCAD010A" xlink:to="lab_optn_TheCompanyMember_7B227CFD92EFDF5CF06DEE2FFCAD010A" xlink:type="arc" />
    <link:label id="lab_optn_CertainStockholdersMember_C6810B03AB9A471B1CA9EE2FFCC45841_terseLabel_en-US" xlink:label="lab_optn_CertainStockholdersMember_C6810B03AB9A471B1CA9EE2FFCC45841" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certain Stockholders</link:label>
    <link:label id="lab_optn_CertainStockholdersMember_C6810B03AB9A471B1CA9EE2FFCC45841_label_en-US" xlink:label="lab_optn_CertainStockholdersMember_C6810B03AB9A471B1CA9EE2FFCC45841" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certain Stockholders [Member]</link:label>
    <link:label id="lab_optn_CertainStockholdersMember_C6810B03AB9A471B1CA9EE2FFCC45841_documentation_en-US" xlink:label="lab_optn_CertainStockholdersMember_C6810B03AB9A471B1CA9EE2FFCC45841" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Certain Stockholders [Member]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_CertainStockholdersMember" xlink:label="loc_optn_CertainStockholdersMember_C6810B03AB9A471B1CA9EE2FFCC45841" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_CertainStockholdersMember_C6810B03AB9A471B1CA9EE2FFCC45841" xlink:to="lab_optn_CertainStockholdersMember_C6810B03AB9A471B1CA9EE2FFCC45841" xlink:type="arc" />
    <link:label id="lab_optn_PublicOfferingMember_C969E5FAB1C9155CA0F2EE2FFC93DE5C_terseLabel_en-US" xlink:label="lab_optn_PublicOfferingMember_C969E5FAB1C9155CA0F2EE2FFC93DE5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_optn_PublicOfferingMember_C969E5FAB1C9155CA0F2EE2FFC93DE5C_label_en-US" xlink:label="lab_optn_PublicOfferingMember_C969E5FAB1C9155CA0F2EE2FFC93DE5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_optn_PublicOfferingMember_C969E5FAB1C9155CA0F2EE2FFC93DE5C_documentation_en-US" xlink:label="lab_optn_PublicOfferingMember_C969E5FAB1C9155CA0F2EE2FFC93DE5C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_PublicOfferingMember" xlink:label="loc_optn_PublicOfferingMember_C969E5FAB1C9155CA0F2EE2FFC93DE5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_PublicOfferingMember_C969E5FAB1C9155CA0F2EE2FFC93DE5C" xlink:to="lab_optn_PublicOfferingMember_C969E5FAB1C9155CA0F2EE2FFC93DE5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:to="lab_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_DA41BB369D5953E8D427EE2779D6C537_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_DA41BB369D5953E8D427EE2779D6C537" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_DA41BB369D5953E8D427EE2779D6C537" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_DA41BB369D5953E8D427EE2779D6C537" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_DA41BB369D5953E8D427EE2779D6C537" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_05D6A719B5B197242C9EEE2779D74A4D_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_05D6A719B5B197242C9EEE2779D74A4D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from IPO</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_05D6A719B5B197242C9EEE2779D74A4D_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_05D6A719B5B197242C9EEE2779D74A4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_05D6A719B5B197242C9EEE2779D74A4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_05D6A719B5B197242C9EEE2779D74A4D" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_05D6A719B5B197242C9EEE2779D74A4D" xlink:type="arc" />
    <link:label id="lab_optn_SaleofStockDiscountsandCommissions_593DECBF95C2098DA571EE2779D75C65_terseLabel_en-US" xlink:label="lab_optn_SaleofStockDiscountsandCommissions_593DECBF95C2098DA571EE2779D75C65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fees and commissions</link:label>
    <link:label id="lab_optn_SaleofStockDiscountsandCommissions_593DECBF95C2098DA571EE2779D75C65_label_en-US" xlink:label="lab_optn_SaleofStockDiscountsandCommissions_593DECBF95C2098DA571EE2779D75C65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Discounts and Commissions</link:label>
    <link:label id="lab_optn_SaleofStockDiscountsandCommissions_593DECBF95C2098DA571EE2779D75C65_documentation_en-US" xlink:label="lab_optn_SaleofStockDiscountsandCommissions_593DECBF95C2098DA571EE2779D75C65" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Discounts and Commissions</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_SaleofStockDiscountsandCommissions" xlink:label="loc_optn_SaleofStockDiscountsandCommissions_593DECBF95C2098DA571EE2779D75C65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_SaleofStockDiscountsandCommissions_593DECBF95C2098DA571EE2779D75C65" xlink:to="lab_optn_SaleofStockDiscountsandCommissions_593DECBF95C2098DA571EE2779D75C65" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_31F6B946CF88E2A9CA97EE2779D700B8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_31F6B946CF88E2A9CA97EE2779D700B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_31F6B946CF88E2A9CA97EE2779D700B8_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_31F6B946CF88E2A9CA97EE2779D700B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_31F6B946CF88E2A9CA97EE2779D700B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_31F6B946CF88E2A9CA97EE2779D700B8" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_31F6B946CF88E2A9CA97EE2779D700B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1A13B98DC005F1FDB2E0EE2FFB7FFA66_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1A13B98DC005F1FDB2E0EE2FFB7FFA66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1A13B98DC005F1FDB2E0EE2FFB7FFA66_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1A13B98DC005F1FDB2E0EE2FFB7FFA66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1A13B98DC005F1FDB2E0EE2FFB7FFA66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1A13B98DC005F1FDB2E0EE2FFB7FFA66" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1A13B98DC005F1FDB2E0EE2FFB7FFA66" xlink:type="arc" />
    <link:label id="lab_optn_SaleofStockDiscounts_C9129DEDDA2DC11E37BAEE2FFB8C99AC_terseLabel_en-US" xlink:label="lab_optn_SaleofStockDiscounts_C9129DEDDA2DC11E37BAEE2FFB8C99AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock discounts</link:label>
    <link:label id="lab_optn_SaleofStockDiscounts_C9129DEDDA2DC11E37BAEE2FFB8C99AC_label_en-US" xlink:label="lab_optn_SaleofStockDiscounts_C9129DEDDA2DC11E37BAEE2FFB8C99AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Discounts</link:label>
    <link:label id="lab_optn_SaleofStockDiscounts_C9129DEDDA2DC11E37BAEE2FFB8C99AC_documentation_en-US" xlink:label="lab_optn_SaleofStockDiscounts_C9129DEDDA2DC11E37BAEE2FFB8C99AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Discounts</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_SaleofStockDiscounts" xlink:label="loc_optn_SaleofStockDiscounts_C9129DEDDA2DC11E37BAEE2FFB8C99AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_SaleofStockDiscounts_C9129DEDDA2DC11E37BAEE2FFB8C99AC" xlink:to="lab_optn_SaleofStockDiscounts_C9129DEDDA2DC11E37BAEE2FFB8C99AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredOfferingCosts_A745EA91226A6239C427EE2FFC438F87_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts_A745EA91226A6239C427EE2FFC438F87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred offering costs</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_A745EA91226A6239C427EE2FFC438F87_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts_A745EA91226A6239C427EE2FFC438F87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_A745EA91226A6239C427EE2FFC438F87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts_A745EA91226A6239C427EE2FFC438F87" xlink:to="lab_us-gaap_DeferredOfferingCosts_A745EA91226A6239C427EE2FFC438F87" xlink:type="arc" />
    <link:label id="lab_optn_VotePerShare_F3E3995AD4F01E6D9ED5EE2779D7B353_terseLabel_en-US" xlink:label="lab_optn_VotePerShare_F3E3995AD4F01E6D9ED5EE2779D7B353" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vote per share</link:label>
    <link:label id="lab_optn_VotePerShare_F3E3995AD4F01E6D9ED5EE2779D7B353_label_en-US" xlink:label="lab_optn_VotePerShare_F3E3995AD4F01E6D9ED5EE2779D7B353" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vote Per Share</link:label>
    <link:label id="lab_optn_VotePerShare_F3E3995AD4F01E6D9ED5EE2779D7B353_documentation_en-US" xlink:label="lab_optn_VotePerShare_F3E3995AD4F01E6D9ED5EE2779D7B353" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vote Per Share</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_VotePerShare" xlink:label="loc_optn_VotePerShare_F3E3995AD4F01E6D9ED5EE2779D7B353" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_VotePerShare_F3E3995AD4F01E6D9ED5EE2779D7B353" xlink:to="lab_optn_VotePerShare_F3E3995AD4F01E6D9ED5EE2779D7B353" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_EF6A3D38536AED148D4CEE2779D81811_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared_EF6A3D38536AED148D4CEE2779D81811" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends declared (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_EF6A3D38536AED148D4CEE2779D81811_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared_EF6A3D38536AED148D4CEE2779D81811" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_EF6A3D38536AED148D4CEE2779D81811" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared_EF6A3D38536AED148D4CEE2779D81811" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared_EF6A3D38536AED148D4CEE2779D81811" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1A1654620DF7AC6785893A5621852044_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1A1654620DF7AC6785893A5621852044" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense at statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1A1654620DF7AC6785893A5621852044_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1A1654620DF7AC6785893A5621852044" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1A1654620DF7AC6785893A5621852044" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1A1654620DF7AC6785893A5621852044" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1A1654620DF7AC6785893A5621852044" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_EB4637180F4CFB53A4503A562185CC7B_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_EB4637180F4CFB53A4503A562185CC7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_EB4637180F4CFB53A4503A562185CC7B_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_EB4637180F4CFB53A4503A562185CC7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_EB4637180F4CFB53A4503A562185CC7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_EB4637180F4CFB53A4503A562185CC7B" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_EB4637180F4CFB53A4503A562185CC7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B8F066C0B6315E8DC7943A5621867B41_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B8F066C0B6315E8DC7943A5621867B41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign rate differential</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B8F066C0B6315E8DC7943A5621867B41_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B8F066C0B6315E8DC7943A5621867B41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B8F066C0B6315E8DC7943A5621867B41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B8F066C0B6315E8DC7943A5621867B41" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B8F066C0B6315E8DC7943A5621867B41" xlink:type="arc" />
    <link:label id="lab_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent_C1A5A382A1FFFE1A42DF3A5621860266_terseLabel_en-US" xlink:label="lab_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent_C1A5A382A1FFFE1A42DF3A5621860266" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of foreign operations</link:label>
    <link:label id="lab_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent_C1A5A382A1FFFE1A42DF3A5621860266_label_en-US" xlink:label="lab_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent_C1A5A382A1FFFE1A42DF3A5621860266" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Operations Impact, Percent</link:label>
    <link:label id="lab_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent_C1A5A382A1FFFE1A42DF3A5621860266_documentation_en-US" xlink:label="lab_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent_C1A5A382A1FFFE1A42DF3A5621860266" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Operations Impact, Percent</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent" xlink:label="loc_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent_C1A5A382A1FFFE1A42DF3A5621860266" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent_C1A5A382A1FFFE1A42DF3A5621860266" xlink:to="lab_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent_C1A5A382A1FFFE1A42DF3A5621860266" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_FE48B1685E9CE8D9F36B3A5621869A7A_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_FE48B1685E9CE8D9F36B3A5621869A7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_FE48B1685E9CE8D9F36B3A5621869A7A_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_FE48B1685E9CE8D9F36B3A5621869A7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_FE48B1685E9CE8D9F36B3A5621869A7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_FE48B1685E9CE8D9F36B3A5621869A7A" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_FE48B1685E9CE8D9F36B3A5621869A7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_8D04B01D7DF3D95F21363A5621865172_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_8D04B01D7DF3D95F21363A5621865172" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax rate changes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_8D04B01D7DF3D95F21363A5621865172_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_8D04B01D7DF3D95F21363A5621865172" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_8D04B01D7DF3D95F21363A5621865172" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_8D04B01D7DF3D95F21363A5621865172" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_8D04B01D7DF3D95F21363A5621865172" xlink:type="arc" />
    <link:label id="lab_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent_ABC1505B06AF90DBFA233A5621863490_terseLabel_en-US" xlink:label="lab_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent_ABC1505B06AF90DBFA233A5621863490" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent_ABC1505B06AF90DBFA233A5621863490_label_en-US" xlink:label="lab_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent_ABC1505B06AF90DBFA233A5621863490" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Exchange Other, Percent</link:label>
    <link:label id="lab_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent_ABC1505B06AF90DBFA233A5621863490_documentation_en-US" xlink:label="lab_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent_ABC1505B06AF90DBFA233A5621863490" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Exchange Other, Percent</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent" xlink:label="loc_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent_ABC1505B06AF90DBFA233A5621863490" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent_ABC1505B06AF90DBFA233A5621863490" xlink:to="lab_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent_ABC1505B06AF90DBFA233A5621863490" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_DD840DBEC4711126493F3A5621870660_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_DD840DBEC4711126493F3A5621870660" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_DD840DBEC4711126493F3A5621870660_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_DD840DBEC4711126493F3A5621870660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_DD840DBEC4711126493F3A5621870660" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_DD840DBEC4711126493F3A5621870660" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_DD840DBEC4711126493F3A5621870660" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F7397C9556F943F3220E3A5621877227_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F7397C9556F943F3220E3A5621877227" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F7397C9556F943F3220E3A5621877227_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F7397C9556F943F3220E3A5621877227" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F7397C9556F943F3220E3A5621877227" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F7397C9556F943F3220E3A5621877227" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F7397C9556F943F3220E3A5621877227" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_96CDCBA3AC71BF26F8B8EE27796CBE39_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_96CDCBA3AC71BF26F8B8EE27796CBE39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_96CDCBA3AC71BF26F8B8EE27796CBE39_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_96CDCBA3AC71BF26F8B8EE27796CBE39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_96CDCBA3AC71BF26F8B8EE27796CBE39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_96CDCBA3AC71BF26F8B8EE27796CBE39" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_96CDCBA3AC71BF26F8B8EE27796CBE39" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_5936FFC843DEFD3099D5EE27796C509E_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_5936FFC843DEFD3099D5EE27796C509E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_5936FFC843DEFD3099D5EE27796C509E_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_5936FFC843DEFD3099D5EE27796C509E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5936FFC843DEFD3099D5EE27796C509E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5936FFC843DEFD3099D5EE27796C509E" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_5936FFC843DEFD3099D5EE27796C509E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_8FBA88A58E9C65B47F54EE27796DD10E_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_8FBA88A58E9C65B47F54EE27796DD10E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_8FBA88A58E9C65B47F54EE27796DD10E_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_8FBA88A58E9C65B47F54EE27796DD10E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8FBA88A58E9C65B47F54EE27796DD10E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8FBA88A58E9C65B47F54EE27796DD10E" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_8FBA88A58E9C65B47F54EE27796DD10E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfSalesMember_CCB0F47F80C9D4E42718EE3CC81C6F58_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember_CCB0F47F80C9D4E42718EE3CC81C6F58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of product sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_CCB0F47F80C9D4E42718EE3CC81C6F58_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember_CCB0F47F80C9D4E42718EE3CC81C6F58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_CCB0F47F80C9D4E42718EE3CC81C6F58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember_CCB0F47F80C9D4E42718EE3CC81C6F58" xlink:to="lab_us-gaap_CostOfSalesMember_CCB0F47F80C9D4E42718EE3CC81C6F58" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2E9587624D3AC616CAAAEE27796D491A_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2E9587624D3AC616CAAAEE27796D491A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2E9587624D3AC616CAAAEE27796D491A_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2E9587624D3AC616CAAAEE27796D491A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2E9587624D3AC616CAAAEE27796D491A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2E9587624D3AC616CAAAEE27796D491A" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2E9587624D3AC616CAAAEE27796D491A" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_ABB4BF1FF6107EA9143EEE27796E28D6_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_ABB4BF1FF6107EA9143EEE27796E28D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_ABB4BF1FF6107EA9143EEE27796E28D6_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_ABB4BF1FF6107EA9143EEE27796E28D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ABB4BF1FF6107EA9143EEE27796E28D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ABB4BF1FF6107EA9143EEE27796E28D6" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_ABB4BF1FF6107EA9143EEE27796E28D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CC80909C1355A9A13DD1EE27796ED152_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CC80909C1355A9A13DD1EE27796ED152" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CC80909C1355A9A13DD1EE27796ED152_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CC80909C1355A9A13DD1EE27796ED152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CC80909C1355A9A13DD1EE27796ED152" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CC80909C1355A9A13DD1EE27796ED152" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CC80909C1355A9A13DD1EE27796ED152" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_58FA0D67CA1B7BB8A528DED0E479D6AC_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_58FA0D67CA1B7BB8A528DED0E479D6AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_58FA0D67CA1B7BB8A528DED0E479D6AC_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_58FA0D67CA1B7BB8A528DED0E479D6AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_58FA0D67CA1B7BB8A528DED0E479D6AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_58FA0D67CA1B7BB8A528DED0E479D6AC" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_58FA0D67CA1B7BB8A528DED0E479D6AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementScenarioAxis_A9600D4CFD60A6103C2FE32FED0BE989_terseLabel_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_A9600D4CFD60A6103C2FE32FED0BE989" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementScenarioAxis_A9600D4CFD60A6103C2FE32FED0BE989_label_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_A9600D4CFD60A6103C2FE32FED0BE989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_A9600D4CFD60A6103C2FE32FED0BE989" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis_A9600D4CFD60A6103C2FE32FED0BE989" xlink:to="lab_us-gaap_StatementScenarioAxis_A9600D4CFD60A6103C2FE32FED0BE989" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_0389B6FA8520C2F93650E32FED0BCFA2_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_0389B6FA8520C2F93650E32FED0BCFA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_0389B6FA8520C2F93650E32FED0BCFA2_label_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_0389B6FA8520C2F93650E32FED0BCFA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_0389B6FA8520C2F93650E32FED0BCFA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_0389B6FA8520C2F93650E32FED0BCFA2" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain_0389B6FA8520C2F93650E32FED0BCFA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioForecastMember_559435A66FB573072FEDE32FED0B5A29_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember_559435A66FB573072FEDE32FED0B5A29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Forecast</link:label>
    <link:label id="lab_us-gaap_ScenarioForecastMember_559435A66FB573072FEDE32FED0B5A29_label_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember_559435A66FB573072FEDE32FED0B5A29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Forecast [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_559435A66FB573072FEDE32FED0B5A29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioForecastMember_559435A66FB573072FEDE32FED0B5A29" xlink:to="lab_us-gaap_ScenarioForecastMember_559435A66FB573072FEDE32FED0B5A29" xlink:type="arc" />
    <link:label id="lab_optn_NotePurchaseAgreementDelayedDrawNotesMember_5D2C8839800CF0845607E32FED0D0469_terseLabel_en-US" xlink:label="lab_optn_NotePurchaseAgreementDelayedDrawNotesMember_5D2C8839800CF0845607E32FED0D0469" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Note Purchase Agreement - Delayed Draw Notes</link:label>
    <link:label id="lab_optn_NotePurchaseAgreementDelayedDrawNotesMember_5D2C8839800CF0845607E32FED0D0469_label_en-US" xlink:label="lab_optn_NotePurchaseAgreementDelayedDrawNotesMember_5D2C8839800CF0845607E32FED0D0469" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note Purchase Agreement - Delayed Draw Notes [Member]</link:label>
    <link:label id="lab_optn_NotePurchaseAgreementDelayedDrawNotesMember_5D2C8839800CF0845607E32FED0D0469_documentation_en-US" xlink:label="lab_optn_NotePurchaseAgreementDelayedDrawNotesMember_5D2C8839800CF0845607E32FED0D0469" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Note Purchase Agreement - Delayed Draw Notes [Member]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_NotePurchaseAgreementDelayedDrawNotesMember" xlink:label="loc_optn_NotePurchaseAgreementDelayedDrawNotesMember_5D2C8839800CF0845607E32FED0D0469" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_NotePurchaseAgreementDelayedDrawNotesMember_5D2C8839800CF0845607E32FED0D0469" xlink:to="lab_optn_NotePurchaseAgreementDelayedDrawNotesMember_5D2C8839800CF0845607E32FED0D0469" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateAxis_E82D8472D329942198AFE32FED0DAB11_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis_E82D8472D329942198AFE32FED0DAB11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_E82D8472D329942198AFE32FED0DAB11_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis_E82D8472D329942198AFE32FED0DAB11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_E82D8472D329942198AFE32FED0DAB11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis_E82D8472D329942198AFE32FED0DAB11" xlink:to="lab_us-gaap_VariableRateAxis_E82D8472D329942198AFE32FED0DAB11" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateDomain_4144C335F38B6D0D81E9E32FED0E15A7_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain_4144C335F38B6D0D81E9E32FED0E15A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_4144C335F38B6D0D81E9E32FED0E15A7_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain_4144C335F38B6D0D81E9E32FED0E15A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_4144C335F38B6D0D81E9E32FED0E15A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain_4144C335F38B6D0D81E9E32FED0E15A7" xlink:to="lab_us-gaap_VariableRateDomain_4144C335F38B6D0D81E9E32FED0E15A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_124C7A3FCC9D059B2208E32FED0E3946_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_124C7A3FCC9D059B2208E32FED0E3946" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">London Interbank Offered Rate (LIBOR)</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_124C7A3FCC9D059B2208E32FED0E3946_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_124C7A3FCC9D059B2208E32FED0E3946" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_124C7A3FCC9D059B2208E32FED0E3946" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_124C7A3FCC9D059B2208E32FED0E3946" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_124C7A3FCC9D059B2208E32FED0E3946" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_25E2E0B836273CFE2514E32FED0F8D2B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_25E2E0B836273CFE2514E32FED0F8D2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_25E2E0B836273CFE2514E32FED0F8D2B_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_25E2E0B836273CFE2514E32FED0F8D2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_25E2E0B836273CFE2514E32FED0F8D2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_25E2E0B836273CFE2514E32FED0F8D2B" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_25E2E0B836273CFE2514E32FED0F8D2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_8D695C99D457AAAAE2BAE32FED0F731E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_8D695C99D457AAAAE2BAE32FED0F731E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_8D695C99D457AAAAE2BAE32FED0F731E_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_8D695C99D457AAAAE2BAE32FED0F731E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8D695C99D457AAAAE2BAE32FED0F731E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8D695C99D457AAAAE2BAE32FED0F731E" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_8D695C99D457AAAAE2BAE32FED0F731E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_0CCE640BEEDDC00611D3E32FED109FD9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_0CCE640BEEDDC00611D3E32FED109FD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior to Second Anniversary</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_0CCE640BEEDDC00611D3E32FED109FD9_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_0CCE640BEEDDC00611D3E32FED109FD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_0CCE640BEEDDC00611D3E32FED109FD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_0CCE640BEEDDC00611D3E32FED109FD9" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_0CCE640BEEDDC00611D3E32FED109FD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_B4CDA917284763D6FA7CE32FED108EAB_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_B4CDA917284763D6FA7CE32FED108EAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">On Or After Second Anniversary</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_B4CDA917284763D6FA7CE32FED108EAB_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_B4CDA917284763D6FA7CE32FED108EAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_B4CDA917284763D6FA7CE32FED108EAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_B4CDA917284763D6FA7CE32FED108EAB" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_B4CDA917284763D6FA7CE32FED108EAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_AC74B6D63D6815138417E32FED105B7D_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_AC74B6D63D6815138417E32FED105B7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">On Or After Third Anniversary</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_AC74B6D63D6815138417E32FED105B7D_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_AC74B6D63D6815138417E32FED105B7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_AC74B6D63D6815138417E32FED105B7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_AC74B6D63D6815138417E32FED105B7D" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_AC74B6D63D6815138417E32FED105B7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodFourMember_3ED64B00BCC82569866AE32FED10ED51_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodFourMember_3ED64B00BCC82569866AE32FED10ED51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After Fourth Anniversary</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodFourMember_3ED64B00BCC82569866AE32FED10ED51_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodFourMember_3ED64B00BCC82569866AE32FED10ED51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period Four [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_3ED64B00BCC82569866AE32FED10ED51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_3ED64B00BCC82569866AE32FED10ED51" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodFourMember_3ED64B00BCC82569866AE32FED10ED51" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_56C15077D3A5AA936F5AE32FED121F69_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_56C15077D3A5AA936F5AE32FED121F69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unused borrowing capacity</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_56C15077D3A5AA936F5AE32FED121F69_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_56C15077D3A5AA936F5AE32FED121F69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unused Borrowing Capacity, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_56C15077D3A5AA936F5AE32FED121F69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_56C15077D3A5AA936F5AE32FED121F69" xlink:to="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_56C15077D3A5AA936F5AE32FED121F69" xlink:type="arc" />
    <link:label id="lab_optn_NumberOfTrailingQuarters_A33EC4DC7AD280DB6616E32FED13CD4B_terseLabel_en-US" xlink:label="lab_optn_NumberOfTrailingQuarters_A33EC4DC7AD280DB6616E32FED13CD4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of trailing quarters</link:label>
    <link:label id="lab_optn_NumberOfTrailingQuarters_A33EC4DC7AD280DB6616E32FED13CD4B_label_en-US" xlink:label="lab_optn_NumberOfTrailingQuarters_A33EC4DC7AD280DB6616E32FED13CD4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Trailing Quarters</link:label>
    <link:label id="lab_optn_NumberOfTrailingQuarters_A33EC4DC7AD280DB6616E32FED13CD4B_documentation_en-US" xlink:label="lab_optn_NumberOfTrailingQuarters_A33EC4DC7AD280DB6616E32FED13CD4B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Trailing Quarters</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_NumberOfTrailingQuarters" xlink:label="loc_optn_NumberOfTrailingQuarters_A33EC4DC7AD280DB6616E32FED13CD4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_NumberOfTrailingQuarters_A33EC4DC7AD280DB6616E32FED13CD4B" xlink:to="lab_optn_NumberOfTrailingQuarters_A33EC4DC7AD280DB6616E32FED13CD4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_B0A915D97DD011475899E33379963A2E_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_B0A915D97DD011475899E33379963A2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, net</link:label>
    <link:label id="lab_us-gaap_Revenues_B0A915D97DD011475899E33379963A2E_label_en-US" xlink:label="lab_us-gaap_Revenues_B0A915D97DD011475899E33379963A2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_B0A915D97DD011475899E33379963A2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_B0A915D97DD011475899E33379963A2E" xlink:to="lab_us-gaap_Revenues_B0A915D97DD011475899E33379963A2E" xlink:type="arc" />
    <link:label id="lab_optn_TotalDebttoTrailingQuarterNetSalesRatio_E130D08B68A03757C045E32FED133A02_terseLabel_en-US" xlink:label="lab_optn_TotalDebttoTrailingQuarterNetSalesRatio_E130D08B68A03757C045E32FED133A02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total debt to trailing quarter net sales ratio</link:label>
    <link:label id="lab_optn_TotalDebttoTrailingQuarterNetSalesRatio_E130D08B68A03757C045E32FED133A02_label_en-US" xlink:label="lab_optn_TotalDebttoTrailingQuarterNetSalesRatio_E130D08B68A03757C045E32FED133A02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Debt to Trailing Quarter Net Sales Ratio</link:label>
    <link:label id="lab_optn_TotalDebttoTrailingQuarterNetSalesRatio_E130D08B68A03757C045E32FED133A02_documentation_en-US" xlink:label="lab_optn_TotalDebttoTrailingQuarterNetSalesRatio_E130D08B68A03757C045E32FED133A02" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Debt to Trailing Quarter Net Sales Ratio</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_TotalDebttoTrailingQuarterNetSalesRatio" xlink:label="loc_optn_TotalDebttoTrailingQuarterNetSalesRatio_E130D08B68A03757C045E32FED133A02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_TotalDebttoTrailingQuarterNetSalesRatio_E130D08B68A03757C045E32FED133A02" xlink:to="lab_optn_TotalDebttoTrailingQuarterNetSalesRatio_E130D08B68A03757C045E32FED133A02" xlink:type="arc" />
    <link:label id="lab_optn_DebtInstrumentInterestRateFloor_725D171E99DD5A009B9EE32FED149D5E_terseLabel_en-US" xlink:label="lab_optn_DebtInstrumentInterestRateFloor_725D171E99DD5A009B9EE32FED149D5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate floor</link:label>
    <link:label id="lab_optn_DebtInstrumentInterestRateFloor_725D171E99DD5A009B9EE32FED149D5E_label_en-US" xlink:label="lab_optn_DebtInstrumentInterestRateFloor_725D171E99DD5A009B9EE32FED149D5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate Floor</link:label>
    <link:label id="lab_optn_DebtInstrumentInterestRateFloor_725D171E99DD5A009B9EE32FED149D5E_documentation_en-US" xlink:label="lab_optn_DebtInstrumentInterestRateFloor_725D171E99DD5A009B9EE32FED149D5E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate Floor</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentInterestRateFloor" xlink:label="loc_optn_DebtInstrumentInterestRateFloor_725D171E99DD5A009B9EE32FED149D5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DebtInstrumentInterestRateFloor_725D171E99DD5A009B9EE32FED149D5E" xlink:to="lab_optn_DebtInstrumentInterestRateFloor_725D171E99DD5A009B9EE32FED149D5E" xlink:type="arc" />
    <link:label id="lab_optn_DebtInstrumentFeeUpfrontFee_DC9F2AE28CC3BD6216F6E32FED157102_terseLabel_en-US" xlink:label="lab_optn_DebtInstrumentFeeUpfrontFee_DC9F2AE28CC3BD6216F6E32FED157102" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront fee</link:label>
    <link:label id="lab_optn_DebtInstrumentFeeUpfrontFee_DC9F2AE28CC3BD6216F6E32FED157102_label_en-US" xlink:label="lab_optn_DebtInstrumentFeeUpfrontFee_DC9F2AE28CC3BD6216F6E32FED157102" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Fee, Upfront Fee</link:label>
    <link:label id="lab_optn_DebtInstrumentFeeUpfrontFee_DC9F2AE28CC3BD6216F6E32FED157102_documentation_en-US" xlink:label="lab_optn_DebtInstrumentFeeUpfrontFee_DC9F2AE28CC3BD6216F6E32FED157102" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument Fee, Upfront Fee</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentFeeUpfrontFee" xlink:label="loc_optn_DebtInstrumentFeeUpfrontFee_DC9F2AE28CC3BD6216F6E32FED157102" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DebtInstrumentFeeUpfrontFee_DC9F2AE28CC3BD6216F6E32FED157102" xlink:to="lab_optn_DebtInstrumentFeeUpfrontFee_DC9F2AE28CC3BD6216F6E32FED157102" xlink:type="arc" />
    <link:label id="lab_optn_DebtInstrumentFeeExitFee_5F9B145128CA98853EA4E32FED15B09D_terseLabel_en-US" xlink:label="lab_optn_DebtInstrumentFeeExitFee_5F9B145128CA98853EA4E32FED15B09D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exit fee</link:label>
    <link:label id="lab_optn_DebtInstrumentFeeExitFee_5F9B145128CA98853EA4E32FED15B09D_label_en-US" xlink:label="lab_optn_DebtInstrumentFeeExitFee_5F9B145128CA98853EA4E32FED15B09D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Fee, Exit Fee</link:label>
    <link:label id="lab_optn_DebtInstrumentFeeExitFee_5F9B145128CA98853EA4E32FED15B09D_documentation_en-US" xlink:label="lab_optn_DebtInstrumentFeeExitFee_5F9B145128CA98853EA4E32FED15B09D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument Fee, Exit Fee</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentFeeExitFee" xlink:label="loc_optn_DebtInstrumentFeeExitFee_5F9B145128CA98853EA4E32FED15B09D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DebtInstrumentFeeExitFee_5F9B145128CA98853EA4E32FED15B09D" xlink:to="lab_optn_DebtInstrumentFeeExitFee_5F9B145128CA98853EA4E32FED15B09D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_834665F2BF2630A807FEE32FED15F85F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_834665F2BF2630A807FEE32FED15F85F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption price rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_834665F2BF2630A807FEE32FED15F85F_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_834665F2BF2630A807FEE32FED15F85F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_834665F2BF2630A807FEE32FED15F85F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_834665F2BF2630A807FEE32FED15F85F" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_834665F2BF2630A807FEE32FED15F85F" xlink:type="arc" />
    <link:label id="lab_optn_DebtInstrumentPrepaymentFee_D7C4EB5E70F35963B042E32FED154C95_terseLabel_en-US" xlink:label="lab_optn_DebtInstrumentPrepaymentFee_D7C4EB5E70F35963B042E32FED154C95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment fee</link:label>
    <link:label id="lab_optn_DebtInstrumentPrepaymentFee_D7C4EB5E70F35963B042E32FED154C95_label_en-US" xlink:label="lab_optn_DebtInstrumentPrepaymentFee_D7C4EB5E70F35963B042E32FED154C95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee</link:label>
    <link:label id="lab_optn_DebtInstrumentPrepaymentFee_D7C4EB5E70F35963B042E32FED154C95_documentation_en-US" xlink:label="lab_optn_DebtInstrumentPrepaymentFee_D7C4EB5E70F35963B042E32FED154C95" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentPrepaymentFee" xlink:label="loc_optn_DebtInstrumentPrepaymentFee_D7C4EB5E70F35963B042E32FED154C95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DebtInstrumentPrepaymentFee_D7C4EB5E70F35963B042E32FED154C95" xlink:to="lab_optn_DebtInstrumentPrepaymentFee_D7C4EB5E70F35963B042E32FED154C95" xlink:type="arc" />
    <link:label id="lab_optn_DebtInstrumentCovenantCashandCashEquivalents_3CE30D7802798C93D035E32FED15E260_terseLabel_en-US" xlink:label="lab_optn_DebtInstrumentCovenantCashandCashEquivalents_3CE30D7802798C93D035E32FED15E260" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Covenant, cash and cash equivalents</link:label>
    <link:label id="lab_optn_DebtInstrumentCovenantCashandCashEquivalents_3CE30D7802798C93D035E32FED15E260_label_en-US" xlink:label="lab_optn_DebtInstrumentCovenantCashandCashEquivalents_3CE30D7802798C93D035E32FED15E260" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Cash and Cash Equivalents</link:label>
    <link:label id="lab_optn_DebtInstrumentCovenantCashandCashEquivalents_3CE30D7802798C93D035E32FED15E260_documentation_en-US" xlink:label="lab_optn_DebtInstrumentCovenantCashandCashEquivalents_3CE30D7802798C93D035E32FED15E260" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentCovenantCashandCashEquivalents" xlink:label="loc_optn_DebtInstrumentCovenantCashandCashEquivalents_3CE30D7802798C93D035E32FED15E260" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DebtInstrumentCovenantCashandCashEquivalents_3CE30D7802798C93D035E32FED15E260" xlink:to="lab_optn_DebtInstrumentCovenantCashandCashEquivalents_3CE30D7802798C93D035E32FED15E260" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_B9C433A0BE44B65A696DE32FED16EF35_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_B9C433A0BE44B65A696DE32FED16EF35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_B9C433A0BE44B65A696DE32FED16EF35_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_B9C433A0BE44B65A696DE32FED16EF35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_B9C433A0BE44B65A696DE32FED16EF35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium_B9C433A0BE44B65A696DE32FED16EF35" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium_B9C433A0BE44B65A696DE32FED16EF35" xlink:type="arc" />
    <link:label id="lab_optn_DebtDiscountAmortizationPeriod_0D3464BEE039A14182FAE32FED16A0D2_terseLabel_en-US" xlink:label="lab_optn_DebtDiscountAmortizationPeriod_0D3464BEE039A14182FAE32FED16A0D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt amortization period</link:label>
    <link:label id="lab_optn_DebtDiscountAmortizationPeriod_0D3464BEE039A14182FAE32FED16A0D2_label_en-US" xlink:label="lab_optn_DebtDiscountAmortizationPeriod_0D3464BEE039A14182FAE32FED16A0D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Discount Amortization Period</link:label>
    <link:label id="lab_optn_DebtDiscountAmortizationPeriod_0D3464BEE039A14182FAE32FED16A0D2_documentation_en-US" xlink:label="lab_optn_DebtDiscountAmortizationPeriod_0D3464BEE039A14182FAE32FED16A0D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Discount Amortization Period</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtDiscountAmortizationPeriod" xlink:label="loc_optn_DebtDiscountAmortizationPeriod_0D3464BEE039A14182FAE32FED16A0D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DebtDiscountAmortizationPeriod_0D3464BEE039A14182FAE32FED16A0D2" xlink:to="lab_optn_DebtDiscountAmortizationPeriod_0D3464BEE039A14182FAE32FED16A0D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_3CD00922277B3A07C766E32FED17F260_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross_3CD00922277B3A07C766E32FED17F260" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_3CD00922277B3A07C766E32FED17F260_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross_3CD00922277B3A07C766E32FED17F260" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_3CD00922277B3A07C766E32FED17F260" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross_3CD00922277B3A07C766E32FED17F260" xlink:to="lab_us-gaap_DeferredFinanceCostsGross_3CD00922277B3A07C766E32FED17F260" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_87483361ABB4CF7BED3DE32FED17730E_terseLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense_87483361ABB4CF7BED3DE32FED17730E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_87483361ABB4CF7BED3DE32FED17730E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense_87483361ABB4CF7BED3DE32FED17730E" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense_87483361ABB4CF7BED3DE32FED17730E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_FC30EC63874B33AAFF533A56216DD5E7_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_FC30EC63874B33AAFF533A56216DD5E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_FC30EC63874B33AAFF533A56216DD5E7_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_FC30EC63874B33AAFF533A56216DD5E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_FC30EC63874B33AAFF533A56216DD5E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_FC30EC63874B33AAFF533A56216DD5E7" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_FC30EC63874B33AAFF533A56216DD5E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense_F3BD46B49549ECC6575B3A56216DDD74_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense_F3BD46B49549ECC6575B3A56216DDD74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense_F3BD46B49549ECC6575B3A56216DDD74_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense_F3BD46B49549ECC6575B3A56216DDD74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_F3BD46B49549ECC6575B3A56216DDD74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_F3BD46B49549ECC6575B3A56216DDD74" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense_F3BD46B49549ECC6575B3A56216DDD74" xlink:type="arc" />
    <link:label id="lab_optn_DeferredTaxAssetsPrepaidLicenseArrangement_562BD6D5243F80A5A5173A688C68DA44_terseLabel_en-US" xlink:label="lab_optn_DeferredTaxAssetsPrepaidLicenseArrangement_562BD6D5243F80A5A5173A688C68DA44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid licensing arrangement</link:label>
    <link:label id="lab_optn_DeferredTaxAssetsPrepaidLicenseArrangement_562BD6D5243F80A5A5173A688C68DA44_label_en-US" xlink:label="lab_optn_DeferredTaxAssetsPrepaidLicenseArrangement_562BD6D5243F80A5A5173A688C68DA44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Prepaid License Arrangement</link:label>
    <link:label id="lab_optn_DeferredTaxAssetsPrepaidLicenseArrangement_562BD6D5243F80A5A5173A688C68DA44_documentation_en-US" xlink:label="lab_optn_DeferredTaxAssetsPrepaidLicenseArrangement_562BD6D5243F80A5A5173A688C68DA44" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Prepaid License Arrangement</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_DeferredTaxAssetsPrepaidLicenseArrangement" xlink:label="loc_optn_DeferredTaxAssetsPrepaidLicenseArrangement_562BD6D5243F80A5A5173A688C68DA44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DeferredTaxAssetsPrepaidLicenseArrangement_562BD6D5243F80A5A5173A688C68DA44" xlink:to="lab_optn_DeferredTaxAssetsPrepaidLicenseArrangement_562BD6D5243F80A5A5173A688C68DA44" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_00212CBCF3FB35769F4B3A56216E89BD_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_00212CBCF3FB35769F4B3A56216E89BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_00212CBCF3FB35769F4B3A56216E89BD_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_00212CBCF3FB35769F4B3A56216E89BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_00212CBCF3FB35769F4B3A56216E89BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_00212CBCF3FB35769F4B3A56216E89BD" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_00212CBCF3FB35769F4B3A56216E89BD" xlink:type="arc" />
    <link:label id="lab_optn_DeferredTaxAssetsInterestExpense_102E58D296D98BB4E7573A56216E891D_terseLabel_en-US" xlink:label="lab_optn_DeferredTaxAssetsInterestExpense_102E58D296D98BB4E7573A56216E891D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_optn_DeferredTaxAssetsInterestExpense_102E58D296D98BB4E7573A56216E891D_label_en-US" xlink:label="lab_optn_DeferredTaxAssetsInterestExpense_102E58D296D98BB4E7573A56216E891D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Interest Expense</link:label>
    <link:label id="lab_optn_DeferredTaxAssetsInterestExpense_102E58D296D98BB4E7573A56216E891D_documentation_en-US" xlink:label="lab_optn_DeferredTaxAssetsInterestExpense_102E58D296D98BB4E7573A56216E891D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Interest Expense</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_DeferredTaxAssetsInterestExpense" xlink:label="loc_optn_DeferredTaxAssetsInterestExpense_102E58D296D98BB4E7573A56216E891D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DeferredTaxAssetsInterestExpense_102E58D296D98BB4E7573A56216E891D" xlink:to="lab_optn_DeferredTaxAssetsInterestExpense_102E58D296D98BB4E7573A56216E891D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_6137CB29ED1DA917B3803A56216EE6AB_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_6137CB29ED1DA917B3803A56216EE6AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_6137CB29ED1DA917B3803A56216EE6AB_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_6137CB29ED1DA917B3803A56216EE6AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_6137CB29ED1DA917B3803A56216EE6AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_6137CB29ED1DA917B3803A56216EE6AB" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_6137CB29ED1DA917B3803A56216EE6AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_41E4CDF2BAEF35398A973A56216E82FB_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_41E4CDF2BAEF35398A973A56216E82FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_41E4CDF2BAEF35398A973A56216E82FB_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_41E4CDF2BAEF35398A973A56216E82FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_41E4CDF2BAEF35398A973A56216E82FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_41E4CDF2BAEF35398A973A56216E82FB" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_41E4CDF2BAEF35398A973A56216E82FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8BC188A2B8046CB66E713A56216E4ADA_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8BC188A2B8046CB66E713A56216E4ADA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8BC188A2B8046CB66E713A56216E4ADA_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8BC188A2B8046CB66E713A56216E4ADA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8BC188A2B8046CB66E713A56216E4ADA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8BC188A2B8046CB66E713A56216E4ADA" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8BC188A2B8046CB66E713A56216E4ADA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_4CB19E8630B8A54B41F53A56216F6633_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_4CB19E8630B8A54B41F53A56216F6633" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_4CB19E8630B8A54B41F53A56216F6633_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_4CB19E8630B8A54B41F53A56216F6633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_4CB19E8630B8A54B41F53A56216F6633" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4CB19E8630B8A54B41F53A56216F6633" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_4CB19E8630B8A54B41F53A56216F6633" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_8A9A3E830BDCE20733453A56216F8532_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_8A9A3E830BDCE20733453A56216F8532" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_8A9A3E830BDCE20733453A56216F8532_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_8A9A3E830BDCE20733453A56216F8532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_8A9A3E830BDCE20733453A56216F8532" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_8A9A3E830BDCE20733453A56216F8532" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_8A9A3E830BDCE20733453A56216F8532" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_DACC0D74FE717B284DA83A56216F2E51_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_DACC0D74FE717B284DA83A56216F2E51" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_DACC0D74FE717B284DA83A56216F2E51_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_DACC0D74FE717B284DA83A56216F2E51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_DACC0D74FE717B284DA83A56216F2E51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_DACC0D74FE717B284DA83A56216F2E51" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_DACC0D74FE717B284DA83A56216F2E51" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_3D1D98839B382B95BFF53A56216F5C0E_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_3D1D98839B382B95BFF53A56216F5C0E" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_3D1D98839B382B95BFF53A56216F5C0E_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_3D1D98839B382B95BFF53A56216F5C0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_3D1D98839B382B95BFF53A56216F5C0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_3D1D98839B382B95BFF53A56216F5C0E" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities_3D1D98839B382B95BFF53A56216F5C0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2CE380FD48B64C907C803A56216F78BF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2CE380FD48B64C907C803A56216F78BF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2CE380FD48B64C907C803A56216F78BF_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2CE380FD48B64C907C803A56216F78BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2CE380FD48B64C907C803A56216F78BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2CE380FD48B64C907C803A56216F78BF" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2CE380FD48B64C907C803A56216F78BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_AC976458954FDE5D8EEF3A56216F4444_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_AC976458954FDE5D8EEF3A56216F4444" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total net deferred tax assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_AC976458954FDE5D8EEF3A56216F4444_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_AC976458954FDE5D8EEF3A56216F4444" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_AC976458954FDE5D8EEF3A56216F4444" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_AC976458954FDE5D8EEF3A56216F4444" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_AC976458954FDE5D8EEF3A56216F4444" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_F81624CD4CB48EB21CC4DED0E25320A1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_F81624CD4CB48EB21CC4DED0E25320A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_F81624CD4CB48EB21CC4DED0E25320A1_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_F81624CD4CB48EB21CC4DED0E25320A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_F81624CD4CB48EB21CC4DED0E25320A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_F81624CD4CB48EB21CC4DED0E25320A1" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_F81624CD4CB48EB21CC4DED0E25320A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_DD6A60BDF0AA0BEE3654DED0E54880D4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_DD6A60BDF0AA0BEE3654DED0E54880D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_DD6A60BDF0AA0BEE3654DED0E54880D4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_DD6A60BDF0AA0BEE3654DED0E54880D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_DD6A60BDF0AA0BEE3654DED0E54880D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_DD6A60BDF0AA0BEE3654DED0E54880D4" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_DD6A60BDF0AA0BEE3654DED0E54880D4" xlink:type="arc" />
    <link:label id="lab_optn_DocumentandEntityInformationAbstract_E10CF69332DFE5216370DED712107CF7_label_en-US" xlink:label="lab_optn_DocumentandEntityInformationAbstract_E10CF69332DFE5216370DED712107CF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:label id="lab_optn_DocumentandEntityInformationAbstract_E10CF69332DFE5216370DED712107CF7_documentation_en-US" xlink:label="lab_optn_DocumentandEntityInformationAbstract_E10CF69332DFE5216370DED712107CF7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_DocumentandEntityInformationAbstract" xlink:label="loc_optn_DocumentandEntityInformationAbstract_E10CF69332DFE5216370DED712107CF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_DocumentandEntityInformationAbstract_E10CF69332DFE5216370DED712107CF7" xlink:to="lab_optn_DocumentandEntityInformationAbstract_E10CF69332DFE5216370DED712107CF7" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_E711ED626FB8C7CFC798DED71220B5E9_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_E711ED626FB8C7CFC798DED71220B5E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_E711ED626FB8C7CFC798DED71220B5E9_label_en-US" xlink:label="lab_dei_EntityRegistrantName_E711ED626FB8C7CFC798DED71220B5E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_E711ED626FB8C7CFC798DED71220B5E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_E711ED626FB8C7CFC798DED71220B5E9" xlink:to="lab_dei_EntityRegistrantName_E711ED626FB8C7CFC798DED71220B5E9" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_6EEECFB700205A4C2E65DED712207E86_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_6EEECFB700205A4C2E65DED712207E86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_6EEECFB700205A4C2E65DED712207E86_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_6EEECFB700205A4C2E65DED712207E86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_6EEECFB700205A4C2E65DED712207E86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_6EEECFB700205A4C2E65DED712207E86" xlink:to="lab_dei_EntityCentralIndexKey_6EEECFB700205A4C2E65DED712207E86" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_146AA6E76155D30A31BEDED7122047AC_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_146AA6E76155D30A31BEDED7122047AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_146AA6E76155D30A31BEDED7122047AC_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_146AA6E76155D30A31BEDED7122047AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_146AA6E76155D30A31BEDED7122047AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_146AA6E76155D30A31BEDED7122047AC" xlink:to="lab_dei_CurrentFiscalYearEndDate_146AA6E76155D30A31BEDED7122047AC" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_0DE85F7966B162F38C3BDED71220DAB7_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_0DE85F7966B162F38C3BDED71220DAB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_0DE85F7966B162F38C3BDED71220DAB7_label_en-US" xlink:label="lab_dei_EntityFilerCategory_0DE85F7966B162F38C3BDED71220DAB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_0DE85F7966B162F38C3BDED71220DAB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_0DE85F7966B162F38C3BDED71220DAB7" xlink:to="lab_dei_EntityFilerCategory_0DE85F7966B162F38C3BDED71220DAB7" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_A6CE4940906EFA835E2BDED71220DAEA_terseLabel_en-US" xlink:label="lab_dei_DocumentType_A6CE4940906EFA835E2BDED71220DAEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_A6CE4940906EFA835E2BDED71220DAEA_label_en-US" xlink:label="lab_dei_DocumentType_A6CE4940906EFA835E2BDED71220DAEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_A6CE4940906EFA835E2BDED71220DAEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_A6CE4940906EFA835E2BDED71220DAEA" xlink:to="lab_dei_DocumentType_A6CE4940906EFA835E2BDED71220DAEA" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_C555DC0A8A4CE19D2687DED712208664_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_C555DC0A8A4CE19D2687DED712208664" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_C555DC0A8A4CE19D2687DED712208664_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_C555DC0A8A4CE19D2687DED712208664" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_C555DC0A8A4CE19D2687DED712208664" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_C555DC0A8A4CE19D2687DED712208664" xlink:to="lab_dei_DocumentPeriodEndDate_C555DC0A8A4CE19D2687DED712208664" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_C5D133559611EB4A16C8DED712203E8F_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_C5D133559611EB4A16C8DED712203E8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_C5D133559611EB4A16C8DED712203E8F_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_C5D133559611EB4A16C8DED712203E8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_C5D133559611EB4A16C8DED712203E8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_C5D133559611EB4A16C8DED712203E8F" xlink:to="lab_dei_DocumentFiscalYearFocus_C5D133559611EB4A16C8DED712203E8F" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_87D8829DEC68CE9B4383DED712200C79_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_87D8829DEC68CE9B4383DED712200C79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_87D8829DEC68CE9B4383DED712200C79_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_87D8829DEC68CE9B4383DED712200C79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_87D8829DEC68CE9B4383DED712200C79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_87D8829DEC68CE9B4383DED712200C79" xlink:to="lab_dei_DocumentFiscalPeriodFocus_87D8829DEC68CE9B4383DED712200C79" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_C72292CF4D30DE39ECD1DED712208F80_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_C72292CF4D30DE39ECD1DED712208F80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_C72292CF4D30DE39ECD1DED712208F80_label_en-US" xlink:label="lab_dei_AmendmentFlag_C72292CF4D30DE39ECD1DED712208F80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_C72292CF4D30DE39ECD1DED712208F80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_C72292CF4D30DE39ECD1DED712208F80" xlink:to="lab_dei_AmendmentFlag_C72292CF4D30DE39ECD1DED712208F80" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_CB83FFC1438AE224526FDED71220F8A9_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_CB83FFC1438AE224526FDED71220F8A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_CB83FFC1438AE224526FDED71220F8A9_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_CB83FFC1438AE224526FDED71220F8A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_CB83FFC1438AE224526FDED71220F8A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_CB83FFC1438AE224526FDED71220F8A9" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_CB83FFC1438AE224526FDED71220F8A9" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_383107E9251B119306E1DED7122037B5_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_383107E9251B119306E1DED7122037B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_383107E9251B119306E1DED7122037B5_label_en-US" xlink:label="lab_dei_EntityPublicFloat_383107E9251B119306E1DED7122037B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_383107E9251B119306E1DED7122037B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_383107E9251B119306E1DED7122037B5" xlink:to="lab_dei_EntityPublicFloat_383107E9251B119306E1DED7122037B5" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_51F0DC66919F20AFFFEADED7122026FD_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_51F0DC66919F20AFFFEADED7122026FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_51F0DC66919F20AFFFEADED7122026FD_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_51F0DC66919F20AFFFEADED7122026FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_51F0DC66919F20AFFFEADED7122026FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_51F0DC66919F20AFFFEADED7122026FD" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_51F0DC66919F20AFFFEADED7122026FD" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_97AAFA33476B37BA8D99DED71220BA49_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_97AAFA33476B37BA8D99DED71220BA49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_97AAFA33476B37BA8D99DED71220BA49_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_97AAFA33476B37BA8D99DED71220BA49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_97AAFA33476B37BA8D99DED71220BA49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_97AAFA33476B37BA8D99DED71220BA49" xlink:to="lab_dei_EntityVoluntaryFilers_97AAFA33476B37BA8D99DED71220BA49" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_8D8213957BBCEAFD5C0CDED712209CBD_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_8D8213957BBCEAFD5C0CDED712209CBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_8D8213957BBCEAFD5C0CDED712209CBD_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_8D8213957BBCEAFD5C0CDED712209CBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_8D8213957BBCEAFD5C0CDED712209CBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_8D8213957BBCEAFD5C0CDED712209CBD" xlink:to="lab_dei_EntityCurrentReportingStatus_8D8213957BBCEAFD5C0CDED712209CBD" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_8B10CA119EB0359BFFFBDED71302319E_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_8B10CA119EB0359BFFFBDED71302319E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_8B10CA119EB0359BFFFBDED71302319E_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_8B10CA119EB0359BFFFBDED71302319E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_8B10CA119EB0359BFFFBDED71302319E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_8B10CA119EB0359BFFFBDED71302319E" xlink:to="lab_dei_EntitySmallBusiness_8B10CA119EB0359BFFFBDED71302319E" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7D14B44E5FC2D8376FBEDED7364F0FF0_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_7D14B44E5FC2D8376FBEDED7364F0FF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7D14B44E5FC2D8376FBEDED7364F0FF0_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_7D14B44E5FC2D8376FBEDED7364F0FF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_7D14B44E5FC2D8376FBEDED7364F0FF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_7D14B44E5FC2D8376FBEDED7364F0FF0" xlink:to="lab_dei_EntityEmergingGrowthCompany_7D14B44E5FC2D8376FBEDED7364F0FF0" xlink:type="arc" />
    <link:label id="lab_dei_EntityExTransitionPeriod_5BDEC66791996B90AAA9DED758131B22_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod_5BDEC66791996B90AAA9DED758131B22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_5BDEC66791996B90AAA9DED758131B22_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod_5BDEC66791996B90AAA9DED758131B22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_5BDEC66791996B90AAA9DED758131B22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_5BDEC66791996B90AAA9DED758131B22" xlink:to="lab_dei_EntityExTransitionPeriod_5BDEC66791996B90AAA9DED758131B22" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_ADFB7E3E868E4B0EF0F3DED77B222C62_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_ADFB7E3E868E4B0EF0F3DED77B222C62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_ADFB7E3E868E4B0EF0F3DED77B222C62_label_en-US" xlink:label="lab_dei_EntityShellCompany_ADFB7E3E868E4B0EF0F3DED77B222C62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_ADFB7E3E868E4B0EF0F3DED77B222C62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_ADFB7E3E868E4B0EF0F3DED77B222C62" xlink:to="lab_dei_EntityShellCompany_ADFB7E3E868E4B0EF0F3DED77B222C62" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636FA198625FBABF6C1BE3007C5994FB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636FA198625FBABF6C1BE3007C5994FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636FA198625FBABF6C1BE3007C5994FB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636FA198625FBABF6C1BE3007C5994FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636FA198625FBABF6C1BE3007C5994FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636FA198625FBABF6C1BE3007C5994FB" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636FA198625FBABF6C1BE3007C5994FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_13AA8922EDCAD5E99845E3007C59479C_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_13AA8922EDCAD5E99845E3007C59479C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_13AA8922EDCAD5E99845E3007C59479C_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_13AA8922EDCAD5E99845E3007C59479C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_13AA8922EDCAD5E99845E3007C59479C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_13AA8922EDCAD5E99845E3007C59479C" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_13AA8922EDCAD5E99845E3007C59479C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8F255C682D030E45E9FBE3007C599AE1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8F255C682D030E45E9FBE3007C599AE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8F255C682D030E45E9FBE3007C599AE1_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8F255C682D030E45E9FBE3007C599AE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8F255C682D030E45E9FBE3007C599AE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8F255C682D030E45E9FBE3007C599AE1" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8F255C682D030E45E9FBE3007C599AE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_F5130ADFF20F3F9857A3E3007C5AAE03_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember_F5130ADFF20F3F9857A3E3007C5AAE03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement Terms</link:label>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_F5130ADFF20F3F9857A3E3007C5AAE03_label_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember_F5130ADFF20F3F9857A3E3007C5AAE03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Terms [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_F5130ADFF20F3F9857A3E3007C5AAE03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAgreementTermsMember_F5130ADFF20F3F9857A3E3007C5AAE03" xlink:to="lab_us-gaap_LicenseAgreementTermsMember_F5130ADFF20F3F9857A3E3007C5AAE03" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_DCF337EC6438068C2A83E3007C5A0379_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_DCF337EC6438068C2A83E3007C5A0379" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_DCF337EC6438068C2A83E3007C5A0379_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_DCF337EC6438068C2A83E3007C5A0379" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_DCF337EC6438068C2A83E3007C5A0379" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_DCF337EC6438068C2A83E3007C5A0379" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_DCF337EC6438068C2A83E3007C5A0379" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromLicenseFeesReceived_D9CCEE5990A657563A29E3007C5A2113_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived_D9CCEE5990A657563A29E3007C5A2113" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate cash payments received from license agreement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLicenseFeesReceived_D9CCEE5990A657563A29E3007C5A2113_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived_D9CCEE5990A657563A29E3007C5A2113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from License Fees Received</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_D9CCEE5990A657563A29E3007C5A2113" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLicenseFeesReceived_D9CCEE5990A657563A29E3007C5A2113" xlink:to="lab_us-gaap_ProceedsFromLicenseFeesReceived_D9CCEE5990A657563A29E3007C5A2113" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0D103484BFC8238345B1E3007C5BAA88_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0D103484BFC8238345B1E3007C5BAA88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing revenues</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0D103484BFC8238345B1E3007C5BAA88_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0D103484BFC8238345B1E3007C5BAA88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0D103484BFC8238345B1E3007C5BAA88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0D103484BFC8238345B1E3007C5BAA88" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0D103484BFC8238345B1E3007C5BAA88" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_373962FAAFE8D434E7D949EC15CAF327_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_373962FAAFE8D434E7D949EC15CAF327" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_373962FAAFE8D434E7D949EC15CAF327_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_373962FAAFE8D434E7D949EC15CAF327" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_373962FAAFE8D434E7D949EC15CAF327" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_373962FAAFE8D434E7D949EC15CAF327" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_373962FAAFE8D434E7D949EC15CAF327" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_66D8A074820D76C4909549EC15CA85E1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems_66D8A074820D76C4909549EC15CA85E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_66D8A074820D76C4909549EC15CA85E1_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems_66D8A074820D76C4909549EC15CA85E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_66D8A074820D76C4909549EC15CA85E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_66D8A074820D76C4909549EC15CA85E1" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems_66D8A074820D76C4909549EC15CA85E1" xlink:type="arc" />
    <link:label id="lab_optn_FutureLiquidityTextBlock_ADB4738D73A7072FB92BDED0E476C643_terseLabel_en-US" xlink:label="lab_optn_FutureLiquidityTextBlock_ADB4738D73A7072FB92BDED0E476C643" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidity</link:label>
    <link:label id="lab_optn_FutureLiquidityTextBlock_ADB4738D73A7072FB92BDED0E476C643_label_en-US" xlink:label="lab_optn_FutureLiquidityTextBlock_ADB4738D73A7072FB92BDED0E476C643" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Liquidity [Text Block]</link:label>
    <link:label id="lab_optn_FutureLiquidityTextBlock_ADB4738D73A7072FB92BDED0E476C643_documentation_en-US" xlink:label="lab_optn_FutureLiquidityTextBlock_ADB4738D73A7072FB92BDED0E476C643" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Liquidity [Text Block]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_FutureLiquidityTextBlock" xlink:label="loc_optn_FutureLiquidityTextBlock_ADB4738D73A7072FB92BDED0E476C643" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_FutureLiquidityTextBlock_ADB4738D73A7072FB92BDED0E476C643" xlink:to="lab_optn_FutureLiquidityTextBlock_ADB4738D73A7072FB92BDED0E476C643" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2BD86E0F0F17D8875F2EDED0E56ED494_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2BD86E0F0F17D8875F2EDED0E56ED494" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service-based stock options activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2BD86E0F0F17D8875F2EDED0E56ED494_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2BD86E0F0F17D8875F2EDED0E56ED494" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2BD86E0F0F17D8875F2EDED0E56ED494" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2BD86E0F0F17D8875F2EDED0E56ED494" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2BD86E0F0F17D8875F2EDED0E56ED494" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1D1C82611F0171D3104BDED0E56E5948_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1D1C82611F0171D3104BDED0E56E5948" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Shares outstanding, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1D1C82611F0171D3104BDED0E56E5948_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1D1C82611F0171D3104BDED0E56E5948" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1D1C82611F0171D3104BDED0E56E5948" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1D1C82611F0171D3104BDED0E56E5948" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1D1C82611F0171D3104BDED0E56E5948" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A1BD84E7970F880580BDDED0E56E0E6D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A1BD84E7970F880580BDDED0E56E0E6D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A1BD84E7970F880580BDDED0E56E0E6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A1BD84E7970F880580BDDED0E56E0E6D" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A1BD84E7970F880580BDDED0E56E0E6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2A89BD924DBDFFD7FD93DED0E56F1FD4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2A89BD924DBDFFD7FD93DED0E56F1FD4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2A89BD924DBDFFD7FD93DED0E56F1FD4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2A89BD924DBDFFD7FD93DED0E56F1FD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2A89BD924DBDFFD7FD93DED0E56F1FD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2A89BD924DBDFFD7FD93DED0E56F1FD4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2A89BD924DBDFFD7FD93DED0E56F1FD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_307511807118457BD14FDED0E56F6C29_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_307511807118457BD14FDED0E56F6C29" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_307511807118457BD14FDED0E56F6C29_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_307511807118457BD14FDED0E56F6C29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_307511807118457BD14FDED0E56F6C29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_307511807118457BD14FDED0E56F6C29" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_307511807118457BD14FDED0E56F6C29" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3C479B3A19E96A0393B1DED0E56F7871_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3C479B3A19E96A0393B1DED0E56F7871" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Shares outstanding, ending (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3C479B3A19E96A0393B1DED0E56F7871" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3C479B3A19E96A0393B1DED0E56F7871" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3C479B3A19E96A0393B1DED0E56F7871" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_414AF0326CAD587A832BDED0E56F048D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_414AF0326CAD587A832BDED0E56F048D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_414AF0326CAD587A832BDED0E56F048D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_414AF0326CAD587A832BDED0E56F048D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_414AF0326CAD587A832BDED0E56F048D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_414AF0326CAD587A832BDED0E56F048D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_414AF0326CAD587A832BDED0E56F048D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F74680DD484BF121D169DED0E56F2D40_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F74680DD484BF121D169DED0E56F2D40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at end of period(in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F74680DD484BF121D169DED0E56F2D40_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F74680DD484BF121D169DED0E56F2D40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F74680DD484BF121D169DED0E56F2D40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F74680DD484BF121D169DED0E56F2D40" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F74680DD484BF121D169DED0E56F2D40" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7F9B81D20648910B8BA2DED0E56FCB4C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7F9B81D20648910B8BA2DED0E56FCB4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service-based stock options weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7F9B81D20648910B8BA2DED0E56FCB4C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7F9B81D20648910B8BA2DED0E56FCB4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7F9B81D20648910B8BA2DED0E56FCB4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7F9B81D20648910B8BA2DED0E56FCB4C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7F9B81D20648910B8BA2DED0E56FCB4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21A80D64D4B3F4233E22DED0E56FD7C9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21A80D64D4B3F4233E22DED0E56FD7C9" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21A80D64D4B3F4233E22DED0E56FD7C9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21A80D64D4B3F4233E22DED0E56FD7C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21A80D64D4B3F4233E22DED0E56FD7C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21A80D64D4B3F4233E22DED0E56FD7C9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21A80D64D4B3F4233E22DED0E56FD7C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8B929ADF7E51A8FA5A9FDED0E5702CEA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8B929ADF7E51A8FA5A9FDED0E5702CEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted, Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8B929ADF7E51A8FA5A9FDED0E5702CEA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8B929ADF7E51A8FA5A9FDED0E5702CEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8B929ADF7E51A8FA5A9FDED0E5702CEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8B929ADF7E51A8FA5A9FDED0E5702CEA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8B929ADF7E51A8FA5A9FDED0E5702CEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40A0C686E36813D71FC7DED0E57002BA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40A0C686E36813D71FC7DED0E57002BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised, Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40A0C686E36813D71FC7DED0E57002BA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40A0C686E36813D71FC7DED0E57002BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40A0C686E36813D71FC7DED0E57002BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40A0C686E36813D71FC7DED0E57002BA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40A0C686E36813D71FC7DED0E57002BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4C5EA7CF481677FBFA5BDED0E5707E24_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4C5EA7CF481677FBFA5BDED0E5707E24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired, Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4C5EA7CF481677FBFA5BDED0E5707E24_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4C5EA7CF481677FBFA5BDED0E5707E24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4C5EA7CF481677FBFA5BDED0E5707E24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4C5EA7CF481677FBFA5BDED0E5707E24" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4C5EA7CF481677FBFA5BDED0E5707E24" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_86DA28CC08F1EF232582DED0E5703972_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_86DA28CC08F1EF232582DED0E5703972" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited, Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_86DA28CC08F1EF232582DED0E5703972_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_86DA28CC08F1EF232582DED0E5703972" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_86DA28CC08F1EF232582DED0E5703972" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_86DA28CC08F1EF232582DED0E5703972" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_86DA28CC08F1EF232582DED0E5703972" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4B9B526228AB8384CE9CDED0E5710F78_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4B9B526228AB8384CE9CDED0E5710F78" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, Weighted average exercise price (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4B9B526228AB8384CE9CDED0E5710F78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4B9B526228AB8384CE9CDED0E5710F78" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4B9B526228AB8384CE9CDED0E5710F78" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0DBDBC06725553A2FF70DED0E5718639_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0DBDBC06725553A2FF70DED0E5718639" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, Weighted average exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0DBDBC06725553A2FF70DED0E5718639_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0DBDBC06725553A2FF70DED0E5718639" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0DBDBC06725553A2FF70DED0E5718639" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0DBDBC06725553A2FF70DED0E5718639" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0DBDBC06725553A2FF70DED0E5718639" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_D29ACDC7D47CFBA40E8CDED0E571CFF1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_D29ACDC7D47CFBA40E8CDED0E571CFF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, Weighted average exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_D29ACDC7D47CFBA40E8CDED0E571CFF1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_D29ACDC7D47CFBA40E8CDED0E571CFF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_D29ACDC7D47CFBA40E8CDED0E571CFF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_D29ACDC7D47CFBA40E8CDED0E571CFF1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_D29ACDC7D47CFBA40E8CDED0E571CFF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_04A3F1B7BFC78C01C227DED0E571F102_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_04A3F1B7BFC78C01C227DED0E571F102" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service-based stock options, additional disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_04A3F1B7BFC78C01C227DED0E571F102_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_04A3F1B7BFC78C01C227DED0E571F102" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_04A3F1B7BFC78C01C227DED0E571F102" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_04A3F1B7BFC78C01C227DED0E571F102" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_04A3F1B7BFC78C01C227DED0E571F102" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0861AE86047380744C6ADED0E572B7B9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0861AE86047380744C6ADED0E572B7B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, Weighted average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0861AE86047380744C6ADED0E572B7B9_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0861AE86047380744C6ADED0E572B7B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0861AE86047380744C6ADED0E572B7B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0861AE86047380744C6ADED0E572B7B9" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0861AE86047380744C6ADED0E572B7B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_61E161D0D0490B590196DED0E57265C2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_61E161D0D0490B590196DED0E57265C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, Weighted average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_61E161D0D0490B590196DED0E57265C2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_61E161D0D0490B590196DED0E57265C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_61E161D0D0490B590196DED0E57265C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_61E161D0D0490B590196DED0E57265C2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_61E161D0D0490B590196DED0E57265C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_67DEACCFFA01773310A1DED0E5724B5C_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_67DEACCFFA01773310A1DED0E5724B5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, Weighted average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_67DEACCFFA01773310A1DED0E5724B5C_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_67DEACCFFA01773310A1DED0E5724B5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_67DEACCFFA01773310A1DED0E5724B5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_67DEACCFFA01773310A1DED0E5724B5C" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_67DEACCFFA01773310A1DED0E5724B5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_FD841BEC39C60BC5761849EC1637488C_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_FD841BEC39C60BC5761849EC1637488C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_FD841BEC39C60BC5761849EC1637488C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_FD841BEC39C60BC5761849EC1637488C" xlink:to="lab_us-gaap_IncomeStatementAbstract_FD841BEC39C60BC5761849EC1637488C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6CE97574615C9076126D49EC16375BD1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6CE97574615C9076126D49EC16375BD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross margin</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6CE97574615C9076126D49EC16375BD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6CE97574615C9076126D49EC16375BD1" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6CE97574615C9076126D49EC16375BD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_2EAC17C3C5BCEDEF86F64A35B8D6CBD4_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_2EAC17C3C5BCEDEF86F64A35B8D6CBD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of product sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_2EAC17C3C5BCEDEF86F64A35B8D6CBD4_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_2EAC17C3C5BCEDEF86F64A35B8D6CBD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2EAC17C3C5BCEDEF86F64A35B8D6CBD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_2EAC17C3C5BCEDEF86F64A35B8D6CBD4" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_2EAC17C3C5BCEDEF86F64A35B8D6CBD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrossProfit_E6F143CA17FB38AAA6444A369BD2EA2B_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit_E6F143CA17FB38AAA6444A369BD2EA2B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross margin</link:label>
    <link:label id="lab_us-gaap_GrossProfit_E6F143CA17FB38AAA6444A369BD2EA2B_label_en-US" xlink:label="lab_us-gaap_GrossProfit_E6F143CA17FB38AAA6444A369BD2EA2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_E6F143CA17FB38AAA6444A369BD2EA2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_E6F143CA17FB38AAA6444A369BD2EA2B" xlink:to="lab_us-gaap_GrossProfit_E6F143CA17FB38AAA6444A369BD2EA2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_DFCA76CA2835753C0E8349EC16378974_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_DFCA76CA2835753C0E8349EC16378974" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_DFCA76CA2835753C0E8349EC16378974_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_DFCA76CA2835753C0E8349EC16378974" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_DFCA76CA2835753C0E8349EC16378974" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_DFCA76CA2835753C0E8349EC16378974" xlink:to="lab_us-gaap_OperatingExpensesAbstract_DFCA76CA2835753C0E8349EC16378974" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_D029BF6312C92B0DD3AD49EC163762AE_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_D029BF6312C92B0DD3AD49EC163762AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_D029BF6312C92B0DD3AD49EC163762AE_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_D029BF6312C92B0DD3AD49EC163762AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_D029BF6312C92B0DD3AD49EC163762AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_D029BF6312C92B0DD3AD49EC163762AE" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_D029BF6312C92B0DD3AD49EC163762AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_04090502EDF4E8ED0A1C49EC1637DEF3_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_04090502EDF4E8ED0A1C49EC1637DEF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_04090502EDF4E8ED0A1C49EC1637DEF3_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_04090502EDF4E8ED0A1C49EC1637DEF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_04090502EDF4E8ED0A1C49EC1637DEF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_04090502EDF4E8ED0A1C49EC1637DEF3" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_04090502EDF4E8ED0A1C49EC1637DEF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_DCA2BF0246BA27CD273449EC1637267F_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_DCA2BF0246BA27CD273449EC1637267F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_DCA2BF0246BA27CD273449EC1637267F_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_DCA2BF0246BA27CD273449EC1637267F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_DCA2BF0246BA27CD273449EC1637267F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_DCA2BF0246BA27CD273449EC1637267F" xlink:to="lab_us-gaap_OperatingExpenses_DCA2BF0246BA27CD273449EC1637267F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_267090600F89F5661D3749EC16373B3F_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_267090600F89F5661D3749EC16373B3F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_267090600F89F5661D3749EC16373B3F_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_267090600F89F5661D3749EC16373B3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_267090600F89F5661D3749EC16373B3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_267090600F89F5661D3749EC16373B3F" xlink:to="lab_us-gaap_OperatingIncomeLoss_267090600F89F5661D3749EC16373B3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_FA6511516EFEC4B282A549EC1637CBD5_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_FA6511516EFEC4B282A549EC1637CBD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (income) expense:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_FA6511516EFEC4B282A549EC1637CBD5_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_FA6511516EFEC4B282A549EC1637CBD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_FA6511516EFEC4B282A549EC1637CBD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_FA6511516EFEC4B282A549EC1637CBD5" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_FA6511516EFEC4B282A549EC1637CBD5" xlink:type="arc" />
    <link:label id="lab_optn_GrantandOtherIncome_D6F93283FF7A83D4946849EC1637037C_negatedLabel_en-US" xlink:label="lab_optn_GrantandOtherIncome_D6F93283FF7A83D4946849EC1637037C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Grant and other income</link:label>
    <link:label id="lab_optn_GrantandOtherIncome_D6F93283FF7A83D4946849EC1637037C_label_en-US" xlink:label="lab_optn_GrantandOtherIncome_D6F93283FF7A83D4946849EC1637037C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant and Other Income</link:label>
    <link:label id="lab_optn_GrantandOtherIncome_D6F93283FF7A83D4946849EC1637037C_documentation_en-US" xlink:label="lab_optn_GrantandOtherIncome_D6F93283FF7A83D4946849EC1637037C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grant and Other Income</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_GrantandOtherIncome" xlink:label="loc_optn_GrantandOtherIncome_D6F93283FF7A83D4946849EC1637037C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_GrantandOtherIncome_D6F93283FF7A83D4946849EC1637037C" xlink:to="lab_optn_GrantandOtherIncome_D6F93283FF7A83D4946849EC1637037C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_A706579867B62E867BC149EC163720C2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_A706579867B62E867BC149EC163720C2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_A706579867B62E867BC149EC163720C2_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_A706579867B62E867BC149EC163720C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_A706579867B62E867BC149EC163720C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_A706579867B62E867BC149EC163720C2" xlink:to="lab_us-gaap_InvestmentIncomeInterest_A706579867B62E867BC149EC163720C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_D4B2CD6F577E84B581DB49EC1637A977_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_D4B2CD6F577E84B581DB49EC1637A977" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_D4B2CD6F577E84B581DB49EC1637A977_label_en-US" xlink:label="lab_us-gaap_InterestExpense_D4B2CD6F577E84B581DB49EC1637A977" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_D4B2CD6F577E84B581DB49EC1637A977" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_D4B2CD6F577E84B581DB49EC1637A977" xlink:to="lab_us-gaap_InterestExpense_D4B2CD6F577E84B581DB49EC1637A977" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_777B82491103B843534949EC16375E60_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_777B82491103B843534949EC16375E60" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency (gains) losses</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_777B82491103B843534949EC16375E60_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_777B82491103B843534949EC16375E60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_777B82491103B843534949EC16375E60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_777B82491103B843534949EC16375E60" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_777B82491103B843534949EC16375E60" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_506641320BD4AA379D8749EC1637D606_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_506641320BD4AA379D8749EC1637D606" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_506641320BD4AA379D8749EC1637D606" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_506641320BD4AA379D8749EC1637D606" xlink:to="lab_us-gaap_NetIncomeLoss_506641320BD4AA379D8749EC1637D606" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityDividendsAdjustment_394A710FBD09EF39229449EC16373A41_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityDividendsAdjustment_394A710FBD09EF39229449EC16373A41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityDividendsAdjustment_394A710FBD09EF39229449EC16373A41_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityDividendsAdjustment_394A710FBD09EF39229449EC16373A41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Dividends, Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:label="loc_us-gaap_TemporaryEquityDividendsAdjustment_394A710FBD09EF39229449EC16373A41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDividendsAdjustment_394A710FBD09EF39229449EC16373A41" xlink:to="lab_us-gaap_TemporaryEquityDividendsAdjustment_394A710FBD09EF39229449EC16373A41" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_A1E791BD07BAB5574FF349EC1637B8ED_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_A1E791BD07BAB5574FF349EC1637B8ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accretion to redemption value</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_A1E791BD07BAB5574FF349EC1637B8ED_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_A1E791BD07BAB5574FF349EC1637B8ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Accretion to Redemption Value, Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_A1E791BD07BAB5574FF349EC1637B8ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_A1E791BD07BAB5574FF349EC1637B8ED" xlink:to="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_A1E791BD07BAB5574FF349EC1637B8ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_53041D76BBEEA5858AA649EC16371CA5_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_53041D76BBEEA5858AA649EC16371CA5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_53041D76BBEEA5858AA649EC16371CA5_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_53041D76BBEEA5858AA649EC16371CA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_53041D76BBEEA5858AA649EC16371CA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_53041D76BBEEA5858AA649EC16371CA5" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_53041D76BBEEA5858AA649EC16371CA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_47ADED516CC1F7AA463549EC16374A8B_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_47ADED516CC1F7AA463549EC16374A8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share of common stock,</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_47ADED516CC1F7AA463549EC16374A8B_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_47ADED516CC1F7AA463549EC16374A8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_47ADED516CC1F7AA463549EC16374A8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_47ADED516CC1F7AA463549EC16374A8B" xlink:to="lab_us-gaap_EarningsPerShareAbstract_47ADED516CC1F7AA463549EC16374A8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_3FFF7380ECE659B68BA549EC1637E118_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_3FFF7380ECE659B68BA549EC1637E118" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_3FFF7380ECE659B68BA549EC1637E118_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_3FFF7380ECE659B68BA549EC1637E118" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_3FFF7380ECE659B68BA549EC1637E118" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_3FFF7380ECE659B68BA549EC1637E118" xlink:to="lab_us-gaap_EarningsPerShareBasic_3FFF7380ECE659B68BA549EC1637E118" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_DD56591A793399AB6F8549EC16377AF5_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_DD56591A793399AB6F8549EC16377AF5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_DD56591A793399AB6F8549EC16377AF5_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_DD56591A793399AB6F8549EC16377AF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_DD56591A793399AB6F8549EC16377AF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_DD56591A793399AB6F8549EC16377AF5" xlink:to="lab_us-gaap_EarningsPerShareDiluted_DD56591A793399AB6F8549EC16377AF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_4D4B3274560836FA36FC49EC16375FC7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_4D4B3274560836FA36FC49EC16375FC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding,</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_4D4B3274560836FA36FC49EC16375FC7_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_4D4B3274560836FA36FC49EC16375FC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_4D4B3274560836FA36FC49EC16375FC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_4D4B3274560836FA36FC49EC16375FC7" xlink:to="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_4D4B3274560836FA36FC49EC16375FC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F11F73DE730090FF412449EC1637314B_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F11F73DE730090FF412449EC1637314B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F11F73DE730090FF412449EC1637314B_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F11F73DE730090FF412449EC1637314B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F11F73DE730090FF412449EC1637314B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F11F73DE730090FF412449EC1637314B" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F11F73DE730090FF412449EC1637314B" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E405E983F77C2F17E46B49EC1637D40B_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E405E983F77C2F17E46B49EC1637D40B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E405E983F77C2F17E46B49EC1637D40B_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E405E983F77C2F17E46B49EC1637D40B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E405E983F77C2F17E46B49EC1637D40B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E405E983F77C2F17E46B49EC1637D40B" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E405E983F77C2F17E46B49EC1637D40B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NatureOfOperations_25556FB6FC3D852EBD0FDED0E483AF1F_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations_25556FB6FC3D852EBD0FDED0E483AF1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_25556FB6FC3D852EBD0FDED0E483AF1F_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations_25556FB6FC3D852EBD0FDED0E483AF1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_25556FB6FC3D852EBD0FDED0E483AF1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_25556FB6FC3D852EBD0FDED0E483AF1F" xlink:to="lab_us-gaap_NatureOfOperations_25556FB6FC3D852EBD0FDED0E483AF1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_D5675AF0825B42876391DED0E16A2CD8_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_D5675AF0825B42876391DED0E16A2CD8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2010 A &amp; R Stock Incentive Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_D5675AF0825B42876391DED0E16A2CD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_D5675AF0825B42876391DED0E16A2CD8" xlink:to="lab_us-gaap_EmployeeStockOptionMember_D5675AF0825B42876391DED0E16A2CD8" xlink:type="arc" />
    <link:label id="lab_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_E6689088424171956D98DED0E16CA51A_verboseLabel_en-US" xlink:label="lab_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_E6689088424171956D98DED0E16CA51A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2017 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:label="loc_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_E6689088424171956D98DED0E16CA51A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_E6689088424171956D98DED0E16CA51A" xlink:to="lab_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_E6689088424171956D98DED0E16CA51A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F6F13E9609F44DEDA1F6DED0E16D9EFE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F6F13E9609F44DEDA1F6DED0E16D9EFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F6F13E9609F44DEDA1F6DED0E16D9EFE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F6F13E9609F44DEDA1F6DED0E16D9EFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F6F13E9609F44DEDA1F6DED0E16D9EFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F6F13E9609F44DEDA1F6DED0E16D9EFE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F6F13E9609F44DEDA1F6DED0E16D9EFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_CA5B7054E902B388B455DED0E16D9411_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_CA5B7054E902B388B455DED0E16D9411" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_CA5B7054E902B388B455DED0E16D9411_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_CA5B7054E902B388B455DED0E16D9411" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_CA5B7054E902B388B455DED0E16D9411" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_CA5B7054E902B388B455DED0E16D9411" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_CA5B7054E902B388B455DED0E16D9411" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_92DA9D4D48A770E1FDADDED0E16DE85F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_92DA9D4D48A770E1FDADDED0E16DE85F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_92DA9D4D48A770E1FDADDED0E16DE85F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_92DA9D4D48A770E1FDADDED0E16DE85F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_92DA9D4D48A770E1FDADDED0E16DE85F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_92DA9D4D48A770E1FDADDED0E16DE85F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_92DA9D4D48A770E1FDADDED0E16DE85F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_984E333ED2A30FB7B7C0DED0E16E1C4D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_984E333ED2A30FB7B7C0DED0E16E1C4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_984E333ED2A30FB7B7C0DED0E16E1C4D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_984E333ED2A30FB7B7C0DED0E16E1C4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_984E333ED2A30FB7B7C0DED0E16E1C4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_984E333ED2A30FB7B7C0DED0E16E1C4D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_984E333ED2A30FB7B7C0DED0E16E1C4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_667EECD1505233332C10DED0E3CE479E_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_667EECD1505233332C10DED0E3CE479E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_667EECD1505233332C10DED0E3CE479E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_667EECD1505233332C10DED0E3CE479E" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_667EECD1505233332C10DED0E3CE479E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_FACA36443CFE76D3D3ACDED0E3CEF45F_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_FACA36443CFE76D3D3ACDED0E3CEF45F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related-party transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_FACA36443CFE76D3D3ACDED0E3CEF45F_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_FACA36443CFE76D3D3ACDED0E3CEF45F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_FACA36443CFE76D3D3ACDED0E3CEF45F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_FACA36443CFE76D3D3ACDED0E3CEF45F" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_FACA36443CFE76D3D3ACDED0E3CEF45F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1D3B242B769F2F786705DED0E1467E92_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1D3B242B769F2F786705DED0E1467E92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1D3B242B769F2F786705DED0E1467E92_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1D3B242B769F2F786705DED0E1467E92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1D3B242B769F2F786705DED0E1467E92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1D3B242B769F2F786705DED0E1467E92" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1D3B242B769F2F786705DED0E1467E92" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A66DAB60A00B810A35D6DED0E14632B3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A66DAB60A00B810A35D6DED0E14632B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A66DAB60A00B810A35D6DED0E14632B3_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A66DAB60A00B810A35D6DED0E14632B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A66DAB60A00B810A35D6DED0E14632B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A66DAB60A00B810A35D6DED0E14632B3" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A66DAB60A00B810A35D6DED0E14632B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDomain_110A1AD603C88C8B128ADED0E1466204_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_110A1AD603C88C8B128ADED0E1466204" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_110A1AD603C88C8B128ADED0E1466204_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_110A1AD603C88C8B128ADED0E1466204" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_110A1AD603C88C8B128ADED0E1466204" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_110A1AD603C88C8B128ADED0E1466204" xlink:to="lab_us-gaap_RelatedPartyDomain_110A1AD603C88C8B128ADED0E1466204" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestorMember_2151AA7F0F0AE741086BDED0E14613B3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestorMember_2151AA7F0F0AE741086BDED0E14613B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investor</link:label>
    <link:label id="lab_us-gaap_InvestorMember_2151AA7F0F0AE741086BDED0E14613B3_label_en-US" xlink:label="lab_us-gaap_InvestorMember_2151AA7F0F0AE741086BDED0E14613B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investor [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_2151AA7F0F0AE741086BDED0E14613B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestorMember_2151AA7F0F0AE741086BDED0E14613B3" xlink:to="lab_us-gaap_InvestorMember_2151AA7F0F0AE741086BDED0E14613B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_1FEF78D659F2FB739B03DED0E1464240_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_1FEF78D659F2FB739B03DED0E1464240" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_1FEF78D659F2FB739B03DED0E1464240_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_1FEF78D659F2FB739B03DED0E1464240" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1FEF78D659F2FB739B03DED0E1464240" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1FEF78D659F2FB739B03DED0E1464240" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis_1FEF78D659F2FB739B03DED0E1464240" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_DB3574E3E53561B14404DED0E146C0E2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_DB3574E3E53561B14404DED0E146C0E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_DB3574E3E53561B14404DED0E146C0E2_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_DB3574E3E53561B14404DED0E146C0E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_DB3574E3E53561B14404DED0E146C0E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_DB3574E3E53561B14404DED0E146C0E2" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain_DB3574E3E53561B14404DED0E146C0E2" xlink:type="arc" />
    <link:label id="lab_optn_FeesForIPOAndSeriesDConvertibleStockMember_10F842CE5D369E0F333CDED0E1467276_terseLabel_en-US" xlink:label="lab_optn_FeesForIPOAndSeriesDConvertibleStockMember_10F842CE5D369E0F333CDED0E1467276" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fees For IPO And Series D Convertible Stock</link:label>
    <link:label id="lab_optn_FeesForIPOAndSeriesDConvertibleStockMember_10F842CE5D369E0F333CDED0E1467276_label_en-US" xlink:label="lab_optn_FeesForIPOAndSeriesDConvertibleStockMember_10F842CE5D369E0F333CDED0E1467276" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fees For IPO And Series D Convertible Stock [Member]</link:label>
    <link:label id="lab_optn_FeesForIPOAndSeriesDConvertibleStockMember_10F842CE5D369E0F333CDED0E1467276_documentation_en-US" xlink:label="lab_optn_FeesForIPOAndSeriesDConvertibleStockMember_10F842CE5D369E0F333CDED0E1467276" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fees For IPO And Series D Convertible Stock [Member]</link:label>
    <link:loc xlink:href="optn-20181231.xsd#optn_FeesForIPOAndSeriesDConvertibleStockMember" xlink:label="loc_optn_FeesForIPOAndSeriesDConvertibleStockMember_10F842CE5D369E0F333CDED0E1467276" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_optn_FeesForIPOAndSeriesDConvertibleStockMember_10F842CE5D369E0F333CDED0E1467276" xlink:to="lab_optn_FeesForIPOAndSeriesDConvertibleStockMember_10F842CE5D369E0F333CDED0E1467276" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_AA131C9521C8746B2E4DDED0E1466CDA_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_AA131C9521C8746B2E4DDED0E1466CDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_AA131C9521C8746B2E4DDED0E1466CDA_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_AA131C9521C8746B2E4DDED0E1466CDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_AA131C9521C8746B2E4DDED0E1466CDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_AA131C9521C8746B2E4DDED0E1466CDA" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_AA131C9521C8746B2E4DDED0E1466CDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_23B3C6AC55D1EC9DE50DDED0E146F9DD_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_23B3C6AC55D1EC9DE50DDED0E146F9DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_23B3C6AC55D1EC9DE50DDED0E146F9DD_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_23B3C6AC55D1EC9DE50DDED0E146F9DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_23B3C6AC55D1EC9DE50DDED0E146F9DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_23B3C6AC55D1EC9DE50DDED0E146F9DD" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_23B3C6AC55D1EC9DE50DDED0E146F9DD" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>optn-20181231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.optinose.com/role/AccruedExpenses" xlink:href="optn-20181231.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/AccruedExpensesDetails" xlink:href="optn-20181231.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/AccruedExpensesTables" xlink:href="optn-20181231.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/Avp825LicenseAgreement" xlink:href="optn-20181231.xsd#Avp825LicenseAgreement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/Avp825LicenseAgreementDetails" xlink:href="optn-20181231.xsd#Avp825LicenseAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/CommitmentsAndContingencies" xlink:href="optn-20181231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/CommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" xlink:href="optn-20181231.xsd#CommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/CommitmentsAndContingenciesLeasesDetails" xlink:href="optn-20181231.xsd#CommitmentsAndContingenciesLeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetails" xlink:href="optn-20181231.xsd#CommitmentsAndContingenciesPurchaseCommitmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/CommitmentsAndContingenciesTables" xlink:href="optn-20181231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedBalanceSheets" xlink:href="optn-20181231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="optn-20181231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="optn-20181231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholders" xlink:href="optn-20181231.xsd#ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholders" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersParenthetical" xlink:href="optn-20181231.xsd#ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedStatementsOfComprehensiveIncomeAndLoss" xlink:href="optn-20181231.xsd#ConsolidatedStatementsOfComprehensiveIncomeAndLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConsolidatedStatementsOfOperations" xlink:href="optn-20181231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConvertibleNotes" xlink:href="optn-20181231.xsd#ConvertibleNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/ConvertibleNotesNarrativeDetails" xlink:href="optn-20181231.xsd#ConvertibleNotesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/DocumentAndEntityInformationDocument" xlink:href="optn-20181231.xsd#DocumentAndEntityInformationDocument" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/EmployeeBenefitPlans" xlink:href="optn-20181231.xsd#EmployeeBenefitPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/EmployeeBenefitPlansDetails" xlink:href="optn-20181231.xsd#EmployeeBenefitPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxes" xlink:href="optn-20181231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxesNarrativeDetails" xlink:href="optn-20181231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="optn-20181231.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="optn-20181231.xsd#IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails" xlink:href="optn-20181231.xsd#IncomeTaxesScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/IncomeTaxesTables" xlink:href="optn-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/Inventory" xlink:href="optn-20181231.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/InventoryDetails" xlink:href="optn-20181231.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/InventoryTables" xlink:href="optn-20181231.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/Liquidity" xlink:href="optn-20181231.xsd#Liquidity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/LiquidityDetails" xlink:href="optn-20181231.xsd#LiquidityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/LongTermDebt" xlink:href="optn-20181231.xsd#LongTermDebt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/LongTermDebtNarrativeDetails" xlink:href="optn-20181231.xsd#LongTermDebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/LongTermDebtScheduleOfLongTermDebtDetails" xlink:href="optn-20181231.xsd#LongTermDebtScheduleOfLongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/LongTermDebtTables" xlink:href="optn-20181231.xsd#LongTermDebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="optn-20181231.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/PropertyAndEquipment" xlink:href="optn-20181231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/PropertyAndEquipmentDetails" xlink:href="optn-20181231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/PropertyAndEquipmentTables" xlink:href="optn-20181231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/RelatedPartyTransactions" xlink:href="optn-20181231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/RelatedPartyTransactionsDetails" xlink:href="optn-20181231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockBasedCompensation" xlink:href="optn-20181231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockBasedCompensationBlackScholesPricingModelOptionsDetails" xlink:href="optn-20181231.xsd#StockBasedCompensationBlackScholesPricingModelOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:href="optn-20181231.xsd#StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockBasedCompensationNarrativeDetails" xlink:href="optn-20181231.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" xlink:href="optn-20181231.xsd#StockBasedCompensationServiceBasedStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:href="optn-20181231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockBasedCompensationTables" xlink:href="optn-20181231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockholdersEquity" xlink:href="optn-20181231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockholdersEquityCommonStockDetails" xlink:href="optn-20181231.xsd#StockholdersEquityCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockholdersEquityDetails" xlink:href="optn-20181231.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/StockholdersEquityWarrantsDetails" xlink:href="optn-20181231.xsd#StockholdersEquityWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SubsequentEvents" xlink:href="optn-20181231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SubsequentEventsDetails" xlink:href="optn-20181231.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="optn-20181231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesAntidilutiveSharesExcludedFromEarningsPerShareDetails" xlink:href="optn-20181231.xsd#SummaryOfSignificantAccountingPoliciesAntidilutiveSharesExcludedFromEarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:href="optn-20181231.xsd#SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="optn-20181231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="optn-20181231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:href="optn-20181231.xsd#SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="optn-20181231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.optinose.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_3461C183A4B9818724B8DED0E54D3B87" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_FE955D6ECF492C20BFE7DED0E54EC74D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3461C183A4B9818724B8DED0E54D3B87" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_FE955D6ECF492C20BFE7DED0E54EC74D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_EA769D5C535A1B2F47DF3A562348AFE3" xlink:type="locator" />
    <link:loc xlink:href="optn-20181231.xsd#optn_AccruedSalesOrganizationExpensesCurrent" xlink:label="loc_optn_AccruedSalesOrganizationExpensesCurrent_4ABA373BAA220A642AE43A61356F72B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_EA769D5C535A1B2F47DF3A562348AFE3" xlink:to="loc_optn_AccruedSalesOrganizationExpensesCurrent_4ABA373BAA220A642AE43A61356F72B3" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_AccruedSellingGeneralandAdministrativeCurrent" xlink:label="loc_optn_AccruedSellingGeneralandAdministrativeCurrent_CEB32936B7CA1801F95A3A562348D49C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_EA769D5C535A1B2F47DF3A562348AFE3" xlink:to="loc_optn_AccruedSellingGeneralandAdministrativeCurrent_CEB32936B7CA1801F95A3A562348D49C" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_AccruedResearchandDevelopmentCurrent" xlink:label="loc_optn_AccruedResearchandDevelopmentCurrent_EE4A946C661162B7201A3A56234846E9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_EA769D5C535A1B2F47DF3A562348AFE3" xlink:to="loc_optn_AccruedResearchandDevelopmentCurrent_EE4A946C661162B7201A3A56234846E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent_5DFE4564918B093356183A562348C429" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_EA769D5C535A1B2F47DF3A562348AFE3" xlink:to="loc_us-gaap_AccruedBonusesCurrent_5DFE4564918B093356183A562348C429" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_FF06CEA79771AAAA22D53A56234823F9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_EA769D5C535A1B2F47DF3A562348AFE3" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_FF06CEA79771AAAA22D53A56234823F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_799A4A068357F7A141373A5623485C84" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_EA769D5C535A1B2F47DF3A562348AFE3" xlink:to="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_799A4A068357F7A141373A5623485C84" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_AccruedProductAllowancesCurrent" xlink:label="loc_optn_AccruedProductAllowancesCurrent_4C4D2482CDB9BEFB9D353A5623486D11" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_EA769D5C535A1B2F47DF3A562348AFE3" xlink:to="loc_optn_AccruedProductAllowancesCurrent_4C4D2482CDB9BEFB9D353A5623486D11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_92C550B9A6828DEF29333A56234818DA" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_EA769D5C535A1B2F47DF3A562348AFE3" xlink:to="loc_us-gaap_InterestPayableCurrent_92C550B9A6828DEF29333A56234818DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_B5EBC9D7BA30CC25997E3A5623485707" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_EA769D5C535A1B2F47DF3A562348AFE3" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_B5EBC9D7BA30CC25997E3A5623485707" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_B9DC6DCE2D71567BA6EC3A562348F2F4" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_EA769D5C535A1B2F47DF3A562348AFE3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_B9DC6DCE2D71567BA6EC3A562348F2F4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_40F5DA12DC8922CE6C45DED0E5252EDC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_A0A5791055D0D42147C8DED0E5258548" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_40F5DA12DC8922CE6C45DED0E5252EDC" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_A0A5791055D0D42147C8DED0E5258548" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/Avp825LicenseAgreement" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_5EC7E2F2EAC455E61966DED0E555DB70" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_1BFAD5A726C82DF45BFDDED0E55502F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_5EC7E2F2EAC455E61966DED0E555DB70" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_1BFAD5A726C82DF45BFDDED0E55502F2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/Avp825LicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_1452CE321C832938FD31E3007C586AD0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636FA198625FBABF6C1BE3007C5994FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_1452CE321C832938FD31E3007C586AD0" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636FA198625FBABF6C1BE3007C5994FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_13AA8922EDCAD5E99845E3007C59479C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636FA198625FBABF6C1BE3007C5994FB" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_13AA8922EDCAD5E99845E3007C59479C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8F255C682D030E45E9FBE3007C599AE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_13AA8922EDCAD5E99845E3007C59479C" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8F255C682D030E45E9FBE3007C599AE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_F5130ADFF20F3F9857A3E3007C5AAE03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8F255C682D030E45E9FBE3007C599AE1" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_F5130ADFF20F3F9857A3E3007C5AAE03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_DCF337EC6438068C2A83E3007C5A0379" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636FA198625FBABF6C1BE3007C5994FB" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_DCF337EC6438068C2A83E3007C5A0379" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_D9CCEE5990A657563A29E3007C5A2113" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_DCF337EC6438068C2A83E3007C5A0379" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_D9CCEE5990A657563A29E3007C5A2113" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0D103484BFC8238345B1E3007C5BAA88" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_DCF337EC6438068C2A83E3007C5A0379" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0D103484BFC8238345B1E3007C5BAA88" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E46D939970164F090EECDED0E463506B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_AACA6470E60A1726B0EADED0E463CE2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E46D939970164F090EECDED0E463506B" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_AACA6470E60A1726B0EADED0E463CE2B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/CommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2238C6CE4D9F192F3E78EDA0A95717D1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_C382B9D040C5EDC88243EDA0A957814A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2238C6CE4D9F192F3E78EDA0A95717D1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_C382B9D040C5EDC88243EDA0A957814A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_39E7815FF7C2F66F69D8EE28214D85E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2238C6CE4D9F192F3E78EDA0A95717D1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_39E7815FF7C2F66F69D8EE28214D85E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_036716696F30CECB884CEE2874F52852" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2238C6CE4D9F192F3E78EDA0A95717D1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_036716696F30CECB884CEE2874F52852" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_466CF593F2EA9646C2ABEDA0A9589A58" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2238C6CE4D9F192F3E78EDA0A95717D1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_466CF593F2EA9646C2ABEDA0A9589A58" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/CommitmentsAndContingenciesLeasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_50AF7AE89E7562E5002EEDA0AAD68925" xlink:type="locator" />
    <link:loc xlink:href="optn-20181231.xsd#optn_NumberOfOperatingLeases" xlink:label="loc_optn_NumberOfOperatingLeases_029E1D48B89401621572EDA0AADA0FE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_50AF7AE89E7562E5002EEDA0AAD68925" xlink:to="loc_optn_NumberOfOperatingLeases_029E1D48B89401621572EDA0AADA0FE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_99C2FF4BE30ECF465CFBEDA0AADAFA3C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_50AF7AE89E7562E5002EEDA0AAD68925" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_99C2FF4BE30ECF465CFBEDA0AADAFA3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_9CA4510C273F8D685A3CEDA0AADB7460" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_50AF7AE89E7562E5002EEDA0AAD68925" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_9CA4510C273F8D685A3CEDA0AADB7460" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_6E8C00A610B6ABF80EB6EDA0AADBD3D7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_50AF7AE89E7562E5002EEDA0AAD68925" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_6E8C00A610B6ABF80EB6EDA0AADBD3D7" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_FutureRentExpense" xlink:label="loc_optn_FutureRentExpense_80230E05889D68D0C9A8EE84641E4059" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_50AF7AE89E7562E5002EEDA0AAD68925" xlink:to="loc_optn_FutureRentExpense_80230E05889D68D0C9A8EE84641E4059" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B4570A67A95D60924422EDA0AAF21327" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_D05ABEFE9BDF55111716EDA0AAF37AA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B4570A67A95D60924422EDA0AAF21327" xlink:to="loc_us-gaap_OtherCommitmentsTable_D05ABEFE9BDF55111716EDA0AAF37AA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_F7E960FD0A7C2C161C7BEDA0AAF473BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_D05ABEFE9BDF55111716EDA0AAF37AA4" xlink:to="loc_srt_RangeAxis_F7E960FD0A7C2C161C7BEDA0AAF473BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_481E481DFA95FBD6CF65EDA0AAF4F1C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_F7E960FD0A7C2C161C7BEDA0AAF473BF" xlink:to="loc_srt_RangeMember_481E481DFA95FBD6CF65EDA0AAF4F1C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_B5199EC6646A73B255FEEDA0AAF586CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_481E481DFA95FBD6CF65EDA0AAF4F1C2" xlink:to="loc_srt_MaximumMember_B5199EC6646A73B255FEEDA0AAF586CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaap_OtherCommitmentsAxis_4E43DAB4682BAF794D3BEDA0AAF55C20" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_D05ABEFE9BDF55111716EDA0AAF37AA4" xlink:to="loc_us-gaap_OtherCommitmentsAxis_4E43DAB4682BAF794D3BEDA0AAF55C20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_B36285375B3C81982779EDA0AAF5CEBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_4E43DAB4682BAF794D3BEDA0AAF55C20" xlink:to="loc_us-gaap_OtherCommitmentsDomain_B36285375B3C81982779EDA0AAF5CEBB" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_MarketSalesforceMember" xlink:label="loc_optn_MarketSalesforceMember_C25661FFF2D45B33A31AEDA0AAF68E13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_B36285375B3C81982779EDA0AAF5CEBB" xlink:to="loc_optn_MarketSalesforceMember_C25661FFF2D45B33A31AEDA0AAF68E13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_671B31586B7BE4F3FAB8EDA0AAF6F2A5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_D05ABEFE9BDF55111716EDA0AAF37AA4" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_671B31586B7BE4F3FAB8EDA0AAF6F2A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:label="loc_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_F3656547B17011C3CECDEDA0AAF71768" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_671B31586B7BE4F3FAB8EDA0AAF6F2A5" xlink:to="loc_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_F3656547B17011C3CECDEDA0AAF71768" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_24387F6DD1C8C2C32DEDEDA0AAF6FBB8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_671B31586B7BE4F3FAB8EDA0AAF6F2A5" xlink:to="loc_us-gaap_ContractualObligation_24387F6DD1C8C2C32DEDEDA0AAF6FBB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_29B2F0DADA87EB1740A8EDA0AAF73329" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_671B31586B7BE4F3FAB8EDA0AAF6F2A5" xlink:to="loc_us-gaap_PurchaseObligation_29B2F0DADA87EB1740A8EDA0AAF73329" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B2D04754E77CBAF9D277DED0E4803B94" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_AF911E9C02E4C37CE54ADED0E4801A39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B2D04754E77CBAF9D277DED0E4803B94" xlink:to="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_AF911E9C02E4C37CE54ADED0E4801A39" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_68B9889CEF1ADABEEA89EE277B6BA334" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_46E0E03A5253BFD003D4EE277B6C9551" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_68B9889CEF1ADABEEA89EE277B6BA334" xlink:to="loc_us-gaap_AssetsAbstract_46E0E03A5253BFD003D4EE277B6C9551" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_C3B04091E48F27C34240EE277B6C296C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_46E0E03A5253BFD003D4EE277B6C9551" xlink:to="loc_us-gaap_AssetsCurrentAbstract_C3B04091E48F27C34240EE277B6C296C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_003FA4CE7F32955B978BEE277B6C122C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C3B04091E48F27C34240EE277B6C296C" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_003FA4CE7F32955B978BEE277B6C122C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8D531E97167211E8259FEE277B6DB020" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C3B04091E48F27C34240EE277B6C296C" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8D531E97167211E8259FEE277B6DB020" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_88ABA2751F48FE49C340EE277B6D36D7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C3B04091E48F27C34240EE277B6C296C" xlink:to="loc_us-gaap_ReceivablesNetCurrent_88ABA2751F48FE49C340EE277B6D36D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_0CB01A648E9A5AED704FEE277B6D1CA5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C3B04091E48F27C34240EE277B6C296C" xlink:to="loc_us-gaap_InventoryNet_0CB01A648E9A5AED704FEE277B6D1CA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_C0E0D51E740BCC798ED1EE277B6D3DF5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C3B04091E48F27C34240EE277B6C296C" xlink:to="loc_us-gaap_OtherAssetsCurrent_C0E0D51E740BCC798ED1EE277B6D3DF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_A61BC6D9DA8953091236EE277B6D872E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C3B04091E48F27C34240EE277B6C296C" xlink:to="loc_us-gaap_AssetsCurrent_A61BC6D9DA8953091236EE277B6D872E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_454F861A09F031632EE0EE277B6E06E7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_46E0E03A5253BFD003D4EE277B6C9551" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_454F861A09F031632EE0EE277B6E06E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_DD27EFB01A35748528B6EE277B6E48F8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_46E0E03A5253BFD003D4EE277B6C9551" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_DD27EFB01A35748528B6EE277B6E48F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_988C20B77B27BFE1F70FEE277B6E3336" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_46E0E03A5253BFD003D4EE277B6C9551" xlink:to="loc_us-gaap_Assets_988C20B77B27BFE1F70FEE277B6E3336" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39A5C0E26F1760730259EE277B6E6B3D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_68B9889CEF1ADABEEA89EE277B6BA334" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39A5C0E26F1760730259EE277B6E6B3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5AA18A09D0B97207A783EE277B6EC90E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39A5C0E26F1760730259EE277B6E6B3D" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5AA18A09D0B97207A783EE277B6EC90E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_B450A228CBEEB56CFBDAEE277B6F9F33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5AA18A09D0B97207A783EE277B6EC90E" xlink:to="loc_us-gaap_AccountsPayableCurrent_B450A228CBEEB56CFBDAEE277B6F9F33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7404A74EA3CF7FFA2A45EE277B6F762A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5AA18A09D0B97207A783EE277B6EC90E" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7404A74EA3CF7FFA2A45EE277B6F762A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_D57EDBA3985B8CA4C91AEE8A14C7266C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5AA18A09D0B97207A783EE277B6EC90E" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_D57EDBA3985B8CA4C91AEE8A14C7266C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_133588E68CCFD0744467EE277B6FCF6E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5AA18A09D0B97207A783EE277B6EC90E" xlink:to="loc_us-gaap_LiabilitiesCurrent_133588E68CCFD0744467EE277B6FCF6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_EE9AF27ABACCFAB944A0EE277B6F9040" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39A5C0E26F1760730259EE277B6E6B3D" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_EE9AF27ABACCFAB944A0EE277B6F9040" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaap_OtherLiabilities_D0D47B4E4C476B28CC25EE277B70D541" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39A5C0E26F1760730259EE277B6E6B3D" xlink:to="loc_us-gaap_OtherLiabilities_D0D47B4E4C476B28CC25EE277B70D541" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_FE86873E0B7B69A0B58BEE277B70D008" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39A5C0E26F1760730259EE277B6E6B3D" xlink:to="loc_us-gaap_Liabilities_FE86873E0B7B69A0B58BEE277B70D008" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_E80798CFFAF05A6216ACEE277B70A799" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39A5C0E26F1760730259EE277B6E6B3D" xlink:to="loc_us-gaap_CommitmentsAndContingencies_E80798CFFAF05A6216ACEE277B70A799" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9044B0A411289A771704EE277B70DE21" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39A5C0E26F1760730259EE277B6E6B3D" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9044B0A411289A771704EE277B70DE21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_B1BD49B5C4835CB6EF60EE277B70A752" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9044B0A411289A771704EE277B70DE21" xlink:to="loc_us-gaap_CommonStockValue_B1BD49B5C4835CB6EF60EE277B70A752" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_CA19345BB9C030F6C8F2EE277B704F25" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9044B0A411289A771704EE277B70DE21" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_CA19345BB9C030F6C8F2EE277B704F25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_423A469E9003432DE685EE277B71D8BC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9044B0A411289A771704EE277B70DE21" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_423A469E9003432DE685EE277B71D8BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3BB7D52AF49168CA8F06EE277B71B23D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9044B0A411289A771704EE277B70DE21" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3BB7D52AF49168CA8F06EE277B71B23D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_BDDDAE01EF1AEE1A8E8AEE277B713145" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9044B0A411289A771704EE277B70DE21" xlink:to="loc_us-gaap_StockholdersEquity_BDDDAE01EF1AEE1A8E8AEE277B713145" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_C16BFF6674D598002EE8EE277B712473" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39A5C0E26F1760730259EE277B6E6B3D" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_C16BFF6674D598002EE8EE277B712473" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8DB0A60E224CFFFC18E5DEF0AFE8DA10" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_B1BEF2659BB904036A3FDEF0AFEC0EFB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8DB0A60E224CFFFC18E5DEF0AFE8DA10" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_B1BEF2659BB904036A3FDEF0AFEC0EFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0D20E4340C92F860770ADEF0AFECC095" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8DB0A60E224CFFFC18E5DEF0AFE8DA10" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0D20E4340C92F860770ADEF0AFECC095" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_8A55A0D526C10B0C951EDEF0AFED501D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8DB0A60E224CFFFC18E5DEF0AFE8DA10" xlink:to="loc_us-gaap_CommonStockSharesIssued_8A55A0D526C10B0C951EDEF0AFED501D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0C51109AD635B41E19F9DEF0AFEDC709" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8DB0A60E224CFFFC18E5DEF0AFE8DA10" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0C51109AD635B41E19F9DEF0AFEDC709" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_7307BDA10D5D3A8DDAFA49EBE8846D42" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3938029DB74A51988EF549EBE88433E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7307BDA10D5D3A8DDAFA49EBE8846D42" xlink:to="loc_us-gaap_StatementTable_3938029DB74A51988EF549EBE88433E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_458E600641048CE895C649EBE8857D2E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3938029DB74A51988EF549EBE88433E3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_458E600641048CE895C649EBE8857D2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_951F111F8D4F9293DB9049EBE885C4FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_458E600641048CE895C649EBE8857D2E" xlink:to="loc_us-gaap_ClassOfStockDomain_951F111F8D4F9293DB9049EBE885C4FE" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember" xlink:label="loc_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember_1930E1355F1E60A98EC149EBE88569E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_951F111F8D4F9293DB9049EBE885C4FE" xlink:to="loc_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember_1930E1355F1E60A98EC149EBE88569E4" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_RedeemableConvertiblePreferredStockSeriesCC1DMember" xlink:label="loc_optn_RedeemableConvertiblePreferredStockSeriesCC1DMember_D360F52CDA85DC60BAF449EBE8859746" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_951F111F8D4F9293DB9049EBE885C4FE" xlink:to="loc_optn_RedeemableConvertiblePreferredStockSeriesCC1DMember_D360F52CDA85DC60BAF449EBE8859746" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_RedeemableConvertiblePreferredStockSeriesC2Member" xlink:label="loc_optn_RedeemableConvertiblePreferredStockSeriesC2Member_A0FEDA46561C0B8E184449EBE886DC89" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_951F111F8D4F9293DB9049EBE885C4FE" xlink:to="loc_optn_RedeemableConvertiblePreferredStockSeriesC2Member_A0FEDA46561C0B8E184449EBE886DC89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3938029DB74A51988EF549EBE88433E3" xlink:to="loc_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C41EB5DC2028AF99FFD649EBE886CA65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C41EB5DC2028AF99FFD649EBE886CA65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_D42F49C14EB623F649BA49EBE88812BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C41EB5DC2028AF99FFD649EBE886CA65" xlink:to="loc_us-gaap_NetIncomeLoss_D42F49C14EB623F649BA49EBE88812BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B5DE6D288B88D23325E549EBE888F87E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C41EB5DC2028AF99FFD649EBE886CA65" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B5DE6D288B88D23325E549EBE888F87E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_E9A14022DF6FCEC041B049EBE888D056" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B5DE6D288B88D23325E549EBE888F87E" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_E9A14022DF6FCEC041B049EBE888D056" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_12DB8353F58C84AE3B7449EBE889EA52" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B5DE6D288B88D23325E549EBE888F87E" xlink:to="loc_us-gaap_ShareBasedCompensation_12DB8353F58C84AE3B7449EBE889EA52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_E51C4C09F2B8DB11CEF549EBE8897A08" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B5DE6D288B88D23325E549EBE888F87E" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_E51C4C09F2B8DB11CEF549EBE8897A08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04BAA57205C6347D4FC549EBE889DB6F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B5DE6D288B88D23325E549EBE888F87E" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04BAA57205C6347D4FC549EBE889DB6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_F0BEC61FE4F59CAEA00849EBE88929D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04BAA57205C6347D4FC549EBE889DB6F" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_F0BEC61FE4F59CAEA00849EBE88929D2" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_IncreaseDecreaseInGrantsandOtherReceivables" xlink:label="loc_optn_IncreaseDecreaseInGrantsandOtherReceivables_330B065D3D3C6956DFAC49EBE88A0645" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04BAA57205C6347D4FC549EBE889DB6F" xlink:to="loc_optn_IncreaseDecreaseInGrantsandOtherReceivables_330B065D3D3C6956DFAC49EBE88A0645" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_IncreaseDecreaseinDepositsandOtherAssets" xlink:label="loc_optn_IncreaseDecreaseinDepositsandOtherAssets_2F9ABFF791AB1F9FC3E349EBE88A8076" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04BAA57205C6347D4FC549EBE889DB6F" xlink:to="loc_optn_IncreaseDecreaseinDepositsandOtherAssets_2F9ABFF791AB1F9FC3E349EBE88A8076" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_E0633646B44358C7289E49EBE88A3CA4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04BAA57205C6347D4FC549EBE889DB6F" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_E0633646B44358C7289E49EBE88A3CA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_CA70F0590D209152F81749EBE88A5734" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04BAA57205C6347D4FC549EBE889DB6F" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_CA70F0590D209152F81749EBE88A5734" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_599910982139B2ABEC7349EBE88A1489" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04BAA57205C6347D4FC549EBE889DB6F" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_599910982139B2ABEC7349EBE88A1489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6091196D3068291415D649EBE88A1CD4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C41EB5DC2028AF99FFD649EBE886CA65" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6091196D3068291415D649EBE88A1CD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7C3DE1AD885346A325E49EBE88A4D81" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7C3DE1AD885346A325E49EBE88A4D81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_DCEA5234B6000742D36F49EBE88B90AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7C3DE1AD885346A325E49EBE88A4D81" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_DCEA5234B6000742D36F49EBE88B90AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6245F955084E06EA66E349EBE88BB0DD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7C3DE1AD885346A325E49EBE88A4D81" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6245F955084E06EA66E349EBE88BB0DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_0EADA54A34D9B3B7316749EBE88BBE30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_0EADA54A34D9B3B7316749EBE88BBE30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0266380FFCE0FAA7C74449EBE88C39C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0266380FFCE0FAA7C74449EBE88C39C8" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan" xlink:label="loc_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan_82D58AA84D186F79509F49EBE88C04A5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A" xlink:to="loc_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan_82D58AA84D186F79509F49EBE88C04A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2F5B8245A7A99916D46E49EBE88C5345" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2F5B8245A7A99916D46E49EBE88C5345" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_CCDB6EBE1F6EE0EE28C949EBE88C1B2F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_CCDB6EBE1F6EE0EE28C949EBE88C1B2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B7710DC936BCA1BCA3BE49EBE88C8B0B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B7710DC936BCA1BCA3BE49EBE88C8B0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_8364BFCE2451817E57A149EBE88C5974" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_8364BFCE2451817E57A149EBE88C5974" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_BCD55EF6A729886FCB0249EBE88D1814" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8B6CAB42522BAB2F860549EBE88BCB7A" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_BCD55EF6A729886FCB0249EBE88D1814" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_972709892096A82D22D249EBE88DBA69" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_972709892096A82D22D249EBE88DBA69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2E1ED88ABCA15347015649EBE88D8BCC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2E1ED88ABCA15347015649EBE88D8BCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5283CA7C95F0E343AD0B49EBE88DD841" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5283CA7C95F0E343AD0B49EBE88DD841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7BD06901A5A250C1E0E049EBE88DF3CD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7BD06901A5A250C1E0E049EBE88DF3CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_65452D1522887234A08049EBE88E84D7" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_65452D1522887234A08049EBE88E84D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_207BB562F194617EB27949EBE88DDCB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_65452D1522887234A08049EBE88E84D7" xlink:to="loc_us-gaap_InterestPaidNet_207BB562F194617EB27949EBE88DDCB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_626C2DEE1F0404F3C9D649F2541B0F5C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_FBCE92560972565D766349EBE8869296" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_626C2DEE1F0404F3C9D649F2541B0F5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_CFD9DFAD9494EEE32AC549EBE88E2A3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_626C2DEE1F0404F3C9D649F2541B0F5C" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_CFD9DFAD9494EEE32AC549EBE88E2A3C" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses" xlink:label="loc_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses_31C21F78CC59A38BB73949EBE88E4E8F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_626C2DEE1F0404F3C9D649F2541B0F5C" xlink:to="loc_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses_31C21F78CC59A38BB73949EBE88E4E8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_74FD09FC49171C7AF60649EBE88E3232" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_626C2DEE1F0404F3C9D649F2541B0F5C" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_74FD09FC49171C7AF60649EBE88E3232" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_31AE8E50EF69CAB6C0D649EBE88E6CE7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_626C2DEE1F0404F3C9D649F2541B0F5C" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_31AE8E50EF69CAB6C0D649EBE88E6CE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_59A7EA860DEBA505F7D249EBE88EAB1B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_626C2DEE1F0404F3C9D649F2541B0F5C" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_59A7EA860DEBA505F7D249EBE88EAB1B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholders" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_B4CD9E590B79F58131DE49EC1609D586" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_0937F1DBFB225F6C505449EC1609931D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_B4CD9E590B79F58131DE49EC1609D586" xlink:to="loc_us-gaap_StatementTable_0937F1DBFB225F6C505449EC1609931D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A082A5C3D7703A98492249EC16099EC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0937F1DBFB225F6C505449EC1609931D" xlink:to="loc_us-gaap_StatementClassOfStockAxis_A082A5C3D7703A98492249EC16099EC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B038BFEAF8152A1CDE8A49EC16091F8C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A082A5C3D7703A98492249EC16099EC2" xlink:to="loc_us-gaap_ClassOfStockDomain_B038BFEAF8152A1CDE8A49EC16091F8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemablePreferredStockMember" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_8CF973D87069AFC606E749EC16093D6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B038BFEAF8152A1CDE8A49EC16091F8C" xlink:to="loc_us-gaap_RedeemablePreferredStockMember_8CF973D87069AFC606E749EC16093D6D" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_RedeemableConvertiblePreferredStockSeriesC2Member" xlink:label="loc_optn_RedeemableConvertiblePreferredStockSeriesC2Member_FAA5690321DA5948C60F49EC16099BE3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B038BFEAF8152A1CDE8A49EC16091F8C" xlink:to="loc_optn_RedeemableConvertiblePreferredStockSeriesC2Member_FAA5690321DA5948C60F49EC16099BE3" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_RedeemableConvertiblePreferredStockSeriesDMember" xlink:label="loc_optn_RedeemableConvertiblePreferredStockSeriesDMember_4D097EB4B25C8669CF3349EC1609375E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B038BFEAF8152A1CDE8A49EC16091F8C" xlink:to="loc_optn_RedeemableConvertiblePreferredStockSeriesDMember_4D097EB4B25C8669CF3349EC1609375E" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_RedeemableConvertiblePreferredStockSeriesCC1DMember" xlink:label="loc_optn_RedeemableConvertiblePreferredStockSeriesCC1DMember_81E6A5C9E21664CFD6FB49EC1609FBEF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B038BFEAF8152A1CDE8A49EC16091F8C" xlink:to="loc_optn_RedeemableConvertiblePreferredStockSeriesCC1DMember_81E6A5C9E21664CFD6FB49EC1609FBEF" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember" xlink:label="loc_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember_7A02AA3A2DBE5964377F49EC1609AC4F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B038BFEAF8152A1CDE8A49EC16091F8C" xlink:to="loc_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember_7A02AA3A2DBE5964377F49EC1609AC4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_445FDF25BBFD4D62CD8149EC16099B9E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0937F1DBFB225F6C505449EC1609931D" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_445FDF25BBFD4D62CD8149EC16099B9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6D0A07EB06558C16646549EC16099A9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_445FDF25BBFD4D62CD8149EC16099B9E" xlink:to="loc_us-gaap_EquityComponentDomain_6D0A07EB06558C16646549EC16099A9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_8FDD6FC0721455D284FB49EC16091A95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6D0A07EB06558C16646549EC16099A9E" xlink:to="loc_us-gaap_CommonStockMember_8FDD6FC0721455D284FB49EC16091A95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_DD2627379C2BD35940BC49EC16099B08" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6D0A07EB06558C16646549EC16099A9E" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_DD2627379C2BD35940BC49EC16099B08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_40BCD399E0FA8934C88749EC16098F17" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6D0A07EB06558C16646549EC16099A9E" xlink:to="loc_us-gaap_RetainedEarningsMember_40BCD399E0FA8934C88749EC16098F17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_63868E2D78C90943FEE049EC16094101" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6D0A07EB06558C16646549EC16099A9E" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_63868E2D78C90943FEE049EC16094101" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_B2E6917114CA9893ADA349EC16095736" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0937F1DBFB225F6C505449EC1609931D" xlink:to="loc_us-gaap_StatementLineItems_B2E6917114CA9893ADA349EC16095736" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B2E6917114CA9893ADA349EC16095736" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_EE614D846FFDFD6EB07349EC16095FB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_EE614D846FFDFD6EB07349EC16095FB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_A0C2600FDFEBA788B9A849EC1609F198" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_A0C2600FDFEBA788B9A849EC1609F198" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_46A93FAFDE582B3AE38149EC160997A6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_SharesOutstanding_46A93FAFDE582B3AE38149EC160997A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7981EB001D4E2F785BB849EC16182128" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7981EB001D4E2F785BB849EC16182128" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_65016156BD6368F6D8C049EC161869A5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_65016156BD6368F6D8C049EC161869A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_782424077FFB12FA261549EC1618F019" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_782424077FFB12FA261549EC1618F019" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_optn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_E4138EE5067B27416B8A49EC1618C404" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_optn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_E4138EE5067B27416B8A49EC1618C404" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_FD0D65199F8A33DE2F6749EC16187A3D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_FD0D65199F8A33DE2F6749EC16187A3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC31829D6727EB27094749EC1618951B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC31829D6727EB27094749EC1618951B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_19A46AD4DAD8C1A9BB2A49EC16184EF3" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_19A46AD4DAD8C1A9BB2A49EC16184EF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_05D6FF046E7AAD6AEB9D49EC16180838" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_05D6FF046E7AAD6AEB9D49EC16180838" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_optn_StockIssuedDuringPeriodValueWarrantsExercised_858DE034CF75669DE68149EC16186951" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_optn_StockIssuedDuringPeriodValueWarrantsExercised_858DE034CF75669DE68149EC16186951" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_BDF9A94B58BA85C18BAD49EC1618C77F" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_BDF9A94B58BA85C18BAD49EC1618C77F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_359CC5D11822882198E749EC1618B550" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_359CC5D11822882198E749EC1618B550" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_FD85824972D9395CE5C549EC16183021" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_FD85824972D9395CE5C549EC16183021" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_BC2DA16AD9E90CE3DAAF49EC16183BF1" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_BC2DA16AD9E90CE3DAAF49EC16183BF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_02CD92079390681CA4C749EC16187077" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_02CD92079390681CA4C749EC16187077" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_40B0698CE5E5D2176ADB49EC1618A519" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_40B0698CE5E5D2176ADB49EC1618A519" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_D3A70EA98E085CE87E0549EC16186059" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_D3A70EA98E085CE87E0549EC16186059" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_AEF3219121C51ABB8FF949EC1618D5EA" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_NetIncomeLoss_AEF3219121C51ABB8FF949EC1618D5EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_D5082D21F6FD2A0B284C49EC16182DBC" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_D5082D21F6FD2A0B284C49EC16182DBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_4CEB3A3E6D1729193DFA49EC161864AE" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_4CEB3A3E6D1729193DFA49EC161864AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_9A84E2F290EDBB4B80DE49EC1618189B" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_SharesOutstanding_9A84E2F290EDBB4B80DE49EC1618189B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_C44600E7487187EA1A8A49EC1618D383" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_E21828B7AA0FF4D7517849EC1609AC81" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_C44600E7487187EA1A8A49EC1618D383" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_9162C3F535405B2DF83249EC15F91A53" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_A572A60EF6EBFBBC7D0749EC15F96926" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_9162C3F535405B2DF83249EC15F91A53" xlink:to="loc_us-gaap_StatementTable_A572A60EF6EBFBBC7D0749EC15F96926" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_06E4355AC3FB5F6ACD8F49EC15F9636F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_A572A60EF6EBFBBC7D0749EC15F96926" xlink:to="loc_us-gaap_StatementClassOfStockAxis_06E4355AC3FB5F6ACD8F49EC15F9636F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_989ED6889D8B7F115C3A49EC15F94C29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_06E4355AC3FB5F6ACD8F49EC15F9636F" xlink:to="loc_us-gaap_ClassOfStockDomain_989ED6889D8B7F115C3A49EC15F94C29" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember" xlink:label="loc_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember_B18A1E1372A2F9D37F5249EC15F92B5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_989ED6889D8B7F115C3A49EC15F94C29" xlink:to="loc_optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember_B18A1E1372A2F9D37F5249EC15F92B5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_E64BF16648FF7239512549EC15F943A3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_A572A60EF6EBFBBC7D0749EC15F96926" xlink:to="loc_us-gaap_StatementLineItems_E64BF16648FF7239512549EC15F943A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_C1BC47BCDFEC40D56CE749EC15F98014" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E64BF16648FF7239512549EC15F943A3" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_C1BC47BCDFEC40D56CE749EC15F98014" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/ConsolidatedStatementsOfComprehensiveIncomeAndLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C8D4497ED51EFE4CBCB649EC1618BF13" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_184CFC5DF6FFEED0CB3D49EC16184B86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C8D4497ED51EFE4CBCB649EC1618BF13" xlink:to="loc_us-gaap_NetIncomeLoss_184CFC5DF6FFEED0CB3D49EC16184B86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_18ADC5DE4B5C882BDF5C49EC1628D3FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C8D4497ED51EFE4CBCB649EC1618BF13" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_18ADC5DE4B5C882BDF5C49EC1628D3FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7B69BA504FC47506693F49EC16285E3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_18ADC5DE4B5C882BDF5C49EC1628D3FF" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7B69BA504FC47506693F49EC16285E3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_606891697F56976FA32649EC1628C9C1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C8D4497ED51EFE4CBCB649EC1618BF13" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_606891697F56976FA32649EC1628C9C1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_FD841BEC39C60BC5761849EC1637488C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6CE97574615C9076126D49EC16375BD1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FD841BEC39C60BC5761849EC1637488C" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6CE97574615C9076126D49EC16375BD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2EAC17C3C5BCEDEF86F64A35B8D6CBD4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FD841BEC39C60BC5761849EC1637488C" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2EAC17C3C5BCEDEF86F64A35B8D6CBD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_E6F143CA17FB38AAA6444A369BD2EA2B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FD841BEC39C60BC5761849EC1637488C" xlink:to="loc_us-gaap_GrossProfit_E6F143CA17FB38AAA6444A369BD2EA2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_DFCA76CA2835753C0E8349EC16378974" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FD841BEC39C60BC5761849EC1637488C" xlink:to="loc_us-gaap_OperatingExpensesAbstract_DFCA76CA2835753C0E8349EC16378974" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_D029BF6312C92B0DD3AD49EC163762AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_DFCA76CA2835753C0E8349EC16378974" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_D029BF6312C92B0DD3AD49EC163762AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_04090502EDF4E8ED0A1C49EC1637DEF3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_DFCA76CA2835753C0E8349EC16378974" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_04090502EDF4E8ED0A1C49EC1637DEF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_DCA2BF0246BA27CD273449EC1637267F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_DFCA76CA2835753C0E8349EC16378974" xlink:to="loc_us-gaap_OperatingExpenses_DCA2BF0246BA27CD273449EC1637267F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_267090600F89F5661D3749EC16373B3F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_DFCA76CA2835753C0E8349EC16378974" xlink:to="loc_us-gaap_OperatingIncomeLoss_267090600F89F5661D3749EC16373B3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_FA6511516EFEC4B282A549EC1637CBD5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FD841BEC39C60BC5761849EC1637488C" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_FA6511516EFEC4B282A549EC1637CBD5" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_GrantandOtherIncome" xlink:label="loc_optn_GrantandOtherIncome_D6F93283FF7A83D4946849EC1637037C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_FA6511516EFEC4B282A549EC1637CBD5" xlink:to="loc_optn_GrantandOtherIncome_D6F93283FF7A83D4946849EC1637037C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_A706579867B62E867BC149EC163720C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_FA6511516EFEC4B282A549EC1637CBD5" xlink:to="loc_us-gaap_InvestmentIncomeInterest_A706579867B62E867BC149EC163720C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_D4B2CD6F577E84B581DB49EC1637A977" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_FA6511516EFEC4B282A549EC1637CBD5" xlink:to="loc_us-gaap_InterestExpense_D4B2CD6F577E84B581DB49EC1637A977" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_777B82491103B843534949EC16375E60" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_FA6511516EFEC4B282A549EC1637CBD5" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_777B82491103B843534949EC16375E60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_506641320BD4AA379D8749EC1637D606" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FD841BEC39C60BC5761849EC1637488C" xlink:to="loc_us-gaap_NetIncomeLoss_506641320BD4AA379D8749EC1637D606" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:label="loc_us-gaap_TemporaryEquityDividendsAdjustment_394A710FBD09EF39229449EC16373A41" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FD841BEC39C60BC5761849EC1637488C" xlink:to="loc_us-gaap_TemporaryEquityDividendsAdjustment_394A710FBD09EF39229449EC16373A41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_A1E791BD07BAB5574FF349EC1637B8ED" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FD841BEC39C60BC5761849EC1637488C" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_A1E791BD07BAB5574FF349EC1637B8ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_53041D76BBEEA5858AA649EC16371CA5" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FD841BEC39C60BC5761849EC1637488C" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_53041D76BBEEA5858AA649EC16371CA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_47ADED516CC1F7AA463549EC16374A8B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FD841BEC39C60BC5761849EC1637488C" xlink:to="loc_us-gaap_EarningsPerShareAbstract_47ADED516CC1F7AA463549EC16374A8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_3FFF7380ECE659B68BA549EC1637E118" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_47ADED516CC1F7AA463549EC16374A8B" xlink:to="loc_us-gaap_EarningsPerShareBasic_3FFF7380ECE659B68BA549EC1637E118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_DD56591A793399AB6F8549EC16377AF5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_47ADED516CC1F7AA463549EC16374A8B" xlink:to="loc_us-gaap_EarningsPerShareDiluted_DD56591A793399AB6F8549EC16377AF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_4D4B3274560836FA36FC49EC16375FC7" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FD841BEC39C60BC5761849EC1637488C" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_4D4B3274560836FA36FC49EC16375FC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F11F73DE730090FF412449EC1637314B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_4D4B3274560836FA36FC49EC16375FC7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F11F73DE730090FF412449EC1637314B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E405E983F77C2F17E46B49EC1637D40B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_4D4B3274560836FA36FC49EC16375FC7" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E405E983F77C2F17E46B49EC1637D40B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/ConvertibleNotes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_15E8A1C8BAFB4F4FB1A8EE277A28AD81" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_486F322182175BA7486FEE277A28D14E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_15E8A1C8BAFB4F4FB1A8EE277A28AD81" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_486F322182175BA7486FEE277A28D14E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/ConvertibleNotesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ECEA10406D68DF83741AEE277A1DD06E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_D4D91B622BB69A68A64DEE277A1DA10A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ECEA10406D68DF83741AEE277A1DD06E" xlink:to="loc_us-gaap_DebtInstrumentTable_D4D91B622BB69A68A64DEE277A1DA10A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_AF1363B627735B1BFEB5EE277A1D1EB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_D4D91B622BB69A68A64DEE277A1DA10A" xlink:to="loc_us-gaap_StatementClassOfStockAxis_AF1363B627735B1BFEB5EE277A1D1EB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D44916B0C36D671B6670EE277A1E9E2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_AF1363B627735B1BFEB5EE277A1D1EB2" xlink:to="loc_us-gaap_ClassOfStockDomain_D44916B0C36D671B6670EE277A1E9E2B" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_RedeemableConvertiblePreferredStockSeriesC2Member" xlink:label="loc_optn_RedeemableConvertiblePreferredStockSeriesC2Member_CC6DE46B917F37F25201EE277A1EC3E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_D44916B0C36D671B6670EE277A1E9E2B" xlink:to="loc_optn_RedeemableConvertiblePreferredStockSeriesC2Member_CC6DE46B917F37F25201EE277A1EC3E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_CABB2C200E989304A4FEEE277A1E21D8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_D4D91B622BB69A68A64DEE277A1DA10A" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_CABB2C200E989304A4FEEE277A1E21D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_F1DD0AAE31D7BE6727BEEE277A1FE5B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_CABB2C200E989304A4FEEE277A1E21D8" xlink:to="loc_us-gaap_DebtConversionNameDomain_F1DD0AAE31D7BE6727BEEE277A1FE5B7" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_SeriesDFinancingMember" xlink:label="loc_optn_SeriesDFinancingMember_BE00CEF2409F020FB5ABEE277A1F4CE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_F1DD0AAE31D7BE6727BEEE277A1FE5B7" xlink:to="loc_optn_SeriesDFinancingMember_BE00CEF2409F020FB5ABEE277A1F4CE0" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember" xlink:label="loc_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember_8A0E92E76D4543C23C58EE277A1F143D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_F1DD0AAE31D7BE6727BEEE277A1FE5B7" xlink:to="loc_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember_8A0E92E76D4543C23C58EE277A1F143D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0F54E19DCA48C9FA2980EE277A1F9EF0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_D4D91B622BB69A68A64DEE277A1DA10A" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0F54E19DCA48C9FA2980EE277A1F9EF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1B25DD6175671F9BBE68EE277A1F4513" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0F54E19DCA48C9FA2980EE277A1F9EF0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1B25DD6175671F9BBE68EE277A1F4513" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_61D95DD1DA84031AB88CEE277A200563" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1B25DD6175671F9BBE68EE277A1F4513" xlink:to="loc_us-gaap_ConvertibleDebtMember_61D95DD1DA84031AB88CEE277A200563" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_129D278547486ABB5779EE277A200F1F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_D4D91B622BB69A68A64DEE277A1DA10A" xlink:to="loc_us-gaap_DebtInstrumentAxis_129D278547486ABB5779EE277A200F1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1E0EE3EEACFA5B6CFD75EE277A206234" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_129D278547486ABB5779EE277A200F1F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1E0EE3EEACFA5B6CFD75EE277A206234" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_TrancheOneMember" xlink:label="loc_optn_TrancheOneMember_3C5DC079B33B82E0C4B0EE277A20C6A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1E0EE3EEACFA5B6CFD75EE277A206234" xlink:to="loc_optn_TrancheOneMember_3C5DC079B33B82E0C4B0EE277A20C6A0" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_TrancheTwoMember" xlink:label="loc_optn_TrancheTwoMember_6AA00B99D2451B110462EE277A21AC84" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1E0EE3EEACFA5B6CFD75EE277A206234" xlink:to="loc_optn_TrancheTwoMember_6AA00B99D2451B110462EE277A21AC84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_D4D91B622BB69A68A64DEE277A1DA10A" xlink:to="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_E5D26641F1B8FBBA90F4EE277A215459" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_E5D26641F1B8FBBA90F4EE277A215459" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_NumberofTranches" xlink:label="loc_optn_NumberofTranches_29D9C8BC01FFDDB65A9BEE277A21BB37" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_optn_NumberofTranches_29D9C8BC01FFDDB65A9BEE277A21BB37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3111D59DE8B03F10E70CEE277A22324D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3111D59DE8B03F10E70CEE277A22324D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_1C3CE0A79C01EA2D212CEE277A22CBB2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_1C3CE0A79C01EA2D212CEE277A22CBB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_935BD629949B0EB4DAC6EE277A22B3AB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_935BD629949B0EB4DAC6EE277A22B3AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_F952947920A516676629EE277A229DF1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_F952947920A516676629EE277A229DF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_6039A408D5D773920114EE277A22694B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_us-gaap_InterestExpenseDebt_6039A408D5D773920114EE277A22694B" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentCouponInterestandFees" xlink:label="loc_optn_DebtInstrumentCouponInterestandFees_84E217AF4CBA328EB288EE277A22B600" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_optn_DebtInstrumentCouponInterestandFees_84E217AF4CBA328EB288EE277A22B600" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentLoanConversionPeriod" xlink:label="loc_optn_DebtInstrumentLoanConversionPeriod_9F36D36886558CD69D05EE277A23F57E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_optn_DebtInstrumentLoanConversionPeriod_9F36D36886558CD69D05EE277A23F57E" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_InterestExpenseDebtBackEndFees" xlink:label="loc_optn_InterestExpenseDebtBackEndFees_3D0E583B2FDA6BAE44A5EE277A2310BA" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_optn_InterestExpenseDebtBackEndFees_3D0E583B2FDA6BAE44A5EE277A2310BA" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_InterestExpenseDebtFrontEndFees" xlink:label="loc_optn_InterestExpenseDebtFrontEndFees_9DD4A1D325C2A397F925EE277A23918F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_optn_InterestExpenseDebtFrontEndFees_9DD4A1D325C2A397F925EE277A23918F" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentFeesCapitalizedtoPrincipal" xlink:label="loc_optn_DebtInstrumentFeesCapitalizedtoPrincipal_0EF913099A882C57AA41EE277A231F5D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_optn_DebtInstrumentFeesCapitalizedtoPrincipal_0EF913099A882C57AA41EE277A231F5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_CE038317D98BFD1A0B99EE277A238483" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_CE038317D98BFD1A0B99EE277A238483" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_EBA1671792F66B600F06EE277A2355B5" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_B094788D4A6888EC8ABAEE277A216B02" xlink:to="loc_us-gaap_ConvertibleDebt_EBA1671792F66B600F06EE277A2355B5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/DocumentAndEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:href="optn-20181231.xsd#optn_DocumentandEntityInformationAbstract" xlink:label="loc_optn_DocumentandEntityInformationAbstract_E10CF69332DFE5216370DED712107CF7" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_E711ED626FB8C7CFC798DED71220B5E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_DocumentandEntityInformationAbstract_E10CF69332DFE5216370DED712107CF7" xlink:to="loc_dei_EntityRegistrantName_E711ED626FB8C7CFC798DED71220B5E9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_6EEECFB700205A4C2E65DED712207E86" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_DocumentandEntityInformationAbstract_E10CF69332DFE5216370DED712107CF7" xlink:to="loc_dei_EntityCentralIndexKey_6EEECFB700205A4C2E65DED712207E86" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_146AA6E76155D30A31BEDED7122047AC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_DocumentandEntityInformationAbstract_E10CF69332DFE5216370DED712107CF7" xlink:to="loc_dei_CurrentFiscalYearEndDate_146AA6E76155D30A31BEDED7122047AC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_0DE85F7966B162F38C3BDED71220DAB7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_DocumentandEntityInformationAbstract_E10CF69332DFE5216370DED712107CF7" xlink:to="loc_dei_EntityFilerCategory_0DE85F7966B162F38C3BDED71220DAB7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_A6CE4940906EFA835E2BDED71220DAEA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_DocumentandEntityInformationAbstract_E10CF69332DFE5216370DED712107CF7" xlink:to="loc_dei_DocumentType_A6CE4940906EFA835E2BDED71220DAEA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_C555DC0A8A4CE19D2687DED712208664" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_DocumentandEntityInformationAbstract_E10CF69332DFE5216370DED712107CF7" xlink:to="loc_dei_DocumentPeriodEndDate_C555DC0A8A4CE19D2687DED712208664" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_C5D133559611EB4A16C8DED712203E8F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_DocumentandEntityInformationAbstract_E10CF69332DFE5216370DED712107CF7" xlink:to="loc_dei_DocumentFiscalYearFocus_C5D133559611EB4A16C8DED712203E8F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_87D8829DEC68CE9B4383DED712200C79" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_DocumentandEntityInformationAbstract_E10CF69332DFE5216370DED712107CF7" xlink:to="loc_dei_DocumentFiscalPeriodFocus_87D8829DEC68CE9B4383DED712200C79" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_C72292CF4D30DE39ECD1DED712208F80" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_DocumentandEntityInformationAbstract_E10CF69332DFE5216370DED712107CF7" xlink:to="loc_dei_AmendmentFlag_C72292CF4D30DE39ECD1DED712208F80" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_CB83FFC1438AE224526FDED71220F8A9" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_DocumentandEntityInformationAbstract_E10CF69332DFE5216370DED712107CF7" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_CB83FFC1438AE224526FDED71220F8A9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_383107E9251B119306E1DED7122037B5" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_DocumentandEntityInformationAbstract_E10CF69332DFE5216370DED712107CF7" xlink:to="loc_dei_EntityPublicFloat_383107E9251B119306E1DED7122037B5" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_51F0DC66919F20AFFFEADED7122026FD" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_DocumentandEntityInformationAbstract_E10CF69332DFE5216370DED712107CF7" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_51F0DC66919F20AFFFEADED7122026FD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_97AAFA33476B37BA8D99DED71220BA49" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_DocumentandEntityInformationAbstract_E10CF69332DFE5216370DED712107CF7" xlink:to="loc_dei_EntityVoluntaryFilers_97AAFA33476B37BA8D99DED71220BA49" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_8D8213957BBCEAFD5C0CDED712209CBD" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_DocumentandEntityInformationAbstract_E10CF69332DFE5216370DED712107CF7" xlink:to="loc_dei_EntityCurrentReportingStatus_8D8213957BBCEAFD5C0CDED712209CBD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_8B10CA119EB0359BFFFBDED71302319E" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_DocumentandEntityInformationAbstract_E10CF69332DFE5216370DED712107CF7" xlink:to="loc_dei_EntitySmallBusiness_8B10CA119EB0359BFFFBDED71302319E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_7D14B44E5FC2D8376FBEDED7364F0FF0" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_DocumentandEntityInformationAbstract_E10CF69332DFE5216370DED712107CF7" xlink:to="loc_dei_EntityEmergingGrowthCompany_7D14B44E5FC2D8376FBEDED7364F0FF0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_5BDEC66791996B90AAA9DED758131B22" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_DocumentandEntityInformationAbstract_E10CF69332DFE5216370DED712107CF7" xlink:to="loc_dei_EntityExTransitionPeriod_5BDEC66791996B90AAA9DED758131B22" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_ADFB7E3E868E4B0EF0F3DED77B222C62" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_DocumentandEntityInformationAbstract_E10CF69332DFE5216370DED712107CF7" xlink:to="loc_dei_EntityShellCompany_ADFB7E3E868E4B0EF0F3DED77B222C62" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3538DD3D6EAF18965031DED0E4D835EE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_AE8C6FA5FE3510798E61DED0E4D8511B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3538DD3D6EAF18965031DED0E4D835EE" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_AE8C6FA5FE3510798E61DED0E4D8511B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_EC1C5EA1D3BAE52B143EE32FECE63A70" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable_B0C25850575DA2998E7AE32FECE75146" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_EC1C5EA1D3BAE52B143EE32FECE63A70" xlink:to="loc_us-gaap_DefinedContributionPlanTable_B0C25850575DA2998E7AE32FECE75146" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DefinedContributionPlanTranchesAxisAxis" xlink:label="loc_optn_DefinedContributionPlanTranchesAxisAxis_EBF4E41618FDDFFAE771E32FECE76C86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_B0C25850575DA2998E7AE32FECE75146" xlink:to="loc_optn_DefinedContributionPlanTranchesAxisAxis_EBF4E41618FDDFFAE771E32FECE76C86" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DefinedContributionPlanTranchesAxisDomain" xlink:label="loc_optn_DefinedContributionPlanTranchesAxisDomain_5BDC90359213ED2CBFB0E32FECE7FD10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_DefinedContributionPlanTranchesAxisAxis_EBF4E41618FDDFFAE771E32FECE76C86" xlink:to="loc_optn_DefinedContributionPlanTranchesAxisDomain_5BDC90359213ED2CBFB0E32FECE7FD10" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DefinedContributionPlanTrancheOneMember" xlink:label="loc_optn_DefinedContributionPlanTrancheOneMember_084221B77E2EA2EECD9EE32FECE763B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_DefinedContributionPlanTranchesAxisDomain_5BDC90359213ED2CBFB0E32FECE7FD10" xlink:to="loc_optn_DefinedContributionPlanTrancheOneMember_084221B77E2EA2EECD9EE32FECE763B4" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DefinedContributionPlanTrancheTwoMember" xlink:label="loc_optn_DefinedContributionPlanTrancheTwoMember_F37D82FEB14C56712AEEE32FECE89D83" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_optn_DefinedContributionPlanTranchesAxisDomain_5BDC90359213ED2CBFB0E32FECE7FD10" xlink:to="loc_optn_DefinedContributionPlanTrancheTwoMember_F37D82FEB14C56712AEEE32FECE89D83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_4A148FFB18F2719DE762E32FECE896D9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_B0C25850575DA2998E7AE32FECE75146" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_4A148FFB18F2719DE762E32FECE896D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_A5694646F464AC290D7BE32FECE8CD9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_4A148FFB18F2719DE762E32FECE896D9" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_A5694646F464AC290D7BE32FECE8CD9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_D1548A5BDE59C85499E9E32FECE91493" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_A5694646F464AC290D7BE32FECE8CD9B" xlink:to="loc_us-gaap_ForeignPlanMember_D1548A5BDE59C85499E9E32FECE91493" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_35551AFD9A0F444F8097E32FECE95EE8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_B0C25850575DA2998E7AE32FECE75146" xlink:to="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_35551AFD9A0F444F8097E32FECE95EE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_EB9BBB25970D7B89A357E32FECE96BB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_35551AFD9A0F444F8097E32FECE95EE8" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_EB9BBB25970D7B89A357E32FECE96BB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_AD3E7BBF0DABA3C80246E32FECE9C271" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_35551AFD9A0F444F8097E32FECE95EE8" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_AD3E7BBF0DABA3C80246E32FECE9C271" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_FB44C0E4E86903858388E32FECEA9FC9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_35551AFD9A0F444F8097E32FECE95EE8" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_FB44C0E4E86903858388E32FECEA9FC9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_E085DEBF3F535BC70BA8DED0E253DB18" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_F81624CD4CB48EB21CC4DED0E25320A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E085DEBF3F535BC70BA8DED0E253DB18" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_F81624CD4CB48EB21CC4DED0E25320A1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5960E575EDCFD7FD02DEEE27791B03CA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_9E8D88C3114903E6A336EE2779200E87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5960E575EDCFD7FD02DEEE27791B03CA" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_9E8D88C3114903E6A336EE2779200E87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_BF3C185C95E9A01C765BEE2779219A56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_9E8D88C3114903E6A336EE2779200E87" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_BF3C185C95E9A01C765BEE2779219A56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_A256433012B40B414CFEEE277923BDD1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_BF3C185C95E9A01C765BEE2779219A56" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_A256433012B40B414CFEEE277923BDD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_0B90A592B0ADBA88899CEE277923AD7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_A256433012B40B414CFEEE277923BDD1" xlink:to="loc_us-gaap_ForeignCountryMember_0B90A592B0ADBA88899CEE277923AD7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_A580E0C38D7CAF00CC30EE2779245CA9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_A256433012B40B414CFEEE277923BDD1" xlink:to="loc_us-gaap_DomesticCountryMember_A580E0C38D7CAF00CC30EE2779245CA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_4E811A208684A28C6A3EEE27792425DF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_A256433012B40B414CFEEE277923BDD1" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_4E811A208684A28C6A3EEE27792425DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_B6320A86D7BE6E3AC205EE277924309B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_9E8D88C3114903E6A336EE2779200E87" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_B6320A86D7BE6E3AC205EE277924309B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_A7FD314097B23FB797B5EE277925E145" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B6320A86D7BE6E3AC205EE277924309B" xlink:to="loc_us-gaap_OperatingLossCarryforwards_A7FD314097B23FB797B5EE277925E145" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_728844566B032BD51E95EE2779258E3C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B6320A86D7BE6E3AC205EE277924309B" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_728844566B032BD51E95EE2779258E3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_FC78E5BF73E6F6055568EE277925E0D5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B6320A86D7BE6E3AC205EE277924309B" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_FC78E5BF73E6F6055568EE277925E0D5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_E6F6961EF1BD5551BDA63A56216D6BC4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_FC30EC63874B33AAFF533A56216DD5E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E6F6961EF1BD5551BDA63A56216D6BC4" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_FC30EC63874B33AAFF533A56216DD5E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_F3BD46B49549ECC6575B3A56216DDD74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_FC30EC63874B33AAFF533A56216DD5E7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_F3BD46B49549ECC6575B3A56216DDD74" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DeferredTaxAssetsPrepaidLicenseArrangement" xlink:label="loc_optn_DeferredTaxAssetsPrepaidLicenseArrangement_562BD6D5243F80A5A5173A688C68DA44" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_FC30EC63874B33AAFF533A56216DD5E7" xlink:to="loc_optn_DeferredTaxAssetsPrepaidLicenseArrangement_562BD6D5243F80A5A5173A688C68DA44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_00212CBCF3FB35769F4B3A56216E89BD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_FC30EC63874B33AAFF533A56216DD5E7" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_00212CBCF3FB35769F4B3A56216E89BD" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DeferredTaxAssetsInterestExpense" xlink:label="loc_optn_DeferredTaxAssetsInterestExpense_102E58D296D98BB4E7573A56216E891D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_FC30EC63874B33AAFF533A56216DD5E7" xlink:to="loc_optn_DeferredTaxAssetsInterestExpense_102E58D296D98BB4E7573A56216E891D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_6137CB29ED1DA917B3803A56216EE6AB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_FC30EC63874B33AAFF533A56216DD5E7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_6137CB29ED1DA917B3803A56216EE6AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_41E4CDF2BAEF35398A973A56216E82FB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_FC30EC63874B33AAFF533A56216DD5E7" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_41E4CDF2BAEF35398A973A56216E82FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8BC188A2B8046CB66E713A56216E4ADA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_FC30EC63874B33AAFF533A56216DD5E7" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8BC188A2B8046CB66E713A56216E4ADA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_4CB19E8630B8A54B41F53A56216F6633" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_FC30EC63874B33AAFF533A56216DD5E7" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_4CB19E8630B8A54B41F53A56216F6633" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_8A9A3E830BDCE20733453A56216F8532" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E6F6961EF1BD5551BDA63A56216D6BC4" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_8A9A3E830BDCE20733453A56216F8532" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_DACC0D74FE717B284DA83A56216F2E51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_8A9A3E830BDCE20733453A56216F8532" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_DACC0D74FE717B284DA83A56216F2E51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_3D1D98839B382B95BFF53A56216F5C0E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_8A9A3E830BDCE20733453A56216F8532" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_3D1D98839B382B95BFF53A56216F5C0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2CE380FD48B64C907C803A56216F78BF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E6F6961EF1BD5551BDA63A56216D6BC4" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2CE380FD48B64C907C803A56216F78BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_AC976458954FDE5D8EEF3A56216F4444" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E6F6961EF1BD5551BDA63A56216D6BC4" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_AC976458954FDE5D8EEF3A56216F4444" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_F05AF53C854D8936F8F03A5621859304" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1A1654620DF7AC6785893A5621852044" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F05AF53C854D8936F8F03A5621859304" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1A1654620DF7AC6785893A5621852044" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_EB4637180F4CFB53A4503A562185CC7B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F05AF53C854D8936F8F03A5621859304" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_EB4637180F4CFB53A4503A562185CC7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B8F066C0B6315E8DC7943A5621867B41" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F05AF53C854D8936F8F03A5621859304" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B8F066C0B6315E8DC7943A5621867B41" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent" xlink:label="loc_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent_C1A5A382A1FFFE1A42DF3A5621860266" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F05AF53C854D8936F8F03A5621859304" xlink:to="loc_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent_C1A5A382A1FFFE1A42DF3A5621860266" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_FE48B1685E9CE8D9F36B3A5621869A7A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F05AF53C854D8936F8F03A5621859304" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_FE48B1685E9CE8D9F36B3A5621869A7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_8D04B01D7DF3D95F21363A5621865172" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F05AF53C854D8936F8F03A5621859304" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_8D04B01D7DF3D95F21363A5621865172" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent" xlink:label="loc_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent_ABC1505B06AF90DBFA233A5621863490" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F05AF53C854D8936F8F03A5621859304" xlink:to="loc_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent_ABC1505B06AF90DBFA233A5621863490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_DD840DBEC4711126493F3A5621870660" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F05AF53C854D8936F8F03A5621859304" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_DD840DBEC4711126493F3A5621870660" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F7397C9556F943F3220E3A5621877227" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F05AF53C854D8936F8F03A5621859304" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F7397C9556F943F3220E3A5621877227" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_C36F4B133899A16413DC49EC14A57EA7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_918DC7105D46D9BC4B2149EC14A50ACF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C36F4B133899A16413DC49EC14A57EA7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_918DC7105D46D9BC4B2149EC14A50ACF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_E1730B1F303C379BAEF249EC14A5415B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C36F4B133899A16413DC49EC14A57EA7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_E1730B1F303C379BAEF249EC14A5415B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2D28ACBBFEF51E35F40C49EC14A5491E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C36F4B133899A16413DC49EC14A57EA7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2D28ACBBFEF51E35F40C49EC14A5491E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_28B453B992872B6EFDA2DED0E4CC39AD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_05ABF16B71C397390FBFDED0E4CD5CF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_28B453B992872B6EFDA2DED0E4CC39AD" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_05ABF16B71C397390FBFDED0E4CD5CF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_A5A831807B8EB1E88707DED0E4CD1FC8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_28B453B992872B6EFDA2DED0E4CC39AD" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_A5A831807B8EB1E88707DED0E4CD1FC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4EED51EB4B46B23EF7FFDED0E4CDD727" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_28B453B992872B6EFDA2DED0E4CC39AD" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4EED51EB4B46B23EF7FFDED0E4CDD727" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_CD71A5973DA36ECAFA34E2E9703A573A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_301D1A5B10F30CAD9165E2E984E05C85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_CD71A5973DA36ECAFA34E2E9703A573A" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_301D1A5B10F30CAD9165E2E984E05C85" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_42F01E582F49B475CA59E2E97313C256" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_6E2907E74A8B192D9446E2EB278E0EB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_42F01E582F49B475CA59E2E97313C256" xlink:to="loc_us-gaap_InventoryRawMaterials_6E2907E74A8B192D9446E2EB278E0EB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_6C60FD318B845C7FDA2EE2EB27971C35" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_42F01E582F49B475CA59E2E97313C256" xlink:to="loc_us-gaap_InventoryWorkInProcess_6C60FD318B845C7FDA2EE2EB27971C35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_5C3E83E04DC038DA4CB9E2EB27AC170A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_42F01E582F49B475CA59E2E97313C256" xlink:to="loc_us-gaap_InventoryFinishedGoods_5C3E83E04DC038DA4CB9E2EB27AC170A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_193A20968806E6D4113DE2EB27BA6551" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_42F01E582F49B475CA59E2E97313C256" xlink:to="loc_us-gaap_InventoryGross_193A20968806E6D4113DE2EB27BA6551" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_A6928A85658F8F325915E2E970F5166D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3AAC03B87FD253060A8DE2EA59EE0D6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_A6928A85658F8F325915E2E970F5166D" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3AAC03B87FD253060A8DE2EA59EE0D6F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/Liquidity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_234B55FAF4353B0128FDDED0E4758925" xlink:type="locator" />
    <link:loc xlink:href="optn-20181231.xsd#optn_FutureLiquidityTextBlock" xlink:label="loc_optn_FutureLiquidityTextBlock_ADB4738D73A7072FB92BDED0E476C643" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_234B55FAF4353B0128FDDED0E4758925" xlink:to="loc_optn_FutureLiquidityTextBlock_ADB4738D73A7072FB92BDED0E476C643" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/LiquidityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4C8541B1DA3C705A679949EC15CA71F4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_373962FAAFE8D434E7D949EC15CAF327" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4C8541B1DA3C705A679949EC15CA71F4" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_373962FAAFE8D434E7D949EC15CAF327" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_C2C7CA9273560FD59F4F49EC15CA5650" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_373962FAAFE8D434E7D949EC15CAF327" xlink:to="loc_srt_CounterpartyNameAxis_C2C7CA9273560FD59F4F49EC15CA5650" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B9AC1D0F36CDACFA955949EC15CA9330" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_C2C7CA9273560FD59F4F49EC15CA5650" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B9AC1D0F36CDACFA955949EC15CA9330" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_TheCompanyMember" xlink:label="loc_optn_TheCompanyMember_83BC6DB74C91CB873CE849EC15CAD733" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B9AC1D0F36CDACFA955949EC15CA9330" xlink:to="loc_optn_TheCompanyMember_83BC6DB74C91CB873CE849EC15CAD733" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_CertainStockholdersMember" xlink:label="loc_optn_CertainStockholdersMember_3F0878B0C2FD58630BA949EC15CA512D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B9AC1D0F36CDACFA955949EC15CA9330" xlink:to="loc_optn_CertainStockholdersMember_3F0878B0C2FD58630BA949EC15CA512D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_D7A51CC253C5C5A7B35449EC15CA4382" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_373962FAAFE8D434E7D949EC15CAF327" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_D7A51CC253C5C5A7B35449EC15CA4382" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A1C4154318731688113549EC15CA784A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_D7A51CC253C5C5A7B35449EC15CA4382" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A1C4154318731688113549EC15CA784A" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_PublicOfferingMember" xlink:label="loc_optn_PublicOfferingMember_FE1C284D4CC0DE7696AA49EC15CA0F47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A1C4154318731688113549EC15CA784A" xlink:to="loc_optn_PublicOfferingMember_FE1C284D4CC0DE7696AA49EC15CA0F47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_66D8A074820D76C4909549EC15CA85E1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_373962FAAFE8D434E7D949EC15CAF327" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_66D8A074820D76C4909549EC15CA85E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_4DEB93CF05216141CA1349EC15CAA26B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_66D8A074820D76C4909549EC15CA85E1" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_4DEB93CF05216141CA1349EC15CAA26B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_BB6999A36BFBB11B6CE749EC15CAD8FA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_66D8A074820D76C4909549EC15CA85E1" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_BB6999A36BFBB11B6CE749EC15CAD8FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_81ED5B3579A01025908549EC15CA6EDD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_66D8A074820D76C4909549EC15CA85E1" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_81ED5B3579A01025908549EC15CA6EDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_A190BD44D307171A931549EC15CA85FD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_66D8A074820D76C4909549EC15CA85E1" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_A190BD44D307171A931549EC15CA85FD" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_SaleofStockDiscountsandCommissions" xlink:label="loc_optn_SaleofStockDiscountsandCommissions_B11F8FD88411CC0644444A43E925FD76" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_66D8A074820D76C4909549EC15CA85E1" xlink:to="loc_optn_SaleofStockDiscountsandCommissions_B11F8FD88411CC0644444A43E925FD76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_2B060E9B61EF6C3F839849EC15CA4BEC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_66D8A074820D76C4909549EC15CA85E1" xlink:to="loc_us-gaap_DeferredOfferingCosts_2B060E9B61EF6C3F839849EC15CA4BEC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_F7586EC8716D23092E20DED0E61021E0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_4980010336C74AE50881DED0E611B3C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_F7586EC8716D23092E20DED0E61021E0" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_4980010336C74AE50881DED0E611B3C3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/LongTermDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_E463E8EA95E45DF13C2EE32FED0A9E51" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_E3BF2294A42F9F2397EEE32FED0A4951" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_E463E8EA95E45DF13C2EE32FED0A9E51" xlink:to="loc_us-gaap_DebtInstrumentTable_E3BF2294A42F9F2397EEE32FED0A4951" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_A9600D4CFD60A6103C2FE32FED0BE989" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_E3BF2294A42F9F2397EEE32FED0A4951" xlink:to="loc_us-gaap_StatementScenarioAxis_A9600D4CFD60A6103C2FE32FED0BE989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_0389B6FA8520C2F93650E32FED0BCFA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_A9600D4CFD60A6103C2FE32FED0BE989" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_0389B6FA8520C2F93650E32FED0BCFA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_559435A66FB573072FEDE32FED0B5A29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_0389B6FA8520C2F93650E32FED0BCFA2" xlink:to="loc_us-gaap_ScenarioForecastMember_559435A66FB573072FEDE32FED0B5A29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_325B1ECDCD214338BA53E32FED0C6170" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_E3BF2294A42F9F2397EEE32FED0A4951" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_325B1ECDCD214338BA53E32FED0C6170" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_80A78079BAA1D2384DC6E32FED0CD1CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_325B1ECDCD214338BA53E32FED0C6170" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_80A78079BAA1D2384DC6E32FED0CD1CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_85EE23E961F9DFDB221CE32FED0CFD81" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_80A78079BAA1D2384DC6E32FED0CD1CE" xlink:to="loc_us-gaap_SeniorNotesMember_85EE23E961F9DFDB221CE32FED0CFD81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2A4FFA355E897E74BB93E32FED0C955A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_E3BF2294A42F9F2397EEE32FED0A4951" xlink:to="loc_us-gaap_DebtInstrumentAxis_2A4FFA355E897E74BB93E32FED0C955A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6171733DB07667B0068DE32FED0DA6F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2A4FFA355E897E74BB93E32FED0C955A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6171733DB07667B0068DE32FED0DA6F6" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_NotePurchaseAgreementMember" xlink:label="loc_optn_NotePurchaseAgreementMember_74CB2D5DD7F15CD79697E32FED0D0EA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6171733DB07667B0068DE32FED0DA6F6" xlink:to="loc_optn_NotePurchaseAgreementMember_74CB2D5DD7F15CD79697E32FED0D0EA5" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_NotePurchaseAgreementDelayedDrawNotesMember" xlink:label="loc_optn_NotePurchaseAgreementDelayedDrawNotesMember_5D2C8839800CF0845607E32FED0D0469" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6171733DB07667B0068DE32FED0DA6F6" xlink:to="loc_optn_NotePurchaseAgreementDelayedDrawNotesMember_5D2C8839800CF0845607E32FED0D0469" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_E82D8472D329942198AFE32FED0DAB11" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_E3BF2294A42F9F2397EEE32FED0A4951" xlink:to="loc_us-gaap_VariableRateAxis_E82D8472D329942198AFE32FED0DAB11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_4144C335F38B6D0D81E9E32FED0E15A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_E82D8472D329942198AFE32FED0DAB11" xlink:to="loc_us-gaap_VariableRateDomain_4144C335F38B6D0D81E9E32FED0E15A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_124C7A3FCC9D059B2208E32FED0E3946" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_4144C335F38B6D0D81E9E32FED0E15A7" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_124C7A3FCC9D059B2208E32FED0E3946" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_25E2E0B836273CFE2514E32FED0F8D2B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_E3BF2294A42F9F2397EEE32FED0A4951" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_25E2E0B836273CFE2514E32FED0F8D2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8D695C99D457AAAAE2BAE32FED0F731E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_25E2E0B836273CFE2514E32FED0F8D2B" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8D695C99D457AAAAE2BAE32FED0F731E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_0CCE640BEEDDC00611D3E32FED109FD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8D695C99D457AAAAE2BAE32FED0F731E" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_0CCE640BEEDDC00611D3E32FED109FD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_B4CDA917284763D6FA7CE32FED108EAB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8D695C99D457AAAAE2BAE32FED0F731E" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_B4CDA917284763D6FA7CE32FED108EAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_AC74B6D63D6815138417E32FED105B7D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8D695C99D457AAAAE2BAE32FED0F731E" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_AC74B6D63D6815138417E32FED105B7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_3ED64B00BCC82569866AE32FED10ED51" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8D695C99D457AAAAE2BAE32FED0F731E" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_3ED64B00BCC82569866AE32FED10ED51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_84701357E6DBF7F966E9E32FED115FAA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_E3BF2294A42F9F2397EEE32FED0A4951" xlink:to="loc_srt_RangeAxis_84701357E6DBF7F966E9E32FED115FAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_C81CAD7B980D6B6D651EE32FED11947E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_84701357E6DBF7F966E9E32FED115FAA" xlink:to="loc_srt_RangeMember_C81CAD7B980D6B6D651EE32FED11947E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_6F9C3A9FB4740C1C1C66E32FED1207B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_C81CAD7B980D6B6D651EE32FED11947E" xlink:to="loc_srt_MinimumMember_6F9C3A9FB4740C1C1C66E32FED1207B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_E3BF2294A42F9F2397EEE32FED0A4951" xlink:to="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_56C15077D3A5AA936F5AE32FED121F69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_56C15077D3A5AA936F5AE32FED121F69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_460A0365C0CEBC681265E32FED13DFA0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_460A0365C0CEBC681265E32FED13DFA0" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_NumberOfTrailingQuarters" xlink:label="loc_optn_NumberOfTrailingQuarters_A33EC4DC7AD280DB6616E32FED13CD4B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_optn_NumberOfTrailingQuarters_A33EC4DC7AD280DB6616E32FED13CD4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_B0A915D97DD011475899E33379963A2E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_us-gaap_Revenues_B0A915D97DD011475899E33379963A2E" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_TotalDebttoTrailingQuarterNetSalesRatio" xlink:label="loc_optn_TotalDebttoTrailingQuarterNetSalesRatio_E130D08B68A03757C045E32FED133A02" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_optn_TotalDebttoTrailingQuarterNetSalesRatio_E130D08B68A03757C045E32FED133A02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_C404A7F96EF39EEEB9F9E32FED148428" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_C404A7F96EF39EEEB9F9E32FED148428" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentInterestRateFloor" xlink:label="loc_optn_DebtInstrumentInterestRateFloor_725D171E99DD5A009B9EE32FED149D5E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_optn_DebtInstrumentInterestRateFloor_725D171E99DD5A009B9EE32FED149D5E" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentFeeUpfrontFee" xlink:label="loc_optn_DebtInstrumentFeeUpfrontFee_DC9F2AE28CC3BD6216F6E32FED157102" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_optn_DebtInstrumentFeeUpfrontFee_DC9F2AE28CC3BD6216F6E32FED157102" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentFeeExitFee" xlink:label="loc_optn_DebtInstrumentFeeExitFee_5F9B145128CA98853EA4E32FED15B09D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_optn_DebtInstrumentFeeExitFee_5F9B145128CA98853EA4E32FED15B09D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_834665F2BF2630A807FEE32FED15F85F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_834665F2BF2630A807FEE32FED15F85F" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentPrepaymentFee" xlink:label="loc_optn_DebtInstrumentPrepaymentFee_D7C4EB5E70F35963B042E32FED154C95" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_optn_DebtInstrumentPrepaymentFee_D7C4EB5E70F35963B042E32FED154C95" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentCovenantCashandCashEquivalents" xlink:label="loc_optn_DebtInstrumentCovenantCashandCashEquivalents_3CE30D7802798C93D035E32FED15E260" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_optn_DebtInstrumentCovenantCashandCashEquivalents_3CE30D7802798C93D035E32FED15E260" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_85EEC673325196C95919E32FED16F873" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_us-gaap_InterestExpenseDebt_85EEC673325196C95919E32FED16F873" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_B9C433A0BE44B65A696DE32FED16EF35" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_B9C433A0BE44B65A696DE32FED16EF35" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtDiscountAmortizationPeriod" xlink:label="loc_optn_DebtDiscountAmortizationPeriod_0D3464BEE039A14182FAE32FED16A0D2" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_optn_DebtDiscountAmortizationPeriod_0D3464BEE039A14182FAE32FED16A0D2" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_InterestExpenseDebtBackEndFees" xlink:label="loc_optn_InterestExpenseDebtBackEndFees_B0F46A3663A2B200094DE32FED171B88" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_optn_InterestExpenseDebtBackEndFees_B0F46A3663A2B200094DE32FED171B88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_3CD00922277B3A07C766E32FED17F260" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_3CD00922277B3A07C766E32FED17F260" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_87483361ABB4CF7BED3DE32FED17730E" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9BBDA35ABC41367723F1E32FED123394" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_87483361ABB4CF7BED3DE32FED17730E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/LongTermDebtScheduleOfLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_CEEE66ECA8532AC6B5CBE32FECF37179" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_06C71A2D720E951451EAE32FECF32106" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_CEEE66ECA8532AC6B5CBE32FECF37179" xlink:to="loc_us-gaap_DebtInstrumentTable_06C71A2D720E951451EAE32FECF32106" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1FEB20CB7AC7C74CD2AFE32FECF472B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_06C71A2D720E951451EAE32FECF32106" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1FEB20CB7AC7C74CD2AFE32FECF472B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6D2743E78A4738670198E32FECF4CAD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1FEB20CB7AC7C74CD2AFE32FECF472B7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6D2743E78A4738670198E32FECF4CAD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_C0D8D6295CD6D7C6F6EAE32FECF48CCB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6D2743E78A4738670198E32FECF4CAD9" xlink:to="loc_us-gaap_SeniorNotesMember_C0D8D6295CD6D7C6F6EAE32FECF48CCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_58857BCA14F3A135DC78E32FECF5A00E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_06C71A2D720E951451EAE32FECF32106" xlink:to="loc_us-gaap_DebtInstrumentAxis_58857BCA14F3A135DC78E32FECF5A00E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_778C1D1CF9117F160788E32FECF5061A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_58857BCA14F3A135DC78E32FECF5A00E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_778C1D1CF9117F160788E32FECF5061A" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_NotePurchaseAgreementMember" xlink:label="loc_optn_NotePurchaseAgreementMember_7D36E7F860B6E77772F1E32FECF6223A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_778C1D1CF9117F160788E32FECF5061A" xlink:to="loc_optn_NotePurchaseAgreementMember_7D36E7F860B6E77772F1E32FECF6223A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_855D1AFB83FE984EE6C1E32FECF6B6D5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_06C71A2D720E951451EAE32FECF32106" xlink:to="loc_us-gaap_DebtInstrumentLineItems_855D1AFB83FE984EE6C1E32FECF6B6D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_04F3493B3978362B122DE32FECF6D95A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_855D1AFB83FE984EE6C1E32FECF6B6D5" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_04F3493B3978362B122DE32FECF6D95A" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentFeeAmountFrontEnd" xlink:label="loc_optn_DebtInstrumentFeeAmountFrontEnd_E16F6C109135D3ADD62BE32FECF69342" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_855D1AFB83FE984EE6C1E32FECF6B6D5" xlink:to="loc_optn_DebtInstrumentFeeAmountFrontEnd_E16F6C109135D3ADD62BE32FECF69342" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_EFBB8953B2F61B839F46E32FECF72117" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_855D1AFB83FE984EE6C1E32FECF6B6D5" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_EFBB8953B2F61B839F46E32FECF72117" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DebtInstrumentFeeAmountBackEnd" xlink:label="loc_optn_DebtInstrumentFeeAmountBackEnd_FCB281C124B220FD50C7E32FECF79B55" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_855D1AFB83FE984EE6C1E32FECF6B6D5" xlink:to="loc_optn_DebtInstrumentFeeAmountBackEnd_FCB281C124B220FD50C7E32FECF79B55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_4E62AABED537A3DEE7A5E32FECF712EC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_855D1AFB83FE984EE6C1E32FECF6B6D5" xlink:to="loc_us-gaap_LongTermDebt_4E62AABED537A3DEE7A5E32FECF712EC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/LongTermDebtTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_D08FF1BAAE68126E39DCDED0E54874F5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_DD6A60BDF0AA0BEE3654DED0E54880D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_D08FF1BAAE68126E39DCDED0E54874F5" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_DD6A60BDF0AA0BEE3654DED0E54880D4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/OrganizationAndDescriptionOfBusiness" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F42FEB97935752E24B9CDED0E4835413" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_25556FB6FC3D852EBD0FDED0E483AF1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F42FEB97935752E24B9CDED0E4835413" xlink:to="loc_us-gaap_NatureOfOperations_25556FB6FC3D852EBD0FDED0E483AF1F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/PropertyAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_619B38B5A87379062681DED0E3127926" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C1F933D2CDF9784CC21DDED0E312021F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_619B38B5A87379062681DED0E3127926" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C1F933D2CDF9784CC21DDED0E312021F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0240ACE0DCFDB4995772E2AA3CDAB161" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_86C85939240313CC3FF3E2AA3CDA56EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0240ACE0DCFDB4995772E2AA3CDAB161" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_86C85939240313CC3FF3E2AA3CDA56EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_C4FCE4D3103D180DF1C5E2F5DA2E91B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_86C85939240313CC3FF3E2AA3CDA56EC" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_C4FCE4D3103D180DF1C5E2F5DA2E91B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_28D9D6276A600FA7F2A1E2F5DA42078F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_C4FCE4D3103D180DF1C5E2F5DA2E91B2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_28D9D6276A600FA7F2A1E2F5DA42078F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_B8F4B900137ACC10E1A3E2F60BE4142B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_28D9D6276A600FA7F2A1E2F5DA42078F" xlink:to="loc_us-gaap_InventoriesMember_B8F4B900137ACC10E1A3E2F60BE4142B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_4AC0EF5CB443DA5C42C0E2F632A7DAC4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_28D9D6276A600FA7F2A1E2F5DA42078F" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_4AC0EF5CB443DA5C42C0E2F632A7DAC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_672628BD005509B41852E2AA3CDAD807" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_86C85939240313CC3FF3E2AA3CDA56EC" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_672628BD005509B41852E2AA3CDAD807" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E19FB0B4F7AEA7938AC4E2AA3CDA7528" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_672628BD005509B41852E2AA3CDAD807" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E19FB0B4F7AEA7938AC4E2AA3CDA7528" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_ComputerEquipmentandSoftwareMember" xlink:label="loc_optn_ComputerEquipmentandSoftwareMember_99492370606CA5255037E2AA3CDB6E06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E19FB0B4F7AEA7938AC4E2AA3CDA7528" xlink:to="loc_optn_ComputerEquipmentandSoftwareMember_99492370606CA5255037E2AA3CDB6E06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_73A74079B9CFA506997EE2AA3CDB13E2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E19FB0B4F7AEA7938AC4E2AA3CDA7528" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_73A74079B9CFA506997EE2AA3CDB13E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_D67547A0DDF942294638E2AA3CDBC78D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E19FB0B4F7AEA7938AC4E2AA3CDA7528" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_D67547A0DDF942294638E2AA3CDBC78D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_81D9560F1543BC8DB202E2AA3CDC69EC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E19FB0B4F7AEA7938AC4E2AA3CDA7528" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_81D9560F1543BC8DB202E2AA3CDC69EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_33936D9E9738B224B2B4E2F43CFE412A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E19FB0B4F7AEA7938AC4E2AA3CDA7528" xlink:to="loc_us-gaap_ConstructionInProgressMember_33936D9E9738B224B2B4E2F43CFE412A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2AF2EA129C57E7CC1D65E2AA3CDCF396" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_86C85939240313CC3FF3E2AA3CDA56EC" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2AF2EA129C57E7CC1D65E2AA3CDCF396" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8073C0606F8BB0280906E2AA3CDC4FD2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2AF2EA129C57E7CC1D65E2AA3CDCF396" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8073C0606F8BB0280906E2AA3CDC4FD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_55CF6FDD4A1812AB8777E2AA3CDC2387" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2AF2EA129C57E7CC1D65E2AA3CDCF396" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_55CF6FDD4A1812AB8777E2AA3CDC2387" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1023972EE7975FDF47AEE2AA3CDCF73D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2AF2EA129C57E7CC1D65E2AA3CDCF396" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1023972EE7975FDF47AEE2AA3CDCF73D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_7A9D1EC2EDCAD32DD18CE2AA3CDDADD6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2AF2EA129C57E7CC1D65E2AA3CDCF396" xlink:to="loc_us-gaap_Depreciation_7A9D1EC2EDCAD32DD18CE2AA3CDDADD6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/PropertyAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A4BFF2B221CB217464CCDED0E4C4D902" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2C52DD0C88A31FCB4496DED0E4C504FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A4BFF2B221CB217464CCDED0E4C4D902" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2C52DD0C88A31FCB4496DED0E4C504FD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_667EECD1505233332C10DED0E3CE479E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_FACA36443CFE76D3D3ACDED0E3CEF45F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_667EECD1505233332C10DED0E3CE479E" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_FACA36443CFE76D3D3ACDED0E3CEF45F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_768780FEB87395BB937CDED0E1463E84" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1D3B242B769F2F786705DED0E1467E92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_768780FEB87395BB937CDED0E1463E84" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1D3B242B769F2F786705DED0E1467E92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A66DAB60A00B810A35D6DED0E14632B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1D3B242B769F2F786705DED0E1467E92" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A66DAB60A00B810A35D6DED0E14632B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_110A1AD603C88C8B128ADED0E1466204" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A66DAB60A00B810A35D6DED0E14632B3" xlink:to="loc_us-gaap_RelatedPartyDomain_110A1AD603C88C8B128ADED0E1466204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_2151AA7F0F0AE741086BDED0E14613B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_110A1AD603C88C8B128ADED0E1466204" xlink:to="loc_us-gaap_InvestorMember_2151AA7F0F0AE741086BDED0E14613B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1FEF78D659F2FB739B03DED0E1464240" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1D3B242B769F2F786705DED0E1467E92" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1FEF78D659F2FB739B03DED0E1464240" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_DB3574E3E53561B14404DED0E146C0E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1FEF78D659F2FB739B03DED0E1464240" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_DB3574E3E53561B14404DED0E146C0E2" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_FeesForIPOAndSeriesDConvertibleStockMember" xlink:label="loc_optn_FeesForIPOAndSeriesDConvertibleStockMember_10F842CE5D369E0F333CDED0E1467276" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_DB3574E3E53561B14404DED0E146C0E2" xlink:to="loc_optn_FeesForIPOAndSeriesDConvertibleStockMember_10F842CE5D369E0F333CDED0E1467276" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_AA131C9521C8746B2E4DDED0E1466CDA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1D3B242B769F2F786705DED0E1467E92" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_AA131C9521C8746B2E4DDED0E1466CDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_23B3C6AC55D1EC9DE50DDED0E146F9DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_AA131C9521C8746B2E4DDED0E1466CDA" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_23B3C6AC55D1EC9DE50DDED0E146F9DD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B28F27EBB73B4A2D9341DED0E4C2FC9E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8717DD30C2C9D3082ADFDED0E4C270E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B28F27EBB73B4A2D9341DED0E4C2FC9E" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8717DD30C2C9D3082ADFDED0E4C270E1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/StockBasedCompensationBlackScholesPricingModelOptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0639CD0AB77F1E4AD748DED0E169A111" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1EC04BB994CA81EC7389DED0E1693DB4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0639CD0AB77F1E4AD748DED0E169A111" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1EC04BB994CA81EC7389DED0E1693DB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2DFC559A472692FA0E08DED0E16A36D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1EC04BB994CA81EC7389DED0E1693DB4" xlink:to="loc_us-gaap_AwardTypeAxis_2DFC559A472692FA0E08DED0E16A36D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8D4197EAF6AE10444DC6DED0E16A0512" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2DFC559A472692FA0E08DED0E16A36D1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8D4197EAF6AE10444DC6DED0E16A0512" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_D5675AF0825B42876391DED0E16A2CD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8D4197EAF6AE10444DC6DED0E16A0512" xlink:to="loc_us-gaap_EmployeeStockOptionMember_D5675AF0825B42876391DED0E16A2CD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_FF11D96EB8B2DACDF45CDED0E16B91A6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1EC04BB994CA81EC7389DED0E1693DB4" xlink:to="loc_us-gaap_PlanNameAxis_FF11D96EB8B2DACDF45CDED0E16B91A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_E8F70B7A5078C1093BD9DED0E16B87C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_FF11D96EB8B2DACDF45CDED0E16B91A6" xlink:to="loc_us-gaap_PlanNameDomain_E8F70B7A5078C1093BD9DED0E16B87C9" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:label="loc_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_E6689088424171956D98DED0E16CA51A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_E8F70B7A5078C1093BD9DED0E16B87C9" xlink:to="loc_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_E6689088424171956D98DED0E16CA51A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34F010247A13980E44E2DED0E16CAA7C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1EC04BB994CA81EC7389DED0E1693DB4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34F010247A13980E44E2DED0E16CAA7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F6F13E9609F44DEDA1F6DED0E16D9EFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34F010247A13980E44E2DED0E16CAA7C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F6F13E9609F44DEDA1F6DED0E16D9EFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_CA5B7054E902B388B455DED0E16D9411" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34F010247A13980E44E2DED0E16CAA7C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_CA5B7054E902B388B455DED0E16D9411" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_92DA9D4D48A770E1FDADDED0E16DE85F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34F010247A13980E44E2DED0E16CAA7C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_92DA9D4D48A770E1FDADDED0E16DE85F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_984E333ED2A30FB7B7C0DED0E16E1C4D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34F010247A13980E44E2DED0E16CAA7C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_984E333ED2A30FB7B7C0DED0E16E1C4D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5095F8C2AA25AE8D272EDED0E530BD6D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_151A91DFCA107EB088EADED0E5314519" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5095F8C2AA25AE8D272EDED0E530BD6D" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_151A91DFCA107EB088EADED0E5314519" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_751D5E4CB7CF1034EFD5DED0E5322404" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_151A91DFCA107EB088EADED0E5314519" xlink:to="loc_us-gaap_PlanNameAxis_751D5E4CB7CF1034EFD5DED0E5322404" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_CC5935168C0A2FB76A8FDED0E532C5E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_751D5E4CB7CF1034EFD5DED0E5322404" xlink:to="loc_us-gaap_PlanNameDomain_CC5935168C0A2FB76A8FDED0E532C5E9" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:label="loc_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_5F48BA7D503E341095BDDED0E532A5B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_CC5935168C0A2FB76A8FDED0E532C5E9" xlink:to="loc_optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember_5F48BA7D503E341095BDDED0E532A5B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F298FB8722C96AB6A9BDED0E533F93A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_151A91DFCA107EB088EADED0E5314519" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F298FB8722C96AB6A9BDED0E533F93A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_07F89B38977DA6BB3F23DED0E533C0DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F298FB8722C96AB6A9BDED0E533F93A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_07F89B38977DA6BB3F23DED0E533C0DF" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear" xlink:label="loc_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear_A53FDABAE9B58130E2F6DED0E534C79E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F298FB8722C96AB6A9BDED0E533F93A" xlink:to="loc_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear_A53FDABAE9B58130E2F6DED0E534C79E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4EE9F68B89DA7703C6EFDED0E534C6A2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6F298FB8722C96AB6A9BDED0E533F93A" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4EE9F68B89DA7703C6EFDED0E534C6A2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_933C1FCFDC9930602031EE2779ABCAC5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34105EB09F634D47D47AEE2779AB5E26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_933C1FCFDC9930602031EE2779ABCAC5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34105EB09F634D47D47AEE2779AB5E26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_C14E8928F1DBC2EC531FEE2779ACE7AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34105EB09F634D47D47AEE2779AB5E26" xlink:to="loc_us-gaap_PlanNameAxis_C14E8928F1DBC2EC531FEE2779ACE7AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_667DCDACA6C90148F794EE2779ACD04F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_C14E8928F1DBC2EC531FEE2779ACE7AE" xlink:to="loc_us-gaap_PlanNameDomain_667DCDACA6C90148F794EE2779ACD04F" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_AmendedandRestated2010StockIncentivePlanMember" xlink:label="loc_optn_AmendedandRestated2010StockIncentivePlanMember_7AF41417315B2758D3DDEE2779ACA4F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_667DCDACA6C90148F794EE2779ACD04F" xlink:to="loc_optn_AmendedandRestated2010StockIncentivePlanMember_7AF41417315B2758D3DDEE2779ACA4F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_237D112B1F4C6E0D0505EE2779AC237B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34105EB09F634D47D47AEE2779AB5E26" xlink:to="loc_us-gaap_AwardTypeAxis_237D112B1F4C6E0D0505EE2779AC237B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4376ECA03173966C71CCEE2779AD0DDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_237D112B1F4C6E0D0505EE2779AC237B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4376ECA03173966C71CCEE2779AD0DDE" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_ServiceBasedStockOptionsMember" xlink:label="loc_optn_ServiceBasedStockOptionsMember_49AB1FCC21826FB6CC8DEE2779AD426F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4376ECA03173966C71CCEE2779AD0DDE" xlink:to="loc_optn_ServiceBasedStockOptionsMember_49AB1FCC21826FB6CC8DEE2779AD426F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34105EB09F634D47D47AEE2779AB5E26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_894C0242A21EA209B337EE2779AE4CF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_894C0242A21EA209B337EE2779AE4CF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2E3FD04E097B5F21CEABEE2779AE92DA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2E3FD04E097B5F21CEABEE2779AE92DA" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease" xlink:label="loc_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease_F2D30316B3E609F6B2A4EE2779AEC07D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:to="loc_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease_F2D30316B3E609F6B2A4EE2779AEC07D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A28B72502242D5D11094EE2779AE1E23" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A28B72502242D5D11094EE2779AE1E23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_86D207A1179C57B7D757EE2779AE7EC4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_86D207A1179C57B7D757EE2779AE7EC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_CD729B35ACA56BD8F32BEE2779AF3367" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_CD729B35ACA56BD8F32BEE2779AF3367" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_82B4DD8EE2FB389FBBECEE2779AF0C22" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_82B4DD8EE2FB389FBBECEE2779AF0C22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_03765D345F4DC0BFB86DEE2779AFE8F3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_03765D345F4DC0BFB86DEE2779AFE8F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_61751BBF974201E672F0EE2779AFB54D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_61751BBF974201E672F0EE2779AFB54D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5DF2795524508D2D39CBEE2779AFD9EB" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5DF2795524508D2D39CBEE2779AFD9EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_CDD82D03AEA052733C9FEE2779B057CF" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_CDD82D03AEA052733C9FEE2779B057CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_486B8688F2F77C00C52CEE2779B063E8" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEC9BACB795E6EFE2166EE2779AD90F3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_486B8688F2F77C00C52CEE2779B063E8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_191CE3AA63F85B746E46DED0E56C4AAC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7DF0D47A8FBAFCB7B8B3DED0E56CF7C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_191CE3AA63F85B746E46DED0E56C4AAC" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7DF0D47A8FBAFCB7B8B3DED0E56CF7C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_87B29F8C84377D6C9D50DED0E56D846D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7DF0D47A8FBAFCB7B8B3DED0E56CF7C7" xlink:to="loc_us-gaap_AwardTypeAxis_87B29F8C84377D6C9D50DED0E56D846D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4B9F7EFFA71CED3BF65DDED0E56D4E83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_87B29F8C84377D6C9D50DED0E56D846D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4B9F7EFFA71CED3BF65DDED0E56D4E83" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_ServiceBasedStockOptionsMember" xlink:label="loc_optn_ServiceBasedStockOptionsMember_E76AC36BF46BB74F5878DED0E56DBD53" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4B9F7EFFA71CED3BF65DDED0E56D4E83" xlink:to="loc_optn_ServiceBasedStockOptionsMember_E76AC36BF46BB74F5878DED0E56DBD53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7502628F37CDB786F501DED0E56D3AE6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7DF0D47A8FBAFCB7B8B3DED0E56CF7C7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7502628F37CDB786F501DED0E56D3AE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2BD86E0F0F17D8875F2EDED0E56ED494" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7502628F37CDB786F501DED0E56D3AE6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2BD86E0F0F17D8875F2EDED0E56ED494" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1D1C82611F0171D3104BDED0E56E5948" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2BD86E0F0F17D8875F2EDED0E56ED494" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1D1C82611F0171D3104BDED0E56E5948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_B55FE515419EE3E66207DED0E56E1E0E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2BD86E0F0F17D8875F2EDED0E56ED494" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_B55FE515419EE3E66207DED0E56E1E0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A1BD84E7970F880580BDDED0E56E0E6D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2BD86E0F0F17D8875F2EDED0E56ED494" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A1BD84E7970F880580BDDED0E56E0E6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2A89BD924DBDFFD7FD93DED0E56F1FD4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2BD86E0F0F17D8875F2EDED0E56ED494" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2A89BD924DBDFFD7FD93DED0E56F1FD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_307511807118457BD14FDED0E56F6C29" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2BD86E0F0F17D8875F2EDED0E56ED494" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_307511807118457BD14FDED0E56F6C29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3C479B3A19E96A0393B1DED0E56F7871" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2BD86E0F0F17D8875F2EDED0E56ED494" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3C479B3A19E96A0393B1DED0E56F7871" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_414AF0326CAD587A832BDED0E56F048D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7502628F37CDB786F501DED0E56D3AE6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_414AF0326CAD587A832BDED0E56F048D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F74680DD484BF121D169DED0E56F2D40" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7502628F37CDB786F501DED0E56D3AE6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F74680DD484BF121D169DED0E56F2D40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7F9B81D20648910B8BA2DED0E56FCB4C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7502628F37CDB786F501DED0E56D3AE6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7F9B81D20648910B8BA2DED0E56FCB4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21A80D64D4B3F4233E22DED0E56FD7C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7F9B81D20648910B8BA2DED0E56FCB4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21A80D64D4B3F4233E22DED0E56FD7C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8B929ADF7E51A8FA5A9FDED0E5702CEA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7F9B81D20648910B8BA2DED0E56FCB4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8B929ADF7E51A8FA5A9FDED0E5702CEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40A0C686E36813D71FC7DED0E57002BA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7F9B81D20648910B8BA2DED0E56FCB4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40A0C686E36813D71FC7DED0E57002BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4C5EA7CF481677FBFA5BDED0E5707E24" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7F9B81D20648910B8BA2DED0E56FCB4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4C5EA7CF481677FBFA5BDED0E5707E24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_86DA28CC08F1EF232582DED0E5703972" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7F9B81D20648910B8BA2DED0E56FCB4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_86DA28CC08F1EF232582DED0E5703972" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4B9B526228AB8384CE9CDED0E5710F78" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7F9B81D20648910B8BA2DED0E56FCB4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4B9B526228AB8384CE9CDED0E5710F78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0DBDBC06725553A2FF70DED0E5718639" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7502628F37CDB786F501DED0E56D3AE6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0DBDBC06725553A2FF70DED0E5718639" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_D29ACDC7D47CFBA40E8CDED0E571CFF1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7502628F37CDB786F501DED0E56D3AE6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_D29ACDC7D47CFBA40E8CDED0E571CFF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_04A3F1B7BFC78C01C227DED0E571F102" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7502628F37CDB786F501DED0E56D3AE6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_04A3F1B7BFC78C01C227DED0E571F102" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0861AE86047380744C6ADED0E572B7B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_04A3F1B7BFC78C01C227DED0E571F102" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0861AE86047380744C6ADED0E572B7B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_61E161D0D0490B590196DED0E57265C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_04A3F1B7BFC78C01C227DED0E571F102" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_61E161D0D0490B590196DED0E57265C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_67DEACCFFA01773310A1DED0E5724B5C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_04A3F1B7BFC78C01C227DED0E571F102" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_67DEACCFFA01773310A1DED0E5724B5C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D6A07ADB18B73914728BEE27796C7D8D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_96CDCBA3AC71BF26F8B8EE27796CBE39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D6A07ADB18B73914728BEE27796C7D8D" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_96CDCBA3AC71BF26F8B8EE27796CBE39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5936FFC843DEFD3099D5EE27796C509E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_96CDCBA3AC71BF26F8B8EE27796CBE39" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5936FFC843DEFD3099D5EE27796C509E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8FBA88A58E9C65B47F54EE27796DD10E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5936FFC843DEFD3099D5EE27796C509E" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8FBA88A58E9C65B47F54EE27796DD10E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_CCB0F47F80C9D4E42718EE3CC81C6F58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8FBA88A58E9C65B47F54EE27796DD10E" xlink:to="loc_us-gaap_CostOfSalesMember_CCB0F47F80C9D4E42718EE3CC81C6F58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2E9587624D3AC616CAAAEE27796D491A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8FBA88A58E9C65B47F54EE27796DD10E" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2E9587624D3AC616CAAAEE27796D491A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ABB4BF1FF6107EA9143EEE27796E28D6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8FBA88A58E9C65B47F54EE27796DD10E" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ABB4BF1FF6107EA9143EEE27796E28D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_3B4A87CC98C0F2C254F8EE3EDB47D89D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8FBA88A58E9C65B47F54EE27796DD10E" xlink:to="loc_us-gaap_InventoriesMember_3B4A87CC98C0F2C254F8EE3EDB47D89D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_6E4C24EAC54176391EC1EE3F3C9D4D46" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8FBA88A58E9C65B47F54EE27796DD10E" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_6E4C24EAC54176391EC1EE3F3C9D4D46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CC80909C1355A9A13DD1EE27796ED152" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_96CDCBA3AC71BF26F8B8EE27796CBE39" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CC80909C1355A9A13DD1EE27796ED152" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_CE2D567A435A50C618FDEE27796E0472" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CC80909C1355A9A13DD1EE27796ED152" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_CE2D567A435A50C618FDEE27796E0472" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A0F028FD2A2C3266073ADED0E563E4B2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_BA6DD5EE8EB7D3133017DED0E5637AEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A0F028FD2A2C3266073ADED0E563E4B2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_BA6DD5EE8EB7D3133017DED0E5637AEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_02B3358A242C744B5101DED0E563CC67" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A0F028FD2A2C3266073ADED0E563E4B2" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_02B3358A242C744B5101DED0E563CC67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C5617ACB43036880F2FBDED0E5643EE6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A0F028FD2A2C3266073ADED0E563E4B2" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C5617ACB43036880F2FBDED0E5643EE6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_767F80BAAB439F16301BEE2779DD19E4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4CABE7C7D8212D9E8C88EE2779DEA4F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_767F80BAAB439F16301BEE2779DD19E4" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4CABE7C7D8212D9E8C88EE2779DEA4F9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/StockholdersEquityCommonStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_785862FF09696988DD17EE2779D4E30D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_11911169C4A98A6D0136EE2779D4863E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_785862FF09696988DD17EE2779D4E30D" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_11911169C4A98A6D0136EE2779D4863E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_63F2B149BFE4B5C5F8AAEE2FFC55A1E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_11911169C4A98A6D0136EE2779D4863E" xlink:to="loc_srt_CounterpartyNameAxis_63F2B149BFE4B5C5F8AAEE2FFC55A1E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6C1E117C230A12A01047EE2FFC6972D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_63F2B149BFE4B5C5F8AAEE2FFC55A1E8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6C1E117C230A12A01047EE2FFC6972D2" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_TheCompanyMember" xlink:label="loc_optn_TheCompanyMember_7B227CFD92EFDF5CF06DEE2FFCAD010A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6C1E117C230A12A01047EE2FFC6972D2" xlink:to="loc_optn_TheCompanyMember_7B227CFD92EFDF5CF06DEE2FFCAD010A" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_CertainStockholdersMember" xlink:label="loc_optn_CertainStockholdersMember_C6810B03AB9A471B1CA9EE2FFCC45841" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6C1E117C230A12A01047EE2FFC6972D2" xlink:to="loc_optn_CertainStockholdersMember_C6810B03AB9A471B1CA9EE2FFCC45841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_E5D21DC4F973326387B8EE2779D5705D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_11911169C4A98A6D0136EE2779D4863E" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_E5D21DC4F973326387B8EE2779D5705D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A2466CD58C57C2C8BE33EE2779D5E946" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_E5D21DC4F973326387B8EE2779D5705D" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A2466CD58C57C2C8BE33EE2779D5E946" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_5E416BCBA94C9F06CA4AEE2779D5CD31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A2466CD58C57C2C8BE33EE2779D5E946" xlink:to="loc_us-gaap_IPOMember_5E416BCBA94C9F06CA4AEE2779D5CD31" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_PublicOfferingMember" xlink:label="loc_optn_PublicOfferingMember_C969E5FAB1C9155CA0F2EE2FFC93DE5C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A2466CD58C57C2C8BE33EE2779D5E946" xlink:to="loc_optn_PublicOfferingMember_C969E5FAB1C9155CA0F2EE2FFC93DE5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6B37FDE88B6BC968760BEE2779D5F39D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_11911169C4A98A6D0136EE2779D4863E" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6B37FDE88B6BC968760BEE2779D5F39D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_F6A1839CFB0B6EEE6914EE2779D5646A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6B37FDE88B6BC968760BEE2779D5F39D" xlink:to="loc_us-gaap_ClassOfStockDomain_F6A1839CFB0B6EEE6914EE2779D5646A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1246A7E8A78F36EE660CEE2779D6C1B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_F6A1839CFB0B6EEE6914EE2779D5646A" xlink:to="loc_us-gaap_CommonStockMember_1246A7E8A78F36EE660CEE2779D6C1B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_11911169C4A98A6D0136EE2779D4863E" xlink:to="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_89885CA622C5834EA505EE2779D69FDD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_89885CA622C5834EA505EE2779D69FDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_DA41BB369D5953E8D427EE2779D6C537" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_DA41BB369D5953E8D427EE2779D6C537" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_513A5CB269BF5E1B3547EE2779D74B00" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_513A5CB269BF5E1B3547EE2779D74B00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_05D6A719B5B197242C9EEE2779D74A4D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_05D6A719B5B197242C9EEE2779D74A4D" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_SaleofStockDiscountsandCommissions" xlink:label="loc_optn_SaleofStockDiscountsandCommissions_593DECBF95C2098DA571EE2779D75C65" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:to="loc_optn_SaleofStockDiscountsandCommissions_593DECBF95C2098DA571EE2779D75C65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_31F6B946CF88E2A9CA97EE2779D700B8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_31F6B946CF88E2A9CA97EE2779D700B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1A13B98DC005F1FDB2E0EE2FFB7FFA66" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1A13B98DC005F1FDB2E0EE2FFB7FFA66" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_SaleofStockDiscounts" xlink:label="loc_optn_SaleofStockDiscounts_C9129DEDDA2DC11E37BAEE2FFB8C99AC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:to="loc_optn_SaleofStockDiscounts_C9129DEDDA2DC11E37BAEE2FFB8C99AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_A745EA91226A6239C427EE2FFC438F87" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:to="loc_us-gaap_DeferredOfferingCosts_A745EA91226A6239C427EE2FFC438F87" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_VotePerShare" xlink:label="loc_optn_VotePerShare_F3E3995AD4F01E6D9ED5EE2779D7B353" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:to="loc_optn_VotePerShare_F3E3995AD4F01E6D9ED5EE2779D7B353" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_EF6A3D38536AED148D4CEE2779D81811" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9314913D40F6EDD65DA5EE2779D626C9" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_EF6A3D38536AED148D4CEE2779D81811" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_E27CF73E107B1AED7779EE2779BFA22F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_492E3F553A97A255C6A0EE2779BFB3D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_E27CF73E107B1AED7779EE2779BFA22F" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_492E3F553A97A255C6A0EE2779BFB3D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_A76D135D657B69C4A0CFEE2779BF7ED8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_492E3F553A97A255C6A0EE2779BFB3D1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_A76D135D657B69C4A0CFEE2779BF7ED8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F8F3FF4725B5B2B22A6DEE2779C07A3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_A76D135D657B69C4A0CFEE2779BF7ED8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F8F3FF4725B5B2B22A6DEE2779C07A3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_28110431BCCBACF7B564EE2779C0F9A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F8F3FF4725B5B2B22A6DEE2779C07A3B" xlink:to="loc_us-gaap_IPOMember_28110431BCCBACF7B564EE2779C0F9A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_67B8A2549839D28A196AEE2779C02B1B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_492E3F553A97A255C6A0EE2779BFB3D1" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_67B8A2549839D28A196AEE2779C02B1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_7B58DD15CA35278DEF8BEE2779C00BBE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_67B8A2549839D28A196AEE2779C02B1B" xlink:to="loc_us-gaap_DebtConversionNameDomain_7B58DD15CA35278DEF8BEE2779C00BBE" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember" xlink:label="loc_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember_8774504C38A32998666EEE2779C1CF6C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_7B58DD15CA35278DEF8BEE2779C00BBE" xlink:to="loc_optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember_8774504C38A32998666EEE2779C1CF6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_1148F9FC08FCB54E62F2EE2779C11BF4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_492E3F553A97A255C6A0EE2779BFB3D1" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_1148F9FC08FCB54E62F2EE2779C11BF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_4CC3037C41B7172CA8E0EE2779C15178" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_1148F9FC08FCB54E62F2EE2779C11BF4" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_4CC3037C41B7172CA8E0EE2779C15178" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_ConversionatConsummationofIPOMember" xlink:label="loc_optn_ConversionatConsummationofIPOMember_8C9E5F4D7A5DA6FDBE06EE2779C1971D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4CC3037C41B7172CA8E0EE2779C15178" xlink:to="loc_optn_ConversionatConsummationofIPOMember_8C9E5F4D7A5DA6FDBE06EE2779C1971D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3004EC8ADFE45F0DDF52EE2779C20093" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_492E3F553A97A255C6A0EE2779BFB3D1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3004EC8ADFE45F0DDF52EE2779C20093" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_C12A27A9B498DEAE47E8EE2779C28F02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3004EC8ADFE45F0DDF52EE2779C20093" xlink:to="loc_us-gaap_ClassOfStockDomain_C12A27A9B498DEAE47E8EE2779C28F02" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_RedeemableConvertiblePreferredStockSeriesDMember" xlink:label="loc_optn_RedeemableConvertiblePreferredStockSeriesDMember_CD8F801782993399BA84EE2779C21BDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_C12A27A9B498DEAE47E8EE2779C28F02" xlink:to="loc_optn_RedeemableConvertiblePreferredStockSeriesDMember_CD8F801782993399BA84EE2779C21BDC" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_RedeemableConvertiblePreferredStockSeriesC2Member" xlink:label="loc_optn_RedeemableConvertiblePreferredStockSeriesC2Member_17031026590148028D24EE2779C2C8EE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_C12A27A9B498DEAE47E8EE2779C28F02" xlink:to="loc_optn_RedeemableConvertiblePreferredStockSeriesC2Member_17031026590148028D24EE2779C2C8EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_52B2D6AFA8606F35A076EE2779C397B6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_C12A27A9B498DEAE47E8EE2779C28F02" xlink:to="loc_us-gaap_CommonStockMember_52B2D6AFA8606F35A076EE2779C397B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_492E3F553A97A255C6A0EE2779BFB3D1" xlink:to="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_11793B513610616D9045EE2779C37872" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_11793B513610616D9045EE2779C37872" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_B7A9398995BE40FFD216EE2779C38D3D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_B7A9398995BE40FFD216EE2779C38D3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_93165E0E5F4F00BDEAE1EE2779C3792F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_93165E0E5F4F00BDEAE1EE2779C3792F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_1A6557EB8AC12D0C0240EE2779C39BDE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_1A6557EB8AC12D0C0240EE2779C39BDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_E072B3861FFE84128A2AEE2779C41D5E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_E072B3861FFE84128A2AEE2779C41D5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4B67B52E0DBA43EFC322EE2779C4015B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4B67B52E0DBA43EFC322EE2779C4015B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_2D9CC30AABC59A4BEADFEE2779C49A1C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_2D9CC30AABC59A4BEADFEE2779C49A1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_E67A202D3692AE6681B6EE2779C4BC24" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_E67A202D3692AE6681B6EE2779C4BC24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2EAB776FBE44EC8D4B31EE2779C5BAC8" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2EAB776FBE44EC8D4B31EE2779C5BAC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1DF071B8F977BE2B05BEEE2779C5D0D4" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1DF071B8F977BE2B05BEEE2779C5D0D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_EBE77D9022BD2202462EEE2779C5D0D9" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7839792BCCAB4050C9E7EE2779C33EC0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_EBE77D9022BD2202462EEE2779C5D0D9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/StockholdersEquityWarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_9137D7F7C5D4BCAAB855EE2779CF8FC9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_F527DBF600BE4AAB0A02EE2779D0C0DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9137D7F7C5D4BCAAB855EE2779CF8FC9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_F527DBF600BE4AAB0A02EE2779D0C0DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A4E320B16F5A5881C40FEE2779D04F62" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9137D7F7C5D4BCAAB855EE2779CF8FC9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A4E320B16F5A5881C40FEE2779D04F62" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_E4D4D1BCA15F226E4FEDEE277891196F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_7CB8E1BD5BC8C780DE5CEE27789141C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_E4D4D1BCA15F226E4FEDEE277891196F" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_7CB8E1BD5BC8C780DE5CEE27789141C7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_8824F9D2BDCF03F46D1CEE277886ACD2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_ED3D4BD162FD6C7B2946EE277887A4F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_8824F9D2BDCF03F46D1CEE277886ACD2" xlink:to="loc_us-gaap_SubsequentEventTable_ED3D4BD162FD6C7B2946EE277887A4F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_C3D2B19DBBF19FE5F656EE2778880446" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_ED3D4BD162FD6C7B2946EE277887A4F7" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_C3D2B19DBBF19FE5F656EE2778880446" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6E1E14E8B38E41D043C8EE277888B044" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_C3D2B19DBBF19FE5F656EE2778880446" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6E1E14E8B38E41D043C8EE277888B044" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_26E8B17C60BF71EC5505EE2778889AAE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6E1E14E8B38E41D043C8EE277888B044" xlink:to="loc_us-gaap_SubsequentEventMember_26E8B17C60BF71EC5505EE2778889AAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_2913392D6FBE355623DAEE2778897909" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_ED3D4BD162FD6C7B2946EE277887A4F7" xlink:to="loc_us-gaap_SubsequentEventLineItems_2913392D6FBE355623DAEE2778897909" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_UpfrontLicenseFeeReceivable" xlink:label="loc_optn_UpfrontLicenseFeeReceivable_BD448601167075F38647EE65F98FFB59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2913392D6FBE355623DAEE2778897909" xlink:to="loc_optn_UpfrontLicenseFeeReceivable_BD448601167075F38647EE65F98FFB59" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_DevelopmentMilestoneEligibility" xlink:label="loc_optn_DevelopmentMilestoneEligibility_3306B2E67EE748C14F8BEE696391F280" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2913392D6FBE355623DAEE2778897909" xlink:to="loc_optn_DevelopmentMilestoneEligibility_3306B2E67EE748C14F8BEE696391F280" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_SalesMilestoneEligibility" xlink:label="loc_optn_SalesMilestoneEligibility_BC312FC32ECC400B9A9CEE68B8826FBF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2913392D6FBE355623DAEE2778897909" xlink:to="loc_optn_SalesMilestoneEligibility_BC312FC32ECC400B9A9CEE68B8826FBF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_291BB199AFB2EE339A41DED0E47832C3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_58FA0D67CA1B7BB8A528DED0E479D6AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_291BB199AFB2EE339A41DED0E47832C3" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_58FA0D67CA1B7BB8A528DED0E479D6AC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesAntidilutiveSharesExcludedFromEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9D1AEFAB26342B41E3D349EC157C5C59" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_168254F27DD5F108CF4749EC157C0DDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9D1AEFAB26342B41E3D349EC157C5C59" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_168254F27DD5F108CF4749EC157C0DDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4F4E37DE4D8BDA09793249EC157C263D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_168254F27DD5F108CF4749EC157C0DDE" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4F4E37DE4D8BDA09793249EC157C263D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3AE9A6DA41343A852E8949EC157C9D85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4F4E37DE4D8BDA09793249EC157C263D" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3AE9A6DA41343A852E8949EC157C9D85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_BFFBE80176A7DD925D1249EC157C2FF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3AE9A6DA41343A852E8949EC157C9D85" xlink:to="loc_us-gaap_EmployeeStockOptionMember_BFFBE80176A7DD925D1249EC157C2FF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_181C376E4D25E88FFAF149EC157CB902" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3AE9A6DA41343A852E8949EC157C9D85" xlink:to="loc_us-gaap_WarrantMember_181C376E4D25E88FFAF149EC157CB902" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_EmployeeStockPurchasePlanMember" xlink:label="loc_optn_EmployeeStockPurchasePlanMember_D3D96737AD2726E30E4349EC157C38E4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3AE9A6DA41343A852E8949EC157C9D85" xlink:to="loc_optn_EmployeeStockPurchasePlanMember_D3D96737AD2726E30E4349EC157C38E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6E5C6FA9B5FDE5AA102449EC157C7390" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_168254F27DD5F108CF4749EC157C0DDE" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6E5C6FA9B5FDE5AA102449EC157C7390" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E71E9F1CBEA5603CA10849EC157C3149" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6E5C6FA9B5FDE5AA102449EC157C7390" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E71E9F1CBEA5603CA10849EC157C3149" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73C57EAC3BE9FCC4C5443A5961300C44" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_0ED8F02B087A85DAB2F73A5963C29876" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73C57EAC3BE9FCC4C5443A5961300C44" xlink:to="loc_us-gaap_ConcentrationRiskTable_0ED8F02B087A85DAB2F73A5963C29876" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_A67D82C541408E9108123A59CC8B6303" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_0ED8F02B087A85DAB2F73A5963C29876" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_A67D82C541408E9108123A59CC8B6303" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2DA05ADE5B312AA619613A5B035EA1F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_A67D82C541408E9108123A59CC8B6303" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2DA05ADE5B312AA619613A5B035EA1F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_459563E6AFC1BD9B61653A59ECCF8722" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2DA05ADE5B312AA619613A5B035EA1F3" xlink:to="loc_us-gaap_AccountsReceivableMember_459563E6AFC1BD9B61653A59ECCF8722" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_39DADDA3E35C9CF2F7AB3A5ACD01CC6E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2DA05ADE5B312AA619613A5B035EA1F3" xlink:to="loc_us-gaap_SalesRevenueNetMember_39DADDA3E35C9CF2F7AB3A5ACD01CC6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_50F9AE28564AA1538B063A5963C22379" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_0ED8F02B087A85DAB2F73A5963C29876" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_50F9AE28564AA1538B063A5963C22379" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_3C535A2567C70236B7843A5977C3365D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_50F9AE28564AA1538B063A5963C22379" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_3C535A2567C70236B7843A5977C3365D" xlink:type="arc" />
    <link:loc xlink:href="optn-20181231.xsd#optn_ConcentrationRiskNumberofClients" xlink:label="loc_optn_ConcentrationRiskNumberofClients_40D2E4430D14C4C8B0873A5C1C6675B5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_50F9AE28564AA1538B063A5963C22379" xlink:to="loc_optn_ConcentrationRiskNumberofClients_40D2E4430D14C4C8B0873A5C1C6675B5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_376B8D723CC658D520F649EC15ABAFB0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_6333ABC4A03C9A1A2CE549EC15AB3F71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_376B8D723CC658D520F649EC15ABAFB0" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_6333ABC4A03C9A1A2CE549EC15AB3F71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaap_CashUninsuredAmount_193877AD714780ACB9C649EC15AB36D7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_376B8D723CC658D520F649EC15ABAFB0" xlink:to="loc_us-gaap_CashUninsuredAmount_193877AD714780ACB9C649EC15AB36D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6AFE410E2EE2A52F3BB449EC15AB1596" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_376B8D723CC658D520F649EC15ABAFB0" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6AFE410E2EE2A52F3BB449EC15AB1596" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_CE41B30AF0B2E3971ADA49EC15ABEFD5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_376B8D723CC658D520F649EC15ABAFB0" xlink:to="loc_us-gaap_AdvertisingExpense_CE41B30AF0B2E3971ADA49EC15ABEFD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_9C25AA710C2D083B89EC49EC15AB13F2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_376B8D723CC658D520F649EC15ABAFB0" xlink:to="loc_us-gaap_RestrictedCash_9C25AA710C2D083B89EC49EC15AB13F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1577EC264AA30057FCDB49FAC3986A7B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_376B8D723CC658D520F649EC15ABAFB0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1577EC264AA30057FCDB49FAC3986A7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_B92B516A99FC4E1090AF49FAFBAE8001" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1577EC264AA30057FCDB49FAC3986A7B" xlink:to="loc_srt_ProductOrServiceAxis_B92B516A99FC4E1090AF49FAFBAE8001" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D25848861728B4C0DD1649FAFBB0B9AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_B92B516A99FC4E1090AF49FAFBAE8001" xlink:to="loc_srt_ProductsAndServicesDomain_D25848861728B4C0DD1649FAFBB0B9AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_527CB3E899C7F2DF3A0B49FB316E77F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D25848861728B4C0DD1649FAFBB0B9AD" xlink:to="loc_us-gaap_LicenseMember_527CB3E899C7F2DF3A0B49FB316E77F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_509E73EA91AE291E2CC349FAC3981526" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1577EC264AA30057FCDB49FAC3986A7B" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_509E73EA91AE291E2CC349FAC3981526" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2263D9EEBED494C302D049FA8191CAAE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_509E73EA91AE291E2CC349FAC3981526" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2263D9EEBED494C302D049FA8191CAAE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7EC85D468831904417CD49EC15BAB9A1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0B89AED08451107A1FED49F6CE7FCE92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7EC85D468831904417CD49EC15BAB9A1" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0B89AED08451107A1FED49F6CE7FCE92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_68932D5E3C353E3310BF49EC15BA45A9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7EC85D468831904417CD49EC15BAB9A1" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_68932D5E3C353E3310BF49EC15BA45A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_E2EED529F84C0BDF296049EC15BAF382" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7EC85D468831904417CD49EC15BAB9A1" xlink:to="loc_us-gaap_UseOfEstimates_E2EED529F84C0BDF296049EC15BAF382" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_F843AF1F94015A291E4049EC15BA8E2C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7EC85D468831904417CD49EC15BAB9A1" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_F843AF1F94015A291E4049EC15BA8E2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3625DCD49E1DE018A26049EC15BA5C3C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7EC85D468831904417CD49EC15BAB9A1" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3625DCD49E1DE018A26049EC15BA5C3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3699E45783239570E74B49EC15BA07E9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7EC85D468831904417CD49EC15BAB9A1" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3699E45783239570E74B49EC15BA07E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_C02EF176131CA33D5C1049F85BC011BF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7EC85D468831904417CD49EC15BAB9A1" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_C02EF176131CA33D5C1049F85BC011BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_FF503274E2D69D01DDBF49EC15BA0BD0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7EC85D468831904417CD49EC15BAB9A1" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_FF503274E2D69D01DDBF49EC15BA0BD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6EA46F82D729F57BA76D49EC15BA4EB7" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7EC85D468831904417CD49EC15BAB9A1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6EA46F82D729F57BA76D49EC15BA4EB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1F134D0B93B49495A0DE49EC15BAE05C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7EC85D468831904417CD49EC15BAB9A1" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1F134D0B93B49495A0DE49EC15BAE05C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0DF75CAC48FCE8A7326B49EC15BA10AE" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7EC85D468831904417CD49EC15BAB9A1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0DF75CAC48FCE8A7326B49EC15BA10AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_EB55BF458F87A32B67E549EC15BAA517" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7EC85D468831904417CD49EC15BAB9A1" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_EB55BF458F87A32B67E549EC15BAA517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_6A3B6DE6881F1E85C77849EC15BA9279" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7EC85D468831904417CD49EC15BAB9A1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_6A3B6DE6881F1E85C77849EC15BA9279" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_12D3DC12FAB3224DACD549EC15BAB2C7" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7EC85D468831904417CD49EC15BAB9A1" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_12D3DC12FAB3224DACD549EC15BAB2C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_3510B581FC2AF9565D8C49EC15BAC54B" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7EC85D468831904417CD49EC15BAB9A1" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_3510B581FC2AF9565D8C49EC15BAC54B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_DC7E9623F7CA9AB3EBC549EC15BA7F1D" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7EC85D468831904417CD49EC15BAB9A1" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_DC7E9623F7CA9AB3EBC549EC15BA7F1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_426FF730253B655D6B4549EC15BA6E3C" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7EC85D468831904417CD49EC15BAB9A1" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_426FF730253B655D6B4549EC15BA6E3C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_EC62D60FCFEC412F0923E2AA3D13FA72" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_344C0CEE3B427FCC5FD0E2AA3D1372F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EC62D60FCFEC412F0923E2AA3D13FA72" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_344C0CEE3B427FCC5FD0E2AA3D1372F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12B7ECD74C114325D637E2AA3D135AF7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_344C0CEE3B427FCC5FD0E2AA3D1372F3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12B7ECD74C114325D637E2AA3D135AF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E3B24A36FD3F661377FFE2AA3D149144" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12B7ECD74C114325D637E2AA3D135AF7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E3B24A36FD3F661377FFE2AA3D149144" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_13DEBD804C225DF2585EE2AA3D141BF3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E3B24A36FD3F661377FFE2AA3D149144" xlink:to="loc_us-gaap_ComputerEquipmentMember_13DEBD804C225DF2585EE2AA3D141BF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7246EDE6A20DE6C0E2C0E2AA3D14B822" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E3B24A36FD3F661377FFE2AA3D149144" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7246EDE6A20DE6C0E2C0E2AA3D14B822" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_02405C8157574794803CE2AA3D14190D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E3B24A36FD3F661377FFE2AA3D149144" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_02405C8157574794803CE2AA3D14190D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_E2131D5F41914B1A2A5CE2AA3D15E75A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E3B24A36FD3F661377FFE2AA3D149144" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_E2131D5F41914B1A2A5CE2AA3D15E75A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_01D6E3F9E052F9B6C1A9E2AA3D15C4FD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_344C0CEE3B427FCC5FD0E2AA3D1372F3" xlink:to="loc_srt_RangeAxis_01D6E3F9E052F9B6C1A9E2AA3D15C4FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3158B71E2E33E8D83F77E2AA3D15131F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_01D6E3F9E052F9B6C1A9E2AA3D15C4FD" xlink:to="loc_srt_RangeMember_3158B71E2E33E8D83F77E2AA3D15131F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_C3FF342138212D8A3245E2AA3D15F914" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3158B71E2E33E8D83F77E2AA3D15131F" xlink:to="loc_srt_MinimumMember_C3FF342138212D8A3245E2AA3D15F914" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_5CE46347CF8F33BF4D7AE2AA3D157AC4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3158B71E2E33E8D83F77E2AA3D15131F" xlink:to="loc_srt_MaximumMember_5CE46347CF8F33BF4D7AE2AA3D157AC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_BE33700B616D89A78724E2AA3D16A0AE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_344C0CEE3B427FCC5FD0E2AA3D1372F3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_BE33700B616D89A78724E2AA3D16A0AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_D0C75350EC8CAECB5DB3E2AA3D16A9DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_BE33700B616D89A78724E2AA3D16A0AE" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_D0C75350EC8CAECB5DB3E2AA3D16A9DE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9F41953228B3280880CA49EC15AB2A09" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_0A4B181B45119DE1334A49EC15AB13B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9F41953228B3280880CA49EC15AB2A09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_0A4B181B45119DE1334A49EC15AB13B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_01761B868992AF4711EB49EC15AB8020" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9F41953228B3280880CA49EC15AB2A09" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_01761B868992AF4711EB49EC15AB8020" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>capture.jpg
<TEXT>
begin 644 capture.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1":17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0>.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QE86YN92!+
M96QL>0    'J'  '   (#   "&H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BK_P  1" (5 2,# 2(  A$! Q$!_\0 'P   04! 0$! 0$
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MQ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDJD5&?WGDYGET:3=2EMV_P CNJ***]8\ **** "BBB@ HHHH **** "BBB@
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M_*O=@0R@J<@C(-?=X2LJM),^$S+#NAB&NCU0M%%%=9YP4444 %%%% !1110
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M^HW6FG3;V(P7JG9*S#:Q]L5GCJ2W)[U\[G&:N$/8TTTWN>G@<O49>TJ:]O\
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M^:VA8?=_VS_0?C7I%3*71 %%%%9C"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"GJ/^J7ZY_I_6J2U:U(G<@[8/\ G]*JK2&/!QS4=I_QZ1Y[C/YTZ0[8
M7/HI_E1$-L$8]%'\J 'FJ6JWG]G:/>WP02?9;>2?83C=M4MC/;I5PU%(JR(R
M2*KHP*LK#(8'J".XIK?4#P:U^)GQ-\;QR-X.T.V@MU;:TL*!S&?=Y#@?E6!_
M8?C_ ,6>.9O"WB'Q%+!>0VWVF59+@M&JD*<!8^"?F%>@>(_A-=Z3J3:_\+[U
MM)U!>7L-^(I?4+G@?[K97Z5R'A'QC)'\;+G4?'*)HMY-9?9)%D1D02 ( 3G[
MH.W.>GO7N4YQ<92H):+M[US=-6]T]>\.:"_AWP?9:(+OS7M83']H5,9)).X*
M<^O?TKSW5VGM]1UJ.]E:Z5)'-PZJ;=WCV+DE(Y067!^]Y9%>L,ZLH964JW*D
M'(;Z>M>9:U+(/%&IB"6XD?SMNUI61E!1<JJK+DIZ?NSG)KSZ$FYR;Z_YF<7J
M5].$G_"1Z69DGBE69562=MI90I 7>T*LW'\.XY KN'54R%4*,YP!CFN%T.RA
MA\0V/F6KP-YFY%E 4%L'H&BC)/7IN_&N[D[TL1\2%/<JR=*YNX&-P])&'ZY_
MK7225SMX,33#_II_,"L49L;=<:,OI@?SJ[X?G\MW&<9JC<_-HX]A_6HK"?R9
M/3-/H(Z*^N\=#6%>7Y8'FEO;O<#S6-/+G/-"0#9YBS=:[SX>^"/MKIK&K1_Z
M.IS!$P_UA_O'V_G].N9X$\&OX@O/ME\K+I\+<]O-;^Z/ZFO:$18XU2-0J* %
M4#  ':E*5M$,=11160PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M ,W46S.%] /ZU M2WQS<D>G^ J):0QMP<6LO^Z:EZ #VJ&Y_X]V]\?SJ8T (
M35/4S=#2;PZ<,W@@D^SCC_6;3MZ\=<=:MDTPT+1@>&2?%/XC^&8\^+O"2RPH
M/FF\AXA_WVN5_2J6L_$[P%X]LEM?%NB7UE.HQ'>0;9'A^C#!(]B"*]1^*)(^
M%GB  \?9/_9EK,\'>'-$UGX8^'O[6TBRO";!,M+ I;O_ !=?UKU(U*/(JKA9
MWMH[=#5.-KV+7@JPTX> =#CM9UU*VME\RUN7B*$D,V&VGE2 2/SKDO$I:?Q-
MJ$-Q(@*R 1QH?-RI4$$KYA(/7CR\<5Z18Z=::1IL-AIL"V]K "L42DD(,DXY
M]R:\\UET_MW556"6:'[2?,, <*K;%R&#0O&S>_';-849<U237]:DQ>IG:=):
M:7K-C)?/%%!YXQN0HJL0<,0R1@8_O8.,UWJ7,%S'YEK-'/'G&^)PZ_F*XS0O
MLLNNVRVL[QL'+/'%%!AQ@Y5C&X&WUS'V[5V?DPPAA!%'$&.2(T"Y/KQ1B+70
MI[D,G>L"^XN)O]Y3^E;TE8%__P ?4OT4_P ZP1FR$'?I[KW7(J@K[6R*LPR;
M692>&%4R,,0?X3BK1(R:X.X@GZ5?\-:%/XDUJ.SBR(\[II,?<3N:HK92WDD<
M4 W2,P51[GBO<?"7A:#POIAA1A+<RX,TN.I]!["E)V0T:]E9P:?916EI&(X8
MEVJH[5/116!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
MD77-VY]3_P#6_I3122DM</G^\?YTHI#&S_ZD_4?SJ0U'/_J&_ _K3B: $/-9
MMS<-J.CWZ:3-LNQ%+%&2=ICEVD*3Z<X.:T37/ZIIUS:7C:KI)/F=9H<<..YQ
MW^E<]>K.DE.*NEOWMW7^1T4*<*C<).SZ=K]F>.Z_'\9(_#U[H^LV1U:RN8O+
MDEBCCF;&0<@IANW<4[PW\97\*:'8:%X@\-7<(L81")%<H[ =RC@<_C7M>GZM
M!J5L9(R$=!^\1CRG_P!;WK*UC6K6XC>WCMH[_ .XRQAXU'T/6NV>;8545*I%
M<KU5M+_(UAAZTYNER:K?I8FT76K;Q#H-IJUBLB6]VF]%E # 9(YQGN*XOQ!J
M%I#KFH&]\/VLCPGB9'D2>90H(;>B$9/0 L.E=II2Q)HULMO!%;QA/EBA0(B\
MGH!TKSKQ#''#XDU(M!# 9)M_^D!6\S*K\X8Q':#C&/,!]<5IA90JOFCLU=>A
MSN#C-Q?0M,^AW^IV<5M?ZG%(9$:WE2]694EVG *N692.1R,5TL$,\$)2YO&N
MVW9$C1JA ],+P?K7&Z)+&FNV3.T2[Y=BM'.6!)!P,+*XYY[**[>2KKZ-(B17
MD-8-]S=2_P"ZO]:WI*P;SFXN"/51^A_QK%&;,QVVOD=JAF<!@_8]:FE'-5V'
M'S#(JR3H_!,0F\56(/.) WY<_P!*]NKQSX90>;XL3>>(8FD4G^+C;_[-7L=9
M3W*04445 PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBFRG;"
MY]%)H Q2VY\^H'\J<*9T<XZ9IXI%!(-T3#U%(#E ?:G5$GR@KZ4"'&O//B1\
M0=,\+-!'::A(^O0.&BL+<;UE#8RDP[ C&/X@<$#U]#7EUSZU\Z^'O&.@>%/$
MWBO5M8LI-4U^35)([% FY\;FR0QX7G R,GL*[,+2YVY6O;IW_P" 7%7/7K73
MXO$5A:ZL;2ZTE[J,//:3)M=3Z$=OZC!P*9<W5K'!)INC6QE>0;'91^?/?^5>
M>7LWQ=U.$>+$1;".T/F0:,F0TD9^\6CZMQV8[O0"NT\$>,],\:6K7EABTOT
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MX1^N?Q]JZRBBL&[LH****0!1110 4444 %%%% !1110 4444 %%%% !1110
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MY8VVO'GT/]#7E.L? .^#L^B:U#,O:.[C*GZ;AG/Y"O<**EQ3W*C.4=CYCO\
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B1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>edsworksa01.jpg
<TEXT>
begin 644 edsworksa01.jpg
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M Q$ /P#B"_E:<TW^<AKK_I8OK_7O"J)S6\TLA[TU<R.NR4A*EJ*=6+ZS@8
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MZ<$$0Q C<'PUN/K;]?4XS[_*MYH?\XW7/_2M?'^N^#^5;S0_YQNN?^E:^/\
M7?& N#A^A?[H^[Y?P&)-"?W5^[]>7Y^9QGW^5;S0_P"<;KG_ *5KX_UWP?RK
M>:'_ #C=<_\ 2M?'^N^,!<'!H7^Z/N^7\!@T)_=7[OUY?GYG&>SS5<SRLYYB
M]<M^Y_C5O@'\Q6P0?F#GA_WPP-2>9_5GG*TS9FZ\:X5>U[&;K-_W5&GZH7O,
MI0@T2GO1Z>W46GZRZRMB769]/C-LO)6'WU-H2D_>*=0W'1/\#.S(+%M<P&I1
M6H5B76;0T^C= QT49JGU"XZJVZLJ.43)[E**6@@*_P 1ZU+Z5!(KG54T=%D5
M?.J*LK1K!&RJ%97J'6+4" ""JLS#U'GCUY;0P5.8T:-$FTZRDZ1Q #.02!PW
MA:2#L=5CSCHB<U3U.6@DZAWL#T8_YSUD$><9^V9[^23]<<>4=5=323C42]\9
M. +IK78$ ]YGCOCS^/%JO+Z$$#]8@_EY]N$'2 C([]S\\G._&"&:0'][(-@#
M\;'BQXU \6WO^.-.2G@(W@A]/LH^UO\ =]/O'GB^/XU-3M_^,6^-L_\ 2FM=
M@,G_ --]L\3)U5U//_K$O8DX_P"E%:P 3C(S,\#!QO\ VV$.Q.RL=64^^2
M3\L]O[>(*6$D!OL-S]1W[CV_ 8QCQP"64@#Q90+#^T?BP\SYW [<^5BXT],/
M_+PD_P#VH[GCCX?E]V,@)U4U/) .HE[8W!/\*:UG/C ,S&>V1O[]CCBFK5;4
MW[Q&HE\;>#=%:QV'@3"=]\8'X]CQ89)WZCV3D>X!V V/]$D'?/M\Q D E2CC
M.-\><=L>.W?Y_+A#-(MK22,2  -;V-B#S<[GD ?<1OAG@4_:"'L/W$=NQ_NG
M?86V.W%^<7Y_&KJ<3G^,6]]RD#_A36L8V(V^V8\GQ^WBF=5-3U#?42]TC=6U
MTUK<[ @$S2=R-_J3Q8.2I1.,> ,YSVW_ +]M_?B5Q6<[C?(&V<* R/V#\P,[
M\*))KW,L@('^L:Z[#GXCSP02-A?#A2TXL?=X22!_9)R0/)?O.]C?S.+W7JSJ
M@DY3J)>_;;_A36MSY!_QS\-L=\[\2G5?4\[G4:^004Y'\*:U@$8VQ]MW['/?
MS].+!&%$@G!.<^<$$^W<D'\A\\\475C<9[#Z_7Q[>/IP\32V_>R=O[1SY>NX
MXN>//O@]UA4@&GAMQ?PH^-C_ '3QQSO\[8OQS5O5 8QJ-?!!(.]TUHX';/\
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MU?U7! &I=^X&22;NKN=B!M_CQ)'G;!V^?%C')*S_ $0<@_+]_P"SA$ZKJ5U
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MAD>*BB:T*(65I-_WTMB 2?ZH/["FPN26.R9!T_3953*T\<<M;* 9Y&17\/\
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M]]5;W/YUV7Q<^CQ:HJQ_P$-O+X_R[?,'%'ZY(-'1$?[2_(MN8B3;>X]1Y][
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MMCY>^W$1TXW^>._;OO@D9WW\]MN#Y  ^P(S_ />R-]]N^ 0?;?@P3V &,YR
M=_VG\_EC/?@VX]1OZ?C:WD =_.PPWGG]?+\NWW8^<GP<'!Q]#X^=\'!P<3MM
MJ=6AM RM:DH2,@94M02D9.PRH@;\* 20!N2; >9.#CG$G!QMSYF_@@_$"Y4-
M&Z[KIJ78%@5:R+-I5C5_4.-IMK!I[J+>>F=NZE,0';(N/4*P;<K#]WVM0+@>
MJM.A0JO.I'V)4N;'0IT,N!_C6Q4=%]7J0Y#:JNENHU-=J-0IU)@-S[%NN$N=
M5*NJ2FETZ&B31VE2I]25#EI@0V Y)FJBR!%:=+#O0VXU.M_BC;0ZG8JU[:6'
M())  [G;G"@$HL@!,;IXB.-U9-CJ!XT@$$GL"+\C&,^#B_F]*M37:%/NAK3N
M^G+;I<BK1*G<#=GW&NB4^500I5;C3JLFF&GPY%(2E2JHS(DM.4X)49B6 #BP
M>%_@#]"+@_(C<>8WP6/D>2/J.1\Q<7';O@X.#@X,)BHRXMEUMULE+C2TN(4/
MZ*VR%H/X*2#^''<QIO<2:YIQI[78[H6FKV#9542ZDC#AE6O2W%J .^[OJ#!Q
MN..&,;?M_:,<=FG*+-F57E2Y>*N]U+>D:6V^VO(.%)@F53VP2K)&&HR "23M
MC.,8IO648-/12;72:5 #W\2,-Y?\+?TY![7OH:4BHS"*^S0PR_\ 3E*\?_E'
MW6\\.F8JJE82I6-LGY[8W^9P=LD=N/>@5I30Z7%93D8P"04GMG)R,;8&<8R<
M#CP:! B5J+4VG1(CS8(;>$@$EHM/=0;2ZT-^D+24J6D%0[]B<H@VXTX65K!6
MDD920I*B",$*"4DI(QO@$ [C;'&?:0=BMK6OML1L>>X/G_CC20Y4WO?8_C:P
M(MS87MOS<8R0*BT\G(42=]L;#MWW&WL,_CCM0+R2<YZB2<_@<8P>X_L&/<VB
MP\X% 94 " H9/?;W._RV&1C('8>PV>I(ZE#&3OOYW [X[;@]L[ =QQ'I"D F
M_G;YV(V%K]]QMOB996Y %^UR;<6/8<_+\[X]CU4^000/U< 9[9QCL=SC.0,[
M>W 74#)&4C'MG(W]\9.=M\;^^<<(T*SWQ]WL3G)\9R?RR,Y]\\5!VWVR3@^0
M/8D @CN1ML3N=]VV]3^K?3M^>)2[E00?*XTWN.XMWQ%:BH[GL=OD,^,=MMOV
M=N*2P<$#(&,G'?OVR?(^O;Z<3GOM^T]P/.,?/?MO\N J2.YX7"-8@@FU^]['
MGU^=OK86PF4D@ D$=NY/MCZ _/\ 'BFM'5X(V'DGMX& =]A@D@CA<A;1)ZCG
MO@$'!QL<^3CV .>%:I%-B15S):UJ2CI3Z4="5/NN+.$--IP/O*S@'.03D[<'
M<<[V&PO^K?KG$>E0/VAM:]AY6YM>VWR]+8MMP8R#G8Y';(P,[[_7MPB6O.2=
MAW]\$@ C( SG'M^'?BX#)J,D+736:9 !4"VS+1]K>4DYP7WD]*$+.X4E 6D'
M "CX\J7,=&&*[3H\%YQ73'J4#_D*UD@!,A Z2A2\  XVR 5=APH)X\^0#\5M
MKV''SL3QOAAV'!XY(^$D<;W)YOSZ\G'FJ4<Y)R#XR3D8QXSOX^N_;?BDI>>Y
MP.^VQP>Y ( _'.=B>)'E%+BVS^N@]) [=C@@DC(4C]50SC?N3LG<<[D[=\J/
M<'MMC(/C;&? QG>51?L-B..QL+6YN;=^>PVPS8;]B+#FYL1>^XM]+#SX Q46
MM(&-OD,[[8!SCR0,_D1YRG6Z!W40-T@!6Y'MMN?H3VSGA.MX$82!OW4H'J!.
M>QR=SL-QOD9P1CA*I80DC(S@X!()W\'OX_/<'SPX=K??]W<]_,WPVY)(OSP!
M]-OH!SQ^>%"G2I."0!G. 2-\93GN#_:1G'"93@&PWWQX S[9(WR1C;./D<\)
MEN[8*4G;L,@ G!'8YR?;<>??A.IT'<[=R-R!\\G/;MOCZ'W4 \\6M<[FW>]N
M=_/B^ @*/BL#N0+V!X[WM].?7C%=;N2<').3OLGOL>^!CLD[?7<<(7G>E)W^
M][[]1&V"=MCL<@D9R-MCQ3<?(P$D=CD]_?L3\M_;W&<X0/N] ).Q.2<#.._G
M(Q@D$8R1W('F0+8[<<W[GN/D/G;D=P#AC-<>2VMO?<&QMN?GN-]MMML0>=2"
MG)W*TY\*_63GSYSVV^HVXX\.:/'\HW7'&X_C3O;_ ..R^.O=]X=:3N?OMC)S
MMA0[CSGVWSG/?(XY!>9__P HG6[_ .U"]/\ XY+XM_2/^DU?K A^]Q^A_'<T
M;K5KTM$.WO+D<<"+T^?^?.,$\'!P<7S&<X.#@X.#!@X.#@X,&#@X.#@P8.#@
MXRKH=IZ_JMJ]IUIY'2I1NN[*/2G^E"G.B$]+;5.64)W*41$/*4=L 9) '",R
MHK.QLJ@LQ\E47)^@&'(C2.D:#4\C*B <EF(50/F2!CIF^#EH;_%MR]5#4ZIQ
M$-5_5ZHMS([JFRF0BV*.IQJGM=:D]0:D25JD] P.I(5@G?C<7#2".K;)^]@C
MVV[X_OMY '%BV?:5"L*UZ'9EMPF:?0K9ID2DTR''24LL1XC26DA _P"MTE1V
MR5*)/?:_XZVT)0DNH3C'ZRD_=^O<G!&P[$[_ #XQ'-:QJ^MJ:MKCQI&T*V^B
M-+)&O /PHJW'G??F^^9;1#+:"DHUYBB578 ?%(;-(VW)+EMCN=\*"RIXC R$
M#)SL">Q"LX\#L<Y(SC''DD@*.%#N0<[ $=\]B /;&-R!C)Q[L)]@0WRIYM"^
MM["%+2%*)40@X)SX( '8[@'BW5+&>HE)))V&"/GG WS^1]QCCGDV138DMR!V
MMMY>I( -]^;[CV*P8GX6%O2_&WE:QY%O*_EBFM0)Q@[9WVW)/G<]@/V_7BGQ
M')\_7Y>V<8']\]^#SC;QOOC]O[>)1P+ @[<VV&U_O^\GMMM,-OU^O^V#&V<]
MQ\M]_P _'?Y8XB$Y_OY(V[ _C[<2J.,D GY 8._R&>W[O;B9"R"%;[CMD_,C
M]^_U/">=CZ[[GM8$<\<]^+>0,3^GMN3N,C.WXX/T_'Z\5$# Z1Y/?!V.V>W;
M(!_K.!Q424GI'3G(!2=CCR<[;;[#QG\N*H2.H?=_ [#8#^_;;..QX:=^_']X
MB]]NQO;[_0\89J!V((]3YW%OS!/^.!(R1VQL3^&!O]?Q[_7CUFD%21MG?)]S
MC \9VVS]#@\><D?>!QDX[$C&V / [^/RQQZT8C W['[VW8?/'[]_<\,<D@6-
MK  ;7\A^?E]V&, #M_EQ_G?O>WGA2&P " -_8#JW[ D?/<?/&^W%1*!C&VP^
M8'_6!SG;MY_'V!TG?/@;?OW\Y\'/Y <1P=@-\$[9R/!&<X'D^-]^(;[$'RXO
M_P OGN>/+Y;<,\OU_A_#:Y[8, ';;(WZB "#V P3\]_^[B(SWR2"!MC/?;<=
M_'< Y&_$".V3OMWWV]\_+.X\D9.1OP$C.=@<'SYWWR/R /S&VV4MVYW[#Z;?
M7;M>P]+%M^?UM_#\<1R0,'&<8^9)[; $Y P-\?NX$G<GZ_/<X/;P!VSL#Y(X
M!TX.Y! SMMY/;\\?>WWX@3C&0 "1N/V9V_5]@=]L9SPI[[<CY=Q?GL""/\L+
M;]?+$_6H[#. ,%/<'?W/8_,$[>/'$I43^MXW)^>/.VYSN,9'UQGB!6G 'SSD
MXSCV 'MW W!SCQCB0KSW(!.X(!V. <Y/]?R [<)\K^7SO;[QS;8'C!R-[CZ_
MP_'_ !&)R4C)/<?(8VP< ''8#8G&W;..*9<&24G"3V.2,_D#V.1CZ>_%!;J0
MCJ_65G&,X&,D' (.Y'R[;XVW3KD#"<H2!OCSYWP,;>/ZN%"D[;@7^7X;$_ES
MS?"A2?OM^N_J>>_;'SI^#@X./H;'SM@XKQW S(9<6%=+;K3B@!]XI0XE9P#@
M9(2<9.,\;2_@J<M^BW-K\2GEWT$YAK8;O+1^\V=79MXVZ_<]PV9%GLV7HCJ+
M?5+,ZY[4=:N&C4V)6[;ILVIS*47)2:?'E)3'E!1C.] .O/P(.4?7^Z.3^D<O
MRK-Y7W[QY5^83F]YA+ET!U2U'YOM [AT2L2\+$M'2J=H!J1KHG2&!>VI-P5.
M[4IO:W*C=EH42R::52K@E0GVJ6BM/*M&86%B9-3J 0-*QK4R,SZBHL$HYWTH
M6<JA(4V-A1XA=!>ZA =F-S+)%"B@J&L6DFB0%M*ZG4%@2+MRYH?C0_#]NV9S
M:ZV:$V3S=U+F+YQ.6OEOY5+JM_5.T]'+8T7TVL+2*7I6]>5VV_/MG4:[KPO*
M\:S'TU9;MB/5*9;\&F2IRI,B4&T);;R[:O\ A!G*QJ5S#Z[ZD\T%;YU:CIY2
M_B*\N?.WRJT6@V]I[?E<HU@:"TB\Z#3M :U1KHU9H%O:<T9;MY+N!$BTZG6X
MBG(U0;455":)3MJV1_@X5LW2SJ#RV5#4ZB0M6=(.>[4RS;WYFZ(F54F*ARO6
M=R86_P PU(IEOZ0UN[[<H$F_ZK5[@IC$F!,N& :%4WZ@U4[K5;-.$]^S+4_P
M82H5ZO\ ,_;\_FOD0?XKXS]2T*N.+HU"D6=JK3W>7R;S$4Z#>%R3=3Z?$MF[
MV+>88H5S6MIFG6%VVIZW*W+GNVX8]2?9(1$SS,P*FC@KP5NR"EJ9:#.H76(?
M$#%6NDBI(GB"I][0*\+?$Y8R8TI0% >5J(@E=;21PU.5O&\E[%9*2.SE6\,P
M+33767XL;,E<[/+G?WPF=>=6T\T\33JCWI\/[GNT2I?*=%URTB:M"I:SZS<T
M]XWUIY<5ZZ"M7JWK&.:*ZK;N-MJ95*-I_<-AT^V'ZO,?U/D0YJ(S_ 0>Y\[G
MMOYXZFJ'_@TM;OS3;DJN/37FGBW)=/-%>FA%MWH).E+4?3W2NEZT:65K5B15
M'+CIU_56^$5*V*70Y- IM"U%TYTT<OZNNQUVS+519#537D2!_@VNF^F.J[%\
M:R<VE3K'*4Q+Y17;:F6IHE-NG66^[EYF=6GM/Z1IK>NGU@ZE5JFZ>T-M5NW"
MU6]3+:U!O2%#B5"CR:%"JU3,FFQU\(>^,&98FJ*IJ)5>^E9T9JAD# %G#/5L
ML)52KL!30!Y4T&1GDDIPQ4,D<39@S+I ,50(:56(N%6WN:!PS:U.J:<JKAL<
MD'!P^3XF&C&GO+M\0'G#T+TGH;UM::Z3\PFIEB61;\BK5&NO4:VK=N&3 I=-
M<K-6>DU.J*AQVTL_;I\AZ5)"0Z\XI:B2QOB"GF6I@@J$#!)X8YD# !@LJ*ZA
M@"0& 87 )%^"<,D0Q2/&UBT;LC6W%T8J;$@&UQM<#;MB9(*B !DG(  R22"
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M6IT[X.#CP<;=B1@G)^N_[N$JG^E1P<#<Y.^=SXQMC<[$=^)%N$[GL?(\]_;
M)V'@#?/OPB+C3BBTF0P7>H9;#S9<"AG*5- ^H"D'/ZHQC?..&* >38?F?T?U
MV<3SW/J>/3GOYF_X#%<R'"3TE)2/!R#C'< #<8[[9R#GN,IZH\OUX48$@L,+
ME*1@'J>=2.DD G'0A04%'!\C<YXE4"DD @D?Y)SXS\O?WX\A]YYV8M8(2[Z2
MFVUJ&4@!"0G(!R4GI (&,=^K/#P ;$;6!\KGC[[CGY^>^&D\CN?7O<7 N=A<
M;7M:UQ<VPL8J$AA>3D?>![E).Q"MC@X^GG<#MQ[_ -K:G1%L/!+J2G!2OLI!
M_63N 3C/<'L0>,739E<:40XVTZD''\VV0.GR<'QC!V(.0!V!XJP*LZ1UN9;+
M:DJ*3D'!("QA0!& >H[D 8..G?AQCN+CL>1]+;$ _=P?QC$A'PF]O)A86V&Q
MW'?;BX[;W'M/$L%"22L-+#2G%*'48SBOYDJ_RE-DX63C( .YXINK"L)3D@'?
MO@GV\'Q[;^.W"6>\'$2 ""0PM??!R!U) "0<GJ P3W!^G"0R2MM"DX'6E*L@
M[DJ2"<D_/?P>_P \. X[[VWVOQW_ .WRPE^"-N_RW%N?4@;_ %Q7<=QD# P,
M$G![G&!G&V>Y^6,<)''#O@8R.^QZL;G/D'8;;^P'M04\G<*/X=QC(.-B<^=Q
MC?.<CNF4^LG8X )Z0>QVV&,C.,D#/? /S+@IV/Y\;'M8[W\R+=]\!8BX7FW)
MYN;7OLRV^M_+G>LMX((QG/D*.=]_F1@ G8 '.=^_"53A5MG &=L8P-MLGN!\
M\YR">**W ,E6?/??MOC&?;/G.=CPF7(Q^J3DXP#OOG8><$8&?D3G?AP'%M]@
M;GC@#8[%KC@#8;G;;#"=UOO;@+P.+=^^WD/3%9QU* 2<;> <D$>^/8[?+?;?
M/'F/O*Z2>Q)[$G?L#\OGL,)\]/$KKY'5G!5OG?).^<GZ9SOY[G;CS'7NH %1
M./)QG!.^/ S[COM[<.'GYD$^NPXYV^9OY<W#"Y-^V_SL1Y;#ULP.W:_:1:BI
MQ.^0'$?_ *@<'/?.,CYYVR>.1;F=_P#*(UL_^T^\_P#XW+XZXTDE2>^.M VW
M42%)P!^P>X/;MQR-\SB@KF'UL4E04#J?>GWDD*!Q7)8.% D'<'<$[\6[I+_2
M:O\ ^PG_ /)BD]:_Z+1<_P"D2?+]WC!?!P<'%[QG>#@X.#@P8.#@X.#!@X.#
M@X,&#C:K\'O3X7AS<TZX)$-4J#I_:5>N);O_ )N)/DMII--=<!V5U.27@D>2
M-MP"-57'0%\"NU\U[7N]2K)8I%I6PVC P#*G3*HXX#WZNEA"._ZN=COQR<\F
M\#*:]P;$P-&-['[5EBN/4:[X[?3< J,\RY"+A:@2D;<0JTO?G=!ZVN1:U\=%
MW8 'N-O^_;OW\GQ[<1]]OR\?+OV_,\!WS_?/!G;'CO\ CVXQRY(![FW'K:Y_
MSN>_GC=?\_UY?X>7;!OC/CM_?^_[N#.WL<_GW_:/Z^#)QCP.#'M[$_EG^K?A
MHOWL+6[]_4^9VWWMM;?<&#;?]GYC\MN ;Y_'^X'[_8<&0<@]\#!W_+]F/PX,
M]_?&!\O&_P"']_/ 2-^+V[D6WT_4BW?\#Q@Q#^O_ &C@XB3^S/Y=_P!F_D]^
M)>H#R!^(\[?MX+W!XN3<"^_:VU^;<;C>V#%9M122/IC).V_MY!'?;;OPI"QC
MV(SY/[_!WVP,C&>$22,]]O./W;?W&>)@LD?N(\['^O'#21P+;V)WMY;?+FXW
MM?GMA"HON+'\>W\/U?%<K((^]XQW[^3Y^>_D^=^(MRG$=EJ&,[9/U^8_,>XW
M&.$O5GSGM[;XS[>V?V\0_OOP >H.W (Y 'XGN1QOOA3OVQZZ*BO([DY&3E6W
MSSMO\SY[<5Q4E@9[GO@DG<D[_7\-MNW'@Y\>_P#5Q,#D@9/SW.<G.#^X?W/
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M11IU4TYNV?08.FE%J]MPA:!% NN--<M&!;+425#J4IZHT!N/+J+SKVY*U/\
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MS!R<X(VQPD6X3W\[JV\Y]_VG?MW[8#K<'DV.W87M]>W<#ZC#.1O;Y?=YG?\
M"_EMB9QSQD$$YQGISG)\C([X/OG\DV">W;N-\[[;YSGW[@X[#?.)E$ G._\
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M=6F2ZW/AJ?Z'F)"(<)G2K#J351A1YT=14P^SZP! "FUI4MMYE8R<+9D-N-.
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M>B'U8R 2"!A15]?/8C.^_P"P$ R>LO<#<@8 &^^_OG;SW\[=]D)DIZ2.D[9
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M!U-)(P*W6-=2Z@I_;9G"\Z2=+ ='.,WHJ%3!X"54\8#O K(BQJ=.\CV8!BK
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M%90QL5N.#N 00/709A#F"EHED5E2%V611MXZ:U&I696(W#6-KCNI!*-X_?4
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M0"=06_.@SE+U&H&F&N-L7SKG;UQ5ZU&6G8C%3+3DUF@5*<MI$6X9\+"C5*?
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MS6]9]L4]ZK7'=-:IEO4*F1QE^H5>L3&8%/AM9( 7(E/M-A2B$I"BI1 !/!@
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M,TUN_JY1V%.2:=8UFJ==JTRJ5!IF%5:E"B4"(X])FJ2W\=V]KSNG4:\+HO\
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M;MP;@@7N//UN#>_&-<N0-7)V '?M;G@ ;7'';;"53IR1VW\C'X[X&2<GSL"
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M&W(MS;M]>+XV+4.21_ 6'Z\^=@!CT'G1ODX2,D8SVWW()_+;\./(>D D@_0
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MJZ@4+?A4UMSI^]MTE)&!@@C)UY\'#!!".(8N;_NX[WV[Z;[6VWV^ZS_%E/\
M:/Y?M'T_@,79>%^7IJ!57:Y>]U7!=E7?6IQVH7#5IM6DJ6LY40Y,>=Z 23]U
ML(2/;BT^#@XEQ&23N3<^9P<=6?PM;C9KO)W9T!,TR)-N5^[:++;.5&%U59Z=
M#9(QV,62AQ SCH)P?''*9QT(?!AN=3UA:RVBXZ%"FW1;]>C,9)6E%3ISD&2L
M GI">N&WG &_?<YXKW4\?B93*UKF&6&7B]AK$;'[I#MW^6XM'2$PBSF-3_;T
M\\(_YM(E'.W,6-RZTJ0OH4!U#()ZLGSGY^-B?'MGB&3V[[_GV&"<$^Y(W[;Y
M'>:0Y_/D*P.K"D[^_P!W?W([['?<GBF=QC(SXR#W'@@XSWW/G)VSQF0N2+^@
MVX%R/*UMA;:WWWQKX-]^]M_,7M^!_7IZ,)IYAU+V2&UD!2<DI .>G'?.?F<C
M!\' ]Q3J0>E2LD8) R?&1MC<CP.W8'R>$\&*Y)0D). A 4HY   2,^-CML=Q
M[=^*;BAU$IP<*(&=CW(SG&X[G8>W?RW:^]_U;;T)!N,1$$\>8^H[&W V^@V%
MAWG6LD[K44YV!QYW\^!V[ ^_CB@I6Q&=L?>&.YSXV'?N?KN1CB5:\ %63[#8
MX._[3G'??MQ06Y@*.X2 21L=MQV&^^W?;?OGA2;["]MAWW^ER.>+806!&Q)O
M>U[C>UN0?NX]#B"W0 220D$ @#)SVQXS_;[]N$*G5G.%$IR?U>YWQMMG'N-L
M>YXBXXHDX)Z,# 4!D$#N=@>^1N=S\L'BEWQV)QVVP4[8VW&21XV'OVR#Z=S]
MUNVWG8WVWVWM>51W.Y.X]/OXQ#N?8_N)V.!M[>!L2<GR)PI2<@'8G. ?88))
M/8XQG SV[[\2;D)( SG.W[?[#DC<8&W 1@$@=]OF.^?S[=^WG&W"C>U_H.;G
M8=B/S[=]\*;=[<V^N)O561NM1/C<)['SO\_8[Y^O$Y=<SOC<8R /88WVV^1V
M)SMN.*6,>3[C;.>V^1\]]]NV>(@9[DDC'OCY>=^W?8';R<\!MN;;6V_(<?7N
M;\'>^"R^0^ZW/^>*A>< QU ]\#';L.XW!\8V&>Y\$]9PDY/8=AC.Q'MM^&<Y
M[ =N*9\$=\$YSM@8S[[>P';B!3DYSC<'VQG_ /Z]_?([<  (%]O,V^6PW/SX
M^0YP6'D/N_7_ &Q4+SNWWB!G!(V/[-_P!.^WRX XYG]=7;.,DC?YD;9P-^_C
M<]I ,><G.<9Q@[GWWW]_K[\ !R#D@;'W&-R1MM@;8SCSCA3I[;<=OEN>;_0;
M\G;?!8;[#?TQ,75X!*U$9/OD^^^![[#;(_(0*E+ !4HCR#[@;?+/U/RVXI%0
M![@D$[$CL=LXV[[]O;B)<2?<[C&PV[D9 WV^><_+P6%^0/6X!&_!'F/2W?G;
M#25!''KM_ '?Z@_CB<';;!&""<  'QMOM[XV\\!(P?H<'&Q[9_/89.1C&^<\
M2]0QW2,@=^QV\$8VP?)..VPW,JE(2"<@A(/;<_,#W[Y'<\(-/?\ 7'EN/NMY
M;X<6 Y/W7/EY7\Q]^)B1[ 9SC^^-P>XV[CV[3%0SW/T [?7/GA/]H;W(R>GR
M-\8^8\'?;.-]AXXD^UI*CA"E 8P0G)P<]P5;9\>_X#A3\F^N]CMV(^7E<DC<
M8:77U/'F.2/.WZN#;?'#+P<'#_\ 2AFISN675:F5^-48E._@(_*M6HW9 MMG
M3I3J;MISBFK7J;;4:M#466I<J/&?DRYB689G"1%$=MGHUG-LR_FN"&?PEF$M
M924K(9O"95JIEA,D8$4IE:+6)#$ A9%8ZP1OE_0W2']-,RS++1734#T/3V=Y
MY',E *V&23)Z&2M6DJG:MHEH8:SPO=DK2TXBGDA4T\@<E6 <>[;!H8N.A&Y@
M^;=%6IYK8C=1>-+$IHS0V&P7"3'Z\AH>J4Y]+^<Z>'<\QNB]FZ>Z=6[7*7 I
MU(NR/?,ZSZQ$HE3KU1I$^FHM]BKPZFQ+N,(?K2A(+K*+FHD>);M6;<(A1QZ
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M<5R>W@^=NP'?VS@GO[;C;B&Y[#(\;X/SSC W/^W?BAZ^2.W[\C<'/YC88_'
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M]^X'_M_C;Y8E#N5=)3@XR<G. D^,>X'@G]PXF)(';SD_(>?KX^N-L<'!P]U
MXV^$'Z_#Y_,X<78$#;<7_P#;_$X@3N2-^^??;N/'C..^2? X.H'P1C!';<8)
M_,X/GQOWQP<'#.P^9_(?Q_5AAH8W#[7( /RL-OP'KW.Y-X[;[9.=LDG R??M
MN-\#P,?*&?;/S!/8Y.^?;;! S\O8G!PXJ+VWY_\ C_$X3Q&VXW / [D7^^_W
M@8EPOL2G?/@^W8;[#;Y_GC@ 4?(\]^KY$>1_;O\ AP<''I\)/[OZ\_PXXYN,
M1!B2/4B^W/ _7^6#I6=B1X[ ^!CW\COV]_)XB$N$_K) '_5.X&_@G&1[?EP<
M''GD^%R!M8 >NX'ZVM;MCT*H//KM\K6_.^)DA7ZOW3OD8!^9.V0!\]_ []^)
MDJ( &3M^'Y^^^#N<;?D<'#5 8D$ BW'W>6)1\/&WU/\ GB0@YR#^W.-\GQ[
M#';B &2<;Y QX[DX'GOW/CW'!P<*P M;N"-_2UOT/RPQD7:UQ^SP?.V#&<$^
MQQC;<G(('[_[=^(=*LG'1CYI.?V$?LVX.#A4%QOYV[?[O\/T<&A=]K6(&Q/D
&#_V^6/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>exhibit1020optnvtmopn_image1.gif
<TEXT>
begin 644 exhibit1020optnvtmopn_image1.gif
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M54 U4% ^$F,'/(P)T* 'ZT0$A2 )@# $\]<$2X $AC!3+C"8V  .DJ"4)D#
M4&8''# $Q. ,MH(D%\ET#$(,83(#@  /3* Y%B8-1J A^^$"@- .)#0,L$!"
M&2 )^J$1"S(,W\ )B(#%'( (V5 %). !0P -@_]D#7W*+T, "^NP#!DQ!-B
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M73D6"P(-IP X'? (W? (1O#$0] 7,[ $.2,)() )T/^ !($B"8CS \6@N)R
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M!,Z0#8\ ")+P"#\P!(3$")C_X# .- GL@#=$J@J+, SCG W+  A]^ T@)$;
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MD^>JI@-5Z 8GEGE>$G "';!X1";J  +YS,*:!S$![B1!W^%) AZ,T/^#'J)
M@R:@PQ 28$0VZH !)""C%36@0AOQX(U'A"Y**EYQJ[R<H!=_8Q4S;@&E.&$-
M-[B !S7P !*6\8L?/W,/H.2 %B>QCB;\X <"?H*333 ,?%@C&]D !S%JT $D
MK.,?>O#3H< <YH>T.#60>D0]Q&0"'M3!"3-8<Q4^,(.IF& /]>!$#P)3!W:P
M@DQ:I+ 1P)GA)ZOB&TPPYY62$@Y)2.(<AICQ4)E+:=!86C7^V4,F5(&).OC
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MZ(8.\ %6$(8?6"9&;"T7[ %.: <J**<.X(%N: 40T$1BH*<ZP!#_DX5E^ %
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M!-G1$&_4SS_</RKX!C=$@G=HA2)0IN\3&>FLK 5E#7FKQ/E8!F>XAY7D@67
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M4+#'.=FL LTF1\C"BBII#P%HO5Q[_?BO8,^9,'D2U5"#"R.(X ,/RR'GP0Q
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M$,2J!#7@!#LX<0T@2(4$G)#%-YRA!*D$QQ#P.(4WFH"5#L@-&M^8P@AHX 1
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1)5:B)5XB)F:B)FZBHP0$ #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gammamri2a01.jpg
<TEXT>
begin 644 gammamri2a01.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@!!1$E32S$P-CI;,3=:0E8Q+C$W6D)6
M,38U,#$N3U544%5473$U,38U7S%?1$5624-%7T903U\T0U]02%0N15!3_]L
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M55],XHKC/FZ$%2O*X=[QQ5+_ "K?*+^L=OG_ (J7K_K.E_*N\H?ZQV^?U_\
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ME:>4W]9#?7_%B^O]=T/FEHX."#_E:>4W]9#?7_%B^O\ 7=+^5IY3?UD-]?\
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MW!3$Z<QNEMB8NBSAN7IY+^6/D'7)#MD0:O0;'65,M,0XJ:6RS%"R6U*D8:R
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M+U3U&M. ,G-MM 49NDH1NJWXXMU=T[>VGH%'V/\ 'YH2I[R5B:W3T*DO.O!
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M&<?7&1KWJ;-_FA;']G*'_E$/2[GT?UCPG8^K^AQY2'\+0_ZXW>#_ .[O9?\
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M9,9K5/?C-S%*^'660([#AR1ZK@[Z4L?3 _[]=6KMP:,[%JM%>0U3)3K94L+
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M_P!*T*WCI9=2^EE7D"SS^V=.U6^U:>I]-;@6Y=*&:W1OAPHQUHDM-JD<%*)
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M /ILK_MW/_$==33DW*2[JO[^%'8^APM%WX1&G,^0-KRYRODAQ:B^TK/ I?\
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M;\-)XN1E!MQ(R^.26GDI4DJ(*@?K8PU*VUV]ID5Q*GOBY$=HN70\\W)D./\
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MX+%D) O.TTK)2DW+0 L@'D@??,,*Z(_: &<?N^O6O>HL_P#FC;7]G:)]<_\
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MH<4I<=C%MLR7&0]R3S=*0M.",C&I/C^/FZTU^.BT]C* U%E--BGUR\I;(0U
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M!QS\W[2>P.AFQ#[/7<ZN77MG6:?466GI%H5^12J3*92W'"XSBW5(#F"E*B.
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M*_[)VRW"HERVC<%%DT>V+-I*VI3%G+G,+CU*76*BE))<0'B]%8;=<+800>.
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M\6XH%,R8_P E24M$  !I8&$ '/U&-:N" N2IQP@+6VA"@!P0DA!2"%)^4D<
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MT20/8Y]ZG_&/9>\]W+RE59ZJR[7H4KXA%3N8@I1)=DK2N3"24E+BG)'S#FD
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M^;M$Z_#_ ))A]:'<;NR7K>\=[/TOB<J2SNN,_:U[@TO??<5\I'^%G\O]L7O
M0< ;?;+#\^0VRMT@@C\!^8/Y:UH@6?U./4*^67^7$I4.6?D!/OQZ(5T3K9=_
MA:&?]L5O".N/\7VRQ(^O+^+*WL$?E@G)'U]^\:UF]'8K9,?]KOTW]L^G RI,
M&(PWSVBV>ET">EG&:1+AX7S=F-Y=(:0PM3:6F4XX!("^&>LG*<I/MGWU=_\
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MOS75*@2T&B)#I4TD8#82<%.,# 3T#T#^/>NFP0M3;#CI:84Z%+5]$DCB5_O
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M#[5G-76')G;N/N<:Z7EQ>+MV[NUM$A3:4V^RBE0F5K6H+;:"4E04#Q*TK"U
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MUM",XCUP34B1J^HHZ8TF&VKIOILWX/'QWMF7O;8M%OV#7FQ&DMXR'4EQEY(
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MUVFQ*);N_P!(J^V=^5"MUS<6K-JNZ@TE^J[64^=8+\-="KU8KZZE&I%09_\
MSG\?K_WZMR\=?._;G:[<[<;RPW&O#R0O;?\ W?5Y U7?+9BF1K+@>._D)<&]
M#-[):@;FUN;<\FLO[:+F76W4+WLJH[>7/5ZLY%<%H73:-1=IU<H]1Q.3[8_+
MO_\ OD]>PR2<8[/OIEYOU_\ ->WI]?6^(-4>N;_@W;OZ.U>_'S2TM+4N%PM+
M2TM'!PM+2TM'!PM+2TM'!PM+2TM'!PM+2TM'!PM+2TM'!PM+2TM'!PM+2TM'
M!PM+2TM'!PL_]W7L!_\ #W_>>]+2TM'!PM+2TM'!PM+2TM'!PM+/T_#\A_\
M'W/]_M]-+2T<'"TM+2T<'"TM+2T<'"TM+2T<'#FLL9N^UQ^-QT(?\:M#U[U5
MG?S.MK^S=$_RB'I:6EW/H_K'B7^7_P!7\./'\_A*/_7;^>']L]L/_D/M;JC+
M2TM$=CZ'Z<1X6EI:6GP<+2TM+1P<+2TM+1P<+2TM+1P<+2TM+1P<+2)R<]?W
M  ?\!@:6EHX.%I:6EHX.%I:6EHX.%I:6EHX.%I:6EHX.%I:6EHX.%I:6EHX.
)%I:6EHX./__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gammamria01.jpg
<TEXT>
begin 644 gammamria01.jpg
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M&J36\/'#U5"[[M5?=7#8Y?GO[M^:[_-5^:K]JKNNZJJJH/Q\7^8/;CO[>_\
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M.IG]8O?^/J/_ *'1T=2 ?C6_B9I_Y_?=]]O_ )P.IGV__P!Q=>QOQ3OB>/\
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M]\33]_WW=_?_ /3]J3_6#]/R^7\B=<?C7OB:+_Y_?=Y_W_ZDI_LR#_K^).F
M/8HW*Q?SFJJ.3[6N1516K]^VWS3V7?KIUFV?D_Y_X'\NIK/R?YWU('^->^)I
M^_[[N_\ O^U)_3__ !!^G_K9.A^->^)I^_Z[N_\ O^U)_K!U'YT.DZ-RO^H_
MS/4@?XU[XFGO_P!OON[]_P#T_:D_P>W_ (0>W\7\/SZX_&O?$T_?]]WG_?\
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MJ[!0/:Z%=R .]$_/;CO[BXC-EV5=EV3YKM[)_"O7&R[;[+MOMO\ 9O\ =O\
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M6LZ+:QX;WU^$4=T^SCU[32;7@H(DFSEL "'+DRI,-7>&+&ED.QL<)7(5\6:
M)XH"Z_[]^/GMTA8*>ZT\_2/<F@2 /<@>W'SU$'T-E_E_ZW_@_3U,%JKH64E'
M%N,-T&LR89%Q>US,V;X]IS*=BAZ.HM8>-W>4DRA*A\?\'L;RBTKL?M+)TYU+
M!N[.NJ+ PITV#%(WK'L<KFW WEPFHEPL5JXN2WH@XU5S(M+CLB?$J67^4%2&
M1L:I?D%E64XYEF]E>:ULJRG&0LZ?'BD<$6+OGXX^?;G^GSWKOTBF2E0!/QR
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M+YKQ^2(B)U];^(6E,1X::*\,?"K&9:9FWM$X%YF;,RDM$S+-JFMXSR8V0>0
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M6J)(#6C'YXLN&Y7\HTASA/9*5CW,>UR$1G+;:7^%*0  D4#P../ZC\[YY('
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M+).[=&1V"><LAZ+NU@G/]V[]68;W5@6BGP9/B#WT6;6Q&=S_ '1Z+=G6EP2
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M-4^+'BYXKXS26D_$&1C6=*Z&FO9)EC&Q($:3JG4Z&&8Z=5:C>AH:,^;-5_\
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M\<^JS=\],GRR/5"PS+];^WR7895I7K!A>183DX:]A5C2\?R:.1;$=U5.DDF
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M0[$FAUA2$[5LSS>=9"O\5TZI+0B&BAD8/DEI-@3'D,/TB3S6I?)$V1DBOL'
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M>3K[R7N(9[GKNJN5=]D3\Y5=[(GR3=RJB?/W]_?KX=4#W/YGOW[^_3>P [T
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M%'IR71OL5[<L$&2%.!D^B,G5G+V21+,>',<[,3([=IY;V([\K4FK A"JCC1
M/Y-=(DHX+8T?C/.DYAV9ZYSXD5\<F)Y_I):W2'82).@7-?@UE%?Q>=6$E1"U
MD^K<-Z<W,)':UI5<]6-L08!V^4.%8GB)(UOFL&;#QBAK78Y"R-"8VX<#!JZ$
MP?X,JUI)AALBN6KJ"'6$.4@W(%'&5JU*-<+#7/7[1GNWU,U:O*.%IYBMWJ'+
MPO3S'WA#D:X33>HT^G RBS,C23KBJMH5;;SZZ0$DJJ=-_:SPA5&MP&+4_P":
M2*#B%&SW*UC@"N;]S8 '<\=:0 VJ2 :V5^7'S8'![>_QV/3YNV3M_P"W;OJ[
M%]-Y^M>$BGUN8U> U.9S\?M9]%;WN45,,E=2ZB$'$>P<7/:1!DA?A>..6WG5
M;2UEF^PJYGHF1V]ZE7W%=DFG[-/-?,5Q+O8[>)$G-,1TCU&U&?(J]6\)KXX1
MP'U4O*:PI23B@A-C2,=F2E!-B" K&A+%>^(QS_P8]2)TWM/PS&%4T>G:1T2N
M,KG^<8Z^[,S:$8G)DD8[&.UEFY6HNSU$/Q,XN1Y7?A0KK[H871:MK Y#F>33
M+*Z%5BCB\BY)4JLJH%5 5S_33)HUDPI&YO"D-@6HKGJS>0*4W)4A=%L.FP3]
M*?8I((*" .2GN*31' <$[TI4" 5(201=?2"!1L%-WP0>_')OJD9E&.X_469)
MNG%ZW.," 6!>"'/J9-;,Q])3&38T6PAV+DDMCAFEETQ)0R'$63#$8;VQ)HA#
M5O(M8YN98Y Q[&H+ZBA.E?&OW3VE] T;6KL."<S"&$[FU/((#'*2,GU'+];9
M<H^F..:?X;?7M_BMK7OIR6&!:ET=JPP(-=6R+$@IMO573!,&.PQV9#;,-5/:
M>-+<DA(A/5,<-[/,I!)TQR*9BCS/G!@*.XQXCT1:6TJ;%[Y-%:@E.<,DV%=0
M7!D(;??AXF+Q1BM35!#G8$J!L$D6>$[BJJ!5VYXXKN0 ::@IG@J"4+2-VPJI
M)XY03RD*[<]R!0YX?-V?]N.3W)(VLEA:4U'6!M)6+XE8V9@,":)'B326EE#I
MFD]3817/CM Z0\D3QM7BQ&(]K7/<RN_QW&L.L\KR7(10RA8&*E90XZ8OTQ="
M"T51CM0V8)#'+/49))R#=XFQA&$-O@<CT:YVXY42QTNPW\(RE('U<LD5@F/;
M'K8Y)Q$FPF-$N\>*U7H1\=W!IF,5[W*O1&[ANX"TEY]28T*MH78UA;I2 A".
MHJ\MM.V?)L#N:JE/.2$X8 "D%:X'+QC1CG;+ H*4ON.#5) H!-<#YL#VJSSW
MZM(V-M"K (2239)*ZY-'F^W?BJNNFT93666?:M9'/-,O+#),NOZ]E8 F/()T
MM9P01('I(+R%(!@6(9C( Y+XP&#<)RMX*]B^Z?:754[);G2;'<FHI.'XY6S)
M.O6>O*7'IN06=1, VPTNPZS)ZB9BU89X75MEDBC1+5\:8;U J@<8'6:JFY.,
M-KGM7 -/[@,BET6'Z<4%5%88&-#SM@JS'"QQ(XTF3G5MY7_@U 1A&J-LJ;((
MQ[$VG%TU^'+'[/\ 0SM=U9UG;%J-9=3<)S#/M7L:S:3&G45-6Z97LS):K36#
M70=@V64ZF5Y*T%_&OY4B226*>]KPL&HD''=@22>3Z4I%;K 'J [\#L>P)!HD
M=-#: L"N25$GGWH[#9-$U:JXH%(X)'1(C=\/</G_ . 7:9VU3Y/P\^S.JIL3
MJ;.BTYNUQC46VHJ;'26Q;Z;JS1L-G%G9WZ,G6<J'C1\7@2Y5D1TTEGZPZEAB
M[C.X7M0R3('8QIQ@]GB.-8W+D<<@MZ6/G6<6%K*NI3[R3FV1YH.PL[FZNWO-
M:&E*]#09LE6B5Y'*=RF9AK%E,C)M3.X')I<:MR#.FWN8+XN$*CIXL8$NDK P
M 0VHV&)M@V)$KGB8]B<&@$-Q$W6&0EJ>:23..)\UT@CC2C3B\I194LCI,B5R
M#]7U'D<5&O<FZ/\ <B>[T26.QN)4>$IV_2H!(6NR22J]RCS5\W=#ZKB?4I&T
M-)22H^LE)(VC:$B[]-J-#D_Q%/-4]?.\G[6'4-988A)U"R3(I9P0#4]G65M#
M ]T )B2'5@V"1&E:[R%?Y"% C5&\;W^15\ &LT^HJ9TX\N3*-'1LR[EH%B =
M%$K8C 1Q-=!KVUW-  ;'1KY(Q*4Z/,57.B\<V$@ 28K)23B$$5D1RM+XR\V/
M(4Q'#&UQW\!*HAC39&IQW549T\J#J=+SNGB!7#;7(\JEMKZ:=7-FK!H( H<(
MXI!VP!M(="SD?'5\EYFO4S6LXHI-NK"HQ 3L4I5':HD@BU; E-)X%D@?^ZTU
M[#IC#Z%;E'8/2-NT%(//J/%DT:Y]O55>J\G$R*%G&05N.4(;,%)*C2I<R:Z2
M2,0<M%<4LEOK5_;#?&USF#&Y'1R/<:,X1"(1'!7=3-J</R&EQ?&*O)I3*Z+O
M86]) N(QJ62@I%NZTH;1Y8RR(XN1H=E%0\Z(1'%(C=V/1'0=O&H<.$2=7Q:N
MBG1Z1+"+"2R5\E727-56BB.<XX"*YK(_E,Q[B*UXV,57JB&[%L=R\.%3).=V
MN9U5A6/,?'JF,",*FO;-6O\ 3ULZW [U8(<ACS/<Q_$1D K3C:QRJE=Q 0&S
MO03M2I:$$*4R5E10A[MM=+: [MH6A:39HU83O45I6A055V$^DIVIW%/\1 4H
MI)*02:H&^5*TW=)!BE>*%1Q(EW#K9%G<FFODV%%5I)=))#J(T6Q>\PYKXXXK
M0/B()D=2M)'39O)2M5@L\IQ29=NB#H\IL['T>(CMQ%MXX,JM98H"4?JK-TLU
M?*G0?7%BV?B:V,,+B,<C4=T;<CQLD#1+2;/]%;3)I>76-1(A:_ON6QI=%7:A
M'F22QHU)#1C%B@+7"A@BN*:5 EL(Y(R <Q&=%O H>O+04>8Y-BUEF@B /^#<
MB++BQG5C3B-'L#RJJ,(T9DKTCS1X=T0)#!438[7(1SG]6(,"7DYL;'0&2_.F
MO(BQ(VY#:Y$EU>QIE*GE(;277:0E2U)2 ;)X54<J8Q"CO2I3GE1H[2W7W2DK
M2AII(6M12A*EJ4A(*BE""3S0- =9D&)Y' R D:ITDPJ?8Q8A'1I!<WD#M#2:
MB(0]F\TX<AIW)("!Y60VA,]SW+'1P6JO%++C4+4BDD64;+\6KQ8S.LJQDG'G
M5Y&Q\8-+&-P9$2S4JRG1)X7.0OJ%1B$>J*USD<G3N,,DZ179K"+D5]E6&Y"/
M'[D;J"_KS'-67"-"$+8]E"8,I9LB,I'H<DA@V"*YSQ(J*3IQ&3Z08QJ3@&31
M,,D MEN,=>\ IY N.A*849T:2\K&.&DQ&"D% /U*\^3T^HY7N7L\IX6^(.'3
M$7-TKETIF1$3$K:B./AI)!)8>4WO0W*0E(66-QM*D[%K)4$X>.U?IK+%]./S
M<"2Y%5M<:;D-[J!;0'B@@.>0IQ8:2XH#U5:0HHMHV.89@>HF"VF'8Y.L;'#L
MCI!8O>4LU(<N=A#K8QD@3:6-&0MA-A4.0I$MZT]F-"5;9<Z+',&-)7J$C.\-
MN]/LJR/#,FCD#<X_;%JY+BC>/R>F<]!R@C?L_P <X+1/8JJY.#OSE<W9)D>S
MW0#6G3G4JRU-=46Z1XEK*)*Q21#DMAWN(OBDA6$OB,A2B53<#P2M<\;"Q1">
M@^;MLI\8SMU9B66:::TT%*7Z(U#P;%[FQ2&U"#A,O(BRXJNX/>=Q V#9,)BE
M4CE7R"<]KD1&-GZ$U+A$XYV3#2^C+Q5R$1XK[4B="6Q$?FNQ\C 0X)<24W$B
MR);C:FMB6FE)6XE]+C(TG'G%P1DI..R>/QZI"XT+)3\=+B8[*^4ZTRZYBYKR
M&X\]EN0ZVRIQITCS%< MK0M<#5FC5@EV>KE\;5?LGLW\JWZJ+\UXM]W>R[+]
M5-]NB3TI&2U5C5QF+-@6,-)+47E-C%CJ9?KN51^<:(Y/9CB(G/\ .V1WUDV3
M?KC\@P_'DJ9DM.LOH"0MIYM;;B; 4D*0XE"Q:%)4+2 4E)2-I'4##C;S27&E
MH=;45;7&U)6A54#2DD@T00:[$$=[ '0Z'0ZH]3=*!UU?_<R?YLG^X[KMUP1R
MH$K=_J\".5OMLJH-R;_R*J?/;W]_LZT0+_V]^>/;\NW;GWZK_P"?U]_L!S[G
M[=7 /@<#?$^)%HUXV^ /]H7D +J08[APF5\@N/?MEB-:I'/ 9$>X;%:A/$X3
M&JI-^I_?B>V=C?\ 8GW#CET)Z<F34E738AZ\L699IE]?F5<# <A!'<[P5$B?
M=Q DBI,:R<4,ED8+$Y-7J"SX'D@-#\3@[Y=F&"^N^'O3UE81L%DZ,5;*\Q@I
M12$5CQQRA#Y&M,9J-5R)Q<A&L5)M/B=WX['MPSR]"MO(K)-QIJVVE0HOC@13
M"R:!;XR^RAO<I&QBY!6!\61RA-%!<]S7F3R()V __P#R61SP4?KS8Y/S==C[
MT>3UL 6JZOD7P.*/ '%5Q\W?'L.JE'Q%IUSD.%]B>:S+*P/;ZB74+4>#&EC5
MY<<M;R^A1[FLBD158=(V1PI)'[)Q&JO8-$>U7=6"=++S(Y.+6OI*M;ET^JCW
M<VSC\H]96Q([6P;A[HHG-.[TMP"2IFQN;9;3*YCD57*D$W<Y0'U2-V3XHX_T
M7CX.X+,<?I9YGJ]DS"OI-^H,N5%V9S0M?86$RL,$3U$UXF*Q&N(B]6)]/\7I
M(F(P,9G6[:>""ID2<CEBG*UC*R%6'R>QASV*)#R(E3'<>;81&N$SR"'&,5WN
MY'R"/*921Z@7>PNDE?L !SQVOO=_>1 IQQ1'!V>QLTD=N!P > +LCFKZ*U3B
M>-9K&;I[>QPW^GELK+W,[(XF/A6>1-@NB8J&'!>UC)[HMR&/+%'<]PU8-CG.
M\K4:^M-W/V(H7<MBF(6%63$=9:8^3U607]Z6)48!1XG ')$2#A,)&A@7$B[J
M7/@D-&>XS32#P"!24%1K(%)[[M+E+JU?Z>6^4Z9XS2_1D;1+"1^IR:^U"7$[
M.= ;D\R#8("NPB#-MAI80JH\R4,<>. T@;VF8U6Q2NXW2G533JCT\UET5G U
M"P/*,QSG3_4'+;<.7S\@N<E@6EKD]O*58-?'DNML@L8TIE25[::KDL.6,QB1
MG.Z>PA;1)*24D41>T@D$V032J-!0!/%7VVD40H  ]Z-$6 +!)X!"21P">WMS
MSU$%@&&,L-6XD&-$DM)%S,3&O. D0 @5TPYRB09&N1P$:G!GOX4:)BJK>;4Z
M?AK]++0:3S887OC7]O+; DQ5>CI,B''?ZLZQV,3S\)(DCCYJY1J]SD17,W3I
MIG;(^R+J@:);/8TS$FWQK A7R"%/*(U&J..Y58U^Y>81*]0()"<=T1'.7'6G
M)2YEJWC>+R/3>/%K&GAI&.X4%K_4<I]KP4;UX(\+1A$XRO:K7/4:.(U@UO.$
M^8+-A(%&[L "N>X!H<>W5=D -*I1MQ2KL5RHD$#: +X-<;C1YYX,FB6BPZW#
M+35[-+*/B-8Z;CC,JESF*HXV.EF1BW6+5I2?DHN0Y'1OF ]4]%!&0R+(16(B
M=2#=HG>QI[VB5.OFJF#/OTOM0%H\DQ+'Z5&MJ'8IC>&Y+5TF%_A7*$^XQV5@
M63V2MFUXQI72(<6!817D>]KVLBU SFNCZ&1\*O[N-$EVV;7^3PJ*4=0Q;"$R
MN>!2L$]2#,^.7TH&/.UI'HY0M&U7(G2 8GCE7D6&XQB>GLZWNLKS^'9892T#
MQ>937=K*8.]!7" O-]20$R.UQGHZ8&4H%BL>I-V0J0' 0NZ) H712*/)KBMH
M]^ #S8LR\).T;#0)Y-$JI('I%@D[A[ BP *(/4A^J_<I+[SL<TQU4MJDV 91
M79!8&R2C%(21-RJ[#4C+#RZ5?#:*5-=,/!:":64)9+BK*5JM"]&I"EJ_:OS/
M4:WL[ KYE#B\B9CM6QC8S(RUL.89 S8RH3PD9:6+Y9WN&Y2$&^.8NY$3I]_<
MI8U/;QI%BF!4ETMYE8W91C6/9/",Z.T@:!1X]EV1D:HE4@%N4LJBI>!$9(E"
ME/&=B <G4?&F^&VVI]]L5[:?&H+6#NYP7/5$&$+&QX4<:HK7V-D1$"'ZA$:X
M9I3MW,;RL1T!"5. A#8!""";"=P!VWZN;(!NP>.W5:2I2]C2;*K22+'?:"+H
M< 6%$@!([A2;!22@5030SR&.>Y (\(2C1CY8WO7THP\.'D2& ;/*BM&KG%7F
MU=DV7M#$0$^N;+))JHMF(+4D1V.*UD<!QJIS,<USY+5<!2R2"1"-5ZC7ZJ+S
ME"TJT#T[CLK)$^"AP,;:0(J%*@+F/,F.5(UG?2U1@7?1LQC0D#M":>,K#,3B
MQJJ[9=$M-,FFT6G[].(>16F8PHT^O#2Q7D-B<&#!E)=2YDF,YQ(H) U=9EES
M92BF1U$-T<;7M>JF35BK!ODD @5W[50/J]5@<BN>6)@DA"BL!0LD4%))X)'
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MF:<2#C1K)L_UU!&D5J'D*K93/(1B\6JU(5_AS2;0G<WW?LJ3CCP\ARD 7QG
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M"X[HS/S%5 R2*!9VAXH&",0+8P3#&I))7,9R$48V_DAHU([]T15:B+JE1+?
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M:W-J+PJI?7>28,3I"#+,/(5BL(\R-[Q/4+"L2JZK#I=;/RG,+N50"CQK6RG
MP\/TF_PR@*@#A!*&1&&62<K"J[FU6#$J-5KC]7L4TOPG0KN8S_'Y^1^HJ!XK
M#H,<=E%K.PZOO,GM00"C!7.D/%;L;$*4?"85\:,Q$1K>2*J2_P 2:21N(2"?
M58)2"+L 7?U4*Y]KZ8"#9*]WEVI5<;2D6; Y/&T[2KD$$CF^F4=LKXRVN19-
M-@O62>FI713,<PHV.\PD^C6-_*,3CXFF(J-8J,0@VJYNRMRF,3X60:S99F-S
M)##IJ9;4LMJ0HYG0Y$PBQZH/!Q'!;'AH-' >XJ/$'9D9FZJBI3I[<&QK1^]G
MQ'N!-L9<PXW/8T3. S '%4?![? $*^086L:_?GR<U43=<5C$:UF8G8QX$(L^
MUO+)EI9'C,:KPP(1PE"WR->,3G*X9%.!!N<9'\%3V]Y5CU+-T-WE@#D@7\6>
MP!OD6;YZKI<H,C9:MBGS0-D\D ?2;4HD<\!-@DV:=1#P/&-2H9LRU(+?S0!J
M+=^*U@%'"HJ,BF,M7)7TS72+TY"Q@D<.0QD>P++8IE:,"HBBZ/X<'$68U:X/
MD%0#+LBSFKT^TODVXP0!8IEIE5<QU/M!&DMDPH&&UI)=A1$!)@I.LJKUA$>
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MN@H@51!X_*MD)*GUEK00),!ZU61U<>+;R*2>.1.&>V8XI$UT-SNLQ30AN3J
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M=7,P%D4$1B*L","38$&1LB=-YN<YI&D9R;XV[\0J]$8JIQ1$1O7VCI3P8<\
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M8E?DE81E;>QB2X0XL8T:$&&"=4L1W*7326QV!+(8Y"09.P)(&;M>LK\67&F
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M;$E>.*Y[3K)1HCB:C4' <\?,D5AE11D5B(PG!O'DQ';JFVR,<275$]DC:*'
M)')//)X/R*&VSQTK+R6T^E!M5E5;2JK[!/<)'%WRFB"*JCU794=S,EG%.LR1
M$CQ(T8J<EC^G,Y'&<Y/*CW%%R](I6^-KE&I=_JHJY]E^8<^OG-*Y(,R,T-A*
M.J*ZM&-$5) #I[.:JN?&:YC5(B(TG)41VZ1RJH\89(,9SU++XO#XBN4LB*B(
M\BL:G%P]G.57!>[D]GNU7JB]9*-D<,U4RO*60V1#*E2]%<UL8;@':>,10%1I
M4;,7F C2-W5_-WMR3II;! *18) H=P*0F_Y@FZX/L>1TJ7UH*DJY]/8FK65
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MX %#K97ZD?X&!7_J<Z3_ /$?B/6MVJO[W+_I)O;_ -C;_K]'6R)U(_P,"O\
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M;EI%DRP<*UTO)!WB^DZ^9%1H=F-21=->HWC5/K[-5GC1%5JH)RM:N[W(D:$
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MKPX(Y[FHJ_73I-A3Z@#P4FZ^2*]@!=]_R'\73@Z%(H\DI4E25<$[0-UU9H6
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MTG<0I(-U14384#SR";X%N"K"QO4H"D$T?2D@I/>RFDD\!2540*)Z<KV^Y[D
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MCN37,04QG!47Y*Q6KNF^^_OTWS5%(22*':T\^WN"3[=ZOOSR>D :!)2E2.;
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M)DCCLI'N5%14<Y[W.3BY')MR<K?LV]VK[;I\EZ\OSZB=<#JMU4:HCVX[??\
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*Z'0Z'0Z.CK__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>nasalpassagea01.jpg
<TEXT>
begin 644 nasalpassagea01.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@!"1$E32S$P-CI;,3=:0E8Q+C$W6D)6
M,38U,#$N3U544%5473$U,38U7S%?14137T1%5E]&4$]?-$-?4$A4+D504__;
M $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M ?_  !$( ,8"C@,!(@ "$0$#$0'_Q  ?    !@,! 0$             !08'
M" D#! H! @O_Q !M$  ! P,# @,% P8'" H+"@\! @,$!081!Q(A  @3,4$)
M%")1815Q@0H6,I&A\!<9(T)8L<$:)"<WEM'7X1@E)C,V.#E2=_$H-#5&1U9R
M='BTMD1(5&)E9G:"AJ2GMRE#15-G<X>4E9?&Q]3_Q  > 0  !P$! 0$
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MU_XI?G\_EGUZ']T(>V6_IX:C?Y :#GT_Z)?4^?R_7U35_P!7[_KZ]'U&?/\
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M7*1^R-=Z365&=AD=X-S(.X!$^8XMS_CYO:]_TY=1?\A-"O\ 1-T/X^;VO?\
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M9^W;3_0K56^[#50J;5;:@W!I_;L,1;*VS*4P]9+P,2[6J('2XMA%2J#4BO\
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M>N_7W_CD>1G._%O'3T$'TP,;9GW_ )N/G \SS^&?(Y'!(^A!..?3H9Y\CYY
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MN,KD14,&0VG'B,F2E2XZG0  DO-H6MO!.0#G'JL.W[M!@$*L&<_N(UZ1^_\
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M]UIP_$<!*LV:C:K(PH'&TD@X(.-5?L..\QI"G7;BT'+;>WQD(OFL!U/Q;5)
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M!QY*%!P><C'F..A_<MW>EC UY[:2 2?/4GY#:<B@YQYY!YX\^3UW;!*0  D
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M''7RBG,I'PNAL\XPE)(SD'G;R%#S\S@_+CI _9;=K&I6CXJI3)A'Q=I_"F9
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MDC(QCR(]2_PO^UF/E%<J@"(/Q<I]SY_+?H'7W/5?8Y=FA24MJYD4H@;<PUY
M&",:YV&1Z^_CE-9]D]W#O+*';^T4AK*D@MS;AK+*ANP=P M)PE(X*N> ,@;1
MTZE&]AUW87,4M4/4_MEJ+BDH6&&M37X\@!8RDAN1:K"R-WPDIR-_!\L]=)DR
M@49]MQQR#'"W#PM;(#I!!.2O_FX\T@\CG[V]J*(5MRFJH&GDL,>*VM+"U@[$
MD\-?$ DX.4J/ 7G(SGI1/V7_ &K*D(/*I@"8Y=ISY9,O;XCZ_H9+^QPY!<24
MH=OZ%1IE5[N#L[""E3P!]8D3@"".*$*A[!+OGI4&1.DU;1-<*$TIZ1)BWH]*
M;;:2G(6IQNVMI24Y4""2O())XZ9ACV2'<]**_#N32=);=<8.^LU1"0XP2E6U
M0MA0(SP%\A7F.,==!]?U%G5AM;%%JERTPJ?2)"'*K)7%<9.$[#'"U-$ ?S5(
MVI ^$8R.G<1JI9_V*IIJ@R%2HJH4:0ZH!)D270AM:T.@[%>(O+BN<$>F0!UV
MC[+CM66\VC1RN"229Y?I]/WNX[P>@ \L^?"3?V.?(Z*=SO47YUQM*E(6F_7%
M( 0!!*2\J-0B-)  GIQSY::^P8[UM7?M&195;T7=8HX;,]^J7O4Z<P'%E04E
MHJMA:7590HA"4!*1CG=D=.=_<VOM""HG[;T!*3@JQJ5.&""#D?[E!MR!CTQC
MR.3UUX=BM.?385[513:4Q9];#;  )^-D.+6C<4A*O#\1*20<@D9&2>IGN*#:
M=Q3D I&/,YSCZ <\<D9(R.>>M*H/LC.TE=!25#KUD*WFU2!9V1\Q4@B5JQGS
MG8>?&/W?LMY2I;C5TK-/6=RTXDA+E?5J(64)"B%)>3N,$#>/,SQP??W-K[0K
MG_;S0$<D_P",JH'  P?^];S'RY&3D@GGKI1_)W/99=R7L]KH[G[RUWK&F4^G
MZL6YI?;-N0[$N>HW#4(DZRJM?%4JCM7$J@TJ*Q%D1KIIWN"V)4MYQUJ6A]IC
MPD%RVOWD?_JQZ^@]/W_LZE?H6O?;M3\\BJ<Y^L=L@#U&!CSZ.L[9^=.;J.IL
M%W<MAH*QM!>%/;FF'C[.^S4-A+J22CY5E!,#*04[$\1PY&L%F4BXT5.\BI95
M#:UU=4ZD!Q*FU^!UY:3X5J !! DG?BFKN%@5!_N0UA><D-JIS=W*<0PJ.1(;
MVTBD!YR.]DB0G:=BV0E+C:CO;W'R3=)CMJ2MQ+2RIX[\J40M*5#X0L'.=PP<
MD[R!R0>GV[@:?'FZU:GOTE*TRH5PNO5:&^X%N/I%.IWB5* 6D)46HZ=B94%9
M6^EHJE-!Q *.F7C(>2HM>*D.NM$[B 6\;CA0V^8.!L(.0%?+/7BN[((O%V),
M_LG<(])K'(W(]0!OO@]?0=M5-MM__P"@H^G_ ,,UY#KN/.9 R>-B&RC8XT1C
M:L[@E(YP?TB#D@C X\A@<\#)?,IJ7'DRV%EB9%+I8=SA"4K5AY*\?[ZA]*E)
M=1E.,G!0H)(^VEU/>MOP6R@E6U9^ %X'E"U[04J4G*D\E)3ZDGK4GR9['AM^
M$RDR$*2"2%@/I.\-DJQM66PI93CGUR1TW2D"">H$8\X_'/Z>'*B2J!B)S.//
M/NC(SQOJCQG-OBG^73A"W$D)6$I(V)*OB*@"HXW$G:$#)P>B*L28MNQG*E(G
M-Q(K8*G-ZL^\$ Y"<C>" A(\0)(0D*!VI/6%Z8_"B*G3/=VF\!>YM94\YN)0
MC:V,X6MP^&&L;@O)*4I );&?2I.KL]J@PI\B+08BDO7)4$H?0VVVH+**.PK"
M2NHRD@^].-DH;22SC#BEA3APPR0H+*ODTPI:C,)!B,3D]$^L0-APV4:G5WN*
MO5M_=/IVFUN+6E^:XI"69DI1=VMTWXO$>JDE V-+<06J?'<,PI\12&E3!@QH
ME!@1:3 C(IU,I;*8L&*VV6X[$9A"$I0T 5J 3L"G'UE3CKJENNKRHGHVH]#I
M-N08U$HD)JGTVG,^$Q'9"=C94$*65N)2"_(>4GQ7WW%+<<.-W"4GK!68BY,9
M+:7PTDH"WR."XELY3&!)& XC(6K(&=N>#T/U_)CI^2?HVZ4^'#H0G0T@C0"<
M[R5$P,JC;IM/!([4XDMLK96LAO*%J0H!K<3A2O'5\*P!G=@@8!'T+7UV[*A/
MIE8:MUU#;CT>; IKSD=3CCCM/9/O<ADA*V (K7B.-KD_ M8"4ME? ^[JK]!I
ML&JP4OO1\EV$7H*FURFI 8;4I$4.>(TT\TV\6G%.H4$K5O2,XZ;*FZDTVC4Q
M4&+284:#'VB(_5%O2);KR6U(=EN .M-+D2%'<\$-I;/DHG/1B9!G(]^=L?\
M#RZ^<K0TS@*7M!4)'@B0<R23L?=IQ.V<+"CU>ITN=3(T>0V]365)CSY-22XF
M8Z%LH6Y+"R4I=2ZIX*#++9\,<H2$)Z6D"ZHSL]4!QQI2@7 I8D(\0E2BEHI9
M&7"MY*5+ "2$I"<G*N(SU'6JX,*8BUA],<JRACW=EN.G"0/A;2T=N =H*<$
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MOVMQ4 /!EYX!1;A 2!E2H&< 2!*CT  SO B)XY;;"U #5&"8W$Q F/Q@8WZ
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M]7F?F.?7HYAR2L(3MP>3N)QY#GX>.3P!GU)\_,Z ;0A+1"<@C./N'D<C!'S
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M%-E,:G1V3X;E6?<3Y.K)6F*R[D*<2VX$X0>FW0#!@>@F(Z;?\3OQ(MM]YU@
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MIHM3DMLM%Q#<<+4!\B>1E1&/BX.WT.0$@'CHW:=1**QM40O"%*+?"@#N!'/
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MIM>RO23537ZKZUWK7:K6Y5.L!AB'7JU,*76J_J3=2UU P3(*,S&+9I(BF<E
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M:I03Y# Q@Y&-PY))*LD'XB=ROTU84H@5N>THEJ8UQMYI(_WRT&R2<#C[7EI
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MVA28%,889C-):;C!3<=M65+.?TW'5K)4XXZ22LJ^(D[@K! Z<J,X4.)*4H2
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M6_=C)BMLOQJ8%+8>99=0428;CB7'6I3",H4@*;)*%+45JPI6-N.L%UU9J%E
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M1(4Q+\B>M]"7&3)ARHC;4J/(*/AZB]V@R+=C:=W"Y1ZK3G*E!E.O75*6S(3
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MLQ+8O^6C8&"EO[#O1N:PX0U+VIL0+@=VD%*1RR4<GPEI44J;(&/T59!/!'F
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M<.YQ<5L)<"U!O;H*:]<-0%)G&"]#9E,MSA35%Q]MXK2^SX$P$-QE*)2%(2'
M^@/ [T))T(P%J@SGK.WA"9Z21,0>//RB"M1  !42!N )P,Q( QT&.G!32*G7
MHM/MZ2^B:EHBH-R6T17'"^V\TRW @O,RU PS3'2M,596\MHNK4A2AP9,V1>2
M;*GPTNO38Z7JNE<F,XQ*6Q/,A+3JGFI:FD-/I@-)W!]XICK=;6V4J2HI,=K!
M-24ZW-N>2W)MQU\L2)2I3KS[<B"S*C1X[S3P\5AM^2&@J0$A1?+96K!SU(A,
M>K56DQV'FGD_9=1>5*;$[W>$[0F6$/>(N02M*6U1UN A84@/M*00G(R1@X](
M@;&",=(,XVP#/IQPK,8P=R#YQ^4_2)CA;WE8MO28BK,=C.M4RXHEP5#3RH,O
M^Z-0F),]%YU[3UF:PI)A3J16TJU'TJEH*'(-714*(PZ*?)]T4;6A>EZ7PFU^
MX_3E]M6JVA$6=9&L% @.*I]2UNLD>[5"3#3MW,1Z?=5$CMW=:]3=:2Y%K#C\
M".(K1?6$J(BM1[.E6.:B_2Z519D*=:\QD,2W*U+A!FIVS4793C:9L!%"J*&Y
M4:-'"7I["=LDEC:@C1BMWZG6BT[GH=GNR*+67[ELO7ANF)AHHNF]7I;":W G
MU,JDMS2U4:TXNH6:S 8F(D46NRZ.HQDP @FDF1Y@3O&T;[S(F8SD1$Y3(P=I
M&YS!D $':=0^HP>HB^"T)]JWA:]L75;S$-^B5RCPJO0)28L,O-4JHL(DL,-X
M:68;C?B.1IK#2LLS&GT$A6XJ6,JD4UN!4'VXD-MPTR6"1$C(<V(B/E#96EH9
M2TL[FO5E(VH(23U7%VZ7M'T>U5G]N5>J,I5O:BRKCU&T"GSUA$<S ?M74#2E
MC8![M,H[CCES4.'\2I=/?GM,?%&*19 ^^VY3)Y2K*5TV?M^O]XO+40?(@9P2
M/(\'GRDFE)6B8 ,03@00 , 9.1^;<D<1SB=*QDP2E0.<I)!WG?<$]"#G<\1J
M[)/\35*\_,D\8Y*W/\WS/4!/:(EE&L-&=6C>M5K)2G<<8 J,CC !SYD8/S.3
MY]3Z[(Q_@9I1YY)'(/HX[\S]<\?/\.JY/:3REM:U6^@+VI5:25\#C/VK)2?Q
M4!]3]QP>JASFI">6%%8E/?4T@X_?#'GU(\_IZWSL[0I7-K*$Y)IZSZNZ$[>7
MD3F#!B.(/S:\M<9J$KX6F1\" <A.<Y X& I6"H>GS//1'!JJ7%'("DI61CQ
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M EB0X4-.J9VI:>::)4TYE*D)!2.L#O=-5N7>\+#:G$MW*K"4HR2E50ZH$[0
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MR$@*5X!6 7$J &4DI4I2%'(4H$'K-76W:=5Y,4+5PX5M*VJ"%MJ&_:A1X4I
M6"4\8 5D\'KS[<*=+2EA)(4G6A4 SJ2HIF?.(/O/IQYQK$*I:UYOYSB'"?FS
M"PL   'Q$P($C?23N>'#M]QQ<JF-%UQQF-(C%EM2RL,?R[3RT-DY*4%0)\(>
M0\AY=33@.MNQ6%M+"VRG 5R!G))00<<^9'.2 >//J%6G[+JIM.+WQ+5,7(P
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MU(C6W1<U4EONE!4*'WK+]59ZUI!&H*6T)TDE*5A(JB9,]+)>&X$I"%*RHY)
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M:?2:OJM=D!FI736*O%ICS;M2I%IT%<)NO^[I8<;A.BFQW69$I23:VU=B$4.
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M8;#4M,=<EIK^4/&5*2<XPH_+ \O3R\CT3V!>;]3930ITA":E$;"6@Z=JI32
M$$\^<AG :6$JW. !Q*0,GI]J?3*8=LFI')*0HH0Z$I"O4+!.>21GD<X!XXZ5
MM]2U74R*AHD-DEM;2P0_3NI *V'0H ZF2>[)&)3 $<17,MINO*=WJ;+=64*=
MIBTMBJI@E;%QHW6TJIKI2.F.\I*T K:43J()UI2H1PU:Z93F0EQ,9&<_"0VD
MIWYP,A"5$@GC 'GCK0K%J2WXR)*X'NR5$J =;2D.)YPK:>0,XP5) ..?3+UI
MET& HMTZB1F'UOJ>7/=D+DO.8 0A#;:EJ;9;!&_8TE!6HY42!CI.5JJOS'%M
MO/(4V"484 "$@C."",  82#]W(ST[T@K"9W($[>7UGITDYXA&ZEQQ:="2F8,
MJ5"M.!!W!.1/B^LXX8QVVW8R$.(6Q&<QN4Y[NA[:3Y':4D'C@;<8!X.>3BDP
MZ?$@R)-0=C;$*!?G.$,!EHI)6[M<5A*<#<I/*P%8 )P"G=3]>K2L,?9LI<9Z
M45)!0IT MISM^,<X424E(SG:<D8QTW5LWK"U/+S:HJ7::@K<<C.)2]'?:!;4
MDG@(7M60"DX4-HQD#)F7+>]1T[%6\V5,*)U)3!5H@%)4#L% 9]8$')%W8Y=O
M+5M%YJ*-SX/0D*6X"-2FR4:%:3!A8(5)Q[]N$Z:O=NH]SU*QM/)3UKVO$#;%
M1OPQ5OK=>"T.R4T5Q64EUM)VH4K& >0"0 \<'3BBV;)0U2&S-G)CI:F5RI!,
MRJU8@)+DF6^]XBT^,X%NH9;VH:WE" !D=*RAPA"87&I;#<*.@JPS&:#+062-
MZPAM*4E2P 5YSD\^>>C\07G$I>6L+<(Y)2K. < 9 Y \QS^/H2?OE2XPW34P
M32T[*RMLLI#;Q!D)#BTB3@C4/OE $Y'#2IO]8&FZ.C^T*5E1U-TYT+>4,:GG
M$ %4@RI.05>+RF..J$&0Y2JB&7? ?$-:FU!"4DK;'BI00A*5*RM&U/KR0H<C
MIZ&P]4Z+ 7,>\=#D6.XXC<AQ 48J O:%!02=QXQC!X/)X^KDM5NHQW/$:+X6
MV2O"<I(4 %# 22"<X'.<C'/GU@MLQ8L=ND++@$5'A-I=5DE'!2 H\C:.,*/&
M>1U&NU;Z@A7>N!87J)2LA2I$^)429409S)B. ;B[4,,14/!]A1A9=450H G>
M.N">NYX0+]E07$3DU6+&JE%D,/MR*;+92^VY&6E25-% \,+R#A6% @' ]2:V
M;BT]I>G^JCUF1X\MJBW,\W/MZ$T%*;COK*5/1FR5[VVXZLMCGE&T9(P#=%1X
M%/>FLM.)#R3\*T+4E3:PK.X;/+ P,8''/W=5Y]Y]GL4Z[K6NVFNEEYE-29G.
MM/I;=IR&S$$,,M(W*)D%*]JR$G<%  =6KEF[5"JAIJJ<6^RE>L=ZHN+0$E(6
ME)4)TJ1("2=(,',9U'LKYHN+W,:;/4ON.LU-.\6U/**PVXT@2HJ4<)*$J S$
MZ<D">(XSZ,BA7(W#"&9IGN(BHCI(CEQ_"GCXY65!)::02HKP"H#"B!T<W13X
MLV%$>8CM0&J1 EO*:2H$//H*UDI6%*"UE1(21\\ <CKU4ZEHI#<^OP*J\PPT
M);DM #<U]?A;4I;<VE?B/H4I"0L[2#E6[&0X-8M^B,:?.UZ$)S<.J4:$NFL5
M A#Z');RT+*U(41AI"$I6H8& DD#(SH%>A"70MATEJH5K2 ZI*D)(2H!22!
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ML_E.*T6>\4K*_M6-^F258-*BD'XN0".1Z=;-V35+_P +/4A4X6>X<=TJ6I2
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M&9+8SY->*D;DX(!&#CG]'C*'OZZ:](6&:)3I>Q'Q*4ZE!:<))4I"'F7%$G:
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M<<3%PY]8J[$JR4UOJV77*5FG6YK2I@MMH25+(DE.K0"D3Z P>+(:,T@04)^
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M 5D(0O>TI"UJ;P'!L*"L92220-"F5!B;&B2([,H!V,AU3;S*P\VA;"' %ME
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M0:G(7;U9ER%+:I5/5- <ASY2%Y9;$)93$,EP-K274I\MH,BE :20C?J8R?/
MVQLD;#;)SR,F<'(,QZB .H@9\AL?/AR;;TW>HJ=K$=]*_@#3SB![W_*HV.ON
MA:@M>US^5\0$-I5YC&.GI@TRK0VTQHZ/$*A'>+KCA=E\J#3G@>"I(6MP8*6D
M$E/F1GI^*-:[-11)D4*V;DNEZ7'6[[S0+7N.XX[$6("IQ^.]3J>ZVIAQ/\I*
M+2EI""A25+/6.U#0I3[YBS:<_-<,:"^RDA%0I#SKA#T&HQ92&)M*D!DI=*'H
M@E,((7L<&#T@M:5I4%I*TJ "D$ I4/X*@0H$;XC)'NE1)*5)6@Z5I(*7 86@
MR)*"<!1 TRI*@$DXX1E.-VQ'H[$.9*D./E$<PT5"4IUD%U6T%*B0VDME.\J4
M74N?#MV^3J-6[7WVV79M3FMMK4U'>BJ==6\VI:\!PJ*BE7QY9(!!WGG!&.G5
MHUJT9"FT%=&BEU*%QG#.]Y?>?<;\".9,AA PJ1PZ)"4@!24''"AT\L:VZ-3:
M4V&VV6%HVOH;9E(4N2^I:4R$J+BMQ80^/'4\HA)6=@&2,PZK9:>\+@M-M0LX
M*DT%*E9."5*6&I))R29DDJ/$\GF;F1#)IT\Q7]%.4!OV=%VK R$#2$M]R7.Y
M[M*0 EM#:4)  2D) '$9J=850JTUT-(*X:EI::\=6Y"W&VE*6KWE64H+0!=.
M]0&< D#/2QMJQ(%Z5:9]@4^AM6S0D/-7%>%U&14&D5!+!0AJC1@G[/;?9/B%
M#OQM-N)#BLCR7='M=RX)-7A5:J3;6LM/BLS519[")->+BMLAE+B5*5#;CK6G
M<\G!0C]/* >EV)+3+-/T^B4VK4BRJ-'I[K=)I#41QJL2V5%;"*I)2H+>B..I
M2_*D/YW)<6E2CN"2\&E 2E 2D   !*1"1 @:0G  &E$:4X^B%6M;CBG'%EQU
M1E;B@C43,DJ4$)4HZIDJ44DF3!X;(:74>I1ENL.T>+07 &?MNX0]#:JP2A3)
M2Q0XC/B2(<=Q)><F.*1%<(/A+.X)ZC#J!951T^N=K4#2V[[H@:LTQ#8LJZ=(
MZ%-IDNGO-R$EIFIPI&6:O0WW$XGT^HIDT>9&<>"VD.K0XB4]0H5\5"XY$Z53
MI-U,0)CIHMO1);,2G!K:GP5.PE;5SX$=Q91&:84AE+N=\=9(ZDE:ET7((S7Y
MUSJ7HM':C/LQZG4K934I$F%&5X:H].,9E3DE;@)0VRVE*4K."L*^'KH+4G.%
M ])D1C<>(F>N #[H'"9V@9&(C ^@#KF1!Q,8Z11TI[A;8U7EPX'=Y3ZIVQZA
M5:)2VKZU T[@0XFE6KRJ+4([M/7J/2),9^/8MZ;6F8WVO(4(+D:H%#E0*$H"
M;3.X.L5BGWS:&HVG_P!I1Z1J3;\2WJA=EI28%5JMMU2W6E5&G2[:AI]X8N:M
M7+:)1#H=/IK[2*XIE$EB2Y#@NH-;.MVC=4UTN1%O6WK!7+GH3M*?-;K!M*G6
MM1(46*M@2!4ZM,\%I3;Z'@4,LQY;LWW=]A\99R,FD%[TOMR?HW:UJ1=K%[Z%
MW35Z5$HMS6Y/JCC^@UXQE!RAU_\ .=40"+9*:][N\I]R3'19RI,CW=+E F36
MVP0E<%)\69; )"0(DA2@,[$"<@8,Z0>#(@@XP",;2GI .#&(WVP.+3=.[F<J
M;EDZ>6B[3&XNI=RUZ@.W=?-I4MRDUO\ -RV5UJYUFW[?>:H%R3JE5)2J76Y\
M20^)%0C5MM\R)<5;?3"ZQ6K5+*J6I5\3K;IUM7-I=7K"K=>M&U9\^71I9C*%
M+NFY:-3WFF84:VKHTQJ"&K7^RF8[U+7"JE&J32Y; <*]TGMY8U!T1DS:T]4*
MS3NX&3(JWASZ13*)2F'K$JD6ET>R:73$IIKUC!N.FI4FIP@8]T2*Q*+CTJ;'
M><,_.X#03^%FV[BD6M4*?;>H-5T^N&P6IE8BN2K6N*W*K'==:H%VQ6<O-B#5
M7#4:+6Z>!.I<MQQ*F)$)UY 32!!C,&<[$3G Q&8Z2.A''"E!"Q. 1Y;9$==H
M$'IUC<&O-=@?:.F%\V_1: S6H5$U'-SMUU@28Z8=Q1+5MJ36JDS16\N0695-
M^S9E42ZLNU%"5J0T7%J)DIV4NPZK;.J-JUN6:K.7<R8M;=2IR5%?37;:CP)-
M5@*=2TXS$J#2BIQCPD(#[+Q*E$D=,=;T^OWUI!J-2;.J-&MI^T-7X-AZ@*O]
MBJ4:=2H5L6%;MMZ@U:!%CMF=6+Q@53PG[3;6KP*U$"%H!8>;2DA[;-2H=K]P
M!MBHUM:JM>%F,VV)BHS%.EU&I6D[)>%1J--0KPZ?.3$:?CL4]P*EOL*9<4E2
MU$ MCF?<=TB0/J $Y/3T)X"I*5@;C(\Q&E4>7J<[^<CB\[M#JGOG;_8%+7)4
M],LZ/5]/:HE:E>+'J%BU^IVTXR[O)5O#$&(X"?-IQ"QE*N).]0 [8;OAT'5?
M6+2J>XJFJKSE(UHM"!*6EHU&/<$)%&OM5):60I]$*X*;'J538C[_ ')RIH>=
M0VW(03/MHC8,$D>A4<G:>02?7.?/G/H3U*L*U-(]!I_HXD^^)^GIL(]P$+5.
MRH4/<H _E)\]HGC)T75?_N74O_,)O_JKW1CD?/HOJPS2ZB/G F#_ .ZN]*'8
M^X[[?3QR-Q[Q^7B)79'_ (F:6.>%KX.3@EUT^9_ G!//KU4K[61Z8C7.T&J>
MDJD/V9MW#R1BLRRVI>T!0!()!!'(]>K;.R5*T:-4L*"N7'3DXQP\Z.,$_C@
M#JL/VH-!=EZW6O5RL>ZM6:Y&=2!EQMQ%5DN-.8'.%^(L''D4D>8.,Z[1&P[R
M>M!F%5-'(3()'>G$CSZCJ)!$3QI/9>"KG5@!6D^S5Q3D &&@HI,_P@".A@GT
MX8O2#4B1.H:*7/<9CS(T=F-,;00E"TI2E(=:VJ44M+"<Y7\07N\P<"1="M.R
MKF<\&J7S3+8\5&YIV<S*6Q)>6,AI<J.E0B)"@2I]QMP9PG"=V\5PT*KQK<DR
MY<=6]TL-I3DG:0#G!.1_.(/KE)P,^B[I>M5&D-N1*Y2*U#,<I":A#B.S*>I\
MK"4^\NQTGW9O!!*G"-A'J.>L(J*IZK%.BJ"7DTR4)0A1+:2A 0D(7H*<:4@;
MSD"<1QO;O+9IPZY0NN,.OO+>6^T&UN)4LG"0L* 2DDG8F3)ZS+FZ-'YM'\:?
M2*M2;BHD<J4Y-IM8@S%(1D%#OA)6Q)<;<RH )C!2#PO."2U3D4Q)"4?S$E1S
MSQE)R"3ZD\8 YS]QZ):;J';DEHA-?A ;BA2B^,JQMP07$_"GG  &/-0(/6[*
MNFVUI)^W*9N'!S,;*LGGS &3SD>7Z\]13=(VRM:D$@*4I6F0H)U'YJ3!,#I)
M)@1/#JCHZME*DU"W'U'YBBTM*B,:E$I&@$YF($>IR=QD[UKX!VHW)_<\'_-]
M>OIY*B0$H.,#R'KDC]^.BQF[K=;3'0*Q25!2@2H/M*7D8)"E9&$\<IQCSQY\
M&KMRVBI =56J:!G;E,IG8D'!!</FE().5GC'U'3@-ZB4I4)]3 Z2/>=_JQPM
M#@<(+2Q!C5I5/009!]QZY\SG70RI;F><8)VI)R>,$#!YX^?XGCG*J!DD$(2"
M<D;1N&?3*@2,\^HX)/KR7R;PT^C'?^?MHM+3M2MDUR"AQ@JY!6A3F\<$8!&3
M\O0F#-U6A)2AQBZZ5(0L@)7'GQWT*5QPDIX5QC@'/.<])OTREA&5)*"(*24I
M.9^<.AC]3QRHO92E#H!P2$*DCJ#@X(.2,^7&O6+$MFYV0BIL1TN%&P.H90%^
M6 -X0DC/).<\\_='Z[NVY\%R3;;[J E2E>"!PL#DD[MQ!R?T_/RX'4CWJ];$
M1IV5(KE,CQXS:I$B2_.CLM,L,@N.O/./.H;;;;;25K4M00VD$J4 .B%.O.AJ
M@ UK5IIC&0$WO;9X_G*PFJ X'*LX(P#TB\Q[6A+%73&M9!"0EQ)66PGPCNGH
M"V](,)TKPD^'SX=V7F/FKE"X"Y<K7JZV.K4E(<-$ITTE0!IE%;1K2[3UJ70"
M%HJVW4)VIQ3@J2J#U3M2^;=#L2935RHV["0XP70-@SN0HH2YG&>,E(R0GTZ)
MXU3H:5%%;MT%30"4IV-*#?/Q*++X0X2?,%*U9&"."!U8.U?>DES1/>6+]M"K
MTQTN(:GPJ[ F0''&U;'$MR8[BF5J2KA24N;DJX.3G"$K=MZ'5-_>_?EG1]Y"
M=CE:@A"4X!)27%G'/)P1\CCCIDFP=TDIMETKK>-7AI:IH72D00"-(;64U"-$
M:4K[Q0"9205+"DZ?3]K-)=$Z^=>S3EZ\O$J)O%@35<H75U<C6ZOV.GJZ:HJ#
M*U >QI+A65)6A*"A<5HQTOEG=(C0F20 DO4MQ 1_S@I00ZV>00%!8QGC/2JA
MLZ9M,)2@6ZI&!L"PA).23\27$) (.<#C!'D3C+O2-*] I.$(U*L=D*.5!%P0
M$D))\PI,C X(\OE@C!QT8T_M?L.N^'(H=_VK*@/!Y3<A%?BB.?""MZ$/"24%
M:2 -H&[) P?+I)=KOK:\U=DJ%$0%FFNU&HCPD*4I% ML*.Y;2M<9(<4!J40Y
MJ[&*I2E/6CM4L:E$J=;8;Y?N[6LD*7-4\+=6*,D_MA"7EQK=:2X3I:\*T^:2
MROWRU$%E;3Z$!43>E;2TK00E*5*RE21P!C'T/&>IW[:"CN-1@Y:0I*4067W$
MG.  KPFE(R<Y&T $'S'ETLI7;/;<-MYU5X4 I0A02DUAE2]R?B! \8Y!/ X.
M<C''F@96DUHQ62O\YJ6I\JQX8J$8DC.#G+R?BP#@$'/)'KE-5!?@E154V- .
MQ4B\5)&V$(%LE*HV60H1X2#(E=%W[&)2MI':K= F"&#0<KT32I PM^JJZGNT
M_P"DE 5D01D%'5?4*@.MJ8@,39"EIVK4VW[LV%<  >*5.$?0-Y]1\PV53K[\
MOQ EA+6,C8DK=6E/IDJ  5PD9V@9YXZ>\V':L1*U-U.EOK:05%!G1BM7F3C^
M4 )^@.5>0.<X1]:C4*$7#%?AI41A06_&4D9R",AP'CCY^6<CCIDY05&I"*RZ
M5JT+02MJW4*Z)IP!(5W8J'QWBP8ZMM*/SE)!E(F&.>>5K>=7+'9C2I?2V0U<
M.<[M4WP))$=X;/3TMOH]21XDE#M32D_)LZD%*^&UHU-JERRT,QVG&D)2HJD/
M$[4$ $A+8.#C/PY& ><<](^\[8DQI8:D+,E2<@ E1&4DIW%!.!ZGTP3C@''4
MD+ <ANHJRC-IS;C1;\)OQXZ%+&US=X;9<"E'@$E(P/4^8Z;6_P"EO*EF1X#A
M2O<0X4JV*25D%0(.% Y'(./PQTJFNMUD;;=IK<]3N+6D.5;Z34UJE& D>T.!
M99;2?$4-A*=<KW@<0UYYPYGYL*&+[='G+:REL4MBH&Q:>7Z<)TZ.ZM=$&$+T
MD)6CVE;Y"@-4@%/$4I-,9I]6CNR?]X+NY;9&\#X@0I0X." <DYR<>@)Z4\_4
M&F4>9":B-^.MMUM2&FPG!4%I\,  9('!*<'(_'HRN:CH:!4X0C<%*;6?B!)!
MPGCY>F2..///1?HUIB-0M3:)3O%:2VNHQD2G'/T8[+<AHO+P.0HM!:4@@8"M
MW(&.KQ0TZZ]"7 I9U@+4I2B9UP00>H!,G/G@':IW:]4]%1Z5:06]6&PE*H 3
M)6$P0(F-LRGTXL=[<NWS6_NEF0*M=4W\U-*8;S:X"Q$:;3-;8<2T^CW<.!<M
M2_#QO>!0 HC"4^5\UI63:FC]HPK0M01VX\-ILA33*&<R"AOQW0EK<C<^Y\2D
M@J ((3\/'3'6DY;]B4&A6I9T*/!I%,B)8#+#I6E;I5XBWPKXCN=4I17DX'
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M9'R:<1Y8X(5E6""*FH!&00\Y,B,SJ]!P^VBO;5HUV]_G%_!+:2[7_.K[+^W
MJNW!6A,^QC/-.Q]NU.H^[>!]I3,^[>%XH<2'=X;;VG]]Z'Z8ZE3X-4O*VS4Z
MC3)#,J!.8J]<I,J*^PXVZVMMZD5* L J;2'6U$M/M[F7T.,K6A0Z'2H0@)TA
M*=(SI@1/G&W"*G'%K+BEJ4LY*RHE1.TE4R< =>(_ZG>SK[.-9K&1IIJAHS"O
M2Q6Y<::S;=7NN^_<69$*JR:W#4PY$N>-+9;B529)EQH[4A,=A3RFFFDL;6@V
M=N^R(]G7:8F)MSMIM^CB>RB/*$.\-21XK2/T02Y>*RA0P#XC92X3R5$]#H=
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MIJEGN*FG9?8)22R\TAQHD*!!T+24X.1C!R.%Z>JJ:1T/TM0_3/I! >8=<9=
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MVW8":91]*8\."E;CH8%S7<\D..XWK!?KCJDJ( 'PD#'IT.AT%<OV)4!5FM9
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5N5#[HAUYUP;PM:E"1L8).W3RX__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>navigateia01.jpg
<TEXT>
begin 644 navigateia01.jpg
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M[./R\.SCX-<Z9_\ .X/]6N7/V%6]XZ/SN#_5KES]A5O>.FFG@T:9_P#.X/\
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MS%5+D&MPB I-++!LUR@XNE),=FJZ8&=R4$_BW9W:Q;9>(  F$0   1$1'@
M'A'B/9PX=O'Y.W6 :1BE"F(=_'G(<HE,4SIL8IBF 0$! 3B!BF 1 0$! 0$0
M$! 1#6K<HTLA ]:]4K7*[E6:&S#'-&7C(:.3ED5@)(F >*0;/$X5XV5E!$MA
ML]FN'K\.3P>4O8J_766.*U2LRP2"&=2EBN_(P66K:C9HK5657KVH7>&Q%)$[
MH:=(W>EN)VFQT,\W>51AF# <JV8JUW=MAQL1Y7S1KP$B,'E^CA*U3K#A<ATB
MK#9$*^P!ZHHR8VVU2!3$&T'$F<,29TKR-GQ5=H&X1BB**RY(YP4LE&\^4#)I
MR\.X*C*12AP'BF#UHB1<O!1N=9(Q5#1WE$F6V&>?/F@-Y?;->9%<EM@"BC))
MX=G)U7F7,VQCR\^9?&EA<+\U8(<$%48-XMTQNET-=1NI#S-/<OX**GCYN[GW
MEYGM?RF *S36DLY%=QM\MRC\#O%"-(:%7&8Q6$R#@%#O<>F=TM8AQ<RF-)T[
MA54VI!B[E,!<5D1-$I^3B\]9GE0K_-T>(.2S>KN /S<.;BRL5F>0"7,X6G%N
M.Q;.<'<5$CB?%+PIF9!M^4_"&/A&(L3'8"3.\%1O6JUP[?[^]PA/BXZD",\/
M"68N2$FZ/D$\4OV0_AHY!/%+]D/X:H"QIW6[)NW^^1&!NZ08>F,17N052;5V
M^L0C'E7O383BF$S4[##G"C9"9'XE.L2KOH*W,B@*#_'R3WE)ZNZQ_ES&>5*\
MC:L>W>N6N"5 @'>1<DW.=FJ?P-9-FL9%_$OB_P#^C"4:LWB8]AT"CPX[*W E
MH8Z]7LXK*&(V%QN12.*>>N#RM;Q\\,L]#,X\/^;&4PMS(XQY 42XSJRB$S?!
MF7PU),Q$U/.<-S3""OQ/P_.V1PCSL.:.K;EZJ&YA,DZ?+^!>(:6(S<<>SS8V
M-2I+A\@GBE^R'\-'()XI?LA_#6'UG&^46/I;?\31UG&^46/I;?\ $UN:Y/69
MR">*7[(?PT<@GBE^R'\-8?6<;Y18^EM_Q-'6<;Y18^EM_P 33369R">*7[(?
MPT<@GBE^R'\-8?6<;Y18^EM_Q-'6<;Y18^EM_P 33369R">*7[(?PT<@GBE^
MR'\-8?6<;Y18^EM_Q-'6<;Y18^EM_P 33369R">*7[(?PT<@GBE^R'\-8?6<
M;Y18^EM_Q-'6<;Y18^EM_P 33369R">*7[(?PT<@GBE^R'\-8?6<;Y18^EM_
MQ-'6<;Y18^EM_P 33369R">*7[(?PT<@GBE^R'\-8?6<;Y18^EM_Q-'6<;Y1
M8^EM_P 33369R">*7[(?PT<@GBE^R'\-8?6<;Y18^EM_Q-'6<;Y18^EM_P 3
M3352V/73I/\ .D1-TZ3(7<ANA I$W*R9"AWP>2!X%(0Y2E#CV\   X\1TX'3
M7OSY[Z6Y_%TV% =M.5E(>EM> [C]T!@'I"/:4VX+(XE,'Z?:!@$! 0[! 0$.
MS6_=+:?.VOI*/W]=U(!SMV#Q^8:VJQ/@\';_ .S%_P!"_P"0TH]->_/GOI;G
M\71TU[\^>^EN?Q=)W2VGSMKZ2C]_1TMI\[:^DH_?U9L/,/L&L^Y\Y_'^@^S2
MCTU[\^>^EN?Q='37OSY[Z6Y_%TG=+:?.VOI*/W]'2VGSMKZ2C]_38>8?8--S
MYS^/]!]FE'IKWY\]]+<_BZ.FO?GSWTMS^+I.Z6T^=M?24?OZ.EM/G;7TE'[^
MFP\P^P:;GSG\?Z#[-*/37OSY[Z6Y_%T=->_/GOI;G\72=TMI\[:^DH_?T=+:
M?.VOI*/W]-AYA]@TW/G/X_T'V:T5@NNMO4V8E7777*$;NR$I5EE52E$<:8]
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M4B@4*Y.[F-N3V7V!]E_N?V0[3D"AQ97#]S@*W79"%RS3H=L .5F&'LOV%-W
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M']RG]W1T5M\W0_N4_NZ[]&FFJ?: DB)LI<441X;C]T !_BD^P W!Y'  ^#X
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M> ME5DH*D6'%.X;;]87"^][)K.GQLPQ@Y"*H5JMF+=PV3;&WKUT4*K.XLG)
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M.24JZF3JM<&9U6D'S"+RU'M@Y250MPINDV4)ER(;<VDLV,8C>WHD!_'F4>J
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MD_6\I[7JK0.Z#[IJPCSF4.Y.;S(D4WP-7)\4VC;WF]J1 /ANVI*[DV$FGJ8
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M%1NH\FJ?.Q3A6':KM5>L.:<()"^E ^%E/_O(;H?_ '!Y'UOHE*8! P (&[!
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MLRI3-7<:]8F,+=J#@JY4  =:W2IWXA#>J5KD(=9!#:@BL1!UW"OU<JNG.H)
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MOR:KZ6S_ !-'2'?DU7TMG^)K.$! 1*8!*8HB4Q3 )3%, \!*8H@ E, ]@@(
M(#V"''7&M/6736Q*[DV]79GRF*B?"*W9"'%PV/RA#&>/Q H<@X\!$P%)Q-P
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MKF4<O1D"BVO^0*E2SX\KEJL +N#N):(I1Y2:/7&BR)VZ98X91[R#I**\]P5
MA&FG3552024664(DBBF=5550P$(FFF43J'.8P@!2$(43&,(@ % 1'L#3#2.9
MEGMRP6UHC>L7#&V69BY13Z_QUE3>$:.:Y2K;9(]G L&#=9"4%\]K#IN_DU9%
M-M&IM5F@,W+MVFLR?W2#*UB$FY.LS$FRZ3(T^5>35=<"X<I#'R4A 3%8=N03
M1632<\["3TJRYIV1=$@.N?33*Y1053::71$"@(CX  1'@ B/  XCP .(C_8
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M3[@LCB41#H_$!$!#L'@(#V" " AK?NL6GCJ^B//9]0*NU5FI?=#MZEV5XR/
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MMTKR,F9F@JW8.R+K-W<>DL8IE2-3%,=L4IS$(8Q%FJQ3"4O$. !P62U%I"U
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M0EG#"DUAGZL]6'!0MA624F4&NZA-^K)>(B;;?8+LY*\VW9U@7;<;[;':08"
MAQ 0$!\ @/$/K#2&6T5LYF!"V"$,>45<H1I2RT>8T@LS6%L[28E!R)GBK9P
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6!&ZZ81W*8P\)!,%).4,VYY(TTU__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>navigateiia01.jpg
<TEXT>
begin 644 navigateiia01.jpg
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M 0XP42/=P']8>KQ#W TSO3$_Q_WF\FOA?$^++O'Q+B%AN[W-L&;Y=F@ +A,
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M<3A_[ L_-WLA=7W/G]?0F;S>>[DO\O[6'?WS2X=WJ_A=GOZ//>R5P ?/ M7
M>X>NU^'J=_+X=_9W]_9IO::L@XM]306*FNBO:*\BLBL4JJ2R2LPR342434*)
M%$U"&,0Y# )#E,)3E$HB SA7I=6E<Z04_ 0L<,&PLDY2+Q7A8L3Q\=/,*V]>
M0TD:-*F+<C&=CSMS)*"W!,LBT#B87*AQUV6&_=+B6-QB)B.>T27BUVDF#G7
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MF)97Z8R&NF6DEYXTWB2>=(+3[I6O$:6;&J1VM>%A&$:-WPC:R H_"0)*JJB
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MR:9+!L@S"IV\17 .5N#W9&#^;6[C;JLT'*/8F/>4P#P[PX\!X" @#Q]8L?9
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M!3#5F?RS&Q9%PQC6DVC'3Z+S33\@SI( ]<+=#VF)R92:(WI;I=Q&J5ZFM @
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MN5&J"]TVYP"#;$+E86KQR,TYMN'(P!47?MW[^,&;<S]21>)2,M$]=KO',M$
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M6T<?+O MS?'EC8V*PMG\G$QD>]LJ<%.H5J:DJFRD)Z(CGS2(F2QTIN ^H/\
M4.I0$)IF)(2<BJG3DB_EFBHOF5*S1475-?;/]U:0P$1W8[..(B/].[B?3_\
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M<#+3L9'R\ZL9P1H1.)CG3E)T_.H[52:)%;I'%9VJFU2 [@Y4Q4K;A*4Q1(8
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M@S$F ;_,PSBJV/VN[0]V9-.BJM28SXHY&G0G\D;EP9;2HY'DLJ3;@JJ9H8F
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M3PM.PB.*);_8LJ8==I.%&KYIF3:]N1QR6(<I\.*$Q*SN+4X&.. #Q$Z\L"0
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M NBCB_\ */-M[\V7$!U.7G!/4M2,ZGB_8+?X : B8PHE,5DW Q3%, \V \!
MP" \!X@/:'I]FE #%'AV\!'N P"41X>X8 ']VN1[O?+_ (AJFJ15*.#8]B-3
MN'%JB/#<%NR*'X(]A2;JLT%* <!   I0 H</2#AIY2,(XIR&.Q05(4Y#*)")
MR J0I@$Z0G*(F("A0$G+*'*)RN47\( TTN#/^R=P_P#$)NT_]5F:=/)KOI'R
M[R\^\/\ U?[)Z*DQ?FL7]6C_ ,$*KWC=I68%+[G#)LWD_%L5DC(.!;/@2NY/
MH- MD);[$C)6-O+47*.8(=]95JBG>,.P*!ZS1(G&K%C#KNY.?M3^4;*RC6OQ
M6U7O;!=)7(.'T:A)X?4VXX?K6/(NMX)OT1E((^.L]&G!51R"JC0;3"5F^V*'
MK4?666.HS)D?.U2CVF&=W(D%(6"42EXR;VC43<MHBHB+JN:KM$JJN>?.J\JZ
MJG(JHB\J(J;ME/7GRJO[^GGZ?140,H[4(K).54,EJR%;;BCE#93D 64G522T
M@I&[2,H9%R0^KQY11;C_ ,^%;TFVCEN0+6OR,<XE'+5\9X0J<897P?MUA:MD
MJHUNV8TGJ?E+&2%:N:<IC@97*4 ]I*&=E*E%[>WECL+#'E)4L2>7VJ*DS:W,
M<:CVV)E[5 NA&X.5JU:[HUX3#1+FHKGKJA$GQES+GRUU14Z%5*\V1Y<N7K7G
M_.JT-LN"LH3>,=VC/*>.ZIA.5S]7:E0:S%5^BL*4C%LJWM6B,#.[:_I49;[:
MY0.$VDHZ;!(6/ITFPB4V<:FA7&E>DY)NZ!X,IS548,R#_;WBT(5;:(60K>WG
M&5^J]0R$MM>W%8USJ>ZY';W*Z33R2R',QM"D\?U%[#MHV-JD=>;3(2JMB*];
ML(ZW,   X   'J!V!HUXD9KN,T4E!"1%553/;U+/++/7/5=>M=*; Z:9Y9IZ
M5SYJ@/@W:7D:B+X$B\E7S&$_2=L9LFO,91N.Z;=H&R6J=R)&6ZJM9S*$Q;+9
M,10EJE,O-H9,H.G0K1G*V&52FGD@V:PS2+>SLZO8>Q$?ZC?2UF:-;  039%%
MRS1=55>1$%.55Y$%$3HRKU$1.3VT1/W(E:!&,VJ6[+9R*;=(@C.;B0$2E'B(
M><8[+P'B(^D8P#^L?5U;_JHAA_M8[./^_=Q/_D:YU;OJGOOREOZH!9?YC<*K
ME^<2_P!,U_)Q:-&C1JBK*JS_  N>0HG%.R*W7^2C,#+KPV7MKL;"6C<U#!/X
M0Q3/73<QBB@QN;KY%C.5DJ\;A8;4MDQ RED@6Z+ZLME7<NQ:$<+!Y_? :Y9P
M"_WRUB)QS2O!5OI_*N&-[#=1;8EA* QKE+!S+:YN,QWAZ#D+M8HS+6296;QS
MO"J[H,X4R+GF,2#&+;01*G+3U>:K2#SU[Y-CJ))4*U)Y,K<1;:*SAW<W98"<
MJZ%TCGT=74S3QQ4JR\=+%FW#4T:5VP8I1KQVJ_0; Q1,\Y@-5?; ]P%1SQ<8
M"Z8W\%AE?:KC._8K/?L?;E;E1MJM,AKE2K"2NRU5BTXS%>0K%E"&=WB#D65@
M;0D_ ,DF*48HVGQ9R3=!N*E-%X8&_P!HQY:\-9'L#"*ROM.Q'0,U.MS6$HG/
M^V#!5GA;AF"+@\:[:,Z6^1W26FIT>1HE-FSY-B*IS5EK,O!99DZO>8M*XFJ#
MB#:V+;!4,WI[*-LQ-P]QA[QFA?#%-<W2Y0=GKE^8S;U]%@ZB)$]XJ3"*J-\D
M0KZ\*29NM78-:S<9E&0L,&08J3:G/5YN3\%)GC+V^>_Y\CWVU6\X#N62L4[I
M'E#R]7[TMDBV9UVT[6[A@_;Q@:Z2<?"6"J.=IL'E2=8[@I0R+9U:(2Y/[8G&
M5*7=2Z4F2T?8+MIE=GFS?;OMIGK+%6Z>Q#C6'JT]/5^-7AZRZG.>>2TPWJ<2
MZ.=U&5"+DI1U$U)@ZY#EI6V$6@X206(=%-2M:R9B#+$Q<GS9K'15XC\D06#J
M_-Y!>.HBO+8^'#V7;'D-_).JUTHKJ21E(J?2\RZ%6,X<)VZ)2/.!&QS@LNVP
M,A8PS98LPDO-<BY.,2M">*X\3*W&HJU&H-,99#MCZ?&]U=RP<OKTPM=/FB25
M,8Q?69J[;7JR_(IDPR);U)Y<0[O\^_ZGN<>\>P.W1Q#CP_S[X]P<?2X]_I:4
MKC@(E$.(E$0, &+PY1>/'@(<H#%$P<0'\(# (AV@(=FL'H3GQM(?LHK[LTH:
M-*4G]"<^-I#]G%?=FCH3GQM(?LXK[LTH:-*4GBR<#V=;2'[.*^[/WZBA(,CX
M"RIUAU@Z0P[G"P%;SO+!CT*C9=DP(BTEE"+,CM&==R,FGU?)""2:#6T)MG*R
MA$Y(0U+_ %JEYJ,'?*C8:?98T)>$L$6YCG\?S@(G635)RDC-W \.BO$'!$7#
M%X42G9O$D'1#%,D Z4Y.2FER!M?P_DFO&K\W6FD:*3IO)P\_4X^"J%LK$XR-
MRV$_6;+7H>/E(>88GXBBNBN9%0@G0=MW+<YTA8TV4<N;8'"$/N+E);(.'#+(
M,X/<?6H-F$G5T3F(W;,L[51E'NS,$TP  -DFOD4AG2@@><CXU=8RA=/V];GL
M@5IM)UO<C7K)6:Y6P85Z(R/,TZRMF[>18<MFK&7N<29N(P7:S1-JY)9Q281K
MI<KDSM8!<-U36&QTI7K;#D?14A$6.!E6ZB:;M@Z9R\3(M5R"DJF59 [AFZ05
M3,9-5(3*$.43$4(("(:YZ;8&B>X_:'1LUV%L6TE,,B<68VWFK<:[0!-ENX1Q
M4B1LMMF;%0W.(S8N]>WG<VC&TAN*ECQ3&/%F%S>-Y;;-EFU<K6^\@ _/PS>C
M:E2+'<' ;;5X$9EV>XFS'6\VBYI%C(STQ3EI.QS&8A;.:6B9-JB^CI.,6@W\
M>_9N" HW=LGK5@JV=-EDS%.DN@HHDH40$IA =*'0G/C:0_9Q7W9J%LQ@O(FW
M^4=W;:B9L\J3EVO)W#;#/29V-(F>?,*SZ1Q'+..=2QA:UC"JL$0!1I$RX.4C
MII%G*187TPYGVAYI:2:$$I)0%SK*H,[SC2WLA@L@4:2[ ,TL-?7.94K=0P\6
M,TP4>P<HD)56$BL F*7*!>R.2%LN\9+5=R0MRRKBNP;F+8[9O6B:0-#*01VB
M=B.-L7&,(DX_$2.K4E[R]8/%JWNXBPM/+$N%FU;XW*&.D6\X><>,6VHN*;.#
MTD[:3CA@W%ND=^;8;@;@,0[H<\9=OB.]T)SXVD/V<5]V:.A.?&TA^SBONS2A
MHU?UP])_0G/C:0_9Q7W9HZ$Y\;2'[.*^[-*&C2E)_0G/C:0_9Q7W9HZ$Y\;2
M'[.*^[-*&C2E)_0G/C:0_9Q7W9HZ$Y\;2'[.*^[-*&C2E)HL%QX_TM( (\!$
M2DBRB/#NXB6- 1]\=18SCL0VC[D^>6SE@7&F1)510JR5JDZA 1=[8+D,0P.(
MK(-:CX.\1:W%-/E'8V! %0(4BQ5$P FI<Z-28LR9!>&1!ER84@/B/Q)#L9X>
M3XKK)@X/(G(2<E8&VVZ*@X . O*!B)BOG$D5%_-*JL:>#<O^(D@':)OSW780
M;H 8&5#R=8(7=;B!LD'*$C1O4\VLI*WQ+3BHL)B5W(D083J$.(GYA$A4^3R%
MX63 D3(/[SB+;'O#J\*RD'ZMCPM?YG;7DL6<:V=OCNI''F5XR]4%YQ20+SZ$
M-D5DOR .#1-9=0H)6QZZU4TUDSI*D(JDJ44U$U"E.FHF<.0<AR& 2G(<@B4Y
M3 )3%$2B @(AJZ]TLN07PM#ME[%517"N$( F.JB_&<NMO*!=W25,T]]GF/.H
MK4?B8 GO#CT==,MTXJ@B)S"PZCC I_\ 5H5Z*\@?@H/"+2^\*2S14)VCUO'D
M;3%LBYK4G8JYFG"*CEG/M[M#Z.D"2T%'-HV*@B61<J$RJX*#INS(X=)- 5.5
M.[4&ZIB)J%D'1DUDR+(J%*P,FLBH4#)K(J S$BR*A1 R:R9CIJ%$#$.8H@.H
MT84Q5C!UCG)M;7QS1#0-GS)NSJ=DBDJE ,VD_5PW09GCBUV9Z P:+2,(1@FF
MS2C'2RC1!JFF@@DDFF0I=EPCMOQYMT:66&Q*M<XBH6!\PD6&/YR]V:V4JC*L
MT'""S/'$59GLJI3H63%<J[^#9N%X_I+9N=D5B@GT<>ZQ!(L,^=<)=KAR+**%
M'&+:\UGQW-D&VI3AW!V0#[3KCJ'(%I8KK2BJMHZVHBA;[6W-9A0FY+H2U5E"
M<D9(P8H0H;((P *!"(*C9%O!+-$+9+-=E\NC+>SW?P&/V+1T9;V>[^ Q^Q:C
ME!Y\N),RO<09!V\9:I;23E9Q/&^78I"&ON(;O!0[-:1*\F[%6WQWN+[ NQ;K
MJ^9BY, ,LJ5-M'R;MVN5H22Y3 <HG*/$A3 4Q@ >!#F 1*0X_P#Z#F #"4AN
M!A IA ! !X4<J&_#)H7Q!-\R#[1-O,2&W&G%5!(78[CK:KM"0&&UMMN";3@@
MX!"EB#@.(2@JKLDH$A 8$A)DJHHF(ER*BHN61"J$*J*HJXO1EO9[OX#'[%HZ
M,M[/=_ 8_8M9>C4:LZQ.C+>SW?P&/V+1T9;V>[^ Q^Q:R]&E*Q.C+>SW?P&/
MV+1T9;V>[^ Q^Q:R]&E*T"-14)NRV<B9VX5 9S<4' Y6@ '^HUT'$.;;)CQ
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MTA,-H9+<(C?9$ !MN1#G/$Y./OX]KPUPA*^Y;)%CP)BMN,]*D6FZ7!BTX,Q
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M9Q_W[N)_\C7.K=]4E]^4M_Z@7Y_"-P]M*K5^<2_TS7\G%HT:-&J*LJTO(Y8
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MZ6UZ*C.)H8\Z<7M=^ 4Z156;+<G%Y5)"L(@*+D#Q99W"IP>XC3,5E<'EV/\
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MF'TK)9SJU9EV60WTW=C9&E'$JO<;+(,C/+J=_*&GE"PCR+3*Y%^YYE(A&?+
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M.(Q/K?'LD_A$9894D+.KU60K[^;@X: :RCQT[B&SX%*?@3 !1,80*4 $1$1
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MDV%)2$H#V]OO"(=WN (!Q]WO[ ]0."=S$KXQ:_)IOM^CF)7QBU^33?;]*4H
M4 [0#A[X^GWB/;VF_.'\+W=') .'?V=W:(^^/$?PA]03<1#TN_2?S$KXQ:_)
MIOM^CF)7QBU^33?;]*4I:-)O,2OC%K\FF^WZ.8E?&+7Y--]OTI2EHTF\Q*^,
M6OR:;[?HYB5\8M?DTWV_2E*6C2;S$KXQ:_)IOM^CF)7QBU^33?;]*4I:-)O,
M2OC%K\FF^WZ.8E?&+7Y--]OTI2EK@>[WR_XAI.YB5\8M?DTWV_1S$F E$S]J
M8 ,41+U<<.(<H.(<>G=G$.SCZ7?I2J;<&?\ 9.X?^(3=I_ZK,TZ>,0 0Y(@
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M]:?[&L]?\*])DMG#!,\R5CIQQ+3+!<IB*LY7!><)!L<IBB40%)UB94H#P$0
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MB.T9ILR,VDT>K&-C2=NR6J/C>B,;45TX\T3>3YT_%<FL68^L"SUQ,U>/D%)
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IDO-/#-(ABE'1$>$C.OY.0)&0[!,K.)C".BQ\8W$Z;%L@557EFE*__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>optinoselogorgba25.jpg
<TEXT>
begin 644 optinoselogorgba25.jpg
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M:&]P(#,N,  X0DE-! 0       \< 5H  QLE1QP"   "  ( .$))300E
M   0_.$?B<BWR7@O-&(T!UAWZ__N  Y!9&]B90!DP     '_VP"$  8$! 0%
M! 8%!08)!@4&"0L(!@8("PP*"@L*"@P0# P,# P,$ P.#Q /#@P3$Q04$Q,<
M&QL;'!\?'Q\?'Q\?'Q\!!P<'#0P-&! 0&!H5$14:'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'__  !$( $<!%@,!
M$0 "$0$#$0'_Q "Z   " @,! 0              !P4& P0( @$!  $% 0$
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M9UPD-Q8C*9G7W2011/.O?V)3;&%QH!4I;G "I2MO'Q):0BO$U;H4JXH*X=;
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MK)Y6.. 8FK!HG;;6":IM4F9:7F(<:4T\^XZ@@B"T:&O E15Y=E=N[^+Z;@'
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@]&3A58_%7S:^*MH\-/+2G!9Z2EHH0BA"*$(H0BA"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>pipeline2019a04.jpg
<TEXT>
begin 644 pipeline2019a04.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (K U$# 2(  A$! Q$!_\0
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M7X,^/WB_1M$\8ZCINEVD\2P6L+*$C!@C8@<>I)_$UY3_ ,-:?%__ *'[5O\
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M]K_\31_PUI\7_P#H?M6_[[7_ .)KR2BCZGAO^?4?N0>VJ_S/[SUO_AK3XO\
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MOL&GR^7&RXW/90.Y^[W9F/U)KC_^&M/B_P#]#]JW_?:__$US_P ;/^2@2?\
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M %[7W_I6]85,'AN:'[N._9=F7&M4M+WG]_FCH/\ AK3XO_\ 0_:M_P!]K_\
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M/M+5M'\(2K\!_A]_PA7ANW7QGHFE3:MKAL5COS\R$B*50-KR;9%9\;F\P<C
MK0_:&\+?"B\^'?CK3M+L]*L]<\,W44%G-H7@V^L/L+B4(8;Z\.Z*;>I $C%
M3\PSD5\>>(_B5XE\6?\ "/'4]4>9O#]G%8:6\4:0M;0QG,:JT:J25/1CEO>N
MC^('[1WQ(^*7AVWT+Q1XIN=4TJ%E<6WDQ1!V48!D,:*9".OSD\\]>:X%EM=3
MIR539W>K[WZIWTTMH='UFFXR7+OMIY>O?7J4/BA\*?\ A6+:;CQAX3\6B^$A
MSX7U3[9Y&W;Q+\J[<[N/7:WI7"T45]#3C*,4IN[[['G2:;NE8****T).\T;_
M )(3XO\ ^QDT3_TEU6N#KO-&_P"2$^+_ /L9-$_])=5K@ZYZ7QU/7_VU&DMH
M^GZL*W?"_@+Q-XX:Y'ASPYJWB VVTSC2[&6Y\K=G;NV*=N=K8SUP?2L*OK/]
MBV:&W^%?QODN/$]SX+@6ST\OK]I%+)+9C?/\ZK$0Y/;Y2#S6.-Q$L-0=6*N[
MKOU:737J71IJK-1?G^1\WZU\-_%WAO4;#3]6\+:UI=_J#B.SM;W3IH9;EB0H
M6-64%SD@8 /)%8^K:3?:#J5QI^IV5QIU_;OLFM;N)HI8F_NLC $'V(K[.7XP
M>%[R#X7> ;'QYJOQ9UO_ (3>PU)O$&JV4UO]DC$JKY2^=F0D[NY88+<CY15[
MXG>"?AI\5?&WQUTU/#&HV'BWPW8W6N'Q*^ILWGS1J&,0M\"-8\X4$Y8KDY!K
MS(YI4C)*M3:7?YI)V=G;7U\CI>%BU>$OZM>VA\,45]V?!G]EWX?>+/!OAW3/
M$?A&;1]5UG2&NQKFK>(1;ZC),4W%[2PC9E>%1R&E"M@$LA[\O^SW\'OA-XX^
M&.F^;H]OXT\9SSW$>IV)\1G3M1M5#,(C:6Y*QS97:?WC@;C][JJZ2SB@E-\K
M?*TNG6^M[VMH][/R)6#FVE=:^OEY>9\=T5]E_"']FGP+I?@W7_$GCBUT^1U\
M03Z+9V'C/Q V@QPQQ9RSR0!]UP<-\@)7"D@]Z\$^,WA7P=\-_C5<6?AV_M?&
M/@R&>"ZC6TU!9%EA.UI+<SQYP0=R;AD@8/6NJCF%+$594J:;:Z]'Z:^?6QG/
M#RIP4Y/<X";PYJUMH=MK4VEWD6CW,K0P:@]NXMY9%^\BR$;688Y .16=7UO^
MT1XT'C_]D7X9ZQ'H]AX?MGUN[AM]-TV,I!;Q1^:B*,]3A<D]R2>,U\D5MA,1
M+$4W*<;--JWH[$5J:IR23OHG]X5WGPG_ .9RYQ_Q3=Y^/W/\_P"'4<'7>?"?
M_F<N,_\ %-WG_LG^?\.HUQ'\-D4_B1P=%%%=!F7M#T'4_$VJ0:9H^G7>K:E/
MD16=C TTTF%+':B@DX )X'0$UN^(/A-XX\)Z9)J6N>#/$&C:=&55[O4-+G@B
M4DX +N@ )/ YKTK]A\?\91>">,_-=_A_HDU>TZG\9O"'PYT_XDQ:A\9->^*M
MQK%E=Z9;^%KW3KJ.VMI79ADO.S+A,[<H5XSPWRX\7%8VK1Q'L:<.;1/9]6UN
ME9;=3MI4(3I\\G;5]NWX_(^,]6\-:OH$%A/JFE7VFPZA +FSDN[=XEN8CTDC
M+ ;U/]X9%9M??6N6?P[U]?V=_#'C'PE>>([W7?#5C8P7*:D]I%8*R(!($C :
M1]QY#$  #@G(KB?A3^SOX-T_6/'2>(O"LOB'3-*\3S:';ZQK^OKH^FPP1OMW
M>9&WF27!_N"/9_M*>*RAFT%3<JL&G\M=6M+ORZV\BI81\UHO\^U^Q\=T5]FZ
M7\!OA#X7^/?Q,\)ZR]KJ$FGI:R>'M&US6Y-,MYS+&))8VND!;<F]50'DC.0W
M+++I'[*/A*_^.VO1ZEHE]X9\':9H US^S=7U2-+5W+%0HO8WD/V7Y68R'YP!
MR!WT>;X=7;32LI=-;I/36_7TOU%]3J=&M['Q;6_8_#[Q3JGAV?Q!9^&M8N]!
MMPQFU2"PE>UCV_>W2A=HQWR>*]B_:F^&_P //"=KX<U?P+JGA\3WGFPZCH>@
M^(3K$-JRX,<B2L!)A@3G<  0 *]9^ 'Q6\96OAO2/'_B_48_#'PG\&Z2^D6F
MDVF^)/$,XC=%18G8B:7.,R< %. /WA%5<?+ZO'$48[]'H[]E:]VWMTZ["AAU
M[1TYO[OS/B6BK&H7"7E_<SQ0+:QRRLZP1_=C!)(4>PZ?A5>O9.([7X(G'QH\
M GI_Q4&G_P#I3'7(7W_'Y<?]=&_G77_!$X^-'@$]/^*@T_\ ]*8_>N0OO^/R
MX_ZZ-_.N=?QI>B_-FC^!>K_0AJ>QL;G5+ZWLK*WEN[RXD6&&W@0O)*[$!551
MR6)(  Y)-05W/P)_Y+=\/O\ L8-/_P#2F.M*DN2$I]D3%<TDB'4O@K\0]%T^
MXOM0\!^)K&QMT,DUS<Z/<1QQJ.K,S(  /4USUUX:U>QT2RUFYTJ^M]'OF9+7
M4);=UMYV4D,(Y"-K$$$$ G&*_0#Q3\7O"GPD^/'BG7M;^-?B#6H[62X1_AW'
MIMTUN'9,"$22,8< \@@+SW R#P?]N>!;?]EOX07'C'PA<>([*\UG48[72[74
M&LX8!)=2[F9T&]M@(VJ" ><GI7SU/-*[4)2I74FMDUNI.RYK7M9:[:GH2PL+
MM*6U_P TNE^_J?%-%?9MK^S/X/\ #OQT^)NES>%;WQ/X<T".TDM%OM833=.M
M//B65OM5V7$@"@X38KD_Q#^*I?$7P%^#/@_]H_3]*UBYM+/POJGAE=6L=/N-
M9D33WO6=E2(WN"XA94+AS@DD=>$/5_:]!NT8M^[S:6[)VWO>SZZ>9G]3J6NV
MM[?H?%M%?:>I?LG^&/$GQP\"Z7;^'-0\(^&]6M+BYOEM=5CO[&;R%#?Z)=%V
MD8-E0WF(I&<J,<CCOVEOA;\*]%^']MKW@O4O"NG:[!?BWFT7P_XK;6EN+9E.
M)LR*LBN& !4#: <Y)JJ>:T*LX4XIWEZ::M:V?=/:Y,L+.,7)M:'SYH/P_P#%
M'BK3KO4-%\-ZOK%A:9^TW5A8RSQ0X&X[V12%XYY/2L"OJO\ 9+^)_B3PCXF\
M"Z%XHOO$^D>#+RXE3P[%8V@ALKV]ED53]H?:K7$(,AR S;6*=!7@'Q;TB_T'
MXI>+=/U1;1=1M]5N5G%@"MOO\UB?+!Y">@/(&,UTT<1.>(G1FE9:IKKJU^'7
MML9SIQC34T_4Y.BBBO0.<[SXW?\ )0'_ .P9I?\ Z;[>N#KO/C=_R4!_^P9I
M?_IOMZX.N?#_ ,&'HOR-*GQR]0HHHKH,S4\/>%=:\77DMIH6CW^M74433R0:
M?;/.Z1@@%RJ D*"1D].13=*\-:OKMKJ%UINE7VH6VGQ>?>36MN\J6T?/SR,H
M(1>#R<#BOHS_ ()^ZJ^@_%/Q=J<4:RR67A.]N51NC%)8& /MD"O:O^$!T>S^
M'WQF^(WA$+_PAWC?PB]_;Q#:#9W7[S[1;D X&UCTZ [E&0M>!B<S>'KRHN/\
MMGYM[?=JO1G?3POM(*:??\#XJT_X*_$/5M.M]0LO ?B:\L+B)9H;JWT>X>*2
M-AE75@F"I'((XQ7)7%G/:W3VTT$D-S&YC>&1"KJP."I!Y!SVKZO_ &BOB9XN
M\ ^!_@7'X:\4:QH4,G@ZSEDATZ^E@CD8(F"Z*0K<<<@UW>N?#=?B_P#M/?!;
M5;ZRCBU#5/"]CXC\0B-5 D>($[W4#^)ECC],8':E',IPBJM:*Y6I-6W]WOZC
M>&BWRP>JM^)\3>)O".N^"[Y++Q#HFHZ%>/&)4M]3M)+>1D)(#!7 )&01GV-9
M%?;O[9G@KQCXF^#6C>-?%^AMH^NZ/KEY9R1&>&9CI]Q*9+=F:)F7"';'C.<D
MG'-?$5>A@<5]<H^TTO=IV=UIY_B<]>E[&?*%%%%>@<X5W?C3_DFWPZ_Z]K[_
M -*WKA*[OQI_R3;X=?\ 7M??^E;USU/BI^OZ,TCM+T_5'"445;TC2[G7-6LM
M-LHC->7DZ6\$8ZO([!5'XDBMVTE=F9=NO!OB"Q\-VOB&YT/4K?0+J3RK?59;
M21;69_F^5)2-K'Y'X!_A;T-8]?IK\2?@SXGU+X8>,/ARFAL/!VC>%[$Z!J(G
MA)GU&US)+B,-O!EW;264#Y6YY%?-^A^'/A'X!_9V^'7C3Q;X"O/%FL:[=WEM
M/]GU6>U1DCN'7>=K8W*H4*J[=W.X]Z^?P^;PK0YN6[<K)1L]U=7NU;1._9H]
M"I@W!VO96OKZV/EJBOMNZ_9S^&'PYU[XSW&NZ+?^(]#\-V.F:IIEJMY+!<1+
M/YA:$LK#(+*JEF4D*,CG)JOX1^!'PP^)'BCX,^)M+\,W6C>&?%TFHVFH>&KC
M4)IE62WAE*LD^X2$%HR>O.!P.16O]L4+.?++E76R_EY[;WO;RM?J3]3G>UU?
M_@V_,^+**^JM#\'_  BURU^('CP^"[Z#PEX&A@LAH$>KRM+J]U+/)&D\LQ.Z
M)<>7E4QCD_-C#:^C_"/X3^(M4^%/B]?#\VB>#_'$EWHUQH=WJ4TAL;U2R0RQ
M3;E=U,BX^8XY&1S@:2S.G&_-"6GIO;FMOO;7MTO<E863VDOQVO:^W<^/J*^J
M5_9BT;0=#\"^$=>MV@\>>*_%L]F;WSG#VFF6[F*0K'NV$NPW*S*<AL#I73?'
MCX"?"'2?!/B&'PYJ?A;0O%.BW"164-KXO:_N]2Q((Y4N;:11Y,@'S;8]V&R#
M@"E_:M#GC!)N[WMIO:^^U_ZL'U6IRMNVG_#GR#X?\-ZMXLU./3=$TN]UG49
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M22>I--HKKI8:%&I.I'>5NVRV2MT1C*I*<5%[(****ZC(**** "BBB@ HHHH
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MTN=2TXR&&*^1WA.^-HSN"LI/#GH1SBN=U749-8U2\OYE59KJ9YW6,$*&9BQ
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MXG_]$X\6_P#@CNO_ (W7[3T4?ZU5O^?2^]A_94/YF?BQ_P *!^)__1./%O\
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M_P ;H_X4#\3_ /HG'BW_ ,$=U_\ &Z_:>BK_ -:JW_/I?>R?[*A_,S\6/^%
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MO_C='_"@?B?_ -$X\6_^".Z_^-U^T]%'^M5;_GTOO8?V5#^9GXL?\*!^)_\
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M /Q='_"W?'7_ $.GB+_P:S__ !=<E11]6H?R+[D'US$_\_)?>SK?^%N^.O\
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MZ_Z'3Q%_X-9__BZY*BCZM0_D7W(/KF)_Y^2^]G6_\+=\=?\ 0Z>(O_!K/_\
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M_P#\77)44?5J'\B^Y!]<Q/\ S\E][.M_X6[XZ_Z'3Q%_X-9__BZ/^%N^.O\
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M8FL1_M+?M)7VC>'-<\%6_P  ?!MO?P7FMZI9^*H]2U74(8G$@M[1K4+Y.]E
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M@5?5?D?C/'?^\T/\+_,****^]/S **** "BBB@ HHHH **** "BBB@ HHHH
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MO+^]L\J;A3<3F66:62.-+<&1_DC<[3^[1#[+10 V.-(8UCC14C4!551@ #H
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MP9_U//\ Y2/_ +?1_P ,&?\ 4\_^4C_[?1_K#EG_ #]_\EE_D'^J><_\^/\
MR:'_ ,D?)E%?6?\ PP9_U//_ )2/_M]'_#!G_4\_^4C_ .WT?ZPY9_S]_P#)
M9?Y!_JGG/_/C_P FA_\ )'R917UG_P ,&?\ 4\_^4C_[?1_PP9_U//\ Y2/_
M +?1_K#EG_/W_P EE_D'^J><_P#/C_R:'_R1\F45]9_\,&?]3S_Y2/\ [?1_
MPP9_U//_ )2/_M]'^L.6?\_?_)9?Y!_JGG/_ #X_\FA_\D?)E%?6?_#!G_4\
M_P#E(_\ M]'_  P9_P!3S_Y2/_M]'^L.6?\ /W_R67^0?ZIYS_SX_P#)H?\
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MKR7_ (:L^%G_ $-'_E/NO_C5'_#5GPL_Z&C_ ,I]U_\ &J/[-QW_ #XG_P"
MO_(/[8RW_H)A_P"!Q_S/6J*\E_X:L^%G_0T?^4^Z_P#C5'_#5GPL_P"AH_\
M*?=?_&J/[-QW_/B?_@+_ ,@_MC+?^@F'_@<?\SUJBO)?^&K/A9_T-'_E/NO_
M (U1_P -6?"S_H:/_*?=?_&J/[-QW_/B?_@+_P @_MC+?^@F'_@<?\SUJBO)
M?^&K/A9_T-'_ )3[K_XU1_PU9\+/^AH_\I]U_P#&J/[-QW_/B?\ X"_\@_MC
M+?\ H)A_X''_ #/6J*\E_P"&K/A9_P!#1_Y3[K_XU1_PU9\+/^AH_P#*?=?_
M !JC^S<=_P ^)_\ @+_R#^V,M_Z"8?\ @<?\SUJBO)?^&K/A9_T-'_E/NO\
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M&X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC**W_1_H?;<,9SB<!B8X:,7.$W\*W3[K]>EOO/T.HHHK\>/W\**** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#@-/\ _'J/]6<P[+[P_P!<LJ_FE_X"?<%%?#__  W!XZ_Z!/AW_P !I_\
MX]1_PW!XZ_Z!/AW_ ,!I_P#X]1_JSF'9?>'^N65?S2_\!/N"BOA__AN#QU_T
M"?#O_@-/_P#'J/\ AN#QU_T"?#O_ (#3_P#QZC_5G,.R^\/]<LJ_FE_X"?<%
M%?#_ /PW!XZ_Z!/AW_P&G_\ CU'_  W!XZ_Z!/AW_P !I_\ X]1_JSF'9?>'
M^N65?S2_\!/N"BO#_P!G_P#:2MOBP&TG64MM,\3)N9(8-RPW2<G,88DAE'52
M3TR.,A?<*^?Q6%JX.JZ-96:/J\%C:&845B,/*\7_ %9^84445R'<%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\N?MC6MQ\3/'_P &
M_@M+?76G^&O&VHWUSX@^QSF*2\L;&W$K6A9?F"2LZ!B,<+UKZCKQC]I?X*:[
M\5--\+Z[X)UFV\/_ !#\&ZE_:VA7M]&SVLC%&CFM;@+\WDS1L58KR.,4 87C
M;]@WX(^*O TN@:?\/M#\+WD<7^@:YH=FEIJ-G.H_=3+<1@2.RMAOG9@Q'S9K
MY1^(7QBT?QA^S'^RUXR^,LEGJ6DVOC*2S\17&IVAO8;I;6.^MGEDA5&,F\Q!
MB-AR6KW;5?'7[6_Q&TF;P?!\(?#?PUO+R%K6Z\=7GBB'4+6%2-KRV]I$/-#D
M$F,.2 <;JV/$7[,NH>"] _9K\*>"[)]6T7P#XEAN]2NY)886$(M;A9;EE9AN
M9I9=Q5 S9<X[F@#YH^,WC/\ 9E^.GA6U\*_LY>$]/O/B_-J=E-H6I>#O"$VE
M3:3,EPC&[FG\B+;$B!R<E@#@X&-R]3\=O#'BJU_;9\=?$SP1)-<^*OAYX9T;
M53I4<FQ-7T]FN5OK1A@C<\0W)P<.BX&<$?HE7B'A#X<>(M+_ &O/B)XVNM/\
MOPQJWAO2M/LK[SXSYL\,DYE38&WK@.O+* <\$T >97GQ&T'XH?M7?LZ>-="O
M$N=!U;P;KU_!<%@ B,MJ2).?E93E6!QM92#TQ7O&B?&CX<?%A[SP[X1^)WAS
M5M8N+67:GAO7+2ZO8%QM,R(K/RA8')4@'&0>E?.'@C]DOQ7\,?VW++7M'MDN
M_@LMCJM]:0-+"JZ1>WPC%S:K$6WM$[PB1=J[%$A'4$M]%:?^SWX"\'PZE=>
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M/4M,^'_B7Q+96UFOA'P?XAT.ZTI(+.[M)A<7%R/M5Y"Y/VZ. %D5@1:!0<Y
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M3O[0\07,EM_9J:XMD+6X@W^5<DQN^Z:97F)88<;$"@'WS1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% ')?%W_DD_C7_ + E[_Z(>OS&K].?
MB[_R2?QK_P!@2]_]$/7YC5^G<)?P*OJOR/QGCO\ WFA_A?YA1117WI^8!111
M0 4444 %%%% !1110 4444 %%%% $]E>W&FWD-U:S26US"XDBFB8JR,#D$$=
M"#7W5^SI^T7;_$ZSCT/7)([;Q5"G!X5;Y0,ET'0, /F7\1QD+\'5]B_LR?LU
M'0VM/&'BNV*ZD,2Z?IL@Q]G[B60?W^X7^'J?F^[\GQ'3PDL)S8AVDOAMO?\
MR[_YGW/"-3'QQRAA%>#^.^UN_KV_RN?4-%%%?D!^^!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5Y]\5OAS>>,M0\&ZYH\\-MK_A?5UO[<W$
MC1QSV\D3V]U SJK,H:&9V! /[R.,\8S7H-?-'[67B?1]#^)GP7L_%7C.\\&>
M#=0O]435+F#Q+<:%#+LLBT*RW$$T3 "3:0"V"<#O@@'O7@?P/HGPW\*Z?X;\
M.67]G:-8JRP6_FO*PW,79F=V9W9F9F9F)9BQ)))KBM0_9E^'6H^8W]C7EA<-
MK5SX@6\TO6;ZQN8+ZXC\NXDAG@F22%95)WQQLL;$[BI/->&6?Q7TGX=^./$F
MO_"SQ3J7Q,^'.B>!]3UOQ##)XIN-=L8+ZVQ):1Q7\\EP8IY4%PKPJ^ BQR%!
MP7]AM_BW\0K[P[H-S;_#C3UU37$DOK:.XU^9-/LK!8HY ]_=BR/D7#&4*($C
ME!*L1(55B #3T7]F7X;^&F\.MH_A^72&\/7]WJ6F'3]3NX/(FNG#W(^24;XY
M&5<Q/F/  VXXJ6X_9Q\ S>'_  UH\&F:AI=OX;MFL]*N='UN^L+VVMVQOA^U
M03I.T;%4+(SE6**2"5!'#^&/VN;7QI\+_"VOZ'X>35/$OB37Y_#&GZ/:ZFDE
MD][ TWG2_;50AK18[>6;SDC9FC *QECMK@;']HKQ1X$^-GQAO?'NBW=C_8N@
M^'[>P\+Z3K#:A:7MY=7=W%"UFTB0C=,SPQLS11D&-MV50,0#Z(\-_!#P3X2U
M'P]?Z3HGV6]T"WO+:PG^U3.ZK=.CW3R%G/G22O&C-++N<MDELLQ+9/@9X)F\
M)WOAE]&9M$O=9/B"XMOMMQF2^-V+PR[_ #-P_?J'V [>-NW;Q7GVO?M*:_\
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MH917NY=G&(RR$H48IIZZW_1H^9S;A_"YS.-3$2DG%6T:_5,_//\ X93^*?\
MT*__ )4+7_X[1_PRG\4_^A7_ /*A:_\ QVOT,HKU_P#6S'?R0^Y__)'@_P"H
MV6_\_)_?'_Y$_//_ (93^*?_ $*__E0M?_CM'_#*?Q3_ .A7_P#*A:__ !VO
MT,HH_P!;,=_)#[G_ /)!_J-EO_/R?WQ_^1/SS_X93^*?_0K_ /E0M?\ X[1_
MPRG\4_\ H5__ "H6O_QVOT,HH_ULQW\D/N?_ ,D'^HV6_P#/R?WQ_P#D3\\_
M^&4_BG_T*_\ Y4+7_P".T?\ #*?Q3_Z%?_RH6O\ \=K]#**/];,=_)#[G_\
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M_P#X[1_PW!X X_XD_B3/?]S;_P#QVK_L;,/^?3_ 7UW#_P Y]!45\_?\-P>
M,_\ ('\28]?(M_\ X]2?\-P> .?^)/XD]OW-O_\ ':/[&S#_ )]/\ ^NX?\
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M\BW_ /CU']C9A_SZ?X!]=P_\Y] T5\^_\-P> .?^)/XD]OW-O_\ ':/^&X/
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MOT_(^O!_8N8?\^G^'^8?7L/_ #GT%17SZ?VX/ /.-&\2>W[FW]_^FOT_(^O
M?VX/ /.-&\2>W[FW]_\ IK]/R/KP?V+F'_/I_A_F'U[#_P Y]!45\^G]N#P#
MSC1O$GM^YM_?_IK]/R/KP']N#P#SC1O$GM^YM_?_ *:_3\CZ\']BYA_SZ?X?
MYA]>P_\ .?05%?/I_;@\ \XT;Q)[?N;?W_Z:_3\CZ\!_;@\ \XT;Q)[?N;?W
M_P"FOT_(^O!_8N8?\^G^'^8?7L/_ #GTCKG_ "$/^V47_HM:H5X[X[_;$\#^
M'?$36-QI?B"206MK-NB@@*[9+>.1>3+_ '7'ZUS_ /PW!X _Z!'B3_P'M_\
MX]4QR?'R2DJ3L_0?US#K1S/H*BOGW_AN#P!_T"/$G_@/;_\ QZC_ (;@\ ?]
M CQ)_P" ]O\ _'JK^QLP_P"?3_ 7UW#_ ,Y]!45\^_\ #<'@#_H$>)/_  'M
M_P#X]1_PW!X _P"@1XD_\![?_P"/4?V-F'_/I_@'UW#_ ,Y]!45\^_\ #<'@
M#_H$>)/_  'M_P#X]1_PW!X _P"@1XD_\![?_P"/4?V-F'_/I_@'UW#_ ,Y]
M!45\^_\ #<'@#_H$>)/_  'M_P#X]1_PW!X _P"@1XD_\![?_P"/4?V-F'_/
MI_@'UW#_ ,Y]!45\^_\ #<'@#_H$>)/_  'M_P#X]1_PW!X _P"@1XD_\![?
M_P"/4?V-F'_/I_@'UW#_ ,Y]!5?OL_V7IGIMD_\ 0Z^;O^&X/ '_ $"/$G_@
M/;__ !ZN@US]L/P/IWAGPS?R:7X@,&H17#Q*D,&Y0DS(=P\W&<K[U+RC'JR=
M)ZC^N8=_;/8J*^??^&X/ '&=(\2>_P#H]O\ _'J/^&X/ '&=(\2>_P#H]O\
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MMF?\G->._P#KYA_])XJ\6K]RP/\ NE+_  Q_)'PU?^+/U?YA1117<8!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 =W\+?\
MCQ\=_P#8MS_^CX*X2N[^%O\ QX^._P#L6Y__ $?!7"5ST_XD_E^1I+X4%%%%
M=!F%%>L?LK^!M$^)'QZ\+>'/$5E_:&C7C7'VBV\V2+?MMI77YD(8?,J]"/RK
MZ F^!W@GQGX=^(<$_P %]<^$W]@Z=<7MEXHOM3O);>9XB=J[+@*I#@9^4-QG
ME3M)\O$9A3PU7V4XO9.^G5VZM-[=$SJIX>56/,G^?3Y'Q/17M>H?LF^+-/\
M!N@>(&UCPY*^OVMI<Z5HZ7[#4+W[0Z*L<<31C+*9$W'.T;OO&JOQ$_9=\3_#
MGPK?Z[+K'AO7H-+FCM]7M="U(7-QI4CG:JW*;1L._*\$\@]N:VCCL-)J*FKM
MV^?]:>NA#H5$KN)X]1117<8!1110!WFC?\D)\7_]C)HG_I+JM<'7>:-_R0GQ
M?_V,FB?^DNJUP=<]+XZGK_[:C26T?3]6%%%%=!F%%%% !1110 4444 %%%%
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MT_W&M_A9U87^/#U1^IM%%%?B9]L?D+^V9_R<UX[_ .OF'_TGBKQ:O:?VS/\
MDYKQW_U\P_\ I/%7BU?N6!_W2E_AC^2/AJ_\6?J_S"BBBNXP"OJ?4O@O\$O
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MGD@*;R4Q&[8&!C QQ72W?[*_CC3/%7BWP_J,=CIU]X;T6;7YVGF8Q7-I'_%
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M'S?$5_ @\,7K>*TY;3UVG"X!\SS,[-G(^?=MYZU]?:E\1-%U?]H3XM+8^._
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MHPVXD)/3H.16SHG[+ZZ>WQGT_P 537MMJ_@;33>V;6CHD-T?G*.P="3&RJK
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M1GD$._!Z'=\5_%_2O@GIOP1\/Z9XCT_QKKO@N\GO=1U;29C/;)!,Y#6L4O\
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M+ _[I2_PQ_)'PU?^+/U?YA1117<8!1110 4444 %%%% !1110 4444 %%%%
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MA>6KL/B5I]I:_%;XCW4-A)8WE_\ ""YNKUKB...>68NZEYA'\ID"JJL5X^7
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M%%% !1110 4444 %%%% !1110!VOP1_Y+1X!YQ_Q4&G\_P#;S'7(7G_'Y/\
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M4_PK]3J*/]9L=VC]S_S#^S*'F?EC_P .]?C!_P ^.D_^#%/\*/\ AWK\8/\
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MX-DM_#'B>X9]!8[+6\D.39$_PGUC)_[Y^G3X'/LB]K?%85>]U7?S7G^?KO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M _R3^Y?_ "0?ZC9E_P _(??+_P"1/SSHK]#/^&4_A9_T*_\ Y4+K_P".T?\
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M _R3^Y?_ "0?ZC9E_P _(??+_P"1/SSHK]#/^&4_A9_T*_\ Y4+K_P".T?\
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M _R3^Y?_ "0?ZC9E_P _(??+_P"1/SSHK]#/^&4_A9_T*_\ Y4+K_P".T?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4D+G]8:* /GG_@GO=0W?[&/PI>!]Z#2?+)Y^\LLBL.G9@1^%?0U%% !1110
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ME^6F]C[.HHHK\?/WX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;PL^DZ/_ &BRW9TF5M'68Q1AMPM6<W2N0-A8R*W+$$ ^OW=8U9F8*JC)9C@
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M"/A'2? OA^VT71+4VFGVY=E5Y7FD=W<O))))(S/)([LSM([%G9F9B22:V**
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D^%(#?NYI5PV1\V<9 (V*** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>powderedsa02.jpg
<TEXT>
begin 644 powderedsa02.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ _1$E32S$P-CI;,3=:0E8Q+C$W6D)6
M,38U,#$N3U544%5473$U,38U7S%?4$]71%]%1%-?-$-?4$A4+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( /T M ,!(@ "$0$#$0'_Q  ?  $   4% 0              !08'" H!
M P0)"P+_Q  ^$  ! P,# @0$ P8% P4!   ! @,$!081  <A$C$($T%1"10B
M87&!D0H5(S)2L4*AP?#Q%F)R)"4ST>&"_\0 '0$!   ' 0$
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M^X2HC]0"-2K>U552;5K4QE2D/B(J/'5A:5)?F+1$:4@X'UH4]YB>>"@'G0Z
MGL+FV&(.RY^]I\FH=06VXZ68O.0B(P2ALI]/XGU/J XR[SG&I@$8]/?@=DCC
M/ [\Y_#C[8XQJDEL5F2Q'::4H*;2$].1R $\X.?P/KZ_CJH"*\.C*E(&!WP0
M2?MW!QR3]OOJ4&X%C?;?K:U^_P!GH<26Z]]38]R-+C4]Q;TUOK%7$+0<X_%0
MSV^^.,?? R1J$RPX4GE6%#/&.XY[\Y_ GG&<@GB'RKPC1O\ Y/SP,8 []^P/
MZG'MC,O2MQ**E*RM0)3G(XQQSSR<_CCMQQQAS+K<CS[=/I]=KZ[XA8G8$]NA
M':PO;2PV"WL-;7Q#ZR7B%9*R1G(R3SCD<''/ID]\]QC4C.J?2X0 2,]L9)]^
MKC'.1S[\=QKD5G=RUXX5YJVTJ[#J3D>W\V<$]\ C/?T.-24O=VV'V7U-Y40#
MTE" 4DD?E@9Y'H1^@HLRW)#7^NFMO4XJ6.VQZ_W[';]<77V)655&DB'(7URZ
M9T,J)(ZG(JP3%<(SU$H2E3"R1RID**BI1.IXU8ELQO*BO[KTNVXR"ABKP:W%
M<"L@$P8+E685C."I!@NH'KAY8XSJ^W56-N9?0D>MO]X'#3334^&&FFFF&&FF
MFF&&FFFF&&FFFF&-"0D%2B  ,DD@  =R2> ![G5HWC2\6%M>$;PT[I;^3&&*
M\[9%.I<:C4@JD)C56YKHKE/MBW(:WXZ,O1Q5*HU,F,17DR9$&%+9BN-R%MN)
MKG?U4J,.1;$& XVA,ZIRG9R'$!Q,B#!@.+4PM![MKDOQU*(P0I"""#@ZM2W]
MMG;KQ$[977LANQ:#E8L2Y50TU)BB5J30JDB11YS-0IDZ#.#$WY29 G,-2X[@
M96GK;Z5H4E2T*O<JJ,MI\URZ;-X)JK*X:^CDS*EIW"3U-"D\;U=/"[,H26:
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ME3SS$9#*X=NWX:+/W)LLP]M-R;1ONOP>BHHIEN3VX=VP9:6PDNQ;9JWRT^H
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M;@U N]95=<J.M]2>I)\J0&U.=*PXG@@@*6E:0!U=(3KK+W2,O$O$_$^9LO\
MY?DL$,;&QLU;4/SB_2ZT^PUW]1RI[V.820\+<.9<IM^.SBHG=+W++141"DK_
M .V6J4A=-;:C0&\ZQXC]#VCCKB+/SKE/06I$=MP%Q:D.J<8;2EF0LHY2L$.%
M3;:')$<*#90>MNO[EU^CWJJ);:ZA4:XUY<Q(CO?*&%%#OTR)C[CJ41?.E!:V
MXPRXXMM/DLA#2E([$ZW*DTG;*G" E)7\FEK*PAPMI?0PXIU2Y"' ZE#G\%OY
M4]3BWW5X>2,#J_M]QJ5<U\W <K5-N1^ RX0L@0Z&TW3V4)+A6M+?FMR5I;*U
M*;+A2I16%:Z^X:B\:3-*B18Y!/5.K<Z@GE#,2&4@@C10!>P+,;=,<>\12PT=
M)3$(T@RW+83%'SNB354TE/'"&DC=)>5%,\K\A#N847G4$MBZBF^+"NU.E1K=
MWLMR)?-)8#<>*Y<JGE5VF,M%"V4T*^Z>\BJT5#9:"$L.2'X++2W$QJ8.M756
MVD[T2DV\_!LZNF^K<5&>\JV*X(5.W(H"F5E2&J?4));H-_TE7G+,=B.:;<K9
M"6*?3'4I0IZQ.:^P\E:7$I4E22DA0"@03V(/<$^W8=_4:DI27Z8^)5(D^1T]
M6(R_,,176>I72VE05'*CRH,E*%9(6VL*4#F)N&<LJ%M% M..?Q/!"\U(9-"7
M$&G@NQ%VDIVB=[ 2,Z73& RSBBNE(,S.DA3PR[/(Q,?PVB_$GFG,:_RQU?XQ
M ?B!B(#B9MX+PHUU2*A,A..^>B2['DQY;"H53BOA'5(9J5/<#4B&J.GR8Z69
M,=LA*0VV4?6G5BM=/_J'R!@%?&.<XSC@D9SDGCD#(.=7LURJ4#<."*7?--=>
MJC# 33KDIZVZ?=]-* O#$6KH;6Q6:4V%)_\ ;:LQ*BI;&&F82^MTVFW[85QV
MF55!)3=%K+*2U<5-C.(D0PL](9N"E!;KM-D9'07&E283I'F,.K;5E-]*S4]$
M*5Z>1!$ JNA\9 +"UB%#JMM[I868FR@,?0^#)LO%1)&E64K*B3Q/PM;R1M(S
M$?\ AIU(IZIFM<*OARNU^2-]2*1/I"U8'2?Z20"<_P O5SG.""._T^Y) %2K
M5"(M-DN=!=&%=2"D842,#*L*Z0!S@E.5$=?4$ "GK1:DK;=;67$J)(4@D@\E
M)'5CI!!.%)'UIQ@@9QJK]&I_1;\EPI!6D+P,\GZ3U=LG )Y!*OJ!^K^8JTPT
M_B3^*+,-U8?$/Y>NHML-];:=L;]GU0(:2*%^92\\494W4ZN%(()!MK8D6L#Y
M8R"O!]XP+BVJ\.GAIV4MVXK-V[W$NUV^J=0MU-Q[JI,&R[#JZKYK5:M2H7;6
M*K%JU)I%(IU&K5/?$24'EPHC$:'&A,2ULL-Y<WPNH%.AV5N7(H[U!O*%5[@I
MU>J>]-'FW3*&Z%XU^3<58O!^&+F?<Z+6I%3FI5:+M)BT>#,I-2$LT:+YK+SV
M*!^SP>,;9?P[WI>]K>(R2S#LC>$T"P[<NBN-4V595CUJF5:KU\2+LC3&E-PZ
M5<+]58A3;H6AU%$?BP':UY='<=J%+S]Z#3Z%3*3"B6W"I4"B)9;<I\:B1H42
MEICO(2ZTN&S3FVH89=;4EQM;"/+<0I*T%25))^?'M;X6K.%N+\S$D<\E'G,T
MF9TF82TQB@K?Q3K4U*4S%Y+/15,KTLRB0M\ D*(D\9/9'LSXHH^)>&J2.-Z:
M.OR0#+*^@AJO&FI32AJ:EEJ$,<3*E=2Q)5P_!R#G:-9)7AD(B^FFFO+<>B8:
M:::88:::VG7FV0"XK!4H)0D<J6H]DH3ZGU]@ 22 "=,,;NFJ3'>6SV*_+M^>
M](@2(LA454IYEQ4,OI4$*;4^E'0VH*(24DDY/&4_5JJC#[,EEN1'=;?8>0%M
M.M+2MMQ"N0I"TDI4#[@Z@"#>QO;0X8W=---1PQ;M<B\79N"Z" 685%BI41G
M-'BO$9QQR[DD \=B,ZH<ZG"R>",GMCW)[#U))QQC.JYW,6VZGN6Z2DO.3J(P
MVGL>*!2>_M_,23G@?IJARR%.')/)P>.PSU=LD<X'OP.^K63<@'7F)M:^[>AT
MU_M8XJ*+J0#K<?*Q!V^7ZZ8@-V2C LZ\)GU#Y:T;G>'3_,"FA3^DC QD*P![
M]P/37G<W)+,C?J[I+A\PF]JJM2R"0$BI.'K<PVX>E"05J_@N)4$J!0I*B1Z'
M>X#>=N]P!PE1LB[.DG  *:#45]\$'D#./L/MKSK:H[\MO?<Q>272+UJ16E*0
MHNDU)\]*$=+J'%%6%);4A2%D!LJ"3SVE[H: Q<?-:[>%E"VZD<N8$6/:]K:V
MVMCC7WLRQ7@U+CEY,[<-;06?*%)L+W !)T!T!%C?6_6_)738T4O-,N(3!><?
M\I#S+T=#4<=3"I,I+?4MWK2@M.F8J/%:"0L1QE[K)L]WIMV-(/TN3I$^J+4.
M,KJ%0E2N_'^!Q*1](!3_ (0.!V#;F2FHFV\XN-)<8_<S[<=(E/+"'VJ>]T)<
MCNRUNE#9#BGFE,F(W+#99+Z4-ML==-%4IF@4=D$ II<'(R#DF,TI7)]R<DX]
M>2#QKJ_A6,+!.1>QG<:VU-P3>Q-B"2I%AW-]\<E<1_OXVC) +RY>Q O?ECAK
M-#< D/XBD7N.NE@!'9<PG.%=L^H!! X SQ@D# SSZ:@KM05GIRK)S@D@G]!Z
MC/;MP3R1SPY,A7/)S[ \#WR1V/MGDY]>-09Q[!'<]\J!!SZ<\ @C/8Y).,<:
MW ( !I<]#H;G3Z;_ &;XQ=)0)8<RCR  MK:VVA[:^?;6*OO-OX2M(.%!:2."
ME8_E4E0(4E8Q])2H+'<$'.MZ)7)%./ER5F5&<2MM3CH2XE32PKJ9FLK2M#S"
MR2'%= \Q*B7P1U.&6#*.?R[GC!QZ#N!COZYQC&O@RL]Q@=AVX_4_EZ#G4Q2X
MU73K>QZ#IO?\^G3&52B'*(R"T8L0+V*FPLT;;H][$\NA(^($6QO5K9NW+K=5
M4;1?10*T\0ZNF><U\M,"@DAR&YQ&=#BE$-PY <+F"F(Z2CR]277V*U9%#ETJ
MLT54N0$J0B33'A'.#U]7S,.8C^&I*L!09D#Z>"D$@&;8=5<@.HP5*CA74&TG
MZV"KDK8*NP! 4J.2$JY4CRW%%1J7/5%OV!';G/M*JG3Y42:YTH:J:4$--L2G
M,) E@?0B2ZE'4H!J2 >A:<34Y73LS$KX9D#!IX@%=&(!YV76.8"QYFD1G&Q<
MKJN83.,QIWH8<T8YEEL$T;()N<3J$U15J8I%G!0*1X3O(C :*2H)MNVKW"?I
M;\2E_6Q"7*=>4RXK"_F7NA =< RV AM'E%/U%25*ZCT@9S'?@O\ Q?U;;R;8
M\*OB:NMQ[:RI.P*%L_N57I7F';*=(*8M.L>ZZF^OJ&W4U\LPK;J\DK%D376Z
M;.?1:<B.]0,02=8;=.GK48Q8>;=4E:2"DMK2HI*5 \I(((.>Q)&JP6G/4TTU
M%7GJ2CRPAW^(AYLIZ%H(7]..DE*D*!2XDD$8)!U;BOV>Y/QGPO/P[GL:3QGG
MDHJ^%%%705)_Z5;2LP/ARHQ/.@O%+$SP2JT3L#L47'-7PCQ+1\:<(S/#, L>
M:Y;([M1YG1E@9::L56^-& ^&2QDAE6.:-D>-2/6Y!"AD?Z'\N,C]-:ZQBO@8
M?%%?W%I]#\%>_MPO2KXH5+<8V&OBLRE.R;PMJCQ%ON;9UR=)679%U6M3(ZW;
M1F/../W#:\-^F/*55+?;>JV3J"",@Y!Y!'8CWU\PN-N#<WX#XAK>'LYC_?4Y
M$E-5(K"GS"AD+?AZZF+;Q3*I#(27@G26GEM+$X'T1X&XUR;C_ARBXCR62\%2
MICJ:5V4U&7UT:K^)H:H*;"6!F%F "S0M%41WBE0EIIKAS)K<1(R"X\O/E,I.
M"K Y4H\]#:>.I9!P2 D*40DZEC;\:S)C4-OK<.5JREIH$=;JP.R<]DC@K6?I
M0.2<D RXEQUQ\RY:B7#PAL9"&$'GH;! QP 5+4.M:@23@)2GDMMJ=69,H^8Z
MH8] A"!]24(3_A0D\X'U+4.IPE7(ENXZJS3&%OK4E*4A03S_ #8!)^^?]2">
M. -AK?U^_O7$NIT ([7N+FX\KCK_ 'MIBR;Q:1*W9<D7A;T!V73[A6EAUQEL
MJ8I57*/+<54 C!3&E@"1'<4$M+=ZV'%)44==3]CMXTBF6K1:G%E1ERX;%."'
MI+<I^JOQF25U9N(E7S45]2&W Z@(6Q*;9&2A]*%N+NOZ/-B2H\HQ95.D(+,B
M',;#D9Y&.4*2,D=2?I*@<@$I4"G(-*]A:9MR-PZG=:KI3^]H*3'MV@59Q,5V
MBLO@"2(KG5\O52D_PF9S02\(O2EZ.TZ7"JUO>2ZFP8[M;38FU_78&]]#IIB?
MIKT&EK]AH -/7U[VQV2MK0ZA#C:DK;<0E:%I.4K0L!25)(X*5)((([@YTU*]
MK5B)4X]31"<2]&IM8E4]M;0RA(^7B3PT, 8#(G!I (!\M"#C!&FKH:XABC5Z
ME-,N.Z&:JINGL7 [3IU&FS2&($TQZ1 @/1A-<Z8K<MJ1&="HCSK;ZFULNM-N
M(7U"EBJ1/4/.;:0^T5$!Z*ZU(:4"3G"VW'$8&< DYQCOQJ]UYAF0VII]IMYI
M8Z5MO-H=;6/92%A2%#[*!&NE?XG7@0\7F\=1V_W0\!&_4S8:[+)H5U4J\MMK
M<NN=M72MSC4IE/J=#K+-;I5%K]L&ZZ.['J%.:;O&UY$"IQ*C'9<N&AL0W_G+
M[*,JAS;,H*"?-<NR9*@R@9AFK5$>7PNL;2QI4RTM/5RQ+-(BP+,8#%&\BM.T
M<0>5;'-,PERRAGKH<NK\V> (QH,L6GDKID+JKFFCJJBEBD>-"9#&9E>1481A
MY.1&NON6DO3;6NBGK8>S-MBY8?2IM7*I%#J+*49Q@]2EIQVY[$$C7FYW?):7
MO3>;C!"FTWM64MJ1TG(14WP.G(\M62DD)64A0!!5DD:[?K[\=GQEO!=>Z=L_
M$!NK?D&L.A]E%)WXV=VIN>%6H:TJCR)5LWU:]'MZFWE3&DK<"ZQ;5Q58,M@N
M20TZ4-GHGI-3E2*[,FRUK7*?JDI^0I1^M;[DEQQPJ23GJ6XI7T'W]#SKOCW<
M/9UGW!,?%55FM3D];09W!D[937Y)F<69T5:D#YCX\L<L:1D(@DIPC,@#AR%_
M@('#OO!\;Y'QM'D]/E4.;4N8Y$F;+FN7YSE=3E=;1M6?LW\-')#4+8LYIJB_
MANX4*I)M(I;L2W&;*MJ:BAII81^X9:QT-]#7FNQ5A]UV0MQ+;CR$.!2(J>IY
MA06A+I+CIU8)&<4FFT]([B#%0 #VQ';Y)4>#C&,9/V&=7NS;@:JNU7DJ4T$F
MDS&5I6HH;*_DI"$.H;Z%M/.I3_"4Z([26SE,=;JUJ(L5AO=5.@*[@0HR3C^I
MME"%$8XR%@YXX)P<\#70'#\;Q)5QN+,M5+ZMJ!?SU%]1>['4WQSC5.M2D,D9
MNH2D+*01RLT<I -R1J%M:Y *6T!MC:D.$9[9Y'.1SSV^^.1GDCUU!'G03@ J
MY^KD\D\@D'L"?4<DG/&N7-=P58SQSG(XSQW!^YZ0,X'&!J //=.0,]2@21V!
M!&.^>< 8)QD< >^ME47UMV UV[GR[]-]-;8R%'!S $"]R+#Z'Z :^9],?3CX
M!)STXYX'( ';/XY')&?SUPB^?11 !X[' QD\9X[@X.0<D_;6PX2LC)R./OD?
M;V'X\_?J[\5Q0&4@$X/?D=N>!C)()[_88&#JH6 -KZ]-+[]_Z[WQG(J=0!?4
M]!8$ Z6UVOUM?K\\<E<C&.I?!Q]1]2>1SG&3GOW(_/'-IE9<ISP4GK<CK4"\
MQD<'/4'F2<@.@@=:1]+Z/X:^>A29==[\G'&.#W '<C! ]1G&>_?C6SD]P< Y
M_P 1!^_<X.3^(_/5)B38']+W&]M=?G\AKBZ-'%+$4< JXY64@ :VW%P>;6X(
M-P0+$$8N$8J42X6&FI#C:IA:0(4U6 ):23T1I"U@9=0<HCR'%A24A,9TD!!;
MV&8BHS^"E2'6U$%)'3@I."DIX*5#';C&, <:HO3*LN [Y:U$1G%E142,,.G
M#R>Y#9('GI /4 '0.I&%7 6JZJZW&8"5I-;0V"P%*2I=4;;0C*&BE("Y2&R5
MI//S3(*D]2T$KHFT2EMD%RPV";:CLFNO13?H#;3,WRR>@#/'SR0L+V'Q$J
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MU*GD!?S,%V4P2<=$NFMN26U X(PMCYEE>?\ "ZDXRD8^4MI;3U*. .2K('
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M>_ZD_P!SJ',?+Z7[=_3^N(\HON?0:=K[6[ ?YQPBUG^;&0?OSQ@YX&.P[?\
MYKZ\KD$9"N^>0?L1C_?]M<S32Y';Z#],.4:#70$;]_O];XVT*) "N_OSS[?G
?_?6YK3'X_J?_ +UKJ&)L----,,----,,----,,?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772364832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information Document - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 01, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_DocumentandEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OptiNose, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001494650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,264,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 682.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DocumentandEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DocumentandEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770708480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 200,990<span></span>
</td>
<td class="nump">$ 234,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">2,310<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Grants and other receivables</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">7,132<span></span>
</td>
<td class="nump">2,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,183<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">212,857<span></span>
</td>
<td class="nump">238,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,884<span></span>
</td>
<td class="nump">2,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">248<span></span>
</td>
<td class="nump">405<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">216,989<span></span>
</td>
<td class="nump">241,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">7,116<span></span>
</td>
<td class="nump">5,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">18,421<span></span>
</td>
<td class="nump">8,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred other income</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">25,697<span></span>
</td>
<td class="nump">14,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">72,500<span></span>
</td>
<td class="nump">71,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other liabilities</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">98,378<span></span>
</td>
<td class="nump">86,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200,000,000 December 31, 2018 and 2017; 41,227,530 and 37,802,556 shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">436,554<span></span>
</td>
<td class="nump">365,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(317,927)<span></span>
</td>
<td class="num">(211,269)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(57)<span></span>
</td>
<td class="num">(111)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">118,611<span></span>
</td>
<td class="nump">154,496<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 216,989<span></span>
</td>
<td class="nump">$ 241,136<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6766681680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">41,227,530<span></span>
</td>
<td class="nump">41,227,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">37,802,556<span></span>
</td>
<td class="nump">37,802,556<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772342016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Gross margin</a></td>
<td class="nump">$ 7,065<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sales</a></td>
<td class="nump">1,588<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">5,477<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">10,099<span></span>
</td>
<td class="nump">16,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">95,618<span></span>
</td>
<td class="nump">31,698<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">105,717<span></span>
</td>
<td class="nump">48,530<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(100,240)<span></span>
</td>
<td class="num">(48,530)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (income) expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_GrantandOtherIncome', window );">Grant and other income</a></td>
<td class="num">(406)<span></span>
</td>
<td class="num">(162)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(2,453)<span></span>
</td>
<td class="num">(303)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">9,229<span></span>
</td>
<td class="nump">910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency (gains) losses</a></td>
<td class="nump">48<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(106,658)<span></span>
</td>
<td class="num">(48,902)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDividendsAdjustment', window );">Deemed dividend</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion to redemption value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,096<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (106,658)<span></span>
</td>
<td class="num">$ (61,967)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share of common stock,</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">basic (in USD per share)</a></td>
<td class="num">$ (2.68)<span></span>
</td>
<td class="num">$ (5.63)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">diluted (in USD per share)</a></td>
<td class="num">$ (2.68)<span></span>
</td>
<td class="num">$ (5.63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>Weighted average common shares outstanding,</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">basic (in shares)</a></td>
<td class="nump">39,765,983<span></span>
</td>
<td class="nump">10,999,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">diluted (in shares)</a></td>
<td class="nump">39,765,983<span></span>
</td>
<td class="nump">10,999,121<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_GrantandOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant and Other Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_GrantandOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDividendsAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDividendsAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929447424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income and Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (106,658)<span></span>
</td>
<td class="num">$ (48,902)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">54<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (106,604)<span></span>
</td>
<td class="num">$ (48,914)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109240241&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773919152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">$ 154,496<span></span>
</td>
<td class="num">$ (151,197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock compensation expense</a></td>
<td class="nump">8,645<span></span>
</td>
<td class="nump">5,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">1,418<span></span>
</td>
<td class="num">(154)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock upon consummation of initial public offering, net of issuance costs</a></td>
<td class="nump">59,917<span></span>
</td>
<td class="nump">125,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">54<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(106,658)<span></span>
</td>
<td class="num">(48,902)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">$ 118,611<span></span>
</td>
<td class="nump">$ 154,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">37,802,556<span></span>
</td>
<td class="nump">4,067,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,068,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="nump">482,190<span></span>
</td>
<td class="nump">41,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of warrants (in shares)</a></td>
<td class="nump">14,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="nump">53,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock upon consummation of initial public offering, net of issuance costs (in shares)</a></td>
<td class="nump">2,875,000<span></span>
</td>
<td class="nump">8,625,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock upon consummation of initial public offering, net of issuance costs</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">41,227,530<span></span>
</td>
<td class="nump">37,802,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid -in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">365,838<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock compensation expense</a></td>
<td class="nump">8,645<span></span>
</td>
<td class="nump">5,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">1,418<span></span>
</td>
<td class="num">(154)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock upon consummation of initial public offering, net of issuance costs</a></td>
<td class="nump">59,914<span></span>
</td>
<td class="nump">125,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">436,554<span></span>
</td>
<td class="nump">365,838<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(211,269)<span></span>
</td>
<td class="num">(151,102)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(106,658)<span></span>
</td>
<td class="num">(48,902)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(317,927)<span></span>
</td>
<td class="num">(211,269)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(111)<span></span>
</td>
<td class="num">(99)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">54<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">$ (57)<span></span>
</td>
<td class="num">$ (111)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,875,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 168,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,680,566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (237,259)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesC2Member', window );">Redeemable Convertible Preferred Stock, Series C2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">687,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesDMember', window );">Redeemable Convertible Preferred Stock, Series D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Sale of Series D preferred stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,117,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Sale of Series D preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesCC1DMember', window );">Redeemable Convertible Preferred Stock, Series C, C1, D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings', window );">Accretion of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,096)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesCC1DMember', window );">Redeemable Convertible Preferred Stock, Series C, C1, D | Additional Paid -in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings', window );">Accretion of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,096)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember', window );">Redeemable Convertible Preferred Stock, Series C, C1, C2, and D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">11,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings', window );">Accretion of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,969)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember', window );">Redeemable Convertible Preferred Stock, Series C, C1, C2, and D | Additional Paid -in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings', window );">Accretion of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(704)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember', window );">Redeemable Convertible Preferred Stock, Series C, C1, C2, and D | Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings', window );">Accretion of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,265)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=109240241&amp;loc=d3e32157-110900<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=109240241&amp;loc=d3e32211-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109240241&amp;loc=d3e32022-110900<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16649-113920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16649-113920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesC2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesC2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesCC1DMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesCC1DMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763439360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember', window );">Redeemable Convertible Preferred Stock, Series C, C1, C2, and D</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773139728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (106,658,000)<span></span>
</td>
<td class="num">$ (48,902,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">539,000<span></span>
</td>
<td class="nump">166,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">8,543,000<span></span>
</td>
<td class="nump">5,096,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="nump">404,000<span></span>
</td>
<td class="nump">198,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(2,310,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_IncreaseDecreaseInGrantsandOtherReceivables', window );">Grants and other receivables</a></td>
<td class="num">(196,000)<span></span>
</td>
<td class="nump">337,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_IncreaseDecreaseinDepositsandOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(762,000)<span></span>
</td>
<td class="nump">2,358,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(4,698,000)<span></span>
</td>
<td class="num">(2,013,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">3,171,000<span></span>
</td>
<td class="nump">392,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">10,150,000<span></span>
</td>
<td class="nump">6,688,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="num">(91,817,000)<span></span>
</td>
<td class="num">(35,680,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,690,000)<span></span>
</td>
<td class="num">(2,406,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash used in investing activities</a></td>
<td class="num">(1,690,000)<span></span>
</td>
<td class="num">(2,406,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock', window );">Proceeds from the sale of Series D preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">36,712,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">63,969,000<span></span>
</td>
<td class="nump">138,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan', window );">Proceeds from the issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">739,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">1,488,000<span></span>
</td>
<td class="nump">134,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments of withholdings on shares withheld for income taxes</a></td>
<td class="num">(70,000)<span></span>
</td>
<td class="num">(288,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Cash paid for financing costs</a></td>
<td class="num">(6,547,000)<span></span>
</td>
<td class="num">(13,433,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="nump">59,579,000<span></span>
</td>
<td class="nump">236,125,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effects of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">64,000<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(33,864,000)<span></span>
</td>
<td class="nump">198,028,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">234,875,000<span></span>
</td>
<td class="nump">36,847,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">201,011,000<span></span>
</td>
<td class="nump">234,875,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of noncash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">8,253,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses', window );">Fixed asset purchases within accounts payable and accrued expenses</a></td>
<td class="nump">146,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1', window );">Fixed asset additions acquired through tenant allowance</a></td>
<td class="nump">361,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Financing costs within accounts payable and accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,454,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of convertible notes payable and accrued interest into Series C-2 preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">237,259,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember', window );">Redeemable Convertible Preferred Stock, Series C, C1, C2, and D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Deemed dividend</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,969,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesCC1DMember', window );">Redeemable Convertible Preferred Stock, Series C, C1, D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Deemed dividend</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,096,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesC2Member', window );">Redeemable Convertible Preferred Stock, Series C2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of convertible notes payable and accrued interest into Series C-2 preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 19,527,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs WIthin Accounts Payable and Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_IncreaseDecreaseInGrantsandOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Grants and Other Receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_IncreaseDecreaseInGrantsandOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_IncreaseDecreaseinDepositsandOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deposits and Other Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_IncreaseDecreaseinDepositsandOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Common Stock Under Employee Stock Purchase Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 25<br> -Paragraph 19A<br> -URI http://asc.fasb.org/extlink&amp;oid=107668666&amp;loc=SL79513924-113897<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stock that is classified as callable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesCC1C2DMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesCC1DMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesCC1DMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesC2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesC2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763468176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Description of Business</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Organization and Description of Business</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">OptiNose,&#160;Inc. (the Company) was incorporated in Delaware in May 2010 (inception) and has facilities in Yardley, Pennsylvania, Ewing, New Jersey, Oslo, Norway and Swindon, England. The Company's predecessor entity, OptiNose AS, was formed under the laws of Norway in September 2000. In 2010, OptiNose AS became a wholly-owned subsidiary of the Company as part of an internal reorganization.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company is a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's first commercial product, XHANCE</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> (fluticasone propionate) nasal spray, 93 mcg, is a therapeutic utilizing its proprietary Optinose Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE was approved by the United States (US) Food and Drug Administration (FDA) in September 2017 for the treatment of nasal polyps in patients 18&#160;years of age or older, and&#160;XHANCE was launched commercially in the US in March 2018.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6615694768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_FutureLiquidityTextBlock', window );">Liquidity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Since inception, the Company's operations have focused on organization and staffing, business planning, raising capital, establishing an intellectual property portfolio, conducting preclinical studies and clinical trials, pursuing regulatory approvals and most recently, preparing for and launching XHANCE. As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company had cash and cash equivalents of </font><font style="font-family:Arial;font-size:10pt;">$200,990</font><font style="font-family:Arial;font-size:10pt;">. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On June 11, 2018, the Company and certain stockholders closed an underwritten public offering (the Offering) of </font><font style="font-family:Arial;font-size:10pt;">5,750,000</font><font style="font-family:Arial;font-size:10pt;"> shares of Company common stock (Common Stock) at a price of </font><font style="font-family:Arial;font-size:10pt;">$22.25</font><font style="font-family:Arial;font-size:10pt;"> per share. The Offering consisted of </font><font style="font-family:Arial;font-size:10pt;">2,875,000</font><font style="font-family:Arial;font-size:10pt;"> shares of Common Stock sold by the Company and </font><font style="font-family:Arial;font-size:10pt;">2,875,000</font><font style="font-family:Arial;font-size:10pt;"> shares of Common Stock sold by certain stockholders. As a result of the Offering, the Company received </font><font style="font-family:Arial;font-size:10pt;">$59,917</font><font style="font-family:Arial;font-size:10pt;"> in net proceeds, after deducting discounts and commissions of </font><font style="font-family:Arial;font-size:10pt;">$3,678</font><font style="font-family:Arial;font-size:10pt;"> and offering expenses of approximately </font><font style="font-family:Arial;font-size:10pt;">$373</font><font style="font-family:Arial;font-size:10pt;"> payable by the Company.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company will likely require additional capital in the future through equity or debt financings, partnerships, collaborations, or other sources in order to meet the debt service obligations under the Company's outstanding senior secured notes (Senior Secured Notes), including repayment, and to carry out the Company's planned development and commercial activities. If additional capital is not secured when required, the Company may need to delay or curtail its operations until such funding is received. The Company is subject to a number of risks similar to other life sciences companies, including, but not limited to, successful discovery, development and commercialization of its products and product candidates, raising additional capital, the development by its competitors of new technological innovations, protection of proprietary technology and market acceptance of the Company's products.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_FutureLiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future Liquidity [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_FutureLiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6705734112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Basis of presentation</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The accompanying consolidated financial statements have been prepared in conformity with US generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Principles of consolidation</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The consolidated financial statements include the accounts of OptiNose,&#160;Inc. and its wholly-owned subsidiaries, OptiNose US,&#160;Inc., OptiNose AS and OptiNose UK&#160;Ltd. All inter-company balances and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Use of estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Stock Split</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On October 10, 2017, the Company&#160;effected a </font><font style="font-family:Arial;font-size:10pt;">2.8879</font><font style="font-family:Arial;font-size:10pt;">-for-1 reclassification, or stock split, of the Company's common stock in connection with its initial public offering, or the IPO. All common share and per share amounts in these consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to reflect the stock split. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of credit risk</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and accounts receivable.The Company generally invests its cash in deposits with high credit quality financial institutions. Additionally, the Company performs periodic evaluations of the relative credit standing of these financial institutions.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has exposure to credit risk in accounts receivable from sales of product. XHANCE is sold to wholesale pharmaceutical distributors and preferred pharmacy network partners, who, in turn, sell XHANCE to pharmacies, hospitals and other customers.&#160;</font><font style="font-family:Arial;font-size:10pt;">Four</font><font style="font-family:Arial;font-size:10pt;"> customers represent approximately </font><font style="font-family:Arial;font-size:10pt;">90%</font><font style="font-family:Arial;font-size:10pt;"> of the Company's accounts receivable at </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;"> customers represent approximately </font><font style="font-family:Arial;font-size:10pt;">94%</font><font style="font-family:Arial;font-size:10pt;"> of the Company's net product sales for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Cash and cash equivalents</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All highly liquid investments purchased with an original maturity date of three months or less at the date of purchase are considered to be cash equivalents. The Company maintains its cash and cash equivalent balances at foreign and domestic financial institutions. Bank deposits with Norwegian banks are insured up to approximately 2,000 Norwegian krone by the Norwegian Banks' Guarantee Fund. Bank deposits with US banks are insured up to $250 by the Federal Deposits Insurance Corporation. The Company had uninsured cash balances of </font><font style="font-family:Arial;font-size:10pt;">$199,507</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$233,772</font><font style="font-family:Arial;font-size:10pt;"> at </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Fair value of financial instruments</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company measures certain assets and liabilities at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The FASB accounting guidance outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company uses quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of the inputs as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level&#160;1&#160;&#8212; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level&#160;2&#160;&#8212; Valuations based on observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level&#160;3&#160;&#8212; Valuations based on inputs that are unobservable and models that are significant to the overall fair value measurement.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">At </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, the Company's financial instruments included cash and cash equivalents, accounts receivable, grants receivable, accounts payable, and accrued expenses. The carrying amounts reported in the Company's financial statements for these instruments approximates their respective fair values because of the short-term nature of these instruments.  In addition, at </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company believes the carrying value of debt approximates fair value as the interest rates are reflective of the rate the Company could obtain on debt with similar terms and conditions. At </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, there were no financial assets or liabilities measured at fair value on a recurring basis.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Accounts receivable</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounts receivable primarily relates to amounts due from customers, which are typically due within 31 to 61 days. The Company analyzes accounts that are past due for collectability. Given the nature and historical collectability of the Company&#8217;s accounts receivable, an allowance for doubtful accounts was not deemed necessary at&#160;</font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prior to receiving FDA approval for XHANCE in September 2017, inventory purchases were expensed as incurred and recorded as a component of research and development expense. Subsequent to receiving FDA approval, inventories are stated at the lower of cost or net realizable value. Costs of inventories, which include amounts related to materials and manufacturing overhead, are determined on a first-in, first-out basis. An assessment of the recoverability of capitalized inventory is performed during each reporting period and any excess and obsolete inventories are written down to their estimated net realizable value in the period in which the impairment is first identified. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Property and equipment</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Property and equipment is recorded at cost less accumulated depreciation. Significant additions or improvements are capitalized, and expenditures for repairs and maintenance are charged to expense as incurred. Gains and losses on disposal of assets are included in the consolidated statements of operations. Depreciation is calculated on a straight-line basis over the estimated useful lives of the respective assets.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The estimated useful lives of property and equipment are as follows:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Computer equipment</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2-3 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Software</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Machinery &amp; production equipment</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5-10 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Furniture &amp; fixtures</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3-5 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Leasehold improvements</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Shorter of lease term or useful life</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Long lived assets</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated. Impairment charges are recognized at the amount by which the carrying amount of an asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell. The Company did </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;">t recognize any impairment or disposition of long-lived assets for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Revenue recognition</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company accounts for revenue in accordance with ASC Topic 606, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Arial;font-size:10pt;">, which was adopted on January 1, 2018. This standard applies to all contracts with customers, with the exception of contracts that are within the scope of other standards, such as leases, insurance and financial instruments. Under ASC Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to be entitled in exchange for those goods or services.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company performs the following five steps to recognize revenue under ASC Topic 606: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only recognizes revenue when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that will be transferred to the customer. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Net Product Revenues</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company sells XHANCE to preferred pharmacy network partners and wholesalers in the US (collectively, Customers). These Customers subsequently resell the Company&#8217;s products to healthcare providers, patients and other retail pharmacies. In addition to agreements with Customers, the Company enters into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts for the purchase of the Company&#8217;s products.  </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company recognizes revenue from product sales at the point the Customer obtains control of the product, which generally occurs upon delivery. The transaction price that is recognized as revenue for products includes an estimate of variable consideration which is described below. Payment terms with Customers do not exceed one year and, therefore, the Company does not account for a financing component in its arrangements. The Company expenses incremental costs of obtaining a contract with a Customer (for example, sales commissions) when incurred as the period of benefit is less than one year. Shipping and handling costs for product shipments to Customers are recorded as selling, general and administrative expenses.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Transaction Price, including Estimates of Variable Consideration</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue from products is recognized at the estimated net sales price (transaction price), which includes estimates of variable consideration. The Company includes estimated amounts in the transaction price to the extent it is determined probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The Company&#8217;s estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of its anticipated performance and all information (historical, current and forecasted) that is reasonably available.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Components of Variable Consideration</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Components of variable consideration include provider chargebacks and discounts, trade discounts and allowances, product returns, government rebates, third-party payor rebates, sales order management fees and other incentives, such as voluntary patient assistance and other allowances that are offered within contracts between the Company and its Customers, payors and other indirect customers relating to the Company&#8217;s sale of products. Those components, as described below, are based on the amounts earned, or to be claimed, on the related sales and are presented as reductions of accounts receivable (if the amount is payable to the Customer) or as a current liability (if the amount is payable to a party other than the Customer). The Company considers all relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;text-decoration:underline;">Variable Consideration - Accounts Receivable Reductions</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Provider Chargebacks and Discounts.</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"> </font><font style="font-family:Arial;font-size:10pt;">Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from the Company.&#160;Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers.&#160;These components of variable consideration are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable.&#160;Reserves for chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel inventories at each reporting period-end that the Company expects will be sold to qualified healthcare providers, as well as chargebacks that Customers have claimed, but for which the Company has not yet issued a credit.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;padding-left:24px;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-24px;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Trade Discounts and Allowances.</font><font style="font-family:Arial;font-size:10pt;">  The Company generally provides Customers with discounts that include incentive fees which are explicitly stated in the Company&#8217;s contracts. These discounts are recorded as a reduction of revenue and accounts receivable in the period in which the related product revenue is recognized. In addition, the Company reimburses (through discounts and allowances) its Customers for sales order management, data and distribution services.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:6px;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-6px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;text-decoration:underline;">Variable Consideration - Current Liabilities</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Product Returns.</font><font style="font-family:Arial;font-size:10pt;">  Consistent with industry practice, the Company has a product returns policy that provides Customers a right of return for product purchased within a specified period prior to and subsequent to the product&#8217;s expiration date. The right of return lapses upon shipment of the goods to a patient. The Company estimates the amount of its products that may be returned and presents this amount as a reduction of revenue in the period the related product revenue is recognized, in addition to establishing a liability. The Company considers several factors in the estimation process, including expiration dates of product shipped to preferred pharmacy network partners and wholesalers, inventory levels within the distribution channel, product shelf life, prescription trends and other relevant factors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Government Rebates</font><font style="font-family:Arial;font-size:10pt;">.  The Company is subject to discount obligations under state Medicaid programs and Medicare. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. For Medicaid, accruals are based on estimates of future Medicaid beneficiary utilization applied to the Medicaid unit rebate formula established by the Center for Medicaid and Medicare Services. The Medicare Part&#160;D prescription drug benefit mandates manufacturers to fund approximately 50% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. To estimate the cost to the Company of this Medicare coverage gap responsibility, the Company estimates the number of patients in the prescription drug coverage gap for whom it will owe an additional liability under the Medicare Part D program. The Company&#8217;s liability for these rebates consists of estimates of claims for the current quarter and estimated future claims that will be made for product that has been recognized as revenue but remains in the distribution channel inventories at the end of the reporting period.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Payor Rebates.</font><font style="font-family:Arial;font-size:10pt;">  The Company contracts with certain third-party payors, primarily health insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. These rebates are based on contractual percentages applied to the amount of product prescribed to patients who are covered by the plan or the organization with which it contracts. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Other Incentives.</font><font style="font-family:Arial;font-size:10pt;">  Other incentives that the Company offers include voluntary patient assistance programs, such as co-pay assistance programs, which are intended to provide financial assistance to qualified commercially insured patients with prescription drug co-payments required by payors and coupon programs for cash payors.&#160;The calculation of the accruals for this assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Licensing Revenues</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Through December 31, 2017, the Company's revenues had been generated pursuant to the terms of a single license agreement (the AVP-825 License Agreement) with Avanir Pharmaceuticals,&#160;Inc. (Avanir) (Note&#160;7). The AVP-825 License Agreement included licensed rights to patented technology, non-refundable up-front payment, research services, and regulatory and sales milestones as well as royalty payments. Through </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, under the terms of the AVP-825 License Agreement, the Company received aggregate cash payments of </font><font style="font-family:Arial;font-size:10pt;">$70,000</font><font style="font-family:Arial;font-size:10pt;"> in connection with the initial signing and the achievement of certain development milestones. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On December 10, 2018, the Company received written notice from Avanir of its election to terminate the AVP-825 License Agreement.&#160;As a result, the AVP-825 License Agreement is expected to terminate on March 10, 2019. We do not expect to receive any additional proceeds from the AVP-825 License Agreement.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prior to the receipt of notice of termination of the License Agreement, the Company analyzed the performance obligations under the AVP-825 License Agreement, the consideration received to date and the consideration the Company could have received in the future as part of its analysis related to ASU 2014-09. The consideration received to date, which included an upfront payment, research and development funding and development milestone payments was recognized in prior years and the Company&#8217;s performance obligations pursuant to the arrangement have been completed. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Advertising expenses</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company expenses the costs of advertising, including promotional expenses, as incurred.  Advertising expenses were </font><font style="font-family:Arial;font-size:10pt;">$9,767</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">and</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">$1,833</font><font style="font-family:Arial;font-size:10pt;"> for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">and</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Research and development</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research and development costs are expensed as incurred. Research and development costs consist primarily of device development, clinical trial related costs and regulatory related costs. The Company enters into agreements with contract research organizations (CROs) to facilitate, coordinate and perform agreed upon research and development activities for the Company's clinical trials. These CRO contracts typically call for the payment of fees for services at the initiation of the contract and/or upon the achievement of certain clinical trial milestones. The Company prepays certain CRO fees whereby the prepayments are recorded as a current or non-current prepaid asset and are amortized into research and development expense over the period of time the contracted research and development services were performed. The Company's CRO contracts generally also included other fees such as project management and pass through fees whereby the Company expenses these costs as incurred, using the Company's best estimate. Pass through fees include, but are not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous costs. Pass through fees incurred are based on the amount of work completed for the clinical trials and are monitored through reporting provided by the Company's CROs.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based compensation</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company measures and recognizes compensation expense for all stock options awarded to employees and nonemployees and shares issued under the employee stock purchase plan based on the estimated fair value of the awards on the respective grant dates. The Company uses the Black-Scholes option pricing model to value its stock option awards and shares issued under the employee stock purchase plan. The Company recognizes compensation expense for time-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company recognizes compensation expense for performance based awards when the performance condition is probable of achievement. Stock-based awards issued to nonemployees are revalued at each reporting period until the award vests. The Company accounts for forfeitures of stock option awards as they occur.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Estimating the fair value of options and shares issued under the employee stock purchase plan requires the input of subjective assumptions, including the estimated fair value of the Company's common stock, the expected life of the options, stock price volatility, the risk-free interest rate and expected dividends. The assumptions used in the Company's Black-Scholes option-pricing model represent management's best estimates and involve a number of variables, uncertainties and assumptions and the application of management's judgment, as they are inherently subjective.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Income taxes</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, the Company has concluded that a full valuation allowance is necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest or penalties in the accompanying consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Grant income</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Government grants are agreements that provide cost reimbursement for certain research and development activities over a contractually defined period. Income from government grants is recognized in the period in which related costs are incurred, provided that the conditions under which government grants were provided have been met and only perfunctory obligations are outstanding. Grant income received in excess of costs incurred is recognized as deferred other income.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Net income (loss) per common share</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Basic net income (loss) per common share is determined by dividing net income (loss) applicable to common stockholders by the weighted average common shares outstanding during the period. For the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, the outstanding common stock options and common stock warrants have been excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted net loss per share are the same.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Diluted net loss per common share for the periods presented do not reflect the following potential common shares, as the effect would be antidilutive:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:76%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,182,873</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,141,367</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Common stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,866,831</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,890,489</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Employee stock purchase plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">31,892</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8,081,596</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,031,856</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Recent accounting pronouncements</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In August 2018, the FASB issued ASU No. 2018-15,&#160;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</font><font style="font-family:Arial;font-size:10pt;">.&#160; ASU 2018-15 requires that certain implementation costs incurred in a cloud computing arrangement be deferred and recognized over the term of the arrangement. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on its results of operations, financial position and cash flows and related disclosures.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In August 2018, the FASB issued ASU No. 2018-13,&#160;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:Arial;font-size:10pt;">.&#160; ASU 2018-13 resulted in certain modifications to fair value measurement disclosures, primarily related to level 3 fair value measurements. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on its disclosures.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09,&#160;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Stock&#160;Compensation - Scope of Modification Accounting</font><font style="font-family:Arial;font-size:10pt;">.&#160; ASU 2017-09 provides guidance on which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The new standard is effective for fiscal years beginning after December 15, 2017. The adoption of ASU 2017-09 did not have a material impact on the Company&#8217;s results of operations, financial position, cash flows and related disclosures.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230). </font><font style="font-family:Arial;font-size:10pt;">ASU No. 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The new standard is effective for fiscal years beginning after December 15, 2017. The Company adopted ASU 2016-18 in the first quarter of 2018, and the guidance has been retrospectively applied to all periods presented. The restricted cash balance included in prepaid expenses and other assets was </font><font style="font-family:Arial;font-size:10pt;">$21</font><font style="font-family:Arial;font-size:10pt;"> as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02,</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#160;Leases (Topic 842)</font><font style="font-family:Arial;font-size:10pt;">. The FASB issued the update to require the recognition of lease assets and liabilities on the balance sheet of lessees. The standard will be effective for fiscal years beginning after December&#160;15, 2018, with early adoption permitted. The ASU requires a modified retrospective transition method with the option to elect a package of practical expedients. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following are other key disclosures, as well as determinations made and actions taken by the Company, related to the adoption of ASC 842:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Elected the optional modified retrospective transition method as of January 1, 2019; therefore prior period amounts will not be restated;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Established and implemented key implementation controls to ensure the Company meets the new reporting and disclosure requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Elected the following transition practical expedients:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to not reassess lease identification, lease classification and initial indirect costs related to those leases entered into prior to the adoption of ASC 842;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to not separate lease and non-lease components for our office lease portfolio;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Made policy elections as of January 1, 2019:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to not apply the recognition and measurement requirements to leases with an initial term of one year or less;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to apply the portfolio approach for the development of the discount rate related to leases with similar characteristics;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to keep leases with an immaterial right-of-use asset at inception, off the balance sheet and recognize this expense on a straight-line basis in the consolidated statements of operations;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">While we continue to assess all the effects of adoption, the Company believes the most significant effect relates to the recognition of right-of-use assets and corresponding liabilities on its consolidated balance sheet, primarily related to its existing facility operating leases, and providing new disclosures with regards to the Company&#8217;s leasing activities.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09,&#160;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Arial;font-size:10pt;">, or ASU-2014-09, which replaced numerous requirements in US&#160;GAAP, including industry-specific requirements. This guidance provides a five-step model to be applied to all contracts with customers, with an underlying principle that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The new standard also defines accounting for certain costs related to origination and fulfillment of contracts with customers, including whether such costs should be capitalized.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This statement requires extensive quantitative and qualitative disclosures covering the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including disclosures on significant judgments made when applying the guidance and assets recognized from costs incurred to obtain or fulfill a contract. The guidance was effective for annual reporting periods beginning after December&#160;15, 2017, and interim periods within that reporting period. An entity could elect to apply the guidance under one of the following two methods: (i)&#160;retrospectively to each prior reporting period presented&#160;&#8212; referred to as the full retrospective method or (ii)&#160;retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings&#160;&#8212; referred to as the modified retrospective method.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company assessed the impact that ASU No. 2014-09 had on its financial statements and related disclosures. Through the January 1, 2018 adoption date, the Company has derived its revenues from a single licensing agreement with Avanir (the AVP-825 License Agreement). The consideration the Company has received to date includes an upfront payment, research and development funding and development milestone payments. The Company analyzed the performance obligations under the AVP-825 License Agreement as well as the consideration received to date as part of its analysis of the impact of ASU 2014-09 on this arrangement. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company adopted ASU 2014-09 on January 1, 2018 using the modified retrospective transition method. No transition adjustments were recognized as a result of the adoption. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6930251024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Inventory consisted of the following: </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,969</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,385</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Work-in-process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,344</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">628</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,819</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7,132</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6705734112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Property and equipment, net, consisted of:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Computer equipment and software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">833</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">389</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">89</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Machinery and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,723</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">609</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">28</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Construction in process</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">481</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,035</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,919</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1,151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,884</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,564</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Depreciation expense was </font><font style="font-family:Arial;font-size:10pt;">$535</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">and </font><font style="font-family:Arial;font-size:10pt;">$164</font><font style="font-family:Arial;font-size:10pt;"> for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively.  In addition, depreciation expense of </font><font style="font-family:Arial;font-size:10pt;">$322</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$10</font><font style="font-family:Arial;font-size:10pt;"> is included within inventory and prepaid expenses and other assets, respectively, as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, which represents depreciation expense related to equipment involved in the manufacturing process.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6930258192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Accrued Expenses</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accrued expenses consisted of:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Contract sales organization expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,482</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,432</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Selling, general and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,812</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Research and development expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">933</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">80</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Bonus expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Payroll and benefit expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">564</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">448</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Employee contributions withheld</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Product revenue allowances</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,856</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">435</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">314</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">18,421</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8,698</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6706136304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AVP-825 License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">AVP-825 License Agreement</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">AVP-825 License Agreement</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In July 2013, the Company's wholly owned subsidiary, OptiNose AS, entered into the AVP-825 License Agreement with Avanir for the exclusive right to sell AVP-825 (now marketed as Onzetra</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;"> Xsail</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">), a product combining a low-dose powder form of sumatriptan with the Company's EDS technology platform, for the acute treatment of migraines in adults and any follow-on products under development that consist of a formulation that contains triptans as the sole active ingredient. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Through </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, under the terms of the AVP-825 License Agreement, the Company received aggregate cash payments of </font><font style="font-family:Arial;font-size:10pt;">$70,000</font><font style="font-family:Arial;font-size:10pt;"> in connection with the initial signing and the achievement of certain development milestones. The Company did </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;">t recognize any licensing revenue during the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On December 10, 2018, the Company received written notice from Avanir of its election to terminate the AVP-825 License Agreement.&#160;As a result, the AVP-825 License Agreement is expected to terminate on March 10, 2019.&#160;Upon termination, the Company may elect to continue to commercialize Onzetra Xsail itself or through a new licensee.&#160; We do not expect to receive any additional proceeds from the AVP-825 License Agreement.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6930258192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Notes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Convertible Notes</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On September&#160;30, 2015, the Company entered into a Senior Secured Convertible Note Purchase Agreement (Notes) with various existing stockholders. The Notes provided the Company with up to </font><font style="font-family:Arial;font-size:10pt;">$30,000</font><font style="font-family:Arial;font-size:10pt;"> in capital available in </font><font style="font-family:Arial;font-size:10pt;">two</font><font style="font-family:Arial;font-size:10pt;"> separate tranches.The first tranche of </font><font style="font-family:Arial;font-size:10pt;">$15,000</font><font style="font-family:Arial;font-size:10pt;"> closed on September&#160;30, 2015. The second tranche of up to </font><font style="font-family:Arial;font-size:10pt;">$15,000</font><font style="font-family:Arial;font-size:10pt;"> was available to the Company until March&#160;30, 2017 but was never drawn. The Notes bore an annual interest rate of </font><font style="font-family:Arial;font-size:10pt;">17%</font><font style="font-family:Arial;font-size:10pt;"> and were scheduled to mature on September&#160;30, 2020 if not otherwise converted to Series C-2 shares. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On March&#160;24, 2017, in connection with the Series&#160;D Financing, the Notes and associated accrued interest and back end fees thereon totaling </font><font style="font-family:Arial;font-size:10pt;">$19,527</font><font style="font-family:Arial;font-size:10pt;"> converted into </font><font style="font-family:Arial;font-size:10pt;">687,474</font><font style="font-family:Arial;font-size:10pt;"> shares of Series&#160;C-2 preferred stock at a per share conversion price of approximately </font><font style="font-family:Arial;font-size:10pt;">$28.40</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company recorded interest expense of </font><font style="font-family:Arial;font-size:10pt;">$862</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:10pt;"> in conjunction with the Notes. Total coupon interest on the Notes and back end fees was </font><font style="font-family:Arial;font-size:10pt;">$743</font><font style="font-family:Arial;font-size:10pt;"> during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The front-end fees of </font><font style="font-family:Arial;font-size:10pt;">$450</font><font style="font-family:Arial;font-size:10pt;"> were recorded as debt discount at issuance and were amortized to interest expense over the </font><font style="font-family:Arial;font-size:10pt;">18 months</font><font style="font-family:Arial;font-size:10pt;"> loan conversion period. During the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:10pt;">, the Company recorded a total of </font><font style="font-family:Arial;font-size:10pt;">$75</font><font style="font-family:Arial;font-size:10pt;"> of interest expense related to the front end fees. Additionally, back end fees of </font><font style="font-family:Arial;font-size:10pt;">$450</font><font style="font-family:Arial;font-size:10pt;"> were amortized to interest expense over the </font><font style="font-family:Arial;font-size:10pt;">18 months</font><font style="font-family:Arial;font-size:10pt;"> loan conversion period of which </font><font style="font-family:Arial;font-size:10pt;">$90</font><font style="font-family:Arial;font-size:10pt;"> was recorded as interest expense and as an increase in the carrying amount of the Notes during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:10pt;">. The Company also incurred </font><font style="font-family:Arial;font-size:10pt;">$265</font><font style="font-family:Arial;font-size:10pt;"> in debt issuance costs during the year ended December&#160;31, 2015 which were amortized to interest expense over the </font><font style="font-family:Arial;font-size:10pt;">18 months</font><font style="font-family:Arial;font-size:10pt;"> loan conversion period.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and 2017, </font><font style="font-family:Arial;font-size:10pt;">none</font><font style="font-family:Arial;font-size:10pt;"> of the Notes were outstanding.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Long-term Debt</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On December 29, 2017, the Company entered into a Senior Secured Note Purchase Agreement (the Senior Secured Notes) with Athyrium Opportunities III Acquisition LP. The Senior Secured Notes provided the Company with up to </font><font style="font-family:Arial;font-size:10pt;">$100,000</font><font style="font-family:Arial;font-size:10pt;"> in capital, of which </font><font style="font-family:Arial;font-size:10pt;">$75,000</font><font style="font-family:Arial;font-size:10pt;"> was issued immediately. The remaining </font><font style="font-family:Arial;font-size:10pt;">$25,000</font><font style="font-family:Arial;font-size:10pt;"> (the Delayed Draw Notes) may be issued between April 1, 2019 and August 14, 2019, subject to the Company achieving trailing </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;"> quarter net revenues (as calculated pursuant to the terms of the Note Purchase Agreement)  of </font><font style="font-family:Arial;font-size:10pt;">$15,000</font><font style="font-family:Arial;font-size:10pt;"> and a pro forma ratio of total debt to trailing </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;"> quarter net revenues not exceeding </font><font style="font-family:Arial;font-size:10pt;">6.50</font><font style="font-family:Arial;font-size:10pt;"> to 1.00, and certain other conditions.  </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Senior Secured Notes bear interest at </font><font style="font-family:Arial;font-size:10pt;">9.0%</font><font style="font-family:Arial;font-size:10pt;"> plus the three-month London Inter-bank Offered Rate (LIBOR) rate, subject to a </font><font style="font-family:Arial;font-size:10pt;">1.0%</font><font style="font-family:Arial;font-size:10pt;"> floor and are scheduled to mature on June 29, 2023. The interest rate was </font><font style="font-family:Arial;font-size:10pt;">11.8125%</font><font style="font-family:Arial;font-size:10pt;"> at </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">. The Senior Secured Notes bore front-end fees of </font><font style="font-family:Arial;font-size:10pt;">1%</font><font style="font-family:Arial;font-size:10pt;"> of the aggregate principal amount, which were paid at issuance. The Company is also required to pay an exit fee of </font><font style="font-family:Arial;font-size:10pt;">2%</font><font style="font-family:Arial;font-size:10pt;"> of any principal payments (whether mandatory, voluntary, or at maturity) made throughout the term of the Note Purchase Agreement. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company is required to make quarterly, interest only payments until the maturity date. The Company may make voluntary prepayments of the Senior Secured Notes, in whole or in part, and subject to certain exceptions, is required to make mandatory prepayments upon the occurrence of certain events as defined in the agreement, including, the occurrence of a change of control.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"> All mandatory and voluntary prepayments of the Senior Secured Notes are subject to the payment of prepayment premiums as follows: (i) if prepayment occurs prior to the second anniversary of the applicable date of issuance, an amount equal to the amount by which (a) the present value of </font><font style="font-family:Arial;font-size:10pt;">102%</font><font style="font-family:Arial;font-size:10pt;"> of the principal prepaid plus all interest that would have accrued on such principal through such second anniversary exceeds (b) the amount of principal prepaid, (ii) if prepayment occurs on or after the second anniversary of the applicable date of issuance but prior to the third anniversary of such issuance, an amount equal to </font><font style="font-family:Arial;font-size:10pt;">2%</font><font style="font-family:Arial;font-size:10pt;"> of the principal prepaid, and (iii) if prepayment occurs on or after the third anniversary of the applicable date of issuance but prior to the fourth anniversary of such issuance, an amount equal to </font><font style="font-family:Arial;font-size:10pt;">1%</font><font style="font-family:Arial;font-size:10pt;"> of the principal prepaid. </font><font style="font-family:Arial;font-size:10pt;">No</font><font style="font-family:Arial;font-size:10pt;"> prepayment premium is due on any principal prepaid after the fourth anniversary of the applicable date of issuance of any Senior Secured Notes.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Senior Secured Notes are secured by a pledge of substantially&#160;all of the Company&#8217;s assets and contains affirmative and negative covenants customary for financings of this type, including limitations on the Company&#8217;s and its subsidiaries&#8217; ability to, among other things, incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, grant certain license rights related to the Company's products, technology and other intellectual property rights, pay dividends and distributions, repay junior indebtedness and enter into affiliate transactions, in each case, subject to certain exceptions.  In addition, the Senior Secured Notes contains financial covenants requiring the Company to maintain (i) at least </font><font style="font-family:Arial;font-size:10pt;">$10,000</font><font style="font-family:Arial;font-size:10pt;"> of cash and cash equivalents and (ii) following the issuance of the Delayed Draw Notes or upon entering into certain exclusive licenses of XHANCE, a total debt to trailing </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;"> quarter net revenue ratio of less than </font><font style="font-family:Arial;font-size:10pt;">6.50</font><font style="font-family:Arial;font-size:10pt;"> to 1.00 initially, and thereafter declining quarterly by equal half-steps to a ratio of less than </font><font style="font-family:Arial;font-size:10pt;">3.00</font><font style="font-family:Arial;font-size:10pt;"> to 1.00. As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company was in compliance with the covenants.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company recorded interest expense of </font><font style="font-family:Arial;font-size:10pt;">$9,229</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$48</font><font style="font-family:Arial;font-size:10pt;"> during the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively, in conjunction with the Senior Secured Notes. Interest expense included total coupon interest, back end fees, front end fees and the amortization of debt issuance costs. The front-end fees of </font><font style="font-family:Arial;font-size:10pt;">$1,000</font><font style="font-family:Arial;font-size:10pt;"> were recorded as debt discount at issuance and are being amortized to interest expense over the </font><font style="font-family:Arial;font-size:10pt;">5.5</font><font style="font-family:Arial;font-size:10pt;"> year term of the loan. Additionally, back end fees of </font><font style="font-family:Arial;font-size:10pt;">$2,000</font><font style="font-family:Arial;font-size:10pt;"> are being amortized to interest expense and are recorded as an increase in the carrying amount throughout the term of the Senior Secured Notes. The Company also incurred </font><font style="font-family:Arial;font-size:10pt;">$2,181</font><font style="font-family:Arial;font-size:10pt;"> in debt issuance costs during the year ended December&#160;31, 2017 which are also being amortized to interest expense over the term of the Senior Secured Notes.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, the long-term debt balance is comprised of the following:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:77%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Face amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">75,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">75,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Front end fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(872</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(999</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1,902</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(2,139</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Back end fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">274</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">72,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">71,863</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6636595056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Convertible Notes</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On September&#160;30, 2015, the Company entered into a Senior Secured Convertible Note Purchase Agreement (Notes) with various existing stockholders. The Notes provided the Company with up to </font><font style="font-family:Arial;font-size:10pt;">$30,000</font><font style="font-family:Arial;font-size:10pt;"> in capital available in </font><font style="font-family:Arial;font-size:10pt;">two</font><font style="font-family:Arial;font-size:10pt;"> separate tranches.The first tranche of </font><font style="font-family:Arial;font-size:10pt;">$15,000</font><font style="font-family:Arial;font-size:10pt;"> closed on September&#160;30, 2015. The second tranche of up to </font><font style="font-family:Arial;font-size:10pt;">$15,000</font><font style="font-family:Arial;font-size:10pt;"> was available to the Company until March&#160;30, 2017 but was never drawn. The Notes bore an annual interest rate of </font><font style="font-family:Arial;font-size:10pt;">17%</font><font style="font-family:Arial;font-size:10pt;"> and were scheduled to mature on September&#160;30, 2020 if not otherwise converted to Series C-2 shares. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On March&#160;24, 2017, in connection with the Series&#160;D Financing, the Notes and associated accrued interest and back end fees thereon totaling </font><font style="font-family:Arial;font-size:10pt;">$19,527</font><font style="font-family:Arial;font-size:10pt;"> converted into </font><font style="font-family:Arial;font-size:10pt;">687,474</font><font style="font-family:Arial;font-size:10pt;"> shares of Series&#160;C-2 preferred stock at a per share conversion price of approximately </font><font style="font-family:Arial;font-size:10pt;">$28.40</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company recorded interest expense of </font><font style="font-family:Arial;font-size:10pt;">$862</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:10pt;"> in conjunction with the Notes. Total coupon interest on the Notes and back end fees was </font><font style="font-family:Arial;font-size:10pt;">$743</font><font style="font-family:Arial;font-size:10pt;"> during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The front-end fees of </font><font style="font-family:Arial;font-size:10pt;">$450</font><font style="font-family:Arial;font-size:10pt;"> were recorded as debt discount at issuance and were amortized to interest expense over the </font><font style="font-family:Arial;font-size:10pt;">18 months</font><font style="font-family:Arial;font-size:10pt;"> loan conversion period. During the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:10pt;">, the Company recorded a total of </font><font style="font-family:Arial;font-size:10pt;">$75</font><font style="font-family:Arial;font-size:10pt;"> of interest expense related to the front end fees. Additionally, back end fees of </font><font style="font-family:Arial;font-size:10pt;">$450</font><font style="font-family:Arial;font-size:10pt;"> were amortized to interest expense over the </font><font style="font-family:Arial;font-size:10pt;">18 months</font><font style="font-family:Arial;font-size:10pt;"> loan conversion period of which </font><font style="font-family:Arial;font-size:10pt;">$90</font><font style="font-family:Arial;font-size:10pt;"> was recorded as interest expense and as an increase in the carrying amount of the Notes during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:10pt;">. The Company also incurred </font><font style="font-family:Arial;font-size:10pt;">$265</font><font style="font-family:Arial;font-size:10pt;"> in debt issuance costs during the year ended December&#160;31, 2015 which were amortized to interest expense over the </font><font style="font-family:Arial;font-size:10pt;">18 months</font><font style="font-family:Arial;font-size:10pt;"> loan conversion period.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and 2017, </font><font style="font-family:Arial;font-size:10pt;">none</font><font style="font-family:Arial;font-size:10pt;"> of the Notes were outstanding.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Long-term Debt</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On December 29, 2017, the Company entered into a Senior Secured Note Purchase Agreement (the Senior Secured Notes) with Athyrium Opportunities III Acquisition LP. The Senior Secured Notes provided the Company with up to </font><font style="font-family:Arial;font-size:10pt;">$100,000</font><font style="font-family:Arial;font-size:10pt;"> in capital, of which </font><font style="font-family:Arial;font-size:10pt;">$75,000</font><font style="font-family:Arial;font-size:10pt;"> was issued immediately. The remaining </font><font style="font-family:Arial;font-size:10pt;">$25,000</font><font style="font-family:Arial;font-size:10pt;"> (the Delayed Draw Notes) may be issued between April 1, 2019 and August 14, 2019, subject to the Company achieving trailing </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;"> quarter net revenues (as calculated pursuant to the terms of the Note Purchase Agreement)  of </font><font style="font-family:Arial;font-size:10pt;">$15,000</font><font style="font-family:Arial;font-size:10pt;"> and a pro forma ratio of total debt to trailing </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;"> quarter net revenues not exceeding </font><font style="font-family:Arial;font-size:10pt;">6.50</font><font style="font-family:Arial;font-size:10pt;"> to 1.00, and certain other conditions.  </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Senior Secured Notes bear interest at </font><font style="font-family:Arial;font-size:10pt;">9.0%</font><font style="font-family:Arial;font-size:10pt;"> plus the three-month London Inter-bank Offered Rate (LIBOR) rate, subject to a </font><font style="font-family:Arial;font-size:10pt;">1.0%</font><font style="font-family:Arial;font-size:10pt;"> floor and are scheduled to mature on June 29, 2023. The interest rate was </font><font style="font-family:Arial;font-size:10pt;">11.8125%</font><font style="font-family:Arial;font-size:10pt;"> at </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">. The Senior Secured Notes bore front-end fees of </font><font style="font-family:Arial;font-size:10pt;">1%</font><font style="font-family:Arial;font-size:10pt;"> of the aggregate principal amount, which were paid at issuance. The Company is also required to pay an exit fee of </font><font style="font-family:Arial;font-size:10pt;">2%</font><font style="font-family:Arial;font-size:10pt;"> of any principal payments (whether mandatory, voluntary, or at maturity) made throughout the term of the Note Purchase Agreement. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company is required to make quarterly, interest only payments until the maturity date. The Company may make voluntary prepayments of the Senior Secured Notes, in whole or in part, and subject to certain exceptions, is required to make mandatory prepayments upon the occurrence of certain events as defined in the agreement, including, the occurrence of a change of control.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"> All mandatory and voluntary prepayments of the Senior Secured Notes are subject to the payment of prepayment premiums as follows: (i) if prepayment occurs prior to the second anniversary of the applicable date of issuance, an amount equal to the amount by which (a) the present value of </font><font style="font-family:Arial;font-size:10pt;">102%</font><font style="font-family:Arial;font-size:10pt;"> of the principal prepaid plus all interest that would have accrued on such principal through such second anniversary exceeds (b) the amount of principal prepaid, (ii) if prepayment occurs on or after the second anniversary of the applicable date of issuance but prior to the third anniversary of such issuance, an amount equal to </font><font style="font-family:Arial;font-size:10pt;">2%</font><font style="font-family:Arial;font-size:10pt;"> of the principal prepaid, and (iii) if prepayment occurs on or after the third anniversary of the applicable date of issuance but prior to the fourth anniversary of such issuance, an amount equal to </font><font style="font-family:Arial;font-size:10pt;">1%</font><font style="font-family:Arial;font-size:10pt;"> of the principal prepaid. </font><font style="font-family:Arial;font-size:10pt;">No</font><font style="font-family:Arial;font-size:10pt;"> prepayment premium is due on any principal prepaid after the fourth anniversary of the applicable date of issuance of any Senior Secured Notes.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Senior Secured Notes are secured by a pledge of substantially&#160;all of the Company&#8217;s assets and contains affirmative and negative covenants customary for financings of this type, including limitations on the Company&#8217;s and its subsidiaries&#8217; ability to, among other things, incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, grant certain license rights related to the Company's products, technology and other intellectual property rights, pay dividends and distributions, repay junior indebtedness and enter into affiliate transactions, in each case, subject to certain exceptions.  In addition, the Senior Secured Notes contains financial covenants requiring the Company to maintain (i) at least </font><font style="font-family:Arial;font-size:10pt;">$10,000</font><font style="font-family:Arial;font-size:10pt;"> of cash and cash equivalents and (ii) following the issuance of the Delayed Draw Notes or upon entering into certain exclusive licenses of XHANCE, a total debt to trailing </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;"> quarter net revenue ratio of less than </font><font style="font-family:Arial;font-size:10pt;">6.50</font><font style="font-family:Arial;font-size:10pt;"> to 1.00 initially, and thereafter declining quarterly by equal half-steps to a ratio of less than </font><font style="font-family:Arial;font-size:10pt;">3.00</font><font style="font-family:Arial;font-size:10pt;"> to 1.00. As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company was in compliance with the covenants.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company recorded interest expense of </font><font style="font-family:Arial;font-size:10pt;">$9,229</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$48</font><font style="font-family:Arial;font-size:10pt;"> during the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively, in conjunction with the Senior Secured Notes. Interest expense included total coupon interest, back end fees, front end fees and the amortization of debt issuance costs. The front-end fees of </font><font style="font-family:Arial;font-size:10pt;">$1,000</font><font style="font-family:Arial;font-size:10pt;"> were recorded as debt discount at issuance and are being amortized to interest expense over the </font><font style="font-family:Arial;font-size:10pt;">5.5</font><font style="font-family:Arial;font-size:10pt;"> year term of the loan. Additionally, back end fees of </font><font style="font-family:Arial;font-size:10pt;">$2,000</font><font style="font-family:Arial;font-size:10pt;"> are being amortized to interest expense and are recorded as an increase in the carrying amount throughout the term of the Senior Secured Notes. The Company also incurred </font><font style="font-family:Arial;font-size:10pt;">$2,181</font><font style="font-family:Arial;font-size:10pt;"> in debt issuance costs during the year ended December&#160;31, 2017 which are also being amortized to interest expense over the term of the Senior Secured Notes.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, the long-term debt balance is comprised of the following:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:77%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Face amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">75,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">75,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Front end fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(872</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(999</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1,902</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(2,139</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Back end fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">274</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">72,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">71,863</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6930084432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Employee Benefit Plans</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For US employees, the Company maintains a defined contribution 401(k) retirement plan, which covers all employees. Employees are eligible to participate in the plan on the first of the month following their date of hire. Under the 401(k)&#160;retirement plan, participating employees may defer up to </font><font style="font-family:Arial;font-size:10pt;">100%</font><font style="font-family:Arial;font-size:10pt;"> of their pre-tax salary, but not more than statutory limits. In October 2017, the Company adopted a 401(k) matching program for its US employees. The Company matches </font><font style="font-family:Arial;font-size:10pt;">100%</font><font style="font-family:Arial;font-size:10pt;"> of the first </font><font style="font-family:Arial;font-size:10pt;">3%</font><font style="font-family:Arial;font-size:10pt;"> of participating employee contributions and </font><font style="font-family:Arial;font-size:10pt;">50%</font><font style="font-family:Arial;font-size:10pt;"> of the next </font><font style="font-family:Arial;font-size:10pt;">2%</font><font style="font-family:Arial;font-size:10pt;"> of participating employee contributions, subject to applicable IRC limits. The Company incurred costs of  $</font><font style="font-family:Arial;font-size:10pt;">645</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$230</font><font style="font-family:Arial;font-size:10pt;"> related to the Company match applicable to employee contributions for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">. The Company's contributions are made in cash. The Company's common stock is not currently an investment option available to participants in the 401(k) retirement plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For Norway and UK employees, the Company maintains defined contribution pension plans which meet statutory requirements of those jurisdictions. The Company incurred costs of $</font><font style="font-family:Arial;font-size:10pt;">81</font><font style="font-family:Arial;font-size:10pt;"> and $</font><font style="font-family:Arial;font-size:10pt;">56</font><font style="font-family:Arial;font-size:10pt;"> related to the pension plans for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763440592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company leases office space under </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;"> operating leases and has leases for certain other equipment. Rent expense is recognized as incurred.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following is a schedule of future minimum annual payments as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> under operating lease agreements:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:89%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">For the years ending December 31:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,630</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,107</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">391</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total future minimum lease payments as of December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,128</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Rent expense related to leases of office space was $</font><font style="font-family:Arial;font-size:10pt;">831</font><font style="font-family:Arial;font-size:10pt;"> and $</font><font style="font-family:Arial;font-size:10pt;">689</font><font style="font-family:Arial;font-size:10pt;"> for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In January 2018, the Company amended its existing office lease agreement for the Company&#8217;s headquarters in Yardley, PA (the Lease Amendment). Under the terms of the Lease Amendment, the Company&#8217;s leased office space was increased from approximately </font><font style="font-family:Arial;font-size:10pt;">20,050</font><font style="font-family:Arial;font-size:10pt;"> square feet to approximately </font><font style="font-family:Arial;font-size:10pt;">30,000</font><font style="font-family:Arial;font-size:10pt;"> square feet, and the term of the lease was extended from March 31, 2018 to May 31, 2021 (the Extended Term), with an option to renew the lease for an additional </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;">-year term.&#160;The Company&#8217;s rent payments during the Extended Term will be approximately </font><font style="font-family:Arial;font-size:10pt;">$2,750</font><font style="font-family:Arial;font-size:10pt;"> in the aggregate, and the Company will also be required to pay its proportionate share of certain operating costs and property taxes applicable to the leased premises.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Purchase commitments</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In November 2017, the Company entered into an agreement with a contract sales organization for the recruitment, deployment and management of a contract sales force to market XHANCE in the US. Subject to certain limited exceptions, the Company could not terminate this agreement until after the first anniversary of the deployment of the sales force (which occurred in March 2018). In December 2018, as a result of the Company's decision to manage its sales force directly, the Company terminated the agreement effective April 1, 2019 and accrued an early termination fee of </font><font style="font-family:Arial;font-size:10pt;">$691</font><font style="font-family:Arial;font-size:10pt;">. The Company estimates the expenses related to the remaining non-cancellable services, all of which will be provided in 2019, to be approximately </font><font style="font-family:Arial;font-size:10pt;">$2,335</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company had </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;"> other material outstanding non-cancellable purchase commitments related to inventory and other goods and services, including pre-commercial manufacturing scale-up and sales and marketing activities.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Employment agreements</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has entered into employment contracts with its officers and certain employees that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Litigation</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. There are no matters currently outstanding.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6706018304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Stockholders' equity</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Common stock</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In October 2017, the Company increased the number of authorized common shares from </font><font style="font-family:Arial;font-size:10pt;">10,624,486</font><font style="font-family:Arial;font-size:10pt;"> to </font><font style="font-family:Arial;font-size:10pt;">200,000,000</font><font style="font-family:Arial;font-size:10pt;"> and completed an initial public offering (IPO) of its common stock, selling </font><font style="font-family:Arial;font-size:10pt;">8,625,000</font><font style="font-family:Arial;font-size:10pt;"> shares at </font><font style="font-family:Arial;font-size:10pt;">$16.00</font><font style="font-family:Arial;font-size:10pt;"> per share.  As a result of the IPO, the Company received </font><font style="font-family:Arial;font-size:10pt;">$125,471</font><font style="font-family:Arial;font-size:10pt;"> in net proceeds, after deducting discounts and commissions of </font><font style="font-family:Arial;font-size:10pt;">$9,660</font><font style="font-family:Arial;font-size:10pt;"> and offering expenses of approximately </font><font style="font-family:Arial;font-size:10pt;">$2,869</font><font style="font-family:Arial;font-size:10pt;"> payable by the Company. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On June 11, 2018, the Company and certain stockholders closed the Offering of </font><font style="font-family:Arial;font-size:10pt;">5,750,000</font><font style="font-family:Arial;font-size:10pt;"> shares of Common Stock at a price of </font><font style="font-family:Arial;font-size:10pt;">$22.25</font><font style="font-family:Arial;font-size:10pt;"> per share. The Offering consisted of </font><font style="font-family:Arial;font-size:10pt;">2,875,000</font><font style="font-family:Arial;font-size:10pt;"> shares of Common Stock sold by the Company and </font><font style="font-family:Arial;font-size:10pt;">2,875,000</font><font style="font-family:Arial;font-size:10pt;"> shares of Common Stock sold by certain stockholders. As a result of the Offering, the Company received </font><font style="font-family:Arial;font-size:10pt;">$59,917</font><font style="font-family:Arial;font-size:10pt;"> in net proceeds, after deducting discounts and commissions of </font><font style="font-family:Arial;font-size:10pt;">$3,678</font><font style="font-family:Arial;font-size:10pt;"> and offering expenses of approximately </font><font style="font-family:Arial;font-size:10pt;">$373</font><font style="font-family:Arial;font-size:10pt;"> payable by the Company.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Each share of common stock entitles the holder to </font><font style="font-family:Arial;font-size:10pt;">one</font><font style="font-family:Arial;font-size:10pt;"> vote on all matters submitted to a vote of the Company&#8217;s stockholders. Subject to preferences that may apply to any outstanding preferred stock, holders of common stock are entitled to receive ratably any dividends that the Company&#8217;s board of directors may declare out of funds legally available for that purpose on a non-cumulative basis. </font><font style="font-family:Arial;font-size:10pt;">No</font><font style="font-family:Arial;font-size:10pt;"> dividends had been declared through </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Common stock warrants</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company had </font><font style="font-family:Arial;font-size:10pt;">1,866,831</font><font style="font-family:Arial;font-size:10pt;"> warrants outstanding to purchase shares of the Company's common stock with an exercise price of </font><font style="font-family:Arial;font-size:10pt;">$8.16</font><font style="font-family:Arial;font-size:10pt;">. The warrants expire on November 1, 2020.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Redeemable convertible preferred stock</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the year ended December&#160;31, 2017, the Company sold </font><font style="font-family:Arial;font-size:10pt;">1,117,578</font><font style="font-family:Arial;font-size:10pt;"> shares of Series&#160;D Preferred Stock at a per share purchase price of </font><font style="font-family:Arial;font-size:10pt;">$32.85</font><font style="font-family:Arial;font-size:10pt;">, resulting in gross proceeds to the Company of </font><font style="font-family:Arial;font-size:10pt;">$36,712</font><font style="font-family:Arial;font-size:10pt;"> (the Series&#160;D Financing). In connection with the Series&#160;D Financing, the Company's existing convertible notes and associated accrued interest and back end fees thereon totaling </font><font style="font-family:Arial;font-size:10pt;">$19,527</font><font style="font-family:Arial;font-size:10pt;"> converted into </font><font style="font-family:Arial;font-size:10pt;">687,474</font><font style="font-family:Arial;font-size:10pt;"> shares of Series&#160;C-2 Preferred Stock at a per share conversion price of approximately </font><font style="font-family:Arial;font-size:10pt;">$28.40</font><font style="font-family:Arial;font-size:10pt;"> (Note&#160;8).</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upon consummation of the IPO in October 2017, all of the outstanding shares of the Company's redeemable convertible preferred stock were converted into an aggregate of </font><font style="font-family:Arial;font-size:10pt;">25,068,556</font><font style="font-family:Arial;font-size:10pt;"> shares of common stock. In connection with the IPO, </font><font style="font-family:Arial;font-size:10pt;">5,000,000</font><font style="font-family:Arial;font-size:10pt;"> shares of preferred stock, with a par value of </font><font style="font-family:Arial;font-size:10pt;">$0.001</font><font style="font-family:Arial;font-size:10pt;"> per share, were authorized for issuance. As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;"> preferred stock was issued or outstanding.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6652476608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Stock-based compensation</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company issues stock-based awards pursuant to its 2010 Stock Incentive Plan. Effective as of October 12, 2017, the Company's 2010 Stock Incentive Plan was amended and restated (A&amp;R Plan). The A&amp;R Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units, deferred stock units, performance shares, stock appreciation rights and other equity-based awards. The Company's employees, officers, directors and other persons are eligible to receive awards under the A&amp;R Plan. As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">8,406,547</font><font style="font-family:Arial;font-size:10pt;"> shares of the Company's common stock were authorized to be issued under the A&amp;R Plan, and </font><font style="font-family:Arial;font-size:10pt;">1,635,295</font><font style="font-family:Arial;font-size:10pt;">&#160;shares were reserved for future awards under the A&amp;R Plan. The number of shares of the Company's common stock authorized under the A&amp;R Plan will automatically increase on January&#160;1st of each year, commencing on January&#160;1, 2018 and continuing until the expiration of the A&amp;R Plan, in an amount equal to </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;"> percent of the total number of shares of the Company's common stock outstanding on December&#160;31</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">st</sup></font><font style="font-family:Arial;font-size:10pt;"> of the preceding calendar year, subject to the discretion of the Company's board of directors or compensation committee to determine a lesser number of shares shall be added for such year.&#160;</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The amount, terms of grants, and exercisability provisions are determined and set by the Company's board of directors or compensation committee. The Company measures employee stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. Stock-based awards issued to non-employees are revalued until the award vests. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Stock options</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has issued service-based and performance-based stock options that generally have a contractual life of up to </font><font style="font-family:Arial;font-size:10pt;">10</font><font style="font-family:Arial;font-size:10pt;">&#160;years and may be exercisable in cash or as otherwise determined by the board of directors. Vesting generally occurs over a period of not greater than </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;"> years. Performance-based options may vest upon the achievement of certain milestones in connection with the Company's development programs. Additionally, the Company has issued stock options in excess of the fair market value of Common Stock on the issuance date that were only exercisable upon a change in control or upon or after an initial public offering. As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, all of the performance conditions related to performance-based stock options issued by the Company have been achieved.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes the activity related to stock option grants to employees and nonemployees for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">exercise price</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">contractual life</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Outstanding at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,251,589</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">9.34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.67</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">472,792</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">19.36</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(491,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(49,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">9.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Outstanding at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,182,873</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.60</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.48</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Exercisable at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,804,999</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.09</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Vested and expected to vest at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,182,873</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.60</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.48</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, stock options to purchase </font><font style="font-family:Arial;font-size:10pt;">472,792</font><font style="font-family:Arial;font-size:10pt;"> shares of common stock were granted to employees that generally vest over </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;"> years. The options had an estimated weighted average grant date fair value of </font><font style="font-family:Arial;font-size:10pt;">$12.85</font><font style="font-family:Arial;font-size:10pt;">. The grant date fair value of each option grant was estimated at the time of grant using the Black-Scholes option-pricing model. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The total aggregate intrinsic value of stock options exercised during the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">and</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;"> was </font><font style="font-family:Arial;font-size:10pt;">$9,255</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">and </font><font style="font-family:Arial;font-size:10pt;">$435</font><font style="font-family:Arial;font-size:10pt;">, respectively. The aggregate intrinsic value of stock options outstanding and stock options exercisable as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> was </font><font style="font-family:Arial;font-size:10pt;">$8,470</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$8,028</font><font style="font-family:Arial;font-size:10pt;">, respectively. At </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, the unrecognized compensation cost related to unvested stock options expected to vest was </font><font style="font-family:Arial;font-size:10pt;">$20,405</font><font style="font-family:Arial;font-size:10pt;">. This unrecognized compensation will be recognized over an estimated weighted-average amortization period of </font><font style="font-family:Arial;font-size:10pt;">2.7 years</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">2017 Employee Stock Purchase Plan </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company's 2017 Employee Stock Purchase Plan (the 2017 Plan) became effective on October 12, 2017. As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">,&#160;</font><font style="font-family:Arial;font-size:10pt;">522,420</font><font style="font-family:Arial;font-size:10pt;"> shares of the Company's common stock were authorized to be issued pursuant to purchase rights granted to its employees or to employees of any of its participating affiliates under the 2017 Plan. 469,283 shares of the Company's common stock were reserved for future issuance under the 2017 Plan. The number of shares of the Company's common stock that may be issued pursuant to rights granted under the 2017 Plan shall automatically increase on January&#160;1st of each year, commencing on January&#160;1, 2018 and continuing until the expiration of the 2017 Plan, in an amount equal to </font><font style="font-family:Arial;font-size:10pt;">one</font><font style="font-family:Arial;font-size:10pt;"> percent of the total number of shares of the Company's common stock outstanding on December&#160;31st of the preceding calendar year, subject to the discretion of the board of directors or compensation committee to determine a lesser number of shares shall be added for such year.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Under the 2017 Plan, eligible employees can purchase the Company&#8217;s common stock through accumulated payroll deductions at such times as are established by the administrator. The 2017 Plan is administered by the compensation committee. Under the 2017 Plan, eligible employees may purchase the Company&#8217;s common stock at 85% of the lesser of the average high and low sales price of the Company's common stock on (i) the first trading day of the relevant offering period and (ii) on the last trading day of the relevant offering period (or, if the relevant offering period has multiple purchase periods, the last trading day of the relevant purchase period). Eligible employees may contribute up to 15% of their eligible compensation. Under the 2017 Plan, a participant may not accrue rights to purchase more than $25 worth of the Company&#8217;s common stock for each calendar year in which such right is outstanding.&#160;</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Effective October 12, 2017, employees who elected to participate in the 2017 Plan commenced payroll withholdings that accumulated through June 30, 2018.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Beginning on January 1, 2018, employees who elected to participate in the 2017 Plan commenced payroll withholdings that accumulate during the following six month offering periods each calendar year while the Purchase Plan is effective:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">January 1 through June 30, and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">July 1 through December 31.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">At the end of each offering period, shares of the Company&#8217;s common stock may be purchased at 85% of the lesser of the average of the high and low sales price of the Company&#8217;s common stock on (i) the first trading day of the relevant offering period and (ii) the last trading day of the relevant offering period (or, if the relevant offering period has multiple purchase periods, the last trading day of the relevant purchase period). In accordance with the guidance in ASC 718-50 &#8211;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#160;Compensation &#8211; Stock Compensation</font><font style="font-family:Arial;font-size:10pt;">, the ability to purchase shares of the Company&#8217;s common stock at the lower of the price on the first day of the offering period or the last day of the offering period (i.e. the purchase date) represents an option and, therefore, the 2017 Plan is a compensatory plan under this guidance. Accordingly, stock-based compensation expense is determined based on the option&#8217;s grant-date fair value as estimated by applying the Black Scholes option-pricing model and is recognized over the requisite service period of the option. The Company has recognized stock-based compensation expense of </font><font style="font-family:Arial;font-size:10pt;">$446</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">and</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">$106</font><font style="font-family:Arial;font-size:10pt;"> during the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively, related to the 2017 Plan.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based compensation expense</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company recorded stock-based compensation expense in the following expense categories of its accompanying consolidated statements of operations for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and  </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cost of product sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">989</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,288</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7,545</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,808</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8,543</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,096</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition, stock-based compensation expense of </font><font style="font-family:Arial;font-size:10pt;">$99</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$2</font><font style="font-family:Arial;font-size:10pt;"> is included within inventory and prepaid expenses and other assets, respectively, as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, which represents the total stock-based compensation expense incurred related to employees involved in the manufacturing process of finished goods and samples during the period.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company utilized the Black-Scholes valuation model for estimating the fair value of stock options granted and the option component of the 2017 Plan. The Company calculated the fair value of each option grant and the option component of the 2017 Plan on the respective dates of grant using the following weighted average assumptions: </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2010 A&amp;R Stock Incentive Plan</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017 Employee Stock Purchase Plan</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Risk free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expected term (in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.95</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.64</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">74.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">80.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Annual dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Option valuation methods, including Black-Scholes, require the input of subjective assumptions, which are discussed below.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The expected term of employee options is determined using the "simplified" method, as prescribed in SEC's Staff Accounting Bulletin (SAB) No.&#160;107, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company's lack of sufficient historical data. The expected term of nonemployee options is equal to the contractual term.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The expected volatility is based on historical volatilities of similar entities within the Company's industry which were commensurate with the expected term assumption as described in SAB No.&#160;107.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The risk-free interest rate is based on the interest rate payable on US Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The expected dividend yield is </font><font style="font-family:Arial;font-size:10pt;">0%</font><font style="font-family:Arial;font-size:10pt;"> because the Company has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.</font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6629474992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Income taxes</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Tax Cuts and Jobs Act (TCJA) was enacted on December 22, 2017 with most changes effective January 1, 2018. Among other changes, the TCJA significantly lowered the US corporate income tax rate from 35% to 21% as of January 1, 2018. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse. As a result of the reduction in the US corporate income tax rate, the Company revalued its net deferred tax assets at December&#160;31, 2017. Due to the full valuation allowance on the Company's deferred tax assets, no tax expense or benefit associated with the re-measurement was recognized in the Company's consolidated statement of operations for the year ended December&#160;31, 2017. The change in the US corporate tax rate is also included in the Company&#8217;s deferred tax table.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The TCJA provided for a one-time transition tax on the deemed repatriation of post-1986 undistributed foreign subsidiary earnings and profits (E&amp;P). As the Company's foreign subsidiaries did not have accumulated E&amp;P, the Company did not record any income tax expense related to the transition tax.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Due to the timing of and the substantial changes made by the TCJA, the Staff of the Securities and Exchange Commission (SEC) issued Staff Accounting Bulletin No. 118 (SAB 118), which provides registrants a measurement period to report the impact of the new US tax law.&#160;During the measurement period, provisional amounts for the effects of the law are recorded to the extent a reasonable estimate can be made.&#160;To the extent that all information necessary is not available, prepared or analyzed, companies may recognize provisional estimated amounts for a period of up to one year following enactment of the TCJA. Accordingly, the Company recorded a preliminary estimate of the impact of the TCJA and the re-measurement of its deferred tax assets and liabilities in 2017. The Company finalized its analysis of the impact of the TCJA and recorded the adjustment, which was not material, in 2018.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Income taxes have been recorded on the following book income (loss) before income tax expense:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Domestic operations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(146,247</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(30,463</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">39,589</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(18,439</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Loss before provision for income taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(106,658</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(48,902</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A reconciliation of income tax expense (benefit) at the US federal statutory income tax rate and the income tax provision in the financial statements is as follows: </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:54%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Income tax expense at statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">21.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Permanent items</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Foreign rate differential</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(4.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Impact of foreign operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(7.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;State taxes, net of federal benefit</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Tax rate changes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(15.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Foreign exchange and other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Change in valuation allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(16.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(16.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Effective income tax rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Tax rate changes includes the impact of the reduction in the US tax rate in 2017 under the TCJA and a reduction in the Norway tax rate in both 2017 and 2018.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The principal components of the Company&#8217;s deferred tax assets and liabilities are as follows: </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.44054580896686%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Deferred tax assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,674</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">972</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Prepaid licensing arrangement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">11,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">55</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Interest expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,267</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">783</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Stock compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,493</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,701</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Research and development credits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,485</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,485</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Net operating losses </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">32,548</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">29,636</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;Total deferred tax assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">53,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">35,632</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Deferred tax liabilities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Fixed assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(409</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;Total deferred tax liabilities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(409</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Less: Valuation allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(52,620</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(35,632</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total net deferred tax assets (liabilities)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During 2018, our wholly-owned subsidiary in Norway licensed certain intellectual property rights related to XHANCE to our US subsidiary. While this transaction did not result in any gain or loss in the condensed consolidated statements of operations, the transaction generated taxable income in both Norway and the US. Norway tax loss carryforwards were utilized to offset the taxable income in Norway and the income reduced the current year US taxable loss.  There were no cash taxes associated with the transaction.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The TCJA, in addition to the changes indicated above, contained other provisions that may have a future impact on the Company. The provisions include limitations on the deductibility of interest based on the amount of adjusted taxable income, the deferral of research and development deductions, the acceleration of deductions related to fixed asset additions, changes to the utilization of net operating loss carry forwards and changes in the carry forward period, and global intangible low-taxed income provisions that subject foreign subsidiary income that exceeds an allowable return to current US taxation.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company had foreign net operating loss (NOL) carry forwards of </font><font style="font-family:Arial;font-size:10pt;">$50,513</font><font style="font-family:Arial;font-size:10pt;"> primarily from its operations in Norway. As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company had federal and state NOLs of </font><font style="font-family:Arial;font-size:10pt;">$86,574</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$57,017</font><font style="font-family:Arial;font-size:10pt;">, respectively. These domestic NOL carry forwards may be subject to an annual limitation in the event of cumulative changes in the ownership interests of significant stockholders over a three&#8209;year period in excess of 50%. This could limit the amount of NOLs that the Company can utilize annually to offset future domestic taxable income, if any. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The federal NOL generated in 2018 has an indefinite carry forward period. The federal NOLs generated prior to 2018 will expire from 2030 through 2037. Some state NOLs will not expire while other state NOLs expire over various periods depending on the rules of the jurisdiction in which they were generated. The earliest state NOL expiration is in 2028.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ASC 740 requires the establishment of a valuation allowance to reduce deferred tax assets if, based on the weight of the available positive and negative evidence it is more likely than not that all or a portion of the deferred tax assets will not be realized. There is insufficient positive evidence to overcome the negative evidence attributable to the Company&#8217;s cumulative operating losses. Consequently, the Company established a full valuation allowance against its net deferred tax assets at </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, respectively, because the Company&#8217;s management was unable to conclude that it is more likely than not that these assets will be fully realized. The Company had a net increase in its valuation allowance of </font><font style="font-family:Arial;font-size:10pt;">$16,988</font><font style="font-family:Arial;font-size:10pt;"> during the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company files income tax returns in Norway, the UK, the US, and various states. The Company is subject to examination by federal, state and foreign jurisdictions. The Company&#8217;s tax years in the US are open under statute from inception to present. All open years may be examined to the extent that tax credits or net operating loss carryforwards are used in future periods. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s policy is to record interest and penalties related to uncertain tax positions in income tax expense.  As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company had </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;"> accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#8217;s statement of operations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6652813728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-party transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-party transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Related-party transactions</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Debt and equity transactions</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All of the Company's convertible debt (see Note&#160;8) was issued to holders of the Company's convertible preferred stock.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the year ended December&#160;31, 2018 and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, the Company reimbursed Avista Capital Holdings, LP and related parties </font><font style="font-family:Arial;font-size:10pt;">$51</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$157</font><font style="font-family:Arial;font-size:10pt;">, respectively in expenses, primarily related to legal fees incurred in conjunction with the Company's Offering of Common Stock in June 2018, the IPO in October 2017 and the issuance of Series D redeemable convertible preferred stock March 2017.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6652504000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Subsequent events</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On January 31, 2019, OptiNose AS, a wholly owned subsidiary of the Company, entered into a license agreement (the Inexia License Agreement) with Inexia Limited (Inexia).</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Under the terms of the Inexia License Agreement, Inexia paid the Company a </font><font style="font-family:Arial;font-size:10pt;">$500</font><font style="font-family:Arial;font-size:10pt;"> upfront payment. For each product developed under the Inexia License Agreement, the Company is eligible to receive up to </font><font style="font-family:Arial;font-size:10pt;">$8,000</font><font style="font-family:Arial;font-size:10pt;"> of development milestone payments and up to </font><font style="font-family:Arial;font-size:10pt;">$37,000</font><font style="font-family:Arial;font-size:10pt;"> of sales milestone payments. In addition, the Company is eligible to receive tiered, low-to-mid single digit royalties based on net sales of any products successfully developed and commercialized under the Inexia License Agreement.  Other than the upfront payment, the Company does not anticipate the receipt of any milestone or royalty payments from Inexia in the near term.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772756848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Basis of presentation</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The accompanying consolidated financial statements have been prepared in conformity with US generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Principles of consolidation</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The consolidated financial statements include the accounts of OptiNose,&#160;Inc. and its wholly-owned subsidiaries, OptiNose US,&#160;Inc., OptiNose AS and OptiNose UK&#160;Ltd. All inter-company balances and transactions have been eliminated in consolidation.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Use of estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of credit risk</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and accounts receivable.The Company generally invests its cash in deposits with high credit quality financial institutions. Additionally, the Company performs periodic evaluations of the relative credit standing of these financial institutions.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Cash and cash equivalents</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All highly liquid investments purchased with an original maturity date of three months or less at the date of purchase are considered to be cash equivalents. The Company maintains its cash and cash equivalent balances at foreign and domestic financial institutions.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Fair value of financial instruments</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company measures certain assets and liabilities at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The FASB accounting guidance outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company uses quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of the inputs as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level&#160;1&#160;&#8212; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level&#160;2&#160;&#8212; Valuations based on observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level&#160;3&#160;&#8212; Valuations based on inputs that are unobservable and models that are significant to the overall fair value measurement.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">At </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, the Company's financial instruments included cash and cash equivalents, accounts receivable, grants receivable, accounts payable, and accrued expenses. The carrying amounts reported in the Company's financial statements for these instruments approximates their respective fair values because of the short-term nature of these instruments.  In addition, at </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company believes the carrying value of debt approximates fair value as the interest rates are reflective of the rate the Company could obtain on debt with similar terms and conditions. At </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, there were no financial assets or liabilities measured at fair value on a recurring basis.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts receivable</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Accounts receivable</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounts receivable primarily relates to amounts due from customers, which are typically due within 31 to 61 days. The Company analyzes accounts that are past due for collectability. Given the nature and historical collectability of the Company&#8217;s accounts receivable, an allowance for doubtful accounts was not deemed necessary at&#160;</font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prior to receiving FDA approval for XHANCE in September 2017, inventory purchases were expensed as incurred and recorded as a component of research and development expense. Subsequent to receiving FDA approval, inventories are stated at the lower of cost or net realizable value. Costs of inventories, which include amounts related to materials and manufacturing overhead, are determined on a first-in, first-out basis. An assessment of the recoverability of capitalized inventory is performed during each reporting period and any excess and obsolete inventories are written down to their estimated net realizable value in the period in which the impairment is first identified. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Property and equipment</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Property and equipment is recorded at cost less accumulated depreciation. Significant additions or improvements are capitalized, and expenditures for repairs and maintenance are charged to expense as incurred. Gains and losses on disposal of assets are included in the consolidated statements of operations. Depreciation is calculated on a straight-line basis over the estimated useful lives of the respective assets.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long lived assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Long lived assets</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated. Impairment charges are recognized at the amount by which the carrying amount of an asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Revenue recognition</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company accounts for revenue in accordance with ASC Topic 606, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Arial;font-size:10pt;">, which was adopted on January 1, 2018. This standard applies to all contracts with customers, with the exception of contracts that are within the scope of other standards, such as leases, insurance and financial instruments. Under ASC Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to be entitled in exchange for those goods or services.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company performs the following five steps to recognize revenue under ASC Topic 606: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only recognizes revenue when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that will be transferred to the customer. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Net Product Revenues</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company sells XHANCE to preferred pharmacy network partners and wholesalers in the US (collectively, Customers). These Customers subsequently resell the Company&#8217;s products to healthcare providers, patients and other retail pharmacies. In addition to agreements with Customers, the Company enters into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts for the purchase of the Company&#8217;s products.  </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company recognizes revenue from product sales at the point the Customer obtains control of the product, which generally occurs upon delivery. The transaction price that is recognized as revenue for products includes an estimate of variable consideration which is described below. Payment terms with Customers do not exceed one year and, therefore, the Company does not account for a financing component in its arrangements. The Company expenses incremental costs of obtaining a contract with a Customer (for example, sales commissions) when incurred as the period of benefit is less than one year. Shipping and handling costs for product shipments to Customers are recorded as selling, general and administrative expenses.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Transaction Price, including Estimates of Variable Consideration</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue from products is recognized at the estimated net sales price (transaction price), which includes estimates of variable consideration. The Company includes estimated amounts in the transaction price to the extent it is determined probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The Company&#8217;s estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of its anticipated performance and all information (historical, current and forecasted) that is reasonably available.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Components of Variable Consideration</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Components of variable consideration include provider chargebacks and discounts, trade discounts and allowances, product returns, government rebates, third-party payor rebates, sales order management fees and other incentives, such as voluntary patient assistance and other allowances that are offered within contracts between the Company and its Customers, payors and other indirect customers relating to the Company&#8217;s sale of products. Those components, as described below, are based on the amounts earned, or to be claimed, on the related sales and are presented as reductions of accounts receivable (if the amount is payable to the Customer) or as a current liability (if the amount is payable to a party other than the Customer). The Company considers all relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;text-decoration:underline;">Variable Consideration - Accounts Receivable Reductions</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Provider Chargebacks and Discounts.</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"> </font><font style="font-family:Arial;font-size:10pt;">Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from the Company.&#160;Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers.&#160;These components of variable consideration are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable.&#160;Reserves for chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel inventories at each reporting period-end that the Company expects will be sold to qualified healthcare providers, as well as chargebacks that Customers have claimed, but for which the Company has not yet issued a credit.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;padding-left:24px;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-24px;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Trade Discounts and Allowances.</font><font style="font-family:Arial;font-size:10pt;">  The Company generally provides Customers with discounts that include incentive fees which are explicitly stated in the Company&#8217;s contracts. These discounts are recorded as a reduction of revenue and accounts receivable in the period in which the related product revenue is recognized. In addition, the Company reimburses (through discounts and allowances) its Customers for sales order management, data and distribution services.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:6px;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-6px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;text-decoration:underline;">Variable Consideration - Current Liabilities</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Product Returns.</font><font style="font-family:Arial;font-size:10pt;">  Consistent with industry practice, the Company has a product returns policy that provides Customers a right of return for product purchased within a specified period prior to and subsequent to the product&#8217;s expiration date. The right of return lapses upon shipment of the goods to a patient. The Company estimates the amount of its products that may be returned and presents this amount as a reduction of revenue in the period the related product revenue is recognized, in addition to establishing a liability. The Company considers several factors in the estimation process, including expiration dates of product shipped to preferred pharmacy network partners and wholesalers, inventory levels within the distribution channel, product shelf life, prescription trends and other relevant factors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Government Rebates</font><font style="font-family:Arial;font-size:10pt;">.  The Company is subject to discount obligations under state Medicaid programs and Medicare. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. For Medicaid, accruals are based on estimates of future Medicaid beneficiary utilization applied to the Medicaid unit rebate formula established by the Center for Medicaid and Medicare Services. The Medicare Part&#160;D prescription drug benefit mandates manufacturers to fund approximately 50% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. To estimate the cost to the Company of this Medicare coverage gap responsibility, the Company estimates the number of patients in the prescription drug coverage gap for whom it will owe an additional liability under the Medicare Part D program. The Company&#8217;s liability for these rebates consists of estimates of claims for the current quarter and estimated future claims that will be made for product that has been recognized as revenue but remains in the distribution channel inventories at the end of the reporting period.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Payor Rebates.</font><font style="font-family:Arial;font-size:10pt;">  The Company contracts with certain third-party payors, primarily health insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. These rebates are based on contractual percentages applied to the amount of product prescribed to patients who are covered by the plan or the organization with which it contracts. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Other Incentives.</font><font style="font-family:Arial;font-size:10pt;">  Other incentives that the Company offers include voluntary patient assistance programs, such as co-pay assistance programs, which are intended to provide financial assistance to qualified commercially insured patients with prescription drug co-payments required by payors and coupon programs for cash payors.&#160;The calculation of the accruals for this assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Licensing Revenues</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Through December 31, 2017, the Company's revenues had been generated pursuant to the terms of a single license agreement (the AVP-825 License Agreement) with Avanir Pharmaceuticals,&#160;Inc. (Avanir) (Note&#160;7). The AVP-825 License Agreement included licensed rights to patented technology, non-refundable up-front payment, research services, and regulatory and sales milestones as well as royalty payments. Through </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, under the terms of the AVP-825 License Agreement, the Company received aggregate cash payments of </font><font style="font-family:Arial;font-size:10pt;">$70,000</font><font style="font-family:Arial;font-size:10pt;"> in connection with the initial signing and the achievement of certain development milestones. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On December 10, 2018, the Company received written notice from Avanir of its election to terminate the AVP-825 License Agreement.&#160;As a result, the AVP-825 License Agreement is expected to terminate on March 10, 2019. We do not expect to receive any additional proceeds from the AVP-825 License Agreement.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prior to the receipt of notice of termination of the License Agreement, the Company analyzed the performance obligations under the AVP-825 License Agreement, the consideration received to date and the consideration the Company could have received in the future as part of its analysis related to ASU 2014-09. The consideration received to date, which included an upfront payment, research and development funding and development milestone payments was recognized in prior years and the Company&#8217;s performance obligations pursuant to the arrangement have been completed. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Advertising expenses</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company expenses the costs of advertising, including promotional expenses, as incurred. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Research and development</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research and development costs are expensed as incurred. Research and development costs consist primarily of device development, clinical trial related costs and regulatory related costs. The Company enters into agreements with contract research organizations (CROs) to facilitate, coordinate and perform agreed upon research and development activities for the Company's clinical trials. These CRO contracts typically call for the payment of fees for services at the initiation of the contract and/or upon the achievement of certain clinical trial milestones. The Company prepays certain CRO fees whereby the prepayments are recorded as a current or non-current prepaid asset and are amortized into research and development expense over the period of time the contracted research and development services were performed. The Company's CRO contracts generally also included other fees such as project management and pass through fees whereby the Company expenses these costs as incurred, using the Company's best estimate. Pass through fees include, but are not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous costs. Pass through fees incurred are based on the amount of work completed for the clinical trials and are monitored through reporting provided by the Company's CROs.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based compensation</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company measures and recognizes compensation expense for all stock options awarded to employees and nonemployees and shares issued under the employee stock purchase plan based on the estimated fair value of the awards on the respective grant dates. The Company uses the Black-Scholes option pricing model to value its stock option awards and shares issued under the employee stock purchase plan. The Company recognizes compensation expense for time-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company recognizes compensation expense for performance based awards when the performance condition is probable of achievement. Stock-based awards issued to nonemployees are revalued at each reporting period until the award vests. The Company accounts for forfeitures of stock option awards as they occur.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Estimating the fair value of options and shares issued under the employee stock purchase plan requires the input of subjective assumptions, including the estimated fair value of the Company's common stock, the expected life of the options, stock price volatility, the risk-free interest rate and expected dividends. The assumptions used in the Company's Black-Scholes option-pricing model represent management's best estimates and involve a number of variables, uncertainties and assumptions and the application of management's judgment, as they are inherently subjective.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Income taxes</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net income (loss) per common share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Net income (loss) per common share</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Recent accounting pronouncements</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In August 2018, the FASB issued ASU No. 2018-15,&#160;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</font><font style="font-family:Arial;font-size:10pt;">.&#160; ASU 2018-15 requires that certain implementation costs incurred in a cloud computing arrangement be deferred and recognized over the term of the arrangement. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on its results of operations, financial position and cash flows and related disclosures.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In August 2018, the FASB issued ASU No. 2018-13,&#160;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:Arial;font-size:10pt;">.&#160; ASU 2018-13 resulted in certain modifications to fair value measurement disclosures, primarily related to level 3 fair value measurements. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on its disclosures.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09,&#160;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Stock&#160;Compensation - Scope of Modification Accounting</font><font style="font-family:Arial;font-size:10pt;">.&#160; ASU 2017-09 provides guidance on which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The new standard is effective for fiscal years beginning after December 15, 2017. The adoption of ASU 2017-09 did not have a material impact on the Company&#8217;s results of operations, financial position, cash flows and related disclosures.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230). </font><font style="font-family:Arial;font-size:10pt;">ASU No. 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The new standard is effective for fiscal years beginning after December 15, 2017. The Company adopted ASU 2016-18 in the first quarter of 2018, and the guidance has been retrospectively applied to all periods presented. The restricted cash balance included in prepaid expenses and other assets was </font><font style="font-family:Arial;font-size:10pt;">$21</font><font style="font-family:Arial;font-size:10pt;"> as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02,</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#160;Leases (Topic 842)</font><font style="font-family:Arial;font-size:10pt;">. The FASB issued the update to require the recognition of lease assets and liabilities on the balance sheet of lessees. The standard will be effective for fiscal years beginning after December&#160;15, 2018, with early adoption permitted. The ASU requires a modified retrospective transition method with the option to elect a package of practical expedients. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following are other key disclosures, as well as determinations made and actions taken by the Company, related to the adoption of ASC 842:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Elected the optional modified retrospective transition method as of January 1, 2019; therefore prior period amounts will not be restated;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Established and implemented key implementation controls to ensure the Company meets the new reporting and disclosure requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Elected the following transition practical expedients:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to not reassess lease identification, lease classification and initial indirect costs related to those leases entered into prior to the adoption of ASC 842;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to not separate lease and non-lease components for our office lease portfolio;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Made policy elections as of January 1, 2019:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to not apply the recognition and measurement requirements to leases with an initial term of one year or less;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to apply the portfolio approach for the development of the discount rate related to leases with similar characteristics;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to keep leases with an immaterial right-of-use asset at inception, off the balance sheet and recognize this expense on a straight-line basis in the consolidated statements of operations;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">While we continue to assess all the effects of adoption, the Company believes the most significant effect relates to the recognition of right-of-use assets and corresponding liabilities on its consolidated balance sheet, primarily related to its existing facility operating leases, and providing new disclosures with regards to the Company&#8217;s leasing activities.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09,&#160;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Arial;font-size:10pt;">, or ASU-2014-09, which replaced numerous requirements in US&#160;GAAP, including industry-specific requirements. This guidance provides a five-step model to be applied to all contracts with customers, with an underlying principle that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The new standard also defines accounting for certain costs related to origination and fulfillment of contracts with customers, including whether such costs should be capitalized.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This statement requires extensive quantitative and qualitative disclosures covering the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including disclosures on significant judgments made when applying the guidance and assets recognized from costs incurred to obtain or fulfill a contract. The guidance was effective for annual reporting periods beginning after December&#160;15, 2017, and interim periods within that reporting period. An entity could elect to apply the guidance under one of the following two methods: (i)&#160;retrospectively to each prior reporting period presented&#160;&#8212; referred to as the full retrospective method or (ii)&#160;retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings&#160;&#8212; referred to as the modified retrospective method.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company assessed the impact that ASU No. 2014-09 had on its financial statements and related disclosures. Through the January 1, 2018 adoption date, the Company has derived its revenues from a single licensing agreement with Avanir (the AVP-825 License Agreement). The consideration the Company has received to date includes an upfront payment, research and development funding and development milestone payments. The Company analyzed the performance obligations under the AVP-825 License Agreement as well as the consideration received to date as part of its analysis of the impact of ASU 2014-09 on this arrangement. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company adopted ASU 2014-09 on January 1, 2018 using the modified retrospective transition method. No transition adjustments were recognized as a result of the adoption. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising costs. For those costs that cannot be capitalized, discloses whether such costs are expensed as incurred or the first period in which the advertising takes place. For direct response advertising costs that are capitalized, describes those assets and the accounting policy used, including a description of the qualifying activity, the types of costs capitalized and the related amortization period. An entity also may disclose its accounting policy for cooperative advertising arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84159346&amp;loc=d3e8275-108329<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 20<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68054294&amp;loc=d3e8384-108330<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109236672&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5212-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=SL6953423-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5093-111524<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6649194192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The estimated useful lives of property and equipment are as follows:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Computer equipment</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2-3 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Software</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Machinery &amp; production equipment</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5-10 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Furniture &amp; fixtures</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3-5 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Leasehold improvements</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Shorter of lease term or useful life</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Property and equipment, net, consisted of:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Computer equipment and software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">833</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">389</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">89</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Machinery and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,723</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">609</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">28</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Construction in process</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">481</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,035</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,919</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1,151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,884</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,564</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive shares excluded from earnings per share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Diluted net loss per common share for the periods presented do not reflect the following potential common shares, as the effect would be antidilutive:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:76%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,182,873</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,141,367</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Common stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,866,831</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,890,489</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Employee stock purchase plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">31,892</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8,081,596</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,031,856</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763530960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Inventory consisted of the following: </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,969</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,385</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Work-in-process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,344</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">628</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,819</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7,132</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6912709008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The estimated useful lives of property and equipment are as follows:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Computer equipment</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2-3 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Software</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Machinery &amp; production equipment</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5-10 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Furniture &amp; fixtures</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3-5 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Leasehold improvements</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Shorter of lease term or useful life</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Property and equipment, net, consisted of:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Computer equipment and software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">833</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">389</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">89</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Machinery and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,723</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">609</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">28</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Construction in process</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">481</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,035</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,919</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1,151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,884</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,564</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763555344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accrued expenses consisted of:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Contract sales organization expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,482</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,432</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Selling, general and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,812</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Research and development expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">933</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">80</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Bonus expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Payroll and benefit expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">564</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">448</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Employee contributions withheld</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Product revenue allowances</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,856</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">435</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">314</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">18,421</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8,698</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6615694768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, the long-term debt balance is comprised of the following:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:77%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Face amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">75,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">75,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Front end fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(872</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(999</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1,902</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(2,139</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Back end fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">274</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">72,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">71,863</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6657672880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Lessee, Operating Lease</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following is a schedule of future minimum annual payments as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> under operating lease agreements:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:89%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">For the years ending December 31:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,630</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,107</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">391</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total future minimum lease payments as of December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,128</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=115931803&amp;loc=d3e12069-110248<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 1,3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164451&amp;loc=d3e36991-112694<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6657036400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">exercise price</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">contractual life</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Outstanding at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,251,589</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">9.34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.67</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">472,792</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">19.36</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(491,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(49,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">9.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Outstanding at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,182,873</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.60</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.48</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Exercisable at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,804,999</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.09</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Vested and expected to vest at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,182,873</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10.60</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.48</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of allocated stock-based compensation expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company recorded stock-based compensation expense in the following expense categories of its accompanying consolidated statements of operations for the years ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and  </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cost of product sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">989</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,288</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7,545</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,808</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8,543</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5,096</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value options using Black-Scholes pricing model</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company calculated the fair value of each option grant and the option component of the 2017 Plan on the respective dates of grant using the following weighted average assumptions: </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2010 A&amp;R Stock Incentive Plan</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017 Employee Stock Purchase Plan</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Risk free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expected term (in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.95</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.64</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">74.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">80.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Annual dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company calculated the fair value of each option grant and the option component of the 2017 Plan on the respective dates of grant using the following weighted average assumptions: </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2010 A&amp;R Stock Incentive Plan</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017 Employee Stock Purchase Plan</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Risk free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expected term (in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.95</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.64</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">74.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">80.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Annual dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6920976656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income before Income Tax, Domestic and Foreign</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Income taxes have been recorded on the following book income (loss) before income tax expense:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Domestic operations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(146,247</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(30,463</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreign operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">39,589</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(18,439</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Loss before provision for income taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(106,658</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(48,902</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A reconciliation of income tax expense (benefit) at the US federal statutory income tax rate and the income tax provision in the financial statements is as follows: </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:54%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Income tax expense at statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">21.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Permanent items</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Foreign rate differential</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(4.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Impact of foreign operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(7.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;State taxes, net of federal benefit</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Tax rate changes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(15.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Foreign exchange and other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(0.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Change in valuation allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(16.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(16.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Effective income tax rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">0.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The principal components of the Company&#8217;s deferred tax assets and liabilities are as follows: </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.44054580896686%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Deferred tax assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,674</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">972</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Prepaid licensing arrangement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">11,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">55</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Interest expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,267</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">783</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Stock compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,493</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,701</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Research and development credits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,485</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,485</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Net operating losses </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">32,548</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">29,636</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;Total deferred tax assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">53,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">35,632</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Deferred tax liabilities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Fixed assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(409</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;Total deferred tax liabilities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(409</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;&#160;Less: Valuation allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(52,620</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(35,632</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total net deferred tax assets (liabilities)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929385600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Liquidity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 11, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,990<span></span>
</td>
<td class="nump">$ 234,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=optn_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares)</a></td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (usd per share)</a></td>
<td class="nump">$ 22.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="nump">$ 59,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_SaleofStockDiscountsandCommissions', window );">Fees and commissions</a></td>
<td class="nump">3,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">$ 373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=optn_TheCompanyMember', window );">The Company | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares)</a></td>
<td class="nump">2,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=optn_CertainStockholdersMember', window );">Certain Stockholders | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares)</a></td>
<td class="nump">2,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_SaleofStockDiscountsandCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Discounts and Commissions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_SaleofStockDiscountsandCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=optn_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=optn_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=optn_TheCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=optn_TheCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=optn_CertainStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=optn_CertainStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929243776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 10, 2017</div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split conversion ratio</a></td>
<td class="nump">2.8879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash, uninsured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199,507,000<span></span>
</td>
<td class="nump">$ 233,772,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on sale of equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,767,000<span></span>
</td>
<td class="nump">1,833,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,065,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6908221328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Concentration Risk (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>customers</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_ConcentrationRiskNumberofClients', window );">Concentration risk, number of clients</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Sales Revenue, Net</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">94.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_ConcentrationRiskNumberofClients', window );">Concentration risk, number of clients</a></td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_ConcentrationRiskNumberofClients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Number of Clients</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_ConcentrationRiskNumberofClients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773165344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6931627168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Antidilutive shares excluded from earnings per share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securites excluded from computation of earnings per share</a></td>
<td class="nump">8,081,596<span></span>
</td>
<td class="nump">4,031,856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securites excluded from computation of earnings per share</a></td>
<td class="nump">6,182,873<span></span>
</td>
<td class="nump">2,141,367<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securites excluded from computation of earnings per share</a></td>
<td class="nump">1,866,831<span></span>
</td>
<td class="nump">1,890,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=optn_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securites excluded from computation of earnings per share</a></td>
<td class="nump">31,892<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=optn_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=optn_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6649194736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 1,969<span></span>
</td>
<td class="nump">$ 1,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">2,344<span></span>
</td>
<td class="nump">628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">2,819<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total inventory</a></td>
<td class="nump">$ 7,132<span></span>
</td>
<td class="nump">$ 2,013<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761526064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 5,035<span></span>
</td>
<td class="nump">$ 2,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(1,151)<span></span>
</td>
<td class="num">(355)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,884<span></span>
</td>
<td class="nump">2,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">535<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=optn_ComputerEquipmentandSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">833<span></span>
</td>
<td class="nump">307<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">389<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,723<span></span>
</td>
<td class="nump">2,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">609<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">481<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=optn_ComputerEquipmentandSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=optn_ComputerEquipmentandSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6931662384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_AccruedSalesOrganizationExpensesCurrent', window );">Contract sales organization expenses</a></td>
<td class="nump">$ 4,482<span></span>
</td>
<td class="nump">$ 1,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_AccruedSellingGeneralandAdministrativeCurrent', window );">Research and development expenses</a></td>
<td class="nump">4,812<span></span>
</td>
<td class="nump">2,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_AccruedResearchandDevelopmentCurrent', window );">Selling, general and administrative expenses</a></td>
<td class="nump">933<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Bonus expense</a></td>
<td class="nump">3,635<span></span>
</td>
<td class="nump">4,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Payroll and benefit expenses</a></td>
<td class="nump">564<span></span>
</td>
<td class="nump">448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent', window );">Employee contributions withheld</a></td>
<td class="nump">359<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_AccruedProductAllowancesCurrent', window );">Product revenue allowances</a></td>
<td class="nump">2,856<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest expense</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">435<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 18,421<span></span>
</td>
<td class="nump">$ 8,698<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_AccruedProductAllowancesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Product Allowances, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_AccruedProductAllowancesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_AccruedResearchandDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Research and Development, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_AccruedResearchandDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_AccruedSalesOrganizationExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Sales Organization Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_AccruedSalesOrganizationExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_AccruedSellingGeneralandAdministrativeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Selling, General and Administrative, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_AccruedSellingGeneralandAdministrativeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred for employer-related costs classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774803632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AVP-825 License Agreement (Details) - License Agreement Terms - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">66 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Aggregate cash payments received from license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Licensing revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773493248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 24, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_InterestExpenseDebtBackEndFees', window );">Interest expense, back end fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_NumberofTranches', window );">Number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">862,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_DebtInstrumentCouponInterestandFees', window );">Coupon interest and back end fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">743,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_DebtInstrumentLoanConversionPeriod', window );">Loan conversion period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_InterestExpenseDebtFrontEndFees', window );">Interest expense, front end fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_DebtInstrumentFeesCapitalizedtoPrincipal', window );">Back end fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=optn_SeriesDFinancingMember', window );">Series D Financing | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt conversion, original debt amount</a></td>
<td class="nump">$ 19,527,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember', window );">Conversion of Convertible notes into Series C2 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt conversion, original debt amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,527,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesC2Member', window );">Redeemable Convertible Preferred Stock, Series C2 | Conversion of Convertible notes into Series C2 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion shares issued (in shares) | shares</a></td>
<td class="nump">687,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">687,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt conversion, price per share (usd per share) | $ / shares</a></td>
<td class="nump">$ 28.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DebtInstrumentCouponInterestandFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Coupon Interest and Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DebtInstrumentCouponInterestandFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DebtInstrumentFeesCapitalizedtoPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Fees Capitalized to Principal</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DebtInstrumentFeesCapitalizedtoPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DebtInstrumentLoanConversionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Loan Conversion Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DebtInstrumentLoanConversionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_InterestExpenseDebtBackEndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Expense, Debt, Back End Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_InterestExpenseDebtBackEndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_InterestExpenseDebtFrontEndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Expense, Debt, Front End Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_InterestExpenseDebtFrontEndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_NumberofTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Tranches</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_NumberofTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=optn_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=optn_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=optn_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=optn_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=optn_SeriesDFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=optn_SeriesDFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesC2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesC2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773562128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>USD ($) </div>
<div>quarter</div>
</th>
<th class="th">
<div>Aug. 14, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_DebtDiscountAmortizationPeriod', window );">Debt amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_InterestExpenseDebtBackEndFees', window );">Interest expense, back end fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,181,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Note Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Unused borrowing capacity</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.8125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_DebtInstrumentFeeUpfrontFee', window );">Upfront fee</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_DebtInstrumentFeeExitFee', window );">Exit fee</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_DebtInstrumentCovenantCashandCashEquivalents', window );">Covenant, cash and cash equivalents</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,229,000<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,902,000<span></span>
</td>
<td class="nump">$ 2,139,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Note Purchase Agreement | Prior to Second Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price rate</a></td>
<td class="nump">102.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Note Purchase Agreement | On Or After Second Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_DebtInstrumentPrepaymentFee', window );">Prepayment fee</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Note Purchase Agreement | On Or After Third Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_DebtInstrumentPrepaymentFee', window );">Prepayment fee</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Note Purchase Agreement | After Fourth Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_DebtInstrumentPrepaymentFee', window );">Prepayment fee</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Note Purchase Agreement | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_DebtInstrumentInterestRateFloor', window );">Interest rate floor</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Note Purchase Agreement - Delayed Draw Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Unused borrowing capacity</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_NumberOfTrailingQuarters', window );">Number of trailing quarters | quarter</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_TotalDebttoTrailingQuarterNetSalesRatio', window );">Total debt to trailing quarter net sales ratio</a></td>
<td class="nump">6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Note Purchase Agreement - Delayed Draw Notes | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_TotalDebttoTrailingQuarterNetSalesRatio', window );">Total debt to trailing quarter net sales ratio</a></td>
<td class="nump">3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Scenario, Forecast | Senior Notes | Note Purchase Agreement - Delayed Draw Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_TotalDebttoTrailingQuarterNetSalesRatio', window );">Total debt to trailing quarter net sales ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DebtDiscountAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Discount Amortization Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DebtDiscountAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DebtInstrumentCovenantCashandCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Cash and Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DebtInstrumentCovenantCashandCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DebtInstrumentFeeExitFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Fee, Exit Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DebtInstrumentFeeExitFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DebtInstrumentFeeUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Fee, Upfront Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DebtInstrumentFeeUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DebtInstrumentInterestRateFloor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate Floor</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DebtInstrumentInterestRateFloor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DebtInstrumentPrepaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DebtInstrumentPrepaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_InterestExpenseDebtBackEndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Expense, Debt, Back End Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_InterestExpenseDebtBackEndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_NumberOfTrailingQuarters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Trailing Quarters</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_NumberOfTrailingQuarters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_TotalDebttoTrailingQuarterNetSalesRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Debt to Trailing Quarter Net Sales Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_TotalDebttoTrailingQuarterNetSalesRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=optn_NotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=optn_NotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=optn_NotePurchaseAgreementDelayedDrawNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=optn_NotePurchaseAgreementDelayedDrawNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6931159440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Schedule of Long Term Debt (Details) - Senior Notes - Note Purchase Agreement - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Face amount</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_DebtInstrumentFeeAmountFrontEnd', window );">Front end fees</a></td>
<td class="num">(872)<span></span>
</td>
<td class="num">(999)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Debt issuance costs</a></td>
<td class="num">(1,902)<span></span>
</td>
<td class="num">(2,139)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_DebtInstrumentFeeAmountBackEnd', window );">Back end fees</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="nump">$ 72,500<span></span>
</td>
<td class="nump">$ 71,863<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DebtInstrumentFeeAmountBackEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Fee Amount, Back End</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DebtInstrumentFeeAmountBackEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DebtInstrumentFeeAmountFrontEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Fee Amount, Front End</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DebtInstrumentFeeAmountFrontEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=optn_NotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=optn_NotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773517008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum annual contributions per employee</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan, cost</a></td>
<td class="nump">$ 645<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan, cost</a></td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_DefinedContributionPlanTranchesAxisAxis=optn_DefinedContributionPlanTrancheOneMember', window );">Defined Contribution Plan, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum annual contributions per employee</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_DefinedContributionPlanTranchesAxisAxis=optn_DefinedContributionPlanTrancheTwoMember', window );">Defined Contribution Plan, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum annual contributions per employee</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DefinedContributionPlanTranchesAxisAxis=optn_DefinedContributionPlanTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DefinedContributionPlanTranchesAxisAxis=optn_DefinedContributionPlanTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DefinedContributionPlanTranchesAxisAxis=optn_DefinedContributionPlanTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DefinedContributionPlanTranchesAxisAxis=optn_DefinedContributionPlanTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6931459568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Leases) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>lease</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_NumberOfOperatingLeases', window );">Number of operating leases | lease</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="nump">$ 831<span></span>
</td>
<td class="nump">$ 689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of real estate property | ft&#178;</a></td>
<td class="nump">20,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_FutureRentExpense', window );">Future rent expense</a></td>
<td class="nump">$ 2,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_FutureRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future Rent Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_FutureRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_NumberOfOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Operating Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_NumberOfOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6651659632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Future Minimum Lease Payments) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Future minimum annual payments, 2019</a></td>
<td class="nump">$ 1,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Future minimum annual payments, 2020</a></td>
<td class="nump">1,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Future minimum annual payments, 2021</a></td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total future minimum lease payments as of December 31, 2018</a></td>
<td class="nump">$ 3,128<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6931225408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Purchase Commitments) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=optn_MarketSalesforceMember', window );">Market Salesforce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,335,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Market Salesforce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees', window );">Early contract termination fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 691,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of early contract termination fees included in liabilities subject to compromise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56145-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114872137&amp;loc=d3e55717-112764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6918054&amp;loc=d3e56015-112765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=optn_MarketSalesforceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=optn_MarketSalesforceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773483472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Common Stock (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 11, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_VotePerShare', window );">Vote per share | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends declared (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_SaleofStockDiscountsandCommissions', window );">Fees and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,624,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=optn_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares) | shares</a></td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (usd per share) | $ / shares</a></td>
<td class="nump">$ 22.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_SaleofStockDiscountsandCommissions', window );">Fees and commissions</a></td>
<td class="nump">$ 3,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="nump">59,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_SaleofStockDiscounts', window );">Sale of stock discounts</a></td>
<td class="nump">3,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">$ 373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=optn_TheCompanyMember', window );">The Company | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares) | shares</a></td>
<td class="nump">2,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=optn_CertainStockholdersMember', window );">Certain Stockholders | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares) | shares</a></td>
<td class="nump">2,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_SaleofStockDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Discounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_SaleofStockDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_SaleofStockDiscountsandCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Discounts and Commissions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_SaleofStockDiscountsandCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_VotePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vote Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_VotePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=optn_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=optn_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=optn_TheCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=optn_TheCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=optn_CertainStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=optn_CertainStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763511664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' equity - Warrants (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding (in shares) | shares</a></td>
<td class="nump">1,866,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761384608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 24, 2017</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock', window );">Proceeds from the sale of Series D preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 36,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesDMember', window );">Redeemable Convertible Preferred Stock, Series D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Series D preferred stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,117,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock', window );">Proceeds from the sale of Series D preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=optn_ConversionatConsummationofIPOMember', window );">Conversion at Consummation of IPO | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued, conversion of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,068,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember', window );">Conversion of Convertible notes into Series C2 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt conversion, original debt amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember', window );">Conversion of Convertible notes into Series C2 Preferred Stock | Redeemable Convertible Preferred Stock, Series C2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion shares issued (in shares)</a></td>
<td class="nump">687,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">687,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt conversion, price per share (usd per share)</a></td>
<td class="nump">$ 28.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Series D preferred stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stock that is classified as callable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=optn_ConversionatConsummationofIPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=optn_ConversionatConsummationofIPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=optn_ConversionofConvertiblenotesintoSeriesC2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesC2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=optn_RedeemableConvertiblePreferredStockSeriesC2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762592144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=optn_ServiceBasedStockOptionsMember', window );">Service Based Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">472,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of common stock (in dollars per share)</a></td>
<td class="nump">$ 12.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of exercised options</a></td>
<td class="nump">$ 9,255<span></span>
</td>
<td class="nump">$ 435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value of options outstanding</a></td>
<td class="nump">8,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value of exercisable options</a></td>
<td class="nump">8,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 20,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation, estimated weighted-average amortization period</a></td>
<td class="text">2 years 8 months 11 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=optn_AmendedandRestated2010StockIncentivePlanMember', window );">Amended and Restated Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized under plan (shares)</a></td>
<td class="nump">8,406,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance under plan (shares)</a></td>
<td class="nump">1,635,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease', window );">Yearly increase in shares reserved for future issuance</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Plan options contractual life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved for Future Issuance, Yearly Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_CommonStockCapitalSharesReservedforFutureIssuanceYearlyIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=optn_ServiceBasedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=optn_ServiceBasedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=optn_AmendedandRestated2010StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=optn_AmendedandRestated2010StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761879936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Service-based stock options (Details) - Service Based Stock Options - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Service-based stock options activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding, beginning (in shares)</a></td>
<td class="nump">6,251,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">472,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(491,654)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(49,854)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding, ending (in shares)</a></td>
<td class="nump">6,182,873<span></span>
</td>
<td class="nump">6,251,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">3,804,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at end of period(in shares)</a></td>
<td class="nump">6,182,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Service-based stock options weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance, Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 9.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">19.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">3.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">9.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance, Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">10.60<span></span>
</td>
<td class="nump">$ 9.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, Weighted average exercise price per share (in dollars per share)</a></td>
<td class="nump">8.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, Weighted average exercise price per share (in dollars per share)</a></td>
<td class="nump">$ 10.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Service-based stock options, additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted average remaining contractual life</a></td>
<td class="text">6 years 5 months 22 days<span></span>
</td>
<td class="text">6 years 8 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted average remaining contractual life</a></td>
<td class="text">5 years 1 month 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, Weighted average remaining contractual life</a></td>
<td class="text">6 years 5 months 22 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=optn_ServiceBasedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=optn_ServiceBasedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929314320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Employee stock purchase plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 8,543<span></span>
</td>
<td class="nump">$ 5,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember', window );">2017 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized under plan (shares)</a></td>
<td class="nump">522,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear', window );">Increase in number of shares issuable each year</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 446<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Increment Each Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedIncrementEachYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762618128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock-based compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 8,543<span></span>
</td>
<td class="nump">$ 5,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">989<span></span>
</td>
<td class="nump">1,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">7,545<span></span>
</td>
<td class="nump">$ 3,808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InventoriesMember', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761594992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Black-Scholes pricing model options (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Annual dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember', window );">2017 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.53%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">7 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">80.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Annual dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">2010 A &amp; R Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.74%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 345 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">74.42%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Annual dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average expected volatility rate of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=optn_TwoThousandSeventeenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6913102576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic operations</a></td>
<td class="num">$ (146,247)<span></span>
</td>
<td class="num">$ (30,463)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign operations</a></td>
<td class="nump">39,589<span></span>
</td>
<td class="num">(18,439)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before provision for income taxes</a></td>
<td class="num">$ (106,658)<span></span>
</td>
<td class="num">$ (48,902)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6931122704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax expense at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent items</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(4.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent', window );">Impact of foreign operations</a></td>
<td class="num">(7.20%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Tax rate changes</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(15.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent', window );">Foreign exchange and other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(16.20%)<span></span>
</td>
<td class="num">(16.70%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Foreign Exchange Other, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Foreign Operations Impact, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6931462736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense', window );">Accrued expenses and other</a></td>
<td class="nump">$ 1,674<span></span>
</td>
<td class="nump">$ 972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_DeferredTaxAssetsPrepaidLicenseArrangement', window );">Prepaid licensing arrangement</a></td>
<td class="nump">11,562<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_DeferredTaxAssetsInterestExpense', window );">Interest expense</a></td>
<td class="nump">1,267<span></span>
</td>
<td class="nump">783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Stock compensation</a></td>
<td class="nump">3,493<span></span>
</td>
<td class="nump">1,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">2,485<span></span>
</td>
<td class="nump">2,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">32,548<span></span>
</td>
<td class="nump">29,636<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">53,029<span></span>
</td>
<td class="nump">35,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(409)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities:</a></td>
<td class="num">(409)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(52,620)<span></span>
</td>
<td class="num">(35,632)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total net deferred tax assets (liabilities)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DeferredTaxAssetsInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Interest Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DeferredTaxAssetsInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DeferredTaxAssetsPrepaidLicenseArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Prepaid License Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DeferredTaxAssetsPrepaidLicenseArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762492480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increase (decrease)</a></td>
<td class="nump">$ 16,988,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, income tax penalties and interest accrued</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">50,513,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">86,574,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 57,017,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6705708848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-party transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Fees For IPO And Series D Convertible Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Amount of transaction</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 157<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=optn_FeesForIPOAndSeriesDConvertibleStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=optn_FeesForIPOAndSeriesDConvertibleStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6705982688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent events (Details) - Subsequent Event<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_UpfrontLicenseFeeReceivable', window );">Upfront license fee receivable</a></td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_DevelopmentMilestoneEligibility', window );">Development milestone eligibility</a></td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_optn_SalesMilestoneEligibility', window );">Sales milestone eligibility</a></td>
<td class="nump">$ 37,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_DevelopmentMilestoneEligibility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development Milestone Eligibility</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_DevelopmentMilestoneEligibility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_SalesMilestoneEligibility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Milestone Eligibility</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_SalesMilestoneEligibility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_optn_UpfrontLicenseFeeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront License Fee Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">optn_UpfrontLicenseFeeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>optn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>90
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (  8Z9DX?(\\#P    !,"   +    7W)E;',O+G)E;'.MDD^+
MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V
M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F'
M.>RGGD7E2B.5^S3%":4A+<TXP)6E/S/WJVR;A5ND9T*YKCM+1[873T$7LF<;
M!I99-G\LCNVW<+ZT+/0:S>,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C
M-R."?S]PN -02P,$%     @ !CIF3B?HAPZ"    L0   !    !D;V-0<F]P
M<R]A<' N>&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(?
MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MUQ]^5V'GC=W9?VQ\$6QJ^'47S1=02P,$%     @ !CIF3IE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MK:CE=1V3^&WAJ3J>3+^0;%8=/XJ?POSJ'I6=)5.4?=6(5E>RC90XK.,[<OM
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MAM*9H[,9O?"N""(6N$"."N2 7GH" R)WB';X!VS)BCS%90I4I@ R2T\&(DA
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M;6C6AJ8V"F1#4QL*KRW5J,#:9*R-C-A0J-!M1H;(06(?5"12D+R3G'624R>
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MH9)ZNE=S;KN#74C6CXT/3=TW^PM02P,$%     @ !CIF3@A5A_2- P  ;0\
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MHW,TQFIG-'UP%L^N][V_U/IHA\?"/7=3 SB]6'.9F]ODWF%O_@=02P,$%
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M:BA+>#A 1V;D]FEU@=%E)+J(^/,VDDOD@E-FEL%D,I),Q.V]-I(XWI+5>L+
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M3N]CG#XTY7%XUV1U?N'EYG]02P,$%     @ !CIF3OKC*<"R 0  T@,  !@
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M%^8N ^[:D+NL:>I S0QD=T111X*1*Z#FM>&R0D#-*Y(A5T#:E_(<O[4$@UP
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M&9U_V=C_&M&!E[*[\B/4^@^V& IJ%XXW_FRF,9L,A_W\@]CRC8O?4$L#!!0
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M8_]K1 =>RN;*CU#K/]AL2*A=..[]V8QC-AH.N^D'L?D;%Q]02P,$%     @
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M_':!.Y R$'D9+Q,GG5,&X/+\QGX?:_>UG(6%.Y1/;>F:C.XI*:$2O72/.#S
M5,\G2J;BO\(%I \/2GR. J6-*REZZU!-+%Z*$J_CWNJX#^,-OYE@ZP ^ ?@,
MV,<\;$P4E7\63N2IP8&8L?>="$^\/7#?FR(X8ROBG1=OO?>2;_=)RBZ!:(HY
MCC%\&3-',,\^I^!K*8[\'SA?A^]6%>XB?/>'PO\0)*L$221(/BQQ+6;W5Q*V
MZ*D"4\=ILJ3 7L=)7GCG@;WE\4W>P\=I_R9,W6I+SNC\R\;^5X@.O)3-E1^A
MQG^PV9!0N7"\\6<SCMEH..RF'\3F;YS_!E!+ P04    "  &.F9.67:PD+0!
M  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q]4V%OVR 0_2N(
M'U!B)VVCR+;4M*HZ:9.B5ML^$_MLHP+G HZ[?U_ KN=MUKX =]Q[]^XXL@'-
MJVT!''E74MN<MLYU!\9LV8+B]@H[T/ZF1J.X\Z9IF.T,\"J"E&3I9G/#%!>:
M%EGTG4R18>^DT' RQ/9*<?/K"!*'G";TT_$LFM8%!RNRCC?P NY[=S+>8C-+
M)11H*U 3 W5.[Y+#<1?B8\ / 8-=G$FHY(SX&HPO54XW01!(*%U@X'Z[P#U(
M&8B\C+>)D\XI W!Y_F1_C+7[6L[<PCW*GZ)R;4[WE%10\UZZ9QR>8*KGFI*I
M^*]P >G#@Q*?HT1IXTK*WCI4$XN7HOC[N L=]V&\V283;!V03H!T!NQC'C8F
MBLH?N.-%9G @9NQ]Q\,3)X?4]Z8,SMB*>.?%6^^]%,G^.F.70#3%',>8=!DS
M1S#//J=(UU(<TW_@Z3I\NZIP&^';/Q3>K!/L5@EVD6#WWQ+78F[_2L(6/55@
MFCA-EI38ZSC)"^\\L'=I?)/?X>.T?^.F$=J2,SK_LK'_-:(#+V5SY4>H]1]L
M-B34+AQO_=F,8S8:#KOI!['Y&Q<?4$L#!!0    (  8Z9DY]K>+^M@$  -(#
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;'U3VV[;, S]%4$?4#E.
MNJ6!;:#I,&Q "P0=MCTK-FT+U<63Y+C]^U*RZWFML1=)I'@.#RDJ&XQ]<BV
M)\]*:I?3UOONP)@K6U#<79D.--[4QBKNT;0-<YT%7D60DBQ-DD],<:%ID47?
MR1:9Z;T4&DZ6N%XI;E^.(,V0TPU]<SR*IO7!P8JLXPW\ /^S.UFTV,Q2"07:
M":.)A3JGMYO#<1?B8\ O 8-;G$FHY&S,4S"^5SE-@B"04/K P'&[P!U(&8A0
MQI^)D\XI W!Y?F/_&FO'6L[<P9V1OT7EVYSN*:F@YKWTCV;X!E,]UY1,Q=_#
M!22&!R68HS32Q964O?-&32PH1?'G<1<Z[L-X<YU.L'5 .@'2&;"/>=B8*"K_
MPCTO,FL&8L?>=SP\\>:08F_*X(RMB'<HWJ'W4FSV^XQ= M$4<QQCTF7,',&0
M?4Z1KJ4XIA_@Z3I\NZIP&^';?Q3>K!/L5@EVD6#WWQ)78FZ2=TG8HJ<*;!.G
MR9'2]#I.\L([#^QM?$3V-WR<]@=N&Z$=.1N/+QO[7QOC :4D5SA"+7ZPV9!0
M^W#\C&<[CMEH>---/XC-W[AX!5!+ P04    "  &.F9.WR/)X+,!  #2 P
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M[?Z0AO@8\"1@<(LS"96<C'D.QK<JIYL@""24/C!PW,YP!U(&(I3Q9^*D<\H
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M!!VV/2LV;0O5Q9/DN/W[4K+K>:VQ%TFD> X/*2H;C'UR+8 GSTIJE]/6^^[
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MJYH*0,%"'00J1G1P\1.H;#8)=1!H)-<(US^!XF91(T6@L73#+8! ?;-%J(-
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M3R#-5-"4OCF>^[;SP<'*?! M? /_?3A;M-C*4O<*M.N-)A::@CZDQU,6XF/
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MR>DS+/4D&"W%?X4K< MWF5B-4G+MOZ@<M9%B8;&I"/8RKUWOUVD^2>Z7L'
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M.GWUW^B-,@TWF6B-(V?2_CO'JU2\ZEET*A5YZZYE;:]M=R>.^S XP.\#_"$
MA_\-"/J X-F L \()P%>5XKMS8XHDJ\$;QW1/=Z&F%V$EZ'N_M$LVF;;>[H]
M4J_><C].5M[-$/6838?Q[S#I/68+8.X1NSDBB :(IY,<,O7!3'T;']QED<$$
M 4@06()PG,"DTFT'22RD[C00RC(T*06 !6$:A7 V(9A-.,O&3Q!,$($$T?/]
MB$&"&,@ 3QY]AXE&E49)A/0/%DI H000FNR.38?)QBWU%_Z##9*",BD@$TQD
MTMF3B[(,)[!,!LID@$PXD<EF;0OB)(55,(*-B0"=:.I,-*LG&-5\K_/@ ,"
M3OR  G8F_H U,>Q-/#?G?#/VH'%;_=1NQP=:L/,P9+T'6P##WL,?,!^&W8>?
ML1^>^P^NV!N=]^:-_9V(2UE+Y\"5?G78 _[,N:*:%"TT7:$_$H8)HV=EAHD>
MB^Y-V4T4;_JO &_X%,G_ 5!+ P04    "  &.F9.=O8AKF$"  #]!P  &0
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MRNS>MC1-L^!FB7K,OL/0$88,B,"P#RXHYF)//YA3W#Q"(XR<^6)D'H4A3K!
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M2\."PUG;:6+FLFL9NH463=\.!4-/MOT+4$L#!!0    (  8Z9DYG"FZ66P(
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M0_ZVV$MIA/68/]C(CO8!<1VT8F]<M[)]-=ZBX\#(87HA9-=GROH?4$L#!!0
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MK9IS>Z;M0K)NN*[0>&=F_P%02P,$%     @ !CIF3EF$]2%$ P  !0\  !D
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M#"8A[$@".I( CJ0PP0(D6#R>[Q0D2!](13H),T6C3$PA\<R)+$$WEH ;2Y@
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M,S,)S4;0?ASRWO2E*?X!4$L#!!0    (  8Z9D[MO7(KT@$  (P$   9
M>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;'64VXZ;,!"&7P7Q &LPAV0C0&JV
M6K52*T5;M;UV8 AH;<S:3MB^?7T@B++N#?:8F?_[Q]@4$Q>OL@-0P3NC@RS#
M3JGQ@)"L.V!$/O 1!OVFY8(1I4-Q07(40!I;Q"C"490C1OHAK J[=A)5P:^*
M]@.<1""OC!'QYPB43V48A_>%E_[2*;. JF(D%_@!ZN=X$CI"BTK3,QADSX=
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M2KZ3W2U3]\UPC!D:4ASU$2VXG!,7_P!02P,$%     @ !CIF3F(7(AVT 0
MQ ,  !D   !X;"]W;W)K<VAE971S+W-H965T-3$N>&UL;5/;CILP$/T5RQ\0
M!T/8; 1(S5:K5FJE:*NVSPX, :TOK.V$[=_7%Q:Q$2_8,SYSSIDQ+D:E7TT'
M8-&[X-*4N+-V.!!BZ@X$,QLU@'0GK=*"61?J"S&#!M:$(L$)W6YS(E@O<56$
MW$E7A;I:WDLX:62N0C#][PA<C25.\$?BI;]TUB=(50SL K_ _AY.VD5D9FEZ
M =+T2B(-;8F_)(=CYO$!\*>'T2SVR'=R5NK5!]^;$F^](>!06\_ W'*#)^#<
M$SD;;Q,GGB5]X7+_P?X<>G>]G)F!)\7_]HWM2KS'J(&67;E]4>,WF/K9830U
M_P-NP!W<.W$:M>(F?%%]-5:)B<59$>P]KKT,ZQA/'NA4MEY IP(Z%Z1!AT2A
MX/PKLZPJM!J1CK,?F+_BY$#=;&J?#*,(9\Z\<=E;E>6T(#=/-&&.$4,_8=(9
M0QS_+$)716@@2!<$R2-=)TA7"=) D'URD-VYC)A=P,@HLL_S?9JL"V6K0MF*
MT.Y.*&(>%T+[39+?J9#%!?C_^R?3EUX:=%;6W668>*N4!4>XW3C3G7M2<\"A
MM7[[X/8Z_E@QL&J8W@R9'V[U'U!+ P04    "  &.F9.(*$99!0#   ]#0
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M@4.&$>PU!.A4OMG04@B1*B 4,#4&A!:NQHME(RA#@87#H+<?,%DJ4>0K0:"
MO3#L< Q8/'2H,>QQ_!\FQ[#+,6!AFOK5YL!)046>E0$MV.P8<#OUW8Z7=L=%
MFA,:VD78\!AP//4=#X**@ [L> Q8GOI& T I#AD-]C.&#.U_CD&0_SU.9O=H
MR^7)M1PJVHM+I^V--9N=VIH'8N]A;WYKVQUW/_^E&7JEKTR>ZDY%ST*;6][=
MQ4<A-#<YHCNSLV?3GDV#AA^U?2W-NQQZE&&@13_V7\G4!&[^ %!+ P04
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M535PJAY%!ZWY<A:24VV.\H)4)X&>'(DSE$11ACAMVK L7.P@RT)<-6M:.,A
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M>SG,AN&@13>./33-WO(O4$L#!!0    (  8Z9DX9'Y\,:P(  +<(   9
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M\D)9+T6<H3RX:*#!9VM]\,3GW2-0Z",%=E%L\4TXSD(WP,*9X\( +#[DB-T
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MF%#U@%\MMGL,!#'[DJ7LRO73CI0\6 =0P0Z%90X_''BUW#?AVV?9NBX3SIL
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MF0K)57+K#':OQRBBA,IO!0=U)6?HR49+!'Z.Z_!*YQ1\M$Q>JQ'N*;S9 ]*
M(X6=WJV!<7%0R[P@ ^,TE+\SA^-VGE"( <89N#'4<PPJY0(=87MX![,W@NL'
M1//YEAJ9V8BHEGH.'*"!?4E@ YW2Y2R9C"#H!@A!YW,&[O)8^3J"*ZA=8M=/
M01\_T9V=04.RJ(WH1JTL85?8;>>:7P"E=8"DE09Y@P>WZ'YT!0ZB]Q%6S#,
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M@@S*P_V@&00E(-2DCP+W)&6M C6Y[D!?.B(M>R4D,\[6LRHT;YJ'IZK8;\"
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M;8OPJRE;"]8AACI1*C ^G)8-WP_!L7/D\<34&=?)YWQD7N7%1W)L4L/51)I
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M235/1*1UUQ$\4ML:'"'48FPC.M\CRRVSO2EXS]QC"(SJGS$B@G1,$F#;I3<
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M4'SM+[4]E"=_1=FL/UV2#SZN:3R9_FZW7*Q )/L-K_0[3M[0B'-G$L=Q!U5
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M.="GIK4Z3V<,R6*/^^9[/<QP,17<OT''_;,+8KJV?]5T[)*:4'ZJ*&GAB4'
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M>84]&:^OJ,Z.7)NF([7O@HP%WK/+B3OB[N:ROA/KK(VK.DXGEU?)U7PJ?JS
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M/=T_C+TIX6;WWIN/V:-!OG\!2[Z^O*;_3N>SY*]E]6508)H14_ DG5Y<))=
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M^2-6XT<9^:9?C6((Q'C[WX+^AS46(H+BY^P-XS<E9#)3X,M8:68XROM=P6=
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M<:+:D=4 /1Z72PT!D<"^%V*D[N73ZL-J)C*6"H%;4?27W6[_ZW\!4$L#!!0
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MLA8HLA8HLA8HLA9'E'4\YIUI^M^2/%F[_IS/QG]=+=X 4$L! A0#%     @
M!CIF3A\CSP/     $P(   L              ( !     %]R96QS+RYR96QS
M4$L! A0#%     @ !CIF3B?HAPZ"    L0   !               ( !Z0
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  &.F9.C!\\<N\    K @
M$0              @ &9 0  9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M"  &.F9.F5R<(Q &  "<)P  $P              @ &W @  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    (  8Z9DZZ0B?VS0(  #8+   8
M      "  ?@(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M"  &.F9.?VP9NJ(#  !^$   &               @ '["P  >&PO=V]R:W-H
M965T<R]S:&5E=#(N>&UL4$L! A0#%     @ !CIF3M-9ZE;Y 0  B04  !@
M             ( !TP\  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4
M Q0    (  8Z9DX(58?TC0,  &T/   8              "  0(2  !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  &.F9.=&S=8A8"  "\
M!0  &               @ '%%0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
M4$L! A0#%     @ !CIF3J\TG PS!@  _"(  !@              ( !$1@
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (  8Z9D[ZXRG
ML@$  -(#   8              "  7H>  !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q02P$"% ,4    "  &.F9.J.F$-/0$  #N&0  &
M@ %B(   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ !CIF
M3JX5<BVP 0  T@,  !@              ( !C"4  'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+ 0(4 Q0    (  8Z9DZ9 O4TL $  -(#   9
M      "  7(G  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%
M  @ !CIF3O*V<&JQ 0  T@,  !D              ( !62D  'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  &.F9.DC/DA[0!  #0 P
M&0              @ %!*P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+
M 0(4 Q0    (  8Z9DX\ZLIXLP$  -(#   9              "  2PM  !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ !CIF3J2<ILJT
M 0  T@,  !D              ( !%B\  'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6Q02P$"% ,4    "  &.F9.&H!":[8!  #2 P  &0
M@ $!,0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (  8Z
M9DY8WC%,M $  -(#   9              "  >XR  !X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L! A0#%     @ !CIF3N48?MBT 0  T@,  !D
M         ( !V30  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M    "  &.F9.67:PD+0!  #2 P  &0              @ '$-@  >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (  8Z9DY]K>+^M@$  -(#
M   9              "  :\X  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
M4$L! A0#%     @ !CIF3M\CR>"S 0  T@,  !D              ( !G#H
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  &.F9."C8*
M[+4!  #2 P  &0              @ &&/   >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;%!+ 0(4 Q0    (  8Z9DX:B)%MM0$  -(#   9
M  "  7(^  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @
M!CIF3GU5N0RT 0  T@,  !D              ( !7D   'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"% ,4    "  &.F9.FPC5.[4!  #2 P  &0
M            @ %)0@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4
M Q0    (  8Z9D[.!4Y@E0(  $(*   9              "  35$  !X;"]W
M;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ !CIF3EFC4[/# 0
M-P0  !D              ( ! 4<  'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q02P$"% ,4    "  &.F9.]45A@K8!  #2 P  &0              @ '[
M2   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (  8Z9D[V
M=N)>N $  -(#   9              "  >A*  !X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL4$L! A0#%     @ !CIF3HC,?M.V 0  T@,  !D
M     ( !UTP  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  8Z9DX"P>*[;@(  )8(   9              "
M ;=6  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ !CIF
M3G;V(:YA @  _0<  !D              ( !7%D  'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6Q02P$"% ,4    "  &.F9.S*/0,/T!  #&!0  &0
M        @ 'T6P  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0
M   (  8Z9DY-O2*=9P(  )\)   9              "  2A>  !X;"]W;W)K
M<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ !CIF3F<*;I9; @  J <
M !D              ( !QF   'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q0
M2P$"% ,4    "  &.F9.)YO8ROD!  !O!0  &0              @ %88P
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (  8Z9DZY#L=W
M&P,  #@-   9              "  8AE  !X;"]W;W)K<VAE971S+W-H965T
M-# N>&UL4$L! A0#%     @ !CIF3HV-JGU] @  L@@  !D
M ( !VF@  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    "  &
M.F9.-]3O\OP!   _!0  &0              @ &.:P  >&PO=V]R:W-H965T
M<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (  8Z9DY9A/4A1 ,   4/   9
M          "  <%M  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#
M%     @ !CIF3ALQ03"\ P  &!,  !D              ( !/'$  'AL+W=O
M<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    "  &.F9.OOK/  \"
M!@  &0              @ $O=0  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM
M;%!+ 0(4 Q0    (  8Z9DZ5<WX)9P(  'L(   9              "  75W
M  !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ !CIF3L;0
M_D4Y @  =08  !D              ( !$WH  'AL+W=O<FMS:&5E=',O<VAE
M970T-RYX;6Q02P$"% ,4    "  &.F9.[;UR*](!  ",!   &0
M    @ &#?   >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (
M  8Z9DZY:UQ#[@$  ( %   9              "  8Q^  !X;"]W;W)K<VAE
M971S+W-H965T-#DN>&UL4$L! A0#%     @ !CIF3FX#EL@R P  ,PX  !D
M             ( !L8   'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"
M% ,4    "  &.F9.8A<B';0!  #$ P  &0              @ $:A   >&PO
M=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (  8Z9DX@H1ED% ,
M #T-   9              "  06&  !X;"]W;W)K<VAE971S+W-H965T-3(N
M>&UL4$L! A0#%     @ !CIF3K&YEV"W @  $ H  !D              ( !
M4(D  'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    "  &.F9.
MHE>^9R<#  "<#   &0              @ $^C   >&PO=V]R:W-H965T<R]S
M:&5E=#4T+GAM;%!+ 0(4 Q0    (  8Z9DZ$K)U,* (  #P&   9
M      "  9R/  !X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%
M  @ !CIF3J9*\C:) @  : D  !D              ( !^Y$  'AL+W=O<FMS
M:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    "  &.F9.,QC5GD0"   2"
M&0              @ &[E   >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+
M 0(4 Q0    (  8Z9DXS,7Z"%P(  (<%   9              "  3:7  !X
M;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ !CIF3AD?GPQK
M @  MP@  !D              ( !A)D  'AL+W=O<FMS:&5E=',O<VAE970U
M.2YX;6Q02P$"% ,4    "  &.F9.$G]DD*P"   5"@  &0
M@ $FG   >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    (  8Z
M9D[84=#!.0(   T'   9              "  0F?  !X;"]W;W)K<VAE971S
M+W-H965T-C$N>&UL4$L! A0#%     @ !CIF3FL'>?/D 0  H@0  !D
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M='EL97,N>&UL4$L! A0#%     @ !CIF3A./^%'M!   IRD   \
M     ( !S2P! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (  8Z9DZX]0,.
M(P(  !(F   :              "  ><Q 0!X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    (  8Z9DYU'BN_[P$  'TE   3
M  "  4(T 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !( $@ JA,  &(V
$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.10.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>146</ContextCount>
  <ElementCount>313</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>66</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/DocumentAndEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002001 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated Statements of Comprehensive Income and Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/ConsolidatedStatementsOfComprehensiveIncomeAndLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Income and Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005000 - Statement - Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders'</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholders</Role>
      <ShortName>Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders'</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005001 - Statement - Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1006000 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/OrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/Liquidity</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2122100 - Disclosure - AVP-825 License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/Avp825LicenseAgreement</Role>
      <ShortName>AVP-825 License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2125100 - Disclosure - Convertible Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.optinose.com/role/ConvertibleNotes</Role>
      <ShortName>Convertible Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2128100 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2131100 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2134100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2135100 - Disclosure - Stockholders' equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2136100 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2137100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2138100 - Disclosure - Related-party transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related-party transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2140100 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2207201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.optinose.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2307302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.optinose.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.optinose.com/role/Inventory</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2316301 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.optinose.com/role/PropertyAndEquipment</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.optinose.com/role/AccruedExpenses</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2328301 - Disclosure - Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/LongTermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.optinose.com/role/LongTermDebt</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2334301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.optinose.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2336301 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.optinose.com/role/StockBasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2337301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.optinose.com/role/IncomeTaxes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/LiquidityDetails</Role>
      <ShortName>Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.optinose.com/role/Liquidity</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Summary of Significant Accounting Policies - Concentration Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Concentration Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2407405 - Disclosure - Summary of Significant Accounting Policies - Property and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2407407 - Disclosure - Summary of Significant Accounting Policies - Antidilutive shares excluded from earnings per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/SummaryOfSignificantAccountingPoliciesAntidilutiveSharesExcludedFromEarningsPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Antidilutive shares excluded from earnings per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.optinose.com/role/InventoryTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2416402 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.optinose.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.optinose.com/role/AccruedExpensesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2422401 - Disclosure - AVP-825 License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/Avp825LicenseAgreementDetails</Role>
      <ShortName>AVP-825 License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.optinose.com/role/Avp825LicenseAgreement</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2425401 - Disclosure - Convertible Notes - Narrative (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.optinose.com/role/ConvertibleNotesNarrativeDetails</Role>
      <ShortName>Convertible Notes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2428402 - Disclosure - Long-Term Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/LongTermDebtNarrativeDetails</Role>
      <ShortName>Long-Term Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2428403 - Disclosure - Long-Term Debt - Schedule of Long Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/LongTermDebtScheduleOfLongTermDebtDetails</Role>
      <ShortName>Long-Term Debt - Schedule of Long Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2431401 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/EmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.optinose.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2434402 - Disclosure - Commitments and Contingencies (Leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/CommitmentsAndContingenciesLeasesDetails</Role>
      <ShortName>Commitments and Contingencies (Leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.optinose.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2434403 - Disclosure - Commitments and Contingencies (Future Minimum Lease Payments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/CommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies (Future Minimum Lease Payments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.optinose.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2434404 - Disclosure - Commitments and Contingencies (Purchase Commitments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetails</Role>
      <ShortName>Commitments and Contingencies (Purchase Commitments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.optinose.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2435402 - Disclosure - Stockholders' equity - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/StockholdersEquityCommonStockDetails</Role>
      <ShortName>Stockholders' equity - Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2435403 - Disclosure - Stockholders' equity - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/StockholdersEquityWarrantsDetails</Role>
      <ShortName>Stockholders' equity - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2435405 - Disclosure - Stockholders' equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.optinose.com/role/StockholdersEquity</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2436402 - Disclosure - Stock-based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2436403 - Disclosure - Stock-based Compensation - Service-based stock options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/StockBasedCompensationServiceBasedStockOptionsDetails</Role>
      <ShortName>Stock-based Compensation - Service-based stock options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2436405 - Disclosure - Stock-based Compensation - Employee stock purchase plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Stock-based Compensation - Employee stock purchase plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2436406 - Disclosure - Stock-based Compensation - Stock-based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Stock-based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2436407 - Disclosure - Stock-based Compensation - Black-Scholes pricing model options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/StockBasedCompensationBlackScholesPricingModelOptionsDetails</Role>
      <ShortName>Stock-based Compensation - Black-Scholes pricing model options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2437402 - Disclosure - Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails</Role>
      <ShortName>Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2437403 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2437404 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2437405 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2438401 - Disclosure - Related-party transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related-party transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.optinose.com/role/RelatedPartyTransactions</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="optn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2440401 - Disclosure - Subsequent events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.optinose.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.optinose.com/role/SubsequentEvents</ParentRole>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>optn-20181231.xml</File>
    <File>optn-20181231.xsd</File>
    <File>optn-20181231_cal.xml</File>
    <File>optn-20181231_def.xml</File>
    <File>optn-20181231_lab.xml</File>
    <File>optn-20181231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>96
<FILENAME>0001494650-19-000020-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001494650-19-000020-xbrl.zip
M4$L#!!0    (  8Z9DXG#'8KDBP! -H3#0 1    ;W!T;BTR,#$X,3(S,2YX
M;6SLO5EW&T>2*/Q\[Z_PI^=+._?%9\;WY-I'/9:IEM33MY_F0$!1Q!@$V 5
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M^9HHJGV\ NLO*>&MMZP2N\#R8+N0P 8"J"RB2C'..,#)2MB<T[5,&[RN)1H
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M'JS7THL.FOF&FW1BBV=W0W1_#+K$&E'<$+ $C<;>RFA5\EO*(R*$ZRF68MO
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M=JE- (@I#-XTXT*707R04UTY.SO@N!?(G2TGM>7,4J.58RB"Y$=EDJ,(<?-
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M_G1J ^E#[]N['NSD(7S\P!H#*&A%4]T*0I2B#GN*TQK*B+QP]1)ZF*IM"=(
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MIE-95^I#5NRDN@D+;SS6X#+1:^]C=$9[%+EG!LE 8K0<?L"N=KJ'58/!=1B
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M=R6;4@G;4:6Z62IH+BG&E?,L$:O?<E-;MWRZ\&C"=RD//TU :_UC.+M.Q]5
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MM04%RRNI$[#+KB;Y#7A21<AE:N]J5R*7<%37*=/.W)7F3Y@S'L%6PB@RI*E
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MOA8J91<1A*!@@SG.O,7*BA!-Z6^*P(6J$8'4Q-DS(\*[7O]Z.,[RN_5QNXC
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MG@U1%G<9'W3?<&2# <1EM"2=X(&O5N6G\ A&>6IX^FKHL=>^T4P(DPZ\L#'
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M7CUW;S#NA9Q-<$[&M+R;8;H8=N1,)$T>(W9JK@N6\+0KBX;65#P7<'Y=$#1
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M0#IB/(SC%%APY$>#5%7%=*>N+$]!10=Q:AM:6031,L7.2UK34!L9.L^"Q4E
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MI:G<L@HD=;,*[DGL[V5P 5!AK+BZJCEC[.]N.YI)G4&NJTZF[?(71X 5[Y/
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M=##V-=15-,M6;!I(ZV([@W';A;V/M77"@'AQ@0*V_]C%<'U%<4S) ODR=2F
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MC=\BX9<\(H+$#Z4)40I(P%$OB&#8ZN(+D#!&"@&4SB/XXB$)LHQ$@(J [3Z
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M@@S_VB/U0A%%3=%$0['&\*LD6_K84&Q--2Q)TPS#N;34BWT2H>H I0R( E0
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M$:;,XC#Q+C+@<5AG<P>U593<HEU171AE?1R"=2WV<INX"G.6JD-S0:^HD2&
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M$V3[*4&>0Q69- _+_@6PNIS=2/)Y=L&GJ4##L,AM9C2*!+GNK LLF;!5XS0
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M9"/018"X\5!#[Z$6'3^I>OVTAQRQV7$?:+%RWU#!99AH3(LI8-Q2>TUF%;;
M@>*(R/8]4*6I8.'-=DAQ@8&@KBWJ:^--YG,-T5,VQW8N%/$B@HV,D'P"%H#H
MW7M!R/Q<M&T4\B"D7UCY&CCJB&GS$36RO77%:QM;+-8U:VRVC&Z&G>8KW!?P
M!,9DJSXZ5+06/+E F6MZU@EB.;:G:LHN#B8/UQLB1E)F4$"F"+%H'"/E3U5(
M2T."P"/(.#I%X(9F /A628!B0>B:8 V3 OH*P"T-TD?641TVVA7T#AP74R#O
M X\>Q1TA88[XU.:Y,(VZ%LS8ZBW&3)7;YD*@0H/;./ZV$<QX2Y!9=_#5W=$R
MSS8.ANY*/7=7LGKIKJ0;S^LO9+UJ=Z37G?UU&TN][-[/I 7 Y1?BN##XE,LU
M7J%Z_0G5JO\'ZF]NPTB^P X=)X=^ WSV)$_E))I+G$O7IJ'%R8"%)X&%[:B!
M7@3($A C)*=4&_18U;8F8"6G6#&F<FSW1=@G!+V3H_B=:/<4^&P%]LEW8OBQ
M+[ ]BF]GW>OCG:3J(UG=F^$]&UJ7U>^CMYX5 U<;N-K U7KC:HHX4O7G-S$:
MF%K_VN_E*+E3?GW?OXX[,/T]^G,6Q/FZ'LY^&9=BC333ZDVI> 0TE](69R"G
M@9RV6#?F2%6>3T\'PN;LBJ,?5^*?D&US+ #^&J=I$2-2QB*QU(E]0[ '8_'X
M5U-- E: @&=QCM$MS^%N;]F:W!>N%VYN2J(^TK7>[JZ>#\XW:I .C'-@G /C
M/"/&J9HC2^RO'^7 -Y^MUI]ASZ/C18[;-$@\\H.P2@KJ2*UYQW/$WA>)MK_?
M"',RPTHR-,TKS^)DW<H2+%( :M]7I@//SNHLU!$TJC6V"R4, >BG'(!N]!*
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M\#$"K,7I:R_#F87Y# XD6 89P[/BE1F>8Q900W*-J!@4951O/41:_IBWC'.
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M'&Z+6K8N*JXBC357UZ=C96II8J&]2*Y\<=K+'HKE%^)3'EQ"&FFX!NIST6-
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M\@JR%;\ CK WJV&JQ2]>1,4/4P:LG^G5&<$"]KS[31%%PW719O%6%H/T_'C
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M>-WQ!B3+0$UOG9HJ2BHU*I:Z@"F?1:Y!/66GZ#\6I#3,B'9\:T8 5D26!K
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M%"AV'D)W>7DI+8A"K74SYAA_2Z'\% )+P/M?M544O\@YAYP347->7\ZX27W
M;FWX5I:.A=8-]F]18S8O%_;E]M4!O8!L%*X3G> H7&(Y%B'V))*CFA_'*] W
MP(:*FYU9-QD$'/_,F.SSJEIQOBA?&'N)]<C/:T# .&(X@B:C:<'2F)@A*C;I
M(3(F9R"U":^+U^ZF#JA$,U#N""H$;UFRS_T"B- S;"3@+0@8^]PSQ[/+=?%D
MN>9^G"#"G2W^%66IL&$(C,PQ:O71+DA(#*9R9:.A>VLOQD]D626>[/"5$.KQ
M&MXQN;XAPJ&[5('!CV^B@!'>:Y&FC[&?IO(\A,=V8(AE5X)72=12AP#\Q<DI
ML53]F/;G)YP":LXG\PZJ6OE+C%",*3^CPZB%F+R]^J-J-_@2<TGG@U=%78\K
M *Z1&[&.#AP]7F.BMPK+@(5\/^ -D&QY5AD78.QYP$8* JZ@(^<YQ_(&=I)"
MB % R#'4\>I[)[[CTBJ'LFA*"JP\E0K1276$4D?.OY\LHP2SDGG'4\SR4'27
MX2UG6&VC]HV4 M_!%239.!X&9;W0@$2'H>@<!/X#TXJC5>S(U[EG8[M?Z.'-
M>UU6LQTU76QYTFJ 39L&;#JI!=ATV'\EM.@KD4U?>[EY_+Z!78\ \PR#S@Q'
M=&SG8&Q 0!N_)?SF[MBO>P, ZIWV.5;N"\XCCA'8ZR::IX]@>_?!8RUGI;=@
MI"/09W^#B!4<(XAG*26%_\E^%G2BC99[ 4V'I]V.47,[$.PZBT,*,C4FG/L_
M*.PTJF]=]9T.C?*K@Y $>'>/7;MZ*L2HNAT<%#PLYVE?CC?*I\G'>5YAOK7S
MLA64X:85UHZQV*[<YZ\1C=!]8'*480OVIA9^JB]<E!$(/)TY3U/*%#9.<628
ML,.!;?P FP\1Y0A-?NQF"X0MX$61B,Z3LGPJ::G0A'*.LK<%88'X&*O\ "!@
M9];7M=, L4S>('G/ I[?YSA%VAGZ[4H<P^ X2PVPZ(DUP"T%AB]F^;6)F'R.
MJNK*Y/@1*>94/^6TX>E72;_RV$+Q.%A5?C;PU%KPK()Y8OIBH9=*]8:<63.=
M%#R5BZG6N5B#!(\JG0]5/CHN/XF2VGS^IFA$*IXU>WXMI19A5,--4FVB+JY-
MXU@\;2;"J''8P1K'S\M39%K0,MZP4I<V''VWW1:U??W;VE(YD%P;8[_?W;W1
MF$E9Z\+/\?@>!=1-+"86TW#3FPM+#5NW7RGCZS0OD/C)F>\UJ 596(#E/7+,
MYOIH33&9/1\Q3H/7DRT'K_.F5P3@E2!9ZO>J^DG-9V96XD9+LJ.\Q4*-O<S;
M0\B1IC'7$C* 1I97U>R>6;_3#,+2.\O'O2N[I(;<\DG8!-@@1VOS6LR$+SP*
MQ#'@PD=COC:2W19=O?K(=U'U637[=<N1\-O.@S\$051@7,7QVG,\6TY2MDQ$
M#8YP*.1[R];?-(WAEN4<*TE]8KZ3Y(- "%'O^2\T*;OX\TTS?_-S=[H;70K7
MJMH:^E9OZ*9.)/S9PP<JMG-EV>_:CV3'PM:/1NX_@=NNDX18^011^F"W&I,E
M<*MD3B4U&QY3]"6C,'A*5*C4)XYNZ4R8&-K'BN5 %296\7TD:YKH\B<8O8+-
M14<^/N&6J5Y[ <M"SQ*OM)4#D.FF'A:Q$*D^$F/C^OC]?H/HXXM 5!)V8L_1
M[-N(/88PB8[<]CSV&[&^0I.+E6S\?F.="-8CX X[-YI\ZCCH3O4)H6/SXC[B
M<L)TV%0_*U+_I(+NF1.D]RX'.8P>D+=!^R_AI2EP V[#:.9]H$'1G>F]$61&
MU4S<DHTO]B10L4?"80"T,=\2"K%B/1Q%SUDAH!['=.3?D&S=8>0>XAU.%VAE
MQ6#J/R..1>P_$$+0:<CNHM2G[V)VB_71M@BE,6>7 R[GOA,I+PF;]$0MLJ3E
MF=5&*5WCWPK]2.Y;$?U,6/MEY(<"3/,)+X-#D-#ETE/+L3$CU\W@K69+ZA'!
M@#E><;5=85)(*2>E@>9JF?3"!6.+TK*$G"11!H5K>7" "E3T4]#C&G)*XL;^
M+69V&%CL,^L+GZPDNE6*;&UY$663>!;%0LPI@H,#9A)-&0B$561^+V*)Z-HE
M9N/PL]+OH]$1LJ;7YPZ<+B)%@Z9 N@G'!'] 5?2B\I:_"<J^*#,KG07UND[P
M\>P',#26T/.7BXB\?D)@UA^$<50ER(E>@@H/N847.>?&CU(YU"(M"7%FW=S[
MRR4M 4O]X7\"OL5$")GBJGM^_D@:*:>O3'+)BF=4:CZ"" O^X36W'F*K)*F8
M6J^ZSEHHC<_8S&^:1'Q!B; %GR-1<QQS>"U_EVQ^H;-Y"RFR'D?F(IY4)$"+
M)=2<G[GR.%G3)Q]*!>F)CDZ_2544)7#M2J\$6KW9,09JD9"G7.VH:O:B"^H4
MNH!1U<6BCE;4 2/+Q\54QK\(-A#,/ZH9TJ]<BLLP_4Z21"ZWB2K$W: ?B=9)
M%#Q@-OK;!DNX!?5$;P+?K,*;AM5Q?(5(]0;L0$]4$KS).D![CC8EE!GNO.:?
M-&G( 9$(4T$+&$B+T" 0^HA/L<D;D\!30.V'];$AG54PUT$<E@^:07*2*(3M
M E$?P$FB0X462MN&/,Z%-$D'J%N*>]O$_H(KI4.ZV76TD4$]IOF2@KEX7QIZ
MUL+D@3N=Q2%\D/NON6N:WONQ=XH!PHK[O?E7 IJ:(,RT<21SQG1GW2= <RSW
MSC-.#U$ *\*,F/#N441\?I"F79HO5H,$0?A^H2<XX+_(?4F$-]W%D<-[-/=?
M^.[Z^CP_QIA:AP4.:#Z=5)!5*H;@MG-8;O*'(AH,(-^BC3LM>7&VIB,$R)C4
M*N"EA-@&P9NX$.<D</P%?1(60-V$WXLODR(3.2. '%!11\4GNE0T9Y[X<_UX
MSE<-\VJO@@H?+$IS4#J'JQP-=^^IFS@69Q8-J*9PWZ+9DMR=D-J#+;('-"_Y
MT!;.,'(-\G5GPN/"UHR,NJ/$8!PQ@P5[)]!46=]#[&L2N##B$)>/4V*A1[E%
M#Q86KSBT7%&KY@G+VVPE74<QWQ09%VP'-H&T5=^\Z&2E\: X_<YQ@.)T>R\&
MQ=E@6QL%D_-&3L4S84ZU@V&=6JKO_6NN6K\JY?OJ J3&2]GH2*2L/ZH#>FHZ
M[O0.5::>D: OTD^]*/FIE](M78].ZE!F=92*Z$O&%)%R;'.7FM+J,C6<3Y,H
MQO_Z81.?"D?';X2"H?DSE.Q*5>Z)TN9Z>IRF\6 3]8;$="K1^7CAD_*\ G"L
MY5=:RVR>VWJ\CRSN P=Y^[^>*U7SZJ3;ILUVR6_#[UWPOV7VVO/G<@JL=-,?
MQ3DM115YFEL\4 (9(ZTH82KR;<7$Q=,4T1;Y3<SLVB+ PEO JX-O_.0^;PA.
MG(4V$<])"QZY*F[0\T"V]JY]CF@CFQSRL$%=NFF,4[Z'KPQ/ZT1;M![U";3H
M?%944CSCR _ _201V>DL]&6Y /C,"(PD]JDF!N$Z\=@P9$$1,R"M!ATX9:%&
MF?+#Y=&BG%CT])NCR.F1H,"3PE;I_CG'T4 U%2;!HFEO>;VA/GL),U KEG(:
MX  \3BL#$VEL]9YL=06&Y1ZMM]Y]?OH*Q,SG$_\>RXTW'ZZMTC2OM.7<<A?R
M _GQG- .B6ZX,%>L&6/*@8H$F4H[<;.=8TR!2L*1]6CK!)Y,$?6OD.51Z25Y
MRJUETTHG0B4%_XQB?PI"19J5LHTHF)>S(AR@KNYBYB]NLQB/XT[2^SC*[NXW
M9@$_%/-C' JX,J]GYRF2@I'8KE3J(#2IR2TT);=06.[H+57KRXU,?=F'"Y$-
M_37'4CQ\X3,I!Y-RV#;E(&KYZ%BK'I_D0H[D$84KZMQ@B>X!%4"4(PZG?,!F
M+2.0^E6A;DRWO>!!(.6X]X!7% I3BH/X**(4IQS\#!G=B*7$ *2SD0+&GA9=
M%X_*?RQ]H5CRH4?E=1 (D"B-D@4RLIZ*%Y.*@Q\ZS"N5!JFS>.W(2!R#Y^D-
M/BUHQ=OA\)D"95!D5/ 7X/Z(JS=[6VNCZ[=SIGB-N58_J#( O&A)'7UM.KQ*
M&,&AJW,KL0ZQ=UXA$"$8GUXG4R*]/N67J+SDB9H7U&WJ>(YBL)'6$5 5X]O:
MDUDPISY:FZCOQC[O-.!'9H4RS.)IW1%X@,8(Z01]L@?ZV,W07_-BBJ^\8J(&
M0W16C([]))\C'ZD8KY!PYET<%.E:?V/8H>R3,KR+'8%YSC^-F0QQ8YEH+$2X
ME7G0VE.@0FERW2NM3$4)PIEU#89.[L?F0/\$UJJ75Q3*P$2GLZ(!KQ=U?:Q"
M 56( *<\ 4S-6*KS0?T>4Z:B]@7M,I:\%1+%8A#K!=64D^56E^I4MFYDO$QO
M4GW\!51YGNR]+*I>+\[N5(&K*"U/-%!:- '4S!UZI7FTP\XOTE!O?%3>]\5;
MS^_ J#M+X7R45I$/G6? 8S[A?8L"?=A0E%<X\PZ5)"W5T/#% )>HU12>B:B7
M:%3Y6RX5ZQ<<B3 C]&+D(]D@((W_&N76M@6F<J%Z:J)'1D5ZPOP[@5;IPJ5G
MC7K6I12AS36(^4WR>1&B=$JF[(DO"TQ*R>R\ZE_R_3\SAU O""-3G2L)CA;7
M%%IX%HY7*$/GWZ)7>HN'+]5EZYA YZ<!R2[' ;P/RLN!2XL' \8K.#*OP(2F
MFT-3*J 4[D#]R?)RX[ 8V;M6PDFUGW)( S^ *Q@!O)LOSKI5S*&9'U"E> ]U
M:"M*XB@.XPJ.GB\@C-$"Z :V%/OE;L>MFNJB++A^/@[J!%/Z#F&.%(UT'E6J
M:#E6A9<80DD3@4?=RNCD1GL9T-A@^G<4W\'NQ5II'ZJOLG@:4&V8])THE'Q1
MR)C_L&'>E%'11D4;%4WW^TRIC4^J:+T>+?VY5 J_7BE!=>VJ6_#I"GD9ON4%
M]6YTBF4TE;_)CSX)/M^36271MZK/:)(7%RHTL"X)5*]/I[!D)C 5I30J:L@J
ME_M4F(5$EF:3MM7*[R%67?+$&(]%J:X%,:CX;XKE.PI:W\^AK530QPT1Y@?S
M+?C:O,-2YZ5PF*6&I"AEB:T4^/GF&A8UJ(2M]2N]K9==67_3@(F+[R&NOT(H
M#;$4D*']K?O\I%ZB:%D"/&M<'J8H& G+GSS.: J?#0\)DDR;TLE[A<GJ(Y$"
MK 9T^:0,V2&/-0+,FOW]R^FD-[1^%5_/Y-<"U6/V $Y1;'WAWB#+2,\G=BZC
MH#'/K!/^LP_6R6]1RO(OQZ+K8^-3\@$<8GT>/X-(A/?&.UQ2YMZ'41#=K6PK
MC,+3F&'&@UR/;'DZCR/JRUCQ:@4UA"@'DN$.V1VJ$<R,TR$)U3K JP$%$84H
M:GGE61RMP#5>R5N2U\??40TV8<^3%_/$A6*!)U]SN8*$]!SHK3OXP1WJ3:F9
MU1R4&I;Y\[AC=SJ=.BPL;P4+F9N[[;@A'^&T<'HGMJZ*#AYN.NYQ&*7TB66D
MI,^JRGFBO2T^G\-<G70[G+TVO&DY!RJ,\#235_P*H1<!&PL$=5&WB+99]C17
M:39\QL_L,("QG[Z(X&LT ,K\6?#LOY%(B[U,SZQ_L!SZ0 :;RDIC!V">U:,3
M.(285-7,3ZQ[KR^\OA>LAK[QZ!'VO22&%F\1I;[8X(R_>T;XQ5!%3YZD5H(F
MY?KE&952K*Y6[(;'%?A*<R>L".)5'M]*I;[J:N$WB02HD]!!:-Y;#>M/_,(T
MM]G-[\@P@]/.5,P ?G)9I79\S."#A=ED8,I3[M H2653J5%R/?KH%* #_% <
MX7-D3DF<2K"7#2^F[ %HF!V<B.0Q8(X'Q\$=UD"VF4<1:"(.UPE\HP7;6T.^
M46@J,CSA+ER^.[V* )'S(J'BY(5V<1":5448/MZQ#BL^M<>C[3%5GSHTKF,Y
M(#2-6<O/77O2[]?AWS07LO>8WF=M<[+SZ7[!,]G79JBH;37PUPTVL05;?'+]
M0@L[&P;B(FS[DQ?*'JW\V(5&WF-<JO_:MER@ (V@3G&-RH41CR_&KX4O2T<2
M.K!="0M/(7 I!T8_\DBLDXNOGQ'>,L*Z+CP?((?(C:+8XVXX'0MQ]X/?W..5
M@1L=(JR0?. CWZ4>R],9Q1VKXR!8A YLJP:#X_]6G3Q1E\=<Q[0423,> NK^
MKR* P.:CQ3\1%9;>B1X8ZC1?XJS25:(NPQV(WA.PM/*DB7Z43T M35$6)S,X
MS#@*3^6?=)$OX-L5\H>SP 0@=QLIZGEZZ'(^>#3'3$O]!2N0A,Z>-MQ'$98<
M!S6*N$ $>)_%%Y?W[\"[C7*'FE<0$GED#AL<&:IDTJ!D.. &@;GQQ,L:/:M<
MID0Z39J$VE9&WD^1]V[A1:K4,"+LE1\EULN;"Y'H&&D&_L+G<86MBV/N?&'J
M%FYZAY_3?0B+!RC)UV5K-90+/\%3,B=D499(2:Y<AX"]JX:/(>PJK A5CGU>
M0U*4+\4^BP@$(R*,5_$D+:7,#P?RHB;][>X;S^Y-#=9-&KG?3SE%D7;P!M\
M1&H_88,8!9(?/ OT3'U?2AL0V".HT@0)8$5+KON=1R<6!T0,&"E:R99WA(<I
M?)#<._@HT4Z;IP/DK\2-53LY';$7.%<K9%J?]X'K2'+D(S4+^2[&V);JWXK:
M-Y/QTGG@P!N]<:D:6FR,VL:1L1>1!U((NQ-SS-.D0 #YW)=NL+BD;5X!:F#!
M?OF>GQD<3>=IB4]=\:22A4:W<_#07.WB!:2-\O'P.HUW7[&>>"@L7"'[Z;\
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MG&A0);_?Y.3XZVSV19]HZX<>K#=>G>+I.(I(X6HLX/&UVFA5+>U8<_^! 65
M8ZK1VK>L7)WH%DGC2M+82K_2_+%@Q5O98%G^$D<[47&I*IJF<_9<A<:"^/ ,
MCP&!^1 9.A^9\YK*NPA+(H%<8DPVB81ZN,5OSD_Q\Z%HXF%\ &8B]D,?!D)2
M:1(1+V;E;A;FB]>>55%<Z@1))*:^)7KSGCY-;BT='8$.$D4^)/SS+)@#(52Q
M[4;2YB_W\9Y1-5&283D[/2"YE[-S7&=)+(VC+-NB [Z)WHRT$"VB DW!H&)M
MQS\SG F$A\\//#\)'P3R;UUCNMBV)@N2@<P93GWB/&'C<'9Y"IV/+EZ181#,
M5V[2 C^9WB@J!/DN\G>DOQ1]$0CCJ)DF.>18%'717'7R]N4ZE2"*$<HL+0S(
MXT\O=O8A)]T2AV&9'^<A;2(AYU9U7ZSX+58&.F&8%8;DRHKCK:L$Q\^T!#GI
MVMW/K)F2?I<8EE?^%:(?M6@^PQ!S 2+2T4Y-'R-1XY-\M$[\#_GBRG756)^
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MY+ST:9<*K!VX>N'$=W[(%^F 09,?<&AD^H176&'\)C%N70C8G67"/LI_K/%
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M23E-6(JUYL79FXJL0&<Y<8BU9%$L<E5NX/@+^H3_4)9D"K]7E%HM,< *4^F
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MOS>;=2^[@\'%9>_R2L+OCP?=ALRPVY^N%R3,H5C$(0.&0/./;V;!7#K_VH:
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M-6-T:7VE[!M^M/O]D,E2/YZY>\J=!5K:EBT$P]- H&O*EI=H9@>>..L%Y,_
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M%4J2?!0_]'U,9C1\ L]DKWT:=]UW:&:I_/@TZCC-6?2>SZB/F,"03&6&'4K
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M]K?-<H7?6W.H_TO[XP__!U!+ P04    "  &.F9.N&F:.9H>   C.@$ %0
M &]P=&XM,C Q.#$R,S%?8V%L+GAM;.U]67,;.;+N^_P*7Y]GM+$O$]-S0IL[
M'.%N*6SW[7.?*K!*=9MB:8JDE_GU)T%2-B519)&UD.IS' Y**F+)3'R5R 02
MB7_\Y]?;T:O/L9Z4U?CGU^0G_/I5'/LJE./KGU___A&=?#Q[]^[U?_[S;__X
M/PC]U^F']Z_.*S^[C>/IJ[,ZVFD,K[Z4TYM7?X0X^?-5JJO;5W]4]9_E9XO0
MHM*K^2^C<OSGW_.'LY/XZNND_/O$W\1;^[[R=CKO^V8ZO?O[FS=?OGSYZ:NK
M1S]5]?4;BC%[\[W6LR7R7^B^&,J/$*&(D9^^3L+K5\#A>#+ONT$G]\6_/BG_
MA<U+$V/,F_FWWXM.RG4%H5GRYK]^??]QSB<JQY.I'?OX^I]_>_5J(8ZZ&L4/
M,;W*/W__\.Y!(]7=M!Q7D_B3KV[?Y )O3KRO9S%<?+V+XTF<0._S1F[JF'Y^
M#<7'P#C1A"[8_H]GBD^_W<6?7T_*V[L1\/JF(V+.X]26HUUI>E2K'](^63?:
M65H/*W5%V.<[3<7[TN<N3J[K&/-KM)6RC;5Z):WIJ#:IW!&A9]7M;3G-[4].
MQN&L&D.!:U!8Y?8A;E"U?R+?SJ:S.OY:CLO;V>W[" KGRGZ;EVPH["[:[I_-
M>>\=L+2VG?[)OYK5_@9Z7BG2GI?MC?;/6#-EV+B!S@@>3ZI1&;(U<6I'>9;\
M>!/CM &A6RKV3>"5K4%*-W%:>CO:F]JUK?1 ^L<I?,Z']3*=V<G-VU'U92<9
M;VR@;X)O+(!P\F[\(0:883(.H2A8KM,2?KT"ZF-=YRJ5_Q-0._]Y4XT"F+9[
ML]B^R^,5RM[0[;/_OL55W=[5\0;LE/)S? =NSFT$JMY7D_TALK7%GEFZO(OU
MW(':FX6G+71'\CT2?JNF3::=]>5[(N<W6V>^/\?&4WNS^AV1>^]F YPN8 *>
M?GLW3E5].Q^I^^^VD;Q+&QV1?0'UJV\QGL9Q3.7T"J:YK9+=5*='LAJ.>X.J
M'1&YT!^?[-?M[\J:HMT3L>L;TJ!J]T3FY94P&\7+=+Z<;>#QR602Y\;K^]*Z
M<E1.R\;>2 =-]\GD14K13[]/-O#M!U#E'Z*OP#X?E8M7NP6G>[3?)[N+AZ<1
MU-8/BL[AQP3L!AB$M_"\O&[%\7Y==,]T,]_LV0J=$?09)H6J_K:=D$<%NR:@
M\9BN+]\U.4V'9VWQCHAY7_YK5@:8Q[>1\:1@UP0T')SGRG=%3C6^_A3KV_/H
MMMI"Z\KV0,:N<V:3NCV0^4/]K3[=@^9&#?7 0+/7\?D:'9%T65_;<?GO^;0(
M<\5YG/BZO,M_7:;3V:0<Q^V^Y2YM=$3V55V!US?]EAT#>$/OFC@3F^KT2%9#
M3#:HVB.1S="XO69')'Z(H^SE7UGH[%,-_HKUC98(MM7KF;R&0]VP>D?$SM>L
M3NTDAKS6$Z&WW-DV&C?7ZI6TTY'U?X):AA*3J[KTY?CZURK$T>7=+D+NHNU>
MV;QWR^??WN^M9.>\%8--6^V5M5UMB-U:Z97TC['^7/HX?SXOT07J&C;:+V/K
MX;*(%VC'W0XM]\IBLTFL2=TNR5QN%^0)<[O?\WR-WDC*FZ7+0=P%!@W;Z(WL
MO6D=BL _LOIJOO'>N(&N")ZY2?S7#"RXB^SQ;Z?OF?(]D=-4:INK=4;<[:VM
MOUVFC^7UN$REAV$Y\;Z:S0,+KJI1V21^9[=6!B7]!/X*Y6B69]N/-[:.DXNO
M?C0+,;RMJ]L+6X^A\.0JUO,O&X]-[UT/*J2S:NP!8XN]Q@_EI+&Z[*3U05GM
ME+-#,M+MNWG0=[3%VD)G'0S*<$-S;H^VGF7#VY&?C>:OX'OX>UD\T[Q?;/.B
MH_AU&L>@T'KI:NT(?>\Q]W??XZCR#V2Y[&4>1I[LQ,V#OF<3=&WMW9LLXS=Q
M-)W</YE+'6&RC$K_C^7C8DG.RF;BV:RN5Y;61M;%T<^OH?=B:YU"<TH3]0)Q
MK",*,,K(&2908H2(B"DSG#QD=93C[ZMZ*=OG>'V*F_SDGI /<1)M=I7SXN7G
M.*KFV'^>C\9UBT X-=(EY+'GB$N:4+#:H, DI9DGYE@3?E;0<E+[5U4-9N+/
MKT$47V)Y?3.=_[IH!6AY J*')P66)=Y,\IN36T3E--[>U\\G('H9K:I_V4%;
MK7#P,8Z@[/4O<1SK'-\83L)M.2XGT\4Z1#- -&ND<)QIX[1"41N.@M8"><;9
MDCN@4-E&2%^/#/K"D=&;$+=#I%.U>%J-9Y,=5.+#\H4&C <5,++$"H2Y<$AB
M!?TE8U7DT42-]P<)>X$@Z5I>0^'A<GH3ZWWFRLT5BP "XU)+A#6CR+G(D(%W
M A&.N3:>:Q7U_@CA+Q@AG0MN**B\&T\CN,'3*_MM'H^\%2+K*X#PO%%!@#94
MPL,K$#T*6$3$C?:.<@FO1POE(5XP-#H3V*#:XWYK9[E]^%0FX+C]5HU],Y6R
M6VL%U=1SFB2B7 5$@Q1(FD 1=<Q0I;3',>T/)OF"P32,--N:MN#<AYF?GHQ&
MU9=\<&?#S-.D6N&(-!13CH3Q'@E+!6),Q87E18,&'1KWQX-Z@7CH26P#&ZR/
M@L6;6Z[/5"QP]"D)11'G5"%,LSPCL0@SFKQ6AL:\,+(O4/0+!$IO@FOM_MI1
MG*P&<]VO,35T?+=4+[#B7'-U>L[U6W%R*L4)N6 GDE!RH0D_-_O#P+Q &/0H
MNA] ^,>;=8N-W:]"KEM?[7C9LT$:@2%ZW+S>VDG'C0_Z#];MCB?S!UQ^7A[^
M&U\O3MH_(/0[C;.XR1INUD+!<  EG RBB5G$+087@2:-HC5"P-2MA)/[+$T/
M*H<&ZPT[-50DJ2A3B2'EE4;:@N/DE&.(J$2BPPX398]]@;L7!#SV$OH6ZV"N
M:#-&WHT_0:_Q_T7[XRSY_FA;;:U@)BK)I$$\!8],$ EIB6% 1,#*B"B2:[&N
M,<S*^1%!KJ5LCP]W7ZKN4+=LJ_#>IL221RSDW0:AP0['FF6O/<"@$)Q,"R]F
MF(7XX\+<_I(=P+K=+Z//8.98TTP\@Q'4O_G?,%/.D($/\W/4FQ9&Y@4*(T-0
M6% $+ASXAE1AQ*-22"H##SPS1-##V8T+(ANL\JR6*X(RP7L",P0+$>'H Z(N
M"+!62**4>^-,BUVG@<(:]AB>QRLX+84RU-R94QWED*[/=C1_>Z=GMJZ_P=O[
M?^UHHV^TN6(1I0PIQ-PE)4A)3A$6@B". _?"I2"%>!DPV&L,JYZ%-10\/D0?
M@>JLPG^+&\*>-I8O!"4T6J>1B\$A8Y1%!(,DF6=.@MT8(V^Q0S100$MG8.A*
M1L-M.B_/_0.U&[>:?Q0KI'0>9&21)9XA3WE 3CN.%-AMD2FF"'?';A1W-^(M
M13-L($K#6?]IX0*8LBYXC)R1#)$40(-%39#V6&/B2'2^Q8+/0 $GG0UZ)P(:
M<(LOAT5/?NBF1NI^4[7"4&V)A.YL$A(I#) WVGAD&68*2Z>];63='C3(I#,X
M="RJH8!Q'_F?SPE/5\/_-T\&FZH5B2D; /'(*YCE8O("><,DR@&;1%KG.3WZ
M5;H.7(2.972 6:)Y2-'C\D4(#@>B.:(4"T0MP4@X'%&RB7J8'XFR+8)$AC00
M6F&@*^$,-?@K&]R/<IX^/)*\!@?;JA:2::("QR@I88!7T']<6(&T@W],QB!\
MHSB WCEOQF2!I918!XL2YC#1VP1O;[ 8&<$$=Y+C2%J$\0_C G<[:%67PCH
MY+<;1&L"0&CPSH5(D2%<(HN=12I)#XJ=.*Y)Q+K9N:4C@<%N(_7\B.\OGJ%M
MXL;!UNLK%)YZ8 1FA8!30M0S!?-Y\B@ED02+#(,$7A  ]AJX9XSAUI(:. 3R
MR(XR'M( [AX1G0EKL+7S*A_*]],_RNG-V6PRK6YC?<_ M^WX:%*]("Y&*Z@!
M22:87ZGD"!P"$(&F@F$N3=(M3HD.8R=W#)6>Y#:H_]3,FGQ<M'#*:^R<1Q$S
MAD1@!DE+'(I!B^2\P2RI%Z0X6MD2'0AG,!-R-1%J$Y]Y?84B^>2E(PJYO!Y
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MMEI<V/#L%6+KL+5GDP5G# NO!>(D)1 53LCSO _@M=&,2>9\BS6IE>2$Z"^
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MC>H5T1O/',FG26U>#R,4R0CO ]@.V*O(")<MEHJ&B5?I$ 5]">V(YI[5U#L
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MM/*D&*7DI)3:VZU?HP]65$.K TZ@IABQ?5&B@ _V/&&400.T<%"08H3,&C%
MOT?W?*B&55>ZPJ_I,EKCUWGV;1I,;_WX6[!D/LRWEZ+,;U4LAK_V[ZJOB[4_
M[X@N<?[+$D.@TV%V(("$\E)Z;XO-F1G%2N5,=KO/-&B MHY7ARS:%.9_?O//
M?H(\/9=8@CR189]TFB'LPSBTVHXE+'&Z4SVSG.S;%-A;;E2&JBNQJ\G_6RVV
M6219<4=&^J+G7[+FEI<V/I<$V3AFD1!:"(LP1M057@'A!:].PM94F@Y). #$
MN^*R31_R=%Q<\/(P2[?EZ-5]%C;W_SH5%"K3/'%200(0LIYYXPP@4!>:AK"
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MN^3<FMOGORR!4A&F++$J*,A02:W1;J\ASE?/@H?@TAG9.II#,#H:HMCA=R6
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MA/1K(?3>>#!(Y6\(XN_)=?BT<<7^EKBN9<_S"8-6AL&%15$0@*'20IAM: 8
MRCH5>CE5H*Z0WMS94A^6+DV]IXVNA'/HY<,)1-(B+BCA1+!@#U'.Y6Y4'G9Y
MGV.OGJ!:L/0C[-)V_;XF"71A_</.*>,5U<QXRVDQ0H8P&?867T=D1Z5?&Z'W
MR(5!;O-#H$!#WH!X$&M\EU[-#U^RL_>Y)!B:U@ N-<9:( <,T:#HGV%JH$Z<
M>E!GS0%25V!?_LA*"6SW7,*4 D#+0-.@@&@( 6&H2'M11E2?::VZ61H76%5
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MR;:UC$.O@5,#K*!37P!9*]@T*U&;SD:/Z<3FHS^.ZV7GOB*A%AD1HXL@Z")
M$,K TZ@(&V 5M0XDW@A6W95-RJ=1B8E5/$YH<:\?39Q 5A".+$92$@2E4'X'
MF8;5E?7SLW!ZT^%J@M*'F$_NUV\?3@@DQ&!,?;!:61B)@-N[6<+B!:GBP];:
MJ@OIB+1K(?->Y#Y(#:U/<??F:YMD\W65JZ^C^>_K;*!T$KO]\8.^^G32$5.J
M?0(1,5QA;XRT@$J-$!#%V+'L]*KVDKM]'0&^=<(U#E$_-MNG=)+>/VPOF9EF
MD[.<-_L:)X@ZY( 6F"&.C7>(0K(=M1<653\&<GY.YD"<.0W - QRG&G<[V^>
M",LD-5):0KD*_^.05L7(.88#C^4T*=JS6%,+O3\3?P:IA@R=-D.DR[%+X,]\
M0P*,<8P [9RU)MCS$-JM5PX"Z6O<[-R1.ZJN6,_B3%78AD&;8_?&G_F&1!-C
ME80<!8N!8<N\XJ88OW"JNC+3D4^K4]I4A6T@M F?JKO>/'M'H@PGP:B(PQ>0
M0BP(Y 4&5/,!'F+LDSJ5@1L&>7RVRFMRY^D5"7:6$0V -D8@RJ1@3!4(.%OC
M!$1K)QI[I$YEW"HRIUS%O5C3_DB=SMWOD[!" ACO$F96>^XE8X4+ D+J5?7<
MA_-/KW5N+M=!HG7I'9S.KYY(C("Q])N6 E@6%RX*7=%O2?A [=F*V+^67"T,
M+D>&@[(INQ5==R+[)<!WO[H_*K07SR3,2X.5])IP @P,_\M8<=0.<"VZ%%N)
MTH954,^:&7L_:M)O\]4BG>@LS[,_XH'DT<-H'.\D/'7ISAEO22@SD +.+594
M*8F9I\6FCZ"OD7;0D67_L>&#HTVBU0]K_&B<GDF1IR8)84 !S*@!QFD33 C$
MZ':$V'K5Y0F10?"A,C35\XZV)8R^Y*-I>/KV?Z]&^3+-#Q;Z./1\HC!VAEC#
ME45AG=2,P6*)P\:2ZMZ7CDSHZJ)L$I>N)O&G]%LZ7Z7'PH?%(XD&2D)J);<6
M0$@X%3(H+1AS*1E6J+J^U9&%6W^25H2B\J3\DBU'LSB(9?:*3[^FRUB&9/$I
M%@LZ-$=+-D\<Q, "H9D(*PVGW "R6V*P M7/X[96D:?1*=L.3/ULP\4]:3&M
M87UB>7*=YN/PB]%M^9(>QUZ2& *(BB:+\U@ZY[3TA>E"!$'5U??6*O>TNU4W
M"%;E=>)PC_PLRPXF"I]HEG!$+>3026DM50!(+0M[ATA+JR_X?.BB;@&>AH3K
MT_2WAS#P]=_*"?9%D\0:Z9%R2!B#M64(,E_H(93#&HN]N$"AUH&F.8&Z[].S
MI+E]/J%>:D@H#!U64@B*G2)%?S60U:-5\C)%60V7WH-1VR*AY^[2!]^0"$P8
MHQYICQ@&2@#NBX6)>D&KWX@.P=")T2Y4#4WYZSQ]&#UN25MNUK]HDEANB-/4
M<> Q#1:'!@05O29&UCBG-7C_6</8-"11DP7#<!3^'"WN8A7/E\7$RXGX^#L2
M;%PP/[@ B$MA)+8 %]8'=8C5N*5K\#ZRML'J:@<H5$CW_2&=+]+GU33WK/9[
MGEZ7$C",8XPHE"RP6<+"GF!>\!K7? W>N]8<+%V)6]UG^7+Z7^MRSO$V\*_+
MHM)O6+'NIZO[(\(_V3;1TI#H=M".$,VH8I+98LS!VJRQ!UR,.ZYID&IM!L6G
MGW=JD^QR;/D_W"H!-N@F1#L'L%200(%\$?5A"M@:5?(NPRW7*#R51;MGN=&C
M\>]N/@G*QL&=_7BK1 -/F,(L^HHU @!(4M"20RUJA, '[T1K'I[N[+=-I6X_
M#8K'.%T7ZOY'GBW*%#]_TR9H*#:,"R'$N0X+%#=\EPG ?2UU;O#.M:;!Z8H
MO\U'FV4HG:RA6"Q6L=];$A]AP?&&B>!$8,R@TIH8S[6S>$=WCD&-/*;!N^1:
M0>B)#QV4P_\\ODLGJW@AP/.?OI^B]8)2"Y77 GLG!7&.F8U$C8\I4*74S"[&
M6*5H/6"&0X4L1\!)&CV&3FW'AA$$71Z'KE2TOK1L2A2M/P^+T9"+UC=1LA9Z
M%S0/H[DR8?<AQJ)MP0'C"4>ZR[()M3.\2XNV3,G:\X#IL'Q"(Z5*F46<8,>%
M(AP+Q@&4HAB=458.,RV\&8&5JUE:#:'WQH-^Y%^E9&W'XN]'[/5*UAI@A65(
M4F.9Y28&?8OUD0AC!G@':EWAG"Q9>QXD_410SR]92X6@7!L%B<<*8FH-+_")
M^1O5#:T>ZM!7W=1KP]*/L.N5*>5<&&BA\1)"[B$#7.Q&"()9.>QMO8[(RM8K
MK8;0>^3"(+?V(5"@(8=ZTR5K+6:.>\& #G^&_T%^9P,CA#L59\T"IJ4%4+ID
M[5G8]#.9BVO6SSP[]+)9 L(D(!)K+'DLQ:,A0K88J94UBM%WG@_3C$^G%CS-
M)39N/N]C?J6;'XV#'FF6N)B':2"0<97#R@;%5!>]EYA4#X1VGOARKG!;@.?2
M@R7.:RTDQ1IY!@.0TA.V'2U'$%9WS'6> %-UIC<*4--S?1O&/7.J;ULEWF@D
MH(&(Q+J;WE)@>-%WJ6GUG);.4UJ:G.G5T.G2Y?;Z;N@#CK;BL80XAI32SE+,
M%;;.<46+D4!4X_;OSC-;JD[B&G!T&MY<.QL.Q3&;N//[*K\=S;>9/6H>5K3%
M.)\^;#*Z]&H1@%ZT^?GK/'M(\^5C^'3,'WW8!*DZ_5S?L>*B3]>S43 MGW7L
M8XFP\>G&"5(>.061-)0[;H*)PZ@+?,?&&H]EJ2AK2V[C7>S^X#!.A97+OB(1
MS @JL40$8(B-P=[C+0J*LAI+7L.QYB8%^N;>TU:P&G0L6H]F43G[?)>FRX]1
MJ%%XQQW7AYHDAGCCB,408 L%L!Z:@+NG5B$GH:Z1$-JN^[IYN6>M(-:5QK2O
MNR?]F8<;)4A8&8P^SA0#P"OND8*;41($N/##]F[7%UX)-M1"ZKWR8I">[B'1
MH1\:?)A_"RMBED]+!+/?/)MHX8F6 ,!@2H2M&3BHPAKJ63P" 4F-FQQ:\X0V
M(: W9X3JP=*5J-<G%Z>3K>MF$7;$J^5=FIM5GL<PSV*1+D]SH/Q+$J(,<)X:
M30@.6ZHA*/P[H("1XE894ID<K7E26R!':WAUQYH#6I1^+)'N6*)UPCAB2&@+
M *5 :@(%184B9@6H[F1M.5&B=4VS>?!Z)TVI-+D2K1,'I== $\^54UQB$29(
M,6Y.D1BV&MJH9,NRIC9Z?Q[V#%)9'3II&HKUF.S^8;5,\UT71O/)Y^QF^<<H
M/URMN63+1$HB$>:  68410$DS+=CT,QU>@BCI$[2J&2R-M'J:GGPJSS O\K3
M@(:??H]_.ZVW'FZ4<*PX 5QJ:;RB@,E8E'X[2A@VZN'IJ6UPHG&@NJ+#+Z/Q
MW72>YB_"'"?Y<*158AFGA"M@K9<DWE; L"C&:;@8X+TL;1*B.:0Z"Q*GHT5Z
ME\TF'^X?\NS;VA%_>H4XTBH1T$K*@(>48&V$U0@4VZIALD8\I;54@389T1Q2
M73'"9.MH^CBB_V$>L+D-J]II2AQKEF L,;/228Z%1C%-0@?T/(D7\Q&(JF<!
MMI96T"8G&H2J=S/C5)V%XPV3H&9C$W4F+[0&2  )6#$%B*]32J5S8M0/PS:*
M55?,4./QZGXUB^5U;?J0I^/IQA68/LS2;>K(BQHQA\9XA$--?2*AU'CFK24J
M&E)*"\X+'=T@++KTGO7/MIY0[7W%^C4]QK5CS1((XBU<R#DN.?76!W7.[:#F
M^)*4W197J_.1ZNZ PQ//CW#@^6,)5])"9Y"S1EF,K(7";$=B8TKW!:FS]65>
M YG6DR/W9?"UGB3Y*5TOH->C\.$O^6B^&*VUNCX^V7>VXH%^?2R1JWBJ::(4
MQ-!(BJ 1G#"-'+'66> @82QHVT/(5#PD%_WXXC>ETQ;/>%\"+=:((,V9],CS
M>,*<%OAP)[M4HX_F,#8GZ(,9C.W!-NATQG+#/A&!+O^21#%FE8XW8 $M(%"8
M6E9 AY&N4>^VJT!T*T1Y<RU12X!VI3$][^;):.+;AQ,81@*590 ;(8S0$ FU
MF\\(D&&'GML0WQ&&U,+LO3!BD.'D81*AORS(19!)J13(IP<3!"E4BGO@@7*<
M0""8+D8#<:<[1DE#JHY(]N0]5L:BCZG]C.75E(:BQE78+8-Q&;=-S;'4 !?C
M)(AT>7OHY6D)%1#LF2EG[0=OVB568\J)PXYBRJ"&A !2C#6F=UZDLG">%,LQ
MHQ9>[YLCEZ0^]$B-AO+/8E%XG^4?KJ_4?/(YC6G]UF1AK\N7T[ B?EYFX]^/
MYZ&5?T,"@1<$&4<M9M(!CS$VN^45\0'FHS4DHZP+O/I6,M8%%1;KZYF+GU50
M.O:\)4%!H3),F5@0P!EI'04[GY*7MGK4IFO>U'>3M0=;Z^[]-;/U:)%.8C)F
M6'A?1'%:\+/O_Z">C<:_!_4P/+&(5]9-Y[>_9)-T=O4P""?\Y[M1GK[IM,J#
M7&_33?[STR/7F[O9U!^C?%+&35__Y0DF'D" " \$E@(X0AS:D(J98!"52@YK
MVY%_<IB+0^,L[]RO^8TDS$A M):2&"7"/S@6<HNCQ%9WZ44YZO#ODC('0P+=
M@CWH,,%F5*?/HKUX+D'6AVU *L(1D\@KX(#8 J PL[!#ME4TXSNCP.LDFQHX
M=J615<?F:73S2<PV*%7_M8W/)<(2*+E3GBD' 2'$&E8@"R@<N.N@(DM>+WC#
M ?8OZC:'\" ]&A?,V'Z8ZNX?9MECNC'0-\;"R0#*P3:)I8Q3Y8% 5!,D.,,2
M%F-$QG9Z)K.<2=NOJ+-V@.TLEW4[[%,%!)X]EG@/H97,::&15<9Z0K?>'Z8E
M5-6]99V%7OK2V6K V#4A3A_P?CEAG/ <:*XHB!7-@<3:%I!HP<W ;U&J)I@#
MTJV%R*7+>9 Z11_B;2@.\N6/[,M=MEK$8^%IK'"4IO,7FTQQ$4#LWO& 2(57
M)8XQ(8$0!!'(H:3,2K%SD=!N;\XHF:->44Q9IT@-QHPYM-'YT33_YVBV2M5B
ML;K?N* _31>_^SQ-BZN</XV61WV2;7\[\<Q#["0#TI,8X%+0%UJ:E<[7N$6W
M-V6U1:_EP,31Z13X>GK<7\N,.U80&R_32:R5#4]QOY6/)F$UT1Q0XB1 &@NA
M":4[E FL[C)M[:AAWZ0?@APN<L'_5SJ]O0L#5M_2?'2;_C.;A;?-ILO'+E?^
MHYU(9-#AI"66",5YP-[' V);*3A!JQ<\;>W@9-^S88ARN<C942P'=OIM.DGG
MDRXGQ;YO)_$R"HRQLTAAX#77W( MY@X:4CT=I;4#I>]E+C0@CI[27 Z:-7_E
MFQSG'?-("A]L2(2,9$HS)3>)]A1C+\M=0OA7ODF:Q/,*$EIO% 3<Z6!!.[7%
M,=YPVZ5#J>U\D]*4:2_?Y"RP!YUO4B5RP2FTU!$35F(/ 2;.6[H=/D*DTQ-B
M?44NRA+@6.3B/!B'[M$VADI,(1,&J)@GSY3PQ6@,=9<4N2@MF..N[6J(7+J<
MAQ^YZ$B\[R-R03T16G%+ 7:80""IML4H%=4#/--154QU(Q?G(35X4_W751S5
M=JM<J-7R+LOCQ:EMF .'OI4 [H746$C.K6):8X]PH>H%*[#3>W@Z,\4KZ[<]
MPU]YB3OI7?YZP+N\Z7AVHR:3M8!'L]=#^# ?Y^M7N-'X[O^FHX-K8Y=]2!3%
MWBJMG-140+R^&&6+*S%<5@^X#3GV<"ZMARZ6KE9P-5L3()WLE\'I:\'+O2 A
MSDG/A!;21E\S-LSYW>B9JI[F.N000-6UMA5,>_)=_CH*B"VGW]*_?)7'R:*=
MD5H%NT%2%P3I$&3,.<2Y5%8"7ZI RE^^RC2)VC%U&H2I@8DEW&Z*CT8<-76H
M2YNB;5]E:<JTYJL\#^QWYZLTD#@AD?#0:H.<H1CZ[?"-"TB\?U]E:0(<\U6>
M!^/0?5B,<6NL,HH9"2 1GDM2C,8",O!K?ZL)YK@SJQHBER[GX?LJ.Q)O0X:\
MNE^KBJ/YY%.Z6$;U.#P#UEIGL+;"LA24S--NRO/>DG#E"2208T@UXE18;&TQ
M-D7*:66]>BA+"R?K"J3.3-MJA]TQMQ B#7VPH1RP@(;];3N6\+OJ]S1?S,&I
MJEMZ'1P'X["^@!/#!'/FC (X3#C)F.'0F$+KCS5ZAJU?5&1)%T>'JP'[%W6;
M0WB0*M,%,[:I$$J:?YN.-SU[=FCZ\*UP)5HE)&PGT!N#H$#,:V:,*)0&2\)/
MAJ=9]2O"K"UH![. #3I8+"0Q !&D$'0* :DQYEM,'3&^>BWC(0>+*SL8>X:_
M*TJ'T=UG\_4,-*.'Z;*( P:K*<S0=.*SW*_BO< ?%HO5*%A.1RA[]KL2Y+ /
M)IP#DFOJ$31.Z0*3>+3C709ZJU*R;7@K;ZZG.G;SNF,QFCQ[7 >81WM#LTV\
M-O'(XK I,8U=/"O*-%*%W\ 9P =XV5T/Y.H!Z<&?R'7?'Z;YYL[(-)]F)W?I
M)KZ1*"0T1Q2@L$58&A1TL/-R.>A0=3?=D$]5U=J=>X!]\(KF^C__3!?+Z?QV
M,\*3Q\<;^DPBF$6 *PAYO)11<\OI3K_ASE0_]=#:%=E]$[@?Y ?/X:TE^(_P
MX'+Q83M13UW3W<+7$F,Y"FHZ5491IJWP&!7JD\>85;]MF?W%Z!8$<)G$?G6^
M??U+.UJFN_._G9'^9$\2@32Q5@01^)CU['4@2R$/8%#U%$C^UX3H6#B7,EG<
M]S0?3Q?I#H@O63!//LR7^72^F([;GB%E/I\ S!FUF%!/K ':Z[ A%\@[42/"
M+OZ:%EU(Y%+FPM5JN5B.YI.@^G4V 0Y^,V&04ZBUEYR$\3K&D0<%QIK6* ,B
M_V)]:V(8O._EY2R/V1POQ]M*-;23'TVH]2C(G")"@;#(8FEVFJB5KGI.#03O
ME>U#$$17=-^=?=U$-?=#_VNVOD,UW=CPB_6^]?SW)ELL?\V6_S==?DK'V>T\
M1HV>WK1I=+6\2_,O=Z/Y%JDCLZ&W/@6SS0ID 59. 8HXQD9NDS(UH-S4B(N_
MQTCCI<CIXN?21EWT6;[]47SNV';2;4<2(EA04X6(-^]R X"AR!328-C5N!+A
M/09#!RV<G@XJ'LJI^>O<XG$.<@H00\$LY,9J+IBG8'-G!F4V+(ZESMO]=6XQ
M3;CU(*9:"Z^5#U-:"[TMA\",YZ:ZOWQXYQ9+4Z:U<XOG@3WH<XO5CCD(KI'T
MP@B".;?,2$M!(0)!6)>WXO9TS*$T!8X><S@/Q\'XRBXA5UQ+SYWWBD/C+-:>
M45L@2YS EW3,H31+.DD:KP3L7]1M#N$+..9P48P=\C$'QYDRF&E/F-:<>"JX
M*/JN+1W@ =)^17C&,8?SH!W, G8P]SW;^I;<OU?3Y>.'^2+HF&N\G\4O/F6S
M63"OX_.M''\XLP\)TE8P!SSPD%LA./7(;67@+)%=5NOMSNU2V7X9J%@&/S7>
MQO$V!T6Z"=UNOI5 "XU #$(/((<60T!T@2F5Y!)O7>V>;^U%=BM)Z5*8WW\Z
MIZ;4.PHI@=(Y[!A#@!>X0@?>4U7)BV%_?3EUQO]UZ9#%8I5.["K?95]O#LH\
M5^V*!*6CVLW9+TL4#"(BCDL.O!" "E"43PYR<S7<7<,[S=0=>]L6PZ4LSD_'
M8G9SL=6DRC=?2Y 24EN)2+![O+?<6UGX,CWTMKH6/KSC3Q>S.->7TZ7P/R!]
MDT[C"<<N^+_G:PD&G$(H  __(91K"XDO<&4&5;\V8GBGIRZ&__7E="G\?Y9P
MU[I9^N9;"8%$>8 1,\I2P97 J#!X/""BNFHS/,6\1P],0_!?"J7_N4G\F4]V
MU^EF\4==.F#*=B'QG# !K"6": \1M)#)0@+(DNJ568:GV_<_ 5J2RN#GQ=O=
M]E4^Z--5$':ZB$DB<>-37\/SH_&RC6E2KT<)]U(+:!%@1$@(M- *%?(QFIAW
M9#+T.&LZ%=+@)]%;I^VK@YF%I^ ZGQZME=11#Q($55C#&+%$8T\0Q@[M\+?<
M='H=7<N3I"NFMA< :%"2@YE)!T/M98XY-S:;FNM%(K1$4EG/'0T2\8HJN;4
M.4#&O:>:94.=4;U)\V)FU9M3TGU-K+,ZDA"@@&&".<P$Q)9#;W@A#8!T];DU
M/$/H4N=6FP*]H.GUQC/>WP0[JRL),=0I;CP1D''N=5CR="$1[M!["K1<[A1K
M4Z07,\GVN-_[FF1G=B569%-(& .$A\XCC*A A42PY-4+)0TOFG.IDZQ=D0YF
MDI6/!O3DR"C9@P18;;4!C"-**5;(>[Y-Y^=0,/R> J3]^\C;$<JE3(K3$8*>
MYDJ]CB46Q1NS3+P.R7BM"'#"%-(RWL/*4VC(]2R'&V9J4%:7,K,Z#S&5TD$
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M#;2Z4R>^!2"R?%IB[WCS;((U48(;(X4!'AE$B8\KI+,!/"MD]3/OK:7AML.
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M):\^W'YXR*M,!+_.>;^L7@$4,YAX$8EB#\  03]$72@,4A:O]H=VZ^)[.RJ
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M$88>#5&@MDO;2$#+/$KRVYP+Z=/TBMV:JU3<1VG$5SD^36ZI&JIZ>>U-4KW
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M"B.>NS# !TV[EL$&7?&ED4=&.?DH^_JU$F./YC3 ;K-D>R@7],.0422V)+D
M^&%*$^+%*:9N' 4X5+K%=E0@R[QXKDUT[SMU>L?SC?-4<D%N*CL55^6TG;25
MSW/1I>%DG?'F+H-%9HKR,LW&E#]O<:JN]N*HY,WC>O^A^I17WXIUWARR16)$
M?!C@.$ZIQR"(>6])A$D)9F*]4(9-VA]NF4>=IN;<X$Z6T@%]^J8-PV<2O]2
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M6J8\T-#R>\DC#;T"20TU1GBE0[:&IA\>1'-?LQ]YM2[J?+.B-"$!#P/3@#'
M&(IHW,>%!"D=+SL^VN2CAKR3)E[%=F10MIKU,:?ILSKE[%L\!G)MGZ^3YQST
MS4>X5^V2!-PXJY?'MY'E&<";":=4<VH_YMLFS;3\G/WX1[&_NRNWFV+W-2VK
M"W<?D#"$(*&Q&Q"*(?^_2PZPC0@@(S)LC6N9*-^VSP/E'/Q^E,V_WSFU$%ZW
M/\ZW&^>VK)RBO9MNG_U0S2^S5VF2!)VUHL8EZ7::1;(N5^V<R&XJ91F7MN@:
M+)' :ZW.%D)HZ\6\D-QKV5=5GI]?R+"*W, C*66\?PPC&#(_Q/#0.8Y#G3.A
MM&--P^,F6:HY7%"\V+>'_"B->V'T754#JATGQP&3MV;'W#(ZZ)U5%IY[(\$Z
M;3N7Q3+]8EQ@U4A?S"?3K@A-?)^E 0Y1'$5!2@E G8"$*S)QA(!.6*6QM.:V
M@X>3=,[;5[)I;273ONVY'+MFLEN-9AK)LTO-F#62*2M=%<L@H8V":6?&*GHG
M2TMV>YNO]Q]NV8]U<W'31][M^; 3FO!N(_X0N\2^95L!\%4<HA#$48Q '. (
M)8C_KY= <*!TW)31P)9G'UNM3:<D[^0Z%=?KK+O+KOA8>RW><['?LODB/XI7
M(ZG9^I!CZ6Q5H4;35J:HA%ZH(Y0*\VEO?O,%DS#?"DY5C!P JI7Z6 92[12M
MG.!Y5L/JZ\%N\JHH-^?':ZT0@RR)(BQ&Y+[KA0#Z_0$Q240H5>F&&@ULN2,J
MND<_;4Y.FNM.GRN,T=1L-<C1=+8:4*/I161>.:U6YY73 *?%J8J3 SBU4B'+
MP*F=HI43/- F<(IYW[FJGG@W^>_9]C%?^2AR*0YI[*> N9Z+$T#ZV$GDP=5#
MH_G3/JOV8VBJ&E?E)3Z7J/X^GQ/3R?;.E_QKL=N)D:8XE*4)80*DRA4PAJ V
M73>&SDP,^%N53B-S"<0\<TX9E;K.+YF1VF62@N,XQ\Q2,20)"&( L8^1#RAD
M@($^=NK2I*,BVVU,,O&MJ.I,[ 6:(6(N#HY^DX6_XY=4M@)^3R^I=)FT7E(U
MQV1?TD^/#P_;O,G7WPH!Z;;\_GYW6U;WS8+L8<-[X'L^2J"/4!2%R/4PB/KH
M+/*24&5NS51,R]-JIS*=35&OMV7]6#49?3O^V(BW]K6E"<6#/HQ5@%SG90[O
MU;HOSVQO("DT.B<B9SO!0]*\ 3B:MG\9>#1>JM+N0ZMZU06'1U[O;[)B\TN^
M7R$0$N('*(6Q%\"0$13&A]X2)4CM5@NUS[:,O.?9(44G3O7""D6[Y,!ETRDU
M0/5*'"'E2LSV;Q^;5#F:/13\"2W^E8O9J?:7KA9P&ON9=0-XTC5Y&1C25O_B
M@HDQ+D@G@K1]B.,Q;KO-85WU_3Z_/QXV%*" HH0QF (/>+RO%XL3VE/D>Y"
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M%Q%_R;FDS]F/0V08X83Z"?.(3Z,(D23U:1L918F;*O5K3,2SW*7YL+_+JV9
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MY33"G%Z9UN8J?1_E&#:)A6K@TG//"JLNN3, J-&&+H-*XXM1&G[0QO.GVXB
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MZ?9,,),W<7!RR7A-+ -_-@KV8JK)DG=O ;-\V.]>[@3-CMNCNJAQ[,7(#4$
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M6!OV%*!YK!C[<JX:99![D=9WN\N_J_\LE_MZ ?-"V$LX3VG$$>(H9W+S/HM
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MC;/"B/0[2A,V83#)'<,,J2431RS/+KNX\NOE=..4.=5E$7Q3[0_=E;4?OTI
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M1QS/X^ERY4SE91SJ/6>TNKFM=G)A2\X-VV?\<OD#UW5YJ/%5?=@O5X<%I\(
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M0\&A"CJ7 O'_@M:IKK^I8E?%*<(\+(0SC[">B(X>7,\=:VU#\8RB3QCON77
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MK3H*"D2/2Q%&&31 "P<%J21DUH@SR]G?/9>.P[ES6_I]C;I'KS\.7ALG$65
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MUBNJ^@;C&5&J904T1JM1\I!28.-Z4%OSJ1_4/B OE?:>2Z@T]-(;[*H36B4
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MUS'K1->KMMK4+.\B!+8U?>^\IST,Y<Y<G-=R5Z$(-69.C=91;F6CV(YH:H1
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MTW]7,EI(SBR\.E?191N@GF1R?DBU5U.0KDVUJ\9O?[)&]U9!0 "S3*1<EIQ
MM<0<6@M8+2*W)^&[21SF0YW,I1N^#I98"35#2&LF%1.*$5O)%H4^L^QPN0K>
M,$GS .WLV4.C24N5AYCA*"3GF&JHO=.TDA$ZG1/LU5/2'*WEVIE+#\.TLU?
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MC_ZSN)J7T5R>#$?W@W&]C65[^P"<EQ #*940R-"4& FNF>YISJD@//>#YI9
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ML(HF_#0L)H/IJ-QWV[SI^Z D \ 2XRT#*BY>$2>_DDT[*>3YD>5H[;[T[1K
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MA!Q%PY9AR[SBII)?.'5FE4-/2+EC(>\)Y>*OREWGGO01E.$DVKY)? $IQ()
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M0% U:F)DUB.[,SZ9;1C7AMA@RNB\#^*?@]EMRF_Z/*U\/7KL[B-@XZ*;QP5
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M_FEX6UP]I+(43W]Z+BG@C7,N3MU42 ,C99BF1B_ -QYSR&M%^75QVGI,"GC
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MSNFN0-=>(LQ9[!IR@(U3:*DC)F[)'@),G+=TMQ*$R-B*D7M P+$ VWG$'WJ
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MXOKG9)E]F4X.;QYEA@6+K60<<V411\QAX,A>\4[1VW$YDQN'1 LTOA"KHDS
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M;BTR,#$X,3(S,2YX;6Q02P$"% ,4    "  &.F9."II&\O 0   'N@  $0
M            @ '!+ $ ;W!T;BTR,#$X,3(S,2YX<V102P$"% ,4    "  &
M.F9.N&F:.9H>   C.@$ %0              @ '@/0$ ;W!T;BTR,#$X,3(S
M,5]C86PN>&UL4$L! A0#%     @ !CIF3I,*]T]]5@  HCD$ !4
M     ( !K5P! &]P=&XM,C Q.#$R,S%?9&5F+GAM;%!+ 0(4 Q0    (  8Z
M9DX(PR-@"L<  +Z7"@ 5              "  5VS 0!O<'1N+3(P,3@Q,C,Q
M7VQA8BYX;6Q02P$"% ,4    "  &.F9.G,V?: 5_   J5@8 %0
M    @ &:>@( ;W!T;BTR,#$X,3(S,5]P<F4N>&UL4$L%!@     &  8 B@$
' -+Y @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
